PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sandvik, H				Sandvik, H			Health information and interaction on the internet: a survey of female urinary incontinence	BRITISH MEDICAL JOURNAL			English	Article							WORLD-WIDE-WEB; MEDICAL INFORMATION; ADVICE; CONTINENCE; REQUESTS; QUALITY; WOMEN	Objective To evaluate the internet as a source of information about urinary incontinence and to explore interactive facilities. Design Limited survey of internet resources. Subjects 75 websites providing information about incontinence and an opportunity for interactivity, 25 web doctors, and two news groups. Main outcome measures Quality scores according to predefined general and specific criteria. Internet popularity indexes according to number of links to websites. Correlation between quality scores and popularity indexes. Results Few sites provided comprehensive information, but the information actually provided was mostly correct Internet popularity indexes did not correlate with quality scores. The most informative site was easily found xith general internet search engines but was not found in any of the medical index sites investigated. Sixty six per cent of sites responded to an email request for advice from a fictitious incontinent woman, half of them within 24 hours. Twelve responders provided vital information that the woman might suffer from drug induced incontinence. Conclusions Excellent information about urinary incontinence was found on the internet, but the number of links to a site did not reflect quality of content. Patients may get valuable advice and comfort from using interactive services.	Univ Bergen, Dept Publ Hlth & Primary Care, N-5009 Bergen, Norway	University of Bergen	Sandvik, H (corresponding author), Univ Bergen, Dept Publ Hlth & Primary Care, Ulriksdal 8C, N-5009 Bergen, Norway.							Borowitz SM, 1998, JAMA-J AM MED ASSOC, V280, P1321, DOI 10.1001/jama.280.15.1321; Eysenbach G, 1998, BRIT MED J, V317, P1496, DOI 10.1136/bmj.317.7171.1496; Eysenbach G, 1998, JAMA-J AM MED ASSOC, V280, P1333, DOI 10.1001/jama.280.15.1333; Fonda D, 1997, EUR UROL, V32, P28; Goldstein M, 1992, J Gerontol Nurs, V18, P15; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; Lim PHC, 1997, NEUROUROL URODYNAM, V16, P609, DOI 10.1002/(SICI)1520-6777(1997)16:6<609::AID-NAU10>3.0.CO;2-9; Marshall HJ, 1996, BRIT J CLIN PHARMACO, V42, P507, DOI 10.1046/j.1365-2125.1996.45217.x; NEWMAN DK, 1999, ACCT ACCESS CONTINEN; NORTON PA, 1988, BRIT MED J, V297, P1187, DOI 10.1136/bmj.297.6657.1187; Sandvik H, 1995, Fam Med, V27, P388; SANDVIK H, 1999, FEMALE URINARY INCON; Seim A, 1996, BRIT MED J, V312, P1459, DOI 10.1136/bmj.312.7044.1459; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.277.15.1244; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209	15	109	113	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					29	32		10.1136/bmj.319.7201.29	http://dx.doi.org/10.1136/bmj.319.7201.29			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390457	Green Published, Bronze			2022-12-01	WOS:000081326500031
J	Taylor, DR; Shi, ST; Romano, PR; Barber, GN; Lai, MMC				Taylor, DR; Shi, ST; Romano, PR; Barber, GN; Lai, MMC			Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein	SCIENCE			English	Article							HEPATITIS-C VIRUS; NONSTRUCTURAL 5A PROTEIN; RNA-BINDING; HUMAN-CELLS; DAI; LOCALIZATION; ORGANIZATION; ACTIVATION; SITES	Most isolates of hepatitis C virus (HCV) infections are resistant to interferon, the only available therapy, but the mechanism underlying this resistance has not been defined. Here it is shown that the HCV envelope protein E2 contains a sequence identical with phosphorylation sites of the interferon-inducible protein kinase PKR and the translation initiation factor eIF2 alpha, a target of PKR. E2 inhibited the kinase activity of PKR and blocked its inhibitory effect on protein synthesis and cell growth. This interaction of E2 and PKR may be one mechanism by which HCV circumvents the antiviral effect of interferon.	Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90089 USA; Small Mol Therapeut, Monmouth Junction, NJ 08852 USA; Univ Miami, Sch Med, Miami, FL 33136 USA	University of Southern California; Howard Hughes Medical Institute; University of Southern California; University of Miami	Lai, MMC (corresponding author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA.		Yang, Chen/G-1379-2010; Lai, Michael M. C./I-7001-2012		NIAID NIH HHS [AI 40038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040038] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Besse S, 1998, EXP CELL RES, V239, P379, DOI 10.1006/excr.1997.3908; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CLEMENS MJ, 1996, TRANSLATIONAL CONTRO, P575; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 1999, NATURE, V398, P90, DOI 10.1038/18057; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; JIMENEZGARCIA LF, 1993, J CELL SCI, V106, P11; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; Raine DA, 1998, FEBS LETT, V436, P343, DOI 10.1016/S0014-5793(98)01163-6; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; TAYLOR DSC, UNPUB; Thomas HC, 1999, HEPATOLOGY, V29, P1333, DOI 10.1002/hep.510290453; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m	23	589	632	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					107	110		10.1126/science.285.5424.107	http://dx.doi.org/10.1126/science.285.5424.107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390359				2022-12-01	WOS:000081199800041
J	Miyata, T; Asami, N; Uragami, T				Miyata, T; Asami, N; Uragami, T			A reversibly antigen-responsive hydrogel	NATURE			English	Article							PHASE-TRANSITIONS; POLYMER GEL; RELEASE; GLUCOSE; COLLAPSE; PH	Stimuli-responsive hydrogels that undergo abrupt changes in volume in response to external stimuli such as pH, temperature and solvent composition have potential applications in biomedicine and the creation of 'intelligent' materials systems, for example as media for drug delivery, separation processes and protein immobilization. Hydrogels have been reported that respond to pH(1-3), temperature(4-13), electric fields(14-16) and saccharides(17-22). For some biomedical applications it would be very useful to have a material whose swelling response was dictated by a specific protein. Here we report such a material, which swells reversibly in a buffer solution in response to a specific antigen. The hydrogel was prepared by grafting the antigen and corresponding antibody to the polymer network, so that binding between the two introduces crosslinks in the network. Competitive binding of the free antigen triggers a change in gel volume owing to breaking of these non-covalent crosslinks. In addition, we show that the hydrogel displays shape-memory behaviour, and that stepwise changes in antigen concentration can induce pulsatile permeation of a protein through the network.	Kansai Univ, Fac Engn, Chem Branch, Osaka 5648680, Japan; Kansai Univ, High Technol Res Ctr, Osaka 5648680, Japan	Kansai University; Kansai University	Miyata, T (corresponding author), Kansai Univ, Fac Engn, Chem Branch, Osaka 5648680, Japan.							AOKI T, 1994, MACROMOLECULES, V27, P947, DOI 10.1021/ma00082a010; BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; BAE YH, 1988, MAKROMOL CHEM-RAPID, V9, P185; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; FEIL H, 1991, J MEMBRANE SCI, V64, P283, DOI 10.1016/0376-7388(91)80099-R; Flory PJ., 1953, PRINCIPLES POLYM CHE; HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; Kataoka K, 1998, J AM CHEM SOC, V120, P12694, DOI 10.1021/ja982975d; KOKUFATA E, 1991, NATURE, V351, P302, DOI 10.1038/351302a0; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; Lee SJ, 1996, J MOL RECOGNIT, V9, P549, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<549::AID-JMR299>3.0.CO;2-C; Miyata T, 1996, MACROMOL CHEM PHYSIC, V197, P1135, DOI 10.1002/macp.1996.021970330; MIYATA T, 1994, MACROMOL CHEM PHYSIC, V195, P1111, DOI 10.1002/macp.1994.021950401; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; NATSUME T, 1994, J BIOL CHEM, V269, P31224; OBIDAT AA, 1996, PHARMACEUT RES, V13, P989; OBIDAT AA, 1997, BIOMATERIALS, V18, P801; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; SHOEMAKER SG, 1987, APPL BIOCHEM BIOTECH, V15, P11, DOI 10.1007/BF02798503; SIEGEL RA, 1988, MACROMOLECULES, V21, P3254, DOI 10.1021/ma00189a021; STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0; TANAKA T, 1978, PHYS REV LETT, V40, P820, DOI 10.1103/PhysRevLett.40.820; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TANAKA T, 1980, PHYS REV LETT, V45, P1636, DOI 10.1103/PhysRevLett.45.1636; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	26	933	970	16	673	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					766	769		10.1038/21619	http://dx.doi.org/10.1038/21619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391240				2022-12-01	WOS:000081101600049
J	Min, KT; Benzer, S				Min, KT; Benzer, S			Preventing neurodegeneration in the Drosophila mutant bubblegum	SCIENCE			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; CHILDHOOD ADRENOLEUKODYSTROPHY; BRAIN DEGENERATION; FATTY-ACIDS; ADRENOMYELONEUROPATHY; GENE; MICE	The Drosophila melanogaster recessive mutant bubblegum (bgm) exhibits adult neurodegeneration, with marked dilation of photoreceptor axons. The bubblegum mutant shows elevated levels of very long chain fatty acids (VLCFAs), as seen in the human disease adrenoleukodystrophy (ALD). In ALD, the excess can be lowered by dietary treatment with "Lorenzo's oil," a mixture of unsaturated fatty acids. Feeding the fly mutant one of the components, glyceryl trioleate oil, blocked the accumulation of excess VLCFAs as well as development of the pathology. Mutant flies thus provide a potential model system for studying mechanisms of neurodegenerative disease and screening drugs for treatment.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology	Benzer, S (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.			min, kyung-tai/0000-0003-0983-4258				AUBOURG P, 1993, NEW ENGL J MED, V329, P745, DOI 10.1056/NEJM199309093291101; BENZER S, 1967, P NATL ACAD SCI USA, V58, P1112, DOI 10.1073/pnas.58.3.1112; COHEN SMZ, 1983, AM J OPHTHALMOL, V95, P82; ForssPetter S, 1997, J NEUROSCI RES, V50, P829, DOI 10.1002/(SICI)1097-4547(19971201)50:5<829::AID-JNR19>3.0.CO;2-W; HAYARAN A, UNPUB; Kobayashi T, 1997, BIOCHEM BIOPH RES CO, V232, P631, DOI 10.1006/bbrc.1997.6340; KOIKE R, 1991, J NEUROL SCI, V103, P188, DOI 10.1016/0022-510X(91)90163-2; Kretzschmar D, 1997, J NEUROSCI, V17, P7425; LAZO O, 1988, P NATL ACAD SCI USA, V85, P7647, DOI 10.1073/pnas.85.20.7647; Lu JF, 1997, P NATL ACAD SCI USA, V94, P9366, DOI 10.1073/pnas.94.17.9366; Min KT, 1997, CURR BIOL, V7, P885, DOI 10.1016/S0960-9822(06)00378-2; Moser HW, 1991, TECHNIQUES DIAGNOSTI, P177; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Mutsuddi M, 1998, CURR BIOL, V8, pR809, DOI 10.1016/S0960-9822(07)00506-4; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; Powers JM, 1998, BRAIN PATHOL, V8, P101; RIZZO WB, 1986, NEUROLOGY, V36, P357, DOI 10.1212/WNL.36.3.357; Uchiyama A, 1996, J BIOL CHEM, V271, P30360, DOI 10.1074/jbc.271.48.30360; UCHIYAMA A, 1998, DNA RES, V5, P169; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0	21	145	152	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1999	284	5422					1985	1988		10.1126/science.284.5422.1985	http://dx.doi.org/10.1126/science.284.5422.1985			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373116				2022-12-01	WOS:000080932700046
J	Wong, JG				Wong, JG			Cold blue	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2168	2168		10.1001/jama.281.23.2168	http://dx.doi.org/10.1001/jama.281.23.2168			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376548				2022-12-01	WOS:000080777000001
J	Ascherio, A; Rimm, EB; Hernan, MA; Giovannucci, E; Kawachi, I; Stampfer, MJ; Willett, WC				Ascherio, A; Rimm, EB; Hernan, MA; Giovannucci, E; Kawachi, I; Stampfer, MJ; Willett, WC			Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; BETA-CAROTENE; LOGISTIC-REGRESSION; VEGETABLES PROTECT; FOLLOW-UP; DIETARY; PLASMA; ANTIOXIDANT; MORTALITY	Background: Antioxidants increase the resistance of low-density lipoprotein to oxidation and may thereby reduce risk for atherosclerosis. Objective: To determine whether intake of vitamin E, vitamin C, or carotenoids predict risk for total or ischemic stroke. Design: Prospective observational study. Setting: The Health Professionals Follow-up Study. Participants: 43 738 men 40 to 75 years of age who did not have cardiovascular disease or diabetes. Measurements: Repeated and validated dietary assessments were done by using a self-administered 131-item food-frequency questionnaire, which included questions on dose and duration of vitamin supplement use. The follow-up period was 8 years. Results: A total of 328 strokes occurred: 210 ischemic, 70 hemorrhagic, and 48 unclassified. After adjustment for age, smoking, hypertension, hypercholesterolemia, body mass index, physical activity, parental history of myocardial infarction, alcohol consumption, and total energy intake, the relative risk for ischemic stroke in the top quintile of vitamin E intake (median, 411 IU/d) compared with the bottom quintile (5.4 IU/d) was 1.18 (95% Cl, 0.77 to 1.82). The relative risk for ischemic stroke in the top quintile of vitamin C intake (1167 mg/d) compared with the bottom quintile (95 mg/d) was 1.03 (Cl, 0.66 to 1.59). Results for total stroke were similar. Associations of vitamin intake with hemorrhagic stroke were also nonsignificant, but the Cls were wide. Neither dose nor duration of vitamin E or vitamin C supplement use was related to risk for total or ischemic stroke. The relative risk for ischemic stroke was 1.16 (Cl, 0.81 to 1.67) in men using 250 IU or more of vitamin E supplementation per day compared with men who used no vitamin E supplements and was 0.93 (Cl, 0.60 to 1.45) in men using 700 mg or more of vitamin C supplementation per day compared with men who used no vitamin C supplements. A significant inverse relation between lutein intake and risk for ischemic stroke was seen but was not independent of other dietary factors. Conclusions: Vitamin E and vitamin C supplements and specific carotenoids did not seem to substantially reduce risk for stroke in this cohort. Modest effects, however, cannot be excluded.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	alberto.ascherio@channing.harvard.edu			NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHESON RM, 1983, LANCET, V1, P1191; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; Azen SP, 1996, CIRCULATION, V94, P2369, DOI 10.1161/01.CIR.94.10.2369; BENDICH A, 1989, J NUTR, V119, P135, DOI 10.1093/jn/119.1.135; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Daviglus ML, 1997, NEUROEPIDEMIOLOGY, V16, P69, DOI 10.1159/000109673; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DONNAN PT, 1993, AM J CLIN NUTR, V57, P917, DOI 10.1093/ajcn/57.6.917; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GEY KF, 1993, AM J CLIN NUTR, V57, P787; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Key TJA, 1996, BMJ-BRIT MED J, V313, P775, DOI 10.1136/bmj.313.7060.775; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; KRITCHEVSKY SB, 1995, CIRCULATION, V92, P2142, DOI 10.1161/01.CIR.92.8.2142; Kushi LH, 1996, AM J EPIDEMIOL, V144, P165, DOI 10.1093/oxfordjournals.aje.a008904; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Mark SD, 1998, EPIDEMIOLOGY, V9, P9, DOI 10.1097/00001648-199801000-00005; Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Ross RK, 1997, CIRCULATION, V96, P50; Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; STAMPFER MJ, 1995, AM J CLIN NUTR, V62, P1365, DOI 10.1093/ajcn/62.6.1365S; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINER M, 1991, J AM COLL NUTR, V10, P466; STEINER M, 1995, AM J CLIN NUTR, V62, P1381, DOI 10.1093/ajcn/62.6.1381S; VOLLSET SE, 1983, LANCET, V2, P742; WALKER AM, 1981, LANCET, V1, P13; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366	42	151	156	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					963	970		10.7326/0003-4819-130-12-199906150-00003	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383366				2022-12-01	WOS:000080894700002
J	Phillips, M; Gleeson, K; Hughes, JMB; Greenberg, J; Cataneo, RN; Baker, L; McVay, WP				Phillips, M; Gleeson, K; Hughes, JMB; Greenberg, J; Cataneo, RN; Baker, L; McVay, WP			Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study	LANCET			English	Article							FIBEROPTIC BRONCHOSCOPY; LIPID-PEROXIDATION; DIAGNOSIS; PENTANE; TUMORS	Background. Many volatile organic compounds (VOCs), principally alkanes and benzene derivatives, have been identified in breath from patients with lung cancer. We investigated whether a combination of VOCs could identify such patients. Methods. We collected breath samples from 108 patients with an abnormal chest radiograph who were scheduled for bronchoscopy. The samples were collected with a portable apparatus, then essayed by gas chromatography and mass spectroscopy. The alveolar gradient of each breath VOC, the difference between the amount in breath and in air, was calculated. Forward stepwise discriminant analysis was used to identify VOCs that discriminated between patients with and without lung cancer. Findings. Lung cancer was confirmed histologically in 60 patients. A combination of 22 breath VOCs, predominantly alkanes, alkane derivatives, and benzene derivatives, discriminated between patients with and without lung cancer, regardless of stage (all p < 0.0003). For stage 1 lung cancer, the 22 VOCs had 100% sensitivity and 81.3% specificity. Cross-validation of the combination correctly predicted the diagnosis in 71.7% patients with lung cancer and 66.7% of those without lung cancer. Interpretation. In patients with an abnormal chest radiograph, a combination of 22 VOCs in breath samples distinguished between patients with and without lung cancer. Prospective studies are needed to confirm the usefulness of breath VOCS for detecting lung cancer in the general population.	St Vincents Med Ctr, Dept Med, Staten Isl, NY 10310 USA; Menssana Res Inc, Ft Lee, NJ USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Med, Penn State Geisenger Hlth Syst,Pulm Crit Care Div, Hershey, PA 17033 USA; Hammersmith Hosp, Imperial Coll Sch Med, Dept Resp Med, London, England; McVay Consulting Associates, Doylestown, PA USA	Saint Vincents Hospital Manhattan; New York Medical College; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Imperial College London	Phillips, M (corresponding author), St Vincents Med Ctr, Dept Med, Staten Isl, NY 10310 USA.	menssana@bellatlantic.net						BOREK C, 1993, ENVIRON HEALTH PERSP, V101, P237, DOI 10.2307/3431732; BRAWLEY OW, 1998, HARRISONS PRINCIPLES; Crosbie SJ, 1997, HUM EXP TOXICOL, V16, P131, DOI 10.1177/096032719701600301; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; FEIG DI, 1994, CANC RES S, V43, pS1890; GORDON SM, 1990, J CHROMATOGR, V511, P291, DOI 10.1016/S0021-9673(01)93292-3; GORDON SM, 1985, CLIN CHEM, V31, P1278; Govert JA, 1996, CHEST, V109, P451, DOI 10.1378/chest.109.2.451; HIETANEN E, 1994, EUR J CLIN NUTR, V48, P575; HUMAD S, 1988, FREE RADICAL RES COM, V5, P101, DOI 10.3109/10715768809066917; Khyshiktuev B. S., 1994, Voprosy Onkologii (St. Petersburg), V40, P161; KNEEPKENS CMF, 1992, CLIN INVEST MED, V15, P163; KNEEPKENS CMF, 1994, FREE RADICAL BIO MED, V17, P127; KNIGHT JA, 1995, ANN CLIN LAB SCI, V25, P111; MAK VHF, 1990, THORAX, V45, P373, DOI 10.1136/thx.45.5.373; MINNA JD, 1998, HARRISONS PRINCIPLES; Olopade CO, 1997, CHEST, V111, P862, DOI 10.1378/chest.111.4.862; ONEILL HJ, 1988, CLIN CHEM, V34, P1613; PAULING L, 1971, P NATL ACAD SCI USA, V68, P2374, DOI 10.1073/pnas.68.10.2374; Phillips M, 1997, ANAL BIOCHEM, V247, P272, DOI 10.1006/abio.1997.2069; PHILLIPS M, 1992, SCI AM, V267, P74, DOI 10.1038/scientificamerican0792-74; PHILLIPS M, 1994, FREE RADICAL RES, V20, P333, DOI 10.3109/10715769409145633; PHILLIPS M, IN PRESS J CHROMAT B; POPP W, 1991, CANCER, V67, P72, DOI 10.1002/1097-0142(19910101)67:1<72::AID-CNCR2820670114>3.0.CO;2-L; POPP W, 1992, CANCER, V70, P2278, DOI 10.1002/1097-0142(19921101)70:9<2278::AID-CNCR2820700911>3.0.CO;2-T; PRAKASH UBS, 1994, J BRONCHOLOGY, V1, P4; PRETI G, 1988, J CHROMATOGR-BIOMED, V432, P1, DOI 10.1016/S0378-4347(00)80627-1; Scheller U, 1996, ARCH BIOCHEM BIOPHYS, V328, P245, DOI 10.1006/abbi.1996.0170; SOBOTKA PA, 1994, J HEART LUNG TRANSPL, V13, P224; WEITZ ZW, 1991, LANCET, V337, P933, DOI 10.1016/0140-6736(91)91569-G	30	689	732	10	314	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 5	1999	353	9168					1930	1933		10.1016/S0140-6736(98)07552-7	http://dx.doi.org/10.1016/S0140-6736(98)07552-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371572				2022-12-01	WOS:000080668500013
J	Soulsby, CT; Morgan, MY				Soulsby, CT; Morgan, MY			Dietary management of hepatic encephalopathy in cirrhotic patients: survey of current practice in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							LIVER-DISEASE; NUTRITION		Univ London Royal Free Hosp, Sch Med, Dept Med, London NW3 2QG, England; Royal Free Hosp, Dept Nutr & Dietet, London NW3 2QG, England	University of London; University College London; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Morgan, MY (corresponding author), Univ London Royal Free Hosp, Sch Med, Dept Med, London NW3 2QG, England.		Morgan, Marsha Y/C-5909-2009					KEARNS PJ, 1992, GASTROENTEROLOGY, V102, P200, DOI 10.1016/0016-5085(92)91801-A; MORGAN TR, 1995, J AM COLL NUTR, V14, P152; NIELSEN K, 1995, BRIT J NUTR, V74, P557, DOI 10.1079/BJN19950158; PHILLIPS GB, 1952, NEW ENGL J MED, V247, P239, DOI 10.1056/NEJM195208142470703; Plauth M, 1997, CLIN NUTR, V16, P43, DOI 10.1016/S0261-5614(97)80022-2	5	35	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1391	1391		10.1136/bmj.318.7195.1391	http://dx.doi.org/10.1136/bmj.318.7195.1391			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334749	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000080524700028
J	Zhang, B; Salituro, G; Szalkowski, D; Li, ZH; Zhang, Y; Royo, I; Vilella, D; Diez, MT; Pelaez, F; Ruby, C; Kendall, RL; Mao, XZ; Griffin, P; Calaycay, J; Zierath, JR; Heck, JV; Smith, RG; Moller, DE				Zhang, B; Salituro, G; Szalkowski, D; Li, ZH; Zhang, Y; Royo, I; Vilella, D; Diez, MT; Pelaez, F; Ruby, C; Kendall, RL; Mao, XZ; Griffin, P; Calaycay, J; Zierath, JR; Heck, JV; Smith, RG; Moller, DE			Discovery of a small molecule insulin mimetic with antidiabetic activity in mice	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; HAMSTER OVARY CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; CRYSTAL-STRUCTURE; OBESE SUBJECTS; PROTEIN; EXPRESSION; SUBSTRATE	Insulin elicits a spectrum of biological responses by binding to its cell surface receptor. In a screen for small molecules that activate the human insulin receptor tyrosine kinase, a nonpeptidyl fungal metabolite (L-783,281) was identified that acted as an insulin mimetic in several biochemical and cellular assays. The compound was selective for insulin receptor versus insulin-like growth factor I (IGFI) receptor and other receptor tyrosine kinases. Oral administration of L-783,281 to two mouse models of diabetes resulted in significant Lowering in blood glucose Levels. These results demonstrate the feasibility of discovering novel insulin receptor activators that may Lead to new therapies for diabetes.	Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Nat Prod Drug Discovery, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Divers & Design, Rahway, NJ 07065 USA; Merck Sharp & Dohme Espana, Ctr Invest Basica, Madrid 28027, Spain; Merck Res Labs, Dept Canc Res, W Point, PA 19486 USA; Karolinska Inst, Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Karolinska Institutet; Karolinska University Hospital	Zhang, B (corresponding author), Merck Res Labs, Dept Mol Endocrinol, R80W250,POB 2000, Rahway, NJ 07065 USA.		Pelaez, Fernando/K-1790-2014	Pelaez, Fernando/0000-0002-4861-586X; Zierath, Juleen/0000-0001-6891-7497				CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAHN BB, 1988, J CLIN INVEST, V82, P691, DOI 10.1172/JCI113649; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; ROSEN OM, 1989, DIABETES, V38, P1508, DOI 10.2337/diabetes.38.12.1508; Seely B.L., 1994, INSULIN RESISTANCE, P187; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WHITE MF, 1994, INSULIN RESISTANCE, P9; ZHANG B, 1994, J BIOL CHEM, V269, P25735; ZHANG B, 1992, J BIOL CHEM, V267, P18320; Zhang B., UNPUB	23	372	409	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					974	977		10.1126/science.284.5416.974	http://dx.doi.org/10.1126/science.284.5416.974			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320380				2022-12-01	WOS:000080198800049
J	Rice, G; Anderson, C; Risch, N; Ebers, G				Rice, G; Anderson, C; Risch, N; Ebers, G			Male homosexuality: Absence of linkage to microsatellite markers at Xq28	SCIENCE			English	Article							MALE SEXUAL ORIENTATION; CHROMOSOME	Several lines of evidence have implicated genetic factors in homosexuality. The most compelling observation has been the report of genetic linkage of male homosexuality to microsatellite markers on the X chromosome. This observation warranted further study and confirmation. Sharing of alleles at position Xq28 was studied in 52 gay male sibling pairs from Canadian families. Four markers at Xq28 were analyzed (DXS1113, BGN, Factor 8, and DXS1108). Allele and haplotype sharing for these markers was not increased over expectation. These results do not support an X-linked gene underlying male homosexuality.	Univ Western Ontario, Dept Clin Neurol Sci, London, ON N6A 5A5, Canada; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Western University (University of Western Ontario); Stanford University	Rice, G (corresponding author), Univ Western Ontario, Dept Clin Neurol Sci, 339 Windermere Rd, London, ON N6A 5A5, Canada.			Ebers, George/0000-0003-4771-4177				BAILEY JM, 1993, ARCH GEN PSYCHIAT, V50, P217; BAILEY JM, 1991, ARCH GEN PSYCHIAT, V48, P1089; BARON M, 1993, BRIT MED J, V307, P337, DOI 10.1136/bmj.307.6900.337; BARON M, 1993, BIOL PSYCHIAT, V33, P759, DOI 10.1016/0006-3223(93)90016-7; BYNE W, 1993, ARCH GEN PSYCHIAT, V50, P228; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; Hauser ER, 1996, GENET EPIDEMIOL, V13, P117, DOI 10.1002/(SICI)1098-2272(1996)13:2<117::AID-GEPI1>3.0.CO;2-5; HINDS D, COMMUNICATION; HU S, 1995, NAT GENET, V11, P248, DOI 10.1038/ng1195-248; PILLARD RC, 1986, ARCH GEN PSYCHIAT, V43, P808; PILLARD RC, 1981, ARCH SEX BEHAV, V10, P465, DOI 10.1007/BF01541437; RISCH N, 1993, SCIENCE, V262, P2063, DOI 10.1126/science.8266107	13	137	144	4	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					665	667		10.1126/science.284.5414.665	http://dx.doi.org/10.1126/science.284.5414.665			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213693				2022-12-01	WOS:000079951100051
J	McGrath, JA				McGrath, JA			Dyskeratosis congenita: new clinical and molecular insights into ribosome function	LANCET			English	Editorial Material							INACTIVATION; CARRIERS		Guys Hosp, St Johns Inst Dermatol, Dept Cell & Mol Pathol, London SE1 7EH, England; Univ London Kings Coll Hosp, London SE1 7EH, England; St Thomas Hosp, Sch Med, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	McGrath, JA (corresponding author), Guys Hosp, St Johns Inst Dermatol, Dept Cell & Mol Pathol, London SE1 7EH, England.		McGrath, John/N-3529-2019; McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964				Devriendt K, 1997, AM J HUM GENET, V60, P581; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Knight S, 1998, BRIT J HAEMATOL, V103, P990, DOI 10.1046/j.1365-2141.1998.01103.x; Luzzatto L, 1998, NAT GENET, V19, P6, DOI 10.1038/ng0598-6; Vulliamy TJ, 1997, BLOOD, V90, P2213; Zinsser F, 1906, IKONOGR DERMATOL HYO, V5, P219	6	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1204	1205		10.1016/S0140-6736(99)00011-2	http://dx.doi.org/10.1016/S0140-6736(99)00011-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217077				2022-12-01	WOS:000079744100005
J	Golombek, MP				Golombek, MP			Martian climate - A message from warmer times	SCIENCE			English	Editorial Material							IMPACT CRATERS; LANDING SITE; MARS; DEGRADATION; MORPHOLOGY; RATES		CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Golombek, MP (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	mgolombek@jpl.nasa.gov						[Anonymous], 1992, LUNAR PLANETARY SCI; ARVIDSON R, 1979, NATURE, V278, P533, DOI 10.1038/278533a0; BAKER VR, 1986, J GEOPHYS RES-SOLID, V91, P3561, DOI 10.1029/JB091iB03p03561; BARLOW NG, 1995, J GEOPHYS RES-PLANET, V100, P23307, DOI 10.1029/95JE02492; BREED CS, 1979, J GEOPHYS RES, V84, P8183, DOI 10.1029/JB084iB14p08183; BRIDGES NT, IN PRESS J GEOPHYS R; Carr M.H, 1996, WATER MARS; Christensen P., 1992, MARS SPACE SCI SERIE, P686; Craddock RA, 1997, J GEOPHYS RES-PLANET, V102, P13321, DOI 10.1029/97JE01084; Golombek MP, 1997, SCIENCE, V278, P1743, DOI 10.1126/science.278.5344.1743; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; GOLOMBEK MP, IN PRESS J GEOPHYS R; GRANT JA, 1993, J GEOPHYS RES-PLANET, V98, P11025, DOI 10.1029/93JE00121; GREELEY R, IN PRESS J GEOPHYS R; Greeley R., 1992, MARS, P730; Hartmann W.K., 1981, BASALTIC VOLCANISM T, P1049; HVILD SF, 1997, SCIENCE, V278, P1768; JUDSON S, 1964, J GEOPHYS RES, V69, P3395, DOI 10.1029/JZ069i016p03395; KRINSLEY DH, 1972, AM SCI, V60, P286; KUENEN PH, 1960, SCI AM, V202, P94; LANDIS GA, 1998, EOS, V79, pF549; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; Matijevic JR, 1997, SCIENCE, V278, P1765, DOI 10.1126/science.278.5344.1765; NEUKUM G, 1976, SCIENCE, V194, P1381, DOI 10.1126/science.194.4272.1381; PARKER TJ, 1993, J GEOPHYS RES-PLANET, V98, P11061, DOI 10.1029/93JE00618; Pettijohn F. J, 1987, SAND SANDSTONE; PIKE RJ, 1984, LUNAR PLANET SCI, V15, P645; SAUNDERS I, 1983, EARTH SURF PROC LAND, V8, P473, DOI 10.1002/esp.3290080508; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; TANAKA KL, 1986, J GEOPHYS RES-SOLID, V91, pE139, DOI 10.1029/JB091iB13p0E139	30	14	14	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 5	1999	283	5407					1470	1471		10.1126/science.283.5407.1470	http://dx.doi.org/10.1126/science.283.5407.1470			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10206878				2022-12-01	WOS:000078959200031
J	Shapiro, MF; Morton, SC; McCaffrey, DF; Senterfitt, JW; Fleishman, JA; Perlman, JF; Athey, LA; Keesey, JW; Goldman, DP; Berry, SH; Bozzette, SA				Shapiro, MF; Morton, SC; McCaffrey, DF; Senterfitt, JW; Fleishman, JA; Perlman, JF; Athey, LA; Keesey, JW; Goldman, DP; Berry, SH; Bozzette, SA		HCSUS Consortium	Variations in the care of HIV-infected adults in the United States - Results from the HIV Cost and Services Utilization Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIRETROVIRAL THERAPY; MANAGED CARE; DRUG-USE; DISEASE; GROWTH; RECOMMENDATIONS; LESSONS; PANEL; RACE	Context Studies of selected populations suggest that not all persons infected with human immunodeficiency virus (HIV) receive adequate care. Objective To examine variations in the care received by a national sample representative of the adult US population infected with HIV. Design Cohort study that consisted of 3 interviews from January 1996 to January 1998 conducted by the HIV Cost and Services Utilization Consortium. Patients and Setting Multistage probability sample of 2864 respondents (68% of those targeted for sampling), who represent the 231 400 persons at least 18 years old, with known HIV infection receiving medical care in the 48 contiguous United States in early 1996 in facilities other than emergency departments, the military, or prisons. The first follow-up consisted of 2466 respondents and the second had 2267 (65% of all surviving sampled subjects). Main Outcome Measures Service utilization (<2 ambulatory visits, at least 1 emergency department visit that did not lead to hospitalization, at least 1 hospitalization) and medication utilization (receipt of antiretroviral therapy and prophylaxis against Pneumocystis carinii pneumonia), Results Inadequate HIV care was commonly reported at the time of interviews conducted from early 1996 to early 1997 but declined to varying degrees by late 1997, Twenty-three percent of patients initially and 15% of patients subsequently had emergency department visits that did not lead to hospitalization, 30% initially and 26% subsequently of those who had CD4 cell counts below 0.20 x 10(9)/L did not receive P carinii pneumonia prophylaxis, and 41% initially and 15% subsequently of those who had CD4 cell counts below 0.50 x 10(9)/L did not receive antiretroviral therapy (protease inhibitor or nonnucleoside reverse transcriptase inhibitor). Inferior patterns of care were seen far many of these measures in blacks and Latinos compared with whites, the uninsured and Medicaid-insured compared with the privately insured, women compared with men, and other risk and/or exposure groups compared with men who had sex with men even after CD4 cell count adjustment. With multivariate adjustment, many differences remained statistically significant. Even by early 1998, fewer blacks, women, and uninsured and Medicaid-insured persons had started taking antiretroviral medication (CD4 cell count adjusted P Values <.001 to <.005). Conclusions Access to care improved from 1996 to 1998 but remained suboptimal. Blacks, Latinos, women, the uninsured, and Medicaid-insured all had less desirable patterns of care. Strategies to ensure optimal care for patients with HIV requires identifying the causes of deficiency and addressing these important shortcomings in care.	Rand Corp, HCSUS Off, Hlth Program, Santa Monica, CA 90407 USA; Rand Corp, Survey Res Grp, Santa Monica, CA 90407 USA; Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA; Cty Los Angeles, AIDS Off, Los Angeles, CA USA; Agcy Hlth Care Policy & Res, Ctr Cost & Financing Studies, Rockville, MD 20852 USA; Univ Chicago, Natl Opin Res Ctr, Survey Operat Ctr, Chicago, IL 60637 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, Hlth Serv Res & Dev Unit, San Diego, CA USA	RAND Corporation; RAND Corporation; University of California System; University of California Los Angeles; Agency for Healthcare Research & Quality; University of Chicago; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Shapiro, MF (corresponding author), Rand Corp, HCSUS Off, Hlth Program, 1700 Main St, Santa Monica, CA 90407 USA.		Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396				BERRY SH, 1988, MR1090AHCPR RAND; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Brick J M, 1996, Stat Methods Med Res, V5, P215, DOI 10.1177/096228029600500302; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; Cunningham WE, 1997, J CLIN EPIDEMIOL, V50, P829, DOI 10.1016/S0895-4356(97)00061-9; DUAN N, 1998, MR1060AHCPR RAND; FLEISHMAN JA, 1994, HEALTH SERV RES, V29, P527; FRANKEL MR, IN PRESS HLTH SERV R; Gold M, 1996, HEALTH AFFAIR, V15, P153, DOI 10.1377/hlthaff.15.3.153; GRAVES EJ, 1997, VITAL HLTH STAT 13, V128, P1; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; Kish L, 1965, SURVEY SAMPLING; Lam NSN, 1996, PROF GEOGR, V48, P321, DOI 10.1111/j.0033-0124.1996.00321.x; MILLER RH, 1994, ANNU REV PUBL HEALTH, V15, P437; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Niemcryk SJ, 1998, J COMMUN HEALTH, V23, P137, DOI 10.1023/A:1018713524788; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; SHALALA D, 1998, BRIEFING PRESS ELIMI; SHAPIRO MF, IN PRESS HLTH SERV R; SIRKEN MG, 1970, J AM STAT ASSOC, V65, P257, DOI 10.2307/2283590; Stone VE, 1997, J GEN INTERN MED, V12, P150, DOI 10.1046/j.1525-1497.1997.012003150.x; Welch WP, 1996, HEALTH AFFAIR, V15, P201, DOI 10.1377/hlthaff.15.3.201	24	594	599	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2305	2315		10.1001/jama.281.24.2305	http://dx.doi.org/10.1001/jama.281.24.2305			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	207FN	10386555	Bronze			2022-12-01	WOS:000080925600030
J	Ascherio, A; Katan, MB; Zock, PL; Stampfer, MJ; Willett, WC				Ascherio, A; Katan, MB; Zock, PL; Stampfer, MJ; Willett, WC			Trans fatty acids and coronary heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MYOCARDIAL-INFARCTION; PLASMA-LIPOPROTEIN; HEALTHY-SUBJECTS; UNITED-STATES; STEARIC-ACID; DIETARY-FAT; RISK; HUMANS; LIPIDS; SERUM		Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands	Harvard University; Harvard T.H. Chan School of Public Health; Wageningen University & Research	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793; Zock, Peter/0000-0002-0322-0565				ALMENDINGEN K, 1995, J LIPID RES, V36, P370; ANDERSON JT, 1961, J NUTR, V75, P388, DOI 10.1093/jn/75.4.388; ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; Aro A, 1997, AM J CLIN NUTR, V65, P1419, DOI 10.1093/ajcn/65.5.1419; Aro A, 1998, NUTR METAB CARDIOVAS, V8, P402; ASCHERIO A, 1994, CIRCULATION, V89, P94, DOI 10.1161/01.CIR.89.1.94; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; BoltonSmith C, 1996, EUR HEART J, V17, P837; Clevidence BA, 1997, ARTERIOSCL THROM VAS, V17, P1657, DOI 10.1161/01.ATV.17.9.1657; *EXP PAN T FATT AC, 1995, AM J CLIN NUTR, V62, pS655; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; HUNTER JE, 1991, AM J CLIN NUTR, V54, P363, DOI 10.1093/ajcn/54.2.363; Judd J, 1998, FASEB J, V12, pA229; JUDD JT, 1994, AM J CLIN NUTR, V59, P861, DOI 10.1093/ajcn/59.4.861; KATAN MB, 1995, LANCET, V346, P1245, DOI 10.1016/S0140-6736(95)91858-2; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI 10.1146/annurev.nutr.15.1.473; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KROMHOUT D, 1995, PREV MED, V24, P308, DOI 10.1006/pmed.1995.1049; Lichtenstein AH, 1999, NEW ENGL J MED, V340, P1933, DOI 10.1056/NEJM199906243402501; LICHTENSTEIN AH, 1993, ARTERIOSCLER THROMB, V13, P154, DOI 10.1161/01.ATV.13.2.154; LITIN L, 1993, NEW ENGL J MED, V329, P1969, DOI 10.1056/NEJM199312233292620; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, J LIPID RES, V33, P1493; NESTEL P, 1992, J LIPID RES, V33, P1029; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; Sundram K, 1997, J NUTR, V127, pS514, DOI 10.1093/jn/127.3.514S; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; Zock PL, 1997, ATHEROSCLEROSIS, V131, P7, DOI 10.1016/S0021-9150(96)06063-7; ZOCK PL, 1992, J LIPID RES, V33, P399	31	351	379	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1994	1998		10.1056/NEJM199906243402511	http://dx.doi.org/10.1056/NEJM199906243402511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210CX	10379026				2022-12-01	WOS:000081088500011
J	Zoller, H; Pietrangelo, A; Vogel, W; Weiss, G				Zoller, H; Pietrangelo, A; Vogel, W; Weiss, G			Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis	LANCET			English	Article							TRANSFERRIN RECEPTOR; NUCLEOTIDE-SEQUENCE; IRON-METABOLISM; HEMOCHROMATOSIS; GENE; MICE; HFE	Background Although the gene for hereditary haemochromatosis has been cloned, the mechanism by which iron uptake is inappropriately increased in this disorder is unclear. Iron absorption is regulated by the duodenal metal transporter, DMT-1, also called NRAMP-2. We investigated the expression of NRAMP-2 in patients with hereditary haemochromatosis. Methods Duodenal biopsy samples were taken from 20 patients with haemochromatosis homozygous for the C282Y mutation and from ten controls. NRAMP-2 expression was assessed by northern blotting and competitive PCR, NRAMP-2 mRNA was sequenced in seven patients and two controls. Findings Duodenal NRAMP-2 mRNA concentrations were increased in patients as estimated by Northern blotting. Accordingly, competitive PCR showed significantly higher NRAMP-2 cDNA concentrations in patients than in controls (mean 3.43 [SD 0.61] vs 1.11 [0.74] log ng competitorx10(4); p<0.001). No mutations were found within the NRAMP-2 mRNA. Duodenal NRAMP-2 mRNA expression was correlated with serum ferritin in controls (r=-0.94, p=0.001) but not in patients (r=-0.18, p=0.8). Interpretation Increased NRAMP-2 mRNA expression in duodenal mucosa of patients with hereditary haemochromatosis may promote duodenal iron uptake and lead to iron overload.	Univ Innsbruck Hosp, Dept Internal Med, A-6020 Innsbruck, Austria; Univ Modena, Dept Med, I-41100 Modena, Italy	Medical University of Innsbruck; Universita di Modena e Reggio Emilia	Weiss, G (corresponding author), Univ Innsbruck Hosp, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.	guenter.weiss@uibk.ac.at	Pietrangelo, Antonello/K-1517-2016; Zoller, Heinz/AAD-7225-2019	Pietrangelo, Antonello/0000-0002-7411-935X; Weiss, Guenter/0000-0003-0709-2158	Telethon [E.0609] Funding Source: Medline	Telethon(Fondazione Telethon)		Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60, DOI [10.1016/B978-0-12-372180-8.50012-3, DOI 10.1016/B978-0-12-372180-8.50012-3]; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kishi F, 1997, MOL IMMUNOL, V34, P839, DOI 10.1016/S0161-5890(97)00110-7; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; POWELL LW, 1994, IRON METABOLISM HLTH, P228; Rothenberg BE, 1996, P NATL ACAD SCI USA, V93, P1529, DOI 10.1073/pnas.93.4.1529; Santos M, 1996, J EXP MED, V184, P1975, DOI 10.1084/jem.184.5.1975; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	21	145	148	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2120	2123		10.1016/S0140-6736(98)11179-0	http://dx.doi.org/10.1016/S0140-6736(98)11179-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382697				2022-12-01	WOS:000080969300013
J	Quill, TE				Quill, TE			Same old seventeen-dollar lamps	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Genesee Hosp, Rochester, NY 14607 USA		Quill, TE (corresponding author), Genesee Hosp, 224 Alexander St, Rochester, NY 14607 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					1022	1024		10.7326/0003-4819-130-12-199906150-00023	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00023			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383354				2022-12-01	WOS:000080894700012
J	Vetter, IR; Arndt, A; Kutay, U; Gorlich, D; Wittinghofer, A				Vetter, IR; Arndt, A; Kutay, U; Gorlich, D; Wittinghofer, A			Structural view of the Ran-importin beta interaction at 2.3 angstrom resolution	CELL			English	Article							NUCLEAR-PROTEIN IMPORT; GTPASE-ACTIVATING PROTEIN; PORE-TARGETING COMPLEX; GDP-BOUND FORM; CRYSTAL-STRUCTURE; LOCALIZATION SIGNAL; TRANSPORT FACTORS; KARYOPHERIN-BETA; FACTOR P97; BINDING	Transport receptors of the Importin beta family shuttle between the nucleus and cytoplasm and mediate transport of macromolecules through nuclear pore complexes. They interact specifically with the GTP-binding protein Ran, which in turn regulates their interaction with cargo. Here, we report the three-dimensional structure of a complex between Ran bound to the nonhydrolyzable GTP analog GppNHp and a 462-residue fragment from Importin beta. The structure of Importin beta shows 10 tandem repeats resembling HEAT and Armadillo motifs. They form an irregular crescent, the concave site of which forms the interface with Ran-triphosphate. The importin-binding site of Ran does not overlap with that of the Ran-binding domain of RanBP2.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Max Planck Society; Ruprecht Karls University Heidelberg	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	wittinghofer@mpi-dortmund.mpg.de	Görlich, Dirk/B-8296-2017	Görlich, Dirk/0000-0002-4343-5210				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Chi NC, 1996, J CELL BIOL, V135, P559, DOI 10.1083/jcb.135.3.559; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; HILLIG R, 1999, IN PRESS MOL CELL; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; IMAMOTO N, 1995, FEBS LETT, V368, P415; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; JAKEL S, 1999, IN PRESS EMBO J; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; VETTER IR, 1999, IN PRESS FEBS LETT; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x	73	278	281	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	1999	97	5					635	646		10.1016/S0092-8674(00)80774-6	http://dx.doi.org/10.1016/S0092-8674(00)80774-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367892	Bronze			2022-12-01	WOS:000080672100012
J	Binder, S; Levitt, AM; Sacks, JJ; Hughes, JM				Binder, S; Levitt, AM; Sacks, JJ; Hughes, JM			Emerging infectious diseases: Public health issues for the 21st century	SCIENCE			English	Editorial Material							VACCINE; SURVEILLANCE; BIOSENSOR; INFLUENZA	Infectious diseases are the third leading cause of death in the United States and the Leading cause worldwide. As the new millennium approaches, the public health community must replenish capacity depleted during years of inadequate funding while simultaneously incorporating new technologies and planning for the Longer term. Among the challenges facing the public health community is the need for coordinated, global, multisectoral approaches to preventing and controlling complex infectious disease problems.	Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Off Director, Natl Ctr Infect Dis, Brooklyn, NY 11215 USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Binder, S (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, F-22,4770 Buford Highway NE, Atlanta, GA 30341 USA.	scb1@cdc.gov						AACH RD, 1980, ANN INTERN MED, V92, P539, DOI 10.7326/0003-4819-92-4-539; [Anonymous], PREV EM INF DIS STRA; Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; Arntzen CJ, 1997, PUBLIC HEALTH REP, V112, P190; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; Bauchner H, 1999, PEDIATRICS, V103, P395, DOI 10.1542/peds.103.2.395; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Busch DF, 1997, CLIN INFECT DIS, V25, P34, DOI 10.1086/514511; CDC, 1997, MMWR-MORBID MORTAL W, V46, P741; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P777; *CDC, 1999, MMWR-MORBID MORTAL W, V48, P285; *CDC, 1997, TRANSL ADV HUM GEN P; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V46, P1245; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P665; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1085; *COMM INT SCI ENG, 1995, INF DIS GLOB HLTH TH; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Corrier DE, 1999, SALMONELLA ENTERICA SEROVAR ENTERITIDIS IN HUMANS AND ANIMALS: EPIDEMIOLOGY, PATHOGENESIS AND CONTROL, P391; Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271; FRICKE W, 1992, TRANSFUSION, V32, P707, DOI 10.1046/j.1537-2995.1992.32893032095.x; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; Institute of Medicine, 1997, AM VIT INT GLOB HLTH; Institute of Medicine, 1992, EM INF MICR THREATS; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; McNicholl JM, 1999, AM J PREV MED, V16, P141, DOI 10.1016/S0749-3797(98)00143-3; MOFFAT AS, 1995, SCIENCE, V268, P658, DOI 10.1126/science.7732373; Ostroff SM, 1998, INFECT DIS CLIN N AM, V12, P231, DOI 10.1016/S0891-5520(05)70420-7; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Poste G, 1998, Nat Biotechnol, V16 Suppl, P19, DOI 10.1038/5403; Reichman LB, 1996, LANCET, V347, P175, DOI 10.1016/S0140-6736(96)90348-7; Relman DA, 1999, SCIENCE, V284, P1308, DOI 10.1126/science.284.5418.1308; Robinson HL, 1997, VACCINE, V15, P785, DOI 10.1016/S0264-410X(96)00249-6; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Snow RW, 1999, PARASITOL TODAY, V15, P99, DOI 10.1016/S0169-4758(99)01395-2; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Talan DA, 1998, ANN EMERG MED, V32, P703, DOI 10.1016/S0196-0644(98)70071-X; Troesch A, 1999, J CLIN MICROBIOL, V37, P49, DOI 10.1128/JCM.37.1.49-55.1999; Turner APF, 1997, NATURE, V387, P555, DOI 10.1038/42365; Webster RG, 1998, EMERG INFECT DIS, V4, P436, DOI 10.3201/eid0403.980325; Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996; World Health Organization, 1996, WORLD HLTH REP; Ziegler C, 1998, CURR OPIN CHEM BIOL, V2, P585, DOI 10.1016/S1367-5931(98)80087-2	45	178	197	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1311	1313		10.1126/science.284.5418.1311	http://dx.doi.org/10.1126/science.284.5418.1311			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334978				2022-12-01	WOS:000080430600041
J	Fan, S; Wang, JA; Yuan, R; Ma, Y; Meng, Q; Erdos, MR; Pestell, RG; Yuan, F; Auborn, KJ; Goldberg, ID; Rosen, EM				Fan, S; Wang, JA; Yuan, R; Ma, Y; Meng, Q; Erdos, MR; Pestell, RG; Yuan, F; Auborn, KJ; Goldberg, ID; Rosen, EM			BRCA1 inhibition of estrogen receptor signaling in transfected cells	SCIENCE			English	Article							TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; DNA-DAMAGE; GENE BRCA1; PROLIFERATION; CANCER; DIFFERENTIATION; EXPRESSION; BREAST	Mutations of the breast cancer susceptibility gene BRCA1 confer increased risk for breast, ovarian, and prostatic cancers, but it is not clear why the mutations are associated with these particular tumor types. In transient transfection assays, BRCA1 was found to inhibit signaling by the Ligand-activated estrogen receptor (ER-alpha) through the estrogen-responsive enhancer element and to block the transcriptional activation function AF-2 of ER-alpha. These results raise the possibility that wild-type BRCA1 suppresses estrogen-dependent transcriptional pathways related to mammary epithelial cell proliferation and that Loss of this ability contributes to tumorigenesis.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Otolaryngol, New Hyde Park, NY 11040 USA; N Shore Univ Hosp, NSUH LIJ Hlth Syst, Dept Radiat Oncol, Manhasset, NY 11030 USA; NIH, Genet & Mol Biol Branch, Natl Human Genome Res Inst, Bethesda, MD 20892 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; Northwell Health; North Shore University Hospital; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Fan, S (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.				NATIONAL CANCER INSTITUTE [R01CA075503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA75503] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Ferguson AT, 1997, CRIT REV ONCOGENESIS, V8, P29, DOI 10.1615/CritRevOncog.v8.i1.20; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STREUWING JP, 1997, NEW ENGL J MED, V336, P1401; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212	22	390	421	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1354	1356		10.1126/science.284.5418.1354	http://dx.doi.org/10.1126/science.284.5418.1354			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334989				2022-12-01	WOS:000080430600052
J	Wang, RF; Wang, X; Atwood, AC; Topalian, SL; Rosenberg, SA				Wang, RF; Wang, X; Atwood, AC; Topalian, SL; Rosenberg, SA			Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen	SCIENCE			English	Article							T-CELL RESPONSES; HLA-DM; INFILTRATING LYMPHOCYTES; HUMAN-MELANOMA; HUMAN HOMOLOG; BETA-CATENIN; KAPPA-B; IDENTIFICATION; PROTEINS; COMPLEX	In an effort to identify tumor-specific antigens recognized by CD4(+) T cells, an approach was developed that allows the screening of an invariant chain-complementary DNA fusion library in a genetically engineered cell line expressing the essential components of the major histocompatibility complex (MHC) class II processing and presentation pathway. This Led to the identification of a mutated form of human CDC27, which gave rise to an HLA-DR4-restricted melanoma antigen, A mutated form of triosephosphate isomerase, isolated by a biochemical method, was also identified as an HLA-DR1-restricted antigen. Thus, this approach may be generally applicable to the identification of antigens recognized by CD4(+) T cells, which could aid the development of strategies for the treatment of patients with cancer, autoimmune diseases, or infectious diseases.	NCI, Surg Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, RF (corresponding author), NCI, Surg Branch, NIH, Bldg 10-2B42,9000 Rockville Pike, Bethesda, MD 20892 USA.				DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006664] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bona CA, 1998, IMMUNOL TODAY, V19, P126, DOI 10.1016/S0167-5699(97)01218-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CLAUSER KR, 1995, P NATL ACAD SCI USA, V92, P5072, DOI 10.1073/pnas.92.11.5072; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Halder T, 1997, CANCER RES, V57, P3238; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ji H, 1997, ELECTROPHORESIS, V18, P605, DOI 10.1002/elps.1150180344; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; MONACH PA, 1995, IMMUNITY, V2, P45, DOI 10.1016/1074-7613(95)90078-0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; Nakano N, 1997, SCIENCE, V275, P678, DOI 10.1126/science.275.5300.678; O'Garra A, 1997, CURR OPIN IMMUNOL, V9, P872, DOI 10.1016/S0952-7915(97)80192-6; OSTRANDROSENBERG S, 1994, CURR OPIN IMMUNOL, V6, P722, DOI 10.1016/0952-7915(94)90075-2; Pardoll DM, 1998, CURR OPIN IMMUNOL, V10, P588, DOI 10.1016/S0952-7915(98)80228-8; Pieper R, 1999, J EXP MED, V189, P757, DOI 10.1084/jem.189.5.757; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; ROCHE PA, 1995, IMMUNITY, V3, P259, DOI 10.1016/1074-7613(95)90111-6; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SANDERSON S, 1995, P NATL ACAD SCI USA, V92, P7217, DOI 10.1073/pnas.92.16.7217; Southwood S, 1998, J IMMUNOL, V160, P3363; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; Topalian SL, 1996, J EXP MED, V183, P1965, DOI 10.1084/jem.183.5.1965; TOPALIAN SL, 1994, P NATL ACAD SCI USA, V91, P9461, DOI 10.1073/pnas.91.20.9461; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wang R., UNPUB; WANG RF, 1995, J EXP MED, V181, P799, DOI 10.1084/jem.181.2.799; Wang RF, 1996, J EXP MED, V184, P2207, DOI 10.1084/jem.184.6.2207; Wang RF, 1998, J IMMUNOL, V161, P3596; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	47	233	266	2	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1351	1354		10.1126/science.284.5418.1351	http://dx.doi.org/10.1126/science.284.5418.1351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334988				2022-12-01	WOS:000080430600051
J	Rodriguez-Esteban, C; Tsukui, T; Yonei, S; Magallon, J; Tamura, K; Belmonte, JCI				Rodriguez-Esteban, C; Tsukui, T; Yonei, S; Magallon, J; Tamura, K; Belmonte, JCI			The T-box genes Tbx4 and Tbx5 regulate limb outgrowth and identity	NATURE			English	Article							PROGRAMMED CELL-DEATH; VERTEBRATE LIMB; CHICK LIMB; BRACHYURY; SPECIFICATION; MESODERM; BMP-2; SHAPE; FGF	During embryonic development, initially similar fields can develop into distinct structures, such as the vertebrate fore- and hindlimbs, Although considerable progress has been made in our understanding of the genetic control underlying the establishment of the different Limb axes(1-3), the molecular cues that specify the differential development of the fore- and hindlimbs are unknown. Possible candidates for genes determining limb identity are PitxI, a gene whose transcripts are detected in the early hind- but not forelimb bud, and two members of the T-box (Tbx) gene family, Tbx4 and Tbx5, which are specifically expressed in the hindlimb and forelimb buds, respectively(4-6). Here we show that Tbx4 and Tbx5 are essential regulators of limb outgrowth whose roles seem to be tightly linked to the activity of three signalling proteins that are required for limb outgrowth and patterning: fibroblast growth factor (FGF), bone morphogenetic protein (BMP) and Wnt. In addition, we provide evidence that Tbx4 and Tbx5 are involved in controlling limb identity. Our findings provide insight into how similar developmental fields can evolve into homologous but distinct structures.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Salk Institute	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu						Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Hadorn E., 1978, P556; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Isaac A, 1998, DEVELOPMENT, V125, P1867; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Li QY, 1997, NAT GENET, V15, P21; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Logan M, 1998, DEVELOPMENT, V125, P2825; Macias D, 1997, DEVELOPMENT, V124, P1109; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MAVES L, 1995, DEVELOPMENT, V121, P1263; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Ohuchi H, 1998, DEVELOPMENT, V125, P51; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; Schwabe JWR, 1998, TRENDS GENET, V14, P229, DOI 10.1016/S0168-9525(98)01477-2; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Smith JC, 1997, COLD SPRING HARB SYM, V62, P337; STEPHENS TD, 1989, DEV BIOL, V133, P1, DOI 10.1016/0012-1606(89)90290-X; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	30	225	232	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					814	818		10.1038/19769	http://dx.doi.org/10.1038/19769			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235264				2022-12-01	WOS:000080058100060
J	Yang, A; Schweitzer, R; Sun, DQ; Kaghad, M; Walker, N; Bronson, RT; Tabin, C; Sharpe, A; Caput, D; Crum, C; McKeon, F				Yang, A; Schweitzer, R; Sun, DQ; Kaghad, M; Walker, N; Bronson, RT; Tabin, C; Sharpe, A; Caput, D; Crum, C; McKeon, F			p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development	NATURE			English	Article							VERTEBRATE LIMB; P53 HOMOLOG; MICE; DIFFERENTIATION; KERATINOCYTE; INVOLVEMENT; EXPRESSION; INITIATION; INDUCTION; CELLS	The p63 gene, a homologue of the tumour-suppressor p53 (refs 1-5), is highly expressed in the basal or progenitor layers of many epithelial tissues(1). Here we report that mice homozygous for a disrupted p63 gene have major defects in their limb, craniofacial and epithelial development. p63 is expressed in the ectodermal surfaces of the limb buds, branchial arches and epidermal appendages, which are all sites of reciprocal signalling that direct morphogenetic patterning of the underlying mesoderm. The limb truncations are due to a failure to maintain the apical ectodermal ridge, a stratified epithelium, essential for Limb development The embryonic epidermis of p63(-/-) mice undergoes an unusual process of non-regenerative differentiation, culminating in a striking absence of all squamous epithelia and their derivatives, including mammary, lacrymal and salivary glands. Taken together, our results indicate that p63 is critical for maintaining the progenitor-cell populations that are necessary to sustain epithelial development and morphogenesis.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Immunol Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; Sanofi Biorech, F-31676 Labege, France; Tufts Univ, Sch Vet Med, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Dept Pathol, Boston, MA 02111 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Sanofi-Aventis; Sanofi France; Tufts University; United States Department of Agriculture (USDA); Tufts University	McKeon, F (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Schweitzer, Ronen/AAY-2127-2020	Schweitzer, Ronen/0000-0002-7425-5028				Augustin M, 1998, MAMM GENOME, V9, P899, DOI 10.1007/s003359900891; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1993, DEV BIOL, V4, P209; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Francis-West P, 1998, MECH DEVELOP, V75, P3, DOI 10.1016/S0925-4773(98)00082-3; GREER J, 1991, J INVEST DERMATOL, V96, P553; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KELLEY RO, 1976, DEV BIOL, V51, P241, DOI 10.1016/0012-1606(76)90141-X; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Loomis CA, 1998, DEVELOPMENT, V125, P1137; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PELLEGRINI G, IN PRESS J CELL BIOL; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; ROBERTS AJ, 1991, J SWIM RES, V7, P5; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Vogel A, 1996, DEVELOPMENT, V122, P1737; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; WATT FM, 1991, PHIL T R SOC LOND B, V358, P553; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	30	1816	1882	3	80	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					714	718		10.1038/19539	http://dx.doi.org/10.1038/19539			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227294				2022-12-01	WOS:000079920100052
J	Teasdale, GM; Nicoll, JAR; Murray, G; Fiddes, M				Teasdale, GM; Nicoll, JAR; Murray, G; Fiddes, M			Association of apolipoprotein E polymorphism with outcome after head injury	LANCET			English	Article							AMYLOID PROTEIN DEPOSITION; ALZHEIMERS-DISEASE; E IMMUNOREACTIVITY; CEREBRAL-ISCHEMIA; BETA-PROTEIN; BRAIN; SURVIVAL; NEURONS; APOE; RAT	Background Variation in outcome after head injury is not fully explained by known prognostic features. Polymorphism of the apolipoprotein E gene (APOE) influences neuropathological findings in patients who die from head injuries. More people who die from head injuries than non-head-injured controls have deposits of amyloid beta-protein in the cerebral cortex, with amyloid beta-protein deposits present predominantly in patients with the APOE epsilon 4 allele. We report a prospective clinical study to test the hypothesis that patients with APOE epsilon 4 have a worse clinical outcome 6 months after head injury than those without APOE epsilon 4. Methods We studied a prospectively recruited series of patients admitted alter a head injury to a neurosurgical unit (n=93). Assessment of severity of the initial injury was by means of the Glasgow Coma Score (GCS). Outcome 6 months after injury was assessed by means of the Glasgow Outcome Scale. APOE genotypes were determined from blood samples by standard methods. Findings Detailed information on outcome was available for 89 patients. 17 (57%) of 30 patients with APOE epsilon 4 had an unfavourable outcome (dead, vegetative state, or severe disability) compared with 16 (27%) of the 59 patients without APOE epsilon 4 (p=0.006). The association remained significant when adjustment was made to control for age, GCS, and computed tomography scan findings (p=0.024). Interpretation Our findings show a significant genetic association of APOE polymorphism with outcome after head injury supporting the hypothesis of a genetically determined influence. Patients with APOE epsilon 4 are more than twice as likely as those without APOE epsilon 4 to have an unfavourable outcome 6 months after head injury. Further studies are under way to confirm and further evaluate this association.	UNIV GLASGOW,DEPT NEUROSURG,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,DEPT NEUROPATHOL,GLASGOW,LANARK,SCOTLAND; UNIV EDINBURGH,MED STAT UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Glasgow; University of Glasgow; University of Edinburgh			Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246; Murray, Gordon/0000-0001-9866-4734				ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1996, ALZHEIMER RES, V2, P37; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; KIDA E, 1995, BRAIN RES, V674, P341, DOI 10.1016/0006-8993(94)01467-V; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MARSHALL LF, 1991, J NEUROSURG, V75, pS59; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NEWMAN MF, 1995, ANN THROAC SURG, V59, P136; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; TEASDALE G, 1979, ACTA NEUROCHIR WIE S, V38, P3; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	26	534	548	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1069	1071		10.1016/S0140-6736(97)04318-3	http://dx.doi.org/10.1016/S0140-6736(97)04318-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213549				2022-12-01	WOS:A1997YA73400010
J	Crowcroft, NS; Infuso, A; Ilef, D; Le Guenno, B; Desenclos, JC; Van Loock, F; Clement, J				Crowcroft, NS; Infuso, A; Ilef, D; Le Guenno, B; Desenclos, JC; Van Loock, F; Clement, J			Risk factors for human hantavirus infection: Franco-Belgian collaborative case-control study during 1995-6 epidemic	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Sci Inst Publ Hlth Louis Pasteur, Dept Epidemiol, Infect Dis Unit, Brussels, Belgium; Reseau Natl Sante Publ, St Maurice, France; Direct Rag Affaires Sanit & Sociales Nord, Lille, France; Inst Pasteur, Ctr Natl Reference Fievres Hemorrag & Arbovirus, Paris, France; Queen Astrid Mil Hosp, Natl Reference Ctr Hantavirus Infect, Belgian Zoonosis Workgrp, B-1120 Brussels, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Queen Astrid Military Hospital	Crowcroft, NS (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England.	mcrowcro@ogks.co.uk						Clement J, 1997, EMERG INFECT DIS, V3, P205, DOI 10.3201/eid0302.970218; CLEMENT J, 1994, LANCET, V343, P114, DOI 10.1016/S0140-6736(94)90841-9; LEGUENNO B, 1994, MED MALADIES INFECT, V24, P512, DOI 10.1016/S0399-077X(05)81257-0; LeGuenno B, 1997, MED MALADIES INFECT, V27, P703, DOI 10.1016/S0399-077X(97)80179-5; VANLOOCK F, IN PRESS CLIN INFECT	5	41	44	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1737	1738		10.1136/bmj.318.7200.1737	http://dx.doi.org/10.1136/bmj.318.7200.1737			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381709	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000081216900031
J	Ohndorf, UM; Rould, MA; He, Q; Pabo, CO; Lippard, SJ				Ohndorf, UM; Rould, MA; He, Q; Pabo, CO; Lippard, SJ			Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins	NATURE			English	Article							ANTICANCER DRUG CISPLATIN; INTRASTRAND CROSS-LINK; HMG-DOMAIN; DUPLEX; BOX; ADDUCT; CRYSTAL; SRY	The anticancer activity of cis-diamminedichloroplatinum(II) (cisplatin) arises from its ability to damage DNA, with the major adducts formed being intrastrand d(GpG) and d(ApG) crosslinks(1). These-crosslinks bend and unwind the duplex, and the altered structure attracts high-mobility-group domain (HMG) and other proteins(2). This binding of HMG-domain proteins to cisplatin-modified DNA-has been postulated to mediate the antitumour properties of the drug(3,4). Many HMG-domain proteins recognize altered DNA structures such as four-way junctions and cisplatin-modified DNA(5), but until now:the molecular basis for this recognition was unknown. Here we describe mutagenesis, hydroxyl-radical footprinting and X-ray studies that elucidate the structure of a 1:1. cisplatin-modified DNA/HMG-domain complex Domain A of the structure-specific HMG-domain protein HMG1 binds to the widened minor groove of a 16-base-pair DNA duplex containing a site-specific cis-[Pt(NH3)(2){d(GpG)-N7(1),-N7(2)}] adduct, The DNA is strongly kinked at a hydrophobic notch created at the platinum-DNA crosslink and protein binding extends exclusively to the 3' side of the platinated strand. A phenylalanine residue at position 37 intercalates into a hydrophobic notch created at the platinum crosslinked d(GpG) site and binding of the domain is dramatically reduced in a mutant in which alanine is substituted for phenylalanine at this position.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balaeff A, 1998, PROTEINS, V30, P113, DOI 10.1002/(SICI)1097-0134(19980201)30:2<113::AID-PROT2>3.0.CO;2-O; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; BernersPrice SJ, 1997, EUR J BIOCHEM, V243, P782, DOI 10.1111/j.1432-1033.1997.00782.x; Broadhurst RW, 1995, BIOCHEMISTRY-US, V34, P16608, DOI 10.1021/bi00051a008; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; Dunham SU, 1998, J AM CHEM SOC, V120, P5395, DOI 10.1021/ja9742592; FALCIOLA L, 1994, NUCLEIC ACIDS RES, V22, P285, DOI 10.1093/nar/22.3.285; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; HARDING JJ, 1994, REDOX REP, V1, P34, DOI 10.1080/13510002.1994.11746953; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEPRE CA, 1990, NUCLEIC ACIDS MOL BI, P9, DOI DOI 10.1007/978-3-642-84150-7_2; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Read C., 1995, NUCL ACIDS MOL BIOL, P222; Rould MA, 1997, METHOD ENZYMOL, V276, P461, DOI 10.1016/S0076-6879(97)76072-5; SHERMAN SE, 1988, J AM CHEM SOC, V110, P7368, DOI 10.1021/ja00230a017; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Weiss MA, 1997, J BIOMOL STRUCT DYN, V15, P177, DOI 10.1080/07391102.1997.10508185; WEMER MH, 1995, CELL, V81, P705; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054; Yoshioka K, 1999, BIOCHEMISTRY-US, V38, P589, DOI 10.1021/bi981834l; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	30	504	514	1	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1999	399	6737					708	712		10.1038/21460	http://dx.doi.org/10.1038/21460			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385126				2022-12-01	WOS:000080932800066
J	Fankhauser, C; Yeh, KC; Lagarias, JC; Zhang, H; Elich, TD; Chory, J				Fankhauser, C; Yeh, KC; Lagarias, JC; Zhang, H; Elich, TD; Chory, J			PKS1, a substrate phosphorylated by phytochrome that modulates light signaling in Arabidopsis	SCIENCE			English	Article							HISTIDINE KINASE; PROTEIN-KINASES; EXPRESSION; GENE; PHOTOMORPHOGENESIS; TRANSDUCTION; PATTERNS; PATHWAY; SYSTEM; FAMILY	Plants constantly monitor their light environment in order to grow and develop optimally, in part through use of the phytochromes, which sense red/far-red Light. A phytochrome binding protein, PKS1 (phytochrome kinase substrate 1), was identified that is a substrate for Light-regulated phytochrome kinase activity in vitro, In vivo experiments suggest that PKS1 is phosphorylated in a phytochrome-dependent manner and negatively regulates phytochrome signaling. The data suggest that phytochromes signal by serine-threonine phosphorylation.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Texas Tech Univ, Dept Biol Sci, Lubbock, TX 79409 USA	Salk Institute; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California Davis; Texas Tech University System; Texas Tech University	Chory, J (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.	chory@salk.edu	Yeh, Kuo-Chen/AAG-4485-2021; Fankhauser, Christian/C-4291-2018; Lagarias, John Clark/L-3139-2013; Fankhauser, Christian/ABE-8757-2021	Yeh, Kuo-Chen/0000-0002-3791-3423; Fankhauser, Christian/0000-0003-4719-5901; Lagarias, John Clark/0000-0002-2093-0403; Fankhauser, Christian/0000-0003-4719-5901	NIGMS NIH HHS [R01GM52413] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Aukerman MJ, 1997, PLANT CELL, V9, P1317, DOI 10.1105/tpc.9.8.1317; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; Brown JM, 1998, CURR BIOL, V8, pR662, DOI 10.1016/S0960-9822(07)00417-4; Chang C, 1998, PLANT PHYSIOL, V117, P723, DOI 10.1104/pp.117.3.723; Devlin PF, 1998, PLANT CELL, V10, P1479, DOI 10.1105/tpc.10.9.1479; Elich TD, 1997, CELL, V91, P713, DOI 10.1016/S0092-8674(00)80458-4; Elich TD, 1997, PLANT CELL, V9, P2271, DOI 10.1105/tpc.9.12.2271; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Goosey L, 1997, PLANT PHYSIOL, V115, P959, DOI 10.1104/pp.115.3.959; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagarias DM, 1997, PLANT CELL, V9, P675, DOI 10.1105/tpc.9.5.675; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lapko VN, 1999, PROTEIN SCI, V8, P1032, DOI 10.1110/ps.8.5.1032; MCMICHAEL RWJ, 1991, THESIS U CALIFORNIA; Neff MM, 1998, PLANT PHYSIOL, V118, P27, DOI 10.1104/pp.118.1.27; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Sakamoto K, 1996, PLANT J, V10, P859, DOI 10.1046/j.1365-313X.1996.10050859.x; SCHNEIDERPOETSCH HAW, 1992, PHOTOCHEM PHOTOBIOL, V56, P839, DOI 10.1111/j.1751-1097.1992.tb02241.x; Shinomura T, 1996, P NATL ACAD SCI USA, V93, P8129, DOI 10.1073/pnas.93.15.8129; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; SOMERS DE, 1995, PLANT J, V7, P413, DOI 10.1046/j.1365-313X.1995.7030413.x; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Whitelam GC, 1997, PLANT CELL ENVIRON, V20, P752, DOI 10.1046/j.1365-3040.1997.d01-100.x; WONG YS, 1989, PLANT PHYSIOL, V91, P709, DOI 10.1104/pp.91.2.709; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zhang H, 1997, BBA-GENE STRUCT EXPR, V1353, P199, DOI 10.1016/S0167-4781(97)00096-1	36	305	329	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1999	284	5419					1539	1541		10.1126/science.284.5419.1539	http://dx.doi.org/10.1126/science.284.5419.1539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348744				2022-12-01	WOS:000080548100041
J	Li, DY; Sorensen, LK; Brooke, BS; Urness, LD; Davis, EC; Taylor, DG; Boak, BB; Wendel, DP				Li, DY; Sorensen, LK; Brooke, BS; Urness, LD; Davis, EC; Taylor, DG; Boak, BB; Wendel, DP			Defective angiogenesis in mice lacking endoglin	SCIENCE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; ENDOTHELIAL-CELLS; BINDING-PROTEIN; SMOOTH-MUSCLE; VASCULOGENESIS; RECEPTOR; HEMATOPOIESIS; PDGF; INVITRO	Endoglin is a transforming growth factor-beta (TCF-beta) binding protein expressed on the surface of endothelial cells. Loss-of-function mutations in the human endoglin gene ENG cause hereditary hemorrhagic telangiectasia (HHT1), a disease characterized by vascular malformations. Here it is shown that by gestational day 11.5, mice lacking endoglin die from defective vascular development. However, in contrast to mice lacking TGF-beta, vasculogenesis was unaffected. Loss of endoglin caused poor vascular smooth muscle development and arrested endothelial remodeling. These results demonstrate that endoglin is essential for angiogenesis and suggest a pathogenic mechanism for HHT1.	Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Physiol, Dallas, TX 75235 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, DY (corresponding author), Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA.		Davis, Elaine/F-3449-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003490, T35HL007744] Funding Source: NIH RePORTER; NHLBI NIH HHS [T35 HL07744-06, K08 HL03490-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; FLAMME I, 1992, DEVELOPMENT, V116, P435; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; SATO T, 1995, NATURE, V376, P7074; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SORENSEN LB, UNPUB; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; WENDEL D, UNPUB; WESTPHAL JR, 1993, J INVEST DERMATOL, V100, P27, DOI 10.1111/1523-1747.ep12349946; YAMASHITA H, 1994, J BIOL CHEM, V269, P1995; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	27	662	701	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1534	1537		10.1126/science.284.5419.1534	http://dx.doi.org/10.1126/science.284.5419.1534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348742				2022-12-01	WOS:000080548100039
J	Hachinski, V				Hachinski, V			Post-stroke depression, not to be underestimated	LANCET			English	Editorial Material									Univ Western Ontario, London Hlth Sci Ctr, Dept Neurol Sci, London, ON N6A 5A5, Canada	London Health Sciences Centre; Western University (University of Western Ontario)	Hachinski, V (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Dept Neurol Sci, London, ON N6A 5A5, Canada.							ASTROM M, 1992, STROKE, V23, P527, DOI 10.1161/01.STR.23.4.527; Enserink M, 1999, SCIENCE, V284, P238, DOI 10.1126/science.284.5412.238; EVANS RL, 1988, STROKE, V19, P1243, DOI 10.1161/01.STR.19.10.1243; Kotila M, 1998, STROKE, V29, P368, DOI 10.1161/01.STR.29.2.368; MORRIS PLP, 1992, MED J AUSTRALIA, V157, P239, DOI 10.5694/j.1326-5377.1992.tb137126.x; Palomaki H, 1999, J NEUROL NEUROSUR PS, V66, P490, DOI 10.1136/jnnp.66.4.490; SHARPE M, 1994, BRIT J PSYCHIAT, V164, P380, DOI 10.1192/bjp.164.3.380; WADE DT, 1987, BRIT J PSYCHIAT, V151, P200, DOI 10.1192/bjp.151.2.200	8	17	22	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1728	1728		10.1016/S0140-6736(99)00139-7	http://dx.doi.org/10.1016/S0140-6736(99)00139-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347982				2022-12-01	WOS:000080667700007
J	Cogoni, C; Macino, G				Cogoni, C; Macino, G			Gene silencing in Neurospora crassa requires a protein homologous to RNA-dependent RNA polymerase	NATURE			English	Article							DOUBLE-STRANDED-RNA; TRANSGENIC PLANTS; SEQUENCE; EXPRESSION; DNA; INTERFERENCE; INACTIVATION; SUPPRESSION; DEGRADATION; CLONING	In plants and fungi, the introduction of transgenes can lead to post-transcriptional gene silencing(1,2). This phenomenon, in which expression of the transgene and of endogenous genes containing sequences homologous to the transgene can be blocked, is involved in virus resistance(3-5) and genome maintenance(6,7). Transgene-induced gene silencing has been termed quelling in Neurospora crassa and co-suppression in plants. Quelling-defective (qde) mutants of N. crassa, in which transgene-induced gene silencing is impaired, have been isolated(8). Here we report the cloning of qde-1, the first cellular component of the gene-silencing mechanism to be isolated, which defines a new gene family conserved among different species including plants, animals and fungi. The qde-1 gene product is similar to an RNA-dependent RNA polymerase found in the tomato(9). The identification of qde-1 strongly supports models that implicate an RNA-dependent RNA polymerase in the post-transcriptional gene-silencing mechanism. The presence of qde-1 homologues in a variety of species of plants and fungi indicates that a conserved gene-silencing mechanism may exist, which could have evolved to preserve genome integrity and to protect the genome against naturally occurring transposons and viruses.	Univ Rome La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Sez Genet Mol, I-00161 Rome, Italy	Sapienza University Rome	Macino, G (corresponding author), Univ Rome La Sapienza, Dipt Biotecnol Cellulari & Ematol, Sez Genet Mol, Viale Regina Elena 324, I-00161 Rome, Italy.							ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; Baulcombe DC, 1996, PLANT MOL BIOL, V32, P79, DOI 10.1007/BF00039378; Bingham PM, 1997, CELL, V90, P385, DOI 10.1016/S0092-8674(00)80496-1; CABIBBO A, 1991, FUNGAL GENET NEWSL, V38, P68; Cogoni C, 1997, TRENDS PLANT SCI, V2, P438, DOI 10.1016/S1360-1385(97)90028-5; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; MANIATIS ST, 1982, MOL CLONING LAB MANU; Matzke MA, 1996, TRENDS PLANT SCI, V1, P382, DOI 10.1016/S1360-1385(96)80313-X; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; MORELLI G, 1993, METHOD ENZYMOL, V214, P412; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x; Schiebel W, 1998, PLANT CELL, V10, P2087, DOI 10.1105/tpc.10.12.2087; SCHMIDHAUSER TJ, 1990, MOL CELL BIOL, V10, P5064, DOI 10.1128/MCB.10.10.5064; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; Stam M, 1997, ANN BOT-LONDON, V79, P3, DOI 10.1006/anbo.1996.0295; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438	30	491	592	3	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	1999	399	6732					166	169		10.1038/20215	http://dx.doi.org/10.1038/20215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335848				2022-12-01	WOS:000080335700054
J	Berger, M; Muhlhauser, I				Berger, M; Muhlhauser, I			Diabetes care and patient-oriented outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTENSIFIED INSULIN THERAPY; SEVERE HYPOGLYCEMIA; TEACHING PROGRAM; BLOOD-GLUCOSE; SURVIVAL; MELLITUS; COMPLICATIONS; METAANALYSIS; HYPERTENSION; EDUCATION		Univ Dusseldorf, Dept Metab Dis & Nutr, WHO Collaborating Ctr Diabet Treatment & Prevent, D-40225 Dusseldorf, Germany; Univ Hamburg, Unit Hlth Sci & Educ, Hamburg, Germany	Heinrich Heine University Dusseldorf; University of Hamburg	Berger, M (corresponding author), Univ Dusseldorf, Dept Metab Dis & Nutr, WHO Collaborating Ctr Diabet Treatment & Prevent, Moorenstr 5, D-40225 Dusseldorf, Germany.	bergermi@uni-duesseldorf.de						Amer Diabet Assoc, 1999, DIABETES CARE, V22, pS42; [Anonymous], 1990, Diabet Med, V7, P360; [Anonymous], 1982, Diabetes, V31 Suppl 5, P1; Berger M, 1996, DIABETOLOGIA, V39, P749, DOI 10.1007/s001250050507; Berger M, 1997, DIABETOLOGIA, V40, pS91, DOI 10.1007/s001250051416; BERGER M, 1995, DIABETIC MED, V12, P201, DOI 10.1111/j.1464-5491.1995.tb00459.x; Bott S, 1997, DIABETOLOGIA, V40, P926, DOI 10.1007/s001250050769; Brunelle RL, 1998, DIABETES CARE, V21, P1726, DOI 10.2337/diacare.21.10.1726; Engler RL, 1996, CIRCULATION, V94, P2297, DOI 10.1161/01.CIR.94.9.2297; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; KOHNER EM, 1993, BRIT MED J, V307, P1195, DOI 10.1136/bmj.307.6913.1195; Kotsanos JG, 1997, DIABETES CARE, V20, P948, DOI 10.2337/diacare.20.6.948; KRONSBEIN P, 1988, LANCET, V2, P1407; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Mayfield JA, 1998, DIABETES CARE, V21, P2161, DOI 10.2337/diacare.21.12.2161; MUHLHAUSER I, 1995, J INTERN MED, V237, P591; Muhlhauser I, 1998, DIABETOLOGIA, V41, P1139, DOI 10.1007/s001250051043; MUHLHAUSER I, 1993, J INTERN MED, V233, P321; MUHLHAUSER I, 1987, DIABETOLOGIA, V30, P681, DOI 10.1007/BF00296989; Muller UA, 1999, DIABETES CARE, V22, pB29; Nathan DM, 1998, LANCET, V352, P832, DOI 10.1016/S0140-6736(98)22937-0; Pahor M, 1998, LANCET, V351, P689, DOI 10.1016/S0140-6736(05)78489-0; Parving HH, 1998, DIABETOLOGIA, V41, P745, DOI 10.1007/s001250050983; PIEBER TR, 1995, DIABETES CARE, V18, P625, DOI 10.2337/diacare.18.5.625; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Sackett D.L., 1997, EVIDENCE BASED MED P; SAWICKI PT, 1995, J HYPERTENS, V13, P933, DOI 10.1097/00004872-199508000-00015; SHAMOON H, 1995, DIABETES CARE, V18, P361; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STAROSTINA EG, 1994, DIABETOLOGIA, V37, P170, DOI 10.1007/s001250050089; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; WASSERMAN DH, 1994, DIABETES CARE, V17, P924, DOI 10.2337/diacare.17.8.924	38	51	52	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1676	1678		10.1001/jama.281.18.1676	http://dx.doi.org/10.1001/jama.281.18.1676			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328053				2022-12-01	WOS:000080161200001
J	Rachez, C; Lemon, BD; Suldan, Z; Bromleigh, V; Gamble, M; Naar, AM; Erdjument-Bromage, H; Tempst, P; Freedman, LP				Rachez, C; Lemon, BD; Suldan, Z; Bromleigh, V; Gamble, M; Naar, AM; Erdjument-Bromage, H; Tempst, P; Freedman, LP			Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex	NATURE			English	Article							THYROID-HORMONE RECEPTOR; COACTIVATOR COMPLEX; PROTEIN; INTERACTS; IDENTIFICATION; SPECIFICITY; CHROMATIN; MEDIATOR; BINDING; MOTIF	Nuclear receptors modulate the transcription of genes in direct response to small, lipophilic ligands. Binding to ligands induces conformational changes in the nuclear receptors that enable the receptors to interact with several types of cofactor that are critical for transcription activation (transactivation)(1). We previously described a distinct set of ligand-dependent proteins called DRIPs, which interact with the vitamin D receptor (VDR); together, these proteins constitute a new cofactor complex(2). DRIPs bind to several nuclear receptors and mediate ligand-dependent enhancement of transcription by VDR and the thyroid-hormone receptor in cell-free transcription assays(2,3). Here we report the identities of thirteen DRIPs that constitute this complex, and show that the complex has a central function in hormone-dependent transactivation by VDR on chromatin templates. The DRIPs are almost indistinguishable from components of another new cofactor complex called ARC, which is recruited by other types of transcription activators to mediate transactivation on chromatin-assembled templates(4,5). Several DRIP/ARC subunits are also components of other potentially related cofactors, such as CRSP6, NAT(7), SMCC8 and the mouse Mediator(9), indicating that unique classes of activators may share common sets or subsets of cofactors. The role of nuclear-receptor ligands may, in part, be to recruit such a cofactor complex to the receptor and, in doing so, to enhance transcription of target genes.	Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, Program Mol Biol, New York, NY 10021 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol Biol & Cell Biol, Berkeley, CA 94720 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Freedman, LP (corresponding author), Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	l-freedman@ski.mskcc.org	Rachez, Christophe/GLR-0102-2022	Rachez, Christophe/0000-0001-8502-4738; Erdjument-Bromage, Hediye/0000-0003-0224-3594				Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Geromanos S, 1998, RAPID COMMUN MASS SP, V12, P551, DOI 10.1002/(SICI)1097-0231(19980515)12:9<551::AID-RCM198>3.3.CO;2-P; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Yoshikawa H, 1998, GENOMICS, V49, P237, DOI 10.1006/geno.1998.5246; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	29	596	624	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					824	828		10.1038/19783	http://dx.doi.org/10.1038/19783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235266				2022-12-01	WOS:000080058100062
J	Shi, HQ; Tsai, WB; Garrison, MD; Ferrari, S; Ratner, BD				Shi, HQ; Tsai, WB; Garrison, MD; Ferrari, S; Ratner, BD			Template-imprinted nanostructured surfaces for protein recognition	NATURE			English	Article							MOLECULAR RECOGNITION; BIOMATERIALS; ENTRAPMENT; ANTIBODIES; ADSORPTION; POLYMERS; WATER	Synthetic materials capable of selectively recognizing proteins are important in separations(1), biosensors(2) and the development of biomedical materials(3-5). The technique of molecular imprinting creates specific recognition sites in polymers by using template molecules(6-9). Molecular recognition is attributed to binding sites that complement molecules in size, shape and chemical functionality(10). But attempts to imprint proteins have met with only limited success(11-15). Here we report a method for imprinting surfaces with protein-recognition sites. We use radio-frequency glow-discharge plasma deposition to form polymeric thin films(16) around proteins coated with disaccharide molecules. The disaccharides become covalently attached to the polymer film, creating polysaccharide-like cavities that exhibit highly selective recognition for a variety of template proteins, including albumin, immunoglobulin G, lysozyme, ribonuclease and streptavidin, Direct imaging of template recognition is achieved by patterning a surface at the micrometre scale with imprinted regions.	Univ Washington, Ctr Bioengn, Seattle, WA 98195 USA; Univ Trento, Trento, Italy; Univ Washington, Dept Chem Engn, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Trento; University of Washington; University of Washington Seattle	Ratner, BD (corresponding author), Univ Washington, Ctr Bioengn, Box 351720, Seattle, WA 98195 USA.		Tsai, Wei-Bor/B-7953-2011					Andrade JD, 1985, SURFACE INTERFACIAL, P1; Ariga K, 1998, ACCOUNTS CHEM RES, V31, P371, DOI 10.1021/ar970014i; Bernard A, 1998, LANGMUIR, V14, P2225, DOI 10.1021/la980037l; BRASH JL, 1991, ACS ADV CHEM SERIES, V199, P3; BYFIELD MP, 1994, BIOSENS BIOELECTRON, V9, P373, DOI 10.1016/0956-5663(94)80038-3; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; CROWE JH, 1990, CRYOBIOLOGY, V27, P219, DOI 10.1016/0011-2240(90)90023-W; GLAD M, 1985, J CHROMATOGR, V347, P11, DOI 10.1016/S0021-9673(01)95465-2; Hjerten S, 1997, CHROMATOGRAPHIA, V44, P227, DOI 10.1007/BF02466386; HORBATSCH M, 1986, Z PHYS D ATOM MOL CL, V2, P183, DOI 10.1007/BF01429072; Horbett TA, 1993, CARDIOVASC PATHOL, V2, P137, DOI DOI 10.1016/1054-8807(93)90054-6); James CD, 1998, LANGMUIR, V14, P741, DOI 10.1021/la9710482; KEMPE M, 1995, J MOL RECOGNIT, V8, P35, DOI 10.1002/jmr.300080106; Lemieux RU, 1996, ACCOUNTS CHEM RES, V29, P373, DOI 10.1021/ar9600087; MALLICK N, 1994, BIOMETALS, V7, P299; Mosbach K, 1996, BIO-TECHNOL, V14, P163, DOI 10.1038/nbt0296-163; Nock S, 1997, FEBS LETT, V414, P233, DOI 10.1016/S0014-5793(97)01040-5; NORDE W, 1992, COLLOID SURFACE, V66, P73, DOI 10.1016/0166-6622(92)80122-I; Paleos CM, 1997, ADV MATER, V9, P695, DOI 10.1002/adma.19970090904; Ratner BD, 1996, J MOL RECOGNIT, V9, P617, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<617::AID-JMR310>3.0.CO;2-D; RATNER BD, 1993, J BIOMED MATER RES, V27, P837, DOI 10.1002/jbm.820270702; SHEA KJ, 1994, TRENDS POLYM SCI, V2, P166; SHI H, UNPUB ADV MAT; SHI H, IN PRESS J BIOMED MA; SHIRAHAMA H, 1990, J COLLOID INTERF SCI, V139, P177, DOI 10.1016/0021-9797(90)90455-W; STEINKE J, 1995, ADV POLYM SCI, V123, P80; VENTON DL, 1995, BBA-PROTEIN STRUCT M, V1250, P117, DOI 10.1016/0167-4838(95)00079-A; VIJAYALAKSHMI MA, 1989, TRENDS BIOTECHNOL, V7, P71, DOI 10.1016/0167-7799(89)90067-X; WEAVER DR, 1992, BIOMATERIALS, V13, P577, DOI 10.1016/0142-9612(92)90025-J; WULFF G, 1995, ANGEW CHEM INT EDIT, V34, P1812, DOI 10.1002/anie.199518121; Yu C, 1997, J ORG CHEM, V62, P4057, DOI 10.1021/jo961784v	31	583	630	6	291	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 15	1999	398	6728					593	597		10.1038/19267	http://dx.doi.org/10.1038/19267			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217142				2022-12-01	WOS:000079754700050
J	Dyer, C				Dyer, C			Doctors as gods	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					64	64		10.1136/bmj.319.7201.64	http://dx.doi.org/10.1136/bmj.319.7201.64			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390489	Green Published			2022-12-01	WOS:000081326500072
J	Glaser, R; Rabin, B; Chesney, M; Cohen, S				Glaser, R; Rabin, B; Chesney, M; Cohen, S			Stress-induced immunomodulation - Implications for infectious diseases?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELLULAR IMMUNE-RESPONSES; HEPATITIS-B VACCINE; PSYCHOLOGICAL STRESS; COMMON COLD; ADRENERGIC-BLOCKADE; DEPRESSIVE SYMPTOMS; MENTAL STRESS; GAY MEN; SUSCEPTIBILITY		Ohio State Univ, Med Ctr, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Clin Immunopathol CLSI, Pittsburgh, PA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, E Orange, NJ USA	University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; Carnegie Mellon University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Glaser, R (corresponding author), Ohio State Univ, Med Ctr, Dept Med Microbiol & Immunol, 2175 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	glaser.1@postbox.acs.ohio-state.edu	Glaser, Ronald/E-3124-2011	Cohen, Sheldon/0000-0003-2248-4600	NIMH NIH HHS [MH00721] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACHEN EA, 1995, PSYCHOSOM MED, V57, P366, DOI 10.1097/00006842-199507000-00008; BENSCHOP RJ, 1994, CIRCULATION, V89, P762, DOI 10.1161/01.CIR.89.2.762; BURACK JH, 1993, JAMA-J AM MED ASSOC, V270, P2568, DOI 10.1001/jama.270.21.2568; Cohen S, 1997, JAMA-J AM MED ASSOC, V277, P1940; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037/0278-6133.17.3.214; Cole SW, 1996, PSYCHOSOM MED, V58, P219, DOI 10.1097/00006842-199605000-00005; Glaser R, 1998, ANN NY ACAD SCI, V840, P649, DOI 10.1111/j.1749-6632.1998.tb09603.x; GLASER R, 1992, PSYCHOSOM MED, V54, P22, DOI 10.1097/00006842-199201000-00005; Glaser R., 1994, HUMAN HERPESVIRUS IN, P245; GRAVENSTEIN S, 1994, J AM GERIATR SOC, V42, P245, DOI 10.1111/j.1532-5415.1994.tb01746.x; HERBERT TB, 1993, PSYCHOSOM MED, V55, P364, DOI 10.1097/00006842-199307000-00004; Ironson G, 1994, Int J Behav Med, V1, P90, DOI 10.1207/s15327558ijbm0101_6; JABAAIJ L, 1993, J PSYCHOSOM RES, V37, P361, DOI 10.1016/0022-3999(93)90138-6; Kiecolt-Glaser JK, 1998, AM PSYCHOL, V53, P1209, DOI 10.1037/0003-066X.53.11.1209; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; LYKETSOS CG, 1993, JAMA-J AM MED ASSOC, V270, P2563, DOI 10.1001/jama.270.21.2563; Mayne TJ, 1996, ARCH INTERN MED, V156, P2233, DOI 10.1001/archinte.156.19.2233; Padgett DA, 1998, P NATL ACAD SCI USA, V95, P7231, DOI 10.1073/pnas.95.12.7231; Ra bin BS, 1999, STRESS IMMUNE FUNCTI; RASSNICK S, 1994, J NEUROSCI, V14, P6033; SOLOMON GF, 1991, PSYCHONEUROIMMUNOLOG, P1081; TOBACH E, 1956, AM J PHYSIOL, V187, P399, DOI 10.1152/ajplegacy.1956.187.2.399; Vedhara K, 1999, LANCET, V353, P627, DOI 10.1016/S0140-6736(98)06098-X; WETMORE L, 1991, EXP NEUROL, V113, P226, DOI 10.1016/0014-4886(91)90179-G	26	122	124	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2268	2270		10.1001/jama.281.24.2268	http://dx.doi.org/10.1001/jama.281.24.2268			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	207FN	10386538				2022-12-01	WOS:000080925600001
J	Izraeli, S; Lowe, LA; Bertness, VL; Good, DJ; Dorward, DW; Kirsch, IR; Kuehn, MR				Izraeli, S; Lowe, LA; Bertness, VL; Good, DJ; Dorward, DW; Kirsch, IR; Kuehn, MR			The SIL gene is required for mouse embryonic axial development and left-right specification	NATURE			English	Article							LEFT-RIGHT ASYMMETRY; SIGNALING PATHWAY; SONIC HEDGEHOG; TRANSCRIPTION FACTOR; NODAL EXPRESSION; NOTOCHORD; ZEBRAFISH; INDUCTION; PATTERN; PITX2	The establishment of the main body axis and the determination of left-right asymmetry are fundamental aspects of vertebrate embryonic development. A link between these processes has been revealed by the frequent finding of midline defects in humans with left-right anomalies(1). This association is also seen in a number of mutations in mouse(2-4) and zebrafish(1,5), and in experimentally manipulated Xenopus embryos(5). However, the severity of laterality defects accompanying abnormal midline development varies(6), and the molecular basis for this variation is unknown. Here we show that mouse embryos lacking the early-response gene SIL have axial midline defects, a block in midline Sonic hedgehog (Shh) signalling and randomized cardiac looping. Comparison with Shh mutant embryos(7), which have axial defects but normal cardiac looping, indicates that the consequences of abnormal midline development for left-right patterning depend on the time of onset, duration and severity of disruption of the normal asymmetric patterns of expression of nodal, lefty-2 and Pitx2.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NCI, Dept Genet, Med Branch, NIH, Bethesda, MD 20889 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Massachusetts System; University of Massachusetts Amherst; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kuehn, MR (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	kirshi@exchange.nih.gov; mkuehn@box-m.nih.gov	Kuehn, Michael R/A-4573-2014	Kuehn, Michael R/0000-0002-7703-9160	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006579] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC009297, ZIABC009297] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama H, 1997, BIOCHEM BIOPH RES CO, V235, P142, DOI 10.1006/bbrc.1997.6750; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; Campione M, 1999, DEVELOPMENT, V126, P1225; Chen JN, 1997, DEVELOPMENT, V124, P4373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CollazoGarcia N, 1995, GENOMICS, V30, P506, DOI 10.1006/geno.1995.1271; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Goldstein AM, 1998, DEV GENET, V22, P278, DOI 10.1002/(SICI)1520-6408(1998)22:3<278::AID-DVG9>3.0.CO;2-3; Good DJ, 1997, NAT GENET, V15, P397, DOI 10.1038/ng0497-397; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Izraeli S, 1997, CELL GROWTH DIFFER, V8, P1171; King T, 1998, MECH DEVELOP, V79, P29, DOI 10.1016/S0925-4773(98)00166-X; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	30	169	172	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1999	399	6737					691	694		10.1038/21429	http://dx.doi.org/10.1038/21429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385121				2022-12-01	WOS:000080932800061
J	Geng, Y; Whoriskey, W; Park, MY; Bronson, RT; Medema, RH; Li, TS; Weinberg, RA; Sicinski, P				Geng, Y; Whoriskey, W; Park, MY; Bronson, RT; Medema, RH; Li, TS; Weinberg, RA; Sicinski, P			Rescue of cyclin D1 deficiency by knockin cyclin E	CELL			English	Article							RETINOBLASTOMA PROTEIN; CELL-PROLIFERATION; S-PHASE; DEPENDENT KINASES; ESTROGEN-RECEPTOR; MAMMARY-GLAND; G1 CYCLIN; E GENE; TRANSCRIPTION; EXPRESSION	D-type cyclins and cyclin E represent two very distinct classes of mammalian G1 cyclins. We have generated a mouse strain in which the coding sequences of the cyclin D1 gene (Ccnd1) have been deleted and replaced by those of human cyclin E (CCNE). In the tissues and cells of these mice, the expression pattern of human cyclin E faithfully reproduces that normally associated with mouse cyclin D1. The replacement of cyclin D1 with cyclin E rescues all phenotypic manifestations of cyclin D1 deficiency and restores normal development in cyclin D1-dependent tissues. Thus, cyclin E can functionally replace cyclin D1. Our analyses suggest that cyclin E is the major downstream target of cyclin D1.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Tufts Univ, Sch Med & Vet Med, Boston, MA 02111 USA; Univ Utrecht, Med Ctr, Jordan Lab, Dept Hematol, NL-3584 CX Utrecht, Netherlands; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Tufts University; Utrecht University; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Sicinski, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.		Medema, Rene H/G-5415-2011; Medema, Rene H/E-2981-2013	Medema, Rene/0000-0002-6754-0381	NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NCI NIH HHS [535CA39826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Botz J, 1996, MOL CELL BIOL, V16, P3401; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Geng Y, 1996, ONCOGENE, V12, P1173; Gudas JM, 1999, MOL CELL BIOL, V19, P612; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Steinberg RH., 1991, PROGR RETINAL RES, V10, P121, DOI 10.1016/0278-4327(91)90011-P; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	25	279	282	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					767	777		10.1016/S0092-8674(00)80788-6	http://dx.doi.org/10.1016/S0092-8674(00)80788-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380928	Bronze			2022-12-01	WOS:000080886300014
J	Rocheleau, CE; Yasuda, J; Shin, TH; Lin, RL; Sawa, H; Okano, H; Priess, JR; Davis, RJ; Mello, CC				Rocheleau, CE; Yasuda, J; Shin, TH; Lin, RL; Sawa, H; Okano, H; Priess, JR; Davis, RJ; Mello, CC			WRM-1 activates the LIT-1 protein kinase to transduce anterior posterior polarity signals in C-elegans	CELL			English	Article							ASYMMETRIC CELL DIVISIONS; CAENORHABDITIS-ELEGANS; BETA-CATENIN; DROSOPHILA EYE; GENE LIN-44; ENCODES; ADHESION; EMBRYOS; IDENTIFICATION; SPECIFICATION	During C. elegans development, Wnt/WG signaling is required for differences in cell fate between sister cells born from anterior/posterior divisions. A beta-catenin-related gene, wrm-1, and the lit-1 gene are effecters of this signaling pathway and appear to downregulate the activity of POP-1, a TCF/LEF-related protein, in posterior daughter cells. We show here that lit-1 encodes a serine/threonine protein kinase homolog related to the Drosophila tissue polarity protein Nemo. We demonstrate that the WRM-1 protein binds to LIT-1 in vivo and that WRM-1 can activate the LIT-1 protein kinase when coexpressed in vertebrate tissue culture cells. This activation leads to phosphorylation of POP-1 and to apparent changes in its subcellular-localization. Our findings provide evidence for novel regulatory avenues for an evolutionarily conserved Wnt/WG signaling pathway.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Japan Soc & Technol Corp, Dept Neuroanat, Ctr Biomed Res, Suita, Osaka 5650871, Japan; Japan Soc & Technol Corp, PRESTO, Suita, Osaka 5650871, Japan; Japan Soc & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Mello, CC (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.		Okano, Hideyuki/I-7584-2019	Yasuda, Jun/0000-0002-3887-6871; Sawa, Hitoshi/0000-0001-9774-7976; Rocheleau, Christian/0000-0001-6738-5636				Ausubel FM, 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; BRENNER S, 1974, GENETICS, V77, P71; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Eisenmann DM, 1998, DEVELOPMENT, V125, P3667; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; Han M, 1997, CELL, V90, P581, DOI 10.1016/S0092-8674(00)80517-6; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Kaletta T, 1997, NATURE, V390, P294, DOI 10.1038/36869; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; Kuhl M, 1997, BIOESSAYS, V19, P101, DOI 10.1002/bies.950190204; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Papavassiliou Athanasios G., 1992, Methods in Molecular and Cellular Biology, V3, P149; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schnabel R., 1997, C ELEGANS, P361; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tournier C, 1999, MOL CELL BIOL, V19, P1569; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; ZHENG L, 1995, DEVELOPMENT, V121, P3045	42	216	228	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					717	726		10.1016/S0092-8674(00)80784-9	http://dx.doi.org/10.1016/S0092-8674(00)80784-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380924	Bronze			2022-12-01	WOS:000080886300010
J	White, NJ; Nosten, F; Looareesuwan, S; Watkins, WM; Marsh, K; Snow, RW; Kokwaro, G; Ouma, J; Hien, TT; Molyneux, ME; Taylor, TE; Newbold, CI; Ruebush, TK; Danis, M; Greenwood, BM; Anderson, RM; Olliaro, P				White, NJ; Nosten, F; Looareesuwan, S; Watkins, WM; Marsh, K; Snow, RW; Kokwaro, G; Ouma, J; Hien, TT; Molyneux, ME; Taylor, TE; Newbold, CI; Ruebush, TK; Danis, M; Greenwood, BM; Anderson, RM; Olliaro, P			Averting a malaria disaster	LANCET			English	Editorial Material							RESISTANT FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; DRUG-RESISTANCE; PYRIMETHAMINE; CHLOROQUINE; SULFADOXINE; ARTEMETHER; AFRICA		Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand; Wellcome Mahidol Univ Oxford, Trop Med Res Programme, Bangkok, Thailand; KEMRI Wellcome Trust Collaborat Res Programme, Nairobi, Kenya; Minist Hlth, Natl Malaria Control Programme, Nairobi, Kenya; Cho Quan Hosp, Ctr Trop Dis, Ho Chi Minh City, Vietnam; Univ Malawi, Coll Med, Zomba, Malawi; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Univ Oxford, Inst Mol Med, Oxford, England; Ctr Dis Control & Prevent, Atlanta, GA USA; Grp Hosp Pitie Salpetriere, F-75634 Paris, France; London Sch Hyg & Trop Med, London WC1, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; WHO, CH-1211 Geneva, Switzerland	Mahidol University; Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; University of Malawi; Liverpool School of Tropical Medicine; University of Liverpool; University of Oxford; Centers for Disease Control & Prevention - USA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of London; London School of Hygiene & Tropical Medicine; University of Oxford; World Health Organization	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.		Snow, Robert William/AFR-1436-2022; White, Nick/AAC-6527-2019; Nosten, Francois/AAC-5509-2019; White, Nicholas J/I-4629-2012	Snow, Robert William/0000-0003-3725-6088; White, Nick/0000-0002-1897-1978; Nosten, Francois/0000-0002-7951-0745; Newbold, Chris/0000-0002-9274-3789; Anderson, Roy/0000-0002-9528-3175				BLOLAND PB, 1993, J INFECT DIS, V167, P932, DOI 10.1093/infdis/167.4.932; BREWER TG, 1994, AM J TROP MED HYG, V51, P251, DOI 10.4269/ajtmh.1994.51.251; Brundtland G. H., 1998, 51 WORLD HLTH ASS GE; Handunnetti SM, 1996, T ROY SOC TROP MED H, V90, P563, DOI 10.1016/S0035-9203(96)90325-9; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; Price RN, 1996, LANCET, V347, P1654, DOI 10.1016/S0140-6736(96)91488-9; Price RN, 1997, T ROY SOC TROP MED H, V91, P574, DOI 10.1016/S0035-9203(97)90032-8; Ronn AM, 1996, T ROY SOC TROP MED H, V90, P179, DOI 10.1016/S0035-9203(96)90129-7; SNOW RW, 1992, T ROY SOC TROP MED H, V86, P237, DOI 10.1016/0035-9203(92)90290-S; van Vugt M, 1998, ANTIMICROB AGENTS CH, V42, P135, DOI 10.1128/AAC.42.1.135; WATKINS WM, 1993, T ROY SOC TROP MED H, V87, P75, DOI 10.1016/0035-9203(93)90431-O; White NJ, 1997, ANTIMICROB AGENTS CH, V41, P1413, DOI 10.1128/AAC.41.7.1413; White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2	13	440	451	0	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1965	1967		10.1016/S0140-6736(98)07367-X	http://dx.doi.org/10.1016/S0140-6736(98)07367-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371589				2022-12-01	WOS:000080668500047
J	Misra, S; Hurley, JH				Misra, S; Hurley, JH			Crystal structure of a phosphatidylinositol 3-phosphate-specific membrane-targeting motif, the FYVE domain of Vps27p	CELL			English	Article							PROTEIN-KINASE-C; BINDING DOMAIN; X-RAY; DIFFRACTION DATA; PHOSPHOLIPASE-C; NMR STRUCTURE; FINGERS; REFINEMENT; PTDINS(3)P; COMPLEX	Phosphatidylinositol 3-phosphate regulates membrane trafficking and signaling pathways by interacting with the FYVE domains of target proteins. The 1.15 Angstrom structure of the Vps27p FYVE domain reveals two antiparallel beta sheets and an alpha helix stabilized by two Zn2+-binding clusters. The core secondary structures are similar to a rabphilin-3A Zn2+-binding domain and to the C1 and LIM domains. Phosphatidylinositol 3-phosphate binds to a pocket formed by the (R/K)(R/K)HHCR motif. A lattice contact shows how anionic ligands can interact with the phosphatidylinositol 3-phosphate-binding site. The tip of the FYVE domain has basic and hydrophobic surfaces positioned so that nonspecific interactions with the phospholipid bilayer can abet specific binding to phosphatidylinositol 3-phosphate.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hurley, JH (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			Misra, Saurav/0000-0002-1385-8554	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036118] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GROSSEKUNSTLEVE RW, 1998, ACTA CRYSTALLOGR D, V54, P905; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; Hurley JH, 1997, PROTEIN SCI, V6, P477; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASTERIS NG, 1994, CELL, V79, P669; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P11, DOI 10.1107/S0907444993008224; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tronrud DE, 1996, J APPL CRYSTALLOGR, V29, P100, DOI 10.1107/S002188989501421X; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; WHITE SH, 1994, CURR OPIN STRUC BIOL, V4, P79, DOI 10.1016/S0959-440X(94)90063-9; Wiedemann C, 1998, NATURE, V394, P426, DOI 10.1038/28752; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xu RX, 1997, BIOCHEMISTRY-US, V36, P10709, DOI 10.1021/bi970833a; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	64	206	208	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					657	666		10.1016/S0092-8674(00)80776-X	http://dx.doi.org/10.1016/S0092-8674(00)80776-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367894	Bronze			2022-12-01	WOS:000080672100014
J	Abdul-Manan, N; Aghazadeh, B; Liu, GA; Majumdar, A; Ouerfelli, O; Siminovitch, KA; Rosen, MK				Abdul-Manan, N; Aghazadeh, B; Liu, GA; Majumdar, A; Ouerfelli, O; Siminovitch, KA; Rosen, MK			Structure of Cdc42 in complex with the GTPase-binding domain of the 'Wiskott-Aldrich syndrome' protein	NATURE			English	Article							ACTIN POLYMERIZATION; CRYSTAL-STRUCTURE; TARGET PROTEINS; KINASE; NMR; EFFECTOR; WASP; RAC; ASSIGNMENT; SURFACE	The Rho-family GTP-hydrolysing proteins (GTPases), Cdc42, Rac and Rho, act as molecular switches in signalling pathways that regulate cytoskeletal architecture, gene expression and progression of the cell cycle(1). Cdc42 and Rac transmit many signals through GTP-dependent binding to effector proteins containing a Cdc42/Rac-interactive-binding (CRIB) motif(2). One such effector, the Wiskott-Aldrich syndrome protein (WASP), is postulated to link activation of Cdc42 directly to the rearrangement of acting(3). Human mutations in WASP cause severe defects in haematopoietic cell function, leading to clinical symptoms of thrombocytopenia, immunodeficiency and eczema. Here we report the solution structure of a complex between activated Cdc42 and a minimal GTPase-binding domain (GBD) from WASP. An extended amino-terminal GBD peptide that includes the CRIB motif contacts the switch I, beta 2 and alpha 5 regions of Cdc42. A carboxy-terminal beta-hairpin and alpha-helix pack against switch II. The Phe-X-His-X-2-His portion of the CRIB motif and the alpha-helix appear to mediate sensitivity to the nucleotide switch through contacts to residues 36-40 of Cdc42. Discrimination between the Rho-family members is likely to be governed by GBD contacts to the switch I and alpha 5 regions of the GTPases. Structural and biochemical data suggest that GBD-sequence divergence outside the CRIB motif may reflect additional regulatory interactions with functional domains that are specific to individual effecters.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Grad Program Physiol & Biophys, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Grad Program Physiol & Biophys, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Grad Program Biochem & Struct Biol, New York, NY 10021 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Rosen, MK (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	rosen@mmmrl.ski.mskcc.org	Siminovitch, Katherine/K-1475-2013					Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Gardner KH, 1997, J AM CHEM SOC, V119, P7599, DOI 10.1021/ja9706514; Gardner KH, 1996, J BIOMOL NMR, V8, P351, DOI 10.1007/BF00410333; Guo W, 1998, BIOCHEMISTRY-US, V37, P14030, DOI 10.1021/bi981352+; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005	30	262	270	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					379	383		10.1038/20726	http://dx.doi.org/10.1038/20726			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360578				2022-12-01	WOS:000080547800065
J	Purnell, BA; Marx, J				Purnell, BA; Marx, J			Microbe management	SCIENCE			English	Editorial Material																			0	3	3	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1301	1301		10.1126/science.284.5418.1301	http://dx.doi.org/10.1126/science.284.5418.1301			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383311				2022-12-01	WOS:000080430600036
J	Michaud, DS; Spiegelman, D; Clinton, SK; Rimm, EB; Curhan, GC; Willett, WC; Giovannucci, EL				Michaud, DS; Spiegelman, D; Clinton, SK; Rimm, EB; Curhan, GC; Willett, WC; Giovannucci, EL			Fluid intake and the risk of bladder cancer in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; ALCOHOLIC BEVERAGE CONSUMPTION; CHLORINATION BY-PRODUCTS; DRINKING-WATER SOURCE; LOWER URINARY-TRACT; WASHINGTON COUNTY; COFFEE-DRINKING; DIETARY FACTORS; KIDNEY-STONES; LIFE-STYLE	Background Studies in animals have shown that the frequency of urination is inversely associated with the level of potential carcinogens in the urothelium. In humans, an increase in total fluid intake may reduce contact time between carcinogens and urothelium by diluting urinary metabolites and increasing the frequency of voiding. The data on fluid intake in relation to the risk of bladder cancer are inconclusive. Methods We examined the relation between total Fluid intake and the risk of bladder cancer over a period of 10 years among 47,909 participants in the prospective Health Professionals Follow-up Study. There were 252 newly diagnosed cases of bladder cancer during the follow-up period, information on total fluid intake was derived from the reported frequency of consumption of the 22 types of beverages on the food-frequency questionnaire, which was completed by each of the 47,909 participants who were free of cancer in 1986. Logistic-regression analyses were performed to adjust for known and suspected risk factors for bladder cancer. Results Total daily fluid intake was inversely associated with the risk of bladder cancer; the multivariate relative risk was 0.51 (95 percent confidence interval, 0.32 to 0.80) for the highest quintile of total daily fluid intake (>2531 mi per day) as compared with the lowest quintile (<1290 mi per day). The consumption of water contributed to a lower risk (relative risk, 0.49 [95 percent confidence interval, 0.28 to 0.86] for greater than or equal to 1440 mi [6 cups] per day vs. <240 mi [1 cup] per day), as did the consumption of other fluids (relative risk, 0.63 [95 percent confidence interval, 0.39 to 0.99] for >1831 mi per day vs. <735 mi per day). Conclusions A high fluid intake is associated with a decreased risk of bladder cancer in men. (N Engl J Med 1999;340:1390-7.) (C) 1999, Massachusetts Medical Society.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Channing Lab, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Ohio State Univ, Arthur G James Canc Hosp & Res Inst, Columbus, OH 43210 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Michaud, DS (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Michaud, Dominique S/I-5231-2014		NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM I CANC RES, 1997, WORLD CANC RES FUND, P338; BRAVER DJ, 1987, J NATL CANCER I, V78, P437; BROWNSON RC, 1987, AM J PUBLIC HEALTH, V77, P1298, DOI 10.2105/AJPH.77.10.1298; CANTOR KP, 1987, J NATL CANCER I, V79, P1269; Cantor KP, 1998, EPIDEMIOLOGY, V9, P21, DOI 10.1097/00001648-199801000-00007; Chyou P H, 1993, Ann Epidemiol, V3, P211; CLAUDE J, 1986, AM J EPIDEMIOL, V124, P578, DOI 10.1093/oxfordjournals.aje.a114430; Curhan GC, 1996, AM J EPIDEMIOL, V143, P240, DOI 10.1093/oxfordjournals.aje.a008734; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; *DEP AGR, 1995, USDA NUTR DAT STAND; DUNHAM LJ, 1968, J NATL CANCER I, V41, P683; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Freedman DM, 1997, CANCER CAUSE CONTROL, V8, P738, DOI 10.1023/A:1018431421567; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HOWE GR, 1980, JNCI-J NATL CANCER I, V64, P701; JENSEN OM, 1986, INT J CANCER, V37, P651, DOI 10.1002/ijc.2910370503; KADLUBAR FF, 1991, CANCER RES, V51, P4371; King WD, 1996, CANCER CAUSE CONTROL, V7, P596, DOI 10.1007/BF00051702; KUNZE E, 1992, CANCER-AM CANCER SOC, V69, P1776, DOI 10.1002/1097-0142(19920401)69:7<1776::AID-CNCR2820690721>3.0.CO;2-P; LAVECCHIA C, 1989, NUTR CANCER, V12, P93, DOI 10.1080/01635588909514006; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MCGEEHIN MA, 1993, AM J EPIDEMIOL, V138, P492, DOI 10.1093/oxfordjournals.aje.a116883; MILLS PK, 1991, AM J EPIDEMIOL, V133, P230, DOI 10.1093/oxfordjournals.aje.a115867; MORRISON AS, 1982, JNCI-J NATL CANCER I, V68, P91; Pak CYC, 1998, LANCET, V351, P1797, DOI 10.1016/S0140-6736(98)01295-1; RIES LAG, 1997, NIH PUBLICATION; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RISCH HA, 1988, AM J EPIDEMIOL, V127, P1179, DOI 10.1093/oxfordjournals.aje.a114911; ROHERTSON GL, 1992, KIDNEY PHYSL PATHOPH, V2, P1595; Rothman N, 1997, CANCER EPIDEM BIOMAR, V6, P1039; Schilter B, 1996, CARCINOGENESIS, V17, P2377, DOI 10.1093/carcin/17.11.2377; SILVERMAN DT, 1992, HEMATOL ONCOL CLIN N, V6, P1; SLATTERY ML, 1988, INT J CANCER, V42, P17, DOI 10.1002/ijc.2910420105; STEINMETZ KA, 1993, CANCER RES, V53, P536; STENSVOLD I, 1994, CANCER CAUSE CONTROL, V5, P401, DOI 10.1007/BF01694753; THOMAS DB, 1983, AM J EPIDEMIOL, V118, P720, DOI 10.1093/oxfordjournals.aje.a113682; TUYNS AJ, 1979, CANCER RES, V39, P2840; VENA JE, 1993, ARCH ENVIRON HEALTH, V48, P191, DOI 10.1080/00039896.1993.9940820; VISCOLI CM, 1993, LANCET, V341, P1432, DOI 10.1016/0140-6736(93)90881-G; WILKINS JR, 1981, AM J EPIDEMIOL, V114, P178, DOI 10.1093/oxfordjournals.aje.a113181; Willett W, 1990, MONOGRAPHS EPIDEMIOL, V15; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; World Health Organization, 1997, WORLD HLTH REP 1997; WYNDER EL, 1963, CANCER-AM CANCER SOC, V16, P1388, DOI 10.1002/1097-0142(196311)16:11<1388::AID-CNCR2820161104>3.0.CO;2-8	45	200	203	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1390	1397		10.1056/NEJM199905063401803	http://dx.doi.org/10.1056/NEJM199905063401803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228189				2022-12-01	WOS:000080090600003
J	Chow, WH; Devesa, SS; Warren, JL; Fraumeni, JF				Chow, WH; Devesa, SS; Warren, JL; Fraumeni, JF			Rising incidence of renal cell cancer in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTENSION; CARCINOMA; OBESITY; TRENDS	Context Clinical surveys have revealed that incidental detection of renal cell carcinoma is rising because of increased use of imaging procedures. Objective To examine incidence, mortality, and survival trends of renal cell and renal pelvis cancers by age, sex, race, and tumor stage at diagnosis, Design Calculation of age-adjusted incidence and mortality rates, along with 5-year relative survival rates, using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Setting and Participants Patients diagnosed as having kidney cancer from 1975 through 1995 in the 9 geographic areas covered by tumor registries in the SEER program, which represent about 10% of the US population. Main Outcome Measures Incidence, mortality, and 5-year relative survival rates by time periods, Results The age-adjusted incidence rates for renal cell carcinoma between 1975 and 1995 for white men, white women, black men, and black women were 9.6, 4.4, 11.1, and 4.9 per 100 000 person-years, respectively. The corresponding rates for renal pelvis cancer were 1.5, 0.7, 0.8, and 0.5 per 100 000 person-years, Renal cell cancer incidence rates increased steadily between 1975 and 1995, by 2.3% annually among white men, 3.1% among white women, 3.9% among black men, and 4.3% among black women. Increases were greatest for localized tumors but were also seen for more advanced and unstaged tumors. In contrast, the incidence rates for renal pelvis cancer declined among white men and remained stable among white women and blacks. Although 5-year relative survival rates for patients with renal cell cancer improved among whites but not among blacks, kidney cancer mortality rates increased in all race and sex groups. Conclusions Increasing detection of presymptomatic tumors by imaging procedures, such as ultrasonography, computed tomography, and magnetic resonance imaging, does not fully explain the upward incidence trends of renal cell carcinoma. Other factors may be contributing to the rapidly increasing incidence of renal cell cancer in the United States, particularly among blacks.	NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chow, WH (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 8100, Bethesda, MD 20892 USA.	choww@exchange.nih.gov			DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010108] Funding Source: NIH RePORTER	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		Benichou J, 1998, AM J EPIDEMIOL, V148, P424; BRETHEAU D, 1995, EUR UROL, V27, P319; DEVESA SS, 1990, CANCER CAUSE CONTROL, V1, P133, DOI 10.1007/BF00053164; DEVESA SS, 1995, AM J EPIDEMIOL, V141, P300, DOI 10.1093/aje/141.4.300; EISNER GM, 1990, AM J KIDNEY DIS, V16, P35; Espeland MA, 1996, J AM GERIATR SOC, V44, P1183, DOI 10.1111/j.1532-5415.1996.tb01367.x; *FED AM SOC EXP BI, 1995, 3 REP NUTR MON US, V1, pES9; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; GROSS TP, 1989, HYPERTENSION S1, V13, P113; Homma Y, 1995, Int J Urol, V2, P77, DOI 10.1111/j.1442-2042.1995.tb00428.x; Jayson M, 1998, UROLOGY, V51, P203, DOI 10.1016/S0090-4295(97)00506-2; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MCCREDIE M, 1994, CANCER SURV, V20, P343; McLaughlin J. K., 1996, CANC EPIDEMIOLOGY PR, P1142; *NAT CTR HLTH STAT, 1997, HLTH US 1996 97, P182; Percy C., 1990, INT CLASSIFICATION D; Ries L, 1998, SEER CANC STAT REV 1; VANZWIETEN PA, 1992, J HYPERTENS, V10, pS1; Weir MR, 1998, HYPERTENSION, V31, P1088, DOI 10.1161/01.HYP.31.5.1088; Yuan JM, 1998, BRIT J CANCER, V77, P1508, DOI 10.1038/bjc.1998.248	21	1182	1234	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1628	1631		10.1001/jama.281.17.1628	http://dx.doi.org/10.1001/jama.281.17.1628			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235157	Bronze			2022-12-01	WOS:000080025900028
J	Olenyuk, B; Whiteford, JA; Fechtenkotter, A; Stang, PJ				Olenyuk, B; Whiteford, JA; Fechtenkotter, A; Stang, PJ			Self-assembly of nanoscale cuboctahedra by coordination chemistry	NATURE			English	Article								Self-assembled polyhedral structures are common in biology. The coats of many viruses, for example, have a structure based on icosahedral symmetry(1). The preparation of synthetic polyhedral molecular assemblies represents a challenging problem, but supramolecular chemistry(2-4) has now advanced to the Feint where the task may be addressed. Macromolecular and supramolecular entities of predefined geometric shape and with well-defined internal environments are potentially important for inclusion phenomena(5-8), molecular recognition(5,6) and catalysis(9). Here we report the use of self-assembly of molecular units driven by coordination to transition-metal ions(10) to prepare a cuboctahedron from 20 tridentate and bidentate subunits in a single step. The cuboctahedron is an archimedean semiregular polyhedron that combines square and triangular faces. Our self-assembled polyhedral capsules, characterized by NMR and electrospray mass spectrometry, are around 5 nanometres in diameter.	Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Stang, PJ (corresponding author), Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA.		Stang, Peter J./Y-2744-2019					Cram D.J., 1994, CONTAINER MOL THEIR, DOI 10.1039/9781847550620-00107; CRAM DJ, 1991, ANGEW CHEM INT EDIT, V30, P1024, DOI 10.1002/anie.199110241; DINUR U, 1991, REV COMPUTATIONAL CH, V2, pCH4; FUJITA M, 1995, NATURE, V378, P469, DOI 10.1038/378469a0; Hansen J.-P., 1976, THEORY SIMPLE LIQUID; Horne R. W., 1974, VIRUS STRUCTURE; Kang JM, 1997, NATURE, V385, P50, DOI 10.1038/385050a0; Lehn J. M., 1996, COMPREHENSIVE SUPRAM, V1-11; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; *MOL SIM INC, 1998, INS 2 97 0; PERSKY NE, 1997, J AM CHEM SOC SOC, V119, P4777; Sanders JK, 1995, SUPRAMOLECULAR CHEM, V107, P2617; Stang PJ, 1997, ACCOUNTS CHEM RES, V30, P502, DOI 10.1021/ar9602011; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; STODDARD JF, 1989, MONOGRAPHS SUPRAMOLE, P1994	15	546	554	8	138	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 29	1999	398	6730					796	799		10.1038/19740	http://dx.doi.org/10.1038/19740			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235260				2022-12-01	WOS:000080058100055
J	Skowyra, D; Koepp, DM; Kamura, T; Conrad, MN; Conaway, RC; Conaway, JW; Elledge, SJ; Harper, JW				Skowyra, D; Koepp, DM; Kamura, T; Conrad, MN; Conaway, RC; Conaway, JW; Elledge, SJ; Harper, JW			Reconstitution of G(1) cyclin ubiquitination with complexes containing SCFGrr1 and Rbx1	SCIENCE			English	Article							N-END RULE; CONJUGATING ENZYME; SACCHAROMYCES-CEREVISIAE; PROTEASOME PATHWAY; RAPID DEGRADATION; DNA-BINDING; G1 CYCLINS; YEAST; PROTEIN; PHOSPHORYLATION	Control of cyclin Levels is critical for proper cell cycle regulation. In yeast, the stability of the Ci,,cyclin Cln1 is controlled by phosphorylation-dependent ubiquitination. Here it is shown that this reaction can be reconstituted in vitro with an SCF E3 ubiquitin ligase complex. Phosphorylated Cln1 was ubiquitinated by SCF (Skp1Cdc53-F-box protein) complexes containing the F-box protein Grr1, Rbx1, and the E2 Cdc34. Rbx1 promotes association of Cdc34 with Cdc53 and stimulates Cdc34 auto-ubiquitination in the context of Cdc53 or SCF complexes. Rbx1, which is also a component of the von Hippe-Lindau tumor suppressor complex, may define a previously unrecognized class of E3-associated proteins.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Harper, JW (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA.			Harper, Jeffrey/0000-0002-6944-7236; Conaway, Joan/0000-0002-2786-0663	NIA NIH HHS [AG11085] Funding Source: Medline; NIGMS NIH HHS [GM41628, GM54137] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054137, R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bailly V, 1997, MOL CELL BIOL, V17, P4536, DOI 10.1128/MCB.17.8.4536; Bailly V, 1997, J BIOL CHEM, V272, P23360, DOI 10.1074/jbc.272.37.23360; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DESHAIES RJ, 1995, P NATL ACAD SCI USA, V92, P1182, DOI 10.1073/pnas.92.4.1182; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FLICK JS, 1991, MOL CELL BIOL, V11, P5101, DOI 10.1128/MCB.11.10.5101; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Potuschak T, 1998, P NATL ACAD SCI USA, V95, P7904, DOI 10.1073/pnas.95.14.7904; Schneider BL, 1998, NATURE, V395, P86, DOI 10.1038/25774; SKOWYRA DK, UNPUB; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	28	355	367	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					662	665		10.1126/science.284.5414.662	http://dx.doi.org/10.1126/science.284.5414.662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213692				2022-12-01	WOS:000079951100050
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Some nerve!	SCIENCE			English	Article									Mednav Com, Byfield, MA 01922 USA		Sikorski, R (corresponding author), Mednav Com, Byfield, MA 01922 USA.							Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					453	453						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10232993				2022-12-01	WOS:000079792200036
J	Hayakawa, K; Asano, M; Shinton, SA; Gui, M; Allman, D; Stewart, CL; Silver, J; Hardy, RR				Hayakawa, K; Asano, M; Shinton, SA; Gui, M; Allman, D; Stewart, CL; Silver, J; Hardy, RR			Positive selection of natural autoreactive B cells	SCIENCE			English	Article							REGION GENE-EXPRESSION; TRANSGENIC MICE; AUTOIMMUNE-DISEASE; CLONAL SELECTION; NORMAL MOUSE; IMMUNOGLOBULIN; ANTIGEN; AUTOANTIBODIES; ANTIBODY; LINEAGE	Lymphocyte development is critically influenced by self-antigens. T cells are subject to both positive and negative selection, depending on their degree of seif-reactivity. Although B cells are subject to negative selection, it has been difficult to test whether self-antigen plays any positive role in B cell development. A murine model system of naturally generated autoreactive B cells with a germ Line gene-encoded specificity for the Thy-1 (CD90) glycoprotein was developed, in which the presence of self-antigen promotes B cell accumulation and serum autoantibody secretion. Thus, B cells can be subject to positive selection, generated, and maintained on the basis of their autoreactivity.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; NCI, Lab Canc & Dev Biol, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Cornell Univ Med Coll, N Shore Univ Hosp, Div Mol Med, Manhasset, NY 11030 USA	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Cornell University; Northwell Health; North Shore University Hospital	Hayakawa, K (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.							ARNOLD LW, 1994, J EXP MED, V179, P1585, DOI 10.1084/jem.179.5.1585; BOYDEN S, 1964, NATURE, V201, P200, DOI 10.1038/201200a0; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; CUNNINGHAM AJ, 1974, NATURE, V252, P749, DOI 10.1038/252749a0; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; DIGHIERO G, 1985, J IMMUNOL, V134, P765; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Hannum LG, 1996, J EXP MED, V184, P1269, DOI 10.1084/jem.184.4.1269; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HARDY RR, 1994, IMMUNOL REV, V137, P91, DOI 10.1111/j.1600-065X.1994.tb00660.x; HARTLEY SB, 1994, INT IMMUNOL, V6, P1417, DOI 10.1093/intimm/6.9.1417; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HAYAKAWA K, 1990, J EXP MED, V172, P869, DOI 10.1084/jem.172.3.869; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Kearney J F, 1992, Curr Top Microbiol Immunol, V182, P81; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lang J, 1996, J EXP MED, V184, P1685, DOI 10.1084/jem.184.5.1685; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MARTIN WJ, 1974, NATURE, V249, P564, DOI 10.1038/249564a0; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Page DM, 1997, J IMMUNOL, V159, P5285; PENNELL CA, 1989, EUR J IMMUNOL, V19, P1289, DOI 10.1002/eji.1830190721; PENNELL CA, 1988, J IMMUNOL, V141, P2788; POTTER M, 1982, MOL IMMUNOL, V19, P1619, DOI 10.1016/0161-5890(82)90273-5; SCHLESINGER M, 1965, NATURE, V207, P429, DOI 10.1038/207429b0	33	462	473	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					113	116		10.1126/science.285.5424.113	http://dx.doi.org/10.1126/science.285.5424.113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390361				2022-12-01	WOS:000081199800043
J	Lynch, KR; O'Neill, GP; Liu, QY; Im, DS; Sawyer, N; Metters, KM; Coulombe, N; Abramovitz, M; Figueroa, DJ; Zeng, ZZ; Connolly, BM; Bai, C; Austin, CP; Chateauneuf, A; Stocco, R; Greig, GM; Kargman, S; Hooks, SB; Hosfield, E; Williams, DL; Ford-Hutchinson, AW; Caskey, CT; Evans, JF				Lynch, KR; O'Neill, GP; Liu, QY; Im, DS; Sawyer, N; Metters, KM; Coulombe, N; Abramovitz, M; Figueroa, DJ; Zeng, ZZ; Connolly, BM; Bai, C; Austin, CP; Chateauneuf, A; Stocco, R; Greig, GM; Kargman, S; Hooks, SB; Hosfield, E; Williams, DL; Ford-Hutchinson, AW; Caskey, CT; Evans, JF			Characterization of the human cysteinyl leukotriene CysLT(1) receptor	NATURE			English	Article							DOUBLE-BLIND TRIAL; GUINEA-PIG LUNG; CHRONIC ASTHMA; ANTAGONIST; MONTELUKAST; POTENT; PHARMACOLOGY; MULTICENTER; EXPRESSION; RESPONSES	The cysteinyl leukotrienes-leukotriene C-4(LTC4), leukotriene D-4(LTD4) and leukotriene E-4(LTE4)-are important mediators of human bronchial asthma(1-3). Pharmacological studies have determined that cysteinyl leukotrienes activate at least two receptors, designated CysLT(1) and CysLT(2) (refs 4-6). The CysLT(1)-selective antagonists, such as montelukast (Singulair)(7-10), zafirlukast (Accolate)(11) and pranlukast (Onon)(12), are important in the treatment of asthma. Previous biochemical characterization of CysLT(1) antagonists and the CysLT(1) receptor has been in membrane preparations from tissues enriched for this receptor(13). Here we report the molecular and pharmacological characterization of the cloned human CysLT(1) receptor. We describe the functional activation (calcium mobilization) of this receptor by LTD4 and LTC4, and competition for radiolabelled LTD4 binding to this receptor by the cysteinyl leukotrienes and three structurally distinct classes of CysLT(1)-receptor antagonists. We detected CysLT(1)-receptor messenger RNA in spleen, peripheral blood leukocytes and lung. In normal human lung, expression of the CysLT(1)-receptor mRNA was confined to smooth muscle cells and tissue macrophages. Finally, we mapped the human CysLT(1)-receptor gene to the X chromosome.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Merck Frosst Canada & Co, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck & Co Inc, Dept Pharmacol, West Point, PA 19486 USA; Merck & Co Inc, Dept Human Genet, West Point, PA 19486 USA	University of Virginia; Merck & Company; Merck & Company; Merck & Company	Evans, JF (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA.	jilly_evans@merck.com		IM, DONG-SOON/0000-0001-8054-8946				CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; CHARETTE L, 1987, BRIT J PHARMACOL, V91, P179, DOI 10.1111/j.1476-5381.1987.tb08997.x; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; ELLIS C, 1998, Patent No. 0874047; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; Grossman J, 1997, J ASTHMA, V34, P321, DOI 10.3109/02770909709067222; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Kolakowski LF, 1998, J NEUROCHEM, V71, P2239; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Martin V, 1999, J BIOL CHEM, V274, P8597, DOI 10.1074/jbc.274.13.8597; McClintock TS, 1996, J CELL PHYSIOL, V167, P1; METTERS KM, 1993, J BIOL CHEM, V268, P6487; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; POTENZA MN, 1994, J NEUROSCI, V14, P1463, DOI 10.1523/JNEUROSCI.14-03-01463.1994; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; UNGRIN MD, IN PRESS ANAL BIOCH; Wright DH, 1998, BRIT J PHARMACOL, V123, P1317; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	28	800	825	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					789	793						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391245				2022-12-01	WOS:000081101600055
J	Will, CL; Schneider, C; Reed, R; Luhrmann, R				Will, CL; Schneider, C; Reed, R; Luhrmann, R			Identification of both shared and distinct proteins in the major and minor spliceosomes	SCIENCE			English	Article							MESSENGER-RNA INTRONS; AT-AC INTRON; BRANCH SITE; U5 SNRNPS; IN-VIVO; COMPLEX; U11	In metazoa ns, two distinct spliceosomes catalyzing pre-messenger RNA splicing have been identified. Here, the human U11/U12 small nuclear ribonucleoprotein (snRNP), a subunit of the minor (U12-dependent) spliceosome, was isolated. Twenty U11/U72 proteins were identified, including subsets unique to the minor spliceosome or common to both spliceosomes. Common proteins include four U2 snRNP polypeptides that constitute the essential splicing factor SF3b. A 35-kilodalton U11-associated protein homologous to the U1 snRNP 70K protein was also identified. These data provide fundamental information about proteins of the minor spliceosome and shed light on its evolutionary relationship to the major spliceosome.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35037 Marburg, Germany; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Max Planck Inst Biophys Chem, Dept Cellular Biochem, D-37070 Gottingen, Germany	Philipps University Marburg; Harvard University; Harvard Medical School; Max Planck Society	Luhrmann, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35037 Marburg, Germany.			Schneider, Claudia/0000-0001-5597-2489				Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; BEHRENS SE, 1993, MOL CELL BIOL, V13, P307, DOI 10.1128/MCB.13.1.307; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Burge C.B., 1999, RNA WORLD, V37, P525; Burge CB, 1998, MOL CELL, V2, P773, DOI 10.1016/S1097-2765(00)80292-0; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; Das B., UNPUB; Frilander MJ, 1999, GENE DEV, V13, P851, DOI 10.1101/gad.13.7.851; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; HALL SL, 1994, J MOL BIOL, V239, P357, DOI 10.1006/jmbi.1994.1377; Hall SL, 1996, SCIENCE, V271, P1716, DOI 10.1126/science.271.5256.1716; Kolossova I, 1997, RNA, V3, P227; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Laggerbauer B, 1996, NUCLEIC ACIDS RES, V24, P868, DOI 10.1093/nar/24.5.868; LAMOND A, 1996, RNA PROCESSING PRACT, P103; NEUGEBAUER KM, 1995, J CELL BIOL, V129, P899, DOI 10.1083/jcb.129.4.899; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; Schneider C., UNPUB; Sharp PA, 1997, CELL, V91, P875, DOI 10.1016/S0092-8674(00)80479-1; Tarn WY, 1996, SCIENCE, V273, P1824, DOI 10.1126/science.273.5283.1824; Tarn WY, 1996, CELL, V84, P801, DOI 10.1016/S0092-8674(00)81057-0; Teigelkamp S, 1997, RNA, V3, P1313; Wang CY, 1998, GENE DEV, V12, P1409, DOI 10.1101/gad.12.10.1409; WASSARMAN KM, 1992, MOL CELL BIOL, V12, P1276, DOI 10.1128/MCB.12.3.1276; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WILL CL, 1997, EUKARYOTIC MRNA PROC, P130; WILL CM, UNPUB; Wu Q, 1996, SCIENCE, V274, P1005, DOI 10.1126/science.274.5289.1005; Yu YT, 1997, P NATL ACAD SCI USA, V94, P6030, DOI 10.1073/pnas.94.12.6030	30	103	107	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					2003	2005		10.1126/science.284.5422.2003	http://dx.doi.org/10.1126/science.284.5422.2003			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373121	Green Submitted			2022-12-01	WOS:000080932700051
J	Wainberg, MA				Wainberg, MA			A new source of resistance to HIV drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							THERAPY; ZIDOVUDINE		McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada	McGill University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, Montreal, PQ H3T 1E2, Canada.							BLOOR S, 1998, 2 INT WORKSH HIV DRU; DEJONG JJ, 1998, 2 INT WORKSH HIV DRU; Iversen AKN, 1996, J VIROL, V70, P1086, DOI 10.1128/JVI.70.2.1086-1090.1996; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; SCHINAZI RF, 1997, INT ANTIVIRAL NEWS, V5, P2; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; WHITCOMB JM, 1998, 2 INT WORKSH HIV DRU; Winters MA, 1998, J CLIN INVEST, V102, P1769, DOI 10.1172/JCI4948	10	2	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2169	2170		10.1001/jama.281.23.2169	http://dx.doi.org/10.1001/jama.281.23.2169			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376549				2022-12-01	WOS:000080777000002
J	Clutton-Brock, TH; O'Riain, MJ; Brotherton, PNM; Gaynor, D; Kansky, R; Griffin, AS; Manser, M				Clutton-Brock, TH; O'Riain, MJ; Brotherton, PNM; Gaynor, D; Kansky, R; Griffin, AS; Manser, M			Selfish sentinels in cooperative mammals	SCIENCE			English	Article							FLORIDA SCRUB JAY; SURICATA-SURICATTA; VIGILANCE BEHAVIOR; MEERKATS	Like humans engaged in risky activities, group members of some animal societies take turns acting as sentinels. Explanations of the evolution of sentinel behavior have frequently relied on kin selection or reciprocal altruism, but recent models suggest that guarding may be an individual's optimal activity once its stomach is full if no other animal is on guard. This paper provides support for this Last explanation by showing that, in groups of meerkats (Suricata suricatta), animals guard from safe sites, and solitary individuals as well as group members spend part of their time on guard. Though individuals seldom take successive guarding bouts, there is no regular rota, and the provision of food increases contributions to guarding and reduces the Latency between bouts by the same individual.	Univ Cambridge, Dept Zool, Large Anim Res Grp, Cambridge CB2 3EJ, England; Univ Pretoria, Mammal Res Inst, ZA-0002 Pretoria, South Africa; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Cambridge; University of Pretoria; University of Edinburgh	Clutton-Brock, TH (corresponding author), Univ Cambridge, Dept Zool, Large Anim Res Grp, Downing St, Cambridge CB2 3EJ, England.		Griffin, Ashleigh/C-6244-2014	Griffin, Ashleigh/0000-0001-7674-9825; O'Riain, M. Justin/0000-0001-5233-8327				Bednekoff PA, 1997, AM NAT, V150, P373, DOI 10.1086/286070; Clutton-Brock TH, 1998, P ROY SOC B-BIOL SCI, V265, P185, DOI 10.1098/rspb.1998.0281; Clutton-Brock TH, 1999, AFR J ECOL, V37, P69, DOI 10.1046/j.1365-2028.1999.00160.x; CLUTTONBROCK TH, IN PRESS J ANIM ECOL; Doolan SP, 1996, J ZOOL, V239, P697, DOI 10.1111/j.1469-7998.1996.tb05472.x; FERGUSON JWH, 1986, ETHOLOGY, V76, P233; GASTON AJ, 1977, ANIM BEHAV, V25, P828, DOI 10.1016/0003-3472(77)90036-7; GRIFFIN AS, 1999, THESIS U EDINBURGH; HAILMAN JP, 1994, ETHOLOGY, V97, P119; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Macdonald D. W., 1992, VELVET CLAW; MCGOWAN KJ, 1989, ANIM BEHAV, V37, P1000, DOI 10.1016/0003-3472(89)90144-9; MORAN G, 1984, Z TIERPSYCHOL, V65, P228; RASA OAE, 1987, S AFR J SCI, V83, P587; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Zar J., 1996, BIOSTAT ANAL; [No title captured]	17	289	302	5	257	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1640	1644		10.1126/science.284.5420.1640	http://dx.doi.org/10.1126/science.284.5420.1640			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356387				2022-12-01	WOS:000080668300035
J	Nightingale, SL				Nightingale, SL			Hypotension and bedside leukocyte reduction filters	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					1978	1978		10.1001/jama.281.21.1978	http://dx.doi.org/10.1001/jama.281.21.1978			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200NN	10359372				2022-12-01	WOS:000080546700006
J	Sullivan, DH; Sun, S; Walls, RC				Sullivan, DH; Sun, S; Walls, RC			Protein-energy undernutrition among elderly hospitalized patients - A prospective study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESTING METABOLIC-RATE; GERIATRIC-PATIENTS; MALNUTRITION; COMPLICATIONS; POPULATION; NUTRITION; MORBIDITY; EQUATION; ILLNESS	Context Numerous studies have identified strong correlations between the severity of nutritional deficits and an increased risk of subsequent morbid events among the hospitalized elderly, but whether inadequate nutrient intake during hospitalization contributes to such nutritional deficits or the risk of adverse outcomes is not known. Objectives To identify the distribution of average daily nutrient intake among the nonterminally ill hospitalized elderly, ascertain what factors contribute to persistently low intakes, and determine whether the adequacy of nutrient intake correlates with the risk of mortality. Design Prospective cohort study conducted from 1994 to 1997, Setting University-affiliated Department of Veterans Affairs hospital. Patients A total of 497 patients 65 years or older (mean [SD] age, 74 [6] years; 97% male; 86% white) with a length of stay of 4 days or more. Main Outcome Measures Daily in-hospital nutrient intake, in-hospital mortality, and 90-day mortality. Results A total of 102 patients (21%) had an average daily in-hospital nutrient intake of less than 50% of their calculated maintenance energy requirements. Admission illness severity, average length of stay, and admission albumin and prealbumin levels for this low nutrient group did not differ significantly from those of the remaining patients. However, the low nutrient group had lower mean (SD) discharge serum total cholesterol (154 [44] mg/dL [4 {1.1} mmol/L] vs 173 [42] mg/dL [4.5 {1.1} mmol/L]; P = .001), albumin (29.1 [6.7] vs 33.2 [6.1] g/L, P = .001), and prealbumin (162 [69] vs 205 [68] mg/L; P = .001) concentrations and a higher rate of in-hospital mortality (relative risk, 8.0; 95% confidence interval, 2.8-22.6) and 90-day mortality (relative risk, 2.9; 95% confidence interval, 1.4-6.1). Contributing to the problem of inadequate nutrient intake, patients were frequently ordered to have nothing by mouth and were not fed by another route. Neither canned supplements nor nutritional support were used effectively. Conclusions Throughout their hospitalization, many elderly patients were maintained on nutrient intakes far less than their estimated maintenance energy requirements, which may contribute to an increased risk of mortality. Given the difficulties reversing established nutritional deficits in the elderly, greater efforts should be made to prevent the development of such deficits during hospitalization.	Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr 182LR, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Biometry, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Donald W Reynolds Dept Geriatr, Little Rock, AR 72205 USA	Geriatric Research Education & Clinical Center; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences	Sullivan, DH (corresponding author), Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Geriatr Res Educ & Clin Ctr 182LR, 4300 W 7th St, Little Rock, AR 72205 USA.							ALPERS DH, 1985, MANUAL NUTR THERAPEU; ANDERSON CF, 1984, MAYO CLIN PROC, V59, P477, DOI 10.1016/S0025-6196(12)60437-6; ARCIERO PJ, 1993, METABOLISM, V42, P950, DOI 10.1016/0026-0495(93)90006-A; BADEN AL, 1992, J AM DIET ASSOC, V92, P77; BIENIA R, 1982, J AM GERIATR SOC, V30, P433, DOI 10.1111/j.1532-5415.1982.tb03378.x; BUZBY GP, 1980, AM J SURG, V139, P160, DOI 10.1016/0002-9610(80)90246-9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CONSTANS T, 1992, J AM GERIATR SOC, V40, P263, DOI 10.1111/j.1532-5415.1992.tb02080.x; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HESSOV I, 1977, ACTA CHIR SCAND, V143, P145; Incalzi RA, 1996, ARCH INTERN MED, V156, P425, DOI 10.1001/archinte.156.4.425; Jeejeebhoy KN, 1976, ANN R COL PHYS SURG, V9, P287; JONES EW, 1973, PUBLICATION HRA; KAMATH SK, 1986, J AM DIET ASSOC, V86, P203; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KLIPSTEINGROBUSCH K, 1995, BRIT J NUTR, V73, P323, DOI 10.1079/BJN19950033; LAWTON MP, 1972, RES PLANNING ACTION, P123; LOCKREM JD, 1991, CLEV CLIN J MED, V58, P477, DOI 10.3949/ccjm.58.6.477; Morley JE, 1997, AM J CLIN NUTR, V66, P760, DOI 10.1093/ajcn/66.4.760; NARAIN P, 1988, J AM GERIATR SOC, V36, P775, DOI 10.1111/j.1532-5415.1988.tb04259.x; PINCHCOFSKY GD, 1985, J AM COLL NUTR, V4, P471, DOI 10.1080/07315724.1985.10720089; POEHLMAN ET, 1992, METABOLISM, V41, P915, DOI 10.1016/0026-0495(92)90177-C; PREVOST EA, 1974, AM J CLIN NUTR, V27, P432; RAMMOHAN M, 1989, J AM DIET ASSOC, V89, P1774; ROZA AM, 1984, AM J CLIN NUTR, V40, P168, DOI 10.1093/ajcn/40.1.168; SANDSTROM B, 1985, HUM NUTR-APPL NUTR, V39A, P87; *SAS I INC, 1990, SAS US GUID STAT VER, V2; SULLIVAN DH, 1995, CLIN GERIATR MED, V11, P661, DOI 10.1016/S0749-0690(18)30264-7; SULLIVAN DH, 1989, JPEN-PARENTER ENTER, V13, P249, DOI 10.1177/0148607189013003249; SULLIVAN DH, 1995, J AM COLL NUTR, V14, P29; TOBIAS AL, 1977, J AM DIET ASSOC, V71, P253; TODD EA, 1984, HUM NUTR-APPL NUTR, V38A, P294; TOMAIOLO PP, 1981, JPEN-PARENTER ENTER, V5, P46, DOI 10.1177/014860718100500146; VOLKERT D, 1992, ANN NUTR METAB, V36, P97, DOI 10.1159/000177704; Yesavage JA, 1983, J PSYCHIATR RES, V17, P31	36	340	352	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					2013	2019		10.1001/jama.281.21.2013	http://dx.doi.org/10.1001/jama.281.21.2013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200NN	10359390	Bronze			2022-12-01	WOS:000080546700031
J	Dunn, D; Wallon, M; Peyron, F; Petersen, E; Peckham, C; Gilbert, R				Dunn, D; Wallon, M; Peyron, F; Petersen, E; Peckham, C; Gilbert, R			Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling	LANCET			English	Article							CONGENITAL TOXOPLASMOSIS; FOLLOW-UP; PREGNANCY; INFECTION; DIAGNOSIS; PREVENTION; INFANTS; WOMEN; AIDS	Background. Women who acquire toxoplasmosis infection during pregnancy (in most cases detected through serological screening) require counselling about the risk of congenital infection and its clinical sequelae, Reliable estimates of risk are not currently available, We undertook an analysis of data from women referred to the toxoplasmosis reference laboratory, Lyon, France, between 1987 and 1995. Methods. Information was collected from clinical notes kept at the laboratory and, where necessary, from the relevant obstetrician or paediatrician via telephone. Methods were developed to derive estimates of the risk of congenital toxoplasmosis by exact duration of gestation at maternal seroconversion. Findings. We analysed obstetric and paediatric data on 603 confirmed maternal toxoplasmosis infections. At least 564 women received antiparasitic drugs according to a standard protocol. Congenital infection status was ascertained in 554 cases, and infected children were followed-up for a median of 54 months. The overall maternal-fetal transmission rate was 29% (95% CI 25-33), which masked a sharp increase in risk with duration of gestation from 6% at 13 weeks to 72% at 36 weeks. However, fetuses infected in early pregnancy were much more likely to show clinical signs of infection. These effects counterbalance, and women who seroconverted at 24-30 weeks of gestation carried the highest risk (10%) of having a congenitally infected child with early clinical signs who was thus at risk of long-term complications. Interpretation. This information will assist the clinical counselling of pregnant women diagnosed with acute toxoplasmosis and may guide individual decisions on investigative and therapeutic options. Further studies are required to determine the long-term risks of clinical symptoms and disability due to congenital toxoplasmosis.	UCL, Sch Med, Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England; Hop Croix Rousse, Lab Parasitol & Pathol Exot, F-69317 Lyon, France; Statens Serum Inst, Parasitol Lab, DK-2300 Copenhagen, Denmark	University of London; University College London; UCL Medical School; CHU Lyon; Statens Serum Institut	Gilbert, R (corresponding author), UCL, Sch Med, Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England.	r.gilbert@ich.ucl.ac.uki	Wallon, martine/D-1340-2013; peckham, catherine s/I-6300-2013	Wallon, martine/0000-0001-8285-8550; Dunn, David/0000-0003-1836-4446; Gilbert, Ruth/0000-0001-9347-2709	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADES AE, 1991, EPIDEMIOL INFECT, V107, P527, DOI 10.1017/S0950268800049220; BACCHETTI P, 1990, J AM STAT ASSOC, V85, P1002, DOI 10.2307/2289596; BERREBI A, 1994, LANCET, V344, P36, DOI 10.1016/S0140-6736(94)91054-5; COUVREUR J, 1985, SEM HOP PARIS, V61, P3015; COZON G, 1993, CYTOMETRY, V14, P569, DOI 10.1002/cyto.990140518; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DEGRUTTOLA V, 1989, BIOMETRICS, V45, P1; DESMONTS G, 1984, ANN PEDIATR-PARIS, V31, P805; Desmonts G., 1982, LYON MED, V248, P115; GILBERT RE, 1995, BRIT MED J, V310, P1037, DOI 10.1136/bmj.310.6986.1037; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; HALL SM, 1992, BMJ-BRIT MED J, V305, P291, DOI 10.1136/bmj.305.6848.291; HINKLEY DV, 1991, J ROYAL STAT SOC B, V10, P1753; HOHLFELD P, 1989, J PEDIATR-US, V115, P765, DOI 10.1016/S0022-3476(89)80660-2; HOHLFELD P, 1994, NEW ENGL J MED, V331, P695, DOI 10.1056/NEJM199409153311102; JEANNEL D, 1990, LANCET, V336, P359, DOI 10.1016/0140-6736(90)91890-M; KOPPE JG, 1989, INT OPHTHALMOL, V13, P387, DOI 10.1007/BF02306486; MCAULEY J, 1994, CLIN INFECT DIS, V18, P38, DOI 10.1093/clinids/18.1.38; *NUM ALG GROUP, 1990, NAG FORTR LIB MAN MA; Peyron F, 1996, NEW ENGL J MED, V334, P993, DOI 10.1056/NEJM199604113341517; PONS JC, 1995, PRESSE MED, V24, P179; PRATLONG F, 1994, PRENATAL DIAG, V14, P191, DOI 10.1002/pd.1970140309; RAEBER PA, 1995, SCHWEIZ MED WSCHR, V125, pS96; Remington JS., 1995, INFECT DIS FETUS NEW, V4, P140; ROIZEN N, 1995, PEDIATRICS, V95, P11; THULLIEZ P, 1992, SCAND J INFECT DIS, P43	26	390	427	1	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 29	1999	353	9167					1829	1833		10.1016/S0140-6736(98)08220-8	http://dx.doi.org/10.1016/S0140-6736(98)08220-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359407				2022-12-01	WOS:000080667800011
J	Kennedy, J; Auclair, K; Kendrew, SG; Park, C; Vederas, JC; Hutchinson, CR				Kennedy, J; Auclair, K; Kendrew, SG; Park, C; Vederas, JC; Hutchinson, CR			Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis	SCIENCE			English	Article							MYCOCEROSIC ACID SYNTHASE; DIELS-ALDER REACTION; ASPERGILLUS-TERREUS; MYCOBACTERIUM-TUBERCULOSIS; OXYGEN-ATOMS; ACYL-COA; ORIGIN; MEVINOLIN; GENE; BIOCHEMISTRY	Polyketides, the ubiquitous products of secondary metabolism in microorganisms, are made by a process resembling fatty acid biosynthesis that allows the suppression of reduction or dehydration reactions at specific biosynthetic steps, giving rise to a wide range of often medically useful products. The Lovastatin biosynthesis cluster contains two type I polyketide synthase genes. Synthesis of the main nonaketide-derived skeleton was found to require the previously known iterative Lovastatin nonaketide synthase (LNKS), plus at least one additional protein (LovC) that interacts with LNKS and is necessary for the correct processing of the growing polyketide chain and production of dihydromonacolin L. The noniterative lovastatin diketide synthase (LDKS) enzyme specifies formation of 2-methylbutyrate and interacts closely with an additional transesterase (LovD) responsible for assembling Lovastatin from this polyketide and monacolin J.	Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Alberta	Vederas, JC (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.		Kennedy, Jonathan/G-5621-2010	Kennedy, Jonathan/0000-0002-9126-1198; Vederas, John/0000-0002-2996-0326	NIAID NIH HHS [AI43031] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043031] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn JH, 1998, MOL GEN GENET, V260, P462, DOI 10.1007/s004380050917; AUCLAIR K, SCIENCE; AUCLAIR K, UNPUB; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; CHAN JK, 1983, J AM CHEM SOC, V105, P3334, DOI 10.1021/ja00348a062; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; Guenzi E, 1998, J BIOL CHEM, V273, P32857, DOI 10.1074/jbc.273.49.32857; HARDMAN JG, 1996, GOODMAN GILMANS PHAR, P885; HENDRICKSON L, UNPUB; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; Ichihara A, 1998, CURR ORG CHEM, V2, P365; JACOBS M, 1995, MYCOTA, V2, P155; Katayama K, 1998, BBA-PROTEIN STRUCT M, V1384, P387, DOI 10.1016/S0167-4838(98)00040-5; Katz L, 1997, CHEM REV, V97, P2557, DOI 10.1021/cr960025+; KENNEDY JD, UNPUB; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KONO Y, 1979, BIOORG CHEM, V8, P391, DOI 10.1016/0045-2068(79)90064-6; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; Liu YQ, 1998, TETRAHEDRON, V54, P15937, DOI 10.1016/S0040-4020(98)01003-5; MONAGHAN RL, 1990, ANNU REV MICROBIOL, V44, P271; MOORE RN, 1985, J AM CHEM SOC, V107, P3694, DOI 10.1021/ja00298a046; NAKAMURA T, 1990, J ANTIBIOT, V43, P1597, DOI 10.7164/antibiotics.43.1597; O'Hagan D., 1991, POLYKETIDE METABOLIT; OIKAWA H, 1994, J AM CHEM SOC, V116, P3605, DOI 10.1021/ja00087a059; RAINWATER DL, 1985, J BIOL CHEM, V260, P616; Rangaswamy V, 1998, P NATL ACAD SCI USA, V95, P15469, DOI 10.1073/pnas.95.26.15469; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Staunton J, 1997, CHEM REV, V97, P2611, DOI 10.1021/cr9600316; TREIBER LR, 1989, J ANTIBIOT, V42, P30, DOI 10.7164/antibiotics.42.30; Vinci VA, 1998, US, Patent No. [5744350 A, 5744350]; Wagschal K, 1996, J CHEM SOC PERK T 1, P2357, DOI 10.1039/p19960002357; Witter DJ, 1996, J ORG CHEM, V61, P2613, DOI 10.1021/jo952117p; YAMAMOTO Y, 1985, J AM CHEM SOC, V107, P2471, DOI 10.1021/ja00294a045; YANG G, 1996, PLANT CELL, V8, P139; YOSHIZAWA Y, 1994, J AM CHEM SOC, V116, P2693, DOI 10.1021/ja00085a089	37	502	555	3	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1368	1372		10.1126/science.284.5418.1368	http://dx.doi.org/10.1126/science.284.5418.1368			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334994				2022-12-01	WOS:000080430600057
J	Wei, J; Buriak, JM; Siuzdak, G				Wei, J; Buriak, JM; Siuzdak, G			Desorption-ionization mass spectrometry on porous silicon	NATURE			English	Article							LASER; LUMINESCENCE; FABRICATION; MOLECULES; CHEMISTRY; WAFERS	Desorption mass spectrometry has undergone significant improvements since the original experiments were performed more than 90 years ago(1). The most dramatic change occurred in the early 1980s with the introduction of an organic matrix(2-4) to transfer energy to the analyte. This reduces ion fragmentation but also introduces background ions from the matrix. Here we describe a matrix-free strategy for biomolecular mass spectrometry based on pulsed-laser desorption-ionization from a porous silicon(5) surface. Our method uses porous silicon to trap analytes deposited on the surface, and laser irradiation to vaporize and ionize them. We show that the method works at femtomole and attomole levels of analyte, and induces little or no fragmentation, in contrast to what is typically observed with other such approaches(6-11). The ability to perform these measurements without a matrix(3,4,12,13) also makes it more amenable to small-molecule analysis. Chemical(14) and structural(15) modification of the porous silicon has enabled optimization of the ionization characteristics of the surface. Our technique offers good sensitivity as well as compatibility with silicon-based microfluidics and microchip technologies.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Scripps Research Institute; Scripps Research Institute	Buriak, JM (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	buriak@purdue.edu; siuzdak@scripps.edu		Siuzdak, Gary/0000-0002-4749-0014; Buriak, Jillian Mary/0000-0002-9567-4328				BARBER M, 1981, NATURE, V293, P270, DOI 10.1038/293270a0; Buriak JM, 1998, J AM CHEM SOC, V120, P1339, DOI 10.1021/ja9740125; Canham L.T., 1997, PROPERTIES POROUS SI, P83; CANHAM LT, 1990, APPL PHYS LETT, V57, P1046, DOI 10.1063/1.103561; CANHAM LT, 1997, PROPERTIES POROUS SI, P44; CANHAM LT, 1997, PROPERTIES POROUS SI, P154; Cullis AG, 1997, J APPL PHYS, V82, P909, DOI 10.1063/1.366536; DOAN VV, 1992, APPL PHYS LETT, V60, P619, DOI 10.1063/1.106572; Hillenkamp F, 1991, Anal Chem, V63, p1193A, DOI 10.1021/ac00024a002; HRUBOWCHAK DM, 1991, ANAL CHEM, V63, P1947, DOI 10.1021/ac00018a010; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Knochenmuss R, 1996, RAPID COMMUN MASS SP, V10, P871, DOI 10.1002/(SICI)1097-0231(19960610)10:8<871::AID-RCM559>3.0.CO;2-R; LIDGARD R, 1995, RAPID COMMUN MASS SP, V9, P128, DOI 10.1002/rcm.1290090205; MACFARLANE RD, 1976, SCIENCE, V191, P920, DOI 10.1126/science.1251202; ODonnell MJ, 1997, ANAL CHEM, V69, P2438, DOI 10.1021/ac961007v; POSTHUMUS MA, 1978, ANAL CHEM, V50, P985, DOI 10.1021/ac50029a040; Rudenauer H.W, 1987, SECONDARY ION MASS S, P1227; Sailor MJ, 1997, ADV MATER, V9, P783, DOI 10.1002/adma.19970091004; Schmuki P, 1998, PHYS REV LETT, V80, P4060, DOI 10.1103/PhysRevLett.80.4060; Stewart MP, 1998, ANGEW CHEM INT EDIT, V37, P3257, DOI 10.1002/(SICI)1521-3773(19981217)37:23<3257::AID-ANIE3257>3.0.CO;2-1; Thomson JJ, 1910, PHILOS MAG, V20, P752, DOI 10.1080/14786441008636962; VARAKIN VN, 1994, HIGH ENERG CHEM+, V28, P406; Wang SL, 1996, APPL SURF SCI, V93, P205, DOI 10.1016/0169-4332(95)00370-3; Zenobi R, 1997, CHIMIA, V51, P801; Zhan Q, 1997, J AM SOC MASS SPECTR, V8, P525, DOI 10.1016/S1044-0305(97)00005-6; [No title captured]; [No title captured]; [No title captured]; [No title captured]	29	925	981	3	236	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					243	246		10.1038/20400	http://dx.doi.org/10.1038/20400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353246				2022-12-01	WOS:000080427400050
J	Houdusse, A; Kalbokis, VN; Himmel, D; Szent-Gyorgyi, AG; Cohen, C				Houdusse, A; Kalbokis, VN; Himmel, D; Szent-Gyorgyi, AG; Cohen, C			Atomic structure of scallop myosin subfragment S1 complexed with MgADP: A novel conformation of the myosin head	CELL			English	Article							PHOSPHATE-RELEASE STEPS; SMOOTH-MUSCLE MYOSIN; X-RAY STRUCTURES; MOTOR DOMAIN; SKELETAL-MUSCLE; REGULATORY DOMAIN; ACTIN; RESOLUTION; NUCLEOTIDE; ACTOMYOSIN	The crystal structure of a proteolytic subfragment from scallop striated muscle myosin, complexed with MgADP, has been solved at 2.5 Angstrom resolution and reveals an unusual conformation of the myosin head. The converter and the lever arm are in very different positions from those in either the pre-power stroke or near-rigor state structures; moreover, in contrast to these structures, the SH1 helix is seen to be unwound. Here we compare the overall organization of the myosin head in these three states and show how the conformation of three flexible "joints" produces rearrangements of the four major subdomains in the myosin head with different bound nucleotides. We believe that this novel structure represents one of the prehydrolysis ("ATP") states of the contractile cycle in which the myosin heads stay detached from actin.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Biophys & Struct Biol Program, Waltham, MA 02254 USA	Brandeis University; Brandeis University; Brandeis University	Cohen, C (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA.			houdusse, anne/0000-0002-8566-0336	NIAMS NIH HHS [AR 17346, AR 15963, AR 41808] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041808, R01AR015963, R37AR015963, R37AR017346, R01AR017346] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; Berger CL, 1996, BIOPHYS J, V71, P3330, DOI 10.1016/S0006-3495(96)79526-7; BIVIN DB, 1993, P NATL ACAD SCI USA, V90, P6791, DOI 10.1073/pnas.90.14.6791; BRENNER B, 1982, P NATL ACAD SCI-BIOL, V79, P7288, DOI 10.1073/pnas.79.23.7288; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CHALOVICH JM, 1983, P NATL ACAD SCI-BIOL, V80, P4909, DOI 10.1073/pnas.80.16.4909; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Grinband J, 1998, BIOPHYS J, V74, pA263; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14949; HOLMES KC, 1997, NOVARTIS FDN S, V213, P76; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; HUSTON EE, 1988, BIOCHEMISTRY-US, V27, P8945, DOI 10.1021/bi00425a011; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalabokis VN, 1997, BIOCHEMISTRY-US, V36, P15834, DOI 10.1021/bi971932r; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liang WC, 1998, P NATL ACAD SCI USA, V95, P12844, DOI 10.1073/pnas.95.22.12844; Linari M, 1998, BIOPHYS J, V74, P2459, DOI 10.1016/S0006-3495(98)77954-8; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Nitao LK, 1998, BIOPHYS J, V74, pA259; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; Patterson B, 1997, J BIOL CHEM, V272, P27612, DOI 10.1074/jbc.272.44.27612; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Van Dijk J, 1998, BIOCHEMISTRY-US, V37, P8385, DOI 10.1021/bi980139a; WELLS JA, 1980, BIOCHEMISTRY-US, V19, P1711, DOI 10.1021/bi00549a030; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	41	307	307	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					459	470		10.1016/S0092-8674(00)80756-4	http://dx.doi.org/10.1016/S0092-8674(00)80756-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338210	Bronze			2022-12-01	WOS:000080299100007
J	Banavar, JR; Maritan, A; Rinaldo, A				Banavar, JR; Maritan, A; Rinaldo, A			Size and form in efficient transportation networks	NATURE			English	Article							POPULATION	Many biological processes, from cellular metabolism to population dynamics, are characterized by allometric scaling (power-law) relationships between size and rate(1-10). An outstanding question is whether typical allometric scaling relationships-the power-law dependence of a biological rate on body mass-can be understood by considering the general features of branching networks serving a particular volume. Distributed networks in nature stern from the need for effective connectivity(11), and occur both in biological systems such as cardiovascular and respiratory networks(1-8) and plant vascular and root systems(1,9,10), and in inanimate systems such as the drainage network of river basins(12), Here we derive a general relationship between size and flow rates in arbitrary networks with local connectivity. Our theory accounts in a general way for the quarter-power allometric scaling of living organisms(1-10), recently derived(8) under specific assumptions for particular network geometries. It also predicts scaling relations applicable to all efficient transportation networks, which we verify from observational data on the river drainage basins. Allometric scaling is therefore shown to originate from the general features of networks irrespective of dynamical or geometric assumptions.	Penn State Univ, Dept Phys, Davey Lab 104, University Pk, PA 16802 USA; Penn State Univ, Ctr Phys Mat, Davey Lab 104, University Pk, PA 16802 USA; SISSA, I-34014 Trieste, Italy; Abdus Salam Int Ctr Theoret Phys, I-34014 Trieste, Italy; MIT, Dept Civil & Environm Engn, Ralph M Parsons Lab, Cambridge, MA 02139 USA; Univ Padua, Dipartimento Ingn Idraul Marittina & Geotecn, Padua, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; International School for Advanced Studies (SISSA); Abdus Salam International Centre for Theoretical Physics (ICTP); Massachusetts Institute of Technology (MIT); University of Padua	Banavar, JR (corresponding author), Penn State Univ, Dept Phys, Davey Lab 104, University Pk, PA 16802 USA.							BONNER JT, 1983, EVOLUTION COMPLEXITY; Brown J.H., 1995, MACROECOLOGY; Calder W. A, 1984, SIZE FUNCTION LIFE H; Damuth JD, 1998, NATURE, V395, P115, DOI 10.1038/25843; Enquist BJ, 1998, NATURE, V395, P163, DOI 10.1038/25977; FELDMAN HA, 1983, RESP PHYSIOL, V52, P149, DOI 10.1016/0034-5687(83)90002-6; McMahon T., 1983, SIZE LIFE; Rodruiguez-Iturbe I., 1997, FRACTAL RIVER BASINS; SCHMIDT NK, 1984, SCALING IS ANIMAL SI; STEVENS PS, 1974, PATTERNS NATURE; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; WILSON EO, 1997, CONSILIENCE UNITY KN	12	568	584	3	116	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	1999	399	6732					130	132		10.1038/20144	http://dx.doi.org/10.1038/20144			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335841				2022-12-01	WOS:000080335700043
J	Sharp, D				Sharp, D			Trends in cancer survival in England and Wales	LANCET			English	Article									The Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), The Lancet, 42 Bedford Sq, London WC1B 3SL, England.							BERRINO F, IN PRESS IARC SCI PU, V151; *CANC RES CAMP, 1999, 2 CRC; Coebergh JXW, 1998, EUR J CANCER, V34, P2137; Coleman MP., 1999, CANC SURVIVAL TRENDS; Selby P, 1996, LANCET, V348, P313, DOI 10.1016/S0140-6736(96)02482-8	5	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1437	1438		10.1016/S0140-6736(99)03340-1	http://dx.doi.org/10.1016/S0140-6736(99)03340-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227241				2022-12-01	WOS:000080020800046
J	Schaeffer, EM; Debnath, J; Yap, G; McVicar, D; Liao, XC; Littman, DR; Sher, A; Varmus, HE; Lenardo, MJ; Schwartzberg, PL				Schaeffer, EM; Debnath, J; Yap, G; McVicar, D; Liao, XC; Littman, DR; Sher, A; Varmus, HE; Lenardo, MJ; Schwartzberg, PL			Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity	SCIENCE			English	Article							TYROSINE KINASES; ANTIGEN RECEPTOR; PROTEIN-KINASE; TRANSDUCTION; PHOSPHORYLATION; RESISTANCE; ACTIVATION; FAMILY; MICE	T cell receptor (TCR) signaling requires activation of Zap-70 and Src family tyrosine kinases, but requirements for other tyrosine kinases are Less clear. Combined deletion in;mice of two Tec kinases, Rlk and Itk, caused marked defects in TCR responses including proliferation, cytokine production, and apoptosis in vitro and adaptive:immune responses to Toxoplasma gondii in vivo. Molecular events immediately downstream from the TCR were intact in rlk(-/-)itk(-/-) cells, but intermediate events including inositol trisphosphate production, calcium mobilization, and mitogen-activated protein kinase activation were impaired, establishing Tec kinases as critical regulators of TCR signaling required for phospholipase C-gamma activation.	Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA; NIAID, NIH, Bethesda, MD 20892 USA; Tularik, S San Francisco, CA 94080 USA; NYU, Med Ctr, Skirball Inst Biomol Med, New York, NY 10016 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); New York University	Schwartzberg, PL (corresponding author), Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA.			Debnath, Jayanta/0000-0002-8745-4069	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000627] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bachmann MF, 1997, J VIROL, V71, P7253, DOI 10.1128/JVI.71.10.7253-7257.1997; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Debnath J, 1999, MOL CELL BIOL, V19, P1498; Denkers EY, 1997, J IMMUNOL, V159, P1903; DESIDERIO S, 1994, CHEM IMMUNOL, V59, P191; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; Liu KQ, 1998, J EXP MED, V187, P1721, DOI 10.1084/jem.187.10.1721; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; SCHAEFFER E, UNPUB; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SchartonKersten TM, 1997, CURR OPIN IMMUNOL, V9, P44, DOI 10.1016/S0952-7915(97)80157-4; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SOZERI O, 1992, ONCOGENE, V7, P2259; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	21	324	342	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					638	641		10.1126/science.284.5414.638	http://dx.doi.org/10.1126/science.284.5414.638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213685				2022-12-01	WOS:000079951100043
J	Kenny-Walsh, E				Kenny-Walsh, E		Irish Hepatol Res Grp	Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							D IMMUNOGLOBULIN; NATURAL-HISTORY; BLOOD-DONORS; NON-A; POSTTRANSFUSION HEPATITIS; VIRUS-INFECTION; LIVER-DISEASE; FOLLOW-UP; TRANSMISSION; TRANSFUSION	Background and Methods In February 1994, batches of anti-D immune globulin used in Ireland during 1977 and 1978 to prevent Rh isoimmunization were found to be contaminated with hepatitis C virus (HCV) from a single infected donor. In March 1994, a national screening program was initiated for all women who had received anti-D immune globulin between 1970 and 1994. Of the 62,667 women who had been screened when this study began, 704 (1.1 percent) had evidence of past or current HCV infection, and 390 of those 704 (55 percent) had positive tests for serum HCV RNA on reverse-transcription-polymerase-chain-reaction analysis. All 390 Were offered a referral for clinical assessment and therapy. We evaluated 376 of these 390 women (96 percent); the other 14 were not seen at one of the designated treatment centers. Results The mean (+/-SD) age of the 376 women was 45+/-6 years at the time of screening. They had been infected with hepatitis C for about 17 years. A total of 304 women (81 percent) reported symptoms, most commonly fatigue (248 women [66 percent]). Serum alanine aminotransferase concentrations were slightly elevated (40 to 99 U per liter) in 176 of 371 women (47 percent), and the concentrations were 100 U per liter or higher in 31 (8 percent). Liver biopsies showed inflammation in 356 of 363 women (98 percent); in most cases the inflammation was slight (41 percent) or moderate (52 percent). Although the biopsy samples from 186 of the 363 women (51 percent) showed evidence of fibrosis, only 7 women (2 percent) had probable or definite cirrhosis. Two of the seven reported excessive alcohol consumption. Conclusions Most of the women with HCV infection 17 years after receiving HCV-contaminated anti-D immune globulin had evidence of slight or moderate hepatic inflammation on liver biopsy, about half had fibrosis, and 2 percent had probable or definite cirrhosis, (N Engl J Med 1999;340:1228-33.) (C) 1999, Massachusetts Medical Society.	Cork Univ Hosp, Dept Med, Cork, Ireland	University College Cork	Kenny-Walsh, E (corresponding author), Cork Univ Hosp, Dept Med, Cork, Ireland.							ALTER HJ, 1993, VIRAL HEPATITIS SCI, P467; ALTER MJ, 1994, NEW ENGL J MED, V330, P784, DOI 10.1056/NEJM199403173301111; Armitage P, 1994, STAT METHODS MED RES; BJORO K, 1994, NEW ENGL J MED, V331, P1607, DOI 10.1056/NEJM199412153312402; *BLOOD TRANSF SERV, 1995, REP EXP GROUP BLOOD; BRECHOT CB, 1993, MOL DIAGN, V1, P2; *CENTR STAT OFF, 1977, ANN VIT STAT; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; CROWE J, 1995, GASTROENTEROLOGY, V108, pA1054, DOI 10.1016/0016-5085(95)28518-0; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; Dienstag JL, 1997, GASTROENTEROLOGY, V112, P651, DOI 10.1053/gast.1997.v112.agast970651; DITTMANN S, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P422; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; FINLAY TA, 1997, REPORT TRIBUNAL INQU, P176; GORDON SC, 1993, HEPATOLOGY, V18, P1338, DOI 10.1002/hep.1840180609; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; LAU JYN, 1993, LANCET, V342, P504; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LUDWIG J, 1994, AM J GASTROENTEROL, V89, pS177; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; Muller R, 1996, J HEPATOL, V24, P52; NISHIOKA K, 1991, LANCET, V338, P1040; PATON A, 1981, BRIT MED J, V283, P1248, DOI 10.1136/bmj.283.6301.1248; POWER JP, 1994, LANCET, V344, P1166, DOI 10.1016/S0140-6736(94)90679-3; POWER JP, 1995, LANCET, V345, P1211, DOI 10.1016/S0140-6736(95)91993-7; Poynard T, 1996, NEW ENGL J MED, V334, P1143; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; SCHIFF RI, 1994, NEW ENGL J MED, V331, P1649, DOI 10.1056/NEJM199412153312409; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Sheehan MM, 1997, HISTOPATHOLOGY, V30, P512, DOI 10.1046/j.1365-2559.1997.5530803.x; SIMMONDS P, 1993, MOL DIAGN, V1, P4; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9; Yamakawa Y, 1996, J VIRAL HEPATITIS, V3, P317, DOI 10.1111/j.1365-2893.1996.tb00104.x; Zeuzem S, 1996, J HEPATOL, V24, P3	40	723	745	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1228	1233		10.1056/NEJM199904223401602	http://dx.doi.org/10.1056/NEJM199904223401602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210705	Bronze			2022-12-01	WOS:000079833800002
J	Levine, M; Rumsey, SC; Daruwala, R; Park, JB; Wang, YH				Levine, M; Rumsey, SC; Daruwala, R; Park, JB; Wang, YH			Criteria and recommendations for vitamin C intake	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY HEART-DISEASE; ASCORBIC-ACID SUPPLEMENTATION; DEHYDROASCORBIC ACID; UNITED-STATES; ANTIOXIDANT VITAMINS; HUMAN NEUTROPHILS; OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; MACULAR DEGENERATION; CHRONIC-HEMODIALYSIS	Recommendations for vitamin C intake are under revision by the Food and Nutrition Board of the National Academy of Sciences, Since 1989 when the last recommended dietary allowance (RDA) of 60 mg was published, extensive biochemical, molecular, epidemiologic, and clinical data have become available. New recommendations can be based on the following 9 criteria: dietary availability, steady-state concentrations in plasma in relationship to dose, steady-state concentrations in tissues in relationship to dose, bioavailability, urine excretion, adverse effects, biochemical and molecular function in relationship to vitamin concentration, direct beneficial effects and epidemiologic observations in relationship to dose, and prevention of deficiency, We applied these criteria to the Food and Nutrition Board's new guidelines, the Dietary Reference Intakes, which include 4 reference values, The estimated average requirement (EAR) is the amount of nutrient estimated to meet the requirement of half the healthy individuals in a life-stage and gender group, Based on an EAR of 100 mg/d of vitamin C, the RDA is proposed to be 120 mg/d, If the EAR cannot be determined, an adequate intake (AI) amount is recommended instead of an RDA. The AI was estimated to be either 200 mg/d from 5 servings of fruits and vegetables or 100 mg/d of vitamin C to prevent deficiency with a margin of safety, The final classification, the tolerable upper intake level, is the highest daily level of nutrient intake that does not pose risk or adverse health effects to almost all individuals in the population. This amount is proposed to be less than 1 g of vitamin C daily. Physicians can tell patients that 5 servings of fruits and vegetables per day may be beneficial in preventing cancer and providing sufficient vitamin C intake for healthy people, and that 1 g or more of vitamin C may have adverse consequences in some people.	NIDDKD, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; USDA, Beltsville Human Nutr Res Ctr, Phytonutrients Lab, Beltsville, MD 20705 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Agriculture (USDA)	Levine, M (corresponding author), NIDDKD, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bldg 10,Room 4D52, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK054506, ZIADK054506] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allard JP, 1998, AIDS, V12, P1653, DOI 10.1097/00002030-199813000-00013; Auer BL, 1998, CLIN CHEM LAB MED, V36, P143, DOI 10.1515/CCLM.1998.027; BAKER EM, 1971, AM J CLIN NUTR, V24, P444; BALCKE P, 1984, ANN INTERN MED, V101, P344, DOI 10.7326/0003-4819-101-3-344; Barton JC, 1998, ANN INTERN MED, V129, P932, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00003; BASCH CE, 1994, AM J PUBLIC HEALTH, V84, P814, DOI 10.2105/AJPH.84.5.814; BLOCK G, 1994, AM J CLIN NUTR, V59, p232S, DOI 10.1093/ajcn/59.1.232S; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BUTZ M, 1994, UROLITHIASIS 2, P133; BYERS T, 1995, AM J CLIN NUTR, V62, P1385, DOI 10.1093/ajcn/62.6.1385S; BYERS T, 1998, VITAMIN C STATE OF T, P29; CAMPBELL GD, 1975, ANN INTERN MED, V82, P810, DOI 10.7326/0003-4819-82-6-810_1; COOK JD, 1984, BLOOD, V64, P721; CORREA P, 1992, CANCER RES, V52, P6735; CROSS CE, 1990, J LAB CLIN MED, V115, P396; Diaz MN, 1997, NEW ENGL J MED, V337, P408, DOI 10.1056/NEJM199708073370607; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; ERDMAN JW, 1982, ASCORBIC ACID CHEM M, P533; Food and Nutrition Board Commission on Life Sciences National Research Council, 1989, REC DIET ALL; *FOOD NUTR BOARD, 1994, SHOULD REC DIET ALL; Friedman GJ, 1940, J CLIN INVEST, V19, P685, DOI 10.1172/JCI101171; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; Galley HF, 1996, FREE RADICAL BIO MED, V20, P139, DOI 10.1016/0891-5849(95)02022-5; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GOGEL HK, 1989, AM J EMERG MED, V7, P474, DOI 10.1016/0735-6757(89)90248-9; GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023; Goodman Gilman G, 1996, GOODMAN GILMANS PHAR, V9th, P3; Graumlich JF, 1997, PHARMACEUT RES, V14, P1133, DOI 10.1023/A:1012186203165; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; HALLBERG L, 1987, ANN NY ACAD SCI, V498, P324, DOI 10.1111/j.1749-6632.1987.tb23771.x; HANKINSON SE, 1992, BMJ-BRIT MED J, V305, P335, DOI 10.1136/bmj.305.6849.335; HELSER MA, 1992, CARCINOGENESIS, V13, P2277, DOI 10.1093/carcin/13.12.2277; Hemila H, 1997, BRIT J NUTR, V77, P59, DOI 10.1017/S0007114500002889; Hitomi K, 1996, Subcell Biochem, V25, P41; JACQUES PF, 1988, ARCH OPHTHALMOL-CHIC, V106, P337, DOI 10.1001/archopht.1988.01060130363022; Jacques PF, 1997, AM J CLIN NUTR, V66, P911, DOI 10.1093/ajcn/66.4.911; JAFFE RM, 1975, ANN INTERN MED, V83, P824, DOI 10.7326/0003-4819-83-6-824; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; JIALAL I, 1990, ATHEROSCLEROSIS, V82, P185, DOI 10.1016/0021-9150(90)90039-L; JIALAL I, 1995, CAN J CARDIOL, V11, pG97; KOPLAN JP, 1986, AM J PUBLIC HEALTH, V76, P287, DOI 10.2105/AJPH.76.3.287; Krebs-Smith SM, 1998, CANCER-AM CANCER SOC, V83, P1425, DOI 10.1002/(SICI)1097-0142(19981001)83:7&lt;1425::AID-CNCR21&gt;3.0.CO;2-5; Kushi LH, 1996, AM J EPIDEMIOL, V144, P165, DOI 10.1093/oxfordjournals.aje.a008904; LACHANCE P, 1994, NUTR REV, V52, P266; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; LEVINE M, 1995, AM J CLIN NUTR, V62, P1347, DOI 10.1093/ajcn/62.6.1347S; Levine M, 1997, METHOD ENZYMOL, V281, P425; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; Levine M, 1998, NATURE, V395, P231, DOI 10.1038/26137; Levine M, 1997, METHOD ENZYMOL, V279, P43; LEVINE M, 1993, WORLD REV NUTR DIET, V72, P114; Levine M, 1996, PRESENT KNOWLEDGE NU, P146; LI MG, 1989, CLIN CHEM, V35, P2330; *LIF SCI RES OFF, 1995, 3 LIF SCI RES OFF; LIND J, 1756, TREATISE SCURVY; Losonczy KG, 1996, AM J CLIN NUTR, V64, P190, DOI 10.1093/ajcn/64.2.190; MARAINI G, 1991, AM J EPIDEMIOL, V133, P541; MaresPerlman JA, 1997, AM J CLIN NUTR, V66, P739, DOI 10.1093/ajcn/66.4.739; MEHTA JB, 1990, LANCET, V336, P944, DOI 10.1016/0140-6736(90)92317-B; MITCH WE, 1981, CLIN PHARMACOL THER, V29, P318, DOI 10.1038/clpt.1981.42; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670, DOI 10.1001/archopht.1989.01070010688028; NIENHUIS AW, 1981, NEW ENGL J MED, V304, P170, DOI 10.1056/NEJM198101153040311; Nyyssonen K, 1997, BRIT MED J, V314, P634, DOI 10.1136/bmj.314.7081.634; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; Patterson BH, 1997, NEW ENGL J MED, V337, P1846, DOI 10.1056/NEJM199712183372513; PATTERSON BH, 1990, AM J PUBLIC HEALTH, V80, P1443, DOI 10.2105/AJPH.80.12.1443; PATTERSON JA, 1995, J AM GERIATR SOC, V43, P919, DOI 10.1111/j.1532-5415.1995.tb05538.x; RAMIREZ J, 1980, AM J CLIN NUTR, V33, P2079, DOI 10.1093/ajcn/33.10.2079; REES DC, 1993, BRIT MED J, V306, P841, DOI 10.1136/bmj.306.6881.841; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; ROBERTSON JM, 1991, AM J CLIN NUTR, V53, pS346, DOI 10.1093/ajcn/53.1.346S; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 1998, J NUTR BIOCHEM, V9, P116, DOI 10.1016/S0955-2863(98)00002-3; Sahyoun NR, 1996, AM J EPIDEMIOL, V144, P501, DOI 10.1093/oxfordjournals.aje.a008957; SCHECTMAN G, 1993, ANN NY ACAD SCI, V686, P335, DOI 10.1111/j.1749-6632.1993.tb39197.x; Schorah CJ, 1996, AM J CLIN NUTR, V63, P760, DOI 10.1093/ajcn/63.5.760; SCHORAH CJ, 1998, VITAMIN C STATE OF T, P41; SCOTT P, 1993, BRIT J SURG, V80, P750, DOI 10.1002/bjs.1800800632; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; Simon JA, 1998, EPIDEMIOLOGY, V9, P316, DOI 10.1097/00001648-199805000-00017; SIMON JA, 1993, EPIDEMIOLOGY, V4, P537, DOI 10.1097/00001648-199311000-00010; SINGH RB, 1995, AM J CARDIOL, V76, P1233, DOI 10.1016/S0002-9149(99)80348-8; SOBALA GM, 1993, CARCINOGENESIS, V14, P291, DOI 10.1093/carcin/14.2.291; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEIN HB, 1976, ANN INTERN MED, V84, P385, DOI 10.7326/0003-4819-84-4-385; SULLIVAN JF, 1970, AM J CLIN NUTR, V23, P1339; SUTTON JL, 1983, HUM NUTR-APPL NUTR, V37, P136; TAYLOR TV, 1974, LANCET, V2, P544; TINCHIERI A, 1991, BR J UROL, V67, P230; URIVETZKY M, 1992, J UROLOGY, V147, P1215, DOI 10.1016/S0022-5347(17)37521-3; *USDA, 1998, USDA NUTR DAT STAND; VALLANCE S, 1988, BRIT J SURG, V75, P366, DOI 10.1002/bjs.1800750424; VANDERSLICE JT, 1991, AM J CLIN NUTR, V54, pS1323, DOI 10.1093/ajcn/54.6.1323s; VITALE S, 1993, EPIDEMIOLOGY, V4, P195, DOI 10.1097/00001648-199305000-00003; WANDZILAK TR, 1994, J UROLOGY, V151, P834, DOI 10.1016/S0022-5347(17)35100-5; Wang YH, 1997, P NATL ACAD SCI USA, V94, P13816, DOI 10.1073/pnas.94.25.13816; WASHKO PW, 1992, ANAL BIOCHEM, V204, P1, DOI 10.1016/0003-2697(92)90131-P; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WILSON DM, 1991, CLIN CHEM, V37, P1229; Yates AA, 1998, J AM DIET ASSOC, V98, P699, DOI 10.1016/S0002-8223(98)00160-6; Yong LC, 1997, AM J EPIDEMIOL, V146, P231, DOI 10.1093/oxfordjournals.aje.a009258; YOUNG IS, 1994, FREE RADICAL BIO MED, V16, P393, DOI 10.1016/0891-5849(94)90041-8; [No title captured]	106	348	356	1	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1415	1423		10.1001/jama.281.15.1415	http://dx.doi.org/10.1001/jama.281.15.1415			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217058				2022-12-01	WOS:000079701000032
J	Force, T; Rosenzweig, A; Choukroun, G; Hajjar, R				Force, T; Rosenzweig, A; Choukroun, G; Hajjar, R			Calcineurin inhibitors and cardiac hypertrophy	LANCET			English	Editorial Material							ACTIVATED PROTEIN-KINASES		Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Unit, Boston, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02129 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School	Force, T (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Unit, Boston, MA 02129 USA.		Rosenzweig, Anthony/AAD-7893-2019; Gabriel, Choukroun/AAL-4969-2021	Force, Thomas/0000-0002-0450-8659				Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; CHOUKROUN G, 1998, CIRCULATION S1, V98, P69; Ding B, 1999, CIRC RES, V84, P729, DOI 10.1161/01.RES.84.6.729; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Luo ZY, 1998, NAT MED, V4, P1092, DOI 10.1038/2578; Meguro T, 1999, CIRC RES, V84, P735, DOI 10.1161/01.RES.84.6.735; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MOLKENTIN JD, 1998, SCIENCE, V282, P1007; MULLER JG, 1998, SCIENCE, V282, P1007; Pitt B, 1998, CIRCULATION, V98, P1987, DOI 10.1161/01.CIR.98.19.1987; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722	17	19	19	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1290	1292		10.1016/S0140-6736(99)90016-8	http://dx.doi.org/10.1016/S0140-6736(99)90016-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218524				2022-12-01	WOS:000080278100006
J	Abbott, GW; Sesti, F; Splawski, I; Buck, ME; Lehmann, WH; Timothy, KW; Keating, MT; Goldstein, SAN				Abbott, GW; Sesti, F; Splawski, I; Buck, ME; Lehmann, WH; Timothy, KW; Keating, MT; Goldstein, SAN			MiRP1 forms I-Kr potassium channels with HERG and is associated with cardiac arrhythmia	CELL			English	Article							LONG-QT SYNDROME; RECTIFIER K+ CURRENT; TORSADES-DE-POINTES; LANGE-NIELSEN-SYNDROME; TIME-DEPENDENT BLOCK; VENTRICULAR MYOCYTES; EXTERNAL CA2+; RAPID COMPONENT; XENOPUS OOCYTES; CAUSE JERVELL	A novel potassium channel gene has been cloned, characterized, and associated with cardiac arrhythmia. The gene encodes MinK-related peptide 1 (MiRP1), a small integral membrane subunit that assembles with HERO, a pore-forming protein, to alter its function. Unlike channels formed only with HERG, mixed complexes resemble native cardiac I-Kr channels in their gating, unitary conductance, regulation by potassium, and distinctive biphasic inhibition by the class III antiarrhythmic E-4031. Three missense mutations associated with long QT syndrome and ventricular fibrillation are identified in the gene for MiRP1. Mutants form channels that open slowly and close rapidly, thereby diminishing potassium currents. One variant, associated with clarithromycin-induced arrhythmia, increases channel blockade by the antibiotic. A mechanism for acquired arrhythmia is revealed: genetically based reduction in potassium currents that remains clinically silent until combined with additional stressors.	Yale Univ, Sch Med, Dept Pediat, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Univ Utah, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; VA Med Ctr, Ann Arbor, MI 48109 USA	Yale University; Yale University; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Michigan System; University of Michigan	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Dept Pediat, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06536 USA.		Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046401, P50HL052338] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00064] Funding Source: Medline; NHLBI NIH HHS [P50-HL52338, R01-HL46401] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antzelevitch C, 1996, J AM COLL CARDIOL, V28, P1836, DOI 10.1016/S0735-1097(96)00377-4; BUSCH AE, 1992, SCIENCE, V255, P1705, DOI 10.1126/science.1553557; Busch AE, 1997, BRIT J PHARMACOL, V122, P187, DOI 10.1038/sj.bjp.0701434; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; CARMELIET E, 1993, CIRC RES, V73, P857, DOI 10.1161/01.RES.73.5.857; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DALEAU P, 1995, CIRCULATION, V91, P3010, DOI 10.1161/01.CIR.91.12.3010; Drici MD, 1998, JAMA-J AM MED ASSOC, V280, P1774, DOI 10.1001/jama.280.20.1774; Duggal P, 1998, CIRCULATION, V97, P142, DOI 10.1161/01.CIR.97.2.142; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; Ho WK, 1998, J PHYSIOL-LONDON, V507, P631, DOI 10.1111/j.1469-7793.1998.631bs.x; Ho WK, 1996, J PHYSIOL-LONDON, V494, P727, DOI 10.1113/jphysiol.1996.sp021528; Howarth FC, 1996, PFLUG ARCH EUR J PHY, V431, P713, DOI 10.1007/BF02253834; Kaczmarek LK, 1997, PHYSIOL REV, V77, P627, DOI 10.1152/physrev.1997.77.3.627; Lee KL, 1998, AM J MED, V104, P395, DOI 10.1016/S0002-9343(98)00059-X; LeesMiller JP, 1997, CIRC RES, V81, P719; Liu SG, 1996, BIOPHYS J, V70, P2704, DOI 10.1016/S0006-3495(96)79840-5; London B, 1997, CIRC RES, V81, P870; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1992, PFLUG ARCH EUR J PHY, V420, P180, DOI 10.1007/BF00374988; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SCAMPS F, 1989, AM J PHYSIOL, V257, pC1086, DOI 10.1152/ajpcell.1989.257.6.C1086; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Sesti F, 1998, J GEN PHYSIOL, V112, P651, DOI 10.1085/jgp.112.6.651; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Tyson J, 1997, HUM MOL GENET, V6, P2179, DOI 10.1093/hmg/6.12.2179; VELDKAMP MW, 1995, CIRCULATION, V92, P3497, DOI 10.1161/01.CIR.92.12.3497; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang SM, 1997, FEBS LETT, V417, P43, DOI 10.1016/S0014-5793(97)01245-3; Wang SM, 1997, J PHYSIOL-LONDON, V502, P45, DOI 10.1111/j.1469-7793.1997.045bl.x; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870; Yang T, 1997, CIRC RES, V80, P782; Yang T, 1996, CIRCULATION, V93, P407, DOI 10.1161/01.CIR.93.3.407; Yang YS, 1998, J GEN PHYSIOL, V112, P665, DOI 10.1085/jgp.112.6.665; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zou AR, 1997, AM J PHYSIOL-HEART C, V272, pH1309, DOI 10.1152/ajpheart.1997.272.3.H1309	56	1007	1075	0	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 16	1999	97	2					175	187		10.1016/S0092-8674(00)80728-X	http://dx.doi.org/10.1016/S0092-8674(00)80728-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219239	Bronze, Green Published			2022-12-01	WOS:000079779800007
J	Baker, CS; Evans, TW; Randle, BJ; Haslam, PL				Baker, CS; Evans, TW; Randle, BJ; Haslam, PL			Damage to surfactant-specific protein in acute respiratory distress syndrome	LANCET			English	Article							BRONCHOALVEOLAR LAVAGE; NEUTROPHIL ELASTASE; PATHOGENESIS; FAILURE; SEPSIS; FLUID; MICE	Background Acute respiratory distress syndrome (ARDS) develops in association with many serious medical disorders. Mortality is at least 40%, and there is no specific therapy. A massive influx of activated neutrophils, which damage pulmonary vascular endothelium and alveolar epithelium, leads to alveolar oedema and pulmonary surfactant dysfunction. In-vitro studies show that neutrophil elastase can cleave surfactant-specific proteins and impair surfactant function. If this happens in vivo in ARDS, the response to surfactant therapy will be limited. Methods Samples of pulmonary surfactant were obtained from the lungs of 18 patients with ARDS and six healthy controls by bronchoalveolar lavage. We separated proteins in these samples according to molecular weight by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). We then used western blotting with monoclonal antibody E8 to detect the major surfactant-specific protein A (SP-A). Findings By contrast with controls, 14 of 18 patients had evidence of in-vivo damage to SP-A that resembled damage caused to SP-A when it is cleaved by neutrophil elastase. Controls showed a single band of normal dimers at 66 kDa, whereas 14 of 18 patients showed multiple bands at 66 kDa, 55 kDA, and 30-36 kDa, and six showed additional bands at 36-40 kDa. Interpretation Direct damage to surfactant-specific proteins occurs in lungs of patients with ARDS, probably by proteolysis. Trials of protein-containing therapeutic surfactant are in progress in ARDS, and our results indicate that the frequent failure to maintain response may result from continuing damage to surfactant by products of activated neutrophils. A combination of surfactant and antiprotease therapy may improve therapeutic prospects.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Cell Biol Unit, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Crit Care Unit, London SW3 6LY, England; Univ Bristol, Dept Obstet & Gynaecol, Bristol BS8 1TH, Avon, England	Imperial College London; Imperial College London; University of Bristol	Haslam, PL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Cell Biol Unit, London SW3 6LY, England.							Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; COCHRANE CG, 1983, J CLIN INVEST, V71, P754, DOI 10.1172/JCI110823; CORBET A, 1992, AM J MED SCI, V304, P246, DOI 10.1097/00000441-199210000-00004; DONNELLY SC, 1995, AM J RESP CRIT CARE, V151, P1428, DOI 10.1164/ajrccm.151.5.7735596; Gregory TJ, 1997, AM J RESP CRIT CARE, V155, P1309, DOI 10.1164/ajrccm.155.4.9105072; GREGORY TJ, 1991, J CLIN INVEST, V88, P1976, DOI 10.1172/JCI115523; Haslam P. L., 1995, European Respiratory Journal, V8, p397S; Haslam P. L., 1997, European Respiratory Journal Supplement, V10, p171S; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; JOHANSSON J, 1994, EUR RESPIR J, V7, P372, DOI 10.1183/09031936.94.07020372; KARINCH AM, 1995, AM J RESP CELL MOL, V12, P77, DOI 10.1165/ajrcmb.12.1.7811473; KUAN SF, 1992, J CLIN INVEST, V90, P97, DOI 10.1172/JCI115861; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CT, 1981, NEW ENGL J MED, V304, P192, DOI 10.1056/NEJM198101223040402; LeVine AM, 1997, J IMMUNOL, V158, P4336; LEWIS JF, 1993, AM REV RESPIR DIS, V147, P218, DOI 10.1164/ajrccm/147.1.218; Liau DF, 1996, BBA-LIPID LIPID MET, V1302, P117, DOI 10.1016/0005-2760(96)00042-2; MCGUIRE WW, 1982, J CLIN INVEST, V69, P543, DOI 10.1172/JCI110480; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NOGEE LM, 1994, J CLIN INVEST, V93, P1860, DOI 10.1172/JCI117173; OOSTING RS, 1991, AM J PHYSIOL, V261, pL77, DOI 10.1152/ajplung.1991.261.2.L77; PISON U, 1989, BIOCHIM BIOPHYS ACTA, V992, P251, DOI 10.1016/0304-4165(89)90082-2; RANDLE BJ, 1992, Patent No. 0511011; ROBERTSON B, 1991, PEDIATR RES, V30, P239, DOI 10.1203/00006450-199109000-00007; RYAN SF, 1991, AM J RESP CELL MOL, V4, P33, DOI 10.1165/ajrcmb/4.1.33; SEEGER W, 1993, EUR RESPIR J, V6, P971; SUTER PM, 1992, AM REV RESPIR DIS, V145, P1016, DOI 10.1164/ajrccm/145.5.1016; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; Tino MJ, 1996, AM J PHYSIOL-LUNG C, V270, pL677, DOI 10.1152/ajplung.1996.270.4.L677; Torres A, 1996, THORAX, V51, P378, DOI 10.1136/thx.51.4.378; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; YASUI S, 1995, EUR RESPIR J, V8, P1293, DOI 10.1183/09031936.95.08081293	35	77	84	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1232	1237		10.1016/S0140-6736(98)09449-5	http://dx.doi.org/10.1016/S0140-6736(98)09449-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217084				2022-12-01	WOS:000079744100012
J	Westphal, RS; Tavalin, SJ; Lin, JW; Alto, NM; Fraser, IDC; Langeberg, LK; Sheng, M; Scott, JD				Westphal, RS; Tavalin, SJ; Lin, JW; Alto, NM; Fraser, IDC; Langeberg, LK; Sheng, M; Scott, JD			Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; D-ASPARTATE RECEPTORS; POSTSYNAPTIC DENSITY; ANCHORING PROTEIN; SUBUNIT NR1; PDZ-DOMAIN; BINDING; SCAFFOLD; CHANNEL; IDENTIFICATION	Regulation of N-methyl-D-aspartate (NMDA) receptor activity by kinases and phosphatases contributes to the modulation of synaptic transmission. Targeting of these enzymes near the substrate is proposed to enhance phosphorylation-dependent modulation. Yotiao, an NMDA receptor-associated protein, bound the type I protein phosphatase (PP1) and the adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (PKA) holoenzyme. Anchored PP1 was active, limiting channel activity, whereas PKA activation overcame constitutive PP1 activity and conferred rapid enhancement of NMDA receptor currents. Hence, yotiao is a scaffold protein that physically attaches PP1 and PKA to NMDA receptors to regulate channel activity.	Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA; Howard Hughes Med Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurobiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Howard Hughes Medical Institute; Oregon Health & Science University; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Scott, JD (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, 3181 SW Sam Jackson Rd, Portland, OR 97201 USA.		Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907	NIGMS NIH HHS [GM 48231] Funding Source: Medline; NINDS NIH HHS [NS10543, NS10202, F32 NS010202] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010202, F32NS010543] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; BLANK T, 1997, P NATL ACAD SCI USA, V94, P14853; Brenman JE, 1998, J NEUROSCI, V18, P8805; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CARR DW, 1992, J BIOL CHEM, V267, P13376; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI KY, 1994, CELL, V78, P499; Corbin J D, 1974, Methods Enzymol, V38, P287; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ehlers MD, 1998, J NEUROSCI, V18, P720; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAUSKEN ZE, 1996, PROTEIN TARGETING PR; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krupp JJ, 1996, MOL PHARMACOL, V50, P1680; LESTER RAJ, 1993, J NEUROSCI, V13, P1088; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Lin JW, 1998, J NEUROSCI, V18, P2017; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; REINHART PH, 1995, J NEUROSCI, V15, P4572; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Snyder GL, 1998, J NEUROSCI, V18, P10297; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilson GF, 1998, P NATL ACAD SCI USA, V95, P10938, DOI 10.1073/pnas.95.18.10938; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	50	411	428	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					93	96		10.1126/science.285.5424.93	http://dx.doi.org/10.1126/science.285.5424.93			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390370				2022-12-01	WOS:000081199800037
J	Feighner, SD; Tan, CP; McKee, KK; Palyha, OC; Hreniuk, DL; Pong, SS; Austin, CP; Figueroa, D; MacNeil, D; Cascieri, MA; Nargund, R; Bakshi, R; Abramovitz, M; Stocco, R; Kargman, S; O'Neill, G; Van der Ploeg, LHT; Evans, J; Patchett, AA; Smith, RG; Howard, AD				Feighner, SD; Tan, CP; McKee, KK; Palyha, OC; Hreniuk, DL; Pong, SS; Austin, CP; Figueroa, D; MacNeil, D; Cascieri, MA; Nargund, R; Bakshi, R; Abramovitz, M; Stocco, R; Kargman, S; O'Neill, G; Van der Ploeg, LHT; Evans, J; Patchett, AA; Smith, RG; Howard, AD			Receptor for motilin identified in the human gastrointestinal system	SCIENCE			English	Article							GROWTH-HORMONE SECRETAGOGUE; BINDING-SITES; SMOOTH-MUSCLE; SEQUENCE; RABBIT; EXPRESSION; LOCALIZATION; ERYTHROMYCIN; PRECURSOR; PITUITARY	Motilin is a 22-amino acid peptide hormone expressed throughout the gastrointestinal (GI) tract of humans and other species. It affects gastric motility by stimulating interdigestive antrum and duodenal contractions. A heterotrimeric guanosine triphosphate-binding protein (G protein)-coupled receptor for motilin was isolated from human stomach, and its amino acid sequence was found to be 52 percent identical to the human receptor for growth hormone secretagogues. The macrolide antibiotic erythromycin also interacted with the cloned motilin receptor, providing a molecular basis for its effects on the human GI tract. The motilin receptor is expressed in enteric neurons of the human duodenum and colon. Development of motilin receptor agonists and antagonists may be useful in the treatment of multiple disorders of GI motility.	Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA; Merck Res Labs, Dept Human Genet, West Point, PA 19486 USA; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H3H 3L1, Canada; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Baylor College of Medicine; Baylor College of Medicine	Howard, AD (corresponding author), Merck Res Labs, Dept Metab Disorders, Bldg RY-80Y-265,126 E Lincoln Ave, Rahway, NJ 07065 USA.	howarda@merck.com		MacNeil, Doug/0000-0001-7089-0668				Benson DA, 1998, NUCLEIC ACIDS RES, V26, P1, DOI 10.1093/nar/26.1.1; BOND CT, 1988, MOL ENDOCRINOL, V2, P175, DOI 10.1210/mend-2-2-175; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; BROWN JC, 1973, CAN J BIOCHEM CELL B, V51, P533, DOI 10.1139/o73-066; BUTTON D, 1993, CELL CALCIUM, V14, P663, DOI 10.1016/0143-4160(93)90091-J; DAIKH DI, 1989, DNA-J MOLEC CELL BIO, V8, P615, DOI 10.1089/dna.1989.8.615; Depoortere I, 1997, AM J PHYSIOL-GASTR L, V272, pG994, DOI 10.1152/ajpgi.1997.272.5.G994; DEPOORTERE I, 1993, PEPTIDES, V14, P1153, DOI 10.1016/0196-9781(93)90169-H; DEPOORTERE I, 1995, REGUL PEPTIDES, V55, P227, DOI 10.1016/0167-0115(94)00111-A; Depoortere I, 1997, BRAIN RES, V777, P103; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; ITOH Z, 1984, AM J PHYSIOL, V247, pG688, DOI 10.1152/ajpgi.1984.247.6.G688; Itoh Z, 1997, PEPTIDES, V18, P593, DOI 10.1016/S0196-9781(96)00333-6; Kenakin T, 1996, PHARMACOL REV, V48, P413; MACIELAG MJ, 1992, PEPTIDES, V13, P565, DOI 10.1016/0196-9781(92)90090-P; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; MILLER P, 1995, PEPTIDES, V16, P11, DOI 10.1016/0196-9781(94)00148-Y; PEETERS T, 1989, AM J PHYSIOL, V257, pG470, DOI 10.1152/ajpgi.1989.257.3.G470; PEETERS TL, 1988, REGUL PEPTIDES, V23, P171, DOI 10.1016/0167-0115(88)90025-0; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Poitras P, 1996, PEPTIDES, V17, P701, DOI 10.1016/0196-9781(96)00053-8; Poitras P, 1994, GUT PEPTIDES BIOCH P, P261; Porter AJ, 1997, GASTROENTEROLOGY, V113, P1916, DOI 10.1016/S0016-5085(97)70011-8; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAKAI T, 1994, REGUL PEPTIDES, V53, P249, DOI 10.1016/0167-0115(94)90173-2; Scarpignato C, 1997, DIGEST DIS, V15, P112, DOI 10.1159/000171626; SEINO Y, 1987, FEBS LETT, V223, P74, DOI 10.1016/0014-5793(87)80512-4; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Smith RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/er.18.5.621; Tonini M, 1996, PHARMACOL RES, V33, P217, DOI 10.1006/phrs.1996.0030; WEBER FH, 1993, AM J GASTROENTEROL, V88, P485; YANO H, 1989, FEBS LETT, V249, P248, DOI 10.1016/0014-5793(89)80633-7	33	305	372	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2184	2188		10.1126/science.284.5423.2184	http://dx.doi.org/10.1126/science.284.5423.2184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381885				2022-12-01	WOS:000081099300054
J	Green, GE; Scott, DA; McDonald, JM; Woodworth, GG; Sheffield, VC; Smith, RJH				Green, GE; Scott, DA; McDonald, JM; Woodworth, GG; Sheffield, VC; Smith, RJH			Carrier rates in the midwestern United States for GJB2 mutations causing inherited deafness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYNDROMIC RECESSIVE DEAFNESS; CONNEXIN 26 GENE; MYOSIN-VIIA GENE; SENSORINEURAL DEAFNESS; HEARING IMPAIRMENT; DFNB1	Context Mutations in the GJB2 gene are the most common known cause of inherited congenital severe-to-profound deafness, The carrier frequency of these mutations is not known. Objectives To determine the carrier rate of deafness-causing mutations in GJB2 in the midwestern United States and the prevalence of these mutations in persons with congenital sensorineural hearing loss ranging in severity from moderate to profound, and to derive revised data for counseling purposes. Design Laboratory analysis, performed in 1998, of samples from probands with hearing loss for mutations in GJB2 using an allele-specific polymerase chain reaction assay, single-strand conformation polymorphism analysis, and direct sequencing. Setting and Subjects Fifty-two subjects younger than 19 years sequentially referred to a midwestern tertiary referral center for hearing loss or cochlear implantation, with moderate-to-profound congenital hearing loss of unknown cause, parental nonconsanguinity, and nonsyndromic deafness with hearing loss limited to a single generation; 560 control neonates were screened for the 35delG mutation. Main Outcome Measure Prevalence of mutations in the GJB2 gene by congenital deafness status. Results Of 52 sequential probands referred for congenital sensorineural hearing loss, 22 (42%) were found to have GJB2 mutations. The 35delG mutation was identified in 29 of the 41 mutant alleles. Of probands' sibs, all homozygotes and compound heterozygotes had deafness. Fourteen of 560 controls were 35delG heterozygotes, for a carrier rate expressed as a mean (SE) of 2.5% (0.66%). The carrier rate for all recessive deafness-causing GJB2 mutations was determined to be 3.01% (probable range, 2.54%-3.56%). Calculated sensitivity and specificity for a screening test based on 35delG mutation alone were 96.9% and 97.4%, respectively, and observed values were 94% and 97%, respectively. Conclusions Our data suggest that mutations in GJB2 are the leading cause of moderate-to-profound congenital inherited deafness in the midwestern United States. Screening of the GJB2 mutation can be offered to individuals with congenital deafness with high sensitivity and specificity by screening only for the 35delG mutation,A positive finding should establish an etiologic diagnosis and affect genetic counseling.	Univ Iowa Hosp & Clin, Dept Otolaryngol Head & Neck Surg, Mol Otolaryngol Res Labs, Iowa City, IA 52242 USA; Univ Iowa Hosp & Clin, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa Hosp & Clin, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Dept Stat & Actuarial Sci, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa; University of Iowa	Smith, RJH (corresponding author), Dept Otolaryngol Head & Neck Surg, Mol Otolaryngol Res Labs, 200 Hawkins Dr, Iowa City, IA 52242 USA.	richard-smith@uiowa.edu		Sheffield, Val/0000-0002-6282-0835; Smith, Richard/0000-0003-1201-6731	NHGRI NIH HHS [HG-00457] Funding Source: Medline; NIDCD NIH HHS [R01-DC02842] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002842] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Antonarakis SE, 1998, HUM MUTAT, V11, P1; Cohen M. M., 1995, HEREDITARY HEARING L, P9; CREMERS CWRJ, 1991, ANN NY ACAD SCI, V630, P191, DOI 10.1111/j.1749-6632.1991.tb19587.x; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; Holden-Pitt L, 1998, AM ANN DEAF, V143, P72; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KOEHN D, 1990, Genetic Counseling, V1, P127; Lench N, 1998, LANCET, V351, P415, DOI 10.1016/S0140-6736(98)24006-2; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; LITTLE S, 1998, CURRENT PROTOCOLS HU; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; LYSAUGHT MT, 1998, STORED TISSUE SAMPLE, P3; MARAZITA ML, 1993, AM J MED GENET, V46, P486, DOI 10.1002/ajmg.1320460504; Morell RJ, 1998, NEW ENGL J MED, V339, P1500, DOI 10.1056/NEJM199811193392103; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; ROSE SP, 1975, THESIS INDIANA U IND; Scott DA, 1998, HUM MUTAT, V11, P387, DOI 10.1002/(SICI)1098-1004(1998)11:5<387::AID-HUMU6>3.0.CO;2-8; US Bureau of the Census, 1998, STAT ABSTR US 1998; VanCamp G, 1997, AM J HUM GENET, V60, P758; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; Zbar RIS, 1998, OTOLARYNG HEAD NECK, V118, P333, DOI 10.1016/S0194-5998(98)70311-0; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	26	282	302	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2211	2216		10.1001/jama.281.23.2211	http://dx.doi.org/10.1001/jama.281.23.2211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376574	Bronze			2022-12-01	WOS:000080777000035
J	Fox, DL; Fisher, DC; Leighton, LR				Fox, DL; Fisher, DC; Leighton, LR			Reconstructing phylogeny with and without temporal data	SCIENCE			English	Article								Conventional cladistic methods of inferring evolutionary relationships exclude temporal data from the initial search for optimal hypotheses, but stratocladistics includes such data. A comparison of the ability of these methods to recover known, simulated evolutionary histories given the same, evolved character data shows that stratocladistics recovers the true phylogeny in over twice as many cares as cladistics (42 versus 18 percent). The comparison involved 550 unique taxon-by-character matrices, representing 15 evolutionary models and fossil records ranging from 100 to 10 percent complete.	Univ Michigan, Museum Paleontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fox, DL (corresponding author), Univ Michigan, Museum Paleontol, 1109 Geddes Rd, Ann Arbor, MI 48109 USA.			Fox, David L/0000-0002-2291-6146				[Anonymous], 1981, SYSTEMATICS BIOGEORA; CLYDE WC, 1996, PALEOBIOLOGY, V23, P1; Farris J.S., 1983, Advances in Cladistics, V2, P7; FARRIS JS, 1989, CLADISTICS, V5, P417, DOI 10.1111/j.1096-0031.1989.tb00573.x; FISHER DC, 1994, INTERPRETING HIERARC, P133; Foote M, 1996, PALEOBIOLOGY, V22, P121, DOI 10.1017/S0094837300016134; Gjelsvik A, 1981, THEORY THIN WALLED B, DOI DOI 10.1115/1.3162198; Hull D.L., 1988, SCI PROCESS, DOI 10.7208/chicago/9780226360492.001.0001; MADDISON WP, 1984, SYST ZOOL, V33, P83, DOI 10.2307/2413134; MADDISON WP, 1992, MACCLADE VER 3 0; NELSON G, 1978, SYST ZOOL, V27, P324, DOI 10.2307/2412883; Paul CRC, 1998, ADEQUACY OF THE FOSSIL RECORD, P1; POLLY PD, 1997, CONTRIB MUS PALEONTO, P1; SCHAEFFER B, 1972, EVOLUTIONARY BIOL, V6, pCH2; Shennan SJ., 2009, INNOVATIONS CULTURAL, P53; SMITH AB, 1998, NATURE          1119; SMITH AB, 1984, SYSTEMATICS FOSSIL R; SOBER E, 1988, RECONSTRUCTING PAST; [No title captured]; [No title captured]; [No title captured]	21	71	72	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1816	1819		10.1126/science.284.5421.1816	http://dx.doi.org/10.1126/science.284.5421.1816			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364549				2022-12-01	WOS:000080809000043
J	Hirose, K; Kadowaki, S; Tanabe, M; Takeshima, H; Iino, M				Hirose, K; Kadowaki, S; Tanabe, M; Takeshima, H; Iino, M			Spatiotemporal dynamics of inositol 1,4,5-trisphosphate that underlies complex Ca2+ mobilization patterns	SCIENCE			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; CALCIUM SPIKING; PLASMA-MEMBRANE; PHOSPHOLIPASE C-DELTA(1); CELLS; OSCILLATIONS; BINDING; TRISPHOSPHATE; 5-PHOSPHATASE; ATP	Inositol 1,4,5-trisphosphate (IP3) is a second messenger that elicits complex spatiotemporal patterns of calcium ion (Ca2+) mobilization and has essential soles in the regulation of many cellular functions. In Madin-Darby canine kidney epithelial cells, green fluorescent protein-tagged pleckstrin homology domain translocated from the plasma membrane to the cytoplasm in response to increased concentration of IP3. The detection of translocation enabled monitoring of IP3 concentration changes within single cells and revealed spatiotemporal dynamics in the concentration of IP3 synchronous with Ca2+ oscillations and intracellular and intercellular IP3 waves that accompanied Ca2+ waves. Such changes in IP3 concentration may be fundamental to Ca2+ signaling.	Univ Tokyo, Fac Med, Dept Pharmacol, Tokyo 1138654, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1138654, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Hirose, K (corresponding author), Univ Tokyo, Fac Med, Dept Pharmacol, Tokyo 1138654, Japan.			Takeshima, Hiroshi/0000-0003-4525-3725; Hirose, Kenzo/0000-0002-8944-6513				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; HIROSE K, UNPUB; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; ROONEY TA, 1993, CELL CALCIUM, V14, P674, DOI 10.1016/0143-4160(93)90094-M; Rottingen JA, 1997, CELL CALCIUM, V21, P195, DOI 10.1016/S0143-4160(97)90044-0; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; SNEYD J, 1995, AM J PHYSIOL-CELL PH, V268, pC1537, DOI 10.1152/ajpcell.1995.268.6.C1537; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417	31	426	442	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1527	1530		10.1126/science.284.5419.1527	http://dx.doi.org/10.1126/science.284.5419.1527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348740				2022-12-01	WOS:000080548100037
J	Keppler, OT; Hinderlich, S; Langner, J; Schwartz-Albiez, R; Reutter, W; Pawlita, M				Keppler, OT; Hinderlich, S; Langner, J; Schwartz-Albiez, R; Reutter, W; Pawlita, M			UDP-GlcNAc 2-epimerase: A regulator of cell surface sialylation	SCIENCE			English	Article							DIFFERENTIATION-DEPENDENT EXPRESSION; ACETYLNEURAMINIC ACID BIOSYNTHESIS; BIFUNCTIONAL ENZYME CATALYZES; FIRST 2 STEPS; SIALIC-ACID; ADHESION MOLECULE; RAT-LIVER; T-CELLS; B-CELLS; 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE	Modification of cell surface molecules with sialic acid is crucial for their function in many biological processes, including cell adhesion and signal transduction, Uridine diphosphate-N-acetylglucosamine 2-epimerase (UDP-GLcNAc 2-epimerase) is an enzyme that catalyzes an early, rate-limiting step in the sialic acid biosynthetic pathway. UDP-GlcNAc 2-epimerase was found to be a major determinant of cell surface sialylation in human hematopoietic cell Lines and a critical regulator of the function of specific cell surface adhesion molecules.	Deutsch Krebsforschungszentrum, Appl Tumor Virol Program, D-69120 Heidelberg, Germany; Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin	Pawlita, M (corresponding author), Deutsch Krebsforschungszentrum, Appl Tumor Virol Program, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	M.Pawlita@dkfz-heidelberg.de	Pawlita, Labor/C-9720-2011	Pawlita, Michael/0000-0002-4720-8306				Abe M, 1996, PATHOL INT, V46, P977, DOI 10.1111/j.1440-1827.1996.tb03577.x; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Bergmann M, 1998, GLYCOBIOLOGY, V8, P963, DOI 10.1093/glycob/8.10.963; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chigorno V, 1996, J BIOL CHEM, V271, P21738, DOI 10.1074/jbc.271.36.21738; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; COLL MJ, 1986, FEBS LETT, V208, P418, DOI 10.1016/0014-5793(86)81060-2; COLLARD JG, 1986, CANCER RES, V46, P3521; DallOlio F, 1996, GLYCOCONJUGATE J, V13, P115, DOI 10.1007/BF01049687; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fritsch M, 1996, J CHROMATOGR A, V727, P223, DOI 10.1016/0021-9673(95)01157-9; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; HAUN G, 1993, J VIROL, V67, P7482, DOI 10.1128/JVI.67.12.7482-7492.1993; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Horstkorte R, 1999, EUR J BIOCHEM, V260, P923, DOI 10.1046/j.1432-1327.1999.00253.x; KANEKO Y, 1995, J HISTOCHEM CYTOCHEM, V43, P945, DOI 10.1177/43.9.7642967; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; Keppler OT, 1999, GLYCOBIOLOGY, V9, P557, DOI 10.1093/glycob/9.6.557; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KEPPLER OT, UNPUB; KIJIMASUDA I, 1988, CANCER RES, V48, P3728; KIKUCHI K, 1971, BIOCHIM BIOPHYS ACTA, V252, P357, DOI 10.1016/0304-4165(71)90017-1; KNIBBS RN, 1993, J BIOL CHEM, V268, P18524; Kniep B, 1996, J BIOCHEM-TOKYO, V119, P456; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; LAI R, 1994, BRIT J HAEMATOL, V87, P251, DOI 10.1111/j.1365-2141.1994.tb04906.x; LAW CL, 1995, J IMMUNOL, V155, P3368; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LUCKA L, UNPUB; MartinezPomares L, 1996, IMMUNOBIOLOGY, V195, P407, DOI 10.1016/S0171-2985(96)80012-X; Maru I, 1996, J BIOL CHEM, V271, P16294, DOI 10.1074/jbc.271.27.16294; Matic M, 1998, INVEST OPHTH VIS SCI, V39, P905; MENDLA K, 1988, BIOCHEM J, V250, P261, DOI 10.1042/bj2500261; NAKAMORI S, 1993, CANCER RES, V53, P3632; OKAMOTO Y, 1980, BIOCHEM J, V188, P905, DOI 10.1042/bj1880905; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1987, J IMMUNOL, V139, P262; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SAMMAR M, 1994, INT IMMUNOL, V6, P1027, DOI 10.1093/intimm/6.7.1027; SGROI D, 1993, J BIOL CHEM, V268, P7011; Shanmugam V, 1997, BIOCHEMISTRY-US, V36, P5729, DOI 10.1021/bi961687w; Spivak C. T, 1966, METHOD ENZYMOL, V9, P612; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; Wagers AJ, 1998, J IMMUNOL, V160, P5122; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237	61	267	285	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1372	1376		10.1126/science.284.5418.1372	http://dx.doi.org/10.1126/science.284.5418.1372			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334995				2022-12-01	WOS:000080430600058
J	Heithoff, DM; Sinsheimer, RL; Low, DA; Mahan, MJ				Heithoff, DM; Sinsheimer, RL; Low, DA; Mahan, MJ			An essential role for DNA adenine methylation in bacterial virulence	SCIENCE			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; SALMONELLA VIRULENCE; PHASE VARIATION; GENES; INFECTION; PATTERNS; PYELONEPHRITIS; EXPRESSION	Salmonella typhimurium lacking DNA adenine methylase (Dam) were fully proficient in colonization of mucosal sites but showed severe defects in colonization of deeper tissue sites. These Dam(-) mutants were totally avirulent and were effective as live vaccines against murine typhoid fever. Dam regulated the expression of at least 20 genes known to be induced during infection; a subset of these genes are among those activated by the PhoP global virulence regulator. PhoP, in turn, affected Dam methylation at specific genomic sites, as Evidenced by alterations in DNA methylation patterns. Dam inhibitors are likely to have broad antimicrobial action, and Dam- derivatives of these pathogens may serve as Live attenuated vaccines.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Mahan, MJ (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.				NIAID NIH HHS [AI23348, AI36373] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023348, R01AI023348, R29AI036373] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANDYOPADHYAY R, 1994, GENE, V140, P67, DOI 10.1016/0378-1119(94)90732-3; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; Conner CP, 1998, P NATL ACAD SCI USA, V95, P4641, DOI 10.1073/pnas.95.8.4641; EARTHART C, 1996, ESCHERICHIA COLI SAL, P1075; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GROISMAN EA, 1995, 2 COMPONENT SIGNAL T, P319, DOI DOI 10.1128/9781555818319; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; HALE WB, 1994, J BACTERIOL, V176, P3438, DOI 10.1128/jb.176.11.3438-3441.1994; Heithoff DM, 1999, J BACTERIOL, V181, P799, DOI 10.1128/JB.181.3.799-807.1999; Heithoff DM, 1997, P NATL ACAD SCI USA, V94, P934, DOI 10.1073/pnas.94.3.934; HEITHOFF DM, UNPUB; Julio SM, 1998, MOL GEN GENET, V258, P178, DOI 10.1007/s004380050721; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; Marinus M.G., 1996, E COLI SALMONELLA CE, P782; MARINUS MG, 1984, GENE, V28, P123, DOI 10.1016/0378-1119(84)90095-7; NEWMAN EB, 1996, CELLULAR MOL BIOL, P1513; ROBERTS JA, 1985, J UROLOGY, V133, P1068, DOI 10.1016/S0022-5347(17)49382-7; ROLAND KL, 1993, J BACTERIOL, V175, P4154, DOI 10.1128/JB.175.13.4154-4164.1993; SLAUCH JM, 1991, J BACTERIOL, V173, P4039, DOI 10.1128/jb.173.13.4039-4048.1991; SMITH CL, 1987, METHOD ENZYMOL, V155, P449; Tavazoie S, 1998, NAT BIOTECHNOL, V16, P566, DOI 10.1038/nbt0698-566; van der Woude M, 1998, J BACTERIOL, V180, P5913, DOI 10.1128/JB.180.22.5913-5920.1998; vanderWoude M, 1996, TRENDS MICROBIOL, V4, P5, DOI 10.1016/0966-842X(96)81498-3; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X	28	384	402	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1999	284	5416					967	970		10.1126/science.284.5416.967	http://dx.doi.org/10.1126/science.284.5416.967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320378				2022-12-01	WOS:000080198800047
J	Rueter, SM; Dawson, TR; Emeson, RB				Rueter, SM; Dawson, TR; Emeson, RB			Regulation of alternative splicing by RNA editing	NATURE			English	Article							PRE-MESSENGER-RNA; ADENOSINE-DEAMINASE; SEQUENCES; CLONING; INOSINE; ENZYME; FORMS	The enzyme ADAR2 is a double-stranded RNA-specific adenosine deaminase which is involved in the editing of mammalian messenger RNAs by the site-specific conversion of adenosine to inosine(1-3) Here we identify several rat ADAR2 mRNAs produced as a result of two distinct alternative splicing events. One such splicing event uses a proximal 3' acceptor site, adding 47 nucleotides to the ADAR2 coding region, changing the predicted reading frame of the mature ADAR2 transcript. Nucleotide-sequence analysis of ADAR2 genomic DNA revealed the presence of adenosine-adenosine (AA) and adenosine-guanosine (AG) dinucleotides at these proximal and distal alternative 3' acceptor sites, respectively. Use of the proximal 3' acceptor depends upon the ability of ADAR2 to edit its own pre-mRNA, converting the intronic AA to an adenosine-inosine (Al) dinucleotide which effectively mimics the highly conserved AG sequence normally found at 3' splice junctions. Our observations indicate that RNA editing can serve as a mechanism for regulating alternative splicing and they suggest a novel strategy by which ADAR2 can modulate its own expression.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Emeson, RB (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Dawson, Toni/P-8599-2016					Ausubel F.M., 1989, SHORT PROTOCOLS MOL; Bass BL, 1997, RNA, V3, P947; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; Deirdre A, 1995, EMBO J, V14, P3236; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; Gerber A, 1997, RNA, V3, P453; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17096; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; OConnell MA, 1997, J BIOL CHEM, V272, P473; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Rueter S.M., 1998, MODIFICATION EDITING, P343; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Tarn WY, 1996, BIOCHIMIE, V78, P1057, DOI 10.1016/S0300-9084(97)86730-2; Zuker M, 1994, Methods Mol Biol, V25, P267	27	474	497	2	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					75	80		10.1038/19992	http://dx.doi.org/10.1038/19992			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331393				2022-12-01	WOS:000080172100058
J	Tang, HL; Cyster, JG				Tang, HL; Cyster, JG			Chemokine up-regulation and activated T cell attraction by maturing dendritic cells	SCIENCE			English	Article							MACROPHAGE-DERIVED-CHEMOKINE; C-C CHEMOKINE; MOLECULAR-CLONING; FLUORESCEIN ISOTHIOCYANATE; LANGERHANS CELLS; IN-VIVO; EXPRESSION; LYMPHOCYTES; RECEPTOR; MURINE	Langerhans' cells migrating from contact-sensitized skin were found to upregulate expression of macrophage-derived chemokine (MDC) during maturation into Lymph node dendritic cells (DCs), Naive T cells did not migrate toward MDC, but antigen-specific T cells rapidly acquired MDC responsiveness in vivo after a subcutaneous injection of antigen. In chemotaxis assays, maturing DCs attracted activated T cells more strongly than naive T cells. These studies identified chemokine up-regulation as part of the Langerhans' cell maturation program to immunogenic T cell-zone DC. Preferential recruitment of activated T cells may be a mechanism used by maturing DCs to promote encounters with antigen-specific T cells.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Cyster, JG (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.				NIAID NIH HHS [AI-40098] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI040098, R01AI040098] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Andrew DP, 1998, J IMMUNOL, V161, P5027; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Chang MS, 1997, J BIOL CHEM, V272, P25229, DOI 10.1074/jbc.272.40.25229; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; FOSSUM S, 1989, RES IMMUNOL, V140, P883, DOI 10.1016/0923-2494(89)90048-5; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HEUFLER C, 1992, J EXP MED, V176, P1221, DOI 10.1084/jem.176.4.1221; HILL S, 1990, IMMUNOLOGY, V71, P277; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; MACATONIA SE, 1986, IMMUNOLOGY, V59, P509; MACATONIA SE, 1987, J EXP MED, V166, P1654, DOI 10.1084/jem.166.6.1654; MACPHERSON GG, 1995, J IMMUNOL, V154, P1317; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; Rodenburg RJT, 1998, J LEUKOCYTE BIOL, V63, P606, DOI 10.1002/jlb.63.5.606; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Schaniel C, 1998, J EXP MED, V188, P451, DOI 10.1084/jem.188.3.451; SCHULER G, 1985, J EXP MED, V161, P526, DOI 10.1084/jem.161.3.526; Shortman K, 1997, STEM CELLS, V15, P409, DOI 10.1002/stem.150409; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; THOMAS WR, 1980, IMMUNOLOGY, V39, P21; Wang BH, 1997, J IMMUNOL, V159, P6148; Youn BS, 1997, BLOOD, V89, P4448, DOI 10.1182/blood.V89.12.4448; [No title captured]	33	245	252	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					819	822		10.1126/science.284.5415.819	http://dx.doi.org/10.1126/science.284.5415.819			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221917				2022-12-01	WOS:000080056200051
J	Rodeghiero, F; Tosetto, A				Rodeghiero, F; Tosetto, A			Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism	ANNALS OF INTERNAL MEDICINE			English	Article						protein C; thromboembolism; venous thrombosis; mutation; factor V	POOR ANTICOAGULANT RESPONSE; COAGULATION-FACTOR-V; INHERITED THROMBOPHILIA; VITA PROJECT; FAMILY HISTORY; FV LEIDEN; THROMBOSIS; GENE; COFACTOR; BLOOD	Background: Resistance to activated protein C due to the factor V R506Q (Leiden) mutation is the most common clotting abnormality in patients with venous thromboembolism. Objective: To evaluate the risk for venous thromboembolism associated with the factor V Leiden mutation or with resistance to activated protein C in the general population. Design: Cross-sectional survey. Setting: General community of Vicenza, Italy. Patients: A population-based sample of 15 109 white persons 18 to 65 years of age who were randomly selected from the census list. Measurements: Sequential validated approach based on participants' reports and Doppler ultrasonography. Resistance to activated protein C was investigated in all participants; 2134 participants with resistance to activated protein C were screened for the factor V Leiden mutation. Results: Carriers of the factor V Leiden mutation had a relative risk of 3.3 (95% CI, 1.7 to 6.1) for venous thromboembolism before 65 years of age. The fraction of cases attributable to the factor V Leiden mutation was 6.6%. By 65 years of age, 5.7% of carriers of the mutation had had venous thromboembolism, mostly after surgery. Participants with a reduced response to activated protein C were at higher risk even if they did not carry the mutation (odds ratio, 1.7 [CI, 1.0 to 2.7]); the attributable risk for venous thromboembolism was 5.1%. Conclusions: The factor V Leiden mutation and resistance to activated protein C are important, independent risk factors for venous thromboembolism. Screening strategies for the factor V Leiden mutation in patients undergoing surgery or experiencing major trauma cannot be recommended, but phenotypic evaluation of resistance to activated protein C should be encouraged in patients with venous thromboembolism.	San Bortolo Hosp, Dept Hematol, I-36100 Vicenza, Italy	ULSS 8 Berica; Ospedale San Bortolo di Vicenza	Rodeghiero, F (corresponding author), San Bortolo Hosp, Dept Hematol, I-36100 Vicenza, Italy.		Tosetto, Alberto/AAM-3200-2020; Tosetto, Alberto/AAB-9320-2022	Tosetto, Alberto/0000-0002-0119-5204; 				ADELI K, 1990, CLIN CHEM, V36, P261; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRIET E, 1994, BRIT J HAEMATOL, V87, P348, DOI 10.1111/j.1365-2141.1994.tb04920.x; Brown K, 1997, BRIT J HAEMATOL, V98, P907, DOI 10.1046/j.1365-2141.1997.3093130.x; Chan WP, 1998, BLOOD, V91, P1135, DOI 10.1182/blood.V91.4.1135; Clayton D., 1993, STAT MODELS EPIDEMIO; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; De Visser MCH, 1998, BRIT J HAEMATOL, V102, P146; DERONDE H, 1994, THROMB HAEMOSTASIS, V72, P880; EHRENFORTH S, 1995, THROMB HAEMOSTASIS, V74, P797; FAIONI EM, 1995, THROMB HAEMOSTASIS, V73, P1375; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; GRIFFIN JH, 1993, BLOOD, V82, P1989; Hille ETM, 1997, BLOOD, V89, P1963, DOI 10.1182/blood.V89.6.1963; HSIEH CC, 1991, STAT MED, V10, P361, DOI 10.1002/sim.4780100308; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kleinbaum D.G., 1982, EPIDEMIOLOGIC RES PR, P1; Kleinbaum D.G., 1988, STUDENTS PARTIAL SOL; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; Mari D, 1996, LANCET, V347, P1044, DOI 10.1016/S0140-6736(96)90181-6; RAO AK, 1995, THROMB HAEMOSTASIS, V73, P1126; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Rodeghiero F, 1996, THROMB HAEMOSTASIS, V76, P226; RODEGHIERO F, 1993, THROMB HAEMOSTASIS, V69, P527; Rodeghiero F, 1997, THROMB HAEMOSTASIS, V78, P636; Ryan DH, 1998, ANN INTERN MED, V128, P270, DOI 10.7326/0003-4819-128-4-199802150-00003; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; *STAT CORP, 1997, STAT STAT SOFTW REL; SUN X, 1994, BLOOD, V83, P3120; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; THIAGARAJAN P, 1986, BLOOD, V68, P869; Tosetto A, 1997, THROMB HAEMOSTASIS, V78, P859; TOSETTO A, 1995, BRIT J HAEMATOL, V89, P227, DOI 10.1111/j.1365-2141.1995.tb08940.x; Tosetto A, 1998, BRIT J HAEMATOL, V102, P147; Tripodi A, 1997, THROMB HAEMOSTASIS, V77, P436; van den Belt AGM, 1998, THROMB HAEMOSTASIS, V79, P259, DOI 10.1055/s-0037-1614975; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; Weiss K. M., 1993, GENETIC VARIATION HU; Williamson D, 1998, BLOOD, V91, P1140, DOI 10.1182/blood.V91.4.1140; ZOLLER B, 1994, J CLIN INVEST, V94, P2521, DOI 10.1172/JCI117623	43	196	196	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					643	+		10.7326/0003-4819-130-8-199904200-00004	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215560				2022-12-01	WOS:000079786600003
J	Geller, G				Geller, G			Weighing burdens and benefits rather than competence - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							CHILDREN		Johns Hopkins Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Geller, G (corresponding author), Johns Hopkins Med Inst, 550 N Broadway, Baltimore, MD 21205 USA.							BINEDELL J, 1998, GENETIC TESTING CHIL, P123; Chapple Alison, 1996, Eur J Genet Soc, V2, P28; CLAYTON EW, 1995, AM J MED GENET, V57, P630, DOI 10.1002/ajmg.1320570423; COHEN CB, 1998, GENETIC TESTING CHIL, P133; FRYER A, 1995, ARCH DIS CHILD, V73, P97, DOI 10.1136/adc.73.2.97; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; MARTEAU TM, 1994, J MED GENET, V31, P743, DOI 10.1136/jmg.31.10.743; WERTZ DC, 1994, JAMA-J AM MED ASSOC, V272, P875, DOI 10.1001/jama.272.11.875; WILFOND BS, 1995, AM J HUM GENET, V57, P1233	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1065	1066						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10336286				2022-12-01	WOS:000080140000037
J	Belluscio, L; Koentges, G; Axel, R; Dulac, C				Belluscio, L; Koentges, G; Axel, R; Dulac, C			A map of pheromone receptor activation in the mammalian brain	CELL			English	Article							ACCESSORY OLFACTORY-BULB; MULTIGENE FAMILY; ODORANT RECEPTORS; ORGANIZATION; SYSTEM; RAT	In mammals, the detection of pheromones is mediated by the vomeronasal system. We have employed gene targeting to visualize the pattern of projections of axons from vomeronasal sensory neurons in the accessory olfactory bulb. Neurons expressing a specific receptor project to multiple glomeruli that reside within spatially restricted domains. The formation of this sensory map in the accessory olfactory bulb and the survival of vomeronasal organ sensory neurons require the expression of pheromone receptors. In addition, we observe individual glomeruli in the accessory olfactory bulb that receive input from more than one type of sensory neuron. These observations indicate that the organization of the vomeronasal sensory afferents is dramatically different from that of the main olfactory system, and these differences have important implications for the logic of olfactory coding in the vomeronasal organ.	Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Harvard University; Howard Hughes Medical Institute; Columbia University; Howard Hughes Medical Institute	Dulac, C (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	dulac@fas.harvard.edu		Dulac, Catherine/0000-0001-5024-5418; Axel, Richard/0000-0002-3141-4076	NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029832] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA-23767-20A1] Funding Source: Medline; NINDS NIH HHS [NS29832-07] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAJAL SRY, 1901, TRAB LAB INVEST BIOL, V1, P141; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Christensen TA, 1997, J NEUROPHYSIOL, V77, P775, DOI 10.1152/jn.1997.77.2.775; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; FARBMAN AI, 1980, DEV BIOL, V74, P205, DOI 10.1016/0012-1606(80)90062-7; FARBMAN AI, 1992, CELL BIOL OLFACTION; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Sorensen PW, 1998, CURR OPIN NEUROBIOL, V8, P458, DOI 10.1016/S0959-4388(98)80032-9; TAKAMI S, 1991, J COMP NEUROL, V311, P65, DOI 10.1002/cne.903110106; TAKAMI S, 1990, BRAIN RES, V510, P339, DOI 10.1016/0006-8993(90)91387-V; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	21	200	207	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					209	220		10.1016/S0092-8674(00)80731-X	http://dx.doi.org/10.1016/S0092-8674(00)80731-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219242	Bronze			2022-12-01	WOS:000079779800010
J	Handa, N; Nureki, O; Kurimoto, K; Kim, I; Sakamoto, H; Shimura, Y; Muto, Y; Yokoyama, S				Handa, N; Nureki, O; Kurimoto, K; Kim, I; Sakamoto, H; Shimura, Y; Muto, Y; Yokoyama, S			Structural basis for recognition of the tra mRNA precursor by the sex-lethal protein	NATURE			English	Article							TRANSFER-RNA-SYNTHETASE; CRYSTAL-STRUCTURE; BINDING DOMAINS; ANTICODON RECOGNITION; ANGSTROM RESOLUTION; SPLICE SITE; COMPLEX; SPECIFICITY; TRANSCRIPT; ELEMENT	The Sex-lethal (Sxl) protein of Drosophila melanogaster regulates alternative splicing of the transformer (tra) messenger RNA precursor by binding to the tra polypyrimidine tract during the sex-determination process. The crystal structure has now been determined at 2.6 Angstrom resolution of the complex formed between two tandemly arranged RNA-binding domains of the Sxl protein and a 12-nucleotide, single-stranded RNA derived from the tra polypyrimidine tract. The two RNA-binding domains have their beta-sheet platforms facing each other to form a V-shaped cleft. The RNA is characteristically extended and bound in this cleft, where the UGUUUUUUU sequence is specifically recognized by the protein. This structure offers the first insight, to our knowledge, into how a protein binds specifically to a cognate RNA without any intramolecular base-pairing.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Genom Sci Ctr, Wako, Saitama 3510106, Japan; RIKEN, Inst Phys & Chem Res, Cellular Signaling Lab, Wako, Saitama 3510106, Japan; Kobe Univ, Fac Sci, Dept Biol, Naka Ku, Kobe, Hyogo 6570013, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Sakyo Ku, Kyoto 6068224, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan	University of Tokyo; RIKEN; RIKEN; Kobe University; Kyoto University	Yokoyama, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338				Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; BURDON IP, 1994, POWER ENG J, V8, P265, DOI 10.1049/pe:19940603; Cai ZP, 1998, NAT STRUCT BIOL, V5, P203, DOI 10.1038/nsb0398-203; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; COLLETTI V, 1994, SKULL BASE SURG, V4, P1, DOI 10.1055/s-2008-1058981; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Good PJ, 1997, SEMIN CELL DEV BIOL, V8, P577, DOI 10.1006/scdb.1997.0183; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Harford JB, 1997, MRNA METABOLISM POST; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; Inoue M, 1997, J MOL BIOL, V272, P82, DOI 10.1006/jmbi.1997.1213; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; Kim I, 1997, NUCLEIC ACIDS RES, V25, P1565, DOI 10.1093/nar/25.8.1565; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; Lee AL, 1997, BIOCHEMISTRY-US, V36, P14306, DOI 10.1021/bi970830y; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; Sakashita E, 1996, J BIOCHEM, V120, P1028; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; Samuels M, 1998, NUCLEIC ACIDS RES, V26, P2625, DOI 10.1093/nar/26.11.2625; Sarig G, 1997, J BIOL CHEM, V272, P4474, DOI 10.1074/jbc.272.7.4474; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; SHAMOO Y, 1995, NUCLEIC ACIDS RES, V23, P725, DOI 10.1093/nar/23.5.725; SIMONS RW, 1998, RNA STRUCTURE FUNCTI; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6	50	311	319	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 15	1999	398	6728					579	585		10.1038/19242	http://dx.doi.org/10.1038/19242			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217141				2022-12-01	WOS:000079754700046
J	Iverson, TM; Luna-Chavez, C; Cecchini, G; Rees, DC				Iverson, TM; Luna-Chavez, C; Cecchini, G; Rees, DC			Structure of the Escherichia coli fumarate reductase respiratory complex	SCIENCE			English	Article							SUCCINATE-UBIQUINONE REDUCTASE; ELECTRON-PARAMAGNETIC-RESONANCE; BOVINE HEART-MITOCHONDRIA; CYTOCHROME BC(1) COMPLEX; MAXIMUM-LIKELIHOOD; PARACOCCUS-DENITRIFICANS; 2.8-ANGSTROM RESOLUTION; QUINONE OXIDOREDUCTASES; NUCLEOTIDE-SEQUENCE; ANGSTROM RESOLUTION	The integral membrane protein fumarate reductase catalyzes the final step of anaerobic respiration when fumarate is the terminal electron acceptor. The homologous enzyme succinate dehydrogenase also plays a prominent role in cellular energetics as a member of the Krebs cycle and as complex II of the aerobic respiratory chain. Fumarate reductase consists of four subunits that contain a covalently linked flavin adenine dinucleotide, three different iron-sulfur clusters, and at Least two quinones, The crystal structure of intact fumarate reductase has been solved at 3.3 angstrom resolution and demonstrates that the cofactors are arranged in a nearly linear manner from the membrane-bound quinone to the active site flavin. Although fumarate reductase is not associated with any proton-pumping function, the two quinones are positioned on opposite sides of the membrane in an arrangement similar to that of the Q-cycle organization observed for cytochrome bc(1).	Dept Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; CALTECH, Div Chem & Chem Engn, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Cecchini, G (corresponding author), Dept Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA.	ceccini@itsa.ucsf.edu; dcrees@caltech.edu						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; ACKRELL BAC, 1989, ARCH BIOCHEM BIOPHYS, V268, P26, DOI 10.1016/0003-9861(89)90561-4; ADMAN ET, 1976, J BIOL CHEM, V251, P3801; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEINERT H, 1977, ARCH BIOCHEM BIOPHYS, V182, P95, DOI 10.1016/0003-9861(77)90287-9; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; CAMMACK R, 1986, BIOCHIM BIOPHYS ACTA, V870, P545, DOI 10.1016/0167-4838(86)90264-5; CECCHINI G, 1986, P NATL ACAD SCI USA, V83, P8898, DOI 10.1073/pnas.83.23.8898; CECCHINI G, 1986, J BIOL CHEM, V261, P1808; COLE ST, 1982, EUR J BIOCHEM, V122, P479; COLE ST, 1982, EUR J BIOCHEM, V126, P211, DOI 10.1111/j.1432-1033.1982.tb06768.x; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DUTTON PL, 1988, BIOL ELECT TRANSFER, P3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; FUKUYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1017, DOI 10.1093/oxfordjournals.jbchem.a124800; Gottschalk G., 1986, BACTERIAL METABOLISM; GRUNDSTROM T, 1982, P NATL ACAD SCI-BIOL, V79, P1111, DOI 10.1073/pnas.79.4.1111; GUEST JR, 1981, J GEN MICROBIOL, V122, P171; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; KOWAL AT, 1995, BIOCHEMISTRY-US, V34, P12284, DOI 10.1021/bi00038a024; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGER A, 1992, ARCH MICROBIOL, V158, P311, DOI 10.1007/BF00245358; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; LOCHER KP, IN PRESS CRC MONOGRA; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; LUNACHAVEZ C, UNPUB; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MORNINGSTAR JE, 1985, J BIOL CHEM, V260, P3631; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; OHNISHI T, 1980, J BIOL CHEM, V255, P3278; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; RUZICKA FJ, 1975, P NATL ACAD SCI USA, V72, P2886, DOI 10.1073/pnas.72.8.2886; SALERNO JC, 1980, BIOCHEM J, V192, P769, DOI 10.1042/bj1920769; SALERNO JC, 1977, FEBS LETT, V82, P179, DOI 10.1016/0014-5793(77)80579-6; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; SINGER TP, 1968, BIOLOGICAL OXIDATION, P339; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; Waldeck AR, 1997, J BIOL CHEM, V272, P19373, DOI 10.1074/jbc.272.31.19373; WALKER WH, 1970, J BIOL CHEM, V245, P4224; WEINER JH, 1986, P NATL ACAD SCI USA, V83, P2056, DOI 10.1073/pnas.83.7.2056; WEINER JH, 1979, J BIOL CHEM, V254, P8590; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	70	342	385	5	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1999	284	5422					1961	1966		10.1126/science.284.5422.1961	http://dx.doi.org/10.1126/science.284.5422.1961			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373108				2022-12-01	WOS:000080932700038
J	DiSanti, MA; Mumma, MJ; Dello Russo, N; Magee-Sauer, K; Novak, R; Rettig, TW				DiSanti, MA; Mumma, MJ; Dello Russo, N; Magee-Sauer, K; Novak, R; Rettig, TW			Identification of two sources of carbon monoxide in comet Hale-Bopp	NATURE			English	Article							PLANETARY-ATMOSPHERES; HALLEY; P/HALLEY; MODEL; GAS; CO; EVOLUTION; TIME; DUST	The composition of ices in comets may reflect that of the molecular cloud in which the Sun formed, or it may show evidence of chemical processing in the pre-planetary accretion disk around the proto-Sun. As carbon monoxide (CO) is ubiquitous in molecular clouds(1,2), its abundance with respect to water could help to determine the degree to which pre-cometary material was processed, although variations in CO abundance may also be influenced by the distance from the Sun at which comets formed(3-5). Observations have not hitherto provided an unambiguous measure of CO in the cometary ice (native CO). Evidence for an extended source of CO associated with comet Halley was provided by the Giotto spacecraft(6-9), but alternative interpretations exist(10). Here we report observations of comet Hale-Bopp which show that about half of the CO in the comet comes directly from ice stored in the nucleus. The abundance of this CO with respect to water (12 per cent) is smaller than in quiescent regions of molecular clouds, but is consistent with that measured in proto-stellar envelopes(11), suggesting that the ices underwent some processing before their inclusion into Hale-Bopp. The remaining CO arises in the coma, probably through thermal destruction of more complex molecules.	Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA; NASA, Goddard Space Flight Ctr, Extraterr Phys Lab, Greenbelt, MD 20771 USA; Rowan Univ, Dept Chem & Phys, Glassboro, NJ 08028 USA; Iona Coll, Dept Phys, New Rochelle, NY 10801 USA; Univ Notre Dame, Dept Phys & Astron, Notre Dame, IN 46556 USA	Catholic University of America; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Rowan University; Iona College; University of Notre Dame	DiSanti, MA (corresponding author), Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA.		Russo, Neil Dello/G-2727-2015; Magee-Sauer, Karen/K-6061-2015; mumma, michael j/I-2764-2013	Russo, Neil Dello/0000-0002-8379-7304; Magee-Sauer, Karen/0000-0002-4979-9875; mumma, michael j/0000-0003-4627-750X				Biver N, 1996, NATURE, V380, P137, DOI 10.1038/380137a0; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; BIVER N, IN PRESS EARTH MOON; BOICE DC, 1990, GEOPHYS RES LETT, V17, P1813, DOI 10.1029/GL017i011p01813; Chiar JE, 1998, ASTROPHYS J, V498, P716, DOI 10.1086/305569; Combi MR, 1996, ICARUS, V123, P207, DOI 10.1006/icar.1996.0150; CRIFO JF, 1995, ASTROPHYS J, V445, P470, DOI 10.1086/175712; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; Dello Russo N, 1998, ICARUS, V135, P377, DOI 10.1006/icar.1998.5990; DELLORUSSO N, 1995, UNPUB ICARUS; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; Green S.F., 1986, ESA SP250, VII, P81; Greenberg JM, 1998, ASTRON ASTROPHYS, V332, P374; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P311; Herzberg G., 1966, MOL SPECTRA MOL STRU; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; HUEBNER WF, 1987, ASTROPHYS J, V320, pL149, DOI 10.1086/184992; HUNTRESS WT, 1991, NATURE, V352, P316, DOI 10.1038/352316a0; Jewitt D, 1999, ASTRON J, V117, P1056, DOI 10.1086/300743; KUNDE VG, 1974, J QUANT SPECTROSC RA, V14, P803, DOI 10.1016/0022-4073(74)90124-1; LAMMERZAHL P, 1987, ASTRON ASTROPHYS, V187, P169; MEIER R, 1993, ASTRON ASTROPHYS, V277, P677; Mumma M. J., 1997, Astronomical Society of the Pacific Conference Series, V122, P369; MUMMA MJ, 1993, PROTOSTARS PLANETS, V3, P1177; RANK DM, 1971, SCIENCE, V174, P1083, DOI 10.1126/science.174.4014.1083; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; SANDFORD SA, 1988, ICARUS, V76, P201, DOI 10.1016/0019-1035(88)90069-3; TURNER BE, 1989, SPACE SCI REV, V51, P235, DOI 10.1007/BF00172023; WEAVER HA, IN PRESS EARTH MOON; Womack M, 1997, ASTRON J, V114, P2789, DOI 10.1086/118687; Xie XF, 1996, ASTROPHYS J, V464, P457, DOI 10.1086/177336; XIE XF, 1992, ASTROPHYS J, V386, P720, DOI 10.1086/171053	32	83	83	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					662	665		10.1038/21378	http://dx.doi.org/10.1038/21378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385117				2022-12-01	WOS:000080932800051
J	Cummings, P; Quan, L				Cummings, P; Quan, L			Trends in unintentional drowning - The role of alcohol and medical care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REGRESSION-ANALYSES; RATES; CHILDREN; RISK	Context During the last few decades, mortality from drowning has decreased in the United States for unknown reasons. It has been hypothesized that this decline may be due to decreased use of alcohol in and around water or improved medical treatment after a submersion. Objectives To estimate changes in unintentional mortality due to submersion, estimate trends in drownings attributable to alcohol use, and assess the role of medical care in these mortality trends. Design A 21-year longitudinal study of case findings, from January 1, 1975, through December 31, 1995. Setting and Participants All residents of King County, Washington, who died unintentionally from submersion and 284 persons hospitalized for submersion who survived. Main Outcome Measures Changes in submersion-related mortality incidence over time, proportion of this mortality that could be attributed to alcohol use, changes over time in the case-fatality rate of treated patients, and estimate of deaths prevented in 1995 compared with projected estimates had there been no change in incidence since 1975, Results There were 539 deaths due to drowning in King County during 21 years. Mortality rates during this period declined by 59% (95% confidence interval [CI], -70% to -46%), The incidence of death attributable to alcohol use decreased by 81% (95% CI, -91% to -57%); this could account for 51% of deaths prevented in 1995, Among 249 comatose patients who received prehospital care, 205 died; the odds of survival decreased 40% over 21 years (P = .40). Among 101 comatose patients who were hospitalized, 63 died; the odds of survival decreased 29% (P = .75). The incidence of survival of comatose hospital patients decreased by 29% from 1975 to 1995 (95% CI, -78% to +125%). We found no evidence that trends in medical treatment prevented any deaths due to drowning in 1995. Conclusions Drowning incidence in King County, Washington, declined because of a decrease in severe submersion episodes rather than an increase in success of medical interventions. Our data support the theory that less use of alcohol around water prevents some deaths, About half of the decrease was unexplained.	Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Childrens Hosp & Med Ctr, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Cummings, P (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Box 359960,325 9th Ave, Seattle, WA 98104 USA.				PHS HHS [R49/CCR010141-03] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER SP, 1992, INJURY FACT BOOK, P181; BENNETT EE, IN PRESS INJ PREV; BIGGART MJ, 1990, J PEDIATR-US, V117, P179, DOI 10.1016/S0022-3476(05)80526-8; BORKENSTEIN RF, 1964, ROLE DRINKING DRIVER, P166; BRENNER RA, 1994, JAMA-J AM MED ASSOC, V271, P1606, DOI 10.1001/jama.271.20.1606; Bureau of the Census, 1992, 1990 CENS POP GEN PO; *CDCP, 1998, CDC WONDER WEBS; CONN AW, 1980, CAN ANAESTH SOC J, V27, P201, DOI 10.1007/BF03007429; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; Glynn RJ, 1996, BMJ-BRIT MED J, V312, P364; GRAF WD, 1995, ANN EMERG MED, V26, P312, DOI 10.1016/S0196-0644(95)70079-X; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; GULAID JA, 1988, MMWR-MORBID MORTAL W, V37, pSS27; HOWLAND J, 1988, ACCIDENT ANAL PREV, V20, P19, DOI 10.1016/0001-4575(88)90011-5; HOWLAND J, 1993, JAMA-J AM MED ASSOC, V270, P91, DOI 10.1001/jama.270.1.91; Howland J., 1993, Morbidity and Mortality Weekly Report, V42, P675; HOWLAND J, 1990, MMWR-MORBID MORTAL W, V39, P332; HURST PM, 1994, ACCIDENT ANAL PREV, V26, P647, DOI 10.1016/0001-4575(94)90026-4; LITTLE RJA, 1987, STAT ANAL MISSING DA, P255; LONG JS, 1997, REGRESSION MODELS CA, P87; MCCARROLL JR, 1962, J CHRON DIS, V15, P811, DOI 10.1016/0021-9681(62)90051-6; McCullagh P, 1989, GEN LINEAR MODELS, P198; MODELL JH, 1980, CAN ANAESTH SOC J, V27, P211, DOI 10.1007/BF03007430; *NAT CTR HLTH STAT, 1997, HLTH US 1996 97 INJ; NICHTER MA, 1989, CRIT CARE MED, V17, P993, DOI 10.1097/00003246-198910000-00005; QUAN L, 1990, J ENVIRON HEALTH, V52, P344; Quan L, 1998, Inj Prev, V4, P203; Rivara FP, 1996, PEDIATRICS, V97, P791; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P54; Rubin DB, 1987, MULTIPLE IMPUTATION, P75; Smith G S, 1998, Inj Prev, V4, P135; SMITH GS, 1994, 122 ANN M AM PUBL HL, P323; *STAT, 1999, STAT STAT SOFTW REL; Treser CD, 1997, J PUBLIC HEALTH POL, V18, P346, DOI 10.2307/3343315; *US BUR CENS, 1998, EL FIL KING COUNT WA; *US DHHS, 1991, DHHS PUBL PHS, P277; WINTEMUTE GJ, 1990, ACCIDENT ANAL PREV, V22, P291, DOI 10.1016/0001-4575(90)90020-L; ZADOR PL, 1991, J STUD ALCOHOL, V52, P302, DOI 10.15288/jsa.1991.52.302	39	59	59	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2198	2202		10.1001/jama.281.23.2198	http://dx.doi.org/10.1001/jama.281.23.2198			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	204RB	10376572				2022-12-01	WOS:000080777000033
J	Kuras, L; Struhl, K				Kuras, L; Struhl, K			Binding of TBP to promoters in vivo is stimulated by activators and requires Pol II holoenzyme	NATURE			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; SACCHAROMYCES-CEREVISIAE; TATA BOXES; YEAST; RECRUITMENT; COMPLEXES; DNA; REPRESSOR	In eukaryotes, transcriptional activators have been proposed to function by recruiting the RNA polymerase II (Pol II) machinery(1-3), by altering the conformation of this machinery(4,5), or by affecting steps after initiation(6-8), but the evidence is not definitive. Genomic footprinting of yeast TATA-box elements reveals activator-dependent alterations of chromatin structure(9) and activator-independent protection(10), but little is known about the association of specific components of the Pol II machinery with promoters in vivo. Here we analyse TATA-box-binding-protein (TBP) occupancy of 30 yeast promoters in vivo. We find that TBP association with promoters is stimulated by activators and inhibited by the Cyc8-Tup1 repressor, and that transcriptional activity correlates strongly with the degree of TBP occupancy. In a small subset of promoters, TBP occupancy is higher than expected when gene activity is low, and the activator-dependent increase is modest. TBP association depends on the Pol II holoenzyme component Srb4, but not on the Kin28 subunit of the transcription factor TFIIH, even though both proteins are generally required for transcription. Thus in yeast cells, TBP association with promoters occurs in concert with the Pol II holoenzyme, activator-dependent recruitment of the Pol II machinery occurs at the vast majority of promoters, and Kin28 acts after the initial recruitment.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.			Kuras, Laurent/0000-0003-2932-0940				Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; Stargell LA, 1996, MOL CELL BIOL, V16, P4456; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	28	398	400	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					609	613		10.1038/21239	http://dx.doi.org/10.1038/21239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376605				2022-12-01	WOS:000080778400062
J	Billings, PR; Hubbard, R; Newman, SA				Billings, PR; Hubbard, R; Newman, SA			Human germline gene modification: a dissent	LANCET			English	Editorial Material							THERAPY; LINE; ENHANCEMENT; PREVENTION; MEDICINE		New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; Harvard Univ, Biol Labs, Cambridge, MA 02138 USA; Heart Texas Hlth Care Syst, Vet Hlth Adm, Grand Prairie, TX 75050 USA	New York Medical College; Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Newman, SA (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.		Newman, Stuart/W-1617-2019					AGIUS E, 1994, WHAT FUTURE FUTURE G, P305; ANDERSON WF, 1992, HUM GENE THER, V3, P1, DOI 10.1089/hum.1992.3.1-1; ANNAS GJ, 1992, GENE MAPPING USING L, P142; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; Bonnicksen AL, 1998, NAT GENET, V19, P10, DOI 10.1038/ng0598-10; BOUQUET M, 1993, BIOL REPROD, V49, P764, DOI 10.1095/biolreprod49.4.764; Cohen CB, 1996, HASTINGS CENT REP, V26, P19, DOI 10.2307/3528572; COOKDEEGAN RM, 1994, POL LIFE SCI, V3, P217; DANIELSON H, 1988, LANCET, V1, P1271; DAVIS BD, 1992, HUM GENE THER, V3, P361, DOI 10.1089/hum.1992.3.4-361; Ewbank J, 1998, NATURE, V392, P645; FLETCHER JC, 1992, LAW MED HEALTHCARE, V20, P2; Fowler G, 1989, Theor Med, V10, P151, DOI 10.1007/BF00539880; FRIEDMAN T, 1991, THERAPY GENETIC DIS; JAENISCH R, 1985, COLD SPRING HARB SYM, V50, P439, DOI 10.1101/SQB.1985.050.01.055; Juengst ET, 1997, J MED PHILOS, V22, P125; KOLATA G, 1998, NY TIMES        0908, pA1; KRIMSKY S, 1990, HUM GENE THER, V1, P171, DOI 10.1089/hum.1990.1.2-171; LAPPE M, 1991, J MED PHILOS, V16, P621, DOI 10.1093/jmp/16.6.621; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LIPPMAN A, 1993, HUM GENE THER, V4, P35; McDonough PG, 1997, ANN NY ACAD SCI, V816, P378, DOI 10.1111/j.1749-6632.1997.tb52165.x; McLaren A, 1998, NATURE, V392, P645, DOI 10.1038/33511; MILLER HI, 1994, LANCET, V344, P316, DOI 10.1016/S0140-6736(94)91345-5; NEEL JV, 1993, HUM GENE THER, V4, P127, DOI 10.1089/hum.1993.4.2-127; NEWMAN SA, INTERPLAY GENETIC PH, P3; *PC, 1982, PRES COMM STUD ETH P, P1; RIFKIN J, 1983, ALGENY; Robertson JA., 1994, CHILDREN CHOICE FREE; STROHMAN RC, 1993, PERSPECT BIOL MED, V37, P112; Tsukui T, 1996, NAT BIOTECHNOL, V14, P982, DOI 10.1038/nbt0896-982; Vishwanath R, 1997, REPROD FERT DEVELOP, V9, P321, DOI 10.1071/R96088; Wadman M, 1998, NATURE, V392, P317, DOI 10.1038/32721; Walters L., 1997, ETHICS HUMAN GENE TH; Wilkins AS, 1997, BIOESSAYS, V19, P257, DOI 10.1002/bies.950190312; WIVEL NA, 1993, SCIENCE, V262, P533, DOI 10.1126/science.8211180; *WORLD COUNC CHURC, 1983, MAN LIF ETH ISS GEN; 1981, FED REG, V46, P6386; 1983, FED REG, V48, P9269	39	16	16	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1873	1875		10.1016/S0140-6736(99)01173-3	http://dx.doi.org/10.1016/S0140-6736(99)01173-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359429				2022-12-01	WOS:000080667800047
J	Mundy, AR				Mundy, AR			Metabolic complications of urinary diversion	LANCET			English	Editorial Material							CYSTOPLASTY		UCL, Inst Urol & Nephrol, London W1P 7PN, England	University of London; University College London	Mundy, AR (corresponding author), UCL, Inst Urol & Nephrol, London W1P 7PN, England.							FILMER RB, 1990, J UROLOGY, V143, P671, DOI 10.1016/S0022-5347(17)40055-3; KOCH MO, 1992, J UROLOGY, V147, P1343, DOI 10.1016/S0022-5347(17)37560-2; KOCH MO, 1985, SURGERY, V98, P561; MCDOUGAL WS, 1992, J UROLOGY, V147, P1199, DOI 10.1016/S0022-5347(17)37517-1; MUNDY AR, 1992, BRIT J UROL, V69, P257, DOI 10.1111/j.1464-410X.1992.tb15524.x; NURSE DE, 1989, BRIT J UROL, V64, P489, DOI 10.1111/j.1464-410X.1989.tb05283.x; Nurse DE, 1996, BRIT J UROL, V77, P684, DOI 10.1046/j.1464-410X.1996.97311.x; NURSE DE, 1989, BRIT J UROL, V63, P165, DOI 10.1111/j.1464-410X.1989.tb05157.x; Stein R, 1998, BRIT J UROL, V82, P798; STEWART M, 1986, ANN ROY COLL SURG, V68, P98	10	20	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1813	1814		10.1016/S0140-6736(99)90023-5	http://dx.doi.org/10.1016/S0140-6736(99)90023-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359400				2022-12-01	WOS:000080667800003
J	Williams, N; Jackson, D; Lambert, PC; Johnstone, JM				Williams, N; Jackson, D; Lambert, PC; Johnstone, JM			Incidence of non-specific abdominal pain in children during school term: population survey based on discharge diagnoses	BRITISH MEDICAL JOURNAL			English	Article									Leicester Royal Infirm, Dept Surg, Leicester LE1 5WW, Leics, England; Leicestershire Hlth Author, Leicester LE5 4QF, Leics, England; Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England	University of Leicester; University of Leicester	Williams, N (corresponding author), Leicester Royal Infirm, Dept Surg, Leicester LE1 5WW, Leics, England.			Lambert, Paul/0000-0002-5337-663X				Clayton D., 1993, STAT MODELS EPIDEMIO; HENDERSON J, 1992, ARCH DIS CHILD, V67, P83, DOI 10.1136/adc.67.1.83; IRVIN TT, 1989, BRIT J SURG, V76, P1121, DOI 10.1002/bjs.1800761105; JONES PF, 1969, BRIT MED J, V1, P284, DOI 10.1136/bmj.1.5639.284; JONES PF, 1990, BRIT J SURG, V77, P365, DOI 10.1002/bjs.1800770404	5	18	19	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1455	1455		10.1136/bmj.318.7196.1455	http://dx.doi.org/10.1136/bmj.318.7196.1455			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346771	Bronze, Green Submitted			2022-12-01	WOS:000080668200023
J	Ramirez-Weber, FA; Kornberg, TB				Ramirez-Weber, FA; Kornberg, TB			Cytonemes: Cellular processes that project to the principal signaling center in Drosophila imaginal discs	CELL			English	Article							WING DISK; DEVELOPMENTAL COMPARTMENTALIZATION; POSTERIOR COMPARTMENTS; HEDGEHOG ACTIVITY; ENGRAILED GENE; MIGRATION; PATTERN; EMBRYO; CELLS; EXPRESSION	Wing imaginal disc cells in Drosophila develop by using information received from a signaling center associated with the anterior/posterior compartment border. We show here that disc cells have thin, actin-based extensions (cytonemes) that project to this signaling center. Cytonemes can be induced when cells from the lateral flanks of a wing disc are cultured next to cells from the A/P border or next to a source of fibroblast growth factor. Mouse limb bud cells also grow projections during a brief culture period, indicating that cytonemes are an attribute of both vertebrate and invertebrate cells. We suggest that cytonemes may be responsible for some forms of long-range cell-cell communication.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kornberg, TB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.							BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Burdine RD, 1998, DEVELOPMENT, V125, P1083; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; GARCIABELLIDO A, 1976, DEV BIOL, V48, P132, DOI 10.1016/0012-1606(76)90052-X; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GARCIABELLIDO A, 1972, GENETICS, V72, P87; Gisselbrecht S, 1996, GENE DEV, V10, P3003, DOI 10.1101/gad.10.23.3003; GUSTAFSON T, 1967, BIOL REV, V42, P442, DOI 10.1111/j.1469-185X.1967.tb01482.x; KARP GC, 1985, DEV BIOL, V112, P276, DOI 10.1016/0012-1606(85)90398-7; KORNBERG T, 1981, DEV BIOL, V86, P363, DOI 10.1016/0012-1606(81)90194-9; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; LOCKE M, 1987, TISSUE CELL, V19, P301, DOI 10.1016/0040-8166(87)90014-0; MCFARLANE S, 1995, NEURON, V15, P1017, DOI 10.1016/0896-6273(95)90091-8; MILLER J, 1995, DEVELOPMENT, V121, P2501; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; MORATA G, 1978, NATURE, V274, P473, DOI 10.1038/274473a0; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; Mullor JL, 1997, DEVELOPMENT, V124, P1227; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; STEINER E, 1976, ROUX ARCH DEV BIOL, V180, P9, DOI 10.1007/BF00848882; Strigini M, 1997, DEVELOPMENT, V124, P4697; STRUHL G, 1981, DEV BIOL, V84, P372, DOI 10.1016/0012-1606(81)90406-1; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TILNEY LG, 1982, J CELL BIOL, V93, P820, DOI 10.1083/jcb.93.3.820; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; Ursprung H, 1972, BIOL IMAGINAL DISKS, P93; WEIR MP, 1982, P NATL ACAD SCI-BIOL, V79, P3232, DOI 10.1073/pnas.79.10.3232; XU T, 1993, DEVELOPMENT, V117, P1223	41	455	461	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					599	607		10.1016/S0092-8674(00)80771-0	http://dx.doi.org/10.1016/S0092-8674(00)80771-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367889	Bronze			2022-12-01	WOS:000080672100009
J	Oliveira, DBG				Oliveira, DBG			Prophylaxis against contrast-induced nephropathy	LANCET			English	Editorial Material							ACUTE-RENAL-FAILURE; AGENTS; RISK		Univ London St Georges Hosp, Sch Med, Dept Renal Med, London SW17 0RE, England	St Georges University London	Oliveira, DBG (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Renal Med, London SW17 0RE, England.			Oliveira, David/0000-0002-7507-5651				Abizaid AS, 1999, AM J CARDIOL, V83, P260, DOI 10.1016/S0002-9149(98)00833-9; BARRETT BJ, 1993, RADIOLOGY, V188, P171, DOI 10.1148/radiology.188.1.8511292; Hans SS, 1998, AM SURGEON, V64, P432; Kolonko A, 1998, J NEPHROL, V11, P151; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Perneger T. V., 1993, Journal of the American Society of Nephrology, V4, P256; Solomon R, 1998, KIDNEY INT, V53, P230, DOI 10.1038/sj.ki.4495510; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Stevens NA, 1999, J AM COLL CARDIOL, V33, P403; Taylor AJ, 1998, CHEST, V114, P1570, DOI 10.1378/chest.114.6.1570; WEISBERG LS, 1994, KIDNEY INT, V45, P259, DOI 10.1038/ki.1994.32	11	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1638	1639		10.1016/S0140-6736(98)90076-9	http://dx.doi.org/10.1016/S0140-6736(98)90076-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335780				2022-12-01	WOS:000080408000005
J	Mainen, ZF; Malinow, R; Svoboda, K				Mainen, ZF; Malinow, R; Svoboda, K			Synaptic calcium transients in single spines indicate that NMDA receptors are not saturated	NATURE			English	Article							LONG-TERM POTENTIATION; DENDRITIC SPINES; MULTIVESICULAR RELEASE; GLUTAMATE DIFFUSION; EXCITATORY SYNAPSES; PYRAMIDAL NEURONS; TIME COURSE; HIPPOCAMPUS; TRANSMITTER; PROBABILITY	At excitatory synapses in the central nervous system, the number of glutamate molecules released from a vesicle is much larger than the number of postsynaptic receptors. But does release of a single vesicle normally saturate these receptors? Answering this question is critical to understanding how the amplitude and variability of synaptic transmission are set and regulated. Here we describe the use of two-photon microscopy(1) to image transient increases in Ca2+ concentration mediated by NMDA (N-methyl-D-aspartate) receptors in single dendritic spines of CAI pyramidal neurons in hippocampal slices. To test for NMDA-receptor saturation, we compared responses to stimulation with single and double pulses. We find that a single release event does not saturate spine NMDA receptors; a second release occurring 10 ms later produces similar to 80% more NMDA-receptor activation. The amplitude of spine NMDA-receptor-mediated [Ca2+] transients (and the synaptic plasticity which depends on this) may thus be sensitive to the number of quanta released by a burst of action potentials and to changes in the concentration profile of glutamate in the synaptic cleft.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Svoboda, K (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.			Mainen, Zachary/0000-0001-7913-9109				Auger C, 1998, J NEUROSCI, V18, P4532; Barbour B, 1997, TRENDS NEUROSCI, V20, P377; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; Denk W, 1997, NEURON, V18, P351, DOI 10.1016/S0896-6273(00)81237-4; Dobrunz LE, 1997, P NATL ACAD SCI USA, V94, P14843, DOI 10.1073/pnas.94.26.14843; FABER DS, 1992, SCIENCE, V258, P1494, DOI 10.1126/science.1279813; Frerking M, 1996, CURR OPIN NEUROBIOL, V6, P395, DOI 10.1016/S0959-4388(96)80125-5; HARRIS KM, 1989, J NEUROSCI, V9, P2982; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; Holmes WR, 1995, BIOPHYS J, V69, P1734, DOI 10.1016/S0006-3495(95)80043-3; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; Mainen ZF, 1998, NAT NEUROSCI, V1, P579, DOI 10.1038/2812; MAINEN ZF, IN RPESS METHODS COM, V18; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MARKRAM H, 1995, J PHYSIOL-LONDON, V485, P1; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; REGEHR WG, 1995, BIOPHYS J, V68, P2156, DOI 10.1016/S0006-3495(95)80398-X; Rusakov DA, 1998, J NEUROSCI, V18, P3158; Schikorski T, 1997, J NEUROSCI, V17, P5858; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; TANG CM, 1994, NEURON, V13, P1385, DOI 10.1016/0896-6273(94)90423-5; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	30	238	244	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	1999	399	6732					151	155		10.1038/20187	http://dx.doi.org/10.1038/20187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335844				2022-12-01	WOS:000080335700050
J	Silverstein, MJ; Lagios, MD; Groshen, S; Waisman, JR; Lewinsky, BS; Martino, S; Gamagami, P; Colburn, WJ				Silverstein, MJ; Lagios, MD; Groshen, S; Waisman, JR; Lewinsky, BS; Martino, S; Gamagami, P; Colburn, WJ			The influence of margin width on local control of ductal carcinoma in situ of the breast	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL ADJUVANT BREAST; IN-SITU; INTRADUCTAL CARCINOMA; RADIATION-THERAPY; DEFINITIVE IRRADIATION; CONSERVING SURGERY; PROGNOSTIC INDEX; INSITU; CLASSIFICATION; REPRODUCIBILITY	Background Ductal carcinoma in situ is a noninvasive carcinoma that is unlikely to recur if completely excised. Margin width, the distance between the boundary of the lesion and the edge of the excised specimen, may be an important determinant of local recurrence, Methods Margin widths, determined by direct measurement or ocular micrometry, and standardized evaluation of the tumor for nuclear grade, comedonecrosis, and size were performed on 469 specimens of ductal carcinoma in situ from patients who had been treated with breast-conserving surgery with or without postoperative radiation therapy, according to the choice of the patient or her physician. We analyzed the results in relation to margin width and whether the patient received postoperative radiation therapy. Results The mean (+/-SE) estimated probability of recurrence at eight years was 0.04+/-0.02 among 133 patients whose excised lesions had margin widths of 10 mm or more in every direction. Among these patients there was no benefit from postoperative radiation therapy. There was also no statistically significant benefit from postoperative radiation therapy among patients with margin widths of 1 to <10 mm. In contrast, there was a statistically significant benefit from radiation among patients in whom margin widths were less than 1 mm. Conclusions Postoperative radiation therapy did not lower the recurrence rate among patients with ductal carcinoma in situ that was excised with margins of 10 mm or more. Patients in whom the margin width is less than 1 mm can benefit from postoperative radiation therapy. (N Engl J Med 1999;340:1455-61.) (C) 1999, Massachusetts Medical Society.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Harold E & Henrietta C Lee Breast Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Surg, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90033 USA; St Marys Hosp, San Francisco, CA USA; Breast Ctr, Van Nuys, CA 91405 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Silverstein, MJ (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Harold E & Henrietta C Lee Breast Ctr, 1441 Eastlake Ave,Rm 7415, Los Angeles, CA 90033 USA.							ASHIKARI R, 1971, CANCER, V28, P1182, DOI 10.1002/1097-0142(1971)28:5<1182::AID-CNCR2820280515>3.0.CO;2-H; BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; Bethwaite P, 1998, J CLIN PATHOL, V51, P450, DOI 10.1136/jcp.51.6.450; BORNSTEIN BA, 1991, CANCER-AM CANCER SOC, V67, P7, DOI 10.1002/1097-0142(19910101)67:1<7::AID-CNCR2820670103>3.0.CO;2-B; BRADLEY SJ, 1990, AM SURGEON, V56, P428; DouglasJones AG, 1996, HISTOPATHOLOGY, V29, P397, DOI 10.1046/j.1365-2559.1996.d01-513.x; FAVERLY DRG, 1994, SEMIN DIAGN PATHOL, V11, P193; FENTIMAN IS, 1986, EUR J SURG ONCOL, V12, P261; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; Fisher B, 1998, J CLIN ONCOL, V16, P441, DOI 10.1200/JCO.1998.16.2.441; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; HOLLAND R, 1990, LANCET, V335, P519, DOI 10.1016/0140-6736(90)90747-S; HOLLAND R, 1997, DUCTAL CARCINOMA IN, P233; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KUSKE RR, 1993, INT J RADIAT ONCOL, V26, P391, DOI 10.1016/0360-3016(93)90955-U; LAGIOS MD, 1982, CANCER-AM CANCER SOC, V50, P1309, DOI 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-#; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LAGIOS MD, 1990, SURG CLIN N AM, V70, P853; LAGIOS MD, 1993, NEW ENGL J MED, V329, P1577; LAGIOS MD, 1995, BREAST J, V1, P68; MCCORMICK B, 1991, INT J RADIAT ONCOL, V21, P289, DOI 10.1016/0360-3016(91)90773-W; Miller R.G., 1981, SURVIVAL ANAL; OTTESEN GL, 1992, AM J SURG PATHOL, V16, P1183, DOI 10.1097/00000478-199212000-00005; PAGE DL, 1995, CANCER, V75, P1219, DOI 10.1002/1097-0142(19950315)75:6<1219::AID-CNCR2820750602>3.0.CO;2-X; POLLER DN, 1994, MODERN PATHOL, V7, P257; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; ROSNER D, 1980, ANN SURG, V192, P139, DOI 10.1097/00000658-198008000-00001; Schnitt SJ, 1996, CANCER, V77, P2189, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2189::AID-CNCR1>3.0.CO;2-L; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; Scott MA, 1997, HUM PATHOL, V28, P967, DOI 10.1016/S0046-8177(97)90013-7; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; Silverstein MJ, 1998, J CLIN ONCOL, V16, P1367, DOI 10.1200/JCO.1998.16.4.1367; SILVERSTEIN MJ, 1995, EUR J CANCER, V31A, P1425, DOI 10.1016/0959-8049(95)00283-O; Silverstein MJ, 1996, CANCER-AM CANCER SOC, V77, P2267, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V; SOLIN LJ, 1991, CANCER-AM CANCER SOC, V68, P2337, DOI 10.1002/1097-0142(19911201)68:11<2337::AID-CNCR2820681102>3.0.CO;2-R; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; Wolmark N, 1998, BREAST CANC RES TREA, V50, P227; ZAFRANI B, 1994, SEMIN DIAGN PATHOL, V11, P208	39	496	517	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1455	1461		10.1056/NEJM199905133401902	http://dx.doi.org/10.1056/NEJM199905133401902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MT	10320383				2022-12-01	WOS:000080198700002
J	Fellers, RS; Leforestier, C; Braly, LB; Brown, MG; Saykally, RJ				Fellers, RS; Leforestier, C; Braly, LB; Brown, MG; Saykally, RJ			Spectroscopic determination the water pair potential	SCIENCE			English	Article							AB-INITIO; DIMER; VIBRATION; SPECTRA; DYNAMICS; CLUSTERS; ENERGY; (D2O)2; VAPOR	A polarizable water pair potential was determined by fitting a potential form to microwave, terahertz, and mid-infrared (D2O)(2) spectra through a rigorous calculation of the water dimer eigenstates. It accurately reproduces most ground state vibration-rotation-tunneling spectra and yields excellent second viral coefficients. The calculated dimer structure and dipole moment are very close to those determined from microwave spectroscopy and high-level ab initio calculations. The dimer binding energy and acceptor switching and donor-acceptor interchange tunneling barriers are in excellent agreement with recent ab initio theory, as are cyclic water trimer and tetramer structures and binding energies.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Montpellier 2, Lab Struct & Dynam Syst Mol & Solides, UMR 5636, F-34095 Montpellier 05, France	University of California System; University of California Berkeley; Universite de Montpellier	Saykally, RJ (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.			SAYKALLY, RICHARD/0000-0001-8942-3656				Burnham CJ, 1999, J CHEM PHYS, V110, P4566, DOI 10.1063/1.478797; CURTISS LA, 1979, J CHEM PHYS, V71, P2703, DOI 10.1063/1.438628; ELROD MJ, 1994, CHEM REV, V94, P1975, DOI 10.1021/cr00031a010; ELROD MJ, 1995, J CHEM PHYS, V103, P933, DOI 10.1063/1.469794; Fellers RS, 1999, J CHEM PHYS, V110, P6306, DOI 10.1063/1.478535; Feyereisen MW, 1996, J PHYS CHEM-US, V100, P2993, DOI 10.1021/jp952860l; FRASER GT, 1991, INT REV PHYS CHEM, V10, P189, DOI 10.1080/01442359109353257; Gregory JK, 1996, J PHYS CHEM-US, V100, P18014, DOI 10.1021/jp9616019; GREGORY JK, 1995, J CHEM PHYS, V102, P7817, DOI 10.1063/1.468982; Halkier A, 1997, THEOR CHEM ACC, V97, P150, DOI 10.1007/s002140050248; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KARYAKIN EN, 1993, MOL PHYS, V78, P1179, DOI 10.1080/00268979300100771; KELL GS, 1989, P ROY SOC LOND A MAT, V425, P49, DOI 10.1098/rspa.1989.0098; Leforestier C, 1997, J CHEM PHYS, V106, P8527, DOI 10.1063/1.473908; Liu K, 1997, J PHYS CHEM A, V101, P8995, DOI 10.1021/jp9707807; Liu K, 1996, SCIENCE, V271, P929, DOI 10.1126/science.271.5251.929; Mas EM, 1996, J CHEM PHYS, V104, P7606, DOI 10.1063/1.471469; MCQUARRIE D. A., 2000, STAT MECH; Millot C, 1998, J PHYS CHEM A, V102, P754, DOI 10.1021/jp972578+; MILLOT C, 1992, MOL PHYS, V77, P439, DOI 10.1080/00268979200102541; ODUTOLA JA, 1980, J CHEM PHYS, V72, P5062, DOI 10.1063/1.439795; Paul JB, 1998, J PHYS CHEM A, V102, P3279, DOI 10.1021/jp980763x; PUGLIANO N, 1992, J CHEM PHYS, V96, P1832, DOI 10.1063/1.462084; REIMERS JR, 1982, CHEM PHYS, V64, P95, DOI 10.1016/0301-0104(82)85006-4; SAYKALLY RJ, 1993, SCIENCE, V259, P1570, DOI 10.1126/science.259.5101.1570; SMITH BJ, 1990, J CHEM PHYS, V92, P1240, DOI 10.1063/1.458133; Solomon S, 1998, J GEOPHYS RES-ATMOS, V103, P3847, DOI 10.1029/97JD03285; Stone A.J., 1995, ORIENT PROGRAM STUDY; WALES DJ, IN PRESS THEORY ATOM, V2; XANTHEAS SS, 1993, J CHEM PHYS, V99, P8774, DOI 10.1063/1.465599	30	213	214	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					945	948		10.1126/science.284.5416.945	http://dx.doi.org/10.1126/science.284.5416.945			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320371				2022-12-01	WOS:000080198800040
J	Karvonen, M; Cepaitis, Z; Tuomilehto, J				Karvonen, M; Cepaitis, Z; Tuomilehto, J			Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study	BRITISH MEDICAL JOURNAL			English	Article							CUMULATIVE INCIDENCE; BCG-VACCINATION; MELLITUS; CHILDHOOD; CHILDREN; FINLAND; IDDM; IMMUNIZATION; RISK	Objectives To determine the effect of Haemophilus influenzae type b vaccination and its timing on the risk of type 1 diabetes in Finnish children. Design Cumulative incidence and relative risk of type 1 diabetes was compared among three birth cohorts of Finnish children: those born during the 24 months before the H influenzae type b vaccination trial, those in the trial cohort who were vaccinated at 3 months of age and later with a booster vaccine, and those in the trial cohort who were vaccinated at 24 months of age only. The probability of type 1 diabetes was estimated using regression analysis assuming that there were no losses to 10 year follow up and no competing risks. Setting Finland (total population 5 million and annual birth rate 1.3%). Subjects 128 936 children born from 1 October 1983 to 1 September 1985, and 116 352 children born from 1 October 1985 to 31 August 1987. Main outcome measures Probability of type 1 diabetes among children vaccinated with H influenzae type b and non-vaccinated children. Results No statistically significant difference was found at any time during the 10 year follow up in the risk of type 1 diabetes between the children born before the vaccination period and those vaccinated at the age of 24 months only (relative risk 1.01). The difference in the risk between the cohort vaccinated first at the age of 3 months and the cohort vaccinated at the age of 24 months only was not statistically significant either (1.06). Conclusion It is unlikely that H influenzae type b vaccination or its timing cause type 1 diabetes in children.	Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, FIN-00300 Helsinki, Finland	Finland National Institute for Health & Welfare	Karvonen, M (corresponding author), Natl Publ Hlth Inst, Diabet & Genet Epidemiol Unit, Mannerheimintie 166, FIN-00300 Helsinki, Finland.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037957] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37957] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOM L, 1991, DIABETOLOGIA, V34, P176, DOI 10.1007/BF00418272; Classen DC, 1997, INFECT DIS CLIN PRAC, V6, P449, DOI 10.1097/00019048-199706070-00007; Classen JB, 1996, DIABETOLOGIA, V39, P500, DOI 10.1007/BF00400684; Classen JB, 1999, BRIT MED J, V318, P193, DOI 10.1136/bmj.318.7177.193; DAHLQUIST G, 1995, DIABETOLOGIA, V38, P873, DOI 10.1007/BF03035306; ESKOLA J, 1990, NEW ENGL J MED, V323, P1381, DOI 10.1056/NEJM199011153232004; FURMAN BL, 1981, BRIT J EXP PATHOL, V62, P504; HARADA M, 1990, DIABETES RES CLIN PR, V8, P85, DOI 10.1016/0168-8227(90)90017-N; Heijbel H, 1997, DIABETES CARE, V20, P173, DOI 10.2337/diacare.20.2.173; HUIYU Q, 1993, J IMMUNOL, V150, P2072; HYOTY H, 1993, DIABETOLOGIA, V36, P1303, DOI 10.1007/BF00400810; Jefferson T, 1998, BRIT MED J, V317, P159, DOI 10.1136/bmj.317.7152.159; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; Parent ME, 1997, DIABETES CARE, V20, P767, DOI 10.2337/diacare.20.5.767; REWERS M, 1988, DIABETES, V37, P1113; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; SHEHADEH N, 1994, LANCET, V343, P706, DOI 10.1016/S0140-6736(94)91583-0; SOMERSALO O., 1960, Ann. Paediat. Fenn., V6, P253; Takala A K, 1994, Duodecim, V110, P1783; TUOMILEHTO J, 1991, DIABETOLOGIA, V34, P282, DOI 10.1007/BF00405089; TUOMILEHTO J, 1995, INT J EPIDEMIOL, V24, P984, DOI 10.1093/ije/24.5.984; TUOMILEHTO J, 1999, IN PRESS DIABETOLOGI, V42	22	69	69	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1169	1172						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221937	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000080277900026
J	Mullikin, JC; McMurray, AA				Mullikin, JC; McMurray, AA			DNA sequencing - Sequencing the genome, fast	SCIENCE			English	Editorial Material									Wellcome Trust, Sanger Ctr, Hinxton CB10 1SA, Cambs, England	Wellcome Trust Sanger Institute	Mullikin, JC (corresponding author), Wellcome Trust, Sanger Ctr, Genome Campus, Hinxton CB10 1SA, Cambs, England.							Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; KAMBARA H, 1993, NATURE, V361, P565, DOI 10.1038/361565a0; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401	4	27	29	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1867	1868		10.1126/science.283.5409.1867	http://dx.doi.org/10.1126/science.283.5409.1867			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10206892				2022-12-01	WOS:000079228600030
J	Simon, DB; Lu, Y; Choate, KA; Velazquez, H; Al-Sabban, E; Praga, M; Casari, C; Bettinelli, A; Colussi, C; Rodriguez-Soriano, J; McCredie, D; Milford, D; Sanjad, S; Lifton, RP				Simon, DB; Lu, Y; Choate, KA; Velazquez, H; Al-Sabban, E; Praga, M; Casari, C; Bettinelli, A; Colussi, C; Rodriguez-Soriano, J; McCredie, D; Milford, D; Sanjad, S; Lifton, RP			Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption	SCIENCE			English	Article							THICK ASCENDING LIMB; FAMILIAL HYPOMAGNESEMIA; MAGNESIUM TRANSPORT; COTRANSPORTER; PERMEABILITY; OCCLUDIN; RABBIT; LOOP	Epithelia permit selective and regulated flux from apical to basolateral surfaces by transcellular passage through cells or paracellular flux between cells. Tight junctions constitute the barrier to paracellular conductance; however, Little is known about the specific molecules that mediate paracellular permeabilities. Renal magnesium ion (Mg2+) resorption occurs predominantly through a paracellular conductance in the thick ascending limb of Henle (TAL), Here, positional cloning has identified a human gene, paracellin-1 (PCLN-1), mutations in which cause renal Mg2+ wasting. PCLN-1 is Located in tight junctions of the TAL and is related to the claudin family of tight junction proteins. These findings provide insight into Mg2+ homeostasis, demonstrate the role of a tight junction protein in human disease, and identify an essential component of a selective paracellular conductance.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; Hosp 12 Octubre, Serv Nefrol, E-28041 Madrid, Spain; Telethon Inst Genet & Med, I-20132 Milan, Italy; Univ Milan, Dept Pediat 2, Milan, Italy; Niguarda Ca Granda Hosp, Div Renal, Milan, Italy; Hosp Cruces, Dept Pediat, E-48903 Baracaldo, Spain; Royal Childrens Hosp, Dept Nephrol, Parkville, Vic 3052, Australia; Childrens Hosp, Dept Nephrol, Birmingham B16 8ET, W Midlands, England; American Univ, Dept Pediat, Beirut, Lebanon	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; King Faisal Specialist Hospital & Research Center; Hospital Universitario 12 de Octubre; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Hospital Universitario Cruces; Royal Children's Hospital Melbourne; American University of Beirut	Lifton, RP (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.		Casari, Giorgio/J-3070-2018	Casari, Giorgio/0000-0002-0115-8980; Colussi, Giacomo/0000-0001-6133-1899	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051696] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK51696] Funding Source: Medline; Telethon [F.1, TGM06S01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Bonnet R, 1895, DEUT MED WOCHENSCHR, V21, P58; BRUNETTE MG, 1974, AM J PHYSIOL, V227, P891, DOI 10.1152/ajplegacy.1974.227.4.891; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; DEROUFFIGNAC C, 1994, PHYSIOL REV, V74, P305, DOI 10.1152/physrev.1994.74.2.305; DISTEFANO A, 1993, RENAL PHYSIOL BIOCH, V16, P157; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Friedman PA, 1998, ANNU REV PHYSIOL, V60, P179, DOI 10.1146/annurev.physiol.60.1.179; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Kelepouris E, 1998, SEMIN NEPHROL, V18, P58; KOKKO JP, 1974, FED PROC, V33, P25; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Meij IC, 1999, AM J HUM GENET, V64, P180, DOI 10.1086/302199; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; MORITA K, 1999, P NATL ACAD SCI USA, V78, P5759; PRAGA M, 1995, KIDNEY INT, V47, P1419, DOI 10.1038/ki.1995.199; QUAMME GA, 1980, AM J PHYSIOL, V238, P187; SHAREGHI GR, 1982, J CLIN INVEST, V69, P759, DOI 10.1172/JCI110514; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEELE TH, 1968, J LAB CLIN MED, V71, P455; Velazquez H, 1998, KIDNEY INT, V54, P464, DOI 10.1046/j.1523-1755.1998.00036.x; Walder RY, 1997, HUM MOL GENET, V6, P1491, DOI 10.1093/hmg/6.9.1491	24	831	860	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					103	106		10.1126/science.285.5424.103	http://dx.doi.org/10.1126/science.285.5424.103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390358				2022-12-01	WOS:000081199800040
J	Socie, G; Stone, JV; Wingard, JR; Weisdorf, D; Henslee-Downey, PJ; Bredeson, C; Cahn, JY; Passweg, JR; Rowlings, PA; Schouten, HC; Kolb, HJ; Klein, JP				Socie, G; Stone, JV; Wingard, JR; Weisdorf, D; Henslee-Downey, PJ; Bredeson, C; Cahn, JY; Passweg, JR; Rowlings, PA; Schouten, HC; Kolb, HJ; Klein, JP		Late Effects Working Comm Int Bone Marr	Long-term survival and late deaths after allogeneic bone marrow transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOGENOUS LEUKEMIA; SEVERE APLASTIC-ANEMIA; CHILDHOOD-CANCER; MYELOID-LEUKEMIA; UNRELATED DONORS; CHEMOTHERAPY; MORTALITY; BLOOD; CURE	Background and Methods It is uncertain whether mortality rates among patients who have undergone bone marrow transplantation return to the level of the mortality rates of the general population. We analyzed the characteristics of 6691 patients listed in the International Bone Marrow Transplant Registry. All the patients were free of their original disease two years after allogeneic bone marrow transplantation. Mortality rates in this cohort were compared with those of an age-, sex-, and nationality-matched general population. Cox proportional-hazards regression was used to identify risk factors for death more than two years after transplantation (late death). Results Among patients who were free of disease two yea rs after transplantation, the probability of living for five more years was 89 percent (95 percent confidence interval, 88 to 90 percent). Among patients who underwent transplantation for aplastic anemia, the risk of death by the sixth year after transplantation did not differ significantly from that of a normal population. Mortality remained significantly higher than normal throughout the study among patients who underwent transplantation for acute lymphoblastic leukemia or chronic myelogenous leukemia and through the ninth year among those who underwent transplantation for acute myelogenous leukemia. Recurrent leukemia was the chief cause of death among patients who received a transplant for leukemia, whereas chronic graft-versus-host disease was the chief cause among those who received a transplant for aplastic anemia. Advanced, long-standing disease before transplantation and active chronic graft-versus-host disease were important risk factors for late death. Conclusions In patients who receive an allogeneic bone marrow transplant as treatment for acute myelogenous or lymphoblastic leukemia, chronic myelogenous leukemia, or aplastic anemia and who are free of their original disease two years later, the disease is probably cured. However, for many years after transplantation, the mortality among these patients is higher than that in a normal population. (N Engl J Med 1999;341:14-21.) (C)1999, Massachusetts Medical Society.	Hop St Louis, Serv Hematol Greffe Moelle, Paris, France; Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Hlth Policy Inst, Milwaukee, WI 53226 USA; Univ Florida, Coll Med, Gainesville, FL USA; Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA; Univ S Carolina, Div Transplantat Med, Columbia, SC 29208 USA; Univ Ottawa, Dept Med, Ottawa, ON, Canada; CHU Besancon, Serv Hematol, F-25030 Besancon, France; Kantonsspital Basel, Dept Med, Basel, Switzerland; Univ Hosp, Dept Internal Med, Maastricht, Netherlands; Univ Munich, Klinikum Grosshadern, Dept Hematol, D-8000 Munich, Germany; Univ Munich, Kinderpoliklin, Dept Hematol Oncol, Munich, Germany; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; Univ Miami, Sch Med, Div Pediat Hematol Oncol, Miami, FL USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Medical College of Wisconsin; State University System of Florida; University of Florida; University of Minnesota System; University of Minnesota Twin Cities; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Ottawa; Universite de Franche-Comte; CHU Besancon; Maastricht University; University of Munich; University of Munich; Medical College of Wisconsin; University of Miami	Socie, G (corresponding author), Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Hlth Policy Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.		passweg, jakob/AAG-3911-2020	Passweg, Jakob R/0000-0001-7092-3351; Wingard, John/0000-0001-7478-5398	NCI NIH HHS [U24-CA-76518, P01-CA-40053, N01-CP-51028] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP051028] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U24CA076518, P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN PK, 1989, BIOMETRICS, V45, P523, DOI 10.2307/2531494; Appelbaum FR, 1997, CANCER, V80, P2199; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BARRETT AJ, 1994, NEW ENGL J MED, V331, P1253, DOI 10.1056/NEJM199411103311902; Beatty PG, 1997, EXP HEMATOL, V25, P1195; Cella D F, 1995, Oncology (Williston Park), V9, P47; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; Deeg HJ, 1998, BLOOD, V91, P3637; deLima M, 1997, BLOOD, V90, P4719, DOI 10.1182/blood.V90.12.4719.4719_4719_4724; Duell T, 1997, ANN INTERN MED, V126, P184, DOI 10.7326/0003-4819-126-3-199702010-00002; Freireich EJ, 1997, CANCER, V80, P2215, DOI 10.1002/(SICI)1097-0142(19971201)80:11+<2215::AID-CNCR9>3.0.CO;2-G; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Goldman JM, 1997, NEW ENGL J MED, V337, P270, DOI 10.1056/NEJM199707243370410; Green DM, 1996, MED PEDIATR ONCOL, V26, P72, DOI 10.1002/(SICI)1096-911X(199601)26:1<72::AID-MPO13>3.0.CO;2-D; HAWKINS MM, 1990, ARCH DIS CHILD, V65, P1356, DOI 10.1136/adc.65.12.1356; HensleeDowney PJ, 1997, BLOOD, V89, P3864, DOI 10.1182/blood.V89.10.3864.3864_3864_3872; Horowitz M M, 1997, Curr Opin Hematol, V4, P395; Hudson MM, 1997, J CLIN ONCOL, V15, P2205, DOI 10.1200/JCO.1997.15.6.2205; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; Klein JP., 2003, SURVIVAL ANAL TECHNI, DOI 10.1007/b97377; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; NICHOLSON HS, 1994, CANCER, V73, P3094; Passweg JR, 1997, BLOOD, V90, P858; ROBERTSON CM, 1994, BRIT MED J, V309, P162, DOI 10.1136/bmj.309.6948.162; Storek J, 1997, AM J HEMATOL, V54, P131, DOI 10.1002/(SICI)1096-8652(199702)54:2<131::AID-AJH6>3.0.CO;2-Y; SULLIVAN KM, 1994, BONE MARROW TRANSPL, P339; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367; ZITTOUN RA, 1995, NEW ENGL J MED, V332, P217, DOI 10.1056/NEJM199501263320403	29	525	536	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					14	21		10.1056/NEJM199907013410103	http://dx.doi.org/10.1056/NEJM199907013410103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387937	Bronze			2022-12-01	WOS:000081195600003
J	Tan, LJ; Williams, MA; Khan, MK; Champion, HC; Nielsen, NH				Tan, LJ; Williams, MA; Khan, MK; Champion, HC; Nielsen, NH		American Medical Association	Risk of transmission of bovine spongiform encephalopathy to humans in the United States - Report of the Council on Scientific Affairs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRION PROTEIN GENE; AMYLOID PLAQUES; SCRAPIE PRION; VARIANT CJD; PRP GENE; BSE; MICE; EPIDEMIOLOGY; CATTLE	Context The risk of possible transmission of bovine spongiform encephalopathy (BSE) in the United States is a substantial public health concern. Objective To systematically review the current scientific literature and discuss legislation and regulations that have been implemented to prevent the disease. Methods Literature review using the MEDLINE, EMBASE, and Lexis/Nexis databases for 1975 through 1997 on the terms bovine spongiform encephalopathy, prion diseases, prions, and Creutzfeldt-Jakob syndrome. The Internet was used to identify regulatory actions and health surveillance. Data Extraction MEDLINE, EMBASE, and Lexis/Nexis databases were searched from 1975 through 1997 for English-language articles that provided information on assessment of transmission risk. Results Unique circumstances in the United Kingdom caused the emergence and propagation of BSE in cattle, including widespread use of meat and bonemeal cattle feed derived from scrapie-infected sheep and the adoption of a new type of processing that did not reduce the amount of infectious prions prior to feeding. Many of these circumstances do not exist in the United States. In the United Kingdom, new variant Creutzfeldt-Jakob disease probably resulted from the ingestion of BSE-contaminated processed beef. The United Kingdom and the European Union now have strong regulations in place to stop the spread of BSE, While BSE has not been observed in the United States, the US government has surveillance and response plans in effect. Conclusions Current risk of transmission of BSE in the United States is minimal because (1) BSE has not been shown to exist in this country; (2) adequate regulations exist to prevent entry of foreign sources of BSE into the United States; (3) adequate regulations exist to prevent undetected cases of BSE from uncontrolled amplification within the US cattle population; and (4) adequate preventive guidelines exist to prevent high-risk bovine materials from contaminating products intended for human consumption.	Amer Med Assoc, Chicago, IL 60610 USA	American Medical Association	Tan, LJ (corresponding author), Care of Dickinson B, Amer Med Assoc, 515 N State St, Chicago, IL 60610 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014; Tan, Litjen/0000-0001-9054-6696				Almond J, 1997, NATURE, V389, P437, DOI 10.1038/38876; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; BECK E, 1964, BRAIN, V87, P153, DOI 10.1093/brain/87.1.153; BERG LJ, 1994, P NATL ACAD SCI USA, V91, P429, DOI 10.1073/pnas.91.2.429; BOLTON DC, 1988, CIBA F SYMP, V135, P164; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; Brown P, 1998, BMJ-BRIT MED J, V317, P1688, DOI 10.1136/bmj.317.7174.1688; Brown P, 1997, JAMA-J AM MED ASSOC, V278, P1008, DOI 10.1001/jama.278.12.1008; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARP RI, 1994, ANN NY ACAD SCI, V724, P221, DOI 10.1111/j.1749-6632.1994.tb38912.x; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collee JG, 1997, LANCET, V349, P715, DOI 10.1016/S0140-6736(96)08496-6; Collee JG, 1997, LANCET, V349, P636, DOI 10.1016/S0140-6736(96)01310-4; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Collinge J, 1997, HUM MOL GENET, V6, P1699, DOI 10.1093/hmg/6.10.1699; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; CUTLIP RC, 1994, J INFECT DIS, V169, P814, DOI 10.1093/infdis/169.4.814; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; Dodelet V, 1996, CAN MED ASSOC J, V155, P549; DUFFY P, 1974, NEW ENGL J MED, V290, P692; ESMONDE TFG, 1993, LANCET, V341, P205, DOI 10.1016/0140-6736(93)90068-R; FRADKIN JE, 1991, JAMA-J AM MED ASSOC, V265, P880, DOI 10.1001/jama.265.7.880; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1993, AM J HUM GENET, V53, P828; Gabizon R, 1997, TRENDS GENET, V13, P264, DOI 10.1016/S0168-9525(97)01116-5; GAJDUSEK DC, 1959, AM J MED, V26, P442, DOI 10.1016/0002-9343(59)90251-7; GAJDUSEK DC, 1985, HUMAN VIRAL INFECTIO, P1519; GIBBS CJ, 1994, J NEUROL NEUROSUR PS, V57, P757, DOI 10.1136/jnnp.57.6.757; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; GUIROY DC, 1993, ACTA NEUROPATHOL, V85, P437, DOI 10.1007/BF00334456; HARRIS DA, 1993, P NATL ACAD SCI USA, V90, P4309, DOI 10.1073/pnas.90.9.4309; HELLMAN KB, 1997, NAT MAN HLTH CAR C 2; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Holman RC, 1996, EMERG INFECT DIS, V2, P333, DOI 10.3201/eid0204.960409; HONSTEAD JP, 1997, NAT MAN HLTH CAR C 2; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; HUESTON WD, 1997, NAT MAN HLTH CAR C 2; Ironside JW, 1996, BRAIN PATHOL, V6, P379, DOI 10.1111/j.1750-3639.1996.tb00869.x; KIMBERLIN RH, 1994, ANN NY ACAD SCI, V724, P210, DOI 10.1111/j.1749-6632.1994.tb38911.x; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Lasmezas CI, 1996, J GEN VIROL, V77, P1601, DOI 10.1099/0022-1317-77-7-1601; MacKnight C, 1996, CAN MED ASSOC J, V155, P529; MARSH RF, 1991, J GEN VIROL, V72, P589, DOI 10.1099/0022-1317-72-3-589; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MEYER N, 1991, J GEN VIROL, V72, P37, DOI 10.1099/0022-1317-72-1-37; *MIN AGR FISH FOOD, 1998, MAFF BSE INF PUBL HL; *MIN AGR FISH FOOD, 1998, MAFF BSE INF SPEC RI; *MIN AGR FISH FOOD, 1998, MAFF BSE INF SEAC M; *MIN AGR FISH FOOD, 1998, MAFF BSE INF INC BSE; *MIN AGR FISH FOOD, 1998, MAFF BSE INF BON BEE; *MIN AGR FISH FOOD, 1998, MAFF BSE INF FEED BA; MURRAY I, 1999, SUNDAY LONDON TIMES; Narang H, 1996, P SOC EXP BIOL MED, V211, P306, DOI 10.3181/00379727-211-43975; Narang H, 1996, P SOC EXP BIOL MED, V212, P208, DOI 10.3181/00379727-212-44009; *NAT CJD SURV UN, 1999, MONTHL CREUTZF FIG; Nathanson N, 1997, AM J EPIDEMIOL, V145, P959, DOI 10.1093/oxfordjournals.aje.a009064; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; *OFF INT EP, 1998, BOV SPONG ENC; *OFF INT EP, 1998, INF REP BOV SPONG EN; Piccardo P, 1998, AM J PATHOL, V152, P1415; PORTER R, 1999, USDA RESTRICTS IMPOR; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Ricketts MN, 1997, EMERG INFECT DIS, V3, P155, DOI 10.3201/eid0302.970208; RIESNER D, 1992, E H S NEURO, P341; ROBAKIS NK, 1986, BIOCHEM BIOPH RES CO, V140, P758, DOI 10.1016/0006-291X(86)90796-5; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; TATEISHI J, 1984, ANN NEUROL, V15, P278, DOI 10.1002/ana.410150313; U. S. Food and Drug Administration, 1997, FED REGISTER, V62, P30936; *US FDA, 1997, FED REGISTER, V62, P52345; *US FDA, 1997, FED REGISTER, V62, P49694; *US FDA, 1999, CHANG GUID ENT REV P; *USDA, 1991, FED REGISTER, V56, P63868; *USDA, 1999, USDA CONT EFF PREV B; *USDA, 1998, BOV SPONG ENC; VONRADOWITZ J, 1998, PA NEWS; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; *WHO, 1999, WHOEMCZOO973; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; WILESMITH JW, 1988, VET REC, V123, P638; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1993, BRIT MED BULL, V49, P960, DOI 10.1093/oxfordjournals.bmb.a072655; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2; Zhang SG, 1997, P NATL ACAD SCI USA, V94, P23, DOI 10.1073/pnas.94.1.23; 1997, MMWR MORB MORTAL WKL, V46, P1066; 1999, WASHINGTON DRUG 0201, P5	103	26	27	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2330	2339		10.1001/jama.281.24.2330	http://dx.doi.org/10.1001/jama.281.24.2330			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386559				2022-12-01	WOS:000080925600034
J	Agnarsson, U; Thorgeirsson, G; Sigvaldason, H; Sigfusson, N				Agnarsson, U; Thorgeirsson, G; Sigvaldason, H; Sigfusson, N			Effects of leisure-time physical activity and ventilatory function on risk for stroke in men: The Reykjavik study	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; MONICA	Background: Stroke is a major ca use of illness, death, and health expenditures. Leisure-time physical activity may reduce the risk for stroke. Objective: To examine the association of leisure-time physical activity and pulmonary function with risk for stroke. Design: Prospective cohort study. Setting: Reykjavik, Iceland. Participants: 4484 men 45 to 80 yea rs of age followed for a mean (+/- SD) of 10.6 +/- 3.6 years. Measurements: Patients underwent physical examination, blood sampling, and spirometry and completed a questionnaire about health and exercise. Computerized hospital records were used to identify strokes, and the Icelandic National Registry was used to identify deaths. Results: New stroke developed in 249 men (5.6%) (hemorrhagic stroke in 44 [18%] and ischemic stroke in 205 [82%]). In a multivariable hazard analysis that controlled for known risk factors for cerebrovascular disease, leisure-time physical activity maintained after 40 years of age was associated with a reduced risk for stroke (relative risk, 0.69 [Cl, 0.47 to 1.01] for total stroke and 0.62 [Cl, 0.40 to 0.97] for ischemic stroke). Risk for stroke increased with diminished ventilatory function (FVC or FEV1) (relative risk, 1.9 [Cl, 1.06 to 3.25] for the lowest compared with the highest quintile). Conclusion: Middle-aged men who participate in leisure-time physical activity and have good pulmonary function seem to have a lower risk for stroke than men who are not active or have diminished pulmonary function.	Natl Univ Hosp Iceland, IS-101 Reykjavik, Iceland; Iceland Heart Assoc, Reykjavik, Iceland	Landspitali National University Hospital; Icelandic Heart Association	Agnarsson, U (corresponding author), Heart Prevent Clin, Lagmuli 9, IS-108 Reykjavik, Iceland.							ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; Eliasson M, 1996, INT J EPIDEMIOL, V25, P1182, DOI 10.1093/ije/25.6.1182; Eriksson KF, 1996, DIABETOLOGIA, V39, P573, DOI 10.1007/BF00403304; GEBSKI V, 1992, SPIDA USERS MANUAL V; Gillum RF, 1997, STROKE, V28, P1527, DOI 10.1161/01.STR.28.8.1527; KIELY DK, 1994, AM J EPIDEMIOL, V140, P608, DOI 10.1093/oxfordjournals.aje.a117298; KRAMSCH DM, 1981, NEW ENGL J MED, V305, P1483, DOI 10.1056/NEJM198112173052501; Lee IM, 1998, STROKE, V29, P2049, DOI 10.1161/01.STR.29.10.2049; Sacco RL, 1998, STROKE, V29, P380, DOI 10.1161/01.STR.29.2.380; SHINTON R, 1991, J EPIDEMIOL COMMUN H, V45, P138, DOI 10.1136/jech.45.2.138; SIGURDSSON E, 1993, EUR HEART J, V14, P584, DOI 10.1093/eurheartj/14.5.584; SIGURDSSON E, 1995, INT J EPIDEMIOL, V24, P58, DOI 10.1093/ije/24.1.58; STRACHAN DP, 1991, BMJ-BRIT MED J, V302, P84, DOI 10.1136/bmj.302.6768.84; Thorvaldsen P, 1997, STROKE, V28, P500, DOI 10.1161/01.STR.28.3.500; *US DEP HHS, 1996, PHYS ACT HLTH REP SU, P102; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; Wei M, 1999, ANN INTERN MED, V130, P89, DOI 10.7326/0003-4819-130-2-199901190-00002; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025	20	54	54	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					987	990		10.7326/0003-4819-130-12-199906150-00006	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383369				2022-12-01	WOS:000080894700005
J	Diskin, CJ; Stokes, TJ; Dansby, LM; Carter, TB; Radcliff, L; Thomas, SG				Diskin, CJ; Stokes, TJ; Dansby, LM; Carter, TB; Radcliff, L; Thomas, SG			Towards an understanding of oedema	BRITISH MEDICAL JOURNAL			English	Article							ONCOTIC PRESSURE; EDEMA		Auburn Univ, Sch Pharm, Hypertens Nephrol Dialysis & Transplantat Clin, Auburn, AL 36849 USA	Auburn University System; Auburn University	Diskin, CJ (corresponding author), Auburn Univ, Sch Pharm, Hypertens Nephrol Dialysis & Transplantat Clin, Auburn, AL 36849 USA.			Diskin, Charles/0000-0002-1403-6261				BREASTED JH, 1930, E SMITH SURG PAPYRUS, P140; Bright R., 1827, REPORT MED CASES SEL; CANAANKUHL S, 1993, AM J PHYSIOL, V264, pF1052, DOI 10.1152/ajprenal.1993.264.6.F1052; Diskin CJ, 1998, NEPHRON, V78, P131, DOI 10.1159/000044900; Guardia JA, 1997, AM J KIDNEY DIS, V30, P822, DOI 10.1016/S0272-6386(97)90088-3; HAMMEL HT, 1995, AM J PHYSIOL-HEART C, V268, pH2133, DOI 10.1152/ajpheart.1995.268.5.H2133; JOLES JA, 1989, AM J PHYSIOL, V257, P23; MILROTO M, 1993, J COLLOID INTERF SCI, V159, P354; MIMRAN A, 1979, NEW ENGL J MED, V301, P1289; RICHET G, 1993, KIDNEY INT, V43, P1385, DOI 10.1038/ki.1993.195; SHARP KA, 1995, BIOPOLYMERS, V36, P227, DOI 10.1002/bip.360360210; Smorenburg C H, 1997, Ned Tijdschr Geneeskd, V141, P719; SPENCER WG, 1938, MEDICINA, P180; Starling EH., 1896, LANCET, V1, P1267	14	23	24	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1610	1613		10.1136/bmj.318.7198.1610	http://dx.doi.org/10.1136/bmj.318.7198.1610			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364127	Green Published			2022-12-01	WOS:000080913100036
J	Owen, DJ; Vallis, Y; Noble, MEM; Hunter, JB; Dafforn, TR; Evans, PR; McMahon, HT				Owen, DJ; Vallis, Y; Noble, MEM; Hunter, JB; Dafforn, TR; Evans, PR; McMahon, HT			A structural explanation for the binding of multiple ligands by the alpha-adaptin appendage domain	CELL			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLE ENDOCYTOSIS; COATED VESICLES; PROTEINS; EPS15; MEMBRANE; DYNAMIN; AP-2; AMPHIPHYSIN; COMPLEXES	The alpha subunit of the endocytotic AP2 adaptor complex contains a 30 kDa "appendage" domain, which is joined to the rest of the protein via a flexible linker. The 1.9 Angstrom resolution crystal structure of this domain reveals a single binding site for its ligands, which include amphiphysin, Eps15, and epsin. This domain when overexpressed in COS7 fibroblasts is shown to inhibit transferrin uptake, whereas mutants in which interactions with its binding partners are abolished do not. DPF/W motifs present in appendage domain-binding partners are shown to play a crucial role in their interactions with the domain. A single site for binding multiple ligands would allow for temporal and spatial regulation in the recruitment of components of the endocytic machinery.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Cambridge, CIMR, Dept Haematol, Cambridge CB2 2XY, England	MRC Laboratory Molecular Biology; University of Oxford; University of Cambridge	Evans, PR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	pre@mrc-lmb.cam.ac.uk; hmm@mrc-lmb.cam.ac.uk	; Dafforn, Tim/A-9072-2015	Noble, Martin/0000-0002-3595-9807; Dafforn, Tim/0000-0003-2257-6679				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CONNOLLY ML, 1985, J APPL CRYSTALLOGR, V18, P499, DOI 10.1107/S0021889885010779; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; De Tulleo L, 1998, EMBO J, V17, P4585, DOI 10.1093/emboj/17.16.4585; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Goodford P, 1996, J CHEMOMETR, V10, P107; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; Iannolo G, 1997, CANCER RES, V57, P240; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cellbio.11.1.677; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; LINDNER R, 1992, J BIOL CHEM, V267, P16567; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; ODRIDGE J, 1998, TRENDS CELL BIOL, V8, P302; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROTH TF, 1964, J CELL BIOL, V20, P313, DOI 10.1083/jcb.20.2.313; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	54	241	252	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					805	815		10.1016/S0092-8674(00)80791-6	http://dx.doi.org/10.1016/S0092-8674(00)80791-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380931	Bronze			2022-12-01	WOS:000080886300017
J	Arai, Y; Yasuda, R; Akashi, K; Harada, Y; Miyata, H; Kinosita, K; Itoh, H				Arai, Y; Yasuda, R; Akashi, K; Harada, Y; Miyata, H; Kinosita, K; Itoh, H			Tying a molecular knot with optical tweezers	NATURE			English	Article							SINGLE ACTIN-FILAMENTS; TORSIONAL RIGIDITY; F-ACTIN; DNA; FORCE; MOTOR; MECHANICS; MYOSIN; STEPS; BOND	Filamentous structures are abundant in cells. Relatively rigid filaments, such as microtubules and actin, serve as intracellular scaffolds that support movement and force, and their mechanical properties are crucial to their function in the cell. Some aspects of the behaviour of DNA, meanwhile, depend critically on ins flexibility-for example, DNA-binding proteins can induce sharp bends in the helix(1). The mechanical characterization of such filaments has generally been conducted without controlling the filament shape, by the observation of thermal motions(2-5) or of the response to external forces(6-9) or flows(10-12). Controlled buckling of a microtubule has been reported(13), but the analysis of the buckled shape was complicated. Here we report the continuous control of the radius of curvature of a molecular strand by tying a knot in it, using optical tweezers to manipulate the strand's ends. We find that actin filaments break at the knot when the knot diameter falls below 0.4 mu m. The pulling force at breakage is around 1 pN, two orders of magnitude smaller than the tensile stress of a straight filament. The flexural rigidity of the filament remained unchanged down to this diameter. We have also knotted a single DNA molecule, opening up the possibility of studying curvature-dependent interactions with associated proteins. We find that the knotted DNA is stronger than actin.	Keio Univ, Fac Sci & Technol, Dept Phys, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; CREST Genet Programming Team 13, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan; Hamamatsu Photon KK, Tsukuba Res Lab, Tsukuba, Ibaraki 3002635, Japan	Keio University; Japan Science & Technology Agency (JST); Hamamatsu Photonics	Harada, Y (corresponding author), Keio Univ, Fac Sci & Technol, Dept Phys, Kohoku Ku, Hiyoshi 3-14-1, Yokohama, Kanagawa 2238522, Japan.		Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; Cluzel P, 1996, SCIENCE, V271, P792, DOI 10.1126/science.271.5250.792; Dupuis DE, 1997, J MUSCLE RES CELL M, V18, P17, DOI 10.1023/A:1018672631256; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Harada Y, 1999, BIOPHYS J, V76, P709, DOI 10.1016/S0006-3495(99)77237-1; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KURACHI M, 1995, CELL MOTIL CYTOSKEL, V30, P221, DOI 10.1002/cm.970300306; Landau L D, 1970, THEORY ELASTICITY; Miyata H, 1996, BBA-GEN SUBJECTS, V1290, P83, DOI 10.1016/0304-4165(96)00003-7; MIYATA H, 1995, BIOPHYS J, V68, pS286; NISHIZAKA T, 1995, NATURE, V377, P251, DOI 10.1038/377251a0; OOSAWA F, 1973, COLD SPRING HARB SYM, V37, P277, DOI 10.1101/SQB.1973.037.01.038; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; Saitta AM, 1999, NATURE, V399, P46, DOI 10.1038/19935; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Smith DE, 1998, SCIENCE, V281, P1335, DOI 10.1126/science.281.5381.1335; Smith SB, 1996, SCIENCE, V271, P795, DOI 10.1126/science.271.5250.795; Suzuki N, 1996, BIOPHYS J, V70, P401, DOI 10.1016/S0006-3495(96)79583-8; Tsuda Y, 1996, P NATL ACAD SCI USA, V93, P12937, DOI 10.1073/pnas.93.23.12937; Yanagida M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P177; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yasuda R, 1996, J MOL BIOL, V263, P227, DOI 10.1006/jmbi.1996.0571	24	249	266	3	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					446	448		10.1038/20894	http://dx.doi.org/10.1038/20894			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365955				2022-12-01	WOS:000080667900042
J	Ibdah, JA; Bennett, MJ; Rinaldo, P; Zhao, YW; Gibson, B; Sims, HF; Strauss, AW				Ibdah, JA; Bennett, MJ; Rinaldo, P; Zhao, YW; Gibson, B; Sims, HF; Strauss, AW			A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHAIN 3-HYDROXYACYL-COA DEHYDROGENASE; TRIFUNCTIONAL PROTEIN-DEFICIENCY; ALPHA-SUBUNIT; MOLECULAR CHARACTERIZATION; G1528C MUTATION; BETA-OXIDATION; DIAGNOSIS; ENZYMES; NEUROPATHY; HEMOLYSIS	Background Acute fatty liver of pregnancy and the HELLP syndrome (hemolysis, elevated liver-enzyme levels, and a low platelet count) are serious hepatic disorders that may occur during pregnancy in women whose fetuses are later found to have a deficiency of long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase. This enzyme resides in the mitochondrial trifunctional protein, which also contains the active site of long-chain 2,3-enoyl-CoA hydratase and long-chain 3-ketoacyl-CoA thiolase. We undertook this study to determine the relation between mutations in the trifunctional protein in infants with defects in fatty-acid oxidation and acute liver disease during pregnancy in their mothers. Methods In 24 children with 3-hydroxyacyl-CoA dehydrogenase deficiency, we used DNA amplification and nucleotide-sequence analyses to identify mutations in the alpha subunit of the trifunctional protein. We then correlated the results with the presence of liver disease during pregnancy in the mothers. Results Nineteen children had a deficiency only of long-chain 3-hydroxyacyl-CoA dehydrogenase and presented with hypoketotic hypoglycemia and fatty liver. In eight children, we identified a homozygous mutation in which glutamic acid at residue 474 was changed to glutamine. Eleven other children were compound heterozygotes, with this mutation in one allele of the alpha-subunit gene and a different mutation in the other allele. While carrying fetuses with the Glu474Gln mutation, 79 percent of the heterozygous mothers had fatty liver of pregnancy or the HELLP syndrome. Five other children, who presented with neonatal dilated cardiomyopathy or progressive neuromyopathy, had complete deficiency of the trifunctional protein (loss of activity of all three enzymes). None had the Glu474Gln mutation, and none of their mothers had liver disease during pregnancy. Conclusions Women with acute liver disease during pregnancy may have a Glu474Gln mutation in long-chain hydroxyacyl-CoA dehydrogenase. Their infants are at risk for hypoketotic hypoglycemia and fatty liver. (N Engl J Med 1999;340:1723-31.) (C) 1999, Massachusetts Medical Society.	Wake Forest Univ, Dept Internal Med, Winston Salem, NC USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA; Mayo Clin, Dept Lab Med, Rochester, MN USA; Mayo Clin, Dept Pathol, Rochester, MN USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Wake Forest University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Mayo Clinic; Mayo Clinic; Washington University (WUSTL); Washington University (WUSTL)	Strauss, AW (corresponding author), St Louis Childrens Hosp, 1 Childrens Pl, St Louis, MO 63110 USA.			Ibdah, Jamal/0000-0002-5646-9014	NIADDK NIH HHS [AM-20407] Funding Source: Medline; NIDDK NIH HHS [5T32 DK-07130, DK-02574] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002574, T32DK007130] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; BENNETT MJ, 1990, ANN CLIN BIOCHEM, V27, P519, DOI 10.1177/000456329002700602; BRACKETT JC, 1995, J CLIN INVEST, V95, P2076, DOI 10.1172/JCI117894; GRIMBERT S, 1993, HEPATOLOGY, V17, P628, DOI 10.1002/hep.1840170417; IJLST L, 1994, BBA-LIPID LIPID MET, V1215, P347, DOI 10.1016/0005-2760(94)90064-7; Ijlst L, 1996, J CLIN INVEST, V98, P1028, DOI 10.1172/JCI118863; Isaacs JD, 1996, PEDIATR RES, V40, P393, DOI 10.1203/00006450-199609000-00005; JACKSON S, 1992, J CLIN INVEST, V90, P1219, DOI 10.1172/JCI115983; JACKSON S, 1991, PEDIATR RES, V29, P406, DOI 10.1203/00006450-199104000-00016; Knox TA, 1996, NEW ENGL J MED, V335, P569, DOI 10.1056/NEJM199608223350807; Mansouri A, 1996, J HEPATOL, V25, P781, DOI 10.1016/S0168-8278(96)80254-6; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PEREZCERDA C, 1993, PRENATAL DIAG, V13, P529, DOI 10.1002/pd.1970130616; REYES H, 1994, GUT, V35, P101, DOI 10.1136/gut.35.1.101; RIELY CA, 1987, ANN INTERN MED, V106, P703, DOI 10.7326/0003-4819-106-5-703; Rinaldo Piero, 1998, Current Opinion in Pediatrics, V10, P615; SCHOEMAN MN, 1991, GASTROENTEROLOGY, V100, P544, DOI 10.1016/0016-5085(91)90228-D; SIBAI BM, 1993, AM J OBSTET GYNECOL, V169, P1000, DOI 10.1016/0002-9378(93)90043-I; SIMS HF, 1995, P NATL ACAD SCI USA, V92, P841, DOI 10.1073/pnas.92.3.841; TEIN I, 1995, PEDIATR NEUROL, V12, P68, DOI 10.1016/0887-8994(94)00109-F; Treem WR, 1996, AM J GASTROENTEROL, V91, P2293; Tyni T, 1998, OPHTHALMOLOGY, V105, P810, DOI 10.1016/S0161-6420(98)95019-9; Tyni T, 1997, J PEDIATR-US, V130, P67, DOI 10.1016/S0022-3476(97)70312-3; Tyni T, 1998, AM J OBSTET GYNECOL, V178, P603, DOI 10.1016/S0002-9378(98)70446-6; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; Ushikubo S, 1996, AM J HUM GENET, V58, P979; USTA IM, 1994, AM J OBSTET GYNECOL, V171, P1342, DOI 10.1016/0002-9378(94)90158-9; VICI CD, 1991, J PEDIATR-US, V118, P744, DOI 10.1016/S0022-3476(05)80039-3; WANDERS RJA, 1989, LANCET, V2, P52, DOI 10.1016/S0140-6736(89)90300-0; WANDERS RJA, 1992, BIOCHEM BIOPH RES CO, V188, P1139, DOI 10.1016/0006-291X(92)91350-Y; WILCKEN B, 1993, LANCET, V341, P407, DOI 10.1016/0140-6736(93)92993-4	31	291	308	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1723	1731		10.1056/NEJM199906033402204	http://dx.doi.org/10.1056/NEJM199906033402204			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352164				2022-12-01	WOS:000080620200004
J	Kruuk, LEB; Clutton-Brock, TH; Albon, SD; Pemberton, JM; Guinness, FE				Kruuk, LEB; Clutton-Brock, TH; Albon, SD; Pemberton, JM; Guinness, FE			Population density affects sex ratio variation in red deer	NATURE			English	Article							PARENTAL INVESTMENT; BREEDING SUCCESS; DOMINANCE RANK; CERVUS-ELAPHUS; ROE DEER; DAUGHTERS; SONS; SELECTION; PATTERNS; MAMMALS	Many mammal populations show significant deviations from an equal sex ratio at birth, but these effects are notoriously inconsistent(1). This may be because more than one mechanism affects the sex ratio and the action of these mechanisms depends on environmental conditions. Here we show that the adaptive relationship between maternal dominance and offspring sex ratio previously demonstrated in red deer (Cervus elaphus)(2,3), where dominant females produced more males, disappeared at high population density. The proportion of males born each year declined with increasing population density and with winter rainfall, both of which are environmental variables associated with nutritional stress during pregnancy. These changes in the sex ratio corresponded to reductions in fecundity, suggesting that they were caused by differential fetal loss. In contrast, the earlier association with maternal dominance is presumed to have been generated pre-implantation. The effects of one source of variation superseded the other within about two generations. Comparison with other ungulate studies indicates that positive associations between maternal quality and the proportion of male offspring born have only been documented in populations below carrying capacity.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Inst Terr Ecol, Banchory AB31 4BY, Kincardine, Scotland	University of Cambridge; University of Edinburgh; UK Centre for Ecology & Hydrology (UKCEH)	Kruuk, LEB (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	Loeske.Kruuk@ed.ac.uk	ALBON, Stephen D/C-6304-2011; Kruuk, Loeske E. B./J-3295-2012; Kruuk, Loeske/AAB-8714-2019; Pemberton, Josephine M/F-3100-2010	ALBON, Stephen D/0000-0002-0811-1333; Kruuk, Loeske E. B./0000-0001-8588-1123; Kruuk, Loeske/0000-0001-8588-1123; 				ALBON SD, 1987, J ANIM ECOL, V56, P69, DOI 10.2307/4800; Birgersson B, 1998, BEHAV ECOL, V9, P404, DOI 10.1093/beheco/9.4.404; Cassinello J, 1996, BEHAV ECOL SOCIOBIOL, V38, P417, DOI 10.1007/s002650050259; CLUTTONBROCK TH, 1986, ANIM BEHAV, V34, P460, DOI 10.1016/S0003-3472(86)80115-4; CLUTTONBROCK TH, 1986, Q REV BIOL, V61, P339, DOI 10.1086/415033; CLUTTONBROCK TH, 1984, NATURE, V308, P358, DOI 10.1038/308358a0; CLUTTONBROCK TH, 1985, NATURE, V313, P131, DOI 10.1038/313131a0; FESTABIANCHET M, 1991, ANIM BEHAV, V42, P71, DOI 10.1016/S0003-3472(05)80607-4; Flint APF, 1997, HORM BEHAV, V31, P296, DOI 10.1006/hbeh.1997.1391; Flint APF, 1997, GEN COMP ENDOCR, V106, P374, DOI 10.1006/gcen.1997.6879; GOMENDIO M, 1990, NATURE, V343, P261, DOI 10.1038/343261a0; GREEN WCH, 1991, BEHAV ECOL SOCIOBIOL, V29, P373, DOI 10.1007/BF00165963; Hewison AJM, 1996, BEHAV ECOL, V7, P461, DOI 10.1093/beheco/7.4.461; HIRAIWAHASEGAWA M, 1993, TRENDS ECOL EVOL, V8, P395, DOI 10.1016/0169-5347(93)90040-V; KENT JP, 1995, BEHAV ECOL SOCIOBIOL, V36, P101, DOI 10.1007/BF00170714; KOJOLA I, 1989, EVOLUTION, V43, P1331, DOI 10.1111/j.1558-5646.1989.tb02582.x; LLOYD PH, 1989, BEHAV ECOL SOCIOBIOL, V25, P411, DOI 10.1007/BF00300187; Meikle DB, 1996, ETHOLOGY, V102, P969, DOI 10.1111/j.1439-0310.1996.tb01174.x; RUTBERG AT, 1986, AM NAT, V127, P89, DOI 10.1086/284469; SCHALL R, 1991, BIOMETRIKA, V78, P719; TRIVERS RL, 1973, SCIENCE, V179, P90, DOI 10.1126/science.179.4068.90; WAUTERS LA, 1995, BEHAV ECOL SOCIOBIOL, V37, P189, DOI 10.1007/s002650050180; [No title captured]; [No title captured]; [No title captured]	25	282	288	2	113	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 3	1999	399	6735					459	461		10.1038/20917	http://dx.doi.org/10.1038/20917			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365956				2022-12-01	WOS:000080667900046
J	Martin, SG; Laroche, T; Suka, N; Grunstein, M; Gasser, SM				Martin, SG; Laroche, T; Suka, N; Grunstein, M; Gasser, SM			Relocalization of telomeric Ku and SIR proteins in response to DNA strand breaks in yeast	CELL			English	Article							ASSEMBLY FACTOR-I; MATING-TYPE LOCI; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; SILENCING FACTORS; REPAIR; CHROMATIN; DAMAGE; REPRESSION; GENES	Telomeric TG-rich repeats and their associated proteins protect the termini of eukaryotic chromosomes from end-to-end fusions. Associated with the cap structure at yeast telomeres is a subtelomeric domain of heterochromatin, containing the silent information regulator (SIR) complex. The Ku70/80 heterodimer (yKu) is associated both with the chromosome end and with subtelomeric chromatin. Surprisingly, both yKu and the chromatin-associated Rap1 and SIR proteins are released from telomeres in a RADS-dependent response to DNA damage. yKu is recruited rapidly to double-strand cuts, while low levels of SIR proteins are detected near cleavage sites at later time points. Consistently, yKu- or SIR-deficient strains are hypersensitive to DNA-damaging agents. The release of yKu from telomeric chromatin may allow efficient scanning of the genome for DNA strand breaks.	Swiss Inst Expt Canc Res, CH-1066 Epalinges, Switzerland; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	Swiss Institute Experimental Cancer Research; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Gasser, SM (corresponding author), Swiss Inst Expt Canc Res, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.	sgasser@eliot.unil.ch	Martin, Sophie/AAE-3198-2019	Martin, Sophie/0000-0002-5317-2557; Gasser, Susan/0000-0003-3610-9123				Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; Boscheron C, 1996, EMBO J, V15, P2184, DOI 10.1002/j.1460-2075.1996.tb00572.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Cockell M, 1998, COLD SPRING HARB SYM, V63, P401, DOI 10.1101/sqb.1998.63.401; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hayashi A, 1998, GENES CELLS, V3, P587, DOI 10.1046/j.1365-2443.1998.00215.x; Jackson SP, 1997, NATURE, V388, P829, DOI 10.1038/42136; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Martini E, 1998, J CELL BIOL, V143, P563, DOI 10.1083/jcb.143.3.563; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; ROSE MD, 1990, METHODS YEAST GENETI; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SCHWARTZ JL, 1989, MUTAT RES, V216, P111, DOI 10.1016/0165-1161(89)90011-3; Shore D, 1998, SCIENCE, V281, P1818, DOI 10.1126/science.281.5384.1818; Siede W, 1996, GENETICS, V142, P91; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8	45	393	402	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	1999	97	5					621	633		10.1016/S0092-8674(00)80773-4	http://dx.doi.org/10.1016/S0092-8674(00)80773-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367891	Bronze			2022-12-01	WOS:000080672100011
J	Nelson, KE; Clayton, RA; Gill, SR; Gwinn, ML; Dodson, RJ; Haft, DH; Hickey, EK; Peterson, LD; Nelson, WC; Ketchum, KA; McDonald, L; Utterback, TR; Malek, JA; Linher, KD; Garrett, MM; Stewart, AM; Cotton, MD; Pratt, MS; Phillips, CA; Richardson, D; Heidelberg, J; Sutton, GG; Fleischmann, RD; Eisen, JA; White, O; Salzberg, SL; Smith, HO; Venter, JC; Fraser, CM				Nelson, KE; Clayton, RA; Gill, SR; Gwinn, ML; Dodson, RJ; Haft, DH; Hickey, EK; Peterson, LD; Nelson, WC; Ketchum, KA; McDonald, L; Utterback, TR; Malek, JA; Linher, KD; Garrett, MM; Stewart, AM; Cotton, MD; Pratt, MS; Phillips, CA; Richardson, D; Heidelberg, J; Sutton, GG; Fleischmann, RD; Eisen, JA; White, O; Salzberg, SL; Smith, HO; Venter, JC; Fraser, CM			Evidence for lateral gene transfer between Archaea and Bacteria from genome sequence of Thermotoga maritima	NATURE			English	Article							ESCHERICHIA-COLI; PROTEIN; EUBACTERIA; SPIROCHETE; TREES	The 1,860,725-base-pair genome of Thermotoga maritima MSB8 contains 1,877 predicted coding regions, 1,014 (54%) of which have functional assignments and 863 (46%) of which are of unknown function. Genome analysis reveals numerous pathways involved in degradation of sugars and plant polysaccharides, and 108 genes that have orthologues only in the genomes of other thermophilic Eubacteria and Archaea. Of the Eubacteria sequenced to date, T. maritima has the highest percentage (24%) of genes that are most similar to archaeal genes. Eighty-one archaeal-like genes are clustered in 15 regions of the T. maritima genome that range in sire from 4 to 20 kilobases. Conservation of gene order between T. maritima and Archaea in many of the clustered regions suggests that lateral gene transfer may have occurred between thermophilic Eubacteria and Archaea.	Inst Genome Res, Rockville, MD 20850 USA	J. Craig Venter Institute	Fraser, CM (corresponding author), Inst Genome Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	btm@tigi.org	Nelson, William C/E-9263-2016; Salzberg, Steven/Q-6514-2019; Eisen, Jonathan A./H-2706-2019; Salzberg, Steven L/F-6162-2011	Nelson, William C/0000-0002-1873-3929; Salzberg, Steven/0000-0002-8859-7432; Eisen, Jonathan A./0000-0002-0159-2197; Salzberg, Steven L/0000-0002-8859-7432; Heidelberg, John/0000-0003-0673-3224; Fraser, Claire/0000-0003-1462-2428				ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; BRONNENMEIER K, 1995, APPL ENVIRON MICROB, V61, P1399, DOI 10.1128/AEM.61.4.1399-1407.1995; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; Dubnau D, 1997, GENE, V192, P191, DOI 10.1016/S0378-1119(96)00804-9; Eisen JA, 1995, J MOL EVOL, V41, P1105; FELIX CR, 1993, ANNU REV MICROBIOL, V47, P791, DOI 10.1146/annurev.micro.47.1.791; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GLUCH MF, 1995, J BACTERIOL, V177, P5473, DOI 10.1128/jb.177.19.5473-5479.1995; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gruber TM, 1997, J BACTERIOL, V179, P1734, DOI 10.1128/jb.179.5.1734-1747.1997; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; Huang YP, 1998, NUCLEIC ACIDS RES, V26, P5300, DOI 10.1093/nar/26.23.5300; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Huber R, 1992, PROKARYOTES, P3809; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; JANSSEN PH, 1992, FEMS MICROBIOL LETT, V96, P213; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lawrence JG, 1997, J MOL EVOL, V44, P383, DOI 10.1007/PL00006158; Lee PJ, 1996, J BACTERIOL, V178, P5579, DOI 10.1128/jb.178.19.5579-5585.1996; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SAIER MH, 1994, MICROBIOL REV, V58, P71, DOI 10.1128/MMBR.58.1.71-93.1994; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; Salzberg SL, 1998, GENE, V217, P57, DOI 10.1016/S0378-1119(98)00374-6; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Sutton G.G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Vargas M, 1998, NATURE, V395, P65, DOI 10.1038/25720; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8	45	1157	1793	6	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					323	329		10.1038/20601	http://dx.doi.org/10.1038/20601			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360571				2022-12-01	WOS:000080547800050
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Dracula's wish	SCIENCE			English	Article									Mednav Com, Byfield, MA 01922 USA		Peters, R (corresponding author), Mednav Com, Byfield, MA 01922 USA.							McLean J, 1916, AM J PHYSIOL, V41, P250, DOI 10.1152/ajplegacy.1916.41.2.250; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Westerduin P, 1994, Bioorg Med Chem, V2, P1267, DOI 10.1016/S0968-0896(00)82078-7	3	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1294	1294		10.1126/science.284.5418.1294	http://dx.doi.org/10.1126/science.284.5418.1294			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383310				2022-12-01	WOS:000080430600035
J	Chook, YM; Blobel, G				Chook, YM; Blobel, G			Structure of the nuclear transport complex karyopherin-beta 2-Ran center dot GppNHp	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; TRANSCRIPTION FACTOR PHO4; KARYOPHERIN-BETA; RAN-GTP; PORE COMPLEX; IMPORT; ASSOCIATION; RAN/TC4; ALPHA; REPEATS	Transport factors in the karyopherin-beta (also called importin-beta) family mediate the movement of macromolecules in nuclear-cytoplasmic transport pathways. Karyopherin-beta 2 (transportin) binds a cognate import substrate and targets It to the nuclear pore complex. In the nucleus, Ran GTP binds karyopherin-beta 2 and dissociates the substrate. Here we present the 3.0 Angstrom structure of the karyopherin-beta 2-Ran GppNHp complex where GppNHp is a non-hydrolysable GTP analogue. Karyopherin-beta 2 contains eighteen HEAT repeats arranged into two continuous orthogonal arches. Ran is clamped in the amino-terminal arch and substrate-binding activity Is mapped to the carboxy-terminal arch. A large loop In HEAT repeat 7 spans both arches. Interactions of the loop with Ran and the C-terminal arch implicate it in GTPase-mediated dissociation of the import-substrate. Ran GppNHp In the complex shows extensive structural rearrangement, compared to Ran GDP, in regions contacting karyopherin-beta 2. This provides a structural basis for the specificity of the karyopherin-beta family for the GTP-bound state of Ran, as well as a rationale for interactions of the karyopherin-Ran complex with the regulatory proteins ranGAP, ranGEF and ranBP1.	Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Chook, YM (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Cell Biol Lab, New York, NY 10021 USA.		Chook, Yuh Min/AAA-9549-2019					Albertini M, 1998, J CELL BIOL, V143, P1447, DOI 10.1083/jcb.143.6.1447; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BISCHOFF FR, 1995, METHOD ENZYMOL, V257, P135; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Enenkel C, 1996, P NATL ACAD SCI USA, V93, P12986, DOI 10.1073/pnas.93.23.12986; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; Fridell RA, 1997, J CELL SCI, V110, P1325; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HIDEA M, 1959, J CELL BIOL, V144, P645; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuhlmann J, 1997, BIOCHEMISTRY-US, V36, P12027, DOI 10.1021/bi970524k; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lounsbury KM, 1997, J BIOL CHEM, V272, P551; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Stewart M, 1998, J MOL BIOL, V284, P1517, DOI 10.1006/jmbi.1998.2204; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; Westbrook EM, 1997, METHOD ENZYMOL, V276, P244, DOI 10.1016/S0076-6879(97)76063-4; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	50	288	294	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					230	237		10.1038/20375	http://dx.doi.org/10.1038/20375			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353245				2022-12-01	WOS:000080427400047
J	Maxwell, PH; Wiesener, MS; Chang, GW; Clifford, SC; Vaux, EC; Cockman, ME; Wykoff, CC; Pugh, CW; Maher, ER; Ratcliffe, PJ				Maxwell, PH; Wiesener, MS; Chang, GW; Clifford, SC; Vaux, EC; Cockman, ME; Wykoff, CC; Pugh, CW; Maher, ER; Ratcliffe, PJ			The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis	NATURE			English	Article							ERYTHROPOIETIN GENE; FACTOR 1-ALPHA; ALPHA-SUBUNIT; HEME PROTEIN; EXPRESSION; STABILIZATION; TRANSCRIPTION; ANGIOGENESIS; HIF-1-ALPHA; PRODUCT	Hypoxia-inducible factor-1 (HIF-1) has a key role in cellular responses to hypoxia, including the regulation of genes involved in energy metabolism, angiogenesis and apoptosis(1-4). The alpha subunits of HIF are rapidly degraded by the proteasome under normal conditions, but are stabilized by hypoxia(5). Cobaltous ions or iron chelators mimic hypoxia, indicating that the stimuli may interact through effects on a ferroprotein oxygen sensor(6,7). Here we demonstrate a critical role for the von Hippel-Lindau (VHL) tumour suppressor gene product pVHL in HIF-1 regulation. In VHL-defective cells, HIF alpha-subunits are constitutively stabilized and HIF-1 is activated. Re-expression of pVHL restored oxygen-dependent instability. pVHL and HIF alpha-subunits co-immunoprecipitate, and pVHL is present in the hypoxic HIF-1 DNA-binding complex. In cells exposed to iron chelation or cobaltous ions, HIF-1 is dissociated from pVHL. These findings indicate that the interaction between HIF-1 and pVHL is iron dependent, and that it is necessary for the oxygen-dependent degradation of HIF alpha-subunits. Thus, constitutive HIF-1 activation may underlie the angiogenic phenotype of VHL-associated tumours. The pVHL/HIF-1 interaction provides a new focus for understanding cellular oxygen sensing.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	University of Oxford; Wellcome Centre for Human Genetics; University of Birmingham; University of Oxford	Ratcliffe, PJ (corresponding author), Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.	peter.ratcliffe@imm.ox.ac.uk	Cockman, Matthew/V-9619-2019; MAHER, EAMONN R/A-9507-2008; Maxwell, Patrick H/C-5557-2008	Cockman, Matthew/0000-0002-3310-4821; MAHER, EAMONN R/0000-0002-6226-6918; Maxwell, Patrick H/0000-0002-0338-2679; Ratcliffe, Peter/0000-0002-2853-806X; Clifford, Steve/0000-0003-4893-2184; Pugh, Chris/0000-0002-5170-1662	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warburg O, 1930, METABOLISM TUMOURS; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	30	3854	4009	13	333	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					271	275		10.1038/20459	http://dx.doi.org/10.1038/20459			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353251				2022-12-01	WOS:000080427400059
J	Renard, JP; Chastant, S; Chesne, P; Richard, C; Marchal, J; Cordonnier, N; Chavatte, P; Vignon, X				Renard, JP; Chastant, S; Chesne, P; Richard, C; Marchal, J; Cordonnier, N; Chavatte, P; Vignon, X			Lymphoid hypoplasia and somatic cloning	LANCET			English	Article							NUCLEAR TRANSPLANTATION; CELL LINE; EMBRYOS; CALVES; ADULT; FETAL	Background Adult somatic cloning by nuclear transfer is associated with high rate of perinatal mortality but there is still no evidence that nuclear transfer itself is responsible for these failures. We report on a longlasting defect linked to somatic cloning. Methods Skin cells grown from an ear biopsy specimen from a 15-day-old calf were used as a source of nuclei. The donor animal was a clone of three females obtained from embryonic cells. Clinical examination, haematological, and biochemical profiles, and echocardiography of the somatic clone were done from birth to death. Findings After 6 weeks of normal development, the somatic cloned calf had a sudden and rapid fall in lymphocyte count and a decrease in haemoglobin. The calf died on day 51 from severe anaemia. Necropsy revealed no abnormality except thymic atrophy and lymphoid hypoplasia. Interpretation Somatic cloning may be the cause of longlasting deleterious effects. Our observation should be taken into account in debates on reproductive cloning in human beings.	INRA, Unite Biol Dev, F-78352 Jouy En Josas, France; INRA, Unite Biol Cellulaire, F-78352 Jouy En Josas, France; INRA, F-91630 Leudeville, France; ENVA, F-94704 Maisons Alfort, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; Ecole Nationale Veterinaire d'Alfort (ENVA)	Renard, JP (corresponding author), INRA, Unite Biol Dev, F-78352 Jouy En Josas, France.		richard, christophe/E-9529-2015; CHASTANT, Sylvie/ABG-2003-2020; Chavatte-Palmer, Pascale/K-7349-2012	CHASTANT, Sylvie/0000-0003-0790-6377; Chavatte-Palmer, Pascale/0000-0002-4581-6092				Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CHESNE P, 1993, CR ACAD SCI III-VIE, V316, P487; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; GARY FB, 1996, THERIOGENOLOGY, V45, P141; Heyman Y, 1996, ANIM REPROD SCI, V42, P427, DOI 10.1016/0378-4320(96)01528-X; HILL JR, 1998, P ANN M SOC THER DEC; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kruip TAM, 1997, THERIOGENOLOGY, V47, P43, DOI 10.1016/S0093-691X(96)00338-X; PRATHER RS, 1987, BIOL REPROD, V37, P859, DOI 10.1095/biolreprod37.4.859; REIK W, 1993, DEVELOPMENT, V119, P933; ROMER I, 1997, CURR BIOL, V7, P277; SIMS M, 1993, P NATL ACAD SCI USA, V90, P6143; Vignon X, 1998, CR ACAD SCI III-VIE, V321, P735, DOI 10.1016/S0764-4469(98)80014-0; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155	18	177	187	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1489	1491		10.1016/S0140-6736(98)12173-6	http://dx.doi.org/10.1016/S0140-6736(98)12173-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232316				2022-12-01	WOS:000080278200013
J	Cosma, MP; Tanaka, TU; Nasmyth, K				Cosma, MP; Tanaka, TU; Nasmyth, K			Ordered recruitment of transcription and chromatin remodeling factors to a cell cycle- and developmentally regulated promoter	CELL			English	Article							YEAST MATING-TYPE; LINKING HISTONE ACETYLATION; ASH1 MESSENGER-RNA; HO GENE; SACCHAROMYCES-CEREVISIAE; SWI/SNF COMPLEX; NUCLEOSOMAL DNA; BINDING PROTEIN; BUDDING YEAST; GCN5 PROTEIN	Gene activation in eukaryotes requires chromatin remodeling complexes like Swi/Snf and histone acetylases like SAGA. How these factors are recruited to promoters is not yet understood. Using CHIP, we measured recruitment of Swi/Snf, SAGA, the repressor Ash1p, and transcription factors Swi5p and SBF to the HO endonuclease promoter as cells progress through the yeast cell cycle. Swi5p's entry into nuclei at the end of anaphase recruits Swi/Snf, which then recruits SAGA. These two factors then facilitate SBF's binding. Ash1p, which only accumulates in daughter cell nuclei, binds to HO soon after Swi5p and aborts recruitment of Swi/Snf, SAGA, and SBF. Swi5p remains at HO for only 5 min. Swi/Snf's and SAGA's subsequent persistence at HO is self sustaining and constitutes an "epigenetic memory" of HO's transient interaction with Swi5p.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Naples Federico II	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at	Tanaka, Tomoyuki U/A-4775-2008; Cosma, Maria Pia/E-8731-2015	Cosma, Maria Pia/0000-0003-4207-5097; Tanaka, Tomoyuki/0000-0002-9886-5947; Nasmyth, Kim/0000-0001-7030-4403				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GONZALEZ I, 1999, IN PRESS CURR BIOL; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GRANT PA, 1998, NATURE, V383, P92; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUNCHOW S, 1989, IN PRESS J CELL SCI, V112; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; OSHIMA Y, 1971, GENETICS, V67, P327; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Perez-Martin J, 1998, MOL CELL BIOL, V18, P1049, DOI 10.1128/MCB.18.2.1049; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Sterner DE, 1999, MOL CELL BIOL, V19, P86; STILLMAN DJ, 1994, GENETICS, V136, P781; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S	67	586	595	3	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					299	311		10.1016/S0092-8674(00)80740-0	http://dx.doi.org/10.1016/S0092-8674(00)80740-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319811	Bronze			2022-12-01	WOS:000080100500004
J	Kim, YH; Park, JH; Hong, SH; Koh, JY				Kim, YH; Park, JH; Hong, SH; Koh, JY			Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator	SCIENCE			English	Article							CORTICAL NEURONAL INJURY; ZINC NEUROTOXICITY; MOUSE HIPPOCAMPUS; CELL-CULTURE; DEATH; INHIBITOR-1; APOPTOSIS; SEIZURE; STROKE; BRAIN	Human recombinant tissue plasminogen activator (tPA) may benefit ischemic stroke patients by dissolving clots. However, independent of thrombolysis, tPA may also have deleterious effects on neurons by promoting excitotoxicity. Zinc neurotoxicity has been shown to be an additional key mechanism in brain injuries. Hence, if tPA affects zinc neurotoxicity, this may provide additional insights into its effect on neuronal death. independent of its proteolytic action. tPA markedly attenuated zinc-induced cell death in cortical culture, and, when injected into cerebrospinal fluid, also reduced kainate seizure-induced hippocampal neuronal death in adult rats.	Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study Cent Nervous Sys, Seoul 138736, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Seoul, South Korea	University of Ulsan; Seoul National University (SNU)	Koh, JY (corresponding author), Univ Ulsan, Coll Med, Natl Creat Res Initiat Ctr Study Cent Nervous Sys, 388-1 Poongnap Dong Songpa Gu, Seoul 138736, South Korea.	jkko@www.amc.seoul.kr	Koh, Jae-Young/C-9014-2011; Kim, Yang-Hee/N-7614-2013	Koh, Jae-Young/0000-0002-4318-495X; Kim, Yang-Hee/0000-0002-0595-8547				Alberts MJ, 1997, AM J CARDIOL, V80, pD29, DOI 10.1016/S0002-9149(97)00582-1; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHOI DW, 1988, NEUROSCIENCE, V24, P67, DOI 10.1016/0306-4522(88)90312-0; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CHOW HS, 1994, BRAIN RES, V639, P102, DOI 10.1016/0006-8993(94)91769-8; FREDERICKSON CJ, 1987, J NEUROSCI METH, V20, P91, DOI 10.1016/0165-0270(87)90042-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Kim YH, 1999, NEUROSCIENCE, V89, P175, DOI 10.1016/S0306-4522(98)00313-3; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; KOH YH, 1984, NEUROSCIENCE, V60, P1049; LAWRENCE D, 1989, EUR J BIOCHEM, V186, P523, DOI 10.1111/j.1432-1033.1989.tb15238.x; Lekieffre D, 1997, BRAIN RES, V776, P88, DOI 10.1016/S0006-8993(97)00992-X; LIJNEN HR, 1995, THROMB HAEMOSTASIS, V74, P387; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Rogove AD, 1998, CURR BIOL, V8, P19, DOI 10.1016/S0960-9822(98)70016-8; Sensi SL, 1997, J NEUROSCI, V17, P9554; Suh S. W., 1996, Society for Neuroscience Abstracts, V22, P2101; Tsirka SE, 1997, J MOL MED, V75, P341, DOI 10.1007/s001090050119; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; Welling TH, 1996, J SURG RES, V66, P36, DOI 10.1006/jsre.1996.0369; WHITELAW A, 1995, ACTA PAEDIATR, V84, P933, DOI 10.1111/j.1651-2227.1995.tb13795.x; Zhang XA, 1997, EUR J NEUROSCI, V9, P760, DOI 10.1111/j.1460-9568.1997.tb01424.x; Zivin JA, 1997, DRUGS, V54, P83, DOI 10.2165/00003495-199700543-00012	34	130	137	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 23	1999	284	5414					647	650		10.1126/science.284.5414.647	http://dx.doi.org/10.1126/science.284.5414.647			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213688				2022-12-01	WOS:000079951100046
J	Salo, JA; Soisalon-Soininen, S; Bondestam, S; Mattila, PS				Salo, JA; Soisalon-Soininen, S; Bondestam, S; Mattila, PS			Familial occurrence of abdominal aortic aneurysm	ANNALS OF INTERNAL MEDICINE			English	Article						aortic aneurysm, abdominal; genetic predisposition to disease; age factors; sex factors; ultrasonography	PERIPHERAL VASCULAR-DISEASE; HIGH PREVALENCE; POPULATION; VARIABILITY; ULTRASOUND; RELATIVES; DIAMETER; AGE	Background: A family history of abdominal aortic aneurysm has been reported to increase the risk for developing the disease. Objective: To determine the risk for abdominal aortic aneurysm in first-degree relatives of patients with the disease. Design: Cross-sectional ultrasonographic screening study. Setting: University Central Hospital, Helsinki, Finland. Patients: 238 of 325 living first-degree relatives of patients having surgery for abdominal aortic aneurysm (age > 50 years; 98 men and 110 women) and 281 controls (135 men and 149 women) without a family history of abdominal aortic aneurysm. Measurements: Ultrasonography was used to measure aortic diameter in 101 male relatives and 140 female relatives (241 of the 325 persons at risk [74%]) and in 281 controls. Results: Three siblings had already undergone surgery for abdominal aortic aneurysm. Eleven siblings (all brothers) (11 of 101 [10.9%]) had ultrasonographic evidence of abdominal aortic aneurysm (aortic diameter > 30 mm). In the control group, 2 men (1.5%) and 2 women (1.3%) had an aneurysm. Thirty siblings and no controls had dilatation of the abdominal aorta (aortic diameter, 20 to 29 mm). Neither the age nor the sex of the proband affected risk for developing abdominal aortic aneurysm among first-degree relatives. Family history increased the risk for an aneurysm by 4.33-fold (95% CI, 1.32-fold to 14.23-fold), male sex increased the risk by 12.21-fold (CI, 2.63-fold to 56.64-fold), and age (by decade) increased the risk by 1.93-fold (CI, 1.15-fold to 3.25-fold). Conclusion: Aging brothers of patients with known abdominal aortic aneurysm have the highest risk for developing the disease; the prevalence of the disease in siblings older than 60 years of age is 18%.	Univ Helsinki, Cent Hosp, Dept Thorac & Cardiovasc Surg, FIN-00290 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Diagnost Radiol, FIN-00290 Helsinki, Finland	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Salo, JA (corresponding author), Univ Helsinki, Cent Hosp, Dept Thorac & Cardiovasc Surg, Haartmaninkatu 4, FIN-00290 Helsinki, Finland.			Mattila, Petri/0000-0003-1911-1811				ADAMS DCR, 1993, EUR J VASCULAR SURG, V7, P709, DOI 10.1016/S0950-821X(05)80721-2; ADAMSON J, 1992, BRIT J SURG, V79, P897, DOI 10.1002/bjs.1800790914; ALLARDICE JT, 1988, BRIT J SURG, V75, P240, DOI 10.1002/bjs.1800750318; BAIRD PA, 1995, LANCET, V346, P601, DOI 10.1016/S0140-6736(95)91436-6; BENGTSSON H, 1989, BRIT J SURG, V76, P589, DOI 10.1002/bjs.1800760620; BENGTSSON H, 1993, J VASC SURG, V18, P74, DOI 10.1067/mva.1993.42107; CLIFTON MA, 1977, BRIT J SURG, V64, P765, DOI 10.1002/bjs.1800641102; COLE CW, 1989, CAN J SURG, V32, P117; COLE CW, 1989, CAN J SURG, V32, P65; COLE J, 1989, BMJ-BRIT MED J, V299, P493; COLLIN J, 1988, LANCET, V2, P613; COLLIN J, 1985, BRIT J SURG, V72, P851, DOI 10.1002/bjs.1800721102; Cronenwett J L, 1995, Semin Vasc Surg, V8, P124; DARLING RC, 1989, J VASC SURG, V10, P39, DOI 10.1067/mva.1989.vs0100039; FITZGERALD P, 1995, BRIT J SURG, V82, P483, DOI 10.1002/bjs.1800820418; GALLAND RB, 1991, BRIT J SURG, V78, P1259, DOI 10.1002/bjs.1800781036; GILLUM RF, 1995, J CLIN EPIDEMIOL, V48, P1289, DOI 10.1016/0895-4356(95)00045-3; Jaakkola P, 1996, EUR J SURG, V162, P611; Jaakkola P, 1996, EUR J VASC ENDOVASC, V12, P230, DOI 10.1016/S1078-5884(96)80112-2; JOHANSEN K, 1986, JAMA-J AM MED ASSOC, V256, P1934, DOI 10.1001/jama.256.14.1934; JOHANSSON G, 1986, BRIT J SURG, V73, P101, DOI 10.1002/bjs.1800730205; JOHNSTON KW, 1994, J VASC SURG, V20, P163, DOI 10.1016/0741-5214(94)90002-7; KARANJIA PN, 1994, STROKE, V25, P627, DOI 10.1161/01.STR.25.3.627; KATZ DA, 1994, J VASC SURG, V19, P980, DOI 10.1016/S0741-5214(94)70209-8; Law M R, 1994, J Med Screen, V1, P110; LEDERLE FA, 1995, J VASC SURG, V21, P945, DOI 10.1016/S0741-5214(95)70222-9; LUCAROTTI ME, 1992, BRIT J SURG, V79, P641, DOI 10.1002/bjs.1800790714; MACSWEENEY STR, 1993, BRIT J SURG, V80, P582, DOI 10.1002/bjs.1800800510; MAJUMDER PP, 1991, AM J HUM GENET, V48, P164; NORRGARD O, 1984, SURGERY, V95, P650; PEARCE WH, 1993, SURGERY, V114, P691; SALO JA, 1989, WORLD J SURG, V13, P484, DOI 10.1007/BF01660764; TILSON MD, 1984, AM J SURG, V147, P551, DOI 10.1016/0002-9610(84)90020-5; TWOMEY A, 1984, BRIT J SURG, V71, P307; WEBSTER MW, 1991, J VASC SURG, V13, P9; WOLF YG, 1995, J VASC SURG, V22, P417, DOI 10.1016/S0741-5214(95)70009-9	36	69	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					637	+		10.7326/0003-4819-130-8-199904200-00003	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215559				2022-12-01	WOS:000079786600002
J	Freed, LA; Levy, D; Levine, RA; Larson, MG; Evans, JC; Fuller, DL; Lehman, B; Benjamin, EJ				Freed, LA; Levy, D; Levine, RA; Larson, MG; Evans, JC; Fuller, DL; Lehman, B; Benjamin, EJ			Prevalence and clinical outcome of mitral-valve prolapse	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENERAL-POPULATION; FOLLOW-UP; REGURGITATION; FEATURES; IDENTIFICATION; ASSOCIATION; DIAGNOSIS; WOMEN; RISK; MEN	Background Mitral-valve prolapse has been described as a common disease with frequent complications. To determine the prevalence of mitral-valve prolapse in the general population, as diagnosed with the use of current two-dimensional echocardiographic criteria, we examined the echocardiograms of 1845 women and 1646 men (mean [+/-SD] age, 54.7+/-10.0 years) who participated in the fifth examination of the offspring cohort of the Framingham Heart Study. Methods Classic mitral-valve prolapse was defined as superior displacement of the mitral leaf lets of more than 2 mm during systole and as a maximal leaflet thickness of at least 5 mm during diastasis, and nonclassic prolapse was defined as displacement of more than 2 mm, with a maximal thickness of less than 5 mm. Results A total of 84 subjects (2.4 percent) had mitral-valve prolapse: 47 (1.3 percent) had classic prolapse, and 37 (1.1 percent) had nonclassic prolapse. Their age and sex distributions were similar to those of the subjects without prolapse. None of the subjects with prolapse had a history of heart failure, one (1.2 percent) had atrial fibrillation, one (1.2 percent) had cerebrovascular disease, and three (3.6 percent) had syncope, as compared with unadjusted prevalences of these findings in the subjects without prolapse of 0.7, 1.7, 1.5, and 3.0 percent, respectively. The frequencies of chest pain, dyspnea, and electrocardiographic abnormalities were similar among subjects with prolapse and those without prolapse. The subjects with prolapse were leaner (P<0.001) and had a greater degree of mitral regurgitation than those without prolapse, but on average the regurgitation was classified as trace or mild. Conclusions In a community-based sample of the population, the prevalence of mitral-valve prolapse was lower than previously reported. The prevalence of adverse sequelae commonly associated with mitral-valve prolapse in studies of patients referred for that diagnosis was also low. (N Engl J Med 1999;341:1-7.) (C)1999, Massachusetts Medical Society.	NHLBI, Framingham Heart Study, Framingham, MA USA; Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Clin Epidemiol, Boston, MA USA; Boston Univ, Sch Med, Div Cardiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Epidemiol & Prevent Med, Boston, MA 02118 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boston University; Boston University	Benjamin, EJ (corresponding author), Boston Univ, Sch Med, Framingham Heart Study, 5 Thurber St, Framingham, MA 01702 USA.		Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Benjamin, Emelia/0000-0003-4076-2336; Larson, Martin/0000-0002-9631-1254	NHLBI NIH HHS [N01-HC-38038, 2-R01-HL-38176-06] Funding Source: Medline; NINDS NIH HHS [5-R01-NS-17950-16] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRYHN M, 1984, ACTA MED SCAND, V215, P157; CHANDRARATNA PAN, 1984, AM J CARDIOL, V54, P1283; COHEN JL, 1987, AM HEART J, V113, P341, DOI 10.1016/0002-8703(87)90275-4; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX R B, 1986, Journal of the American College of Cardiology, V8, P763; DEVEREUX RB, 1989, ANN INTERN MED, V111, P305, DOI 10.7326/0003-4819-111-4-305; DEVEREUX RB, 1994, AM J CARDIOL, V74, P1024, DOI 10.1016/0002-9149(94)90853-2; DEVEREUX RB, 1986, AM J MED, V81, P751, DOI 10.1016/0002-9343(86)90339-6; DEVEREUX RB, 1982, LANCET, V2, P792; DUREN DR, 1988, J AM COLL CARDIOL, V11, P42; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1988, NIH PUBLICATION; KANNEL WB, 1974, DHEW PUBLICATION; LEATHAM A, 1980, AM HEART J, V99, P659, DOI 10.1016/0002-8703(80)90740-1; LEVINE RA, 1989, CIRCULATION, V80, P589, DOI 10.1161/01.CIR.80.3.589; LEVINE RA, 1988, J AM COLL CARDIOL, V11, P1010, DOI 10.1016/S0735-1097(98)90059-6; LEVINE RA, 1987, CIRCULATION, V75, P756, DOI 10.1161/01.CIR.75.4.756; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1987, AM HEART J, V113, P1281, DOI 10.1016/0002-8703(87)90956-2; Louie EK, 1996, J AM COLL CARDIOL, V28, P465, DOI 10.1016/0735-1097(96)00160-X; MARKIEWICZ W, 1978, AM HEART J, V96, P555, DOI 10.1016/0002-8703(78)90172-2; MARKIEWICZ W, 1976, CIRCULATION, V53, P464, DOI 10.1161/01.CIR.53.3.464; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; Maron BJ, 1999, JAMA-J AM MED ASSOC, V281, P650, DOI 10.1001/jama.281.7.650; NIDORF SM, 1993, J AM SOC ECHOCARDIOG, V6, pS8; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P305; PERLOFF JK, 1989, CIRCULATION, V80, P710, DOI 10.1161/01.CIR.80.3.710; PROCACCI PM, 1976, NEW ENGL J MED, V294, P1086, DOI 10.1056/NEJM197605132942004; SAHN DJ, 1977, AM J CARDIOL, V39, P422, DOI 10.1016/S0002-9149(77)80100-8; SAVAGE DD, 1983, AM HEART J, V106, P571, DOI 10.1016/0002-8703(83)90704-4; SAVAGE DD, 1983, AM HEART J, V106, P577, DOI 10.1016/0002-8703(83)90705-6; Shah P M, 1994, J Am Soc Echocardiogr, V7, P286; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; VIVALDI MT, 1994, CIRCULATION, V90, P222; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WARTH DC, 1985, J AM COLL CARDIOL, V5, P1173, DOI 10.1016/S0735-1097(85)80021-8; WEISSMAN NJ, 1994, AM J CARDIOL, V73, P1080, DOI 10.1016/0002-9149(94)90287-9; WILCKEN DEL, 1988, CIRCULATION, V78, P10, DOI 10.1161/01.CIR.78.1.10; ZUPPIROLI A, 1995, AM J CARDIOL, V75, P1028, DOI 10.1016/S0002-9149(99)80718-8	40	664	685	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					1	7		10.1056/NEJM199907013410101	http://dx.doi.org/10.1056/NEJM199907013410101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387935				2022-12-01	WOS:000081195600001
J	Hart, CL; Smith, GD; Hole, DJ; Hawthorne, VM				Hart, CL; Smith, GD; Hole, DJ; Hawthorne, VM			Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: Results from a prospective cohort study of Scottish men with 21 years of follow up	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MIDDLE-AGED MEN; ALL-CAUSE MORTALITY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; SOCIOECONOMIC POSITION; BLOOD-PRESSURE; BRITISH MEN; BEER; POPULATION; WOMEN	Objectives To relate alcohol consumption to mortality. Design Prospective cohort study. Setting 27 workplaces in the west of Scotland. Participants 5766 men aged 35-64 when screened in 1970-3 who answered questions on their usual weekly alcohol consumption. Main outcome measures Mortality from all causes, coronary heart disease, stroke, and alcohol related causes over 21 years of follow up related to units of alcohol consumed per week. Results Risk for all cause mortality was similar for non-drinkers and men drinking up to 14 units a week. Mortality risk then showed a graded association with alcohol consumption (relative rate compared with non-drinkers 1.34 (95% confidence interval 1.14 to 1.58) for 15-21 units a week, 1.49 (1.27 to 1.75) for 22-34 units, 1.74 (1.47 to 2.06) for 35 or more units). Adjustment for risk factors attenuated the increased relative risks, but they remained significantly above 1 for men drinking 22 or more units a week. There was no strong relation between alcohol consumption and mortality from coronary heart disease after adjustment A strong positive relation was seen between alcohol consumption and risk of mortality from stroke,with men drinking 35 or more units having double the risk of non-drinkers, even after adjustment. Conclusions The overall association between alcohol consumption and mortality is unfavourable for men drinking over 22 units a week, and there is no clear evidence of any protective effect for men drinking less than this.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ Glasgow, W Scotland Canc Surveillance Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	University of Bristol; University of Glasgow; University of Glasgow; University of Michigan System; University of Michigan	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				[Anonymous], 1965, LANCET, V1, P775; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; Brenner H, 1997, INT J EPIDEMIOL, V26, P85, DOI 10.1093/ije/26.1.85; Carstairs V., 1991, DEPRIVATION HLTH SCO; CHOUDHURY SR, 1994, INT J EPIDEMIOL, V23, P940, DOI 10.1093/ije/23.5.940; COX DR, 1972, J R STAT SOC B, V34, P187; DAVEYSMITH G, 1992, JAMA-J AM MED ASSOC, V267, P70; DIGHT S, 1976, SCOTTISH DRINKING HA; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; General Register Office, 1966, CLASS OCC 1966; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Hart CL, 1997, INT J EPIDEMIOL, V26, P508, DOI 10.1093/ije/26.3.508; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; HOLE D, 1993, J EPIDEMIOL COMMUNIT, V47, P402; ISO H, 1995, STROKE, V26, P767, DOI 10.1161/01.STR.26.5.767; Kauhanen J, 1997, EPIDEMIOLOGY, V8, P310, DOI 10.1097/00001648-199705000-00014; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Keil U, 1997, EPIDEMIOLOGY, V8, P150, DOI 10.1097/00001648-199703000-00005; MARMOT MG, 1994, BRIT MED J, V308, P1263, DOI 10.1136/bmj.308.6939.1263; McKee M, 1998, J ROY SOC MED, V91, P402, DOI 10.1177/014107689809100802; *OFF NAT STAT, 1997, HLTH AD BRIT 1841 19; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; Prineas R.J, 1982, MINNESOTA MANUAL ELE; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; Renaud SC, 1998, EPIDEMIOLOGY, V9, P184, DOI 10.1097/00001648-199803000-00014; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Rose G.A., 1982, CARDIOVASCULAR SURVE; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; *SAS I, 1991, P217 SAS I; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, J HUM HYPERTENS, V2, P71; SHINTON R, 1993, J NEUROL NEUROSUR PS, V56, P458, DOI 10.1136/jnnp.56.5.458; SMIT JWA, 1995, AM J CARDIOL, V76, pA89; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P153; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Wannamethee SG, 1996, STROKE, V27, P1033, DOI 10.1161/01.STR.27.6.1033; WESTIN S, 1995, BRIT MED J, V311, P1167, DOI 10.1136/bmj.311.7013.1167a; White IR, 1996, BRIT MED J, V312, P1179; *WHO, 1977, CLASS DIS 9 REV; WOODWARD M, 1995, J EPIDEMIOL COMMUN H, V49, P354, DOI 10.1136/jech.49.4.354; Yuan JM, 1997, BRIT MED J, V314, P18, DOI 10.1136/bmj.314.7073.18	47	197	204	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1725	1729		10.1136/bmj.318.7200.1725	http://dx.doi.org/10.1136/bmj.318.7200.1725			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381706	Green Published, Bronze, Green Submitted, Green Accepted			2022-12-01	WOS:000081216900028
J	Masutani, C; Kusumoto, R; Yamada, A; Dohmae, N; Yokoi, M; Yuasa, M; Araki, M; Iwai, S; Takio, K; Hanaoka, F				Masutani, C; Kusumoto, R; Yamada, A; Dohmae, N; Yokoi, M; Yuasa, M; Araki, M; Iwai, S; Takio, K; Hanaoka, F			The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta	NATURE			English	Article							ESCHERICHIA-COLI DINB; SACCHAROMYCES-CEREVISIAE; THYMINE DIMER; EXCISION-REPAIR; HUMAN HOMOLOG; REPLICATION; MUTAGENESIS; BYPASS; CELLS; ZETA	Xeroderma pigmentosum variant (XP-V) is an inherited disorder which is associated with increased incidence of sunlight-induced skin cancers, Unlike other xeroderma pigmentosum cells (belonging to groups XP-A to XP-G), XP-V cells carry out normal nucleotide-excision repair processes but are defective in their replication of ultraviolet-damaged DNA(1,2). It has been suspected for some time that the XPV gene encodes a protein that is involved in trans-lesion DNA synthesis; but the gene product has never been isolated Using an improved cell-free assay for trans-lesion DNA synthesis, we have recently isolated a DNA polymerase from HeLa cells that continues replication on damaged DNA by bypassing ultraviolet-induced thymine dimers in XP-V cell extracts(3). Here we show that this polymerase is a human homologue of the yeast Rad30 protein, recently identified as DNA polymerase eta (ref. 4). This polymerase and yeast Rad30 are members of a family of damage-bypass replication proteins(5-10) which comprises the Escherichia coli proteins UmuC and DinB and the yeast Rev1 protein. We found that all XP-V cells examined carry mutations in their DNA polymerase eta gene. Recombinant human DNA polymerase eta corrects the inability of XP-V cell extracts to carry out DNA replication by bypassing thymine dimers on damaged DNA. Together these results indicate that DNA polymerase eta could be the XPV gene product.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Nara Inst Sci & Technol, Nara 63001, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Osaka 5650871, Japan; Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan	Osaka University; Nara Institute of Science & Technology; Osaka University; RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.		Masutani, Chikahide/I-6160-2014; Araki, Marito/T-4283-2019; Dohmae, Naoshi/C-2040-2011	Araki, Marito/0000-0002-3502-5000; Dohmae, Naoshi/0000-0002-5242-9410; Masutani, Chikahide/0000-0002-8600-8227; Yamada, Ayumi/0000-0002-6085-8928				Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Friedberg EC, 1995, DNA REPAIR MUTAGENES; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; JASPERS NGJ, 1981, EXP CELL RES, V136, P81, DOI 10.1016/0014-4827(81)90039-2; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MASUTANI C, IN PRESS EMBO J; McDonald JP, 1997, GENETICS, V147, P1557; McGregor WG, 1999, MOL CELL BIOL, V19, P147; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Roush AA, 1998, MOL GEN GENET, V257, P686; Smith BT, 1998, GENETICS, V148, P1599; Svoboda DL, 1998, CANCER RES, V58, P2445; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Xiao W, 1998, CARCINOGENESIS, V19, P945, DOI 10.1093/carcin/19.5.945	24	1103	1130	0	238	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					700	704		10.1038/21447	http://dx.doi.org/10.1038/21447			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385124				2022-12-01	WOS:000080932800064
J	Mak, V; Zielenski, J; Tsui, LC; Durie, P; Zini, A; Martin, S; Longley, TB; Jarvi, KA				Mak, V; Zielenski, J; Tsui, LC; Durie, P; Zini, A; Martin, S; Longley, TB; Jarvi, KA			Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONGENITAL BILATERAL ABSENCE; INTRACYTOPLASMIC SPERM INJECTION; TRANSMEMBRANE CONDUCTANCE REGULATOR; IN-VITRO FERTILIZATION; VAS-DEFERENS; CFTR GENE; EPIDIDYMAL SPERM; MALE-INFERTILITY; DISSEMINATED BRONCHIECTASIS; INVITRO FERTILIZATION	Context Infertile men with obstructive azoospermia may have mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, many of which are rare in classic cystic fibrosis and not evaluated in most routine mutation screening. Objective To assess how often CFTR mutations or sequence alterations undetected by routine screening are detected with more extensive screening in obstructive azoospermia, Design Routine screening for the 31 most common CFTR mutations associated with the CF phenotype in white populations, testing for the 5-thymidine variant of the polythymidine tract of intron 8 (IVS8-5T) by allele-specific oligonucleotide hybridization, and screening of all exons through multiplex heteroduplex shift analysis followed by direct DNA sequencing. Setting Male infertility clinic of a Canadian university-affiliate hospital. Subjects Of 198 men with obstructive (n = 149) or nonobstructive (n = 49; control group) azoospermia, 64 had congenital bilateral absence of the vas deferens (CBAVD), 10 had congenital unilateral absence of the vas deferens (CUAVD), and 75 had epididymal obstruction (56/75 were idiopathic), Main Outcome Measure Frequency of mutations found by routine and nonroutine tests in men with obstructive vs nonobstructive azoospermia, Results Frequency of mutations and the IVS8-5T variant in the nonobstructive azoospermia group (controls) (2% and 5.1% allele frequency, respectively) did not differ significantly from that in the general population (2% and 5,2%, respectively), In the CBAVD group, 72 mutations were found by DNA sequencing and IVS8-5T testing (47 and 25, respectively; P<.001 and P=.002 vs controls) vs 39 by the routine panel (P<.001 vs controls). In the idiopathic epididymal obstruction group, 24 mutations were found by DNA sequencing and IVS8-5T testing (12 each; P=.01 and P=.14 vs controls) vs 5 by the routine panel (P=.33 vs controls). In the CUAVD group, 2 mutations were found by routine testing (P=.07 vs controls) vs 4 (2 each, respectively; P=.07 and P=.40 vs controls) by DNA sequencing and IVS8-5T testing. The routine panel did not identify 33 (46%) of 72, 2 (50%) of 4, and 19 (79%) of 24 detectable CFTR mutations and IVS8-5T in the CBAVD, CUAVD, and idiopathic epididymal obstruction groups, respectively. Conclusions Routine testing for CFTR mutations may miss mild or rare gene alterations. The barrier to conception for men with obstructive infertility has been overcome by assisted reproductive technologies, thus raising the concern of iatrogenically transmitting pathogenic CFTR mutations to the progeny.	Mt Sinai Hosp, Dept Surg, Div Urol, Toronto, ON M5G 1X5, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Programme Integrat Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Surg, Div Urol, Toronto, ON, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto	Jarvi, KA (corresponding author), Mt Sinai Hosp, Dept Surg, Div Urol, 1525-600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Tsui, Lap-chee/A-1081-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049096] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49096-03] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AZNAREZ I, 1998, PEDIATR PULM, V17, P332; Bienvenu T, 1996, CONTRACEPT FERTIL S, V24, P495; Bienvenu T, 1997, ANN GENET-PARIS, V40, P5; Bienvenu T, 1996, HUM MUTAT, V7, P182, DOI 10.1002/(SICI)1098-1004(1996)7:2<182::AID-HUMU19>3.3.CO;2-Y; BLADOU F, 1991, HUM REPROD, V6, P1284, DOI 10.1093/oxfordjournals.humrep.a137527; BURGER J, 1991, LANCET, V337, P974, DOI 10.1016/0140-6736(91)91603-R; CASALS T, 1995, HUM GENET, V95, P205; *CENS OP DIV, 1996, STAT CAN 1996 CENS N; Cha KY, 1997, FERTIL STERIL, V67, P985, DOI 10.1016/S0015-0282(97)81428-8; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; Cohn JA, 1998, NEW ENGL J MED, V339, P653, DOI 10.1056/NEJM199809033391002; COSTES B, 1995, EUR J HUM GENET, V3, P285; CULARD JF, 1994, HUM GENET, V93, P467; CUMMINS JM, 1995, HUM REPROD, V10, P138, DOI 10.1093/humrep/10.suppl_1.138; CUPPENS H, 1994, HUM MOL GENET, V3, P607, DOI 10.1093/hmg/3.4.607; DEKRETSER DM, 1995, REPROD FERT DEVELOP, V7, P137; Donat R, 1997, BRIT J UROL, V79, P74, DOI 10.1046/j.1464-410X.1997.30816.x; DORK T, 1994, HUM GENET, V93, P67; Dork T, 1997, HUM GENET, V100, P365, DOI 10.1007/s004390050518; Dumur V, 1996, HUM GENET, V97, P7; DURIEU I, 1995, MEDICINE, V74, P42, DOI 10.1097/00005792-199501000-00004; Durieu I, 1997, REV MED INTERNE, V18, P114, DOI 10.1016/S0248-8663(97)84676-0; FRIEDMAN KJ, 1995, AM J RESP CRIT CARE, V152, P1353, DOI 10.1164/ajrccm.152.4.7551394; FUKUGAKI H, 1994, J ASSIST REPROD GEN, V11, P452, DOI 10.1007/BF02215707; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HARARI O, 1995, FERTIL STERIL, V64, P360, DOI 10.1016/S0015-0282(16)57736-X; HENDRY WF, 1993, BMJ-BRIT MED J, V307, P1579, DOI 10.1136/bmj.307.6919.1579; Jarvi K, 1998, FERTIL STERIL, V70, P724, DOI 10.1016/S0015-0282(98)00247-7; JARVI K, 1995, LANCET, V345, P1578, DOI 10.1016/S0140-6736(95)91131-6; JEZEQUEL P, 1995, CLIN CHEM, V41, P833; Johnson MD, 1998, FERTIL STERIL, V70, P397, DOI 10.1016/S0015-0282(98)00209-X; Kanavakis E, 1998, MOL HUM REPROD, V4, P333, DOI 10.1093/molehr/4.4.333; KAPLAN E, 1968, NEW ENGL J MED, V279, P65, DOI 10.1056/NEJM196807112790203; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; LANDING BH, 1969, ARCH PATHOL, V88, P569; Lawler AM, 1998, FERTIL STERIL, V70, P412; Lissens W, 1996, HUM REPROD, V11, P55, DOI 10.1093/humrep/11.suppl_4.55; Madgar I, 1996, HUM REPROD, V11, P2151; Mak V, 1997, HUM MOL GENET, V6, P2099, DOI 10.1093/hmg/6.12.2099; Mak V, 1996, J UROLOGY, V156, P1245, DOI 10.1016/S0022-5347(01)65561-7; Mansour RT, 1997, HUM REPROD, V12, P1974, DOI 10.1093/humrep/12.9.1974; MATHIEU C, 1992, FERTIL STERIL, V57, P871; MERCIER B, 1995, AM J HUM GENET, V56, P272; MESCHEDE D, 1994, LANCET, V343, P1566, DOI 10.1016/S0140-6736(94)92964-5; MICKLE J, 1995, HUM REPROD, V10, P1728, DOI 10.1093/oxfordjournals.humrep.a136164; Miller PW, 1996, AM J HUM GENET, V59, P45; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; OATES RD, 1994, J ANDROL, V15, P1; OATES RD, 1992, J ASSIST REPROD GEN, V9, P36, DOI 10.1007/BF01204112; OSBORNE LR, 1993, HUM MOL GENET, V2, P1605, DOI 10.1093/hmg/2.10.1605; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; PATRIZIO P, 1993, HUM REPROD, V8, P215, DOI 10.1093/oxfordjournals.humrep.a138025; Patrizio P, 1996, MOL MED TODAY, V2, P24, DOI 10.1016/1357-4310(96)88755-7; PATRIZIO P, 1988, LANCET, V2, P1364; Pignatti PF, 1996, AM J HUM GENET, V58, P889; PIGNATTI PF, 1995, HUM MOL GENET, V4, P635, DOI 10.1093/hmg/4.4.635; RAVEHAREL N, 1995, AM J HUM GENET, V56, P1359; SCHLEGEL PN, 1995, UROLOGY, V46, P238, DOI 10.1016/S0090-4295(99)80199-X; Schlegel PN, 1996, J UROLOGY, V155, P1644, DOI 10.1016/S0022-5347(01)66152-4; SCHOYSMAN R, 1982, INT J ANDROL S, V5, P120; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; Shin D, 1997, J UROLOGY, V158, P1794, DOI 10.1016/S0022-5347(01)64131-4; SILBER SJ, 1988, FERTIL STERIL, V50, P525; SILBER SJ, 1990, NEW ENGL J MED, V323, P1788, DOI 10.1056/NEJM199012273232602; Son IP, 1996, J ASSIST REPROD GEN, V13, P69, DOI 10.1007/BF02068873; TAUSSIG LM, 1972, NEW ENGL J MED, V287, P586, DOI 10.1056/NEJM197209212871204; TEMPLE-SMITH P D, 1985, Journal of In Vitro Fertilization and Embryo Transfer, V2, P119, DOI 10.1007/BF01131497; VALMAN HB, 1969, LANCET, V2, P566; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; YOUNG D, 1970, J REPROD FERTIL, V23, P541; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7; ZIELENSKI J, 1995, AM J HUM GENET, V57, P958; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	76	96	97	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2217	2224		10.1001/jama.281.23.2217	http://dx.doi.org/10.1001/jama.281.23.2217			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376575	Bronze			2022-12-01	WOS:000080777000036
J	Jasmer, RM; Hahn, JA; Small, PM; Daley, CL; Behr, MA; Moss, AR; Creasman, JM; Schecter, GF; Paz, EA; Hopewell, PC				Jasmer, RM; Hahn, JA; Small, PM; Daley, CL; Behr, MA; Moss, AR; Creasman, JM; Schecter, GF; Paz, EA; Hopewell, PC			A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997	ANNALS OF INTERNAL MEDICINE			English	Article							NEW-YORK-CITY; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; OUTBREAK; POPULATION; HOMELESS; PTBN12	Background: To decrease tuberculosis case rates and cases due to recent infection (clustered cases) in San Francisco, California, tuberculosis control measures were intensified beginning in 1991 by focusing on prevention of Mycobacterium tuberculosis transmission and on the use of preventive therapy. Objective: To describe trends in rates of tuberculosis cases and clustered cases in San Francisco from 1991 through 1997. Design: Population-based study. Setting: San Francisco, California. Patients: Persons with tuberculosis diagnosed between 1 January 1991 and 31 December 1997. Measurements: DNA fingerprinting was performed. During sequential 1-year intervals, changes in annual case rates per 100 000 persons for all cases, clustered cases (cases with M. tuberculosis isolates having identical fingerprint patterns), and cases in specific subgroups with high rates of clustering (persons born in the United States and HIV-infected persons) were examined. Results: Annual tuberculosis case rates peaked at 51.2 cases per 100 000 persons in 1992 and decreased significantly thereafter to 29.8 cases per 100 000 persons in 1997 (P < 0.001). The rate of clustered cases decreased significantly over time in the entire study sample (from 10.4 cases per 100 000 persons in 1991 to 3.8 cases per 100 000 persons in 1997 [P < 0.001]), in persons born in the United States (P < 0.001), and in HIV-infected persons (P = 0.003). Conclusions: The rates of tuberculosis cases and clustered tuberculosis cases decreased both overall and among persons in high-risk groups. This occurred in a period during which tuberculosis control measures were intensified.	Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Gen Hosp, Ctr Med, San Francisco, CA 94110 USA; Francis J Curry Natl TB Ctr, San Francisco, CA 94110 USA; Dept Publ Hlth, San Francisco, CA USA; Stanford Univ, Dept Med, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Stanford University	Jasmer, RM (corresponding author), Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Gen Hosp, Ctr Med, Room K1,1001 Potrero Ave, San Francisco, CA 94110 USA.		Hahn, Judith/J-5813-2014; Daley, Charles L./AAC-3231-2021	Hahn, Judith/0000-0002-2697-8264; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034238, U01AI035969] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07185] Funding Source: Medline; NIAID NIH HHS [AI 34238, AI 35969] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; *CA DEP HLTH SERV, 1998, REP TUB CAL 1997; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; Glynn JR, 1999, AM J EPIDEMIOL, V149, P366, DOI 10.1093/oxfordjournals.aje.a009822; HOPEWELL PC, 1996, TUBERCULOSIS, P113; Kalbfleisch JD., 2002, STAT ANAL FAILURE TI, V2, DOI [10.1002/9781118032985, DOI 10.1016/0197-2456(81)90009-X]; MCGOWAN JE, 1995, J HOSP INFECT, V30, P282, DOI 10.1016/0195-6701(95)90031-4; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; POULET S, 1995, ARCH MICROBIOL, V163, P87, DOI 10.1007/s002030050176; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P604; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; *SF DEP PUBL HLTH, 1997, 1997 HIV CONS REP HI; SMALL PM, 1993, J CLIN MICROBIOL, V31, P1677, DOI 10.1128/JCM.31.7.1677-1682.1993; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; *US BUR CENS, 1992, 1990 CENS POP HOUS; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Woelffer GB, 1996, AM J MED SCI, V311, P17, DOI 10.1097/00000441-199601000-00004; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; Yeh RW, 1998, J INFECT DIS, V177, P1107, DOI 10.1086/517406; 1998, MMWR MORB MORTAL WKL, V47, P253	33	153	156	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					971	978		10.7326/0003-4819-130-12-199906150-00004	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383367				2022-12-01	WOS:000080894700003
J	Bengtsson, BA; Johannsson, G				Bengtsson, BA; Johannsson, G			Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults	LANCET			English	Editorial Material							INTIMA-MEDIA THICKNESS; HYPOPITUITARISM; ULTRASOUND; MORTALITY		Sahlgrens Univ Hosp, Res Ctr Endocrinol & Metab, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Bengtsson, BA (corresponding author), Sahlgrens Univ Hosp, Res Ctr Endocrinol & Metab, S-41345 Gothenburg, Sweden.			Johannsson, Gudmundur/0000-0003-3484-8440				BLANKENHORN DH, 1993, CIRCULATION, V88, P20, DOI 10.1161/01.CIR.88.1.20; Boger RH, 1996, J CLIN INVEST, V98, P2706, DOI 10.1172/JCI119095; Capaldo B, 1997, J CLIN ENDOCR METAB, V82, P1378, DOI 10.1210/jc.82.5.1378; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; LEHMANN ED, 1991, LANCET, V338, P1075, DOI 10.1016/0140-6736(91)91929-O; MARKUSSIS V, 1992, LANCET, V340, P1188, DOI 10.1016/0140-6736(92)92892-J; Pfeifer M, 1999, J CLIN ENDOCR METAB, V84, P453, DOI 10.1210/jc.84.2.453; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; Rosen T, 1998, CLIN ENDOCRINOL, V48, P525, DOI 10.1046/j.1365-2265.1998.00473.x; Sverrisdottir YB, 1998, J CLIN ENDOCR METAB, V83, P1881, DOI 10.1210/jc.83.6.1881; WIKSTRAND J, 1994, J INTERN MED, V236, P555, DOI 10.1111/j.1365-2796.1994.tb00845.x	11	25	25	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1898	1899		10.1016/S0140-6736(99)90092-2	http://dx.doi.org/10.1016/S0140-6736(99)90092-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371563				2022-12-01	WOS:000080668500004
J	Learmont, JC; Geczy, AF; Mills, J; Ashton, LJ; Raynes-Greenow, CH; Garsia, RJ; Dyer, WB; McIntyre, L; Oelrichs, RB; Rhodes, DI; Deacon, NJ; Sullivan, JS				Learmont, JC; Geczy, AF; Mills, J; Ashton, LJ; Raynes-Greenow, CH; Garsia, RJ; Dyer, WB; McIntyre, L; Oelrichs, RB; Rhodes, DI; Deacon, NJ; Sullivan, JS		Sydney Blood Bank Cohort Res Grp	Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1 - A report from the Sydney Blood Bank Cohort	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; SYSTEMIC LUPUS-ERYTHEMATOSUS; NEF GENE; MONONUCLEAR-CELLS; TYPE-1 INFECTION; SINGLE-DONOR; AIDS; LYMPHOCYTES; RECIPIENTS	Background and Methods The Sydney Blood Bank Cohort consists of a blood donor and eight transfusion recipients who were infected before 1985 with a strain of human immunodeficiency virus type 1 (HIV-1) with a deletion in the region in which the nef gene and the long terminal repeat overlap. Two recipients have died since 1994, at 77 and 83 years of age, of causes unrelated to HIV infection; one other recipient, who had systemic lupus erythematosus, died in 1987 at 22 years of age of causes possibly related to HIV. We present longitudinal immunologic and virologic data on the six surviving members and one deceased member of this cohort through September 30, 1998. Results The five surviving recipients remain asymptomatic 14 to 18 years after HIV-1 infection without any antiretroviral therapy; however, the donor commenced therapy in February 1999. In three recipients plasma concentrations of HIV-1 RNA are undetectable (<200 copies per milliliter), and in two of these three the CD4 lymphocyte counts have declined by 9 and 30 cells per cubic millimeter per year (P=0.3 and P=0.5, respectively). The donor and two other recipients have median plasma concentrations of HIV-1 RNA of 645 to 2850 copies per milliliter; the concentration has increased in the donor (P<0.001). The CD4 lymphocyte counts in these three cohort members have declined by 16 to 73 cells per cubic millimeter per year (P<0.001). In the recipient who died after 12 years of infection, the median plasma concentration of HIV-1 RNA was 1400 copies per milliliter, with a decline in CD4 lymphocyte counts of 17 cells per cubic millimeter per year (P=0.2). Conclusions After prolonged infection with this attenuated strain of HIV-1, there is evidence of immunologic damage in three of the four subjects with detectable plasma HIV-1 RNA. The CD4 lymphocyte counts appear to be stable in the three subjects in whom plasma HIV-1 RNA remains undetectable. (N Engl J Med 1999;340:1715-22.) (C) 1999, Massachusetts Medical Society.	Australian Red Cross Blood Serv NSW, Sydney, NSW 2000, Australia; Natl Ctr HIV Epidemiol & Clin Res, Fairfield, Vic, Australia; Macfarlane Burnet Ctr Med Res, Fairfield, Vic, Australia; Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Royal Prince Alfred Hosp, Sydney, NSW, Australia	Australian Red Cross Blood Service; University of New South Wales Sydney; Kirby Institute; University of New South Wales Sydney; Kirby Institute; University of Sydney	Learmont, JC (corresponding author), Australian Red Cross Blood Serv NSW, 153 Clarence St, Sydney, NSW 2000, Australia.	jlearmont@arcbs.redcross.org.au						ARCHER GT, 1988, P 4 INT C ACQ IMM DE, P354; ASHTON LJ, 1994, LANCET, V344, P718, DOI 10.1016/S0140-6736(94)92210-1; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; Cameron RG, 1996, AUST NZ J MED, V26, P800, DOI 10.1111/j.1445-5994.1996.tb00628.x; Cohen I, 1997, SCIENCE, V278, P24, DOI 10.1126/science.278.5335.24; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Dean M, 1996, SCIENCE, V274, P1069; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Desrosiers R.C., 1994, J NIH RES, V6, P54; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P411, DOI 10.1089/aid.1992.8.411; DESROSIERS RC, 1994, J NIH RES, V6, P56; Dyer WB, 1999, J VIROL, V73, P436, DOI 10.1128/JVI.73.1.436-443.1999; Dyer WB, 1997, AIDS, V11, P1565, DOI 10.1097/00002030-199713000-00004; FAIRLEY CK, 1994, INT J STD AIDS, V5, P177, DOI 10.1177/095646249400500304; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P333, DOI 10.1089/aid.1994.10.333; Greenough TC, 1999, NEW ENGL J MED, V340, P236, DOI 10.1056/NEJM199901213400314; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; Greenway AL, 1998, AIDS, V12, P555, DOI 10.1097/00002030-199806000-00003; GREENWAY AL, 1994, VIROLOGY, V198, P245, DOI 10.1006/viro.1994.1027; GURUSINGHE AD, 1995, J MED VIROL, V46, P238, DOI 10.1002/jmv.1890460312; Hessol N A, 1996, AIDS, V10 Suppl A, pS69, DOI 10.1097/00002030-199601001-00010; ILYINSKII PO, 1994, J VIROL, V68, P5933, DOI 10.1128/JVI.68.9.5933-5944.1994; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOPECSCHRADER E, 1993, AIDS, V7, P1009, DOI 10.1097/00002030-199307000-00016; LEARMONT J, 1995, AIDS RES HUM RETROV, V11, P1, DOI 10.1089/aid.1995.11.1; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; LEARMONT J, 1996, 11 INT C AIDS VANC J, P33; LEARMONT J, 1994, P 10 INT C AIDS YOK, V2, P254; LEONG KH, 1991, ANN RHEUM DIS, V50, P811, DOI 10.1136/ard.50.11.811; Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Munoz A, 1996, STAT MED, V15, P2459, DOI 10.1002/(SICI)1097-0258(19961130)15:22<2459::AID-SIM464>3.0.CO;2-Q; Munoz A, 1997, AIDS, V11, pS69; NEATE EV, 1987, AUST NZ J MED, V17, P461, DOI 10.1111/j.1445-5994.1987.tb00096.x; Oelrichs R, 1998, AIDS RES HUM RETROV, V14, P811, DOI 10.1089/aid.1998.14.811; OPERSKALSKI EA, 1995, J INFECT DIS, V172, P648, DOI 10.1093/infdis/172.3.648; PORGES AJ, 1992, J RHEUMATOL, V19, P1191; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Ruprecht RM, 1996, SCIENCE, V271, P1790; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; 1997, ANTIVIRAL AGENTS B, V10, P353	49	270	279	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1715	1722		10.1056/NEJM199906033402203	http://dx.doi.org/10.1056/NEJM199906033402203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352163				2022-12-01	WOS:000080620200003
J	Lagergren, J; Bergstrom, R; Nyren, O				Lagergren, J; Bergstrom, R; Nyren, O			Association between body mass and adenocarcinoma of the esophagus and gastric cardia	ANNALS OF INTERNAL MEDICINE			English	Article						body mass index; stomach neoplasms; esophageal neoplasms; adenocarcinoma; obesity	INCREASING INCIDENCE; PORTION SIZE; OBESITY; TOBACCO; ALCOHOL; HEIGHT; INDEX; RISK; PREVALENCE; OVERWEIGHT	Background: The incidence of esophageal and gastric cardia adenocarcinoma is, for unknown reasons, increasing dramatically. A weak and inconsistent association between body mass index (BMI) and adenocarcinoma of the esophagus and gastric cardia has been reported. Objective: To reexamine the association between BMI and development of adenocarcinoma of the esophagus and gastric cardia. Design: Nationwide, population-based case-control study. Setting: Sweden, 1995 through 1997. Patients: Patients younger than 80 years of age who had recently received a diagnosis were eligible. Comprehensive organization ensured rapid case ascertainment. Controls were randomly selected from the continuously updated population register. Interviews were conducted with 189 patients with adenocarcinoma of the esophagus and 262 patients with adenocarcinoma of the gastric cardia; for comparison, 167 patients with incident esophageal squamous-cell carcinoma and 820 controls were also interviewed. Measurements: Odds ratios were determined from BMI and cancer case-control status. Odds ratios estimated the relative risk for the two adenocarcinomas studied and were calculated by multivariate logistic regression with adjustment for potential confounding factors. Results: A strong dose-dependent relation existed between BMI and esophageal adenocarcinoma. The adjusted odds ratio was 7.6 (95% CI, 3.8 to 15.2) among persons in the highest BMI quartile compared with persons in the lowest. Obese persons (persons with a BMI > 30 kg/m(2)) had an odds ratio of 16.2 (CI, 6.3 to 41.4) compared with the leanest persons (persons with a BMI < 22 kg/m(2)). The odds ratio for patients with cardia adenocarcinoma was 2.3 (CI, 1.5 to 3.6) in those in the highest BMI quartile compared with those in the lowest BMI quartile and 4.3 (CI, 2.1 to 8.7) among obese persons. Esophageal squamous-cell carcinoma was not associated with BMI. Conclusions: The association between BMI and esophageal adenocarcinoma is strong and is not explained by bias or confounding. The carcinogenic mechanism, however, remains to be clarified. The increasing prevalence of obesity in western countries could be important in understanding the increasing occurrence of this tumor.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Uppsala Univ, Dept Stat, S-75120 Uppsala, Sweden	Karolinska Institutet; Uppsala University	Lagergren, J (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, S-17177 Stockholm, Sweden.	Jesper.Lagergren@mep.ki.se		Lagergren, Jesper/0000-0002-5143-5448	NATIONAL CANCER INSTITUTE [R01CA057947] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57947-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHESON RM, 1964, BRIT J PREV SOC MED, V18, P25; [Anonymous], 1985, WHO TECH REP SER, P1; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Breslow NE., 1980, IARC SCI PUBL, P5; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; FAGGIANO F, 1992, EPIDEMIOLOGY, V3, P379, DOI 10.1097/00001648-199207000-00015; FERRARA A, 1995, DIABETES CARE, V18, P220, DOI 10.2337/diacare.18.2.220; FLYVBJERG A, 1990, DIABETES ANN, V5, P642; GARROW JS, 1985, INT J OBESITY, V9, P147; HAGEN J, 1987, INT SURG, V72, P1; HANSSON LE, 1993, INT J CANCER, V54, P402, DOI 10.1002/ijc.2910540309; Ji BT, 1997, CANCER EPIDEM BIOMAR, V6, P481; KABAT GC, 1993, CANCER CAUSE CONTROL, V4, P123, DOI 10.1007/BF00053153; Kahn C. R., 1995, ENDOCRINOLOGY, P1373; Kim R, 1997, CANCER EPIDEM BIOMAR, V6, P369; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUSKOWSKAWOLK A, 1993, J EPIDEMIOL COMMUN H, V47, P103, DOI 10.1136/jech.47.2.103; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; LAVECCHIA C, 1990, INT J CANCER, V45, P275, DOI 10.1002/ijc.2910450212; MERCER CD, 1987, J MED, V18, P135; MITCHELL HS, 1962, J AM DIET ASSOC, V40, P521; MUST A, 1993, AM J EPIDEMIOL, V138, P56, DOI 10.1093/oxfordjournals.aje.a116777; Nelson M, 1996, BRIT J NUTR, V76, P31, DOI 10.1079/BJN19960007; PERA M, 1993, GASTROENTEROLOGY, V104, P510, DOI 10.1016/0016-5085(93)90420-H; Powell J, 1992, Eur J Cancer Prev, V1, P265, DOI 10.1097/00008469-199204000-00008; POWER C, 1988, INT J OBESITY, V12, P445; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P127; Seidell JC, 1997, BRIT MED BULL, V53, P238, DOI 10.1093/oxfordjournals.bmb.a011611; STENELARSEN G, 1988, SCAND J GASTROENTERO, V23, P427, DOI 10.3109/00365528809093890; VAUGHAN TL, 1995, CANCER EPIDEM BIOMAR, V4, P85; Zhang ZF, 1996, CANCER EPIDEM BIOMAR, V5, P761	33	506	520	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					883	+		10.7326/0003-4819-130-11-199906010-00003	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375336				2022-12-01	WOS:000080547900002
J	Pal, DK; Nandy, S; Sander, JWAS				Pal, DK; Nandy, S; Sander, JWAS			Towards a coherent public-health analysis for epilepsy	LANCET			English	Editorial Material									UCL, Inst Child Hlth, Neurosci Unit, London WC1N 3BG, England; UCL, Inst Neurol, Epilepsy Res Grp, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Sander, JWAS (corresponding author), UCL, Inst Child Hlth, Neurosci Unit, London WC1N 3BG, England.		Sander, Josemir/C-1576-2008	Sander, Josemir/0000-0001-6041-9661; Nandy, Shailen/0000-0003-1066-9181				Pal DK, 1998, LANCET, V351, P19, DOI 10.1016/S0140-6736(97)06250-8; Sander JWAS, 1996, J NEUROL NEUROSUR PS, V61, P433, DOI 10.1136/jnnp.61.5.433; The World Bank, 1993, INV HLTH WORLD DEV I; *WHO, 1990, IN SUPP PEOPL EP; *WHO, 1978, APPL ADV NEUR CONTR; *WHO, 1975, WHO TECHN REP SER, V564; *WHO, 1985, COMM CONTR EP REP IN; *WORLD BANK, 1999, WORLD DEV IND	8	10	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1817	1818		10.1016/S0140-6736(99)00189-0	http://dx.doi.org/10.1016/S0140-6736(99)00189-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359404				2022-12-01	WOS:000080667800007
J	Harkin, DP; Bean, JM; Miklos, D; Song, YH; Truong, VB; Englert, C; Christians, FC; Ellisen, LW; Maheswaran, S; Oliner, JD; Haber, DA				Harkin, DP; Bean, JM; Miklos, D; Song, YH; Truong, VB; Englert, C; Christians, FC; Ellisen, LW; Maheswaran, S; Oliner, JD; Haber, DA			Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1	CELL			English	Article							INTERACT IN-VIVO; CELL-CYCLE; DNA-DAMAGE; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; MAMMALIAN-CELLS; GENE-EXPRESSION; PROTEIN; P53; PHOSPHORYLATION	The breast cancer susceptibility gene BRCA1 encodes a protein implicated in the cellular response to DNA damage, with postulated roles in homologous recombination as well as transcriptional regulation. To identify downstream target genes, we established cell lines with tightly regulated inducible expression of BRCA1. High-density oligonucleotide arrays were used to analyze gene expression profiles at various times following BRCA1 induction. A major BRCA1 target is the DNA damage-responsive gene GADD45. Induction of BRCA1 triggers apoptosis through activation of c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), a signaling pathway potentially linked to GADD45 gene family members. The p53-independent induction of GADD45 by BRCA1 and its activation of JNK/SAPK suggest a pathway for BRCA1-induced apoptosis.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Affymetrix, Santa Clara, CA 95051 USA	Harvard University; Massachusetts General Hospital; Harvard University; Affymetrix	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.		Ellisen, Leif W/AAA-6572-2022	Ellisen, Leif W/0000-0003-0444-7910; Song, Young-Han/0000-0002-0758-3654; Bean, James/0000-0001-6733-5794; Englert, Christoph/0000-0002-5931-3189	NATIONAL CANCER INSTITUTE [R37CA058596, R01CA058596] Funding Source: NIH RePORTER; NCI NIH HHS [CA58596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON S, 1998, NAT GENET, V19, P1; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Honkoop AH, 1998, BRIT J CANCER, V77, P621, DOI 10.1038/bjc.1998.99; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jarvis EM, 1998, CANCER GENET CYTOGEN, V101, P109, DOI 10.1016/S0165-4608(97)00267-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; LIU CY, 1996, GENE DEV, V90, P2112; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; Tomlinson GE, 1998, CANCER RES, V58, P3237; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; YAN MH, 1994, NATURE, V372, P798; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	44	489	505	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 28	1999	97	5					575	586		10.1016/S0092-8674(00)80769-2	http://dx.doi.org/10.1016/S0092-8674(00)80769-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367887	Bronze			2022-12-01	WOS:000080672100007
J	Harrison, LH; Dwyer, DM; Maples, CT; Billmann, L				Harrison, LH; Dwyer, DM; Maples, CT; Billmann, L			Risk of meningococcal infection in college students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAMPUS BAR PATRONAGE; UNITED-STATES; DISEASE; VACCINATION; MENINGITIS; OUTBREAK	Context The number of meningococcal outbreaks on college campuses have been increasing in the past few years. However, no published studies have documented the incidence of invasive meningococcal infection in college students or whether the incidence is higher than in the general population of the same age. Objective To compare the incidence of invasive meningococcal infection in Maryland college students with that of the general population of the same age, Design Retrospective cohort study. Setting and Patients Maryland residents with meningococcal infection from 1992-1997 identified from active, laboratory-based, statewide surveillance for invasive meningococcal disease, Main Outcome Measures Incidence of invasive meningococcal infection. Results Of 228 patients with invasive meningococcal infection, 67 were aged 16 to 30 years; 11 and 3 of these attended Maryland 4- and 2-year colleges, respectively, Of these, 12 (86%) had infection caused by Neisseria meningitidis serogroups included in the current meningococcal vaccine. The average annual incidence was 1.74 per 100 000 among students in 4-year schools vs 1.44 per 100 000 for the general population of the same age (P = .60). Among students in 4-year schools, the incidence was 3.24 per 100 000 in on-campus residents vs 0.96 per 100 000 in off-campus residents (relative risk, 3.4; 95% confidence interval, 1.0-11.6; P = .05). Conclusions The incidence of meningococcal infection in college students is similar to the incidence in the general population of the same age, but college students residing on campus appear to be at higher risk than those residing off campus.	Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Med, Pittsburgh, PA 15261 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Maryland Dept Hlth & Mental Hyg, Epidemiol & Dis Control Program, Community & Publ Hlth Adm, Baltimore, MD USA; George Washington Univ, Dept Epidemiol & Biostat, Sch Publ Hlth & Hlth Serv, Washington, DC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Maryland Department of Health & Mental Hygiene; George Washington University	Harrison, LH (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, 521 Parran Hall,130 DeSoto St, Pittsburgh, PA 15261 USA.							*AM COLL HLTH ASS, 1999, REC MEN MEN VACC; BROOME CV, 1986, J ANTIMICROB CHEMOTH, V18, P25, DOI 10.1093/jac/18.Supplement_A.25; BRUNDAGE JF, 1987, EVOLUTION MENINGOCOC, P5; *CONTR PREV MEN DI, 1997, MMWR MORB MORT WKLY, V46, P1; Control and prevention of serogroup C meningococcal disease, 1997, MMWR-MORBID MORTAL W, V46, P13; Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015; FISCHER M, 1998, 36 ANN M INF DIS SOC; FROESCHLE JE, IN PRESS CLIN INFECT; HARRISON LH, 1995, JAMA-J AM MED ASSOC, V273, P419, DOI 10.1001/jama.273.5.419; Harrison LH, 1998, J INFECT DIS, V177, P998, DOI 10.1086/515260; HARRISON LH, 1987, EVOLUTION MENINGOCOC, P27; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; IMREY PB, 1995, J CLIN MICROBIOL, V33, P3133, DOI 10.1128/JCM.33.12.3133-3137.1995; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; JACKSON LA, 1995, AM J PUBLIC HEALTH, V85, P843, DOI 10.2105/AJPH.85.6.843; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; MOORE PS, 1992, CLIN INFECT DIS, V14, P515, DOI 10.1093/clinids/14.2.515; NGUYENVANTAM JS, 1998, 11 INT PATH NELS C N; Roberts CL, 1996, AM J PUBLIC HEALTH, V86, P1155, DOI 10.2105/AJPH.86.8_Pt_1.1155; Rosenstein N, 1998, JAMA-J AM MED ASSOC, V279, P435, DOI 10.1001/jama.279.6.435; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; *SER Y MEN DIS ILL, 1996, MMWR-MORBID MORTAL W, V45, P1010; WOODS CW, 1998, 36 ANN M INF DIS SOC	23	112	115	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1906	1910		10.1001/jama.281.20.1906	http://dx.doi.org/10.1001/jama.281.20.1906			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349894	Bronze			2022-12-01	WOS:000080427300030
J	Parks, DJ; Blanchard, SG; Bledsoe, RK; Chandra, G; Consler, TG; Kliewer, SA; Stimmel, JB; Willson, TM; Zavacki, AM; Moore, DD; Lehmann, JM				Parks, DJ; Blanchard, SG; Bledsoe, RK; Chandra, G; Consler, TG; Kliewer, SA; Stimmel, JB; Willson, TM; Zavacki, AM; Moore, DD; Lehmann, JM			Bile acids: Natural ligands for an orphan nuclear receptor	SCIENCE			English	Article							BINDING-PROTEIN; CHOLESTEROL 7-ALPHA-HYDROXYLASE; MOLECULAR-CLONING; EXPRESSION; COACTIVATORS; IDENTIFICATION; FLUORESCENCE; TRANSPORT; ASSAYS; TISSUE	Bile acids regulate the transcription of genes that control cholesterol homeostasis through molecular mechanisms that are poorly understood. Physiological concentrations of free and conjugated chenodeoxycholic acid, Lithocholic acid, and deoxycholic acid activated the farnesoid X receptor (FXR; NR1H4), an orphan nuclear receptor. As Ligands, these bile acids and their conjugates modulated interaction of FXR with a peptide derived from steroid receptor coactivator 1. These results provide evidence for a nuclear bile acid signaling pathway that may regulate cholesterol homeostasis.	Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Baylor College of Medicine	Willson, TM (corresponding author), Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA.		feinstein, doug/M-9414-2019		NIDDK NIH HHS [R01 DK53366, F32 DK09793] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053366, F32DK009793] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; CRESTANI M, 1994, BIOCHEM BIOPH RES CO, V198, P546, DOI 10.1006/bbrc.1994.1080; DICKSON EFG, 1995, J PHOTOCH PHOTOBIO B, V27, P3; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FUJITA M, 1995, EUR J BIOCHEM, V233, P406, DOI 10.1111/j.1432-1033.1995.406_2.x; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GONG YZ, 1994, P NATL ACAD SCI USA, V91, P4741, DOI 10.1073/pnas.91.11.4741; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Kanda T, 1996, FEBS LETT, V384, P131, DOI 10.1016/0014-5793(96)00291-8; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MALLORY A, 1973, GASTROENTEROLOGY, V64, P26; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; PARKS DE, UNPUB; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; Sippel CJ, 1997, J BIOL CHEM, V272, P18290, DOI 10.1074/jbc.272.29.18290; SOINI E, 1990, ANN BIOL CLIN-PARIS, V48, P567; TWISK J, 1995, EUR J BIOCHEM, V228, P596, DOI 10.1111/j.1432-1033.1995.tb20299.x; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; ZAVACKI AM, UNPUB; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	31	1764	1868	9	117	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1365	1368		10.1126/science.284.5418.1365	http://dx.doi.org/10.1126/science.284.5418.1365			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334993				2022-12-01	WOS:000080430600056
J	Levine, C				Levine, C			The loneliness of the long-term care giver	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									United Hosp Fund, New York, NY 10118 USA		Levine, C (corresponding author), United Hosp Fund, New York, NY 10118 USA.							Angell M, 1999, NEW ENGL J MED, V340, P48, DOI 10.1056/NEJM199901073400108; Arno PS, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.2.182; BARUSCH AS, 1995, SOC WORK, V40, P315; Cassel CK, 1999, HEALTH AFFAIR, V18, P118, DOI 10.1377/hlthaff.18.1.118; GRAHAM J, 1999, CHICAGO TRIBUNE 0117; Levine C, 1999, ANN INTERN MED, V130, P148, DOI 10.7326/0003-4819-130-2-199901190-00010; LEVINE C, IN PRESS J HLTH AGIN; Levine C., 1998, ROUGH CROSSINGS FAMI; MINTZ S, 1999, COMMUNICATION   0106; SCHOFIELD H, 1998, FAMILY CAREGIVERS DI	10	69	72	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1587	1590		10.1056/NEJM199905203402013	http://dx.doi.org/10.1056/NEJM199905203402013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332025				2022-12-01	WOS:000080358900013
J	Swearingen, B; Biller, BMK; Barker, FG; Katznelson, L; Grinspoon, S; Klibanski, A; Zervas, NT				Swearingen, B; Biller, BMK; Barker, FG; Katznelson, L; Grinspoon, S; Klibanski, A; Zervas, NT			Long-term mortality after transsphenoidal surgery for Cushing disease	ANNALS OF INTERNAL MEDICINE			English	Article							MACROADENOMAS; MICROSURGERY	Background: Untreated Cushing disease historically has a high mortality rate, but the long-term survival of patients with Cushing disease after transsphenoidal surgery has not been reported. Objective: To determine long-term mortality rate in patients who are treated for Cushing disease with current management techniques. Design: Retrospective case series. Setting: Tertiary care center. Patients: 161 patients (32 men and 129 women; mean age, 38 years) who were treated for Cushing disease between 1978 and 1996. Intervention: Transsphenoidal adenomectomy and as-needed adjunctive therapy. Measurement: Record review with follow-up interview. Results: The cure rate for patients with microadenomas who had no previous therapy was 90% (123 of 137). No perioperative deaths occurred (0 of 193 procedures [95% CI, 0.0% to 1.9%]). Follow-up data (mean, 8.7 years) were obtained for 99% of patients (159 of 161). Six patients died. The 5- and 10-year survival rates were 99% (CI, 97% to 100%) and 93% (CI, 88% to 99%), respectively. Survival was similar to that seen in an age- and sex-matched sample that was based on U.S. population data (standardized mortality ratio, 0.98 [CI, 0.44 to 2.2]; P > 0.2). Conclusion: Survival of patients treated for Cushing disease with current management techniques between 1978 and 1996 was better than the poor survival historically associated with this disorder.	Massachusetts Gen Hosp, Neurol Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Swearingen, B (corresponding author), Massachusetts Gen Hosp, Neurol Serv, Fruit St, Boston, MA 02114 USA.							BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BIGOS ST, 1980, J CLIN ENDOCR METAB, V50, P348, DOI 10.1210/jcem-50-2-348; Blevins LS, 1998, J CLIN ENDOCR METAB, V83, P63, DOI 10.1210/jc.83.1.63; CHANDLER WF, 1987, J NEUROSURG, V66, P204, DOI 10.3171/jns.1987.66.2.0204; Cushing H, 1932, B JOHNS HOPKINS HOSP, V50, P137; ETXABE J, 1994, CLIN ENDOCRINOL, V40, P479, DOI 10.1111/j.1365-2265.1994.tb02486.x; FAHLBUSCH R, 1986, J ROY SOC MED, V79, P262, DOI 10.1177/014107688607900504; Katznelson L, 1998, J CLIN ENDOCR METAB, V83, P1619, DOI 10.1210/jc.83.5.1619; Klein JP., 2003, SURVIVAL ANAL TECHNI, DOI 10.1007/b97377; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; Meier CA, 1997, ENDOCRIN METAB CLIN, V26, P741, DOI 10.1016/S0889-8529(05)70280-2; ORIORDAIN DS, 1994, SURGERY, V116, P1088; ORTH DN, 1971, NEW ENGL J MED, V285, P243, DOI 10.1056/NEJM197107292850501; PLOTZ CM, 1952, AM J MED, V13, P597, DOI 10.1016/0002-9343(52)90027-2; SALASSA RM, 1978, MAYO CLIN PROC, V53, P24; *STAT SCI, 1995, S PLUS GUID STAT MAT; TINDALL GT, 1990, J NEUROSURG, V72, P363, DOI 10.3171/jns.1990.72.3.0363; VERHEUL HA, 1993, LANCET, V341, P872, DOI 10.1016/0140-6736(93)93073-A	18	190	193	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					821	824		10.7326/0003-4819-130-10-199905180-00015	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00015			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366371				2022-12-01	WOS:000080305000004
J	Chin, L; Artandi, SE; Shen, Q; Tam, A; Lee, SL; Gottlieb, GJ; Greider, CW; DePinho, RA				Chin, L; Artandi, SE; Shen, Q; Tam, A; Lee, SL; Gottlieb, GJ; Greider, CW; DePinho, RA			p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis	CELL			English	Article							MOUSE CELLS LACKING; DNA-DAMAGE; LIFE-SPAN; IMMORTAL CELLS; YEAST TELOMERE; SENESCENCE; FIBROBLASTS; ARREST; GROWTH; RNA	Maintenance of telomere length and function is critical for the efficient proliferation of eukaryotic cells. Here, we examine the interactions between telomere dysfunction and p53 in cells and organs of telomerase-deficient mice. Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis. Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis. Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process. Together, these studies establish a key role for p53 in the cellular response to telomere dysfunction in both normal and neoplastic cells, question the significance of crisis as a tumor suppressor mechanism, and identify a biologically relevant stage of advanced crisis, termed genetic catastrophe.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Quest Diagnost Inc, Anat Pathol, Teterboro, NJ 07608 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Johns Hopkins University	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	depinho@dfci.harvard.edu		DePinho, Ronald/0000-0002-5625-577X; Greider, Carol/0000-0002-5494-8126	NIAMS NIH HHS [K08AR02104-01] Funding Source: Medline; NICHD NIH HHS [R01HD34880, R01HD28317] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317, R01HD034880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002104] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VENKATACHALAM S, 1996, EMBO, V17, P4657; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	44	760	794	1	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					527	538		10.1016/S0092-8674(00)80762-X	http://dx.doi.org/10.1016/S0092-8674(00)80762-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338216	Bronze			2022-12-01	WOS:000080299100013
J	Koechlin, E; Basso, G; Pietrini, P; Panzer, S; Grafman, J				Koechlin, E; Basso, G; Pietrini, P; Panzer, S; Grafman, J			The role of the anterior prefrontal cortex in human cognition	NATURE			English	Article							WORKING-MEMORY; EPISODIC MEMORY; RETRIEVAL; RECOGNITION; ACTIVATION; SYSTEM; BRAIN; TASK	Complex problem-solving and planning involve the most anterior part of the frontal lobes including the fronto-polar prefrontal cortex (FPPC)(1-6), which is especially well developed in humans compared with other primates(7,8). The specific role of this region in human cognition, however, is poorly understood. Here we show using functional magnetic resonance imaging, that bilateral regions in the FPPC alone are selectively activated when subjects have to keep in mind a main goal while performing concurrent (sub)goals. Neither keeping in mind a goal over time (working memory) nor successively allocating attentional resources between alternative goals (dual-task performance) could by themselves activate these regions. Our results indicate that the FPPC selectively mediates the human ability to hold in mind goals while exploring and processing secondary goals, a process generally required in planning and reasoning.	NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Grafman, J (corresponding author), NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA.	jgr@box-j.nih.gov	Koechlin, Etienne/E-5061-2016; Koechlin, Etienne/AAF-5717-2021; Basso, Gianpaolo/A-9208-2012; Pietrini, Pietro/Z-4202-2019	Koechlin, Etienne/0000-0002-6514-9311; Koechlin, Etienne/0000-0002-6514-9311; Basso, Gianpaolo/0000-0002-6245-9402; Grafman, Jordan H./0000-0001-8645-4457; Pietrini, Pietro/0000-0002-6768-5556				[Anonymous], 1983, CANADIAN PSYCHOL; Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Corbetta M, 1998, P NATL ACAD SCI USA, V95, P831, DOI 10.1073/pnas.95.3.831; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duvernoy H. M., 1991, HUMAN BRAIN SURFACE; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Furey ML, 1997, P NATL ACAD SCI USA, V94, P6512, DOI 10.1073/pnas.94.12.6512; Fuster J., 1989, DISSERT ABSTRACTS IN, V60, P255; GALABURDA AM, 1978, SCIENCE, V199, P852, DOI 10.1126/science.341314; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; GRAFTON ST, 1995, J COGNITIVE NEUROSCI, V7, P497, DOI 10.1162/jocn.1995.7.4.497; MacLeod AK, 1998, NEUROIMAGE, V7, P41, DOI 10.1006/nimg.1997.0308; Owen AM, 1996, EUR J NEUROSCI, V8, P353, DOI 10.1111/j.1460-9568.1996.tb01219.x; Pallier C, 1997, BEHAV RES METH INS C, V29, P322, DOI 10.3758/BF03200583; PETRIDES M, 1994, HDB NEUROPSYCHOLOGY, P59; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; Sirigu A, 1995, ANN NY ACAD SCI, V769, P277, DOI 10.1111/j.1749-6632.1995.tb38145.x; SPECTOR L, 1994, HDB NEUROPSYCHOLOGY, P377; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Stuss D.T., 1986, FRONTAL LOBES; Talairach J, 1988, CO PLANAR STEREOTAXI; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; Wharton CM, 1998, TRENDS COGN SCI, V2, P54, DOI 10.1016/S1364-6613(98)01122-X	27	714	723	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1999	399	6732					148	151		10.1038/20178	http://dx.doi.org/10.1038/20178			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335843				2022-12-01	WOS:000080335700049
J	Houtsmuller, AB; Rademakers, S; Nigg, AL; Hoogstraten, D; Hoeijmakers, JHJ; Vermeulen, W				Houtsmuller, AB; Rademakers, S; Nigg, AL; Hoogstraten, D; Hoeijmakers, JHJ; Vermeulen, W			Action of DNA repair endonuclease ERCC1/XPF in living cells	SCIENCE			English	Article							NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-F; GREEN-FLUORESCENT PROTEIN; XERODERMA-PIGMENTOSUM; PHOTOBLEACHING RECOVERY; ULTRAVIOLET-LIGHT; COMPLEX; DIFFUSION; TRANSCRIPTION; ERCC4	To study the nuclear organization and dynamics of nucleotide excision repair (NER), the endonuclease ERCC1/XPF (for excision repair cross complementation group 1/xeroderma pigmentosum group F) was tagged with green fluorescent protein and its mobility was monitored in Living Chinese hamster ovary cells. In the absence of DNA damage, the complex moved freely through the nucleus, with a diffusion coefficient (15 +/- 5 square micrometers per second) consistent with its molecular size. Ultraviolet Light-induced DNA damage caused a transient dose-dependent immobilization of ERCC1/XPF, likely due to engagement of the complex in a single repair event. After 4 minutes, the complex regained mobility. These results suggest (i) that NER operates by assembly of individual NER factors at sites of DNA damage rather than by preassembly of holocomplexes and (ii) that ERCC1/XPF participates in repair of DNA damage in a distributive fashion rather than by processive scanning of large genome segments.	Erasmus Univ, Dept Cell Biol & Genet, Ctr Med Genet, CBG, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Pathol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Dept Cell Biol & Genet, Ctr Med Genet, CBG, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Vermeulen, Wim/W-8708-2019; Hoeijmakers, Jan/AAX-6972-2021	Vermeulen, Wim/0000-0003-3616-734X; 				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Friedberg EC, 1995, DNA REPAIR MUTAGENES; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; Guzder SN, 1998, J BIOL CHEM, V273, P6292, DOI 10.1074/jbc.273.11.6292; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; JACKSON DA, 1994, J CELL SCI, V107, P1745; Koehler DR, 1996, NUCLEIC ACIDS RES, V24, P2877, DOI 10.1093/nar/24.15.2877; MCCREADY SJ, 1984, J CELL SCI, V70, P189; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; OH EY, 1989, J BIOL CHEM, V264, P1336; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RADEMAKERS S, UNPUB; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; SANCAR A, 1996, ANNU REV BIOCHEM, V43, P135; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WEY CL, 1981, BIOPHYS J, V33, P225, DOI 10.1016/S0006-3495(81)84883-7; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yagi T, 1997, MUTAGENESIS, V12, P41, DOI 10.1093/mutage/12.1.41	37	284	290	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					958	961		10.1126/science.284.5416.958	http://dx.doi.org/10.1126/science.284.5416.958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320375				2022-12-01	WOS:000080198800044
J	Komeili, A; O'Shea, EK				Komeili, A; O'Shea, EK			Roles of phosphorylation sites in regulating activity of the transcription factor Pho4	SCIENCE			English	Article							CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN; PHO80-PHO85; PROMOTER; YEAST; IDENTIFICATION; SEQUENCES; NUCLEUS; REGULON	Transcription factors are often phosphorylated at multiple sites. Here it is shown that multiple phosphorylation sites on the budding yeast transcription factor Pho4 play distinct and separable roles in regulating the factor's activity. Phosphorylation of Pho4 at two sites promotes the factor's nuclear export and phosphorylation at a third site inhibits its nuclear import. Phosphorylation of a fourth site blocks the interaction of Pho4 with the transcription factor Pho2. Multiple phosphorylation sites provide overlapping and partially redundant Layers of regulation that function to efficiently control the activity of Pho4.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	O'Shea, EK (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 513 Parnassus Ave, San Francisco, CA 94143 USA.	oshea@biochem.ucsf.edu						Barbaric S, 1996, NUCLEIC ACIDS RES, V24, P4479, DOI 10.1093/nar/24.22.4479; BRAZAS RM, 1993, MOL CELL BIOL, V13, P5524, DOI 10.1128/MCB.13.9.5524; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOMEILI A, UNPUB; Magbanua JPV, 1997, J BIOCHEM, V121, P1182; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; STRAWN J, 1980, COMPUT MUSIC J, V4, P3, DOI 10.2307/3679635; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973	20	234	237	4	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1999	284	5416					977	980		10.1126/science.284.5416.977	http://dx.doi.org/10.1126/science.284.5416.977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320381				2022-12-01	WOS:000080198800050
J	Bergmark, K; Avall-Lundqvist, E; Dickman, PW; Henningsohn, L; Steineck, G				Bergmark, K; Avall-Lundqvist, E; Dickman, PW; Henningsohn, L; Steineck, G			Vaginal changes and sexuality in women with a history of cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DYSFUNCTION; CARCINOMA; RADIATION; THERAPY; SURGERY	Background In women with cervical cancer, treatment causes changes in vaginal anatomy and function. The effect of these changes on sexual function and the extent, if any, to which they distress women are not known. Methods In 1996 and 1997, we attempted to contact 332 women with a history of early-stage cervical cancer (age range, 26 to 80 years) who had been treated in 1991 and 1992 at the seven departments of gynecological oncology in Sweden and 489 women without a history of cancer (controls) to ask them to answer an anonymous questionnaire about vaginal changes and sexual function. Results We received completed questionnaires from 256 of the women with a history of cervical cancer and 350 of the controls. A total of 167 of 247 women with a history of cancer (68 percent) and 236 of 330 controls (72 percent) reported that they had regular vaginal intercourse. Twenty-six percent of the women who had cancer and 11 percent of the controls reported insufficient vaginal lubrication for sexual intercourse, 26 percent of the women who had cancer and 3 percent of the controls reported a short vagina, and 23 percent of the women who had cancer and 4 percent of the controls reported an insufficiently elastic vagina. Twenty-six percent of the women who had cancer reported moderate or much distress due to vaginal changes, as compared with 8 percent of the women in the control group. Dyspareunia was also more common among the women who had cervical cancer. The frequency of orgasms and orgasmic pleasure was similar in the two groups. Among the women who had cervical cancer, the type of treatment received had little if any effect on the prevalence of specific vaginal changes. Conclusions Women who have been treated for cervical cancer have persistent vaginal changes that compromise sexual activity and result in considerable distress. (N Engl J Med 1999;340:1383-9.) (C) 1999, Massachusetts Medical Society.	Karolinska Hosp, Div Epidemiol, S-17176 Stockholm, Sweden; Karolinska Inst, Radiumhemmet, Dept Oncol, Div Gynecol Oncol, Stockholm, Sweden; Karolinska Inst, Radiumhemmet, Dept Oncol, Div Clin Epidemiol, Stockholm, Sweden; Huddinge Hosp, Dept Urol, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet	Steineck, G (corresponding author), Karolinska Hosp, Div Epidemiol, Norrbacka S-2 06, S-17176 Stockholm, Sweden.		Avall-Lundqvist, Elisabeth/C-9292-2009; Steineck, Gunnar/W-1515-2019; Dickman, Paul W/B-4572-2013	Steineck, Gunnar/0000-0002-0787-3969; Dickman, Paul W/0000-0002-5788-3380; Henningsohn, Lars/0000-0002-5521-8934				ABITBOL MM, 1974, AM J OBSTET GYNECOL, V119, P181, DOI 10.1016/0002-9378(74)90031-3; ANDERSEN BL, 1989, J CONSULT CLIN PSYCH, V57, P683, DOI 10.1037/0022-006X.57.6.683; Benedet J, 1998, J EPIDEMIOL BIOSTAT, V3, P5; BERTELSEN K, 1983, DAN MED BULL, V30, P31; Borjeson S, 1997, CANCER NURS, V20, P260; BOS G, 1986, INT C SERIES, V707, P575; BRUNER DW, 1993, INT J RADIAT ONCOL, V27, P825, DOI 10.1016/0360-3016(93)90455-5; CORNEY RH, 1993, BRIT J OBSTET GYNAEC, V100, P73, DOI 10.1111/j.1471-0528.1993.tb12955.x; FLAY LD, 1995, INT J RADIAT ONCOL, V31, P399, DOI 10.1016/0360-3016(94)E0139-B; Helgason A, 1996, BRIT J CANCER, V73, P1417, DOI 10.1038/bjc.1996.268; HELGASON AR, 1997, J EPIDEMIOL BIOSTAT, V2, P213; KRUMM S, 1993, J PSYCHOSOM OBST GYN, V14, P51, DOI 10.3109/01674829309084430; PISANI P, 1985, INT J CANCER, V55, P891; PITKIN RM, 1971, RADIOLOGY, V99, P417, DOI 10.1148/99.2.417; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P271; *SAS I, 1990, SAS PROC GUID VERS 6, P350; SCHOVER LR, 1989, CANCER, V63, P204, DOI 10.1002/1097-0142(19890101)63:1<204::AID-CNCR2820630133>3.0.CO;2-U; SEIBEL MM, 1980, OBSTET GYNECOL, V55, P484; Steineck G, 1998, ACTA ONCOL, V37, P15, DOI 10.1080/028418698423131; STEINECK G, 1992, EPIDEMIOLOGY, V3, P477, DOI 10.1097/00001648-199211000-00003; VASICKA A, 1958, OBSTET GYNECOL, V11, P403	21	493	503	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1383	1389		10.1056/NEJM199905063401802	http://dx.doi.org/10.1056/NEJM199905063401802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228188				2022-12-01	WOS:000080090600002
J	Saitta, AM; Soper, PD; Wasserman, E; Klein, ML				Saitta, AM; Soper, PD; Wasserman, E; Klein, ML			Influence of a knot on the strength of a polymer strand	NATURE			English	Article							MECHANICAL-PROPERTIES; MOLECULAR-DYNAMICS; TOPOLOGY; DNA; POLYETHYLENE; BEHAVIOR	Many experiments have been done to determine the relative strengths of different knots, and these show that the break in a knotted rope almost invariably occurs at the point just outside the 'entrance' to the knot(1). The influence of knots on the properties of polymers has become of great interest,in part because of their effect on mechanical properties(2). Knot theory(3,4) applied to the topology of macromolecules(5-8) indicates that the simple trefoil or 'overhand' knot is likely to be present in any long polymer strand(9-12). Fragments of DNA have been observed to contain such knots in experiments(13,14) and computer simulations(15). Here we use ab initio computational methods(16) to investigate the effect of a trefoil knot on the breaking strength of a polymer strand. We find that the knot weakens the strand significantly, and that, like a knotted rope, it breaks under tension at the entrance to the knot.	Univ Penn, Dept Chem, Ctr Mol Modeling, Philadelphia, PA 19104 USA; Dupont Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA	University of Pennsylvania; DuPont	Klein, ML (corresponding author), Univ Penn, Dept Chem, Ctr Mol Modeling, Philadelphia, PA 19104 USA.		Saitta, Antonino Marco/D-9605-2015	Saitta, Antonino Marco/0000-0002-3298-2040				Ancilotto F, 1997, SCIENCE, V275, P1288, DOI 10.1126/science.275.5304.1288; ARAI Y, IN PRESS NATURE; Ashley CW., 1993, ASHLEY BOOK KNOTS; ATIYHA MF, 1990, GEOMETRY PHYSICS KNO; BAYER RK, 1994, COLLOID POLYM SCI, V272, P910, DOI 10.1007/BF00658889; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; CAR R, 1985, PHYS REV LETT, V55, P2471, DOI 10.1103/PhysRevLett.55.2471; DEGENNES PG, 1984, MACROMOLECULES, V17, P703, DOI 10.1021/ma00134a030; FRANKKAMENETSKII MD, 1975, NATURE, V258, P398, DOI 10.1038/258398a0; FRISCH HL, 1993, NEW J CHEM, V17, P697; FRISCH HL, 1961, J AM CHEM SOC, V83, P3789, DOI 10.1021/ja01479a015; KARASAWA N, 1991, J PHYS CHEM-US, V95, P2260, DOI 10.1021/j100159a031; Katritch V, 1997, NATURE, V388, P148, DOI 10.1038/40582; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; MANSFIELD ML, 1994, MACROMOLECULES, V27, P5924, DOI 10.1021/ma00098a057; MARTYNA GJ, IN PRESS COMP PHYS C; Mislow K., 1965, INTRO STEREOCHEMISTR; Montanari B, 1997, CHEM PHYS LETT, V272, P347, DOI 10.1016/S0009-2614(97)00455-7; Mundy CJ, 1996, FARADAY DISCUSS, V104, P17, DOI 10.1039/fd9960400017; Schill G., 1971, CATENANES ROTAXANES; SCHLICK T, 1992, SCIENCE, V257, P1110, DOI 10.1126/science.257.5073.1110; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SIEPMANN JI, 1993, NATURE, V365, P330, DOI 10.1038/365330a0; VANRENSBURG EJJ, 1992, J PHYS A-MATH GEN, V25, P6557, DOI 10.1088/0305-4470/25/24/010; WALBA DM, 1985, TETRAHEDRON, V41, P3161, DOI 10.1016/S0040-4020(01)96671-2; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458	26	179	181	4	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					46	48		10.1038/19935	http://dx.doi.org/10.1038/19935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331387	Green Submitted			2022-12-01	WOS:000080172100049
J	Pound, CR; Partin, AW; Eisenberger, MA; Chan, DW; Pearson, JD; Walsh, PC				Pound, CR; Partin, AW; Eisenberger, MA; Chan, DW; Pearson, JD; Walsh, PC			Natural history of progression after PSA elevation following radical prostatectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RETROPUBIC PROSTATECTOMY; PROGNOSTIC FACTORS; CANCER; RECURRENCE; CARCINOMA; ANTIGEN; MEN; SURVIVAL; LEUPROLIDE; VARIABLES	Context In men who develop an elevated serum prostate-specific antigen level (PSA) after having undergone a radical prostatectomy, the natural history of progression to distant metastases and death due to prostate cancer is unknown. Objective To characterize the time course of disease progression in men with biochemical recurrence after radical prostatectomy. Design A retrospective review of a large surgical series with median (SD) follow-up of 5.3 (3.7) years (range, 0.5-15 years) between April 1982 and April 1997, Setting An urban academic tertiary referral institution. Patients A total of 1997 men undergoing radical prostatectomy, by a single surgeon, for clinically localized prostate cancer. None received neoadjuvant therapy, and none had received adjuvant hormonal therapy prior to documented distant metastases. Main Outcome Measures After surgery, men were followed up with PSA assays and digital rectal examinations every 3 months for the first year, semiannually for the second year, and annually thereafter. A detectable serum PSA level of at least 0.2 ng/mL was evidence of biochemical recurrence. Distant metastases were diagnosed by radionuclide bone scan, chest radiograph, or other body imaging, which was performed at the time of biochemical recurrence and annually thereafter. Results The actuarial metastasis-free survival for all 1997 men was 82% (95% confidence interval, 76%-88%) at 15 years after surgery, Of the 1997 men, 315 (15%) developed biochemical PSA level elevation. Eleven of these underwent early hormone therapy after the recurrence and are not included in the study. Of the remaining 304 men, 103 (34%) developed metastatic disease within the study period. The median actuarial time to metastases was 8 years from the time of PSA level elevation. in survival analysis, time to biochemical progression (P<.001), Gleason score (P<.001), and PSA doubling time (P<.001) were predictive of the probability and time to the development of metastatic disease. An algorithm combining these parameters was constructed to stratify men into risk groups. Once men developed metastatic disease, the median actuarial time to death was 5 years. The time interval from surgery to the appearance of metastatic disease was predictive of time until death (P<.02). Conclusions Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy. These data may be useful in the design of clinical trials, the identification of men for enrollment into experimental protocols, and counseling men regarding the timing of administration of adjuvant therapies.	Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Merck Res Labs, Dept Epidemiol, Blue Bell, PA USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Merck & Company	Partin, AW (corresponding author), Johns Hopkins Hosp, James Buchanan Brady Urol Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.		Chan, Doris/O-1227-2014	Chan, Doris/0000-0002-4990-986X	NATIONAL CANCER INSTITUTE [R29CA058326] Funding Source: NIH RePORTER; NCI NIH HHS [CA58326] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; Bauer JJ, 1997, CANCER, V79, P952, DOI 10.1002/(SICI)1097-0142(19970301)79:5<952::AID-CNCR12>3.0.CO;2-1; Byar D P, 1988, NCI Monogr, P165; BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C; CATALONA WJ, 1994, J UROLOGY, V152, P1837, DOI 10.1016/S0022-5347(17)32397-2; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; Dillioglugil O, 1997, UROLOGY, V50, P93, DOI 10.1016/S0090-4295(97)00106-4; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; GOLIMBU M, 1987, UROLOGY, V30, P427, DOI 10.1016/0090-4295(87)90373-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAMOLOWSKY EV, 1988, J UROLOGY, V139, P1242, DOI 10.1016/S0022-5347(17)42879-5; Krongrad A, 1997, JAMA-J AM MED ASSOC, V278, P44; LEPOR H, 1989, J UROLOGY, V141, P82, DOI 10.1016/S0022-5347(17)40596-9; OHORI M, 1994, J UROLOGY, V152, P1843, DOI 10.1016/S0022-5347(17)32398-4; PARTIN AW, 1994, UROLOGY, V43, P649, DOI 10.1016/0090-4295(94)90180-5; PARTIN AW, 1995, UROLOGY, V45, P831, DOI 10.1016/S0090-4295(99)80091-0; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; Patel A, 1997, J UROLOGY, V158, P1441, DOI 10.1016/S0022-5347(01)64238-1; Pound CR, 1997, UROL CLIN N AM, V24, P395, DOI 10.1016/S0094-0143(05)70386-4; Scher H I, 1992, Semin Urol, V10, P55; Schroder FH, 1998, CAMPBELLS UROLOGY, V3, P2627; SGRIGNOLI AR, 1994, J UROLOGY, V152, P1077, DOI 10.1016/S0022-5347(17)32507-7; SHARIFI R, 1990, J UROLOGY, V143, P68, DOI 10.1016/S0022-5347(17)39868-3; SOLOWAY MS, 1990, CANCER, V66, P1017; STECKEL J, 1994, AUA UPDATE SERIES, V13, P166; TRAPASSO JG, 1994, J UROLOGY, V152, P1821, DOI 10.1016/S0022-5347(17)32394-7; Veltri R W, 1998, Semin Urol Oncol, V16, P106; WALSH PC, 1989, J UROLOGY, V141, P1032; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6; ZINCKE H, 1992, CANCER, V70, P312	32	2388	2444	0	67	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1591	1597		10.1001/jama.281.17.1591	http://dx.doi.org/10.1001/jama.281.17.1591			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235151	Bronze			2022-12-01	WOS:000080025900022
J	LeBoff, MS; Kohlmeier, L; Hurwitz, S; Franklin, J; Wright, J; Glowacki, J				LeBoff, MS; Kohlmeier, L; Hurwitz, S; Franklin, J; Wright, J; Glowacki, J			Occult vitamin D deficiency in postmenopausal US women with acute hip fracture	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARATHYROID-HORMONE LEVELS; FEMORAL-NECK FRACTURE; BONE TURNOVER; ELDERLY WOMEN; PROXIMAL FEMUR; OLDER WOMEN; OSTEOPOROSIS; OSTEOMALACIA; POPULATION; CALCIUM	Context Low vitamin D levels may contribute to hip fractures in women, although limited data are available on vitamin D levels in US women admitted with acute hip fractures. Objective To determine whether postmenopausal women with hip fractures have low vitamin D and high parathyroid hormone levels compared with nonosteoporotic and osteoporotic women admitted for elective joint replacement. Design Comparative case series conducted between January 1995 and June 1998, Setting and Patients Ninety-eight postmenopausal community-dwelling women with no secondary causes of bone loss admitted for hip replacement, of whom 30 women had acute hip fractures and 68 women were admitted for elective joint replacement. Of the women admitted for elective joint replacement, 17 had osteoporosis and 51 did not. Women with comorbid conditions or who were taking medications that affect bone density and turnover were excluded. Main Outcome Measures Primary measures were levels of vitamin D and parathyroid hormone; secondary measures were body composition and markers of bone turnover. Results Women with hip fractures had lower levels of 25-hydroxyvitamin D than women without osteoporosis admitted for elective joint replacement (P=.02) and than women with osteoporosis admitted for elective joint replacement (P=.01) (medians, 32.4, 49.9, and 55.0 nmol/L, respectively; comparisons adjusted for age and estrogen intake). Parathyroid hormone levels were higher in women with fractures than women in the nonosteoporotic control group (P<.001) or than elective osteoporotic women (P=.001) (medians, 5.58, 3.26, and 3.79 pmol/L, respectively; comparisons adjusted for age and estrogen intake). Fifteen patients (50.0%) with hip fractures had deficient vitamin D levels (less than or equal to 30.0 nmol/L) and 11 (36.7%) had a parathyroid hormone level greater than 6.84 pmol/L, Levels of N-telopeptide, a marker of bone resorption, were greater in the women with hip fractures than in the elective nonosteoporotic controls (P=.004). Conclusions Postmenopausal community-living women who presented with hip fracture showed occult vitamin D deficiency. Repletion of vitamin D and suppression of parathyroid hormone at the time of fracture may reduce future fracture risk and facilitate hip fracture repair. Because vitamin D deficiency is preventable, heightened awareness is necessary to ensure adequate vitamin D nutrition, particularly in northern latitudes.	Brigham & Womens Hosp, Div Endocrine Hypertens, Skeletal Hlth & Osteoporosis Program, Dept Internal Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Endocrine Hypertens, Skeletal Hlth & Osteoporosis Program, Dept Orthoped Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	LeBoff, MS (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, Skeletal Hlth & Osteoporosis Program, Dept Internal Med, 221 Longwood Ave, Boston, MA 02115 USA.	msleboff@bics.bwh.harvard.edu			NIA NIH HHS [R01 AG 13519, R01 AG 12271] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012271, R01AG013519] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARON JE, 1974, LANCET, V1, P229; AKESSON K, 1993, CALCIFIED TISSUE INT, V53, P162, DOI 10.1007/BF01321832; BAKER MR, 1979, BRIT MED J, V1, P589, DOI 10.1136/bmj.1.6163.589; Boonen S, 1996, J ENDOCRINOL, V149, P13, DOI 10.1677/joe.0.1490013; BOUILLON RA, 1987, AM J CLIN NUTR, V45, P755, DOI 10.1093/ajcn/45.4.755; Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158; Chalmers J, 1969, Clin Orthop Relat Res, V63, P196; Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COMPSTON JE, 1989, CLIN ENDOCRINOL, V31, P667, DOI 10.1111/j.1365-2265.1989.tb01291.x; Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; EL-HAJJ FULEIHAN G, 1995, J BONE MINER RES, V10, P1004; Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307; GUNDBERG CM, 1991, J CLIN ENDOCR METAB, V72, P438, DOI 10.1210/jcem-72-2-438; Haden ST, 1999, CALCIFIED TISSUE INT, V64, P275, DOI 10.1007/s002239900618; HARMA M, 1987, ANN CLIN RES, V19, P378; HORDON LD, 1990, BONE MINER, V11, P247, DOI 10.1016/0169-6009(90)90063-L; JOHNSTON CC, 1985, J CLIN ENDOCR METAB, V61, P551, DOI 10.1210/jcem-61-3-551; JONGEN MJM, 1984, CLIN CHEM, V30, P399; KAMEL S, 1994, BONE MINER, V26, P197, DOI 10.1016/S0169-6009(08)80169-9; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Khosla S, 1997, J CLIN ENDOCR METAB, V82, P1522, DOI 10.1210/jc.82.5.1522; KRISKA AM, 1992, DIABETES METAB REV, V8, P355, DOI 10.1002/dmr.5610080404; LIPS P, 1982, METAB BONE DIS RELAT, V4, P85, DOI 10.1016/0221-8747(82)90021-2; LIPS P, 1983, J CLIN ENDOCR METAB, V57, P204, DOI 10.1210/jcem-57-1-204; LIPS P, 1995, J BONE MINER RES, V10, pS496; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002-9343(92)90682-2; OOMS ME, 1995, J BONE MINER RES, V10, P1177; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; PEACOCK M, 1985, 6 WORKSH VIT D, P569; Prestwood KM, 1996, OSTEOPOROSIS INT, V6, P314, DOI 10.1007/BF01623391; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; SOKOLOFF L, 1978, AM J SURG PATHOL, V2, P21, DOI 10.1097/00000478-197803000-00003; SOLOMON L, 1973, S AFR J SURG, V11, P269; Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201; WEBB AR, 1990, AM J CLIN NUTR, V51, P1075, DOI 10.1093/ajcn/51.6.1075	38	356	373	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1505	1511		10.1001/jama.281.16.1505	http://dx.doi.org/10.1001/jama.281.16.1505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227320	Bronze			2022-12-01	WOS:000079857400032
J	Hirota, H; Chen, J; Betz, UAK; Rajewsky, K; Gu, Y; Ross, J; Muller, W; Chien, KR				Hirota, H; Chen, J; Betz, UAK; Rajewsky, K; Gu, Y; Ross, J; Muller, W; Chien, KR			Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress	CELL			English	Article							LEUKEMIA INHIBITORY FACTOR; INTERLEUKIN-6 DEFICIENT MICE; RXR-ALPHA; DEPENDENT PATHWAYS; VENTRICULAR MYOCYTES; TARGETED DISRUPTION; SIGNALING PATHWAYS; GENE-EXPRESSION; STEM-CELLS; IN-VITRO	Biomechanical stress is a major stimulus for cardiac hypertrophy and the transition to heart failure. By generating mice that harbor a ventricular restricted knockout of the gp130 cytokine receptor via Cre-loxP-mediated recombination, we demonstrate a critical role for a gp130-dependent myocyte survival pathway in the transition to heart failure. Such conditional mutant mice have normal cardiac structure and function, but during aortic pressure overload, these mice display rapid onset of dilated cardiomyopathy and massive induction of myocyte apoptosis versus the control mice that exhibit compensatory hypertrophy. Thus, cardiac myocyte apoptosis is a critical point in the transition between compensatory cardiac hypertrophy and heart failure. gp130-dependent cytokines may represent a novel therapeutic strategy for preventing in vivo heart failure.	Univ Calif San Diego, Sch Med, Salk NHLBI Program Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Cologne, Genet Inst, D-50931 Cologne, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Cologne	Chien, KR (corresponding author), Univ Calif San Diego, Sch Med, Salk NHLBI Program Mol Med, La Jolla, CA 92093 USA.	kchien@ucsd.edu	Muller, Werner/B-9044-2008; Chen, Ju/E-5579-2011	Muller, Werner/0000-0002-1297-9725; Rajewsky, Klaus/0000-0002-6633-6370				Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; BALLIGAND JL, 1994, J BIOL CHEM, V269, P27580; BERNAD A, 1994, IMMUNITY, V1, P725, DOI 10.1016/S1074-7613(94)80014-6; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Chen J, 1998, DEVELOPMENT, V125, P1943; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CHIEN KR, 1998, MOL BASIS CARDIOVASC, P211; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; Gruber PJ, 1998, DEVELOPMENT, V125, P4427; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KUBALAK SW, 1996, METH MOL G, V8, P470; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; Nandurkar HH, 1997, BLOOD, V90, P2148; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Olivetti G, 1997, NEW ENGL J MED, V336, P1131, DOI 10.1056/NEJM199704173361603; Palakodeti V, 1997, AM J PHYSIOL-HEART C, V273, pH1283, DOI 10.1152/ajpheart.1997.273.3.H1283; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; RAMSAY AJ, 1994, SCIENCE, V264, P561, DOI 10.1126/science.8160012; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; Romani L, 1996, J EXP MED, V183, P1345, DOI 10.1084/jem.183.4.1345; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Ross RS, 1996, DEVELOPMENT, V122, P1799; Ruiz-Lozano P, 1998, DEVELOPMENT, V125, P533; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; THORBURN A, 1993, J BIOL CHEM, V268, P2244; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WARE CB, 1995, DEVELOPMENT, V121, P1283; Wollert KC, 1997, J MOL MED-JMM, V75, P492, DOI 10.1007/s001090050134; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	57	524	583	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					189	198		10.1016/S0092-8674(00)80729-1	http://dx.doi.org/10.1016/S0092-8674(00)80729-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219240	Bronze			2022-12-01	WOS:000079779800008
J	Hirsch, JA; Schubert, C; Gurevich, VV; Sigler, PB				Hirsch, JA; Schubert, C; Gurevich, VV; Sigler, PB			The 2.8 angstrom crystal structure of visual arrestin: A model for arrestin's regulation	CELL			English	Article							ROD OUTER SEGMENTS; PROTEIN-COUPLED RECEPTORS; PHOSPHORYLATED RHODOPSIN; SALT BRIDGES; ANOMALOUS DIFFRACTION; SECONDARY STRUCTURE; IN-VIVO; BINDING; SELECTIVITY; STABILITY	G protein-coupled signaling is utilized by a wide variety of eukaryotes for communicating information from the extracellular environment. Signal termination is achieved by the action of the arrestins, which bind to activated, phosphorylated G protein-coupled receptors. We describe here crystallographic studies of visual arrestin in its basal conformation. The salient features of the structure are a bipartite molecule with an unusual polar core. This core is stabilized in part by an extended carboxy-terminal tail that locks the molecule into an inactive state. In addition, arrestin is found to be a dimer of two asymmetric molecules, suggesting an intrinsic conformational plasticity. In conjunction with biochemical and mutagenesis data, we propose a molecular mechanism by which arrestin is activated for receptor binding.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA; Yale Univ, Dept Biochem & Mol Biophys, New Haven, CT 06511 USA; Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85372 USA	Howard Hughes Medical Institute; Yale University; Yale University; Banner Research; Banner Health; Banner Sun Health Research Institute	Sigler, PB (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06511 USA.	sigler@csb.yale.edu	Hirsch, Joel/AAC-8000-2021; Gurevich, Vsevolod/A-3236-2008	Hirsch, Joel/0000-0001-7544-8668; Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324] Funding Source: NIH RePORTER; NEI NIH HHS [EY11500] Funding Source: Medline; NIGMS NIH HHS [GM22324] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ATON BR, 1984, BIOCHEMISTRY-US, V23, P1737, DOI 10.1021/bi00303a024; AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FUCHS S, 1995, NAT GENET, V10, P360, DOI 10.1038/ng0795-360; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gerstein M, 1998, PROTEIN SCI, V7, P445; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Gros R, 1997, J CLIN INVEST, V99, P2087, DOI 10.1172/JCI119381; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kawamura Satoru, 1995, P105; KLEYWEGT GJ, 1994, U MAP FINAL MODEL, P59; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P314; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; Sindelar CV, 1998, PROTEIN SCI, V7, P1898, DOI 10.1002/pro.5560070906; Tan S, 1998, NATURE, V391, P660, DOI 10.1038/35563; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; WALDBURGER CD, 1995, NAT STRUCT BIOL, V2, P122, DOI 10.1038/nsb0295-122; Wimley WC, 1996, P NATL ACAD SCI USA, V93, P2985, DOI 10.1073/pnas.93.7.2985; Xu J, 1997, NATURE, V389, P505, DOI 10.1038/39068	61	331	340	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					257	269		10.1016/S0092-8674(00)80735-7	http://dx.doi.org/10.1016/S0092-8674(00)80735-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219246	Bronze			2022-12-01	WOS:000079779800014
J	Logan, S				Logan, S			Iron deficiency and developmental deficit - the jury is still out - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							WEIGHT-GAIN		UCL, Sch Med, Inst Child Hlth, Systemat Reviews Training Unit, London WC1N 1EH, England	University of London; University College London; UCL Medical School	Logan, S (corresponding author), UCL, Sch Med, Inst Child Hlth, Systemat Reviews Training Unit, London WC1N 1EH, England.			Logan, Stuart/0000-0002-9279-261X				AUKETT MA, 1986, ARCH DIS CHILD, V61, P849, DOI 10.1136/adc.61.9.849; Childs F, 1997, ARCH DIS CHILD, V76, P144, DOI 10.1136/adc.76.2.144; DeMaeyer E, 1985, World Health Stat Q, V38, P302; IDJRADINATA P, 1994, LANCET, V343, P1252, DOI 10.1016/S0140-6736(94)92151-2; IDJRADINATA P, 1993, LANCET, V311, P14; Lozoff B., 1996, Pediatric Research, V39, p136A; MOFFATT MEK, 1994, J PEDIATR-US, V125, P527, DOI 10.1016/S0022-3476(94)70003-6	7	8	8	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 13	1999	318	7185					697	698						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	182JK	10215375				2022-12-01	WOS:000079495700021
J	Vidal, R; Frangione, B; Rostagno, A; Mead, S; Revesz, T; Plant, G; Ghiso, J				Vidal, R; Frangione, B; Rostagno, A; Mead, S; Revesz, T; Plant, G; Ghiso, J			A stop-codon mutation in the BRI gene associated with familial British dementia	NATURE			English	Article							CEREBRAL AMYLOID ANGIOPATHY; CREUTZFELDT-JAKOB DISEASE; ALZHEIMERS-DISEASE; PLAQUE-FORMATION; PROTEIN; VARIANT	Familial British dementia (FBD), previously designated familial cerebral amyloid angiopathy-British type(1), is an autosomal dominant disorder of undetermined origin characterized by progressive dementia, spasticity, and cerebellar ataxia, with onset at around the fifth decade of life. Cerebral amyloid angiopathy, non-neuritic and perivascular plaques and neurofibrillary tangles are the predominant pathological lesions(1-4). Here we report the identification of a unique 4K protein subunit named ABri from isolated amyloid fibrils. This highly insoluble peptide is a fragment of a putative type-II single-spanning transmembrane precursor that is encoded by a novel gene, BRI; located on chromosome 13. A single base substitution at the scop codon of this gene generates a longer open reading frame, resulting in a larger, 277-residue precursor. Release of the 34 carboxy-terminal amino acids from the mutated precursor generates the ABri amyloid subunit. The mutation creates a cutting site for the restriction enzyme XbaI, which is useful for detecting asymptomatic carriers. Antibodies against the amyloid or homologous synthetic peptides recognize both parenchymal and vascular lesions in FED patients. A point mutation at the stop codon of BRI therefore results in the generation of the ABri peptide, which is deposited as amyloid fibrils causing neuronal disfunction and dementia.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Inst Neurol, Dept Neuropathol, London WC1N 3BG, England	New York University; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	Ghiso, J (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.	ghisoj01@popmail.med.nyu.edu	Mead, Simon/E-9414-2011; Rostagno, Agueda/A-5801-2008; Revesz, Tamas/A-8732-2010	Mead, Simon/0000-0002-4326-1468; Revesz, Tamas/0000-0003-2501-0259; Rostagno, Agueda/0000-0002-6817-2074				AIKAWA H, 1985, ANN NEUROL, V17, P297, DOI 10.1002/ana.410170313; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baumann MH, 1996, BIOCHEM BIOPH RES CO, V219, P238, DOI 10.1006/bbrc.1996.0211; CORSELLIS JAN, 1954, BRAIN, V77, P571, DOI 10.1093/brain/77.4.571; COURTENMYERS G, 1987, NEUROLOGY, V37, P269; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GHISO J, 1995, J NEUROL SCI, V129, P74, DOI 10.1016/0022-510X(94)00274-R; GHISO J, 1994, MOL NEUROBIOL, V8, P49, DOI 10.1007/BF02778007; KEOHANE C, 1985, J NEUROL NEUROSUR PS, V48, P1175, DOI 10.1136/jnnp.48.11.1175; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; PEARLMAN RL, 1988, NEUROLOGY, V38, P1249, DOI 10.1212/WNL.38.8.1249; PLANT GT, 1990, BRAIN, V113, P721, DOI 10.1093/brain/113.3.721; Revesz T, 1999, ACTA NEUROPATHOL, V97, P170, DOI 10.1007/s004010050970; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Vidal R, 1996, AM J PATHOL, V148, P361; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; Worster-Drought C, 1940, BRAIN, V63, P237, DOI 10.1093/brain/63.3.237; Worster-Drought C, 1933, J NEUROL PSYCHOPATHO, V14, P27; Worster-Drougt C, 1944, BRAIN, V67, P38, DOI 10.1093/brain/67.1.38	23	379	405	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					776	781						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391242				2022-12-01	WOS:000081101600052
J	Turner, BJ; Newschaffer, CJ; Zhang, DZ; Fanning, T; Hauck, WW				Turner, BJ; Newschaffer, CJ; Zhang, DZ; Fanning, T; Hauck, WW			Translating clinical trial results into practice: The effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Conference on Women and HIV	MAY 04-07, 1997	LOS ANGELES, CA				HUMAN-IMMUNODEFICIENCY-VIRUS; PRENATAL-CARE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; ZIDOVUDINE USE; HEART-DISEASE; TRANSMISSION; COHORT; EXPERIENCE; TYPE-1	Background: The success of Pediatric AIDS Clinical Trials Group (PACTG) Protocol 076 in preventing vertical HIV transmission prompted intensive efforts to inform laypersons and professionals about the trial's results. Objective: To explore community responsiveness to these efforts by assessing temporal, maternal, and health care factors associated with prescribed antiretroviral therapy before and after PACTG Protocol 076, Design: Retrospective cohort study. Setting: New York State Medicaid program. Patients: 2607 HIV-infected women who delivered a living child between January 1993 and September 1996. Measurements: Adjusted odds of being prescribed antiretroviral treatment in the second or third trimester for women who delivered in period 1 (during the trial [January 1993 to February 1994]), period 2 (after the trial's end and announcement of the results to publication of the results [March 1994 to November 1994]), and period 3 (after publication of the trial results [December 1994 to September 1996]). Results: The adjusted odds of being prescribed antiretroviral therapy increased 21% per month in period 2 and decreased to 3% per month in period 3. In all time periods, the adjusted odds of being prescribed antiretroviral therapy were at least 60% greater (P < 0.05) for women who were treated at an institution that performed HIV clinical trials, received HIV-focused ambulatory care, or had adequate prenatal care visits. After the trial, women receiving methadone treatment had at least twofold (95% CI, 1.5- to 4.3-fold) greater adjusted odds of being prescribed antiretroviral therapy than women who did not take any illicit drugs. Latin-American women, older women, and women born in the United States had greater adjusted odds (P < 0.05) of being prescribed treatment in period 3. Conclusion: Community practice responded rapidly to efforts to disseminate the results of PACTG Protocol 076; however, the absolute increase in prescribed therapy was greatest for women who had adequate prenatal visits or were receiving HIV-focused care, care at a site that performed clinical trials, or methadone therapy.	Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; New York State Dept Hlth, Albany, NY 12237 USA	Jefferson University; State University of New York (SUNY) System	Turner, BJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, 1025 Walnut St,Room 132, Philadelphia, PA 19107 USA.	barbara.turner@mail.tju.edu			NIDA NIH HHS [R01 DA07904] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007904] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		*AM PUBL HLTH ASS, 1998, AM PUBL HLTH ASS M; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; Avanzini F, 1997, EUR HEART J, V18, P1447; Bobat R, 1996, PEDIATR INFECT DIS J, V15, P604, DOI 10.1097/00006454-199607000-00009; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P807, DOI 10.1001/jama.271.11.807; Fanning TR, 1995, AIDS PUBLIC POLICY J, V10, P39; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gwinn M, 1997, JAMA-J AM MED ASSOC, V277, P299, DOI 10.1001/jama.277.4.299a; Healton C, 1996, AM J PREV MED, V12, P47, DOI 10.1016/S0749-3797(18)30258-7; ISCOE NA, 1994, CAN MED ASSOC J, V150, P1109; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; Laine C, 1998, AIDS, V12, P417, DOI 10.1097/00002030-199804000-00011; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; McDermott J, 1997, PAEDIATR PERINAT EP, V11, P105, DOI 10.1046/j.1365-3016.1997.d01-4.x; *NY DEP HLTH MEM, 1993, HLTH FAC SER, V23; Phillips KA, 1997, J ACQ IMMUN DEF SYND, V14, P174, DOI 10.1097/00042560-199702010-00012; PSATY BM, 1995, JAMA-J AM MED ASSOC, V273, P1436, DOI 10.1001/jama.273.18.1436; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; Silverman NS, 1997, AM J PERINAT, V14, P341, DOI 10.1055/s-2007-994157; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; Smith Sidney C. Jr., 1998, American Journal of Medicine, V104, p23S, DOI 10.1016/S0002-9343(98)00043-6; Sullivan PS, 1998, BLOOD, V91, P301, DOI 10.1182/blood.V91.1.301.301_301_308; Turner BJ, 1998, J GEN INTERN MED, V13, P16, DOI 10.1046/j.1525-1497.1998.00003.x; Turner BJ, 1997, J ACQ IMMUN DEF SYND, V14, P327, DOI 10.1097/00042560-199704010-00004; TURNER BJ, 1995, J ACQ IMMUN DEF SYND, V9, P371; Turner BJ, 1996, J ACQ IMMUN DEF SYND, V12, P259, DOI 10.1097/00042560-199607000-00005; Wiznia AA, 1996, JAMA-J AM MED ASSOC, V275, P1504, DOI 10.1001/jama.275.19.1504; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; 1989, N Y STATE J MED, V89, P542; 1998, MMWR MORB MORTAL WKL, V47, P688	37	31	31	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					979	986		10.7326/0003-4819-130-12-199906150-00005	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	206TE	10383368				2022-12-01	WOS:000080894700004
J	Atzpodien, J; Dittmar, KEJ				Atzpodien, J; Dittmar, KEJ			Immunologic crosstalk	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Med Hsch Hannover, D-30623 Hannover, Germany; Gesell Brotechnol Forsch, D-38124 Braunschweig, Germany	Hannover Medical School	Atzpodien, J (corresponding author), Med Hsch Hannover, D-30623 Hannover, Germany.								0	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1732	1732		10.1056/NEJM199906033402205	http://dx.doi.org/10.1056/NEJM199906033402205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352165				2022-12-01	WOS:000080620200005
J	Ivanov, PC; Amaral, LAN; Goldberger, AL; Havlin, S; Rosenblum, MG; Struzik, ZR; Stanley, HE				Ivanov, PC; Amaral, LAN; Goldberger, AL; Havlin, S; Rosenblum, MG; Struzik, ZR; Stanley, HE			Multifractality in human heartbeat dynamics	NATURE			English	Article							RATE-VARIABILITY; TIME-SERIES; FLUCTUATION; TURBULENCE; FORMALISM; WAVELETS; MODEL; CHAOS	There is evidence that physiological signals under healthy conditions may have a fractal temporal structure(1). Here we investigate the possibility that time series generated by certain physiological control systems may be members of a special class of complex processes, termed multifractal, which require a large number of exponents to characterize their scaling properties(2-6). We report on evidence for multifractality in a biological dynamical system, the healthy human heartbeat, and show that the multifractal character and nonlinear properties of the healthy heart rate are encoded in the Fourier phases. We uncover a loss of multifractality for a life-threatening condition, congestive heart failure.	Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA; Boston Univ, Dept Phys, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Bar Ilan Univ, Gonda Goldschmid Ctr, Ramat Gan, Israel; Bar Ilan Univ, Dept Phys, Ramat Gan, Israel; Univ Potsdam, Dept Phys, D-14415 Potsdam, Germany; Ctr Math & Comp Sci, NL-1098 SJ Amsterdam, Netherlands	Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Bar Ilan University; Bar Ilan University; University of Potsdam	Ivanov, PC (corresponding author), Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA.		Amaral, LAN/A-4980-2008; Havlin, Shlomo/ABF-1527-2020; Ivanov, Plamen Ch./E-8004-2012; Struzik, Zbigniew/E-4295-2012; Amaral, Luis N./C-5485-2009	Amaral, LAN/0000-0002-3762-789X; Ivanov, Plamen Ch./0000-0001-7629-762X; Struzik, Zbigniew/0000-0002-1352-8897; 				AKSELROD S, 1981, SCIENCE, V213, P220, DOI 10.1126/science.6166045; Amaral LAN, 1998, PHYS REV LETT, V81, P2388, DOI 10.1103/PhysRevLett.81.2388; BARABASI AL, 1995, FRACTAL CONCEPTS SUR, pCH24; BASSINGTHWAIGHT.JB, 1994, FRACTAL PHYSL; Daubechies I., 1992, 10 LECT WAVELETS SOC, V61; Dewey T. G., 1997, FRACTALS MOL BIOPHYS; Hausdorff JM, 1996, J APPL PHYSIOL, V80, P1448, DOI 10.1152/jappl.1996.80.5.1448; HURST HE, 1951, T AM SOC CIV ENG, V116, P770; Ivanov PC, 1998, EUROPHYS LETT, V43, P363, DOI 10.1209/epl/i1998-00366-3; Ivanov PC, 1996, NATURE, V383, P323, DOI 10.1038/383323a0; KANTERS JK, 1994, J CARDIOVASC ELECTR, V5, P128; KOBAYASHI M, 1982, IEEE T BIO-MED ENG, V29, P456, DOI 10.1109/TBME.1982.324972; Lefebvre J. H., 1993, Chaos, V3, P267, DOI 10.1063/1.165990; Malik M., 1995, HEART RATE VARIABILI; MENEVEAU C, 1987, PHYS REV LETT, V59, P1424, DOI 10.1103/PhysRevLett.59.1424; MOODY GB, 1983, COMPUTERS CARDIOL, V9, P39; MUZY JF, 1994, INT J BIFURCAT CHAOS, V4, P245, DOI 10.1142/S0218127494000204; MUZY JF, 1991, PHYS REV LETT, V67, P3515, DOI 10.1103/PhysRevLett.67.3515; Peng CK, 1995, J ELECTROCARDIOL, V28, P59, DOI 10.1016/S0022-0736(95)80017-4; PENG CK, 1995, CHAOS, V5, P82, DOI 10.1063/1.166141; Poon CS, 1997, NATURE, V389, P492, DOI 10.1038/39043; SHLESINGER MF, 1987, ANN NY ACAD SCI, V504, P214, DOI 10.1111/j.1749-6632.1987.tb48734.x; STANLEY HE, 1988, NATURE, V335, P405, DOI 10.1038/335405a0; STNALEY HE, 1996, FRACTALS DISORDERED, P1; Sugihara G, 1996, P NATL ACAD SCI USA, V93, P2608, DOI 10.1073/pnas.93.6.2608; TAKAYASU H, 1997, FRACTALS PHYSICAL SC; Thurner S, 1998, PHYS REV LETT, V80, P1544, DOI 10.1103/PhysRevLett.80.1544; VICSEK T, 1991, J PHYS A-MATH GEN, V24, pL845, DOI 10.1088/0305-4470/24/15/010; VICSEK T, 1993, FRACTAL GROWTH PHENO; YAMAMOTO Y, 1993, BIOL CYBERN, V69, P205, DOI 10.1007/BF00198960	30	1257	1317	2	128	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					461	465		10.1038/20924	http://dx.doi.org/10.1038/20924			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365957	Green Published, Green Submitted			2022-12-01	WOS:000080667900047
J	Mott, HR; Owen, D; Nietlispach, D; Lowe, PN; Manser, E; Lim, L; Laue, ED				Mott, HR; Owen, D; Nietlispach, D; Lowe, PN; Manser, E; Lim, L; Laue, ED			Structure of the small G protein Cdc42 bound to the GTPase-binding domain of ACK	NATURE			English	Article							WISKOTT-ALDRICH-SYNDROME; CRYSTAL-STRUCTURE; TARGET PROTEINS; RAC; EFFECTOR; KINASE; FAMILY; RHO; SURFACE; PROGRAM	The proteins Cdc42 and Rac are members of the Rho family of small GTPases (G proteins), which control signal-transduction pathways that lead to rearrangements of the cell cytoskeleton, cell differentiation and cell proliferation. They do so by binding to downstream effector proteins(1). Some of these, known as CRIB (for Cdc42/Rac interactive-binding) proteins(2), bind to both Cdc42 and : Rac, such as the PAK1-3 serine/threonine kinases(3), whereas others are specific for Cdc42, such as the ACK tyrosine kinases(4,5) and the Wiscott-Aldrich-syndrome proteins (WASPs)(6,7). The effector loop of Cdc42 and Rac (comprising residues 30-40, also called switch I), is one of two regions which change conformation on exchange of GDP for GTP, This region is almost identical in Cdc42 and Racs, indicating that it does not determine the specificity of these G proteins. Here we report the solution structure of the complex of Cdc42 with the GTPase-binding domain of ACK(4,5). Both proteins undergo significant conformational changes on binding, to form a new type of G-protein/effector complex. The interaction extends the beta-sheet in Cdc42 by binding an extended strand from ACK, as seen in Ras/effector interactions(8,9), but it also involves other regions of the G protein that are important for determining the specificity of effector binding.	Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, Cambridge CB2 1GA, England; Glaxo Wellcome Med Res Ctr, Stevenage SG1 2NY, Herts, England; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 119076, Singapore; Inst Neurol, London WC1N 1PJ, England	University of Cambridge; GlaxoSmithKline; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London	Laue, ED (corresponding author), Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	e.d.laue@bioc.cam.ac.uk	Manser, Edward/ABD-2301-2020; Mott, Helen/AAV-3873-2020	Mott, Helen/0000-0002-7890-7097; Nietlispach, Daniel/0000-0003-4364-9291; Laue, Ernest/0000-0002-7476-4148				Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; Guo W, 1998, BIOCHEMISTRY-US, V37, P14030, DOI 10.1021/bi981352+; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leonard DA, 1997, BIOCHEMISTRY-US, V36, P1173, DOI 10.1021/bi9622837; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thompson G, 1998, BIOCHEMISTRY-US, V37, P7885, DOI 10.1021/bi980140+; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	30	143	145	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					384	388		10.1038/20732	http://dx.doi.org/10.1038/20732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360579				2022-12-01	WOS:000080547800066
J	Ona, VO; Li, MW; Vonsattel, JPG; Andrews, LJ; Khan, SQ; Chung, WM; Frey, AS; Menon, AS; Li, XJ; Stieg, PE; Yuan, JY; Penney, JB; Young, AB; Cha, JHJ; Friedlander, RM				Ona, VO; Li, MW; Vonsattel, JPG; Andrews, LJ; Khan, SQ; Chung, WM; Frey, AS; Menon, AS; Li, XJ; Stieg, PE; Yuan, JY; Penney, JB; Young, AB; Cha, JHJ; Friedlander, RM			Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease	NATURE			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; NEURONAL INTRANUCLEAR INCLUSIONS; TROPHIC FACTOR WITHDRAWAL; TRANSGENIC MICE; IL-1-BETA-CONVERTING ENZYME; POLYGLUTAMINE TRACT; CYSTEINE PROTEASE; FAMILY PROTEASES; CELL-DEATH; GENE	Huntington's disease is an autosomal-dominant progressive neurodegenerative disorder resulting in specific neuronal loss and dysfunction in the striatum and cortex(1). The disease is universally fatal, with a mean survival following onset of 15-20 years and, at present, there is no effective treatment. The mutation in patients with Huntington's disease is an expanded CAG/polyglutamine repeat in huntingtin, a protein of unknown function with a relative molecular mass of 350,000 (M-r 350K)(2). The length of the CAG/polyglutamine repeat is inversely correlated with the age of disease onset. The molecular pathways mediating the neuropathology of Huntington's disease are poorly understood. Transgenic mice expressing exon 1 of the human huntingtin gene with an expanded CAG/polyglutamine repeat develop a progressive syndrome with many of the characteristics of human Huntington's disease(3). Here we demonstrate evidence of caspase-1 activation in the brains of mice and humans with the disease. In this transgenic mouse model of Huntington's disease, expression of a dominant-negative caspase-1 mutant extends survival and delays the appearance of neuronal inclusions, neurotransmitter receptor alterations and onset of symptoms, indicating that caspase-1 is important in the pathogenesis of the disease. In addition, we demonstrate that intracerebroventricular administration of a caspase inhibitor delays disease progression and mortality in the mouse model of Huntington's disease.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Neurol Serv, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neuropathol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA; Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Emory University; Harvard University; Harvard Medical School	Friedlander, RM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg,Neurol Serv, Boston, MA 02115 USA.	rfriedlander@rics.bwh.harvard.edu						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Burne JF, 1996, J NEUROSCI, V16, P2064; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Harper PS, 1991, HUNTINGTONS DIS; Hurlbert MS, 1999, DIABETES, V48, P649, DOI 10.2337/diabetes.48.3.649; Kim M, 1999, J NEUROSCI, V19, P964; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Kosinski CM, 1997, EXP NEUROL, V144, P239, DOI 10.1006/exnr.1997.6441; Lee SC, 1995, BRAIN BEHAV IMMUN, V9, P345, DOI 10.1006/brbi.1995.1032; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lunkes A, 1998, HUM MOL GENET, V7, P1355, DOI 10.1093/hmg/7.9.1355; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Persichetti F, 1996, NEUROBIOL DIS, V3, P183, DOI 10.1006/nbdi.1996.0018; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Reddy PH, 1998, NAT GENET, V20, P198, DOI 10.1038/2510; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158	30	506	575	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					263	267		10.1038/20446	http://dx.doi.org/10.1038/20446			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353249				2022-12-01	WOS:000080427400057
J	Ferrari, G; Langen, H; Naito, M; Pieters, J				Ferrari, G; Langen, H; Naito, M; Pieters, J			A coat protein on phagosomes involved in the intracellular survival of mycobacteria	CELL			English	Article							ACTIN-BINDING-PROTEIN; GREEN FLUORESCENT PROTEIN; CLASS-II MOLECULES; WD-REPEAT; ENDOPLASMIC-RETICULUM; BACTERIAL PATHOGENS; VESICLE FORMATION; INVARIANT CHAIN; LYSOSOME FUSION; SEC13P COMPLEX	Mycobacteria are intracellular pathogens that can survive within macrophage phagosomes, thereby evading host defense strategies by largely unknown mechanisms. We have identified a WD repeat host protein that was recruited to and actively retained on phagosomes by living, but not dead, mycobacteria. This protein, termed TACO, represents a component of the phagosome coat that is normally released prior to phagosome fusion with or maturation into lysosomes. In macrophages lacking TACO, mycobacteria were readily transported to lysosomes followed by their degradation. Expression of TACO in nonmacrophages prevented lysosomal delivery of mycobacteria and prolonged their intracellular survival. Active retention of TACO on phagosomes by living mycobacteria thus represents a mechanism preventing cargo delivery to lysosomes, allowing mycobacteria to survive within macrophages.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Hoffmann La Roche Ag, CH-4002 Basel, Switzerland; Niigata Univ, Sch Med, Dept Pathol, Niigata 9518510, Japan	Roche Holding; Niigata University	Pieters, J (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.			Pieters, Jean/0000-0002-5284-9757				ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BERLIN RD, 1978, CELL, V15, P327, DOI 10.1016/0092-8674(78)90002-8; Beverley SM, 1996, CELL, V87, P787, DOI 10.1016/S0092-8674(00)81984-4; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; Blocker A, 1998, J CELL SCI, V111, P303; BRANDBORG LL, 1990, HEPATOLOGY TXB LIVER, P1086; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; Ferrari G, 1997, J CELL BIOL, V139, P1433, DOI 10.1083/jcb.139.6.1433; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; Grogan A, 1997, J CELL SCI, V110, P3071; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; Hasan Z, 1997, MOL MICROBIOL, V24, P545, DOI 10.1046/j.1365-2958.1997.3591731.x; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; ISOBE Y, 1977, ACTA HISTOCHEM CYTOC, V10, P161, DOI 10.1267/ahc.10.161; JOHNSON JP, 1981, EUR J IMMUNOL, V11, P825, DOI 10.1002/eji.1830111015; KIELIAN MC, 1982, J CELL BIOL, V93, P875, DOI 10.1083/jcb.93.3.875; KING SM, 1995, J CELL BIOL, V131, P399, DOI 10.1083/jcb.131.2.399; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1986, J EXP MED, V163, P54, DOI 10.1084/jem.163.1.54; Lefkovits I, 1985, IMMUNOLOGICAL METHOD, V3, P163; LI QW, 1994, J BIOL CHEM, V269, P31777; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NIBBERING PH, 1989, CLIN EXP IMMUNOL, V75, P147; NIIWA H, 1991, GENE, V108, P193; NORTH RJ, 1974, INFECT IMMUN, V10, P66, DOI 10.1128/IAI.10.1.66-71.1974; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; Rauchenberger R, 1997, CURR BIOL, V7, P215, DOI 10.1016/S0960-9822(97)70093-9; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; RUSSELL DG, 1995, TRENDS CELL BIOL, V5, P125, DOI 10.1016/S0962-8924(00)88963-1; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SMALL PLC, 1994, SCIENCE, V263, P637, DOI 10.1126/science.8303269; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; WARDLE EN, 1987, LIVER, V7, P63; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	63	431	454	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					435	447		10.1016/S0092-8674(00)80754-0	http://dx.doi.org/10.1016/S0092-8674(00)80754-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338208	Bronze			2022-12-01	WOS:000080299100005
J	Montaner, JSG				Montaner, JSG			Induction/maintenance treatment regimens for HIV - New England Journal of Medicine maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION; PROLONGED SUPPRESSION; INDUCTION THERAPY; VIRAL LOAD; ZIDOVUDINE; INDINAVIR; LAMIVUDINE; TRIAL; INDIVIDUALS; INITIATION		Univ British Columbia, St Pauls Hosp, Vancouver, BC V5Z 1M9, Canada; Canadian HIV Trials Network, Vancouver, BC, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, Vancouver, BC V5Z 1M9, Canada.							Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cooper DA, 1998, NEW ENGL J MED, V339, P1319, DOI 10.1056/NEJM199810293391810; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISCHL M, 1998, 12 WORLD AIDS C JUN; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hall DB, 1998, AIDS, V12, pF41, DOI 10.1097/00002030-199807000-00001; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Montaner JSG, 1998, LANCET, V352, P1919, DOI 10.1016/S0140-6736(98)07532-1; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MONTANER JSG, 1998, 38 INT C ANT AG CHEM; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; RENAUD M, 1998, 12 WORLD AIDS C JUN; STASZEWSKI S, 1998, 12 WORLD AIDS C JUN; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	24	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1680	1682		10.1001/jama.281.18.1680	http://dx.doi.org/10.1001/jama.281.18.1680			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328054				2022-12-01	WOS:000080161200002
J	Stevens, RJ; Publicover, NG; Smith, TK				Stevens, RJ; Publicover, NG; Smith, TK			Induction and organization of Ca2+ waves by enteric neural reflexes	NATURE			English	Article							PIG SMALL-INTESTINE; INTERSTITIAL-CELLS; ELECTRICAL RHYTHMICITY; CIRCULAR MUSCLE; NERVE PATHWAYS; DISTENSION; CAJAL; MUSCULARIS; MUCOSA; ILEUM	The motility of the gastrointestinal tract consists of local, nonpropulsive mixing (pendular or segmental) and propulsive (peristaltic) movements(1-5). It is generally considered that mixing movements are produced by intrinsic pacemakers which generate rhythmic contractions(4-6), and peristalsis by intrinsic excitatory and inhibitory neural reflex pathways(1-5,7,8), but the relationship between mixing and peristalsis is poorly understood4-6. Peristalsis is compromised in mice lacking interstitial cells of Cajal(9), suggesting that these pacemaker cells(10-14) may also be involved in neural reflexes. Here we show that mixing movements within longitudinal muscle result from spontaneously generated waves of elevated internal calcium concentration which originate from discrete locations (pacing sites), spread with anisotropic conduction velocities in all directions, and terminate by colliding with each other or with adjacent neurally suppressed regions. Excitatory neural reflexes control the spread of excitability by inducing new pacing sites and enhancing the overall frequency of pacing, whereas inhibitory reflexes suppress the ability of calcium waves to propagate. We provide evidence that the enteric nervous system organizes mixing movements to generate peristalsis, linking the neural regulation of pacemakers to both types of gut motility.	Univ Nevada, Sch Med, Biomed Engn Program, Reno, NV 89557 USA; Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Smith, TK (corresponding author), Univ Nevada, Sch Med, Biomed Engn Program, Reno, NV 89557 USA.			Smith, Terence/0000-0002-2120-2766				Bayliss W M, 1899, J Physiol, V24, P99; Bayliss WM, 1900, J PHYSIOL-LONDON, V26, P107; BURNSTOCK G, 1960, AM J PHYSIOL, V199, P553, DOI 10.1152/ajplegacy.1960.199.3.553; CHRISTENSEN J, 1994, PHYSL GASTROINTESTIN, V1, P991; COSTA M, 1976, N-S ARCH PHARMACOL, V294, P47, DOI 10.1007/BF00692784; COSTA M, 1982, MEDIATORS DRUGS GAST, P279; COUSINS HM, 1993, J PHYSIOL-LONDON, V471, P61, DOI 10.1113/jphysiol.1993.sp019891; GILLESPIE JS, 1962, J PHYSIOL-LONDON, V162, P54, DOI 10.1113/jphysiol.1962.sp006914; HIRST GDS, 1975, J PHYSIOL-LONDON, V244, P113, DOI 10.1113/jphysiol.1975.sp010786; HOLMAN ME, 1958, J PHYSIOL-LONDON, V141, P464, DOI 10.1113/jphysiol.1958.sp005989; HOLMAN ME, 1981, SMOOTH MUSCLE ASSESS, P311; Horowitz B, 1999, ANNU REV PHYSIOL, V61, P19, DOI 10.1146/annurev.physiol.61.1.19; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Huizinga JD, 1998, J PHYSIOL-LONDON, V506, P843, DOI 10.1111/j.1469-7793.1998.843bv.x; Koh SD, 1998, J PHYSIOL-LONDON, V513, P203, DOI 10.1111/j.1469-7793.1998.203by.x; KOSTERLITZ HW, 1959, J PHYSIOL-LONDON, V146, P369, DOI 10.1113/jphysiol.1959.sp006198; MACKENNA B R, 1972, Journal of Physiology (Cambridge), V220, P33; OZAKI H, 1991, AM J PHYSIOL, V260, pC917, DOI 10.1152/ajpcell.1991.260.5.C917; Publicover NG, 1995, PACEMAKER ACTIVITY I, P175; SMIH TK, 1998, J PHYSIOL-LONDON, V506, P563; SMITH T, 1995, TXB GASTROENTEROLOGY, P234; SMITH TK, 1987, AM J PHYSIOL, V252, pC290, DOI 10.1152/ajpcell.1987.252.3.C290; Smith TK, 1998, J PHYSIOL-LONDON, V512, P893, DOI 10.1111/j.1469-7793.1998.893bd.x; SMITH TK, 1988, J AUTONOM NERV SYST, V25, P205, DOI 10.1016/0165-1838(88)90025-2; SMITH TK, 1992, J NEUROSCI, V12, P1502; Thomsen L, 1998, NAT MED, V4, P848, DOI 10.1038/nm0798-848; TOMITA T, 1966, J PHYSIOL-LONDON, V183, P450, DOI 10.1113/jphysiol.1966.sp007876; Ward SM, 1997, J PHYSIOL-LONDON, V505, P241, DOI 10.1111/j.1469-7793.1997.241bc.x	28	55	55	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					62	66		10.1038/19973	http://dx.doi.org/10.1038/19973			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331390				2022-12-01	WOS:000080172100055
J	Tsukaguchi, H; Tokui, T; Mackenzie, B; Berger, UV; Chen, XZ; Wang, YX; Brubaker, RF; Hediger, MA				Tsukaguchi, H; Tokui, T; Mackenzie, B; Berger, UV; Chen, XZ; Wang, YX; Brubaker, RF; Hediger, MA			A family of mammalian Na+-dependent L-ascorbic acid transporters	NATURE			English	Article							NA+/GLUCOSE COTRANSPORTER SGLT1; DEHYDROASCORBIC ACID; BIOCHEMICAL FUNCTIONS; AQUEOUS-HUMOR; VITAMIN-C; CELLS; SPECIFICITY; MECHANISM; CURRENTS	Vitamin C (L-ascorbic acid) is essential for many enzymatic reactions, in which it serves to maintain prosthetic metal ions in their reduced forms (for example, Fe2+, Cu+)(1,2), and for scavenging free radicals in order to protect tissues from oxidative damage(3). The facilitative sugar transporters of the GLUT type can transport the oxidized form of the vitamin, dehydroascorbic acid(4-6), but these transporters are unlikely to allow significant physiological amounts of vitamin C to be taken up in the presence of normal glucose concentrations, because the vitamin is present in plasma essentially only in its reduced form(7). Here we describe the isolation of two L-ascorbic acid transporters, SVCT1 and SVCT2, from rat complementary DNA libraries, as the first step in investigating the importance of L-ascorbic acid transport in regulating the supply and metabolism of vitamin C. We find that SVCT1 and SVCT2 each mediate concentrative, high-affinity L-ascorbic acid transport that is stereospecific and is driven by the Na+ electrochemical gradient. Despite their close sequence homology and similar functions, the two isoforms of the transporter are discretely distributed: SVCT1 is mainly confined to epithelial systems (intestine, kidney, liver), whereas SVCT2 serves a host of metabolically active cells and specialized tissues in the brain, ey and other organs.	Brigham & Womens Hosp, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Dept Ophthalmol, Rochester, MN 55905 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Mayo Clinic	Hediger, MA (corresponding author), Brigham & Womens Hosp, Dept Med, Membrane Biol Program, 75 Francis St, Boston, MA 02115 USA.			Hediger, Matthias/0000-0003-1946-027X; Mackenzie, Bryan/0000-0002-9661-8838				Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; BOWERSKOMRO DM, 1991, J NUTR, V121, P57, DOI 10.1093/jn/121.1.57; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DIALLINAS G, 1995, J BIOL CHEM, V270, P8610; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; FRANCESCHI RT, 1995, AM J PHYSIOL-CELL PH, V268, pC1430, DOI 10.1152/ajpcell.1995.268.6.C1430; GUIMARAES MJ, 1995, DEVELOPMENT, V121, P3335; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HAMMARSTROM LARS, 1966, ACTA PHYSIOL SCAND, V70, P1, DOI 10.1111/j.1748-1716.1966.tb03661.x; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HELBIG H, 1989, AM J PHYSIOL, V256, pC44, DOI 10.1152/ajpcell.1989.256.1.C44; KODAMA T, 1985, OPHTHALMIC RES, V17, P331, DOI 10.1159/000265396; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; MACKENZIE B, 1999, BIOMEMBRANE TRANSPOR, P327; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; PADH H, 1991, NUTR REV, V49, P65, DOI 10.1111/j.1753-4887.1991.tb07407.x; REISS GR, 1986, ARCH OPHTHALMOL-CHIC, V104, P753; Romero MF, 1998, METHOD ENZYMOL, V296, P17; ROSE RC, 1991, COMP BIOCHEM PHYS A, V100, P273, DOI 10.1016/0300-9629(91)90470-W; ROSE RC, 1993, FASEB J, V7, P1135, DOI 10.1096/fasebj.7.12.8375611; ROSE RC, 1997, VITAMIN C HLTH DIS, P143; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Segel IH, 1976, BIOCH CALCULATIONS; TOGGENBURGER G, 1981, BIOCHIM BIOPHYS ACTA, V646, P433, DOI 10.1016/0005-2736(81)90312-6; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6	29	687	715	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					70	75		10.1038/19986	http://dx.doi.org/10.1038/19986			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331392				2022-12-01	WOS:000080172100057
J	Southgate, MT				Southgate, MT			Messages	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1571	1571		10.1001/jama.281.17.1571	http://dx.doi.org/10.1001/jama.281.17.1571			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235136				2022-12-01	WOS:000080025900001
J	Guidotti, LG; Rochford, R; Chung, J; Shapiro, M; Purcell, R; Chisari, FV				Guidotti, LG; Rochford, R; Chung, J; Shapiro, M; Purcell, R; Chisari, FV			Viral clearance without destruction of infected cells during acute HBV infection	SCIENCE			English	Article							HEPATITIS-B VIRUS; TRANSGENIC MICE; INTRACELLULAR INACTIVATION; T-CELLS; HEPATOCYTE; RECOVERY; CHIMPANZEES; REPLICATION; EXPRESSION; THERAPY	Viral clearance during hepatitis B virus (HBV) infection has been thought to reflect the destruction of infected hepatocytes by CD8(+) T lymphocytes. However, in this study, HBV DNA was shown to Largely disappear from the Liver and the blood of acutely infected chimpanzees Long before the peak of T cell infiltration and most of the Liver disease. These results demonstrate that noncytopathic antiviral mechanisms contribute to viral clearance during acute viral hepatitis by purging HBV replicative intermediates from the cytoplasm and covalently closed circular viral DNA from the nucleus of infected cells.	Scripps Res Inst, Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Bioqual Inc, Rockville, MD 20850 USA; NIH, Bethesda, MD 20892 USA	Scripps Research Institute; University of Michigan System; University of Michigan; BIOQUAL Inc.; National Institutes of Health (NIH) - USA	Chisari, FV (corresponding author), Scripps Res Inst, Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.		Chisari, Francis V/A-3086-2008; Guidotti, Luca G. G/I-8542-2018	Guidotti, Luca G. G/0000-0002-0205-2678; Chisari, Francis/0000-0002-4832-1044	NCI NIH HHS [R37 CA40489] Funding Source: Medline; NIAID NIH HHS [R01 AI20001, R01 AI40696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040696, R01AI020001] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER LF, 1975, J INFECT DIS, V132, P451, DOI 10.1093/infdis/132.4.451; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Bertoni R, 1998, J IMMUNOL, V161, P4447; BOCK CT, 1994, VIRUS GENES, V8, P215, DOI 10.1007/BF01703079; Cavanaugh VJ, 1998, J VIROL, V72, P2630, DOI 10.1128/JVI.72.4.2630-2637.1998; FEUTREN G, 1984, J IMMUNOL METHODS, V75, P85, DOI 10.1016/0022-1759(84)90227-8; FOUREL I, 1994, J VIROL, V68, P8321, DOI 10.1128/JVI.68.12.8321-8330.1994; Franco A, 1997, J IMMUNOL, V159, P2001; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Guidotti LG, 1996, CURR OPIN IMMUNOL, V8, P478, DOI 10.1016/S0952-7915(96)80034-3; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; Guidotti LG, 1996, P NATL ACAD SCI USA, V93, P4589, DOI 10.1073/pnas.93.10.4589; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; GUIDOTTI LG, UNPUB; HUME DA, 1987, J LEUKOCYTE BIOL, V42, P474, DOI 10.1002/jlb.42.5.474; JILBERT AR, 1992, J VIROL, V66, P1377, DOI 10.1128/JVI.66.3.1377-1388.1992; KAJINO K, 1994, J VIROL, V68, P5792, DOI 10.1128/JVI.68.9.5792-5803.1994; MORALEDA G, 1997, J VIROL, V71, P9292; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NEWBOLD JE, 1995, J VIROL, V69, P3350, DOI 10.1128/JVI.69.6.3350-3357.1995; PIGNATELLI M, 1986, HEPATOLOGY, V6, P349, DOI 10.1002/hep.1840060303; Rehermann B, 1996, NAT MED, V2, P1104, DOI 10.1038/nm1096-1104; Rochford R, 1997, VIRAL IMMUNOL, V10, P183, DOI 10.1089/vim.1997.10.183; Tay CH, 1998, CURR TOP MICROBIOL, V230, P193; TUTTLEMAN JS, 1986, CELL, V47, P451, DOI 10.1016/0092-8674(86)90602-1	25	960	1051	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					825	829		10.1126/science.284.5415.825	http://dx.doi.org/10.1126/science.284.5415.825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221919				2022-12-01	WOS:000080056200053
J	Hirayama, T; Kieber, JJ; Hirayama, N; Kogan, M; Guzman, P; Nourizadeh, S; Alonso, JM; Dailey, WP; Dancis, A; Ecker, JR				Hirayama, T; Kieber, JJ; Hirayama, N; Kogan, M; Guzman, P; Nourizadeh, S; Alonso, JM; Dailey, WP; Dancis, A; Ecker, JR			Responsive-to-antagonist1, a Menkes/Wilson disease-related copper transporter, is required for ethylene signaling in Arabidopsis	CELL			English	Article							RECEPTOR GENE FAMILY; MENKES-DISEASE; SACCHAROMYCES-CEREVISIAE; RESPONSE PATHWAY; CANDIDATE GENE; BIOCHEMICAL-CHARACTERIZATION; FUNCTIONAL EXPRESSION; TRANSDUCTION PATHWAY; IRON UPTAKE; PROTEIN	Ethylene is an important regulator of plant growth. We identified an Arabidopsis mutant, responsive-to-antagonist1 (ran1), that shows ethylene phenotypes in response to treatment with trans-cyclooctene, a potent receptor antagonist. Genetic epistasis studies revealed an early requirement for RAN1 in the ethylene pathway. RAN1 was cloned and found to encode a protein with similarity to copper-transporting P-type ATPases, including the human Menkes/Wilson proteins and yeast Ccc2p. Expression of RAN1 complemented the defects of a ccc2 Delta mutant, demonstrating its function as a copper transporter. Transgenic CaMV 35S::RAN1 plants showed constitutive expression of ethylene responses, due to cosuppression of RAN1. These results provide an in planta demonstration that ethylene signaling requires copper and reveal that RAN1 acts by delivering copper to create functional hormone receptors.	Univ Penn, Div Hematol Oncol, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Div Hematol Oncol, Dept Chem, Philadelphia, PA 19104 USA; Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Ecker, JR (corresponding author), Univ Penn, Div Hematol Oncol, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA.		HIRAYAMA, Takashi/B-2496-2011; Alonso, Jose M/K-6826-2014; Kieber, Joseph/GLN-6328-2022; Guzman, Plinio/A-3073-2012; Ecker, Joseph R/B-9144-2008	HIRAYAMA, Takashi/0000-0002-3868-2380; Alonso, Jose M/0000-0001-7087-1571; Kieber, Joseph/0000-0002-5766-812X; Ecker, Joseph R/0000-0001-5799-5895				Abeles F.B., 2012, ETHYLENE PLANT BIOL; BAULCOMBE DC, 1986, NATURE, V321, P446, DOI 10.1038/321446a0; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEYER EM, 1976, PLANT PHYSIOL, V58, P268, DOI 10.1104/pp.58.3.268; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; CHELLY J, 1993, NAT GENET, V5, P317, DOI 10.1038/ng1293-317; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; DANCIS A, 1994, J BIOL CHEM, V269, P25660; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Gamble RL, 1998, P NATL ACAD SCI USA, V95, P7825, DOI 10.1073/pnas.95.13.7825; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; Hua J, 1998, PLANT CELL, V10, P1321, DOI 10.1105/tpc.10.8.1321; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ITZHAKI H, 1993, PLANT MOL BIOL, V22, P43, DOI 10.1007/BF00038994; Johnson PR, 1998, ANNU REV GENET, V32, P227, DOI 10.1146/annurev.genet.32.1.227; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; ROMAN G, 1995, GENETICS, V139, P1393; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; Sambongi Y, 1997, J BIOCHEM-TOKYO, V121, P1169, DOI 10.1093/oxfordjournals.jbchem.a021711; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Sisler EC, 1996, PLANT GROWTH REGUL, V18, P79, DOI 10.1007/BF00028491; SISLER EC, 1990, PLANT HORMONE ETHYLE, P81; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; THOMPSON JS, 1983, J AM CHEM SOC, V105, P3522, DOI 10.1021/ja00349a026; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	46	287	315	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					383	393		10.1016/S0092-8674(00)80747-3	http://dx.doi.org/10.1016/S0092-8674(00)80747-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319818	Bronze			2022-12-01	WOS:000080100500011
J	Mannick, JB; Hausladen, A; Liu, LM; Hess, DT; Zeng, M; Miao, QX; Kane, LS; Gow, AJ; Stamler, JS				Mannick, JB; Hausladen, A; Liu, LM; Hess, DT; Zeng, M; Miao, QX; Kane, LS; Gow, AJ; Stamler, JS			Fas-induced caspase denitrosylation	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; NITRIC-OXIDE; S-NITROSYLATION; INHIBITS APOPTOSIS; ACTIVATION; SUPPRESSION; MECHANISMS; P21(RAS); RECEPTOR; NEURONS	Only a few intracellular S-nitrosylated proteins have been identified, and it is unknown if protein S-nitrosylation/denitrosylation is a component of signal transduction cascades. Caspase-3 zymogens were found to be S-nitrosylated on their catalytic-site cysteine in unstimulated human cell Lines and denitrosylated upon activation of the Fas apoptotic pathway. Decreased caspase-3 S-nitrosylation was associated with an increase in intracellular caspase activity. Fas therefore activates caspase-3 not only by inducing the cleavage of the caspase zymogen to its active subunits, but also by stimulating the denitrosylation of its active-site thiol. Protein S-nitrosylation/denitrosylation can thus serve as a regulatory process in signal transduction pathways.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Resp Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Div Cardiovasc Med, Durham, NC 27710 USA	Harvard University; Dana-Farber Cancer Institute; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Mannick, JB (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Gow, Andrew/N-8566-2013; Gow, Andrew/AAR-2309-2020	Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158; Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL52529, HL59130] Funding Source: Medline; NIGMS NIH HHS [GM57601-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529, R01HL059130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM057601] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; Boulakia CA, 1996, ONCOGENE, V12, P529; Buga GM, 1998, AM J PHYSIOL-REG I, V275, pR1256, DOI 10.1152/ajpregu.1998.275.4.R1256; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CELL GROWTH DIFFER, V9, P415; Estevez AG, 1998, J NEUROSCI, V18, P3708; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GENEVIVA GD, 1998, AM J PHYSIOL, V275, pL717; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Z, 1998, NEURON, V20, P1039, DOI 10.1016/S0896-6273(00)80484-5; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MANNICK JA, UNPUB; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MANNICK JB, 1997, J BIOL CHEM, V272, P24124; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; Ogura T, 1997, BIOCHEM BIOPH RES CO, V236, P365, DOI 10.1006/bbrc.1997.6948; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P8087, DOI 10.1073/pnas.89.17.8087; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Tenneti L, 1997, NEUROSCI LETT, V236, P139, DOI 10.1016/S0304-3940(97)00780-5; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773	35	642	674	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					651	654		10.1126/science.284.5414.651	http://dx.doi.org/10.1126/science.284.5414.651			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213689				2022-12-01	WOS:000079951100047
J	McIntire, DD; Bloom, SL; Casey, BM; Leveno, KJ				McIntire, DD; Bloom, SL; Casey, BM; Leveno, KJ			Birth weight in relation to morbidity and mortality among newborn infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAUTERINE GROWTH-RETARDATION; FETAL; PREGNANCIES; RISK	Background At any given gestational age, infants with low birth weight have relatively high morbidity and mortality. It is not known, however, whether there is a threshold weight below which morbidity and mortality are significantly greater, or whether that threshold varies with gestational age. Methods We analyzed the neonatal outcomes of death, five-minute Apgar score, umbilical-artery blood pH, and morbidity due to prematurity for all singleton infants delivered at Parkland Hospital, Dallas, between January 11 1988, and August 31, 1996. A distribution of birth weights according to week of gestation at birth was created. Infants in the 26th through 75th percentiles for weight served as the reference group. Data on preterm infants (those born at 24 to 36 weeks of gestation) were analyzed separately from data on infants delivered at term (37 or more weeks of gestation). Results A total of 122,754 women and adolescents delivered singleton live infants without malformations between 24 and 43 weeks of gestation. Among the 12,317 preterm infants who were analyzed, there was no specific birth-weight percentile at which morbidity and mortality increased. Among 82,361 infants who were born at term and whose birth weights were at or below the 75th percentile, however, the rate of neonatal death increased from 0.03 percent in the reference group (26th through 75th percentile for weight) to 0.3 percent for those with birth weights at or below the 3rd percentile (P<0.001). The incidence of five-minute Apgar scores of 3 or less and umbilical-artery blood pH values of 7.0 or less was approximately doubled for infants at or below the 3rd birth-weight percentile (P=0.003 and P<0.001, respectively). The incidence of intubation at birth, seizures during the first day of life, and sepsis was also significantly increased among term infants with birth weights at or below the 3rd percentile. These differences persisted after adjustment for the mother's race and parity and the infant's sex. Conclusions Mortality and morbidity are increased among infants born at term whose birth weights are at or below the 3rd percentile for their gestational age. (N Engl J Med 1999;340:1234-8.) (C) 1999, Massachusetts Medical Society.	Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	McIntire, DD (corresponding author), Univ Texas, SW Med Ctr, Dept Obstet & Gynecol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							BATTAGLI.FC, 1967, J PEDIATR-US, V71, P159, DOI 10.1016/S0022-3476(67)80066-0; BREART G, 1982, DEV PHARMACOL THERAP, V4, P116, DOI 10.1159/000457366; CUNNINGHAM FG, 1997, WILLIAMS OBSTET, P839; GARDOSI J, 1992, LANCET, V339, P283, DOI 10.1016/0140-6736(92)91342-6; JIMENEZ JM, 1983, OBSTET GYNECOL, V61, P438; KRAMER MS, 1990, PEDIATRICS, V86, P707; LAATIKAINEN TJ, 1988, AM J OBSTET GYNECOL, V159, P891, DOI 10.1016/S0002-9378(88)80163-7; LUBCHENCO LO, 1963, PEDIATRICS, V32, P793; Manning F. A., 1995, FETAL MED PRINCIPLES, P317; *NIH, 1984, NIH PUBL; Piper JM, 1996, OBSTET GYNECOL, V87, P169, DOI 10.1016/0029-7844(95)00400-9; Seeds JW, 1998, AM J OBSTET GYNECOL, V178, P658, DOI 10.1016/S0002-9378(98)70475-2; SPINILLO A, 1995, J REPROD MED, V40, P209; USHER R, 1969, J PEDIATR-US, V74, P901, DOI 10.1016/S0022-3476(69)80224-6; VELLEMAN PF, 1980, J AM STAT ASSOC, V75, P609, DOI 10.2307/2287657	15	875	899	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1234	1238		10.1056/NEJM199904223401603	http://dx.doi.org/10.1056/NEJM199904223401603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210706				2022-12-01	WOS:000079833800003
J	Weber, TK; Chin, HM; Rodriguez-Bigas, M; Keitz, B; Gilligan, R; O'Malley, L; Urf, E; Diba, N; Pazik, J; Petrelli, NJ				Weber, TK; Chin, HM; Rodriguez-Bigas, M; Keitz, B; Gilligan, R; O'Malley, L; Urf, E; Diba, N; Pazik, J; Petrelli, NJ			Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONPOLYPOSIS COLON-CANCER; DNA MISMATCH REPAIR; MLH1 MUTATIONS; HNPCC FAMILIES; SSCP ANALYSIS; HEREDITARY; GENE; SURVIVAL; HOMOLOG; LOCUS	Context Germline mutations of the DNA mismatch repair(MMR) genes hMLH1 and hMSH2 have been shown to cosegregate with the colorectal cancer phenotype in multiple hereditary non polyposis colorectal cancer (HNPCC) pedigrees. However, the frequency of these mutations among African American patients with colorectal cancer is unknown. Objective To investigate the frequency of germline alterations of the DNA MMR genes hMLH1 and hMSH2 among African Americans affected by HNPCC and early-age onset colorectal cancer. Design, Setting, and Patients Forty unrelated African American HNPCC and early-age onset colorectal cancer patients (8 women, 3 men) were identified from the cancer registry at a National Cancer institute-designated referral center, 11 of whom were available for and agreed to study participation from January 1997 to February 1998. The mean age of the subjects was 44 years. An additional 50 age- and sex-matched African Americans without personal or family history of colorectal, endometrial, ovarian, urinary tract, or upper gastrointestinal tract malignancy were also studied as a polymorphism control population. In all subjects, genomic DNA was amplified by polymerase chain reaction for all hMLH1 and hMSH2 exons and screened using single-strand conformation polymorphism (SSCP) analysis. Samples demonstrating significant SSCP shifts underwent automated nucleotide sequencing analysis. Main Outcome Measure Frequency of hMLH1 and hMSH2 germline alterations in the affected and control subjects. Results Germline hMLH1 and hMSH2 mutations were detected in 3 (27%) of the African American colorectal cancer probands studied. Each mutation was novel. Two hMLH1 (an A-->T transversion at codon 26 and a GG-->AT substitution across codons 177 and 178) mutations and 1 hMSH2 mutation (a C-->T transition at codon 389) were identified in 3 female study subjects. Six other hMLH1 and hMSH2 alterations were detected but were presumed to be polymorphisms. Neither missense mutation (at codons 26 and 389) was detected in the control population. Conclusions The results of our analysis support an association between the 3 mutations reported and predisposition to colorectal cancer. Further studies are needed to define DNA MMR gene-associated colorectal cancer in African Americans, an understudied population at increased risk of fatal colorectal cancer.	Roswell Pk Canc Inst, Div Surg Oncol, Buffalo, NY 14263 USA; Catholic Univ, Coll Med, St Vincents Hosp, Dept Surg, Suwon, South Korea; Univ Manchester, Fac Med, Manchester, Lancs, England	Roswell Park Cancer Institute; Catholic University of Korea; University of Manchester	Weber, TK (corresponding author), Roswell Pk Canc Inst, Div Surg Oncol, Elm & Carlton St, Buffalo, NY 14263 USA.	weber@sc3102.med.buffalo.edu			NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck NE, 1997, HUM GENET, V99, P219, DOI 10.1007/s004390050343; BORING CC, 1992, CA-CANCER J CLIN, V42, P7, DOI 10.3322/canjclin.42.1.7; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; Cooper GS, 1997, CANCER EPIDEM BIOMAR, V6, P283; FAN E, 1993, MUTAT RES, V288, P85, DOI 10.1016/0027-5107(93)90210-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Froggatt NJ, 1996, EUR J CANCER, V32A, P178, DOI 10.1016/0959-8049(95)00464-5; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; KohonenCorish M, 1996, AM J HUM GENET, V59, P818; KOLODNER RD, 1995, CANCER RES, V55, P242; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; Lewis CM, 1996, CANCER RES, V56, P1382; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; Mauillon JL, 1996, CANCER RES, V56, P5728; MAYBERRY RM, 1995, J NATL CANCER I, V87, P1686, DOI 10.1093/jnci/87.22.1686; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moisio AL, 1996, AM J HUM GENET, V59, P1243; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NAROD SA, 1991, LANCET, V338, P82; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1995, GASTROENTEROLOGY, V109, P2031, DOI 10.1016/0016-5085(95)90774-2; Percesepe A, 1997, INT J CANCER, V71, P373, DOI 10.1002/(SICI)1097-0215(19970502)71:3<373::AID-IJC12>3.0.CO;2-H; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PURTILO DT, 1987, CANCER GENET CYTOGEN, V24, P11, DOI 10.1016/0165-4608(87)90079-3; RodriguezBigas MA, 1996, DIS COLON RECTUM, V39, P649, DOI 10.1007/BF02056944; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TANNERGARD P, 1995, CANCER RES, V55, P6092; Tomlinson IPM, 1997, J MED GENET, V34, P39, DOI 10.1136/jmg.34.1.39; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Viel A, 1997, GENE CHROMOSOME CANC, V18, P8, DOI 10.1002/(SICI)1098-2264(199701)18:1<8::AID-GCC2>3.0.CO;2-7; Wahlberg SS, 1997, INT J CANCER, V74, P134, DOI 10.1002/(SICI)1097-0215(19970220)74:1<134::AID-IJC22>3.3.CO;2-1; Warthin AS, 1925, J CANCER RES CLIN, V9, P279; Watson P, 1998, CANCER, V83, P259, DOI 10.1002/(SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.0.CO;2-L; Weber T, 1996, LANCET, V348, P465, DOI 10.1016/S0140-6736(05)64545-X; Weber TK, 1997, CANCER RES, V57, P3798; White RL, 1998, CANCER RES, V58, P4038; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1996, AM J HUM GENET, V58, P300; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804; Xia L, 1996, CANCER RES, V56, P2289; Yamamoto H, 1998, CANCER RES, V58, P997; 1999, MSH2 MLH1 MUTATION D	61	38	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2316	2320		10.1001/jama.281.24.2316	http://dx.doi.org/10.1001/jama.281.24.2316			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386556	Bronze			2022-12-01	WOS:000080925600031
J	Bradley, KA; Merrill, JO				Bradley, KA; Merrill, JO			"Doctor, is wine good for my heart?"	LANCET			English	Editorial Material							ALCOHOL-CONSUMPTION; DRINKING; WOMEN; AUDIT; RISK		VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev & Primary & Specialty Med Car, Seattle, WA 98108 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bradley, KA (corresponding author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev & Primary & Specialty Med Car, Seattle, WA 98108 USA.							Andreasson S, 1998, ALCOHOL CLIN EXP RES, V22, p359S, DOI 10.1111/j.1530-0277.1998.tb04391.x; Bradley KA, 1998, J GEN INTERN MED, V13, P627, DOI 10.1046/j.1525-1497.1998.cr187.x; Bradley KA, 1998, JAMA-J AM MED ASSOC, V280, P166, DOI 10.1001/jama.280.2.166; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; O'Connor PG, 1998, NEW ENGL J MED, V338, P592, DOI 10.1056/NEJM199802263380907; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Samet JH, 1996, ARCH INTERN MED, V156, P2287, DOI 10.1001/archinte.156.20.2287; Volk RJ, 1997, ADDICTION, V92, P197, DOI 10.1046/j.1360-0443.1997.9221978.x; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663	9	6	6	2	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1815	1816		10.1016/S0140-6736(99)90188-5	http://dx.doi.org/10.1016/S0140-6736(99)90188-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359402				2022-12-01	WOS:000080667800005
J	Miller, HI				Miller, HI			Policy forum: Genetic engineering - A rational approach to labeling biotech-derived foods	SCIENCE			English	Article									Stanford Univ, Hoover Inst, Stanford, CA 94305 USA; Competit Enterprise Inst, Washington, DC 20036 USA	Stanford University	Miller, HI (corresponding author), Stanford Univ, Hoover Inst, Stanford, CA 94305 USA.	miller@hoover.stanford.edu						AYERS T, 1998, SCIENCE, V281, P714; CHRISPEELS M, 1994, PLANTS GENES AGR, P348; *CTR FOOD SAF APPL, 1996, FOODS DER NEW PLANT; *FOOD DRUG LAW I, 1993, COMP FOOD DRUG LAWS, P30; GOODMAN RM, 1987, SCIENCE, V236, P48, DOI 10.1126/science.236.4797.48; *I FOOD TECHN, 1996, APPR OV PLANTS INH T; JAMES C, 1998, ISAAA BRIEFS, V8; MILLER HI, 1993, JAMA-J AM MED ASSOC, V269, P910; MILLER HI, 1997, POLICY CONTROVERSY B, pCH3; National Research Council, 1989, FIELD TEST GEN MOD O; *NIH OFF DIR, 1992, NAT BIOT POL BOARD R, pE27; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; TAKEMOTO K, 1994, GENOBASE 1 1 ESCHERI; WILLIAMS N, 1998, SCIENCE, V281, P769; 1992, FED REG         0529, V57, P22984	15	14	15	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1999	284	5419					1471	1472		10.1126/science.284.5419.1471	http://dx.doi.org/10.1126/science.284.5419.1471			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10383324				2022-12-01	WOS:000080548100020
J	Zhao, YU; Sheng, HZ; Amini, R; Grinberg, A; Lee, E; Huang, SP; Taira, M; Westphal, H				Zhao, YU; Sheng, HZ; Amini, R; Grinberg, A; Lee, E; Huang, SP; Taira, M; Westphal, H			Control of hippocampal morphogenesis and neuronal differentiation by the LIM homeobox gene Lhx5	SCIENCE			English	Article							EMBRYONIC CEREBRAL-CORTEX; DENTATE GYRUS; C-ELEGANS; MICE; EXPRESSION; FOREBRAIN; HOMEODOMAIN; MULTIPLE; REELER; CELLS	The mammalian hippocampus contains the neural circuitry that is crucial for cognitive functions such as Learning and memory. The development of such circuitry is dependent on the generation and correct placement of the appropriate number and types of neurons. Mice Lacking function of the LIM homeobox gene Lhx5 showed a defect in hippocampus development. Hippocampal neural precursor cells were specified and proliferated, but many of them failed to either exit the cell cycle or to differentiate and migrate properly. Lhx5 is therefore essential for the regulation of precursor cell proliferation and the control of neuronal differentiation and migration during hippocampal development.	NICHHD, Lab Mammalian Genes & Dev, Bethesda, MD 20892 USA; NICHHD, Genet Mol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Westphal, H (corresponding author), NICHHD, Lab Mammalian Genes & Dev, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000071] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000071] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAYER SA, 1980, J COMP NEUROL, V190, P115, DOI 10.1002/cne.901900108; Bertuzzi S, 1996, GENOMICS, V36, P234, DOI 10.1006/geno.1996.0458; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CAVINESS VS, 1973, J COMP NEUROL, V151, P113, DOI 10.1002/cne.901510203; CAVINESS VS, 1979, J COMP NEUROL, V185, P423; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Furuta Y, 1997, DEVELOPMENT, V124, P2203; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Grove EA, 1998, DEVELOPMENT, V125, P2315; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; Hobert O, 1998, J NEUROSCI, V18, P2084; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nakajima K, 1997, P NATL ACAD SCI USA, V94, P8196, DOI 10.1073/pnas.94.15.8196; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Pellegrini M, 1996, DEVELOPMENT, V122, P3893; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Porter FD, 1997, DEVELOPMENT, V124, P2935; ROBINSON GW, 1991, NEW BIOL, V3, P1183; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng HZ, 1997, DEV DYNAM, V208, P266, DOI 10.1002/(SICI)1097-0177(199702)208:2<266::AID-AJA13>3.0.CO;2-1; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; SORIANO E, 1994, J COMP NEUROL, V342, P571, DOI 10.1002/cne.903420406; TOYAMA R, 1995, DEV BIOL, V170, P583, DOI 10.1006/dbio.1995.1238; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; Yoshida M, 1997, DEVELOPMENT, V124, P101	35	128	134	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1155	1158		10.1126/science.284.5417.1155	http://dx.doi.org/10.1126/science.284.5417.1155			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325223				2022-12-01	WOS:000080359100033
J	Jacques, PF; Selhub, J; Bostom, AG; Wilson, PWF; Rosenberg, IH				Jacques, PF; Selhub, J; Bostom, AG; Wilson, PWF; Rosenberg, IH			The effect of folic acid fortification on plasma folate and total homocysteine concentrations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURAL-TUBE DEFECTS; CORONARY HEART-DISEASE; SERUM TOTAL HOMOCYSTEINE; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; RISK FACTOR; MICROBIOLOGICAL ASSAY; LACTOBACILLUS-CASEI; SUPPLEMENTATION; PREVENTION	Background In 1996, the Food and Drug Administration issued a regulation requiring all enriched grain products to be fortified with folic acid to reduce the risk of neural-tube defects in newborns. Fortification (140 mu g per 100 g) began in 1996, and the process was essentially complete by mid-1997. Methods To assess the effect of folic acid fortification on folate status, we measured plasma folate and total homocysteine concentrations (a sensitive marker of folate status) using blood samples from the fifth examination (January 1991 to December 1994) of the Framingham Offspring Study cohort for baseline values and the sixth examination (January 1995 to August 1998) for follow-up values. We divided the cohort into two groups on the basis of the date of their follow-up examination: the study group consisted of 350 subjects who were seen after fortification (September 1997 to March 1998), and the control group consisted of 756 subjects who were seen before fortification (January 1995 to September 1996). Results Among the subjects in the study group who did not use vitamin supplements, the mean folate concentrations increased from 4.6 to 10.0 ng per milliliter (11 to 23 nmol per liter) (P<0.001) from the baseline visit to the follow-up visit, and the prevalence of low folate concentrations (<3 ng per milliliter [7 nmol per liter]) decreased from 22.0 to 1.7 percent (P< 0.001). The mean total homocysteine concentration decreased from 10.1 to 9.4 mu mol per liter during this period (P<0.001), and the prevalence of high homocysteine concentrations (>13 mu mol per liter) decreased from 18.7 to 9.8 percent (P<0.001). In the control group, there were no statistically significant changes in concentrations of folate or homocysteine. Conclusions The fortification of enriched grain products with folic acid was associated with a substantial improvement in folate status in a population of middle-aged and older adults. (N Engl J Med 1999;340:1449-54.) (C) 1999, Massachusetts Medical Society.	Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Mem Hosp Rhode Isl, Div Gen Internal Med, Providence, RI USA; NHLBI, Framingham Heart Study, Framingham, MA USA	Tufts University; United States Department of Agriculture (USDA); Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rosenberg, IH (corresponding author), Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016		NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Afman L, 1999, FASEB J, V13, pA891; [Anonymous], 1996, FED REGISTER, V61, P8781; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Gregory JF, 1998, FASEB J, V12, pA511; HERBERT V, 1994, MODERN NUTR HLTH DIS, V1, P402; HOPKINS PN, 1995, ARTERIOSCL THROM VAS, V15, P1314, DOI 10.1161/01.ATV.15.9.1314; HORNE DW, 1988, CLIN CHEM, V34, P2357; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Oakley GP, 1998, NEW ENGL J MED, V338, P1060, DOI 10.1056/NEJM199804093381509; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; *SAS I, 1989, SAS US GUID VERS 6; Schorah CJ, 1998, EUR J CLIN NUTR, V52, P407, DOI 10.1038/sj.ejcn.1600576; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SHIN YS, 1983, CLIN CHIM ACTA, V127, P77, DOI 10.1016/0009-8981(83)90077-3; SMITHELLS RW, 1983, LANCET, V1, P1027; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; Tucker KL, 1997, JAMA-J AM MED ASSOC, V277, P714; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; VERGEL RG, 1990, PRENATAL DIAG, V10, P149, DOI 10.1002/pd.1970100303; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; WALD N, 1991, LANCET, V338, P131; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WILCKEN DEL, 1988, METABOLISM, V37, P697, DOI 10.1016/0026-0495(88)90093-5; 1993, FED REG, V58, P53305	42	855	878	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1449	1454		10.1056/NEJM199905133401901	http://dx.doi.org/10.1056/NEJM199905133401901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MT	10320382				2022-12-01	WOS:000080198700001
J	Zemlin, F; Schuster, R; Beckmann, E; Carrascosa, JL; Valpuesta, JM; Ertl, G				Zemlin, F; Schuster, R; Beckmann, E; Carrascosa, JL; Valpuesta, JM; Ertl, G			Stress-induced recrystallization of a protein crystal by electron irradiation	NATURE			English	Article							SELF-ORGANIZED CRITICALITY; AVALANCHE DYNAMICS; MICROSCOPE; NOISE; DNA	Ordering of a system of particles into its thermodynamically stable state usually proceeds by thermally activated mass transport of its constituents. Particularly at low temperature, the activation barrier often hinders equilibration-this is what prevents a glass from crystallizing(1) and a pile of sand from flattening under gravity. But if the driving force for mass transport (that is, the excess energy of the system) is increased, the activation barrier can be overcome and structural changes are initiated(2). Here we report the reordering of radiation-damaged protein crystals under conditions where transport is initiated by stress rather than by thermal activation, After accumulating a certain density of radiation-induced defects during observation by transmission electron microscopy, the distorted crystal recrystallizes, The reordering is induced by stress caused by the defects at temperatures that are low enough to suppress diffusive mass transport. We propose that this defect-induced reordering might be a general phenomenon.	Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany; Univ Autonoma Madrid, CSIC, Natl Biotechnol Ctr, E-28049 Madrid, Spain	Max Planck Society; Fritz Haber Institute of the Max Planck Society; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Schuster, R (corresponding author), Max Planck Gesell, Fritz Haber Inst, Faradayweg 4-6, D-14195 Berlin, Germany.		Valpuesta, José M/T-1977-2017; Valpuesta, Jose M/AAA-6002-2019	Valpuesta, José M/0000-0001-7468-8053; 				BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381; Bragg L., 1942, J SCI INSTRUM, V19, P148; BRAGG WL, 1947, P ROY SOC LOND A MAT, V190, P474; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; Debenedetti P.G, 1996, METASTABLE LIQUIDS C; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Frette V, 1996, NATURE, V379, P49, DOI 10.1038/379049a0; KNAPEK E, 1982, ULTRAMICROSCOPY, V10, P71, DOI 10.1016/0304-3991(82)90189-9; MASSOBRIO C, 1989, PHYS REV LETT, V62, P1142, DOI 10.1103/PhysRevLett.62.1142; Paczuski M, 1996, PHYS REV E, V53, P414, DOI 10.1103/PhysRevE.53.414; SYMONS MCR, 1995, RADIAT PHYS CHEM, V45, P837, DOI 10.1016/0969-806X(94)E0035-H; SYMONS MCR, 1982, ULTRAMICROSCOPY, V10, P41, DOI 10.1016/0304-3991(82)90185-1; Tadic B, 1996, PHYS REV LETT, V77, P3843, DOI 10.1103/PhysRevLett.77.3843; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; Zemlin F, 1996, ULTRAMICROSCOPY, V63, P227, DOI 10.1016/0304-3991(96)00038-1	17	11	11	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					51	54		10.1038/19947	http://dx.doi.org/10.1038/19947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331388				2022-12-01	WOS:000080172100051
J	Spiess, C; Beil, A; Ehrmann, M				Spiess, C; Beil, A; Ehrmann, M			A temperature-dependent switch from chaperone to protease in a widely conserved heat shock protein	CELL			English	Article							PERIPLASMIC ALPHA-AMYLASE; ESCHERICHIA-COLI; BETA-GALACTOSIDASE; DISULFIDE BONDS; DEGP PROTEASE; GENE; SYSTEM; HTRA; DEGRADATION; MALS	Misfolding or unfolding of polypeptides can occur as a consequence of environmental stress and spontaneous mutation. The abundance of general chaperones and proteases suggests that cells distinguish between proteins that can be refolded and "hopeless" cases fated to enter the proteolytic pathway. The mechanisms controlling this key metabolic decision are not well understood. We show here that the widely conserved heat shock protein DegP (HtrA) has both general molecular chaperone and proteolytic activities. The chaperone function dominates at low temperatures, while the proteolytic activity is present at elevated temperatures. These results show that a single cellular factor can switch between two key pathways, controlling protein stability and turnover. Implications of this finding for intracellular protein metabolism are discussed.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany	University of Konstanz	Ehrmann, M (corresponding author), Univ Konstanz, Fak Biol, D-78457 Constance, Germany.	michael.ehrmann@uni-konstanz.de	Ehrmann, Michael/A-7307-2012; Taylor, Graham/A-4027-2012	Ehrmann, Michael/0000-0002-1927-260X; Spiess, Christoph/0000-0002-0570-9700				Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Betton JM, 1998, J BIOL CHEM, V273, P8897, DOI 10.1074/jbc.273.15.8897; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAVARD D, 1995, FEMS MICROBIOL LETT, V125, P173; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; DONG JM, 1993, GENE, V136, P227; FREUNDLIEB S, 1986, J BIOL CHEM, V261, P2946; Geme JWS, 1998, MOL MICROBIOL, V27, P617; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Guigueno A, 1997, J BACTERIOL, V179, P3260, DOI 10.1128/jb.179.10.3260-3269.1997; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Kihara A, 1998, J BIOL CHEM, V273, P29770, DOI 10.1074/jbc.273.45.29770; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P10053, DOI 10.1093/nar/16.21.10053; Missiakas D, 1998, MOL MICROBIOL, V28, P1059, DOI 10.1046/j.1365-2958.1998.00865.x; NEU HC, 1965, J BIOL CHEM, V240, P3685; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nichtl A, 1998, J MOL BIOL, V282, P1083, DOI 10.1006/jmbi.1998.2075; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Prinz WA, 1996, EMBO J, V15, P5209, DOI 10.1002/j.1460-2075.1996.tb00906.x; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; SCHNEIDER E, 1992, J BIOL CHEM, V267, P5148; SKORKOGLONEK J, 1995, J BIOL CHEM, V270, P11140, DOI 10.1074/jbc.270.19.11140; SNYDER WB, 1995, J BACTERIOL, V177, P953, DOI 10.1128/jb.177.4.953-963.1995; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; Spiess C, 1997, J BIOL CHEM, V272, P22125, DOI 10.1074/jbc.272.35.22125; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; Waller PRH, 1996, J BACTERIOL, V178, P1146, DOI 10.1128/jb.178.4.1146-1153.1996; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	42	619	645	0	49	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					339	347		10.1016/S0092-8674(00)80743-6	http://dx.doi.org/10.1016/S0092-8674(00)80743-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319814	Bronze			2022-12-01	WOS:000080100500007
J	Gu, LQ; Braha, O; Conlan, S; Cheley, S; Bayley, H				Gu, LQ; Braha, O; Conlan, S; Cheley, S; Bayley, H			Stochastic sensing of organic analytes by a pore-forming protein containing a molecular adapter	NATURE			English	Article							SYNTHETIC RECEPTORS; ALPHA-HEMOLYSIN; STAPHYLOCOCCUS-AUREUS; CHANNEL; RECOGNITION; THERMODYNAMICS; CYCLODEXTRINS; COMPLEXATION; BIOSENSORS; MEMBRANES	The detection of organic molecules is important in many areas, including medicine, environmental monitoring and defence(1-5) Stochastic sensing is an approach that relies on the observation of individual binding events between analyte molecules and a single receptor(6). Engineered transmembrane protein pores are promising sensor elements for stochastic detection(6), and in their simplest manifestation they produce a fluctuating binary ('on/off') response in the transmembrane electrical current. The frequency of occurrence of the fluctuations reveals the concentration of the analyte, and its identity can be deduced from the characteristic magnitude and/or duration of the fluctuations. Genetically engineered versions of the bacterial pare-forming protein alpha-haemolysin have been used to identify and quantify divalent metal ions in solution(6). But it is not immediately obvious how versatile binding sites for organic ligands might be obtained by engineering of the pore structure. Here we show that stochastic sensing of organic molecules can be procured from alpha-haemolysin by equipping the channel with an internal, non-covalently bound molecular 'adapter' whim mediates channel blocking by the analyte. We use cyclodextrins as the adapters because these fit comfortably inside the pore and present a hydrophobic cavity suitable for binding a variety of organic analytes. Moreover, at single sensing element of this sort can be used to analyse a mixture of organic molecules with different binding characteristics. We envisage the use of other adapters, so that the pore could be 'programmed' for a rang of sensing functions.	Texas A&M Univ, Univ Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Braha, O (corresponding author), Texas A&M Univ, Univ Hlth Sci Ctr, Dept Med Biochem & Genet, 440 Reynolds Med Bldg, College Stn, TX 77843 USA.	obraha@medicine.tamu.edu; bayley@tamu.edu	Conlan, Sean/B-4401-2008	Conlan, Sean/0000-0001-6848-3465; Bayley, Hagan/0000-0003-2499-6116				Arduini A, 1997, CURR OPIN CHEM BIOL, V1, P467, DOI 10.1016/S1367-5931(97)80040-3; Bayley H, 1997, SCI AM, V277, P62, DOI 10.1038/scientificamerican0997-62; Beer PD, 1997, CURR OPIN CHEM BIOL, V1, P475, DOI 10.1016/S1367-5931(97)80041-5; Bezrukov SM, 1996, MACROMOLECULES, V29, P8517, DOI 10.1021/ma960841j; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; Blanchet MA, 1996, NAT STRUCT BIOL, V3, P934, DOI 10.1038/nsb1196-934; Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5; Chen HD, 1997, CURR OPIN CHEM BIOL, V1, P458, DOI 10.1016/S1367-5931(97)80039-7; COLQUHOUN D, 1982, PHILOS T ROY SOC B, V300, P1, DOI 10.1098/rstb.1982.0156; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; CROOKS RM, 1998, ACCOUNTS CHEM RES, V31, P199; Czarnik AW, 1998, NATURE, V394, P417, DOI 10.1038/28728; Dickinson TA, 1996, NATURE, V382, P697, DOI 10.1038/382697a0; Gouaux E, 1998, J STRUCT BIOL, V121, P110, DOI 10.1006/jsbi.1998.3959; Hartgerink JD, 1998, CHEM-EUR J, V4, P1367, DOI 10.1002/(SICI)1521-3765(19980807)4:8<1367::AID-CHEM1367>3.0.CO;2-B; Hellinga HW, 1998, TRENDS BIOTECHNOL, V16, P183, DOI 10.1016/S0167-7799(98)01174-3; INOUE Y, 1993, J AM CHEM SOC, V115, P475, DOI 10.1021/ja00055a017; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; Lonergan MC, 1996, CHEM MATER, V8, P2298, DOI 10.1021/cm960036j; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Rekharsky MV, 1998, CHEM REV, V98, P1875, DOI 10.1021/cr970015o; Schmid B, 1998, PROTEIN SCI, V7, P1603, DOI 10.1002/pro.5560070714; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; WALKER B, 1992, J BIOL CHEM, V267, P10902; [No title captured]	29	593	680	12	165	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 22	1999	398	6729					686	690		10.1038/19491	http://dx.doi.org/10.1038/19491			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227291				2022-12-01	WOS:000079920100044
J	Rodriguez, I; Feinstein, P; Mombaerts, P				Rodriguez, I; Feinstein, P; Mombaerts, P			Variable patterns of axonal projections of sensory neurons in the mouse vomeronasal system	CELL			English	Article							PUTATIVE PHEROMONE RECEPTORS; GREEN FLUORESCENT PROTEIN; ACCESSORY OLFACTORY-BULB; MULTIGENE FAMILY; GENE-EXPRESSION; ODORANT RECEPTORS; MOLECULAR-BASIS; ORGANIZATION; MAMMALS; MAP	The vomeronasal system mediates pheromonal effects in mammals. We have employed gene targeting technology to introduce mutations in a putative pheromone receptor gene, VR(i)2, in the germline of mice. By generating alleles differentially tagged with the histological markers taulacZ and tauGFP, we show that VR(i)2 is monoallelically expressed in a given neuron. Axons of VR(i)2-expressing neurons converge onto numerous glomeruli in the accessory olfactory bulb. The pattern of axonal projections is complex and variable. This wiring diagram is substantially different from that of the main olfactory system. The projection pattern is disrupted by deleting the coding region of VR(i)2, but an unrelated seven-transmembrane protein, the odorant receptor M71, can partially substitute for VR(i)2.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Mombaerts, P (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.			rodriguez, ivan/0000-0002-6468-0565				Berghard A, 1996, J NEUROSCI, V16, P909; BRAND A, 1995, TRENDS GENET, V11, P324, DOI 10.1016/S0168-9525(00)89091-5; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CAJAL SRY, 1911, HISTOLOGIE SYSTEME N, V2, P647; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chess A, 1998, ADV IMMUNOL, V69, P437, DOI 10.1016/S0065-2776(08)60613-6; Chess A, 1998, SCIENCE, V279, P2067, DOI 10.1126/science.279.5359.2067; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; FARBMAN AI, 1992, CELL BIOL OLFACTION; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HALPERN M, 1995, BRAIN RES, V677, P157, DOI 10.1016/0006-8993(95)00159-N; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Herrada G, 1997, CELL, V90, P763, DOI 10.1016/S0092-8674(00)80536-X; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Jia CP, 1996, BRAIN RES, V719, P117, DOI 10.1016/0006-8993(96)00110-2; KARLSON P, 1959, NATURE, V183, P55, DOI 10.1038/183055a0; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LANCET D, 1994, NATURE, V372, P321, DOI 10.1038/372321a0; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Meisami E, 1998, MICROSC RES TECHNIQ, V43, P476, DOI 10.1002/(SICI)1097-0029(19981215)43:6<476::AID-JEMT2>3.3.CO;2-M; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 1996, COLD SPRING HARB SYM, V61, P135; Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487; RESSLER KJ, 1994, CELL, V79, P1245, DOI 10.1016/0092-8674(94)90015-9; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; ROYET JP, 1988, J COMP NEUROL, V270, P559, DOI 10.1002/cne.902700409; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Saito H, 1998, MOL BRAIN RES, V60, P215, DOI 10.1016/S0169-328X(98)00183-1; Silver LM, 1995, MOUSE GENETICS CONCE, P3; Sorensen PW, 1996, CHEM SENSES, V21, P245, DOI 10.1093/chemse/21.2.245; TAKAMI S, 1991, J COMP NEUROL, V311, P65, DOI 10.1002/cne.903110106; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; WILSON EO, 1963, SCI AM, V208, P100, DOI 10.1038/scientificamerican0563-100; Yoshihara Y, 1999, NEURON, V22, P33, DOI 10.1016/S0896-6273(00)80676-5; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	46	298	308	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 16	1999	97	2					199	208		10.1016/S0092-8674(00)80730-8	http://dx.doi.org/10.1016/S0092-8674(00)80730-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219241	Bronze			2022-12-01	WOS:000079779800009
J	de Silva, NR; Sirisena, JLGJ; Gunasekera, DPS; Ismail, MM; de Silva, HJ				de Silva, NR; Sirisena, JLGJ; Gunasekera, DPS; Ismail, MM; de Silva, HJ			Effect of mebendazole therapy during pregnancy on birth outcome	LANCET			English	Article								Background In areas endemic for hookworm, routine antenatal mebendazole therapy could greatly reduce the prevalence of anaemia in pregnancy. At present, however, this is not a widely accepted control strategy because of a lack of data on the safety of the drug. We assessed the effect of mebendazole therapy during pregnancy on birth outcome. Methods A cross-sectional study was done in Sri Lanka, where prescription of mebendazole to women in the second trimester of pregnancy is recommended. Two hospitals were chosen for the study, and women who gave birth there between May, 1996, and March, 1997, were recruited. We compared the rates of major congenital defects, stillbirth, perinatal death, and low birthweight (less than or equal to 1500 g) among babies of mothers who had taken mebendazole during pregnancy with those whose mothers had not taken an anthelmintic (controls). Findings The rate of major congenital defects was not significantly higher in the mebendazole group than in the control group (97 [1.8%] of 5275 vs 26 [1.5%] of 1737; odds ratio 1.24 [95% CI 0.8-1.91], p=0.39). Among 407 women who had taken mebendazole in the first trimester (contrary to medical advice), 10 (2.5%) had major congenital defects (odds ratio vs controls 1.66 [0.81-3.56], p=0.23). The proportions of stillbirths and perinatal deaths were significantly lower in the mebendazole group (1.9 vs 3.3%, 0.55 [95% CI 0.4-0.77]), as was the proportion of low-birthweight babies (1.1 vs 2.3%, 0.47 [95% CI 0.32-0.71]). Interpretation Mebendazole therapy during pregnancy is not associated with a significant increase in major congenital defects, but our results indicate that it should be avoided during the first trimester. This therapy could offer beneficial effects to pregnant women in developing countries, where intestinal helminthiases are endemic.	Univ Kelaniya, Fac Med, Dept Parasitol, Ragama, Sri Lanka; Univ Colombo, Fac Med, Colombo, Sri Lanka	University Kelaniya; University of Colombo	de Silva, NR (corresponding author), Univ Kelaniya, Fac Med, Dept Parasitol, POB 6, Ragama, Sri Lanka.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				[Anonymous], 1994, NAT STRAT BROAD PLAN; ATUKORALA TMS, 1994, AM J CLIN NUTR, V60, P286, DOI 10.1093/ajcn/60.2.286; Auer H., 1994, Applied Parasitology, V35, P146; BASKERVILLE M, 1988, LAB ANIM, V22, P263, DOI 10.1258/002367788780746412; DELATOUR P, 1976, THERAPIE, V31, P505; deSilva N, 1997, DRUGS, V53, P769, DOI 10.2165/00003495-199753050-00004; DOLLERY C, 1991, THERAPEUTIC DRUGS, V2, pM12; GILMAN AG, 1992, GOODMAN GILMANS PHAR, V2, P964; *GOV SRI LANK MIN, 1997, ANN HLTH B 1996; GRAHAMESMITH DG, 1992, OXFORD TXB CLIN PHAR, P248; LEACH FN, 1990, ARCH DIS CHILD, V65, P399, DOI 10.1136/adc.65.4.399; NEVIN C, 1982, CLIN OBSTET GYNECOL, V9, P3; Pawlowski ZS, 1991, HOOKWORM INFECT ANAE; Reynolds J.E.F., 1993, MARTINDALE THE EXTRA; SHEPARD TH, 1983, CATALOG TERATOGENIC; SIRISENA J, 1993, KANDY MED J, V2, P58; Sorensen Eigil, 1996, Ceylon Medical Journal, V41, P37; WHO, 1994, WHOCTDSIP961; WHO, 1996, WORLD HLTH REP 1996, P43; WHO, 1997, WORLD HLTH REP 1997, P51	20	95	98	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1145	1149		10.1016/S0140-6736(98)06308-9	http://dx.doi.org/10.1016/S0140-6736(98)06308-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209979				2022-12-01	WOS:000079858400013
J	Novak, R; Henriques, B; Charpentier, E; Normark, S; Tuomanen, E				Novak, R; Henriques, B; Charpentier, E; Normark, S; Tuomanen, E			Emergence of vancomycin tolerance in Streptococcus pneumoniae	NATURE			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; ENTEROCOCCUS-FAECIUM; PENICILLIN TOLERANCE; BACTERIAL-MENINGITIS; PROTEINS; IDENTIFICATION; PNEUMOCOCCI; INFECTIONS; MECHANISMS	Streptococcus pneumoniae, the pneumococcus, is the most common cause of sepsis and meningitis(1). Mwultiple-antibiotic-resistant strains are widespread, and vancomycin is the antibiotic of last resort(2,3). Emergence of vancomycin resistance In this community-acquired bacterium would be catastrophic. Antibiotic tolerance, the ability of bacteria to survive but not grow in the presence of antibiotics, is a precursor phenotype to resistance(4) Here we show that loss of function of the VncS histidine kinase of a two-component sensor-regulator system in S. pneumoniae produced tolerance to vancomycin and other classes of antibiotic. Bacterial two-component systems monitor environmental parameters through a sensor histidine-kinase/phosphatase, which phosphorylates/dephosphorylates a response regulator that in turn mediates changes in gene expression. These results indicate that signal transduction is critical for the bactericidal activity of antibiotics. Experimental meningitis caused by the vncS mutant failed to respond to vancomycin. Clinical isolates tolerant to vancomycin were identified and DNA sequencing revealed nucleotide alterations in vncS. We conclude that broad antibiotic tolerance of S. pneumoniae has emerged in the community by a molecular mechanism that eliminates sensitivity to the current cornerstone of therapy vancomycin.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Karolinska Inst, Swedish Inst Infect Dis Control, S-17182 Stockholm, Sweden	St Jude Children's Research Hospital; Karolinska Institutet; Swedish Institute for Infectious Disease Control	Tuomanen, E (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	elaine.tuomanen@stjude.org	Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716				*AM AC PED, 1997, RED BOOK REP COMM IN, P410; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P626; CHEN JD, 1987, GENE, V55, P179, DOI 10.1016/0378-1119(87)90278-2; Dowson CG, 1997, J APPL MICROBIOL, V83, pS42, DOI 10.1046/j.1365-2672.83.s1.5.x; Evers S, 1996, J BACTERIOL, V178, P1302, DOI 10.1128/jb.178.5.1302-1309.1996; FRIEDLAND IR, 1992, PEDIATR INFECT DIS J, V11, P433, DOI 10.1097/00006454-199206000-00002; HOLMAN TR, 1994, BIOCHEMISTRY-US, V33, P4625, DOI 10.1021/bi00181a024; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; LACKS S, 1960, BIOCHIM BIOPHYS ACTA, V39, P508, DOI 10.1016/0006-3002(60)90205-5; LIU HH, 1985, J INFECT DIS, V152, P365, DOI 10.1093/infdis/152.2.365; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; MOREILLON P, 1990, ANTIMICROB AGENTS CH, V34, P33, DOI 10.1128/AAC.34.1.33; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; Novak R, 1998, MOL MICROBIOL, V29, P1285, DOI 10.1046/j.1365-2958.1998.01016.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEARCE BJ, 1993, MOL MICROBIOL, V9, P1037, DOI 10.1111/j.1365-2958.1993.tb01233.x; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SHOCKLEY TE, 1970, GENETICS, V64, P397; Silva JC, 1998, P NATL ACAD SCI USA, V95, P11951, DOI 10.1073/pnas.95.20.11951; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TAUBER MG, 1994, METHOD ENZYMOL, V235, P92; TOMASZ A, 1964, P NATL ACAD SCI USA, V51, P480, DOI 10.1073/pnas.51.3.480; TOMASZ A, 1970, NATURE, V227, P138, DOI 10.1038/227138a0; TUOMANEN E, 1988, J INFECT DIS, V158, P36, DOI 10.1093/infdis/158.1.36; WILLIAMSON R, 1980, J BACTERIOL, V144, P105, DOI 10.1128/JB.144.1.105-113.1980; ZIGHELBOIM S, 1981, REV INFECT DIS, V3, P267	29	270	286	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					590	593		10.1038/21202	http://dx.doi.org/10.1038/21202			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376600				2022-12-01	WOS:000080778400057
J	Hofer, TP; Hayward, RA; Greenfield, S; Wagner, EH; Kaplan, SH; Manning, WG				Hofer, TP; Hayward, RA; Greenfield, S; Wagner, EH; Kaplan, SH; Manning, WG			The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL RESOURCE USE; MANAGED CARE; SELECTION BIAS; COMPLICATIONS; CAPITATION; SURGEONS; HMOS	Context. Physician profiling is widely used by many health care systems, but little is known about the reliability of commonly used profiling systems. Objectives. To determine the reliability of a set of physician performance measures for diabetes care,one of the most common conditions in medical practice, and to examine whether physicians could substantially improve their profiles by preferential patient selection. Design and Setting. Cohort study performed from 1990 to 1993 at 3 geographically and organizationally diverse sites, including a large staff-model health maintenance organization, an urban university teaching clinic, and a group of private-practice physicians in an urban area. Participants. A total of 3642 patients with type 2 diabetes cared for by 232 different physicians. Main Outcome Measures. Physician profiles for their patients' hospitalization and clinic visit rates, total laboratory resource utilization rate and level of glycemic control by average hemoglobin A(1c) level with and without detailed case-mix adjustment. Results. For profiles based on hospitalization rates, visit rates, laboratory utilization rates, and glycemic control, 4% or less of the overall variance was attributable to differences in physician practice and the reliability of the median physician's case-mix-adjusted profile was never better than 0.40. At this low level of physician effect, a physician would need to have more than 100 patients with diabetes in a panel for profiles to have a reliability of 0.80 or better (while more than 90% of all primary care physicians at the health maintenance organization had fewer than 60 patients with diabetes). For profiles of glycemic control, high outlier physicians could dramatically improve their physician profile simply by pruning from their panel the 1 to 3 patients with the highest hemoglobin A(1c) levels during the prior year. This advantage from gaming could not be prevented by even detailed case-mix adjustment. Conclusions. Physician "report cards" for diabetes,one of the highest-prevalence conditions in medical practice, were unable to detect reliably true practice differences within the 3 sites studied. Use of individual physician profiles may foster an environment in which physicians can most easily avoid being penalized by avoiding or deselecting patients with high prior cost, poor adherence;or response to treatments.	Vet Affairs Ctr Practice Management & Outcomes Re, Ann Arbor, MI USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; New England Med Ctr, Primary Care Outcomes Res Inst, Boston, MA 02111 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA	University of Michigan System; University of Michigan; Tufts Medical Center; Group Health Cooperative; University of Chicago	Hofer, TP (corresponding author), Ann Arbor VA HSR&D US Mail, 3rd Floor,Lobby L,POB 130170, Ann Arbor, MI 48113 USA.		Hofer, Timothy Philip/AAC-9238-2022	Kaplan, Sherrie/0000-0002-8644-5849; Greenfield, Sheldon/0000-0003-4628-1998; Hofer, Timothy/0000-0003-0434-8787	AHRQ HHS [HSO 6665-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Blum JD, 1996, AM J LAW MED, V22, P173; BRAVO G, 1991, J CLIN EPIDEMIOL, V44, P381, DOI 10.1016/0895-4356(91)90076-L; Carmines E.G., 1979, SAGE U PAPER SERIES; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; FEINGLASS J, 1991, HEALTH SERV RES, V26, P183; Gelman A., 1995, BAYESIAN DATA ANAL; GLEASON JR, 1996, STATA TECHNICAL B RE, V6, P167; Goldstein H., 2011, MULTILEVEL STAT MODE, V4th, DOI DOI 10.1002/9780470973394; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; GREENFIELD S, 1994, DIABETES CARE, V17, P32; GREENFIELD S, 1995, MED CARE, V33, pAS47; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; HAYWARD RA, 1994, MED CARE, V32, P788, DOI 10.1097/00005650-199408000-00003; HELLINGER FJ, 1995, INQUIRY-J HEALTH CAR, V32, P135; *I ED MULT MOD PRO, 1998, MLWIN COMP PROGR REL; JAMES W, 1961, 4TH P BERK S MATH ST, V1, P361; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; KERR EA, 1995, ANN INTERN MED, V123, P500, DOI 10.7326/0003-4819-123-7-199510010-00004; Kuczynski YT, 1997, J VASC SURG, V26, P193, DOI 10.1016/S0741-5214(97)70179-4; LICHTENSTEIN R, 1992, MED CARE, V30, P329, DOI 10.1097/00005650-199204000-00004; Liner RS, 1997, AM J LAW MED, V23, P511; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; McCullagh P, 2019, GEN LINEAR MODELS; MCDOWELL J, 1996, MEASURING HLTH GUIDE; MCMAHON LF, 1989, ANN INTERN MED, V111, P318, DOI 10.7326/0003-4819-111-4-318; MILLER ME, 1993, MED CARE, V31, pYS16, DOI 10.1097/00005650-199305001-00004; Newhouse J P, 1989, Health Care Financ Rev, V10, P41; NEWHOUSE JP, 1994, HEALTH AFFAIR, V13, P132, DOI 10.1377/hlthaff.13.1.132; OHAGAN A, 1994, KENDALLS ADV THEOR B, V2; Orav EJ, 1996, MED CARE, V34, pSS87; PORELL FW, 1990, MED CARE, V28, P604, DOI 10.1097/00005650-199007000-00006; Spoeri RK, 1997, ANN INTERN MED, V127, P726, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00058; *STATA CORP, 1997, STATA STAT SOFTW COM; STEIN C, 1956, P 3 BERK S MATH STAT, V1, P137; Vijan S, 1997, J GEN INTERN MED, V12, P567, DOI 10.1046/j.1525-1497.1997.07111.x; WELCH HG, 1994, NEW ENGL J MED, V330, P607, DOI 10.1056/NEJM199403033300906; Wennberg DE, 1998, ANN INTERN MED, V128, P866, DOI 10.7326/0003-4819-128-10-199805150-00012; 1997, MED HLTH, V51, P1	38	412	433	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2098	2105		10.1001/jama.281.22.2098	http://dx.doi.org/10.1001/jama.281.22.2098			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	202TJ	10367820	Bronze			2022-12-01	WOS:000080668000032
J	Gilbert, RJC; Jimenez, JL; Chen, SX; Tickle, IJ; Rossjohn, J; Parker, M; Andrew, PW; Saibil, HR				Gilbert, RJC; Jimenez, JL; Chen, SX; Tickle, IJ; Rossjohn, J; Parker, M; Andrew, PW; Saibil, HR			Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae	CELL			English	Article							STREPTOLYSIN-O; PERFRINGOLYSIN-O; CHOLESTEROL-BINDING; LIPOSOMAL MEMBRANES; PROTEIN TOXIN; THETA-TOXIN; VIRULENCE; MECHANISM; CYTOLYSIN; MUTAGENESIS	The human pathogen Streptococcus pneumoniae produces soluble pneumolysin monomers that bind host cell membranes to form ring-shaped, oligomeric pores. We have determined three-dimensional structures of a helical oligomer of pneumolysin and of a membrane-bound ring form by cryo-electron microscopy. Fitting the four domains from the crystal structure of the closely related perfringolysin reveals major domain rotations during pore assembly. Oligomerization results in the expulsion of domain 3 from its original position in the monomer. However, domain 3 reassociates with the other domains in the membrane pore form. The base of domain 4 contacts the bilayer, possibly along with an extension of domain 3. These results reveal a two-stage mechanism for pore formation by the cholesterol-binding toxins.	Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England; Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Leicester, Dept Microbiol & Immunol, Leicester LE1 8AH, Leics, England	University of London; Birkbeck University London; University of Leicester; St. Vincent's Institute of Medical Research; University of Leicester	Saibil, HR (corresponding author), Univ London Birkbeck Coll, Dept Crystallog, Malet St, London WC1E 7HX, England.		Rossjohn, Jamie/F-9032-2013; Parker, Michael W/F-9069-2013; Andrew, Peter W/G-7526-2012	Rossjohn, Jamie/0000-0002-2020-7522; Parker, Michael W/0000-0002-3101-1138; Tickle, Ian/0000-0003-2977-0650	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alexander JE, 1998, MICROB PATHOGENESIS, V24, P167, DOI 10.1006/mpat.1997.0185; ALONSODEVELASCO E, 1995, MICROBIOL REV, V59, P591, DOI 10.1128/MMBR.59.4.591-603.1995; Bayley H, 1997, CURR BIOL, V7, pR763, DOI 10.1016/S0960-9822(06)00399-X; BERRY AM, 1989, INFECT IMMUN, V57, P2037, DOI 10.1128/IAI.57.7.2037-2042.1989; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BUCKINGHAM L, 1983, BIOCHIM BIOPHYS ACTA, V729, P115, DOI 10.1016/0005-2736(83)90462-5; *CCP4, 1994, ACTA CRYSTALLOGR D, V50, P750; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DEKRUIJFF B, 1990, BIOSCIENCE REP, V10, P127; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gilbert RJC, 1998, J MOL BIOL, V284, P1223, DOI 10.1006/jmbi.1998.2258; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; HARRIS RW, 1991, J BIOL CHEM, V266, P6936; HILL J, 1994, INFECT IMMUN, V62, P757, DOI 10.1128/IAI.62.2.757-758.1994; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Jones S, 1996, MOL MICROBIOL, V21, P1219, DOI 10.1046/j.1365-2958.1996.00074.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Killian JA, 1996, BIOCHEMISTRY-US, V35, P1037, DOI 10.1021/bi9519258; Korchev YE, 1998, BIOCHEM J, V329, P571; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHELL TJ, 1991, MOL MICROBIOL, V5, P1883, DOI 10.1111/j.1365-2958.1991.tb00812.x; Morgan P, 1996, REV MED MICROBIOL, V7, P221, DOI DOI 10.1097/00013542-199610000-00004; MORGAN PJ, 1994, J BIOL CHEM, V269, P25315; MORGAN PJ, 1995, FEBS LETT, V371, P77, DOI 10.1016/0014-5793(95)00887-F; NAKAMURA M, 1995, BIOCHEMISTRY-US, V34, P6513, DOI 10.1021/bi00019a032; Nakamura M, 1998, J BIOCHEM, V123, P1145; OLOFSSON A, 1993, FEBS LETT, V319, P125, DOI 10.1016/0014-5793(93)80050-5; Olson R, 1999, NAT STRUCT BIOL, V6, P134; PALMER M, 1995, EUR J BIOCHEM, V231, P388, DOI 10.1111/j.1432-1033.1995.tb20711.x; Palmer M, 1996, J BIOL CHEM, V271, P26664, DOI 10.1074/jbc.271.43.26664; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; Rossjohn J, 1998, J MOL BIOL, V284, P449, DOI 10.1006/jmbi.1998.2167; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; WATSON KC, 1972, J CLIN PATHOL, V25, P885, DOI 10.1136/jcp.25.10.885	44	149	160	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					647	655		10.1016/S0092-8674(00)80775-8	http://dx.doi.org/10.1016/S0092-8674(00)80775-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367893	Bronze			2022-12-01	WOS:000080672100013
J	O'Brien, E; Staessen, JA				O'Brien, E; Staessen, JA			What is "hypertension"?	LANCET			English	Editorial Material							AMBULATORY BLOOD-PRESSURE; NORMALITY; PAMELA		Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland; Katholieke Univ Leuven, Hypertensie & Cardiovasc Revalidatie Eenheld, Louvain, Belgium	KU Leuven	O'Brien, E (corresponding author), Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland.		Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				Chalmers J, 1999, J HYPERTENS, V17, P151; IMAI Y, 1993, HYPERTENSION, V22, P990; *JOINT NAT COMM PR, 1997, ARCH INTERN MED, V157, P2443; Mancia G, 1995, J HYPERTENS, V13, P1377; Nielsen PE, 1995, AM J HYPERTENS, V8, P978; O'Brien, 1998, Blood Press Monit, V3, P131; OBRIEN E, 1991, J HYPERTENS, V9, P355, DOI 10.1097/00004872-199104000-00007; OBRIEN F, 1995, BLOOD PRESSURE, V4, P256; PICKERING T, 1995, AM J HYPERTENS, V9, P1; Sega R, 1997, HYPERTENSION, V30, P1; Staessen, 1996, Blood Press Monit, V1, P13; Staessen JA, 1996, NEPHROL DIAL TRANSPL, V11, P241, DOI 10.1093/oxfordjournals.ndt.a027247; STAESSEN JA, 1994, J HYPERTENS, V12, pS1; Staessen JA, 1997, HYPERTENSION, V29, P30, DOI 10.1161/01.HYP.29.1.30	14	25	25	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1541	1543		10.1016/S0140-6736(99)00157-9	http://dx.doi.org/10.1016/S0140-6736(99)00157-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334248				2022-12-01	WOS:000080278300004
J	Gerszten, RE; Garcia-Zepeda, EA; Lim, YC; Yoshida, M; Ding, HA; Gimbrone, MA; Luster, AD; Luscinskas, FW; Rosenzweig, A				Gerszten, RE; Garcia-Zepeda, EA; Lim, YC; Yoshida, M; Ding, HA; Gimbrone, MA; Luster, AD; Luscinskas, FW; Rosenzweig, A			MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions	NATURE			English	Article							LEUKOCYTE ADHESION; CHEMOATTRACTANT PROTEIN-1; CHEMOTACTIC CYTOKINES; APOLIPOPROTEIN-E; CC CHEMOKINES; IN-VITRO; CELLS; ATHEROSCLEROSIS; MICE; ALPHA-4-BETA-1	Monocytes contribute to the development of atherosclerotic lesions in mouse models(1-3), The chemoattractant proteins (chemokines), monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), are found in human atheroma(4,5), and mice lacking receptors for these chemokines are less susceptible to atherosclerosis and have fewer monocytes in vascular lesions(6,7). Although MCP-1 has a powerful effect on monocytes, IL-8 is thought to act predominantly on neutrophils and it is unclear how it could recruit monocytes(6,8). Here we investigate the ability of chemokines to control the interaction of monocytes under now conditions with vascular endothelium that has been transduced to express specific leukocyte-adherence receptors. We find that MCP-I and IL-8 can each rapidly cause rolling monocytes to adhere firmly onto monolayers expressing E-selectin, whereas related chemokines do not. These effects do not correlate with either the induction of a calcium transient or chemotaxis. We conclude that chemokines are important modulators of monocyte-endothelial interactions under now conditions. Moreover, our finding that IL-8 is a powerful trigger for firm adhesion of monocytes to vascular endothelium reveals an unexpected role for this chemokine in monocyte recruitment.	Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Pathol, Div Vasc Res, Boston, MA 02115 USA; Tokyo Med & Dent Univ, Med Res Inst, Tokyo, Japan	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Tokyo Medical & Dental University (TMDU)	Rosenzweig, A (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.		Rosenzweig, Anthony/AAD-7893-2019; Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Berkhout TA, 1997, J BIOL CHEM, V272, P16404, DOI 10.1074/jbc.272.26.16404; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CHUNTHARAPAI A, 1994, J IMMUNOL, V153, P5682; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Gerszten RE, 1998, CIRC RES, V82, P871; Gerszten RE, 1996, CIRC RES, V79, P1205, DOI 10.1161/01.RES.79.6.1205; GRABER N, 1990, J IMMUNOL, V145, P819; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; KOCH AE, 1993, AM J PATHOL, V142, P1423; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; LUSCINSKAS FW, 1996, J IMMUNOL, V156, P326; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; WHEELER ME, 1988, J CLIN INVEST, V82, P1211, DOI 10.1172/JCI113718; WOLDEMARCARR M, 1996, IMMUNITY, V4, P179; Yoshida M, 1998, J IMMUNOL, V161, P933; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	29	1017	1060	0	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					718	723		10.1038/19546	http://dx.doi.org/10.1038/19546			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227295				2022-12-01	WOS:000079920100053
J	Lake, JA; Jain, R; Rivera, MC				Lake, JA; Jain, R; Rivera, MC			Genomics - Mix and match in the tree of life	SCIENCE			English	Editorial Material							CHIMERIC ORIGIN; ARCHAEA		Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Lake, JA (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.		Rivera, Maria/GYU-2150-2022					Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; Day Martin, 1998, P144; Feng DF, 1997, P NATL ACAD SCI USA, V94, P13028, DOI 10.1073/pnas.94.24.13028; GOLDING GB, 1995, MOL BIOL EVOL, V12, P1; Hall Ruth M., 1998, P53; HENSEL R, 1989, CAN J MICROBIOL, V35, P81, DOI 10.1139/m89-012; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; KUNST F, 1997, NATURE, V390, P205; LAKE JA, 1982, P NATL ACAD SCI-BIOL, V79, P5948, DOI 10.1073/pnas.79.19.5948; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; Pennisi E, 1998, SCIENCE, V280, P672, DOI 10.1126/science.280.5364.672; Ribeiro S, 1998, MOL BIOL EVOL, V15, P779, DOI 10.1093/oxfordjournals.molbev.a025983; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; SMITH JA, 1993, SEMIN VET MED SURG, V8, P90; Sogin ML, 1991, CURR OPIN GENET DEV, V1, P457, DOI 10.1016/S0959-437X(05)80192-3; Syvanen M, 1998, HORIZONTAL GENE TRAN; ZILLIG W, 1992, ORIGIN EVOLUTION CEL, P47	18	45	47	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 26	1999	283	5410					2027	2028		10.1126/science.283.5410.2027	http://dx.doi.org/10.1126/science.283.5410.2027			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	180DH	10206909				2022-12-01	WOS:000079369800030
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Designer Jell-O	SCIENCE			English	Editorial Material																		Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1872	1872						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10206893				2022-12-01	WOS:000079228600034
J	Duchamp-Viret, P; Chaput, MA; Duchamp, A				Duchamp-Viret, P; Chaput, MA; Duchamp, A			Odor response properties of rat olfactory receptor neurons	SCIENCE			English	Article							HOMEOTIC TRANSFORMATION; TARGETED DISRUPTION; BRANCHIAL REGION; CHICK HINDBRAIN; CRANIAL NERVES; MOTOR-NEURONS; NEURAL CREST; MUTANT MICE; HOX CODE; SYSTEM	Molecular biology studies of olfaction have identified a multigene family of molecular receptors that are Likely to be involved in odor transduction mechanisms. However, because previous functional data on peripheral coding were mainly collected from inferior vertebrates, it has been difficult to document the degree of specificity of odor interaction mechanisms. As a matter of fact, studies of the functional expression of olfactory receptors have not demonstrated the Low or high specificity of olfactory receptors. In this study, the selectivity of olfactory receptor neurons was investigated in the rat at the cellular Level under physiological conditions by unitary extracellular recordings. Individual olfactory receptor neurons were broadly responsive to qualitatively distinct odor compounds. We conclude that peripheral coding is based on activated arrays of olfactory receptor cells with overlapping tuning profiles.	Univ Lyon 1, CNRS, Lab Neurosci & Syst Sensoriels, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Duchamp-Viret, P (corresponding author), Univ Lyon 1, CNRS, Lab Neurosci & Syst Sensoriels, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	pduchamp@olfac.univ-lyon1.fr	Duchamp-Viret, Patricia/N-9827-2017	Duchamp-Viret, Patricia/0000-0002-7730-266X				Alexandre D, 1996, DEVELOPMENT, V122, P735; Bateson W., 1894, MAT STUDY VARIATION; BELL E, IN PRESS MECH DEV; BUCK L, 1993, CHEM SENSES, V18, P203, DOI 10.1093/chemse/18.2.203; Burke AC, 1996, DEV BIOL, V178, P192, DOI 10.1006/dbio.1996.0210; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; DUCHAMPVIRET P, 1989, J NEUROPHYSIOL, V61, P1085, DOI 10.1152/jn.1989.61.5.1085; DuchampViret P, 1997, PROG NEUROBIOL, V53, P561, DOI 10.1016/S0301-0082(97)00049-X; Gavalas A, 1997, DEVELOPMENT, V124, P3693; Gavalas A, 1998, DEVELOPMENT, V125, P1123; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; Goddard JM, 1996, DEVELOPMENT, V122, P3217; Goulding M, 1998, NEURON, V21, P943, DOI 10.1016/S0896-6273(00)80612-1; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HILL J, 1995, MECH DEVELOP, V50, P3, DOI 10.1016/0925-4773(94)00321-D; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; PATA I, UNPUB; POURQUIE O, 1990, DEVELOPMENT, V109, P743; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; Tiret L, 1998, DEVELOPMENT, V125, P279; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Wingate RJT, 1996, DEVELOPMENT, V122, P2143; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	35	220	226	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2171	2174		10.1126/science.284.5423.2171	http://dx.doi.org/10.1126/science.284.5423.2171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381881	Green Submitted			2022-12-01	WOS:000081099300050
J	Carr, A; Samaras, K; Thorisdottir, A; Kaufmann, GR; Chisholm, DJ; Cooper, DA				Carr, A; Samaras, K; Thorisdottir, A; Kaufmann, GR; Chisholm, DJ; Cooper, DA			Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; X-RAY ABSORPTIOMETRY; MYOCARDIAL-INFARCTION; DENSITY-LIPOPROTEIN; INSULIN-RESISTANCE; INFECTED PATIENTS; BODY-COMPOSITION; HDL-CHOLESTEROL; RISK; TRIGLYCERIDE	Background The prevalence and severity of lipodystrophy syndrome with long-term therapy for HIV-1 infection that includes a protease inhibitor is unknown. We studied the natural course of the syndrome to develop diagnostic criteria and identifying markers that. predict its severity. Methods We assessed 113 patients who were receiving HIV-1 protease inhibitors (mean 21 months) and 45 HIV-1-infected patients (28 with follow-up) never treated with a protease inhibitor. Lipodystrophy was assessed by questionnaire (including patients' rating of severity), physical examination, and dual-energy x-ray absorptiometry. Body composition and lasting lipid and glycaemic variables were compared with data obtained 8 months previously. Oral glucose tolerance was investigated. Findings There was 98% concordance between patients' reports of the presence or absence of lipodystrophy (reported by 83% of protease-inhibitor recipients and 4% of treatment-naive patients; p=0.0001) and physical examination. Patients' ratings of lipodystrophy were significantly associated with declining total body fat (p=0.02). Lower body fat was independently associated with longer duration of protease inhibitor therapy and lower bodyweight before therapy, and more severe lipodystrophy was associated with higher previous (p<0.03) and current (p less than or equal to 0.01) triglyceride and C-peptide concentrations, and less peripheral and greater central fat (p=0.005 and 0.09, respectively). Body fat declined a mean 1.2 kg over 8 months in protease-inhibitor recipients (p=0.05). The prevalence of hyperlipidaemia remained stable over time (74% of treated patients vs 28% of naive patients; p=0.0001). Impaired glucose tolerance occurred in 16% of protease-inhibitor recipients and diabetes mellitus in 7%; in all but three patients these abnormalities were detected on 2 h post-glucose load values. Interpretation Diagnosis and rating severity of lipodystrophy is aided by the combination of physical examination, patient's rating, and measurement of body fat, fasting triglycerides, and C-peptide. Weight before therapy, fasting triglyceride, and C-peptide concentrations early in therapy, and therapy duration seem to predict lipodystrophy severity. Lipodystrophy was common and progressive after almost 2 years of protease inhibitor therapy, but. was not usually severe. Hyperlipidaemia and impaired glucose tolerance were also common.	St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Univ New S Wales, Garvan Inst Med Res, Div Metab, Sydney, NSW, Australia	St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; Kirby Institute; Garvan Institute of Medical Research; University of New South Wales Sydney	Carr, A (corresponding author), St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia.	acarr@stvincents.com.au	Chisholm, Donald J/J-9332-2013	Chisholm, Donald J/0000-0002-5349-5735				BURCHFIEL CM, 1995, CIRCULATION, V92, P1430, DOI 10.1161/01.CIR.92.6.1430; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CHIDIAC C, 1995, AIDS, V9, P215, DOI 10.1097/00002030-199502000-00022; Coyle P, 1996, MED J AUSTRALIA, V165, P587, DOI 10.5694/j.1326-5377.1996.tb138654.x; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Dube MP, 1997, LANCET, V350, P713, DOI 10.1016/S0140-6736(05)63513-1; FULLER JH, 1980, LANCET, V1, P1373; Gavin JR, 1999, DIABETES CARE, V22, pS5; Gaziano JM, 1997, CIRCULATION, V96, P2520, DOI 10.1161/01.CIR.96.8.2520; HAARBO J, 1991, CLIN PHYSIOL, V11, P331, DOI 10.1111/j.1475-097X.1991.tb00662.x; Herry I, 1997, CLIN INFECT DIS, V25, P937, DOI 10.1086/597649; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Jeppesen J, 1998, CIRCULATION, V97, P1029, DOI 10.1161/01.CIR.97.11.1029; KERULY JE, 1998, 5 C RETR OPP INF FEB; Lamarche B, 1996, ATHEROSCLEROSIS, V119, P235, DOI 10.1016/0021-9150(95)05653-X; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; LUMPKIN MM, 1997, FDA PUBLIC HLTH 0611; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Miller KK, 1998, CLIN INFECT DIS, V27, P68, DOI 10.1086/514638; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; OSULLIVAN AJ, 1994, J CLIN ENDOCR METAB, V78, P381, DOI 10.1210/jc.78.2.381; ROSENBURG HE, 1998, 5 C RETR OPP INF FEB; Roth VR, 1998, CLIN INFECT DIS, V27, P65, DOI 10.1086/514639; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Striker R, 1998, CLIN INFECT DIS, V27, P218, DOI 10.1086/517682; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Viraben R, 1998, AIDS, V12, pF37, DOI 10.1097/00002030-199806000-00001; Welborn TA, 1997, METABOLISM, V46, P35, DOI 10.1016/S0026-0495(97)90315-2	33	1221	1251	3	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2093	2099		10.1016/S0140-6736(98)08468-2	http://dx.doi.org/10.1016/S0140-6736(98)08468-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382692				2022-12-01	WOS:000080969300008
J	Newell-Price, J; Grossman, A				Newell-Price, J; Grossman, A			Diagnosis and management of Cushing's syndrome	LANCET			English	Editorial Material							CORTICOTROPIN-RELEASING HORMONE; DIFFERENTIAL-DIAGNOSIS; SERUM CORTISOL; DISEASE		St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England	University of London; Queen Mary University London	Newell-Price, J (corresponding author), St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England.							CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; Dickstein G, 1996, J CLIN ENDOCR METAB, V81, P2934, DOI 10.1210/jc.81.8.2934; HALL WA, 1994, ANN INTERN MED, V120, P817, DOI 10.7326/0003-4819-120-10-199405150-00001; Invitti C, 1999, J CLIN ENDOCR METAB, V84, P440, DOI 10.1210/jc.84.2.440; KENNEDY L, 1984, BRIT MED J, V289, P1188, DOI 10.1136/bmj.289.6453.1188; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; McCance DR, 1996, CLIN ENDOCRINOL, V44, P1, DOI 10.1046/j.1365-2265.1996.614436.x; MILLER DL, 1992, RADIOLOGY, V185, P143, DOI 10.1148/radiology.185.1.1523298; Newell-Price J, 1998, ENDOCR REV, V19, P647, DOI 10.1210/er.19.5.647; NEWELLPRICE J, 1995, CLIN ENDOCRINOL, V43, P545, DOI 10.1111/j.1365-2265.1995.tb02918.x; NewellPrice J, 1997, J CLIN ENDOCR METAB, V82, P176, DOI 10.1210/jc.82.1.176; NIEMAN LK, 1993, J CLIN ENDOCR METAB, V77, P1308, DOI 10.1210/jc.77.5.1308; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; TRAINER PJ, 1995, J CLIN ENDOCR METAB, V80, P412, DOI 10.1210/jc.80.2.412; TRAINER PJ, 1993, CLIN ENDOCRINOL, V38, P73, DOI 10.1111/j.1365-2265.1993.tb00975.x	15	19	20	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2087	2088		10.1016/S0140-6736(99)99091-8	http://dx.doi.org/10.1016/S0140-6736(99)99091-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382687				2022-12-01	WOS:000080969300003
J	Jung, JN; Zheng, MH; Goldfarb, M; Zaret, KS				Jung, JN; Zheng, MH; Goldfarb, M; Zaret, KS			Initiation of mammalian liver development from endoderm by fibroblast growth factors	SCIENCE			English	Article							EMBRYONIC MOUSE LUNG; HEART TUBE FORMATION; TRANSCRIPTION FACTOR; ALPHA-FETOPROTEIN; GENE-EXPRESSION; MICE LACKING; HEPATOCYTE DIFFERENTIATION; BRANCHING MORPHOGENESIS; PANCREATIC MESENCHYME; VENTRAL MORPHOGENESIS	The signaling molecules that elicit embryonic induction of the liver from the mammalian gut endoderm or induction of other gut-derived organs are unknown. Close proximity of cardiac mesoderm, which expresses fibroblast growth factors (FGFs) 1, 2, and 8, causes the foregut endoderm to develop into the liver. Treatment of isolated foregut endoderm from mouse embryos with FGF1 or FGF2, but not FGF8, was sufficient to replace cardiac mesoderm as an inducer of the Liver gene expression program, the latter being the first step of hepatogenesis. The hepatogenic; response was restricted to endoderm tissue, which selectively coexpresses FGF receptors 1 and 4. Further studies with FGFs and their specific inhibitors showed that FGF8 contributes to the morphogenetic outgrowth of the hepatic endoderm. Thus, different FGF signals appear to initiate distinct phases of liver development during mammalian organogenesis.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA	Brown University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Zaret, KS (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Box G-J363, Providence, RI 02912 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036477, R01GM036477] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36477] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Cardoso WV, 1997, DEV DYNAM, V208, P398, DOI 10.1002/(SICI)1097-0177(199703)208:3<398::AID-AJA10>3.0.CO;2-X; CASCIO S, 1991, DEVELOPMENT, V113, P217; Celli G, 1998, EMBO J, V17, P1642, DOI 10.1093/emboj/17.6.1642; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Dufort D, 1998, DEVELOPMENT, V125, P3015; Ericson J, 1998, DEVELOPMENT, V125, P1005; FUKUDATAIRA S, 1981, J EMBRYOL EXP MORPH, V63, P111; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; GUZ Y, 1995, DEVELOPMENT, V121, P11; Hentsch B, 1996, GENE DEV, V10, P70, DOI 10.1101/gad.10.1.70; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HOUSSAINT E, 1980, CELL DIFFER DEV, V9, P269, DOI 10.1016/0045-6039(80)90026-3; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jung J. H., UNPUB; Kettunen P, 1998, DEV DYNAM, V211, P256, DOI 10.1002/(SICI)1097-0177(199803)211:3<256::AID-AJA7>3.0.CO;2-G; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LEDOUARIN NM, 1975, MED BIOL, V53, P427; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MAKOVER A, 1989, DIFFERENTIATION, V40, P17, DOI 10.1111/j.1432-0436.1989.tb00809.x; MANLEY NR, 1995, DEVELOPMENT, V121, P1989; MATSUZAKI K, 1989, P NATL ACAD SCI USA, V86, P9911, DOI 10.1073/pnas.86.24.9911; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; NAHON JL, 1988, J BIOL CHEM, V263, P11436; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOGAWA H, 1995, DEVELOPMENT, V121, P1015; Offield MF, 1996, DEVELOPMENT, V122, P983; OHTA T, 1995, BRIT J CANCER, V72, P824, DOI 10.1038/bjc.1995.420; Ohuchi H, 1997, DEVELOPMENT, V124, P2235; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PARLOW MH, 1991, DEV BIOL, V146, P139, DOI 10.1016/0012-1606(91)90454-B; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; POLIARD A, 1988, DIFFERENTIATION, V39, P59, DOI 10.1111/j.1432-0436.1988.tb00081.x; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; REUTER R, 1990, DEVELOPMENT, V110, P1031; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SELL S, 1985, DEV BRAIN RES, V22, P49, DOI 10.1016/0165-3806(85)90067-7; SHIROJRI N, 1991, CANCER RES, V51, P2611; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; STARK KL, 1991, DEVELOPMENT, V113, P641; SUGI Y, 1995, DEV DYNAM, V202, P115, DOI 10.1002/aja.1002020203; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; Tucker AS, 1998, EUR J ORAL SCI, V106, P122, DOI 10.1111/j.1600-0722.1998.tb02163.x; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Weinstein M, 1998, DEVELOPMENT, V125, P3615; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; Zhu XL, 1996, DEV DYNAM, V207, P429, DOI 10.1002/(SICI)1097-0177(199612)207:4<429::AID-AJA7>3.0.CO;2-J	71	543	579	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1998	2003		10.1126/science.284.5422.1998	http://dx.doi.org/10.1126/science.284.5422.1998			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373120				2022-12-01	WOS:000080932700050
J	Gross, CP; Anderson, GF; Rowe, NR				Gross, CP; Anderson, GF; Rowe, NR			The relation between funding by the National Institutes of Health and the burden of disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLOBAL BURDEN; LIFE; PERSPECTIVE; MORTALITY; ILLNESS; QALYS; COST	Background. The Institute of Medicine has proposed that the amount of disease-specific research funding provided by the National Institutes of Health (NIH) be systematically and consistently compared with the burden of disease for society. Methods. We performed a cross-sectional study comparing estimates of disease-specific funding in 1996 with data on six measures of the burden of disease. The measures were total mortality, years of life lost, and number of hospital days in 1994 and incidence, prevalence, and disability-adjusted life-years (one disability-adjusted life-year is defined as the loss of one year of healthy life to disease) in 1990. With the use of these measures as explanatory variables in a regression analysis, predicted funding was calculated and compared with actual funding. Results. There was no relation between the amount of NIH funding and the incidence, prevalence, or number of hospital days attributed to each condition or disease (P = 0.82, P = 0.23, and P = 0.21, respectively). The numbers of deaths (r = 0.40, P = 0.03) and years of life lost (r = 0.42, P = 0.02) were weakly associated with funding, whereas the number of disability-adjusted life-years was strongly predictive of fundi ng (r = 0.62, P < 0.001). When the latter th ree measures were used to predict expected funding, the conclusions about the appropriateness of funding for some diseases varied according to the measure used. However, the acquired immunodeficiency syndrome, breast cancer, diabetes mellitus, and dementia all received relatively generous funding, regardless of which measure was used as the basis for calculating support. Research on chronic obstructive pulmonary disease, perinatal conditions, and peptic ulcer was relatively underfunded. Conclusions. The amount of NIH funding for research on a disease is associated with the burden of the disease; however, different measures of the burden of disease may yield different conclusions about the appropriateness of disease-specific funding levels. (N Engl J Med 1999;340:1881-7). (C) 1999, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Gross, CP (corresponding author), Yale Univ, Sch Med, Primary Care Ctr, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.							AHRENS EH, 1992, CRISIS CLIN RES OVER, P236; ANDERSON C, 1993, SCIENCE, V260, P483, DOI 10.1126/science.8475380; [Anonymous], SCI OPP PUBL NEEDS I; Davidoff AJ, 1996, INT J TECHNOL ASSESS, V12, P9, DOI 10.1017/S026646230000934X; *DEP HLTH HUM SERV, 1989, DHHS PUBL; Glied S, 1996, AM J PUBLIC HEALTH, V86, P1723, DOI 10.2105/AJPH.86.12.1723; Gold MR, 1996, COST EFFECTIVENESS H, P425; Graves EJ, 1997, VITAL HLTH STAT, V13; HAENSZEL W, 1950, AM J PUBLIC HEALTH, V40, P17, DOI 10.2105/AJPH.40.1.17; HATZIANDREU E, 1988, REV INFECT DIS, V10, P159; Istook Jr. Ernest, 1997, J NIH RES, V9, P26; KINDIG DA, 1997, PURCHASING POPULATIO, P47; KOOPMANSCHAP MA, 1994, HEALTH ECON, V3, P385, DOI 10.1002/hec.4730030606; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; Marshall E, 1997, SCIENCE, V276, P344, DOI 10.1126/science.276.5311.344; MORROW RH, 1995, AM J PUBLIC HEALTH, V85, P1356, DOI 10.2105/AJPH.85.10.1356; MURRAY C, 1996, GLOBAL HLTH STAT COM, V2, P20; MURRAY CJ, 1995, SUMMARY GLOBAL BURDE, P43; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P495; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; *NAT CTR HLTH STAT, 1996, WORK TABL 1 DEATH EA; *NAT CTR HLTH STAT, 1993, VIT STAT US 1989, V2, P1; *NIH, 1996, C JUST; *NIH, 1995, NIH EXTR TRENDS FISC; *OFF FIN MAN, 1996, NIH EXTR DAT TRENDS; *OFF FIN MAN, 1996, NIH KEY FACTS HIST F; Office of the Director, 1997, DIS SPEC EST DIR IND; ROMEDER JM, 1977, INT J EPIDEMIOL, V6, P143, DOI 10.1093/ije/6.2.143; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SONDIK EJ, 1990, J NATL CANCER I, V82, P825; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; Williams A, 1996, SOC SCI MED, V43, P1795, DOI 10.1016/S0277-9536(96)00082-2; *WORK GROUP PRIOR, 1995, SETT RES PRIOR NAT I	34	321	324	1	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1881	1887		10.1056/NEJM199906173402406	http://dx.doi.org/10.1056/NEJM199906173402406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	206EC	10369852				2022-12-01	WOS:000080863500006
J	Taylor, B; Miller, E; Farrington, CP; Petropoulos, MC; Favot-Mayaud, I; Li, J; Waight, PA				Taylor, B; Miller, E; Farrington, CP; Petropoulos, MC; Favot-Mayaud, I; Li, J; Waight, PA			Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; ADVERSE EVENTS; CASE SERIES; PERTUSSIS; DISORDERS; CHILDREN	Background. We undertook an epidemiological study to investigate whether measles, mumps, and rubella (MMR) vaccine may be causally associated with autism. Methods. Children with autism born since 1979 were identified from special needs/disability registers and special schools in eight North Thames health districts, UK. Information from clinical records was linked to immunisation data held on the child health computing system. We looked for evidence of a change in trend in incidence or age at diagnosis associated with the introduction of MR IR vaccination to the UK in 1988. Clustering of onsets within defined postvaccination periods was investigated by the case-series method. Findings. We identified 498 cases of autism (261 of core autism, 166 of atypical autism, and 71 of Asperger's syndrome). In 293 cases the diagnosis could be confirmed by the criteria of the International Classification of Diseases, tenth revision (ICD10: 214 [82%] core autism, 52 [31%] atypical autism. 27 [38%] Asperger's syndrome). There was a steady increase in cases by year of birth with no sudden "step-up" or change in the trend line after the introduction of MMR vaccination. There was no difference in age at diagnosis between the cases vaccinated before or after 18 months of age and those never vaccinated. There was no temporal association between onset of autism within 1 or 2 years after vaccination with MMR (relative incidence compared with control period 0.94 [95% Cl 0.60-1.47] and 1.09 [0.79-1.52]). Developmental regression was not clustered in the months after vaccination (relative incidence within 2 months and 4 months after MMR vaccination 0.92 [0.38-2.21] and 1.00 [0.52-1.95]). No significant temporal clustering for age at onset of parental concern was seen far cases of core autism or atypical autism with the exception of a single interval within 6 months of MMR vaccination. This appeared to be an artifact related to the difficulty of defining precisely the onset of symptoms in this disorder. Interpretation. Our analyses do not support a causal association between MMR vaccine and autism. If such an association occurs, it is so rare that it could not be identified in this large regional sample.	UCL, Royal Free & Univ Coll Med Sch, Dept Community Child Hlth, London NW3 2QG, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England; Open Univ, Dept Stat, Milton Keynes, Bucks, England	University of London; University College London; Public Health England; Open University - UK	Taylor, B (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Community Child Hlth, Royal Free Campus, London NW3 2QG, England.			Petropoulos, Maria-Christina/0000-0003-0618-7016; Farrington, Conor Patrick/0000-0002-7148-2612				Bedford H, 1998, LANCET, V351, P907, DOI 10.1016/S0140-6736(05)70320-2; *CDSC, 1998, COMMUN DIS REP CDR W, V8, P345; Chadwick N, 1998, J MED VIROL, V55, P305, DOI 10.1002/(SICI)1096-9071(199808)55:4&lt;305::AID-JMV9&gt;3.0.CO;2-4; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; Farrington CP, 1996, AM J EPIDEMIOL, V143, P1165; FARRINGTON CP, 1995, BIOMETRICS, V51, P228, DOI 10.2307/2533328; FARRINGTON P, 1995, LANCET, V345, P567, DOI 10.1016/S0140-6736(95)90471-9; Fombonne E, 1997, J AM ACAD CHILD PSY, V36, P1561, DOI 10.1016/S0890-8567(09)66566-7; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; GILLBERG C, 1998, AUTISM, V2, P423; Lee JW, 1998, LANCET, V351, P905, DOI 10.1016/S0140-6736(98)26012-0; Morrell JM, 1997, AM J PRIMATOL, V41, P37, DOI 10.1002/(SICI)1098-2345(1997)41:1<37::AID-AJP3>3.0.CO;2-0; NICHOLL A, 1998, BMJ-BRIT MED J, V316, P715; SIEGEL B, 1988, J DEV BEHAV PEDIATR, V9, P199; THOMPSON NP, 1995, EUR J GASTROEN HEPAT, V7, P385; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; Wing L, 1996, BRIT MED J, V312, P327	19	461	473	0	519	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2026	2029		10.1016/S0140-6736(99)01239-8	http://dx.doi.org/10.1016/S0140-6736(99)01239-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376617	Green Accepted			2022-12-01	WOS:000080812200012
J	Dasen, JS; O'Connell, SM; Flynn, SE; Treier, M; Gleiberman, AS; Szeto, DP; Hooshmand, F; Aggarwal, AK; Rosenfeld, MG				Dasen, JS; O'Connell, SM; Flynn, SE; Treier, M; Gleiberman, AS; Szeto, DP; Hooshmand, F; Aggarwal, AK; Rosenfeld, MG			Reciprocal interactions of Pit1 and GATA2 mediate signaling gradient-induced determination of pituitary cell types	CELL			English	Article							BINDING TRANSCRIPTION FACTORS; HEART TUBE FORMATION; SYNERGISTIC INTERACTIONS; VENTRAL MORPHOGENESIS; HEMATOPOIETIC DEFECT; HOMEODOMAIN PROTEIN; GONADAL DEVELOPMENT; NUCLEAR RECEPTOR; GENE-EXPRESSION; DNA-BINDING	The mechanisms by which transient gradients of signaling molecules lead to emergence of specific cell types remain a central question in mammalian organogenesis. Here, we demonstrate that the appearance of four ventral pituitary cell types is mediated via the reciprocal interactions of two transcription factors, Pit1 and GATA2, which are epistatic to the remainder of the cell type-specific transcription programs and serve as the molecular memory of the transient signaling events. Unexpectedly, this program includes a DNA binding-independent function of Pit1, suppressing the ventral GATA2-dependent gonadotrope program by inhibiting GATA2 binding to gonadotrope- but not thyrotrope-specific genes, indicating that both DNA binding-dependent and -independent actions of abundant determining factors contribute to generate distinct cell phenotypes.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Icahn School of Medicine at Mount Sinai	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.		Treier, Mathias/AAD-6388-2021	gleiberman, anatoli/0000-0001-8491-0826				Bieberich CJ, 1996, J BIOL CHEM, V271, P31779, DOI 10.1074/jbc.271.50.31779; COULY G, 1988, DEVELOPMENT, V103, P101; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; DiMattia GE, 1997, DEV BIOL, V182, P180, DOI 10.1006/dbio.1996.8472; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; Ericson J, 1998, DEVELOPMENT, V125, P1005; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; Gordon DF, 1997, J BIOL CHEM, V272, P24339, DOI 10.1074/jbc.272.39.24339; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JACOBSON AG, 1979, J EXP ZOOL, V207, P351, DOI 10.1002/jez.1402070303; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; JAPON MA, 1994, J HISTOCHEM CYTOCHEM, V42, P117; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LIN SC, 1994, DEVELOPMENT, V120, P515; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Ma GT, 1997, DEVELOPMENT, V124, P907; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RUSCH J, 1996, CURR OPIN GENE DEV, V6, P16; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; SOMSON MW, 1996, NATURE, V384, P327; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; Takuma N, 1998, DEVELOPMENT, V125, P4835; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; Treier M, 1996, CURR OPIN CELL BIOL, V8, P833, DOI 10.1016/S0955-0674(96)80085-8; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Viger RS, 1998, DEVELOPMENT, V125, P2665; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Woods B, 1997, AGING MENT HEALTH, V1, P11, DOI 10.1080/13607869757335; Zhou YH, 1998, EMBO J, V17, P6689, DOI 10.1093/emboj/17.22.6689	47	236	243	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					587	598		10.1016/S0092-8674(00)80770-9	http://dx.doi.org/10.1016/S0092-8674(00)80770-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367888	Bronze			2022-12-01	WOS:000080672100008
J	McKenney, D; Pouliot, KL; Wang, Y; Murthy, V; Ulrich, M; Doring, G; Lee, JC; Goldmann, DA; Pier, GB				McKenney, D; Pouliot, KL; Wang, Y; Murthy, V; Ulrich, M; Doring, G; Lee, JC; Goldmann, DA; Pier, GB			Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen	SCIENCE			English	Article							CAPSULAR POLYSACCHARIDE ADHESIN; COAGULASE-NEGATIVE STAPHYLOCOCCI; BACTERIAL VIRULENCE GENES; IN-VIVO; HOST TISSUES; TYPE-5; IDENTIFICATION; ENDOCARDITIS; EPIDERMIDIS; SELECTION	Vaccines based on preferential expression of bacterial antigens during human infection have not been described. Staphylococcus aureus synthesized poly-N-succinyl beta-1-6 glucosamine (PNSG) as a surface polysaccharide during human and animal infection, but few strains expressed PNSC in vitro. All S. aureus strains examined carried genes for PNSG synthesis. Immunization protected mice against kidney infections and death from strains that produced little PNSG in vitro. Nonimmune infected animals made antibody to PNSG, but serial in vitro cultures of kidney isolates yielded mostly cells that did not produce PNSC. PNSG is a candidate for use in a vaccine to protect against S. aureus infection.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Klinikum, Inst Hyg, Dept Gen & Environm Hyg, D-72074 Tubingen, Germany	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Eberhard Karls University of Tubingen	Pier, GB (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 75 Francis St, Boston, MA 02115 USA.		Pier, Gerald/AAO-2692-2021	Pier, Gerald/0000-0002-9112-2331; Lee, Jean/0000-0002-8094-5180	NIAID NIH HHS [AI2335] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBUS A, 1991, INFECT IMMUN, V59, P1008, DOI 10.1128/IAI.59.3.1008-1014.1991; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Archer GL, 1998, CLIN INFECT DIS, V26, P1179, DOI 10.1086/520289; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; FATTOM A, 1992, INFECT IMMUN, V60, P584, DOI 10.1128/IAI.60.2.584-589.1992; FATTOM A, 1993, INFECT IMMUN, V61, P1023, DOI 10.1128/IAI.61.3.1023-1032.1993; Fattom AI, 1996, INFECT IMMUN, V64, P1659, DOI 10.1128/IAI.64.5.1659-1665.1996; FOURNIER JM, 1984, INFECT IMMUN, V45, P87, DOI 10.1128/IAI.45.1.87-93.1984; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; Herbert S, 1997, J INFECT DIS, V176, P431, DOI 10.1086/514061; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Jarvis WR, 1997, AM J INFECT CONTROL, V25, P477; KARAKAWA WW, 1985, J CLIN MICROBIOL, V22, P445, DOI 10.1128/JCM.22.3.445-447.1985; KOJIMA Y, 1990, J INFECT DIS, V162, P435, DOI 10.1093/infdis/162.2.435; Lee JC, 1997, INFECT IMMUN, V65, P4146, DOI 10.1128/IAI.65.10.4146-4151.1997; LEE JC, 1990, J CLIN MICROBIOL, V28, P2612, DOI 10.1128/JCM.28.12.2612-2615.1990; LEE JC, 1987, INFECT IMMUN, V55, P2191, DOI 10.1128/IAI.55.9.2191-2197.1987; LEE JC, 1997, STAPHYLOCOCCI HUMAN, P631; Lowe AM, 1998, MOL MICROBIOL, V27, P967, DOI 10.1046/j.1365-2958.1998.00741.x; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; MAMO W, 1994, FEMS IMMUNOL MED MIC, V10, P47, DOI 10.1111/j.1574-695X.1994.tb00010.x; McKenney D, 1998, INFECT IMMUN, V66, P4711, DOI 10.1128/IAI.66.10.4711-4720.1998; MCKENNEY D, UNPUB; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; MILES H, 1992, J DAIRY SCI, V75, P596, DOI 10.3168/jds.S0022-0302(92)77797-2; MOREAU M, 1990, CARBOHYD RES, V201, P285, DOI 10.1016/0008-6215(90)84244-O; MULLER E, 1993, J INFECT DIS, V168, P1211, DOI 10.1093/infdis/168.5.1211; MURTHY SVKN, 1983, CARBOHYD RES, V117, P113, DOI 10.1016/0008-6215(83)88080-X; NICKERSON SC, 1995, J DAIRY SCI, V78, P1607, DOI 10.3168/jds.S0022-0302(95)76785-6; Nilsson IM, 1998, J CLIN INVEST, V101, P2640, DOI 10.1172/JCI1823; SCHENNINGS T, 1993, MICROB PATHOGENESIS, V15, P227, DOI 10.1006/mpat.1993.1073; Schwan WR, 1998, INFECT IMMUN, V66, P567, DOI 10.1128/IAI.66.2.567-572.1998; SHIRO H, 1995, CIRCULATION, V92, P2715, DOI 10.1161/01.CIR.92.9.2715; SLAUCH JM, 1994, METHOD ENZYMOL, V235, P481; Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701; SOMPOLINSKY D, 1985, J CLIN MICROBIOL, V22, P828, DOI 10.1128/JCM.22.5.828-834.1985; TAKEDA S, 1991, CIRCULATION, V84, P2539, DOI 10.1161/01.CIR.84.6.2539; Tenover FC, 1998, J CLIN MICROBIOL, V36, P1020, DOI 10.1128/JCM.36.4.1020-1027.1998; WANG Y, 1994, CARBOHYD RES, V260, P305, DOI 10.1016/0008-6215(94)84048-2; WEST TE, 1987, J GEN MICROBIOL, V133, P431	43	275	294	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1523	1527		10.1126/science.284.5419.1523	http://dx.doi.org/10.1126/science.284.5419.1523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348739				2022-12-01	WOS:000080548100036
J	Thiemann, DR; Coresh, J; Oetgen, WJ; Powe, NR				Thiemann, DR; Coresh, J; Oetgen, WJ; Powe, NR			The association between hospital volume and survival after acute myocardial infarction in elderly patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COOPERATIVE CARDIOVASCULAR PROJECT; CORONARY ANGIOPLASTY VOLUME; SHORT-TERM MORTALITY; THROMBOLYTIC THERAPY; CARDIOLOGISTS; PHYSICIAN; OUTCOMES; MODELS; TRIAL; CARE	Background Patients with chest pain thought to be due to acute coronary ischemia are typically taken by ambulance to the nearest hospital. The potential benefit of field triage directly to a hospital that treats a large number of patients with myocardial infarction is unknown. Methods We conducted a retrospective cohort study of the relation between the number of Medicare patients with myocardial infarction that each hospital in the study treated (hospital volume) and longterm survival among 98,898 Medicare patients 65 years of age or older. We used proportional-hazards methods to adjust for clinical, demographic, and health-system-related variables, including the availability of invasive procedures, the specialty of the attending physician, and the area of residence of the patient (rural, urban, or metropolitan). Results The patients in the quartile admitted to hospitals with the lowest volume were 17 percent more likely to die within 30 days after admission than patients in the quartile admitted to hospitals with the highest volume (hazard ratio, 1.17; 95 percent confidence interval, 1.09 to 1.26; P<0.001), which resulted in 2.3 more deaths per 100 patients. The crude mortality rate at one year was 29.8 percent among the patients admitted to the lowest-volume hospitals, as compared with 27.0 percent among those admitted to the highest-volume hospitals. There was a continuous inverse dose-response relation between hospital volume and the risk of death. In an analysis of subgroups defined according to age, history of cardiac disease, Killip class of infarction, presence or absence of contraindications to thrombolytic therapy, and time from the onset of symptoms, survival at high-volume hospitals was consistently better than at low-volume hospitals. The availability of technology for angioplasty and bypass surgery was not independently associated with overall mortality. Conclusions Patients with acute myocardial infarction who are admitted directly to hospitals that have more experience treating myocardial infarction, as reflected by their case volume, are more likely to survive than are patients admitted to low-volume hospitals. (N Engl J Med 1999;340:1640-8.) (C) 1999. Massachusetts Medical Society.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Biostat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21287 USA; Johns Hopkins Univ, Program Med Technol & Practice Assessment, Baltimore, MD 21287 USA; Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21287 USA; Maryland Healthcare Associates, Clinton, MD USA; Delmarva Fdn Med Care, Easton, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Thiemann, DR (corresponding author), Johns Hopkins Univ, Dept Med, Carnegie 568, Baltimore, MD 21287 USA.				NCRR NIH HHS [RR00035, RR00072] Funding Source: Medline; PHS HHS [K01 A600561] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM HOSP ASS, 1997, 1994 ANN SURV HOSP D; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; BRODIE BR, 1994, CIRCULATION, V90, P156, DOI 10.1161/01.CIR.90.1.156; Casale PN, 1998, J AM COLL CARDIOL, V32, P885, DOI 10.1016/S0735-1097(98)00325-8; *CENS BUR, 1992, CENS POP HOUS 1990 S; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP AGR EC RES SE, 1997, ZIPFIP FIL; Every NR, 1997, CIRCULATION, V96, P1770, DOI 10.1161/01.CIR.96.6.1770; *FIBR THER TRIAL C, 1994, LANCET, V343, P742; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HANNAN EL, 1992, HEALTH SERV RES, V27, P517; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; HUGHES RG, 1988, MED CARE, V26, P1057, DOI 10.1097/00005650-198811000-00004; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; Jollis JG, 1998, NEW ENGL J MED, V338, P983, DOI 10.1056/NEJM199804023381410; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Nash IS, 1997, J AM COLL CARDIOL, V29, P475, DOI 10.1016/S0735-1097(96)00528-1; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; Nieto FJ, 1996, AM J EPIDEMIOL, V143, P1059; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Phibbs CS, 1996, JAMA-J AM MED ASSOC, V276, P1054, DOI 10.1001/jama.276.13.1054; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P2438; *STAT, 1997, STATA VERS 5 0; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; *TX MED FDN, 1998, COOP CARD PROJ; White HD, 1998, CIRCULATION, V97, P1632, DOI 10.1161/01.CIR.97.16.1632	38	307	311	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1999	340	21					1640	1648		10.1056/NEJM199905273402106	http://dx.doi.org/10.1056/NEJM199905273402106			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	199QY	10341277				2022-12-01	WOS:000080494200006
J	Dworkin, RH				Dworkin, RH			Prevention of postherpetic neuralgia	LANCET			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ACUTE HERPES-ZOSTER; RANDOMIZED TRIAL; DOUBLE-BLIND; DIABETIC NEUROPATHY; ORAL ACYCLOVIR; PAIN; AMITRIPTYLINE; METAANALYSIS; THERAPY		Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14642 USA	University of Rochester	Dworkin, RH (corresponding author), Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14642 USA.							BEUTNER KR, 1995, ANTIMICROB AGENTS CH, V39, P1546, DOI 10.1128/AAC.39.7.1546; Bowsher D, 1997, J PAIN SYMPTOM MANAG, V13, P327, DOI 10.1016/S0885-3924(97)00077-8; BYASSMITH MG, 1995, PAIN, V60, P267, DOI 10.1016/0304-3959(94)00121-T; DWORKIN RH, 1994, LANCET, V343, P1648, DOI 10.1016/S0140-6736(94)93106-2; Dworkin RH, 1998, J INFECT DIS, V178, pS76, DOI 10.1086/514260; DWORKIN RH, 1998, HDB PAIN SYNDROMES B; Harati Y, 1998, NEUROLOGY, V50, P1842, DOI 10.1212/WNL.50.6.1842; Jackson JL, 1997, ARCH INTERN MED, V157, P909, DOI 10.1001/archinte.157.8.909; JOHNSON R, 1995, J INFECTION, V30, P193; McQuay HJ, 1996, PAIN, V68, P217, DOI 10.1016/S0304-3959(96)03140-5; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; Watson CPN, 1998, NEUROLOGY, V51, P1166, DOI 10.1212/WNL.51.4.1166; Watson CPN, 1998, NEUROLOGY, V50, P1837; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304; Wood MJ, 1996, CLIN INFECT DIS, V22, P341, DOI 10.1093/clinids/22.2.341; WOOD MJ, 1995, MANAGEMENT STRATEGIE	18	27	28	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1636	1637		10.1016/S0140-6736(99)00003-3	http://dx.doi.org/10.1016/S0140-6736(99)00003-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335778				2022-12-01	WOS:000080408000003
J	Sabatini, DM; Barrow, RK; Blackshaw, S; Burnett, PE; Lai, MM; Field, ME; Bahr, BA; Kirsch, J; Betz, H; Snyder, SH				Sabatini, DM; Barrow, RK; Blackshaw, S; Burnett, PE; Lai, MM; Field, ME; Bahr, BA; Kirsch, J; Betz, H; Snyder, SH			Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling	SCIENCE			English	Article							P70 S6 KINASE; ATAXIA-TELANGIECTASIA GENE; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN PROTEIN; CELL-LINE; EARLY G1; YEAST; PHOSPHORYLATION; HOMOLOG; TARGET	RAFT1 (rapamycin and FKBP12 target 1; also called FRAP or mTOR) is a member of the ATM (ataxia telangiectasia mutated)-related family of proteins and functions as the in vivo mediator of the effects of the immunosuppressant rapamycin and as an important regulator of messenger RNA translation. In mammalian cells RAFT1 interacted with gephyrin, a widely expressed protein necessary for the clustering of glycine receptors at the cell membrane of neurons. RAFT1 mutants that could not associate with gephyrin failed to signal to downstream molecules, including the p70 ribosomal 56 kinase and the eIF-4E binding protein, 4E-BP1. The interaction with gephyrin ascribes a function to the Large amino-terminal region of an ATM-related protein and reveals a role in signal transduction for the clustering protein gephyrin.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Johns Hopkins University; University of Connecticut; Max Planck Society	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.			/0000-0002-1446-7256	NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Blackshaw S, 1997, J NEUROSCI, V17, P8074; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Gao FB, 1998, BIOESSAYS, V20, P70, DOI 10.1002/(SICI)1521-1878(199801)20:1<70::AID-BIES10>3.0.CO;2-5; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; Kawasaki BT, 1997, J NEUROSCI RES, V49, P381, DOI 10.1002/(SICI)1097-4547(19970801)49:3<381::AID-JNR13>3.0.CO;2-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; KRUPPA J, 1977, J CELL BIOL, V74, P414, DOI 10.1083/jcb.74.2.414; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABATINI DM, UNPUB; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037	38	151	157	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1161	1164		10.1126/science.284.5417.1161	http://dx.doi.org/10.1126/science.284.5417.1161			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325225				2022-12-01	WOS:000080359100035
J	Annas, GJ				Annas, GJ			Waste and longing - The legal status of placental-blood banking	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRANSPLANTATION; FUTURE		Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				*AM COLL OBST GYN, 1997, COMM OP ROUT STOR UM; ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; ANNAS GJ, 1993, JAMA-J AM MED ASSOC, V270, P2346, DOI 10.1001/jama.270.19.2346; Annas GJ, 1995, J LAW MED ETHICS, V23, P360, DOI 10.1111/j.1748-720X.1995.tb01378.x; ANNAS GJ, 1993, STANDARD CARE LAW AM, P167; BARON CH, 1975, BOSTON U LAW REV, V55, P159; Curran William J., 1959, NEW YORK U LAW REV, V34, P891; DeLillo Don, 1997, UNDERWORLD; FOX RC, 1974, COURAGE FAIL; GRADY D, 1998, NY TIMES        1201, pD6; GRADY D, 1998, NY TIMES        0415, pA1; *I MED COMM ASS GE, 1994, ASS GEN RISKS IMPL H; Kulynych Jennifer, 1998, Univ Richmond Law Rev, V32, P407; LIND SE, 1994, TRANSFUSION, V34, P828, DOI 10.1046/j.1537-2995.1994.34994378287.x; Parkman R, 1998, NEW ENGL J MED, V339, P1628, DOI 10.1056/NEJM199811263392209; Rubinstein P, 1998, NEW ENGL J MED, V339, P1565, DOI 10.1056/NEJM199811263392201; Schenk Jennifer L., 1997, MD J CONT LEGAL ISSU, V8, P151; Starr Douglas P., 1998, BLOOD EPIC HIST MED; Sugarman J, 1997, JAMA-J AM MED ASSOC, V278, P938, DOI 10.1001/jama.278.11.938; SUGARMAN J, 1995, JAMA-J AM MED ASSOC, V274, P1783, DOI 10.1001/jama.274.22.1783; Titmuss R. M., 1970, GIFT RELATIONSHIP HU; Zilberstein M, 1997, LANCET, V349, P642, DOI 10.1016/S0140-6736(96)05267-1	22	79	81	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1521	1524		10.1056/NEJM199905133401923	http://dx.doi.org/10.1056/NEJM199905133401923			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	194MT	10320393	Green Published			2022-12-01	WOS:000080198700031
J	Meinardi, JR; Middeldorp, S; de Kam, PJ; Koopman, MMW; van Pampus, ECM; Hamulyak, K; Prins, MH; Buller, HR; van der Meer, J				Meinardi, JR; Middeldorp, S; de Kam, PJ; Koopman, MMW; van Pampus, ECM; Hamulyak, K; Prins, MH; Buller, HR; van der Meer, J			Increased risk for fetal loss in carriers of the factor V Leiden mutation	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED PROTEIN-C; COAGULATION-FACTOR-V; VENOUS THROMBOEMBOLISM; RECURRENT MISCARRIAGE; RESISTANCE; THROMBOSIS; ASSOCIATION; INFARCTION; ABORTION; WOMEN	Background: An increased risk for fetal loss caused by placental thrombosis is probable in carriers of the factor V Leiden mutation but has not been demonstrated consistently in previous studies. Objective: To determine the overall risk for fetal loss and the separate risks for miscarriage and stillbirth in carriers of the factor V Leiden mutation. Design: Retrospective cohort study. Setting: Three university hospitals. Participants: 228 carriers of the factor V Leiden mutation (77 propositi, 151 relatives) and 121 noncarrier relatives (controls). All participants had been pregnant at least once. Measurements: Risks for fetal loss, miscarriage (defined as fetal loss within 20 weeks of gestation),and stillbirth (defined as fetal loss after >20 weeks of gestation) in women and in pregnancies were estimated and compared in carriers and noncarriers. Adjusted odds ratios were calculated by using multiple regression analysis. A random-effects model was used for comparisons of pregnancies. Results: Fetal loss occurred in 31.6% of carriers and 22.3% of noncarriers, miscarriage occurred in 29.4% of carriers and 17.4% of noncarriers. and stillbirth occurred in 5.7% of carriers and 5.0% of noncarriers. Fetal loss recurred in 10.1% of carriers and 4.1% of noncarriers (odds ratio, 2.60 [95% CI, 0.96 to 7.03]). Adjusted odds ratios were 2.12 (CI, 1.35 to 3.33) for fetal loss, 2.08 (CI, 1.33 to 3.25) for miscarriage, and 1.60 (CI, 0.58 to 4.43) for stillbirth when pregnancies in carriers and noncarriers were compared. Homozygous carriers had a greater risk for fetal loss (odds ratio; 2.01 [CI, 0.94 to 4.32]) and stillbirth (odds ratio, 4.85 [CI, 0.82 to 25.58]) than heterozygous carriers. Conclusions: Carriers of the factor V Leiden mutation have a greater risk for fetal loss (particularly miscarriage) than noncarriers. These data further suggest a greater risk for recurrence of fetal loss in carriers than in noncarriers and a greater risk for fetal loss and stillbirth in homozygous carriers than in heterozygous carriers.	Univ Groningen Hosp, Div Haemostasis Thrombosis & Rheol, NL-9713 GZ Groningen, Netherlands	University of Groningen	Meinardi, JR (corresponding author), Univ Groningen Hosp, Div Haemostasis Thrombosis & Rheol, Hanzeplein 1, NL-9713 GZ Groningen, Netherlands.		Middeldorp, Saskia/ABI-8197-2020	Middeldorp, Saskia/0000-0002-1006-6420				Balasch J, 1997, HUM REPROD, V12, P1094; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Brenner B, 1997, BRIT J HAEMATOL, V97, P551, DOI 10.1046/j.1365-2141.1997.882901.x; Diggle P., 2002, ANAL LONGITUDINAL DA; DizonTomson DS, 1997, AM J OBSTET GYNECOL, V177, P402, DOI 10.1016/S0002-9378(97)70205-9; DizonTownson DS, 1997, J REPROD IMMUNOL, V34, P217, DOI 10.1016/S0165-0378(97)00039-9; Grandone E, 1997, THROMB HAEMOSTASIS, V77, P822; Middeldorp S, 1998, ANN INTERN MED, V128, P15, DOI 10.7326/0003-4819-128-1-199801010-00003; Preston FE, 1996, LANCET, V348, P913, DOI 10.1016/S0140-6736(96)04125-6; Rai R, 1996, BRIT J HAEMATOL, V92, P489, DOI 10.1046/j.1365-2141.0000.d01-1465.x; Rai RS, 1996, BRIT J OBSTET GYNAEC, V103, P842, DOI 10.1111/j.1471-0528.1996.tb09887.x; Ridker PM, 1998, ANN INTERN MED, V128, P1000, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00007; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Sanson BJ, 1996, THROMB HAEMOSTASIS, V75, P387; STIRRAT GM, 1990, LANCET, V336, P673, DOI 10.1016/0140-6736(90)92159-F; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	17	130	131	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					736	739		10.7326/0003-4819-130-9-199905040-00013	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357692				2022-12-01	WOS:000080062300004
J	Haggard, M				Haggard, M			Commentary: Plausible candidates for treatment of glue ear - is one issue really three?	BRITISH MEDICAL JOURNAL			English	Editorial Material									MRC, Inst Hearing Res, Nottingham NG7 2RD, England		Haggard, M (corresponding author), MRC, Inst Hearing Res, Univ Pk, Nottingham NG7 2RD, England.							Buxton M, 1996, J Health Serv Res Policy, V1, P35; Haggard MP, 1991, SCREENING CHILDRENS	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1178	1178						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10383203				2022-12-01	WOS:000080277900030
J	Monaghan, J				Monaghan, J			Time to add chemotherapy to radiotherapy for cervical cancer	LANCET			English	Editorial Material									Queen Elizabeth Hosp, Dept Gynecol Oncol, Gateshead NE9 6SX, Tyne & Wear, England		Monaghan, J (corresponding author), Queen Elizabeth Hosp, Dept Gynecol Oncol, Gateshead NE9 6SX, Tyne & Wear, England.							GROGAN M, 1999, 30 ANN M SOC GYN ONC; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502	4	11	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1288	1289		10.1016/S0140-6736(99)00073-2	http://dx.doi.org/10.1016/S0140-6736(99)00073-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218522				2022-12-01	WOS:000080278100004
J	McCauliffe, DP				McCauliffe, DP			Distinguishing subacute cutaneous from other types of lupus erythematosus	LANCET			English	Editorial Material									Univ N Carolina, Sch Med, Dept Dermatol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	McCauliffe, DP (corresponding author), Univ N Carolina, Sch Med, Dept Dermatol, Chapel Hill, NC 27599 USA.							BIELSA I, 1994, ARCH DERMATOL, V130, P54, DOI 10.1001/archderm.130.1.54; Chlebus E, 1998, J AM ACAD DERMATOL, V38, P405, DOI 10.1016/S0190-9622(98)70497-9; Crowson AN, 1997, HUM PATHOL, V28, P67, DOI 10.1016/S0046-8177(97)90281-1; LEHMANN P, 1990, J AM ACAD DERMATOL, V22, P181, DOI 10.1016/0190-9622(90)70020-I; McCauliffe Daniel P., 1993, P302; McCauliffe DP, 1997, LUPUS, V6, P158, DOI 10.1177/096120339700600211; REED BR, 1985, ANN INTERN MED, V103, P49, DOI 10.7326/0003-4819-103-1-49; SONTHEIMER RD, 1989, MED CLIN N AM, V73, P1073, DOI 10.1016/S0025-7125(16)30620-4; SONTHEIMER RD, 1979, ARCH DERMATOL, V115, P1409, DOI 10.1001/archderm.115.12.1409; Sontheimer Richard D., 1993, P285; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WOLSKA H, 1989, INT J DERMATOL, V28, P98, DOI 10.1111/j.1365-4362.1989.tb01327.x	12	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1527	1528		10.1016/S0140-6736(05)61117-8	http://dx.doi.org/10.1016/S0140-6736(05)61117-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326532				2022-12-01	WOS:000073868000005
J	Lu, PJ; Wulf, G; Zhou, XZ; Davies, P; Lu, KP				Lu, PJ; Wulf, G; Zhou, XZ; Davies, P; Lu, KP			The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein	NATURE			English	Article							PAIRED HELICAL FILAMENTS; SUBSTRATE RECOGNITION; DISEASE; DEMENTIA; MITOSIS; CHROMOSOME-17; EXPRESSION; MUTATIONS; ISOFORMS; DISTINCT	One of the neuropathological hallmarks of Alzheimer's disease is the neurofibrillary tangle, which contains paired helical filaments (PHFs) composed of the microtubule-associated protein tau(1,2). Tau is hyperphosphorylated in PHFs(3-5), and phosphorylation of tau abolishes its ability to bind microtubules and promote microtubule assembly(6,7). Restoring the function of phosphorylated tau might prevent or reverse PHF formation in Alzheimer's disease. Phosphorylation on a serine or threonine that precedes proline (pS/T-P) alters the rate of prolyl isomerization and creates a binding site for the WW domain of the prolyl isomerase Pin1 (refs 8-14), Pin1 specifically isomerizes pS/T-P bonds and regulates the function of mitotic phosphoproteins(8-10,12). Here we show that Pin1 binds to only one pT-P motif in tau and copurifies with PHFs, resulting in depletion of soluble Pin1 in the brains of Alzheimers disease patients. Pin1 can restore the ability of phosphorylated tau to bind microtubules and promote microtubule assembly in vitro, As depletion of Pin1 induces mitotic arrest and apoptotic cell death(8), sequestration of Pin1 into PHFs may contribute to neuronal death. These findings provide a new insight into the pathogenesis of Alzheimer's disease.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.		Wulf, Gerburg/AAS-6713-2021					ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kondratick CM, 1996, J NEUROCHEM, V67, P2405; Kosik KS, 1996, ANN NY ACAD SCI, V777, P114, DOI 10.1111/j.1749-6632.1996.tb34409.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lu KP, 1996, NATURE, V380, P544; LU KP, IN PRESS PROG CELL C; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Nagy Z, 1997, ACTA NEUROPATHOL, V93, P294, DOI 10.1007/s004010050617; Preuss U, 1998, EUR J CELL BIOL, V76, P176, DOI 10.1016/S0171-9335(98)80032-0; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1997, J NEUROSCI, V17, P3588; VINCENT IJ, 1992, P NATL ACAD SCI USA, V89, P2878, DOI 10.1073/pnas.89.7.2878; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	30	601	629	0	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					784	788						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391244				2022-12-01	WOS:000081101600054
J	Holash, J; Maisonpierre, PC; Compton, D; Boland, P; Alexander, CR; Zagzag, D; Yancopoulos, GD; Wiegand, SJ				Holash, J; Maisonpierre, PC; Compton, D; Boland, P; Alexander, CR; Zagzag, D; Yancopoulos, GD; Wiegand, SJ			Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; IN-VIVO; MOLECULAR-CLONING; TIE2 RECEPTOR; ANGIOGENESIS; EXPRESSION; CELLS; GENES; TEK; VASCULOGENESIS	In contrast with the prevailing view that most tumors and metastases begin as avascular masses, evidence is presented here that a subset of tumors instead initially grows by coopting existing host vessels. This coopted host vasculature does not immediately undergo angiogenesis to support the tumor but instead regresses, leading to a secondarily avascular tumor and massive tumor cell loss. Ultimately, however, the remaining tumor is rescued by robust angiogenesis at the tumor margin. The expression patterns of the angiogenic antagonist angiopoietin-2 and of pro-angiogenic vascular endothelial growth factor (VEGF) suggest that these proteins may be critical regulators of this balance between vascular regression and growth.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; NYU, Med Ctr, Kaplan Canc Ctr, Dept Pathol,Microvasc & Mol Neurooncol Lab, New York, NY 10016 USA	Regeneron; New York University	Yancopoulos, GD (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.							ANAKA S, 1999, J CLIN INVEST, V103, P341; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLASH J, UNPUB; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; KIM KJ, 1993, NATURE, V362, P741; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MORGENBESSER SD, 1995, EMBO J, V14, P743, DOI 10.1002/j.1460-2075.1995.tb07053.x; MORSE JK, 1993, J NEUROSCI, V13, P4146; NAGANO N, 1993, ACTA NEUROPATHOL, V86, P117, DOI 10.1007/BF00334878; Papapetropoulos A, 1999, LAB INVEST, V79, P213; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Pezzella F, 1997, AM J PATHOL, V151, P1417; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Valenzuela DM, 1999, P NATL ACAD SCI USA, V96, P1904, DOI 10.1073/pnas.96.5.1904; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WESSELING P, 1994, J NEUROSURG, V81, P902, DOI 10.3171/jns.1994.81.6.0902; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; ZAGZAG D, IN PRESS EXP NEUROL; ZIEGLER SF, 1993, ONCOGENE, V8, P663	41	1695	1829	2	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1994	1998		10.1126/science.284.5422.1994	http://dx.doi.org/10.1126/science.284.5422.1994			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373119				2022-12-01	WOS:000080932700049
J	Matray, TJ; Kool, ET				Matray, TJ; Kool, ET			A specific partner for abasic damage in DNA	NATURE			English	Article							APURINIC APYRIMIDINIC SITES; DEOXYRIBONUCLEIC-ACID; REPLICATION FIDELITY; OLIGODEOXYNUCLEOTIDES; FLUORESCENCE; SELECTIVITY; POLYMERASES; MECHANISM; INSERTION; CRYSTAL	In most-models of DNA replication, Watson-Crick hydrogen bonding drives the incorporation of nucleotides into the new strand of DNA and maintains the complementarity of bases with the template strand. Studies with nonpolar analogues of thymine and adenine, however, have shown that replication is still efficient in the absence of hydrogen bonds(1-4). The replication of base pairs might also be influenced by steric exclusion, whereby inserted nucleotides need to be the correct size and shape to fit the active site against a template base(5,6). A simple steric-exclusion model map not require Watson-Crick hydrogen bonding to explain the fidelity of replication, nor should canonical purine and pyrimidine shapes be necessary for enzymatic synthesis of a base pair if each can fit into the DNA double helix without steric strain(6). Here we test this idea by using a pyrene nucleoside triphosphate (dPTP) in which the fluorescent 'base' is nearly as large as an entire Watson-Crick base pair. We show that the non-hydrogen-bonding dPTP is efficiently and specifically inserted by DNA polymerases opposite sites that lack DNA bases. The efficiency of this process approaches that of a natural base pair and the specificity is 10(2)-10(4)-fold. We use these properties to sequence abasic lesions in DNA, which are a common form of DNA damage in vivo(7). In addition to their application in identifying such genetic lesions, our results show that neither hydrogen bonds nor purine and pyrimidine structures are required to form a base pair with high efficiency and selectivity. These findings confirm that steric complementarity is an important factor in the fidelity of DNA synthesis.	Univ Rochester, Dept Chem, Rochester, NY 14627 USA	University of Rochester	Kool, ET (corresponding author), Univ Rochester, Dept Chem, Rochester, NY 14627 USA.							Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Diederichsen U, 1998, ANGEW CHEM INT EDIT, V37, P1655, DOI 10.1002/(SICI)1521-3773(19980703)37:12<1655::AID-ANIE1655>3.0.CO;2-2; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fygenson DK, 1997, J BIOL CHEM, V272, P27931, DOI 10.1074/jbc.272.44.27931; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; IDE H, 1993, BIOCHEMISTRY-US, V32, P8276, DOI 10.1021/bi00083a031; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Matray TJ, 1998, J AM CHEM SOC, V120, P6191, DOI 10.1021/ja9803310; Maulik G, 1999, NUCLEIC ACIDS RES, V27, P1316, DOI 10.1093/nar/27.5.1316; MILLICAN TA, 1984, NUCLEIC ACIDS RES, V12, P7435, DOI 10.1093/nar/12.19.7435; MISHRA MC, 1991, J CHEM SOC CHEM COMM, P1276; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; Paris PL, 1998, NUCLEIC ACIDS RES, V26, P3789, DOI 10.1093/nar/26.16.3789; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; Ren RXF, 1996, J AM CHEM SOC, V118, P7671, DOI 10.1021/ja9612763; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; Shibutani S, 1997, J BIOL CHEM, V272, P13916, DOI 10.1074/jbc.272.21.13916; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WEISS B, 1972, ADV ENZYMOL REL AREA, V60, P1	30	215	232	3	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					704	708		10.1038/21453	http://dx.doi.org/10.1038/21453			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385125				2022-12-01	WOS:000080932800065
J	Heymann, SJ; Brewer, TF; Wilson, ME; Fineberg, HV				Heymann, SJ; Brewer, TF; Wilson, ME; Fineberg, HV			The need for global action against multidrug-resistant tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ANTITUBERCULOSIS-DRUG-RESISTANCE; UNITED-STATES; EPIDEMIOLOGY; SURVEILLANCE; PROGRAM; HEALTH		Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Heymann, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, 677 Huntington Ave, Boston, MA 02115 USA.							AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; BASS J, 1992, AM REV RESPIR DIS, V146, P1623; Boulahbal F, 1989, Bull Int Union Tuberc Lung Dis, V64, P23; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; *CDCP, 1997, REP TUB US 1996; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Crofton J., 1997, GUIDELINES MANAGEMEN; ESPINAL MA, 1998, INT J TUBERC LUNG S2, V2, pS371; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; Heath TC, 1998, INT J TUBERC LUNG D, V2, P647; Kim SJ, 1997, INT J TUBERC LUNG D, V1, P302; Lambregts-van Weezenbeek CSB, 1998, INT J TUBERC LUNG D, V2, P288; Laszlo A, 1997, INT J TUBERC LUNG D, V1, P231; Manns BJ, 1997, INT J TUBERC LUNG D, V1, P225; MARTIN A, 1996, AIDS WORLD, V2, P390; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; NAZARSTEWART V, 1992, AM REV RESPIR DIS, V146, P57, DOI 10.1164/ajrccm/146.1.57; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; REICHMAN LB, 1993, AM J PUBLIC HEALTH, V83, P639, DOI 10.2105/AJPH.83.5.639; TELZAK EE, 1995, NEW ENGL J MED, V333, P907, DOI 10.1056/NEJM199510053331404; WHO, 1997, ANT DRUG RES WORLD W, P60; *WHO TUB PROGR, 1995, WHO REP TUB EP 1995; WILSON ME, 1995, EMERG INFECT DIS, V1, P39, DOI 10.3201/eid0102.950201; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; 1998, TUBERC MONITOR   MAY, P53	27	26	29	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2138	2140		10.1001/jama.281.22.2138	http://dx.doi.org/10.1001/jama.281.22.2138			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367825				2022-12-01	WOS:000080668000037
J	Kohen, A; Cannio, R; Bartolucci, S; Klinman, JP				Kohen, A; Cannio, R; Bartolucci, S; Klinman, JP			Enzyme dynamics and hydrogen tunnelling in a thermophilic alcohol dehydrogenase	NATURE			English	Article							ELIMINATION-REACTIONS; FLEXIBILITY; CATALYSIS; STABILITY	Biological catalysts (enzymes) speed up reactions by many orders of magnitude using fundamental physical processes to increase chemical reactivity. Hydrogen tunnelling has increasingly been found to contribute to enzyme reactions at room temperature(1), Tunnelling is the phenomenon by which a particle transfers through a reaction barrier as a result of its wave-like property(1-3). In reactions involving small molecules, the relative importance of tunnelling increases as the temperature is reduced(4). We have now investigated whether hydrogen tunnelling occurs at elevated temperatures in a biological system that functions physiologically under such conditions, Using a thermophilic alcohol dehydrogenase (ADH), we find that hydrogen tunnelling makes a significant contribution at 65 degrees C; this is analogous to previous findings with mesophilic ADH at 25 degrees C (ref. 5), Contrary to predictions for tunnelling through a rigid barrier, the tunnelling with. the thermophilic ADH decreases at and below room temperature. These findings provide experimental evidence for a role of thermally excited enzyme fluctuations in modulating enzyme-catalysed bond cleavage.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; CNR, ISA, I-83100 Avellino, Italy; Univ Naples Federico 2, Dipartimento Chim Organ & Biol, I-80134 Naples, Italy	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR); University of Naples Federico II	Klinman, JP (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	klinman@socrates.berkeley.edu		Bartolucci, Simonetta/0000-0002-1968-2959				Antoniou D, 1998, J CHEM PHYS, V108, P3620, DOI 10.1063/1.475756; Antoniou D, 1997, P NATL ACAD SCI USA, V94, P12360, DOI 10.1073/pnas.94.23.12360; Bell R P, 1980, TUNNELING EFFECT CHE; BENDERSKII VA, 1994, ADV CHEM PHYS, V88, P151; BORGIS D, 1993, CHEM PHYS, V170, P315, DOI 10.1016/0301-0104(93)85117-Q; BORGIS D, 1989, NATO ADV SCI I A-LIF, V178, P293; Brooks C. L., 1988, ADV CHEM PHYS, VLXXI, P75; BROOKS CL, 1988, ADV CHEM PHYS, V71, P14; Brooks III C. L., 1988, ADV CHEM PHYS, VLXXI, P33; BRUNO WJ, 1992, BIOPHYS J, V63, P689, DOI 10.1016/S0006-3495(92)81654-5; CANNIO R, 1994, EUR J BIOCHEM, V222, P345, DOI 10.1111/j.1432-1033.1994.tb18873.x; CHA Y, 1989, SCIENCE, V243, P1325, DOI 10.1126/science.2646716; Guagliardi A, 1996, INT J BIOCHEM CELL B, V28, P239, DOI 10.1016/1357-2725(95)00138-7; Hwang JK, 1997, CHEM PHYS LETT, V271, P223, DOI 10.1016/S0009-2614(97)00482-X; Kohen A, 1997, BIOCHEMISTRY-US, V36, P2603, DOI 10.1021/bi962492r; Kohen A, 1998, ACCOUNTS CHEM RES, V31, P397, DOI 10.1021/ar9701225; Lakatos S, 1978, BIOCHEM SOC T, V6, P1195, DOI 10.1042/bst0061195; LIN S, 1994, J AM CHEM SOC, V116, P6107, DOI 10.1021/ja00093a007; Melander L., 1987, REACTION RATES ISOTO; RASMUSSEN BF, 1992, NATURE, V357, P423, DOI 10.1038/357423a0; Rucker J, 1999, J AM CHEM SOC, V121, P1997, DOI 10.1021/ja9824425; RUDD PM, 1994, BIOCHEMISTRY-US, V33, P17, DOI 10.1021/bi00167a003; SAUNDERS WH, 1985, J AM CHEM SOC, V107, P164, DOI 10.1021/ja00287a029; SOMERO GN, 1979, NATURE, V282, P100, DOI 10.1038/282100a0; Steinfeld J.I., 1998, CHEM KINETICS DYNAMI; VARLEY PG, 1991, J MOL BIOL, V220, P531, DOI 10.1016/0022-2836(91)90028-5; VIHINEN M, 1987, PROTEIN ENG, V1, P477, DOI 10.1093/protein/1.6.477; VOL'KENSHTEIN M V, 1972, Molecular Biology (English Translation of Molekulyarnaya Biologiya (Moscow)), V6, P347; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406	30	470	477	6	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					496	499		10.1038/20981	http://dx.doi.org/10.1038/20981			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365965				2022-12-01	WOS:000080667900055
J	Gallagher, RB				Gallagher, RB			Evolutionary biology - The male's dilemma	SCIENCE			English	Editorial Material							GONADAL-STEROIDS; IMMUNOCOMPETENCE							Gallagher, Richard/0000-0001-5639-2187				FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; HASSELQUIST D, IN PRESS BEHAV ECOL; Leitner G, 1996, POULTRY SCI, V75, P1373, DOI 10.3382/ps.0751373; McCurdy DG, 1998, OIKOS, V82, P303, DOI 10.2307/3546970; Ros AFH, 1997, AM NAT, V150, P201, DOI 10.1086/286063; Verhulst S, 1999, P NATL ACAD SCI USA, V96, P4478, DOI 10.1073/pnas.96.8.4478	6	4	4	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1140	1140		10.1126/science.284.5417.1140	http://dx.doi.org/10.1126/science.284.5417.1140			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10366348				2022-12-01	WOS:000080359100028
J	Petersen, BE; Bowen, WC; Patrene, KD; Mars, WM; Sullivan, AK; Murase, N; Boggs, SS; Greenberger, JS; Goff, JP				Petersen, BE; Bowen, WC; Patrene, KD; Mars, WM; Sullivan, AK; Murase, N; Boggs, SS; Greenberger, JS; Goff, JP			Bone marrow as a potential source of hepatic oval cells	SCIENCE			English	Article							WHOLE-ORGAN TRANSPLANTATION; LIVER-REGENERATION; STEM-CELLS; ADULT-RAT; ACTIVATION; COMPARTMENT; EXPRESSION; TISSUE; DAMAGE; CDNA	Bone marrow stem cells develop into hematopoietic and mesenchymal Lineages but have not been known to participate in production of hepatocytes, biliary : cells, or oval cells during Liver regeneration. Cross-sex or cross-strain bone marrow and whole Liver transplantation Were used to trace the origin of the repopulating Liver cells. Transplanted rats were treated with 2-acetylaminofluorene, to block hepatocyte proliferation, and then hepatic injury, to induce oval cell proliferation. Markers for Y chromosome, dipeptidyl peptidase IV enzyme, and L21-6 antigen were used to identify Liver cells of bone marrow origin. From these cells, a proportion of the regenerated hepatic cells were shown to be, donor-derived. Thus, a stem cell associated with the bone marrow has epithelial cell Lineage capability.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Transplantat Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Radiat Oncol, Pittsburgh, PA 15261 USA; McGill Univ, Dept Hematol Oncol, Montreal, PQ H3A 2T5, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; McGill University	Petersen, BE (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Transplantat Pathol, Pittsburgh, PA 15261 USA.							An J, 1997, J ANDROL, V18, P289; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; EVARTS RP, 1989, CANCER RES, V49, P1541; FAUSTO N, 1994, LIVER BIOL PATHOBIOL, pCH78; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FUJIO K, 1994, LAB INVEST, V70, P511; GRISHAM JW, 1997, STEM CELLS, pCH8; Hagios C, 1998, PHILOS T R SOC B, V353, P857, DOI 10.1098/rstb.1998.0250; HIXSON DC, 1992, ROLE CELL TYPES HEPA, pCH8; LOJDO Z, 1979, HISTOCHEMISTRY, V57, P107; MURASE N, 1995, TRANSPLANTATION, V60, P158, DOI 10.1097/00007890-199507270-00009; Murase N, 1996, TRANSPLANTATION, V61, P1, DOI 10.1097/00007890-199601150-00001; Novikoff PM, 1996, AM J PATHOL, V148, P1473; Omori M, 1997, AM J PATHOL, V150, P1179; Omori N, 1997, HEPATOLOGY, V26, P720, DOI 10.1002/hep.510260325; Petersen BE, 1997, AM J PATHOL, V151, P905; Petersen BE, 1998, HEPATOLOGY, V27, P1030, DOI 10.1002/hep.510270419; Petersen BE, 1998, HEPATOLOGY, V27, P433, DOI 10.1002/hep.510270218; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; THORGEIRSSON SS, 1993, P SOC EXP BIOL MED, V204, P253; YAGIHASHI A, 1995, TRANSPLANT P, V27, P1519	21	1900	2275	2	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1168	1170		10.1126/science.284.5417.1168	http://dx.doi.org/10.1126/science.284.5417.1168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325227				2022-12-01	WOS:000080359100037
J	Kramer, EM; Irish, VF				Kramer, EM; Irish, VF			Evolution of genetic mechanisms controlling petal development	NATURE			English	Article							MADS-BOX; FLOWER DEVELOPMENT; MOLECULAR EVOLUTION; HOMEOBOX GENE; ARABIDOPSIS; EXPRESSION; DIVERSIFICATION; PISTILLATA; APETALA3; PLANTS	Molecular genetic studies in Arabinopsis thaliana and other higher-eudicot flowering plants have led to the development of the 'ABC' model of the determination of organ identity in flowers, in which three classes of gene, A, B and C, are thought to work together to determine organ identity(1,2). According to this model, the B-class genes APETALA3 (AP3) and PISTILLATA (PI) act to specify petal and stamen identity, Here we test whether the roles of these genes are conserved throughout the angiosperms by analysing the expression of AP3 and PI orthologues in the lower eudicot subclass Ranunculidae, We show that, although expression of these orthologues in the stamens is conserved, the expression patterns in the petals differ from those found in the higher eudicots, The differences between these expression patterns suggest that the function of AP3 and PI homologues as R-class organ-identity genes is not rigidly conserved among all angiosperms. These observations have important implications for understanding the evolution of both angiosperm petals and the genetic mechanisms that control the identities of floral organs.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Irish, VF (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208104, New Haven, CT 06520 USA.	vivian.irish@yale.edu						Bowman JL, 1997, J BIOSCIENCE, V22, P515, DOI 10.1007/BF02703197; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Carr SM, 1997, PLANTA, V201, P179, DOI 10.1007/s004250050117; CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DECRAENE LPR, 1992, CAN J BOT, V70, P1765, DOI 10.1139/b92-219; DRINNAN AN, 1994, EARLY EVOLUTION FLOW, P93; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; HARDENACK S, 1994, PLANT CELL, V6, P1775, DOI 10.1105/tpc.6.12.1775; Irish VF, 1998, ADV BOT RES, V28, P197; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; KOSUGE K, 1994, PLANT SYST EVOL, P185; Kramer EM, 1998, GENETICS, V149, P765; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; MEYEROWITZ EM, 1991, DEVELOPMENT, P157; PURUGGANAN MD, 1995, GENETICS, V140, P345; SMITH LG, 1992, DEVELOPMENT, V116, P21; SOMMER H, 1991, DEVELOPMENT, P169; Takhtajan A., 1991, EVOLUTIONARY TRENDS; THEISSEN G, 1995, CURR OPIN GENET DEV, V5, P628, DOI 10.1016/0959-437X(95)80032-8; ZACHGO S, 1995, DEVELOPMENT, V121, P2861	22	196	213	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1999	399	6732					144	148		10.1038/20172	http://dx.doi.org/10.1038/20172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335842				2022-12-01	WOS:000080335700048
J	Sasieni, P; Adams, J				Sasieni, P; Adams, J			Effect of screening on cervical cancer mortality in England and Wales: Analysis of trends with an age period cohort model	BRITISH MEDICAL JOURNAL			English	Article									Imperial Canc Res Fund, Dept Math Stat & Epidemiol, London WC2A 3PX, England	Cancer Research UK	Sasieni, P (corresponding author), Imperial Canc Res Fund, Dept Math Stat & Epidemiol, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Sasieni, Peter/0000-0003-1509-8744				BERAL V, 1974, LANCET, V1, P1037; *OFF POP CENS SURV, 1998, MON POP HLTH SER; Rooney C, 1996, Popul Trends, P29; Sasieni PD, 1996, BRIT J CANCER, V73, P1001, DOI 10.1038/bjc.1996.196	4	121	129	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1244	1245						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231253				2022-12-01	WOS:000080278000024
J	Diefenbach, A; Schindler, H; Rollinghoff, M; Yokoyama, WM; Bogdan, C				Diefenbach, A; Schindler, H; Rollinghoff, M; Yokoyama, WM; Bogdan, C			Requirement for type 2 NO synthase for IL-12 signaling in innate immunity	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; NATURAL-KILLER-CELLS; LEISHMANIA-MAJOR; INTERFERON-GAMMA; TYROSINE KINASE; T-CELLS; ACTIVATION; MICE; INTERLEUKIN-12; INFECTION	Interleukin-12 (IL-12) and type 2 NO synthase (NOS2) are crucial for defense against bacterial and parasitic pathogens, but their relationship in innate immunity is unknown. in the absence of NOS2 activity, IL-12 was unable to prevent spreading of Leishmania parasites, did not stimulate natural killer (NK) cells for cytotoxicity or interferon-gamma (IFN-gamma) release, and failed to activate Tyk2 kinase and to tyrosine phosphorylate Stat4 (the central signal transducer of IL-12) in NK cells. Activation of Tyk2 in NK cells by IFN-alpha/beta also required NOS2. Thus, NOS2-derived NO is a prerequisite for cytokine signaling and function in innate immunity.	Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, D-91054 Erlangen, Germany; Washington Univ, Sch Med, Howard Hughes Med Inst, Div Rheumatol, St Louis, MO 63110 USA	University of Erlangen Nuremberg; Howard Hughes Medical Institute; Washington University (WUSTL)	Bogdan, C (corresponding author), Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, Wasserturmstr 3, D-91054 Erlangen, Germany.		Diefenbach, Andreas/T-2589-2018	Diefenbach, Andreas/0000-0002-9176-9530; Bogdan, Christian/0000-0002-2300-0631				BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Bogdan C, 1997, Behring Inst Mitt, P58; Bogdan C, 1998, J EXP MED, V187, P1361, DOI 10.1084/jem.187.9.1361; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Denkers EY, 1998, IMMUNOLOGIST, V6, P116; Diefenbach A, 1998, IMMUNITY, V8, P77, DOI 10.1016/S1074-7613(00)80460-4; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; Hierholzer C, 1998, J EXP MED, V187, P917, DOI 10.1084/jem.187.6.917; Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO;2-K; KARLHOFER FM, 1995, J EXP MED, V181, P1785, DOI 10.1084/jem.181.5.1785; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LASKAY T, 1995, EUR J IMMUNOL, V25, P2220, DOI 10.1002/eji.1830250816; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rothe H, 1996, BIOCHEM BIOPH RES CO, V224, P159, DOI 10.1006/bbrc.1996.1000; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; SCHARTONKERSTEN T, 1995, J IMMUNOL, V154, P5320; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; STOUT RD, 1993, CURR OPIN IMMUNOL, V5, P398, DOI 10.1016/0952-7915(93)90059-2; Tarrant TK, 1999, J EXP MED, V189, P219, DOI 10.1084/jem.189.2.219; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Thuring H, 1995, EUR J IMMUNOL, V25, P3229, DOI 10.1002/eji.1830251205; Trinchieri G, 1996, J LEUKOCYTE BIOL, V59, P505, DOI 10.1002/jlb.59.4.505; Yu CR, 1996, J IMMUNOL, V157, P126	30	156	160	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					951	955		10.1126/science.284.5416.951	http://dx.doi.org/10.1126/science.284.5416.951			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320373				2022-12-01	WOS:000080198800042
J	Horowitz, HS				Horowitz, HS			Proper use of fluoride products in fluoridated communities	LANCET			English	Editorial Material							RISK-FACTORS; DENTAL FLUOROSIS; ENAMEL FLUOROSIS; CHILDREN				Horowitz, HS (corresponding author), 6307 Herkos Court, Bethesda, MD 20817 USA.							BARNHART WE, 1974, J DENT RES, V53, P1317, DOI 10.1177/00220345740530060301; Dean HT., 1954, INT DENT J, V4, P311; HOROWITZ HS, 1992, J PUBLIC HEALTH DENT, V52, P216, DOI 10.1111/j.1752-7325.1992.tb02276.x; Horowitz HS, 1996, J PUBLIC HEALTH DENT, V56, P253, DOI 10.1111/j.1752-7325.1996.tb02448.x; HOROWITZ HS, 1986, J PUBLIC HEALTH DENT, V46, P179, DOI 10.1111/j.1752-7325.1986.tb03139.x; OSUJI OO, 1988, J DENT RES, V67, P1488, DOI 10.1177/00220345880670120901; Pendrys DG, 1998, AM J EPIDEMIOL, V148, P967, DOI 10.1093/oxfordjournals.aje.a009573; Pendrys DG, 1996, AM J EPIDEMIOL, V143, P808	8	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1462	1462		10.1016/S0140-6736(99)90026-0	http://dx.doi.org/10.1016/S0140-6736(99)90026-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232310				2022-12-01	WOS:000080278200007
J	Michaelsson, K; Baron, JA; Farahmand, BY; Persson, I; Ljunghall, S				Michaelsson, K; Baron, JA; Farahmand, BY; Persson, I; Ljunghall, S			Oral-contraceptive use and risk of hip fracture: a case-control study	LANCET			English	Article							BONE-MINERAL DENSITY; DISTAL FOREARM; WOMEN; AGE; OSTEOPOROSIS; MASS; DETERMINANTS; PREVENTION; MENOPAUSAL; CALCIUM	Background Epidemiological studies indicate a protective effect of postmenopausal oestrogen therapy on the risk of osteoporotic fractures. Whether premenopausal oestrogen exposure in the form of oral contraceptives also reduces the risk of osteoporotic fractures remains uncertain. Method We did a population-based case control study of hip fracture among Swedish postmenopausal women, 50-81 years of age, through mailed questionnaires and telephone interviews. Of those women who were eligible, 1327 (82.5%) cases and 3312 (81.6%) randomly selected controls responded. Findings 130 (11.6%) cases and 562 (19.1%) controls reported ever-use of oral contraceptives. Ever-use of oral contraceptives was associated with a 25% reduction in hip fracture risk (odds ratio 0.75 [95% CI 0.59-0.96]). Women who had ever used a high-dose pill (equivalent to greater than or equal to 50 pg ethinylestradiol per tablet) had a 44% lower risk for hip fracture than never-users (0.56 [0.42-0.75]). No overall trend was observed with duration of oral-contraceptive use, or time since last use. However, when making comparisons with women who have never used oral contraceptives, the odds ratios for hip-fracture were 0.69 (0.51-0.94) for use after age 40, 0.82 (0.57-1.16) for use at ages 30-39, and 1.26 (0.76-2.09) for use before age 30. Interpretation Our results imply that in postmenopausal women, oral-contraceptive use late in reproductive life may reduce the risk of hip fracture, although we recognise the limitations of the case-control method.	Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; Stockholm Cty Council, Dept Epidemiol, Stockholm, Sweden; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Dartmouth College; Dartmouth College; Stockholm County Council; Karolinska Institutet	Michaelsson, K (corresponding author), Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden.	Karl.Michaelsson@ortopedi.uu.se	Michaelsson, Karl/AAM-9094-2021	Michaelsson, Karl/0000-0003-2815-1217	NINR NIH HHS [NR 1 RO 1 CA58427] Funding Source: Medline	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BARAN DT, 1994, OSTEOPOROSIS INT, V4, P31; Christiansen C, 1990, Osteoporos Int, V1, P7; COOPER C, 1993, BONE, V14, P41, DOI 10.1016/8756-3282(93)90254-8; CORSON SL, 1993, J REPROD MED, V38, P1015; DeCherney A, 1996, AM J OBSTET GYNECOL, V174, P15, DOI 10.1016/S0002-9378(96)70366-6; ENZELSBERGER H, 1988, MATURITAS, V9, P375, DOI 10.1016/0378-5122(88)90103-X; FORTNEY JA, 1994, J REPROD MED, V39, P105; GAMBACCIANI M, 1994, OBSTET GYNECOL, V83, P392; GOLDSMITH NF, 1975, J BONE JOINT SURG AM, V57, P657, DOI 10.2106/00004623-197557050-00014; GOULDING A, 1977, CLIN ENDOCRINOL, V6, P449, DOI 10.1111/j.1365-2265.1977.tb03328.x; Hansen M A, 1991, Osteoporos Int, V1, P95; HEANEY RP, 1992, J INTERN MED, V231, P169, DOI 10.1111/j.1365-2796.1992.tb00520.x; HILLARD TC, 1991, CALCIFIED TISSUE INT, V49, pS55, DOI 10.1007/BF02555090; HRESCHYSHYN MM, 1998, AM J OBSTET GYNECOL, V159, P318; Johansson C, 1996, MATURITAS, V24, P97, DOI 10.1016/0378-5122(95)01024-6; KLEEREKOPER M, 1991, ARCH INTERN MED, V151, P1971, DOI 10.1001/archinte.151.10.1971; LINDSAY R, 1986, CONTRACEPTION, V34, P333, DOI 10.1016/0010-7824(86)90086-7; Magnusson C, 1998, INT J CANCER, V76, P29, DOI 10.1002/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.0.CO;2-#; MALLMIN H, 1994, OSTEOPOROSIS INT, V4, P298, DOI 10.1007/BF01622186; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; MUSEY VC, 1987, AM J OBSTET GYNECOL, V157, P312, DOI 10.1016/S0002-9378(87)80159-X; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem-65-4-697; NISCHAN P, 1993, AM J EPIDEMIOL, V138, P697, DOI 10.1093/oxfordjournals.aje.a116907; Norell SE, 1998, INT J EPIDEMIOL, V27, P1033, DOI 10.1093/ije/27.6.1033; ONeill TW, 1996, J EPIDEMIOL COMMUN H, V50, P288, DOI 10.1136/jech.50.3.288; ONeill TW, 1997, OSTEOPOROSIS INT, V7, P72, DOI 10.1007/BF01623464; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; Rizzoli R, 1997, LANCET, V349, pS20, DOI 10.1016/S0140-6736(97)90007-6; STEINBERG KK, 1987, J CLIN ENDOCR METAB, V65, P697; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; TUPPURAINEN M, 1994, OSTEOPOROSIS INT, V4, P93, DOI 10.1007/BF01623231	34	101	103	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1481	1484		10.1016/S0140-6736(98)09044-8	http://dx.doi.org/10.1016/S0140-6736(98)09044-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232314				2022-12-01	WOS:000080278200011
J	Hillier, BJ; Christopherson, KS; Prehoda, KE; Bredt, DS; Lim, WA				Hillier, BJ; Christopherson, KS; Prehoda, KE; Bredt, DS; Lim, WA			Unexpected modes of PDZ domain scaffolding revealed by structure of nNOS-syntrophin complex	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; MULTIPLE ISOMORPHOUS REPLACEMENT; SKELETAL-MUSCLE; RECEPTOR LOCALIZATION; SIGNALING COMPLEXES; PROTEIN; RECOGNITION; DYSTROPHIN; CHANNELS; MOTIFS	The PDZ protein interaction domain of neuronal nitric oxide synthase (nNOS) can heterodimerize with the PDZ domains of postsynaptic density protein 95 and syntrophin through interactions that are not mediated by recognition of a typical carboxyl-terminal motif, The nNOS-syntrophin PDZ complex structure revealed that the domains interact in an unusual Linear head-to-tail arrangement, The nNOS PDZ domain has two opposite interaction surfaces-one face has the canonical peptide binding groove, whereas the other has a beta-hairpin "finger." This nNOS beta finger docks in the syntrophin peptide binding groove, mimicking a peptide Ligand, except that a sharp beta turn replaces the normally required carboxyl terminus, This structure explains how PDZ domains can participate in diverse interaction modes to assemble protein networks.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.							Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CCP4, 1979, SUIT PROGR PROT CRYS; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Gee SH, 1998, J BIOL CHEM, V273, P21980, DOI 10.1074/jbc.273.34.21980; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; JONES TA, 1996, ACTA CRYSTALLOGR D, V52, P30; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Schepens J, 1997, FEBS LETT, V409, P53, DOI 10.1016/S0014-5793(97)00481-X; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Thomas GD, 1998, P NATL ACAD SCI USA, V95, P15090, DOI 10.1073/pnas.95.25.15090; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; van Huizen R, 1998, EMBO J, V17, P2285, DOI 10.1093/emboj/17.8.2285; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	30	440	450	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					812	815		10.1126/science.284.5415.812	http://dx.doi.org/10.1126/science.284.5415.812			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221915				2022-12-01	WOS:000080056200049
J	Rye, HS; Roseman, AM; Chen, SX; Furtak, K; Fenton, WA; Saibil, HR; Horwich, AL				Rye, HS; Roseman, AM; Chen, SX; Furtak, K; Fenton, WA; Saibil, HR; Horwich, AL			GroEL-GroES cycling: ATP and nonnative polypeptide direct alternation of folding-active rings	CELL			English	Article							CHAPERONIN GROEL; PROTEIN; BINDING; RELEASE; SUBSTRATE; COMPLEXES; DYNAMICS; CONSEQUENCES; INTERMEDIATE; NUCLEOTIDES	The double-ring chaperonin GroEL mediates protein folding in the central cavity of a ring bound by ATP and GroES, but it is unclear how GroEL cycles from one folding-active complex to the next. We observe that hydrolysis of ATP within the cis ring must occur before either nonnative polypeptide or GroES can bind to the trans ring, and this is associated with reorientation of the trans ring apical domains. Subsequently, formation of a new cis-ternary complex proceeds on the open trans ring with polypeptide binding first, which stimulates the ATP-dependent dissociation of the cis complex (by 20- to 50-fold), followed by GroES binding. These results indicate that, in the presence of nonnative protein, GroEL alternates its rings as folding-active cis complexes, expending only one round of seven ATPs per folding cycle.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England	Howard Hughes Medical Institute; Yale University; Yale University; University of London; Birkbeck University London	Horwich, AL (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.		Roseman, Alan/AAE-6689-2019	Roseman, Alan/0000-0002-4783-2619; Rye, Hays/0000-0002-9420-3137	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRUNGER AT, 1992, X PLOY V 3 1 MANUAL; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Corrales FJ, 1996, FOLD DES, V1, P265, DOI 10.1016/S1359-0278(96)00040-5; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; Gutfreund H, 1995, KINETICS LIFE SCI; Inbar E, 1997, BIOCHEMISTRY-US, V36, P12276, DOI 10.1021/bi9714870; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kad NM, 1998, J MOL BIOL, V278, P267, DOI 10.1006/jmbi.1998.1704; Katsumata K, 1996, J MOL BIOL, V258, P827, DOI 10.1006/jmbi.1996.0290; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROY H, 1992, PROTEIN SCI, V1, P925, DOI 10.1002/pro.5560010711; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; Sparrer H, 1996, J MOL BIOL, V258, P74, DOI 10.1006/jmbi.1996.0235; Sparrer H, 1997, J BIOL CHEM, V272, P14080, DOI 10.1074/jbc.272.22.14080; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Torok Z, 1996, J BIOL CHEM, V271, P16180, DOI 10.1074/jbc.271.27.16180; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	36	272	274	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					325	338		10.1016/S0092-8674(00)80742-4	http://dx.doi.org/10.1016/S0092-8674(00)80742-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319813	Bronze			2022-12-01	WOS:000080100500006
J	Naar, AM; Beaurang, PA; Zhou, S; Abraham, S; Solomon, W; Tjian, R				Naar, AM; Beaurang, PA; Zhou, S; Abraham, S; Solomon, W; Tjian, R			Composite co-activator ARC mediates chromatin-directed transcriptional activation	NATURE			English	Article							RNA-POLYMERASE-II; CREB-BINDING PROTEIN; COMPLEX; RECEPTOR; COACTIVATOR; INTERACTS; ACETYLATION; MECHANISMS; DOMAIN; YEAST	Gene activation in eukaryotes is regulated by complex mechanisms in which the recruitment and assembly of the transcriptional machinery is directed by gene- and cell-type-specific DNA-binding proteins(1). When DNA is packaged into chromatin, the regulation of gene activation requires new classes of chromatin-targeting activity(2), In humans, a multisubunit cofactor functions in a chromatin-selective manner to potentiate synergistic gene activation by the transcriptional activators SREBP-1a and Sp1 (ref, 3). Here we show that this activator-recruited cofactor (ARC) interacts directly with several different activators, including SREBP-1a, VP16 and the p65 subunit of NF-kappa B, and strongly enhances transcription directed by these activators in vitro with chromatin-assembled DNA templates. The ARC complex consists of 16 or more subunits; some of these are novel gene products, whereas others are present in other multisubunit cofactors, such as CRSP4, NAT(5) and mammalian Mediator(6). Detailed analysis indicates that the ARC complex is probably identical to the nuclear hormone-receptor cofactor DRIP7. Thus, ARC/DRIP is a large composite coactivator that belongs to a family of related cofactors and is targeted by different classes of activator to mediate transcriptional stimulation.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, Brooklyn, NY 11203 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Tjian, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.							DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEE JK, 1995, EXPERT SYST APPL, V9, P3, DOI 10.1016/0957-4174(94)00043-U; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	25	356	366	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 29	1999	398	6730					828	832		10.1038/19789	http://dx.doi.org/10.1038/19789			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235267				2022-12-01	WOS:000080058100063
J	Barton, MB; Elmore, JG; Fletcher, SW				Barton, MB; Elmore, JG; Fletcher, SW			Breast symptoms among women enrolled in a health maintenance organization: Frequency, evaluation, and outcome	ANNALS OF INTERNAL MEDICINE			English	Article						breast diseases; breast neoplasms; health maintenance organizations; primary health care; outcome and process assessment (health care)	MALPRACTICE LITIGATION; GENERAL SURGEON; FAMILY HISTORY; MEDICAL-CARE; CANCER; DISEASE; AGE; GUIDELINES; DIAGNOSIS; BIOPSY	Background: Few data exist about visits to primary care clinicians for breast symptoms in the United States. Objective: To determine how often women present with breast symptoms, how these symptoms are evaluated, and how often cancer is diagnosed. Design: Retrospective cohort study. Setting: Staff-model division of a large health maintenance organization (HMO) in New England. Patients: 2400 women who were 40 to 69 years of age as of 1 July 1983 and were continuously enrolled in the HMO until 30 June 1995. Measurements: Information on all breast-related encounters from 1 July 1983 to 30 June 1993 was abstracted. Type of symptom, clinicians' findings and recommendations, and all subsequent evaluations were recorded. Cases of cancer diagnosed subsequent to the symptom were determined. Results: Sixteen percent of the HMO population presented with a breast symptom during the 10-year period, for a rate of 22.8 presentations per 1000 person-years. Women younger than 50 years of age presented nearly twice as often as older women (P = 0.001). Women with breast symptoms had lower rates of screening than other women before presenting but higher rates of screening afterward (P < 0.001). Symptoms were evaluated beyond the initial visit in 66% of patients, and invasive procedures were performed in 27% of patients. Cancer was found in 6.2% of patients and 4.5% of episodes; rates of cancer detection varied significantly by type of symptom but not by patient age. Conclusions: Breast symptoms among women 40 to 70 years of age were common in this primary care practice. Evaluation beyond initial examinations was frequent, and invasive procedures were performed for 27% of patients. Cancer was diagnosed in more than 4% of episodes, indicating that follow-up of breast symptoms is important in primary care practices.	Harvard Pilgrim Hlth Care Fdn, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Washington, Sch Med, Seattle, WA 98195 USA	Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle	Barton, MB (corresponding author), Harvard Pilgrim Hlth Care Fdn, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 200, Boston, MA 02215 USA.	mary_barton@hms.harvard.edu						*AM COLL PHYS, 1985, ANN INTERN MED, V103, P143; *AM COLL RAD, 1993, BREAST IM REP DAT SY; *AM MED ASS, 1994, PHYS CURR PROC TERM; American college of Radiology, 1995, BREAST IM REP DAT SY; ANDERSON LM, 1995, AM J PUBLIC HEALTH, V85, P840, DOI 10.2105/AJPH.85.6.840; [Anonymous], 1986, CAN MED ASSOC J, V134, P724; BAKER LH, 1982, CA-CANCER J CLIN, V32, P194, DOI 10.3322/canjclin.32.4.194; Ballo MS, 1996, CANCER, V78, P773; BARNETT GO, 1979, P IEEE, V67, P1226, DOI 10.1109/PROC.1979.11438; BERNSTEIN AB, 1991, MED CARE, V29, P196; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Bywaters J L, 1977, J R Coll Gen Pract, V27, P353; Cochrane RA, 1997, EUR J SURG ONCOL, V23, P198, DOI 10.1016/S0748-7983(97)92220-4; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; DAWSON C, 1993, ANN ROY COLL SURG, V75, P83; DAWSON C, 1993, ANN ROY COLL SURG, V75, P79; DEVITT JE, 1989, LANCET, V2, P1257; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; GOODSON WH, 1985, AM J SURG, V150, P271, DOI 10.1016/0002-9610(85)90135-7; GUI GPH, 1995, ANN ROY COLL SURG, V77, P24; Gundry KR, 1998, AM J ROENTGENOL, V171, P41, DOI 10.2214/ajr.171.1.9648760; Healy BP, 1997, J WOMENS HEALTH, V6, P141, DOI 10.1089/jwh.1997.6.141; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KERN KA, 1992, ARCH SURG-CHICAGO, V127, P542; Liberman L, 1998, AM J ROENTGENOL, V171, P35, DOI 10.2214/ajr.171.1.9648759; LOCKER AP, 1989, LANCET, V1, P887; *MAP CORP, 1995, MAPM 2 0 DESKT MAPP; MCKINNA JA, 1992, EUR J CANCER, V28A, P911; MITNICK JS, 1995, J AM COLL SURGEONS, V181, P315; MOORE FD, 1978, NEW ENGL J MED, V299, P304, DOI 10.1056/NEJM197808102990610; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; NICHOLS S, 1980, BRIT MED J, V281, P1450, DOI 10.1136/bmj.281.6253.1450; Physician Insurers Association of America, 1995, BREAST CANC STUD JUN; Pijnappel RM, 1997, EUR J RADIOL, V24, P120, DOI 10.1016/S0720-048X(96)01140-0; PREECE PE, 1976, LANCET, V2, P670; ROBERTS MM, 1987, BRIT J SURG, V74, P1020, DOI 10.1002/bjs.1800741121; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; *SAS I INC, 1996, SAS VERS 6 10; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; Shaw A D, 1995, Eur J Surg Oncol, V21, P284, DOI 10.1016/S0748-7983(95)91525-7; STANDERTSKJOLDNORDENSTAM CG, 1980, ANN CHIR GYNAECOL, V69, P48; STERNS EE, 1992, CAN J SURG, V35, P41; WOO B, 1985, JAMA-J AM MED ASSOC, V254, P1480, DOI 10.1001/jama.254.11.1480; 1997, MMWR MORB MORTAL WKL, V46, P937; 1996, FED REG, V61, P59490; 1990, CA CANC J CLIN, V40, P77	46	107	112	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					651	+		10.7326/0003-4819-130-8-199904200-00005	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215561				2022-12-01	WOS:000079786600004
J	Gianakos, D				Gianakos, D			Conversations with Stella	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Lynchburg Family Practice Residency, Lynchburg, VA 24501 USA		Gianakos, D (corresponding author), Lynchburg Family Practice Residency, Lynchburg, VA 24501 USA.	dean.gianakos@centrahealth.com							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					698	699		10.7326/0003-4819-130-8-199904200-00020	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215570				2022-12-01	WOS:000079786600013
J	Chen, YA; Scales, SJ; Patel, SM; Doung, YC; Scheller, RH				Chen, YA; Scales, SJ; Patel, SM; Doung, YC; Scheller, RH			SNARE complex formation is triggered by Ca2+ and drives membrane fusion	CELL			English	Article							NEUROTRANSMITTER RELEASE; SYNAPTIC EXOCYTOSIS; SECRETORY VESICLES; CALCIUM CHANNELS; SYNAPTOTAGMIN-I; CORE COMPLEX; N-TYPE; PROTEIN; IDENTIFICATION; NEUROTOXINS	Neurotransmitter exocytosis, a process mediated by a core complex of syntaxin, SNAP-25, and VAMP (SNAREs), is inhibited by SNARE-cleaving neurotoxins. Botulinum neurotoxin E inhibition of norepinephrine release in permeabilized PC12 cells can be rescued by adding a 65 aa C-terminal fragment of SNAP-25 (S25-C). Mutations along the hydrophobic face of the S25-C helix result in SNARE complexes with different thermostabilities, and these mutants rescue exocytosis to different extents. Rescue depends on the continued presence of both S25-C and Ca2+ and correlates with complex formation. The data suggest that Ca2+ triggers S25-C binding to a low-affinity site, initiating trans-complex formation. Pairing of SNARE proteins on apposing membranes leads to bilayer fusion and results in a high-affinity cis-SNARE complex.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.	scheller@cmgm.stanford.edu	Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283				Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BAUERFEIND R, 1995, FEBS LETT, V364, P328, DOI 10.1016/0014-5793(95)00419-A; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BINZ T, 1994, J BIOL CHEM, V269, P1617; Blank PS, 1998, J GEN PHYSIOL, V112, P559, DOI 10.1085/jgp.112.5.559; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; Matthews G, 1996, ANNU REV NEUROSCI, V19, P219; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Montecucco C, 1998, CURR OPIN CELL BIOL, V10, P530, DOI 10.1016/S0955-0674(98)80069-0; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; OSHRY L, 1991, BIOCHIM BIOPHYS ACTA, V1066, P239, DOI 10.1016/0005-2736(91)90192-B; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Poirier MA, 1998, J BIOL CHEM, V273, P11370, DOI 10.1074/jbc.273.18.11370; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; Schekman R, 1998, NATURE, V396, P514, DOI 10.1038/24986; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; Sheng ZH, 1996, NATURE, V379, P451, DOI 10.1038/379451a0; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STEEGMAIER M, 1998, J BIOL CHEM, V143, P957; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tahara M, 1998, J BIOL CHEM, V273, P33667, DOI 10.1074/jbc.273.50.33667; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Washbourne P, 1997, FEBS LETT, V418, P1, DOI 10.1016/S0014-5793(97)01328-8; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	42	348	357	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					165	174		10.1016/S0092-8674(00)80727-8	http://dx.doi.org/10.1016/S0092-8674(00)80727-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219238	Bronze			2022-12-01	WOS:000079779800006
J	Pronovost, PJ; Jenckes, MW; Dorman, T; Garrett, E; Breslow, MJ; Rosenfeld, BA; Lipsett, PA; Bass, E				Pronovost, PJ; Jenckes, MW; Dorman, T; Garrett, E; Breslow, MJ; Rosenfeld, BA; Lipsett, PA; Bass, E			Organizational characteristics of intensive care units related to outcomes of abdominal aortic surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT CHARACTERISTICS; MORTALITY; MEDICARE; VOLUME; IMPACT; POPULATION; HOSPITALS; MARYLAND; QUALITY; DISEASE	Context Morbidity and mortality rates in intensive care units (ICUs) vary widely among institutions, but whether ICU structure and care processes affect these outcomes is unknown. Objective To determine whether organizational characteristics of ICUs are related to clinical and economic outcomes for abdominal aortic surgery patients who typically; receive care in an ICU. Design Observational study, with patient data collected retrospectively and ICU data collected prospectively. Setting All Maryland hospitals that performed abdominal aortic surgery from 1994 to 1996. Patients and Participants We analyzed hospital discharge data for patients in nonfederal acute care hospitals in Maryland who had a principal procedure code for abdominal aortic surgery from January 1994 through December 1996 (n = 2987) We obtained information about ICU organizational characteristics by surveying ICU medical directors at the 46 Maryland hospitals that performed abdominal aortic surgery. Thirty-nine (85%) of the ICU directors completed this survey. Main Outcome Measures In-hospital mortality and hospital and ICU length of stay. Results For patients undergoing abdominal aortic surgery, in-hospital mortality varied among hospitals from 0% to 66%. In multivariate analysis adjusted for patient demographics, comorbid disease, severity of illness, hospital and surgeon volume, and hospital characteristics, not having daily rounds by an ICU physician was associated with a 3-fold increase in in-hospital mortality (odds ratio [OR], 3.0; 95% confidence interval [CI], 1.9-4.9). Furthermore, not having daily rounds by an ICU physician was associated with an increased risk of cardiac arrest (OR, 2.9; 95% CI, 1.2-7.0), acute renal failure (OR, 2.2; 95% CI, 1.3-3.9), septicemia (OR, 1.8, 95 % CI, 1.2-2.6), platelet transfusion (OR, 6.4; 95% CI, 3.2-12.4), and reintubation (OR, 2.0; 95% CI, 1.0-4.1). Not having daily rounds by an ICU physician, having an ICU nurse-patient ratio of less than 1:2, not having monthly review of morbidity and mortality, and extubating patients in the operating room were associated with increased resource use. Conclusions Organizational characteristics of ICUs are related to differences among hospitals in outcomes of abdominal aortic surgery. Clinicians and hospital leaders should consider the potential impact of ICU organizational characteristics on outcomes of patients having high-risk operations.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Program Med Technol & Practice Assessment, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biostat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Pronovost, PJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care, 600 N Wolfe St,Meyer 297A, Baltimore, MD 21287 USA.			dorman, todd/0000-0002-8616-8677; Bass, Eric/0000-0001-9106-527X				Angus DC, 1996, JAMA-J AM MED ASSOC, V276, P1075, DOI 10.1001/jama.276.13.1075; Berenson RA., 1984, INTENSIVE CARE UNITS; BROWN JJ, 1989, CHEST, V96, P127, DOI 10.1378/chest.96.1.127; Carson SS, 1996, JAMA-J AM MED ASSOC, V276, P322, DOI 10.1001/jama.276.4.322; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHASSIN MR, 1989, HEALTH SERV RES, V24, P1; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Dardik A, 1998, J VASC SURG, V28, P413, DOI 10.1016/S0741-5214(98)70126-0; *DEL HASK SELLS, 1996, J HOPK HOSP REP CLIN; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; FLOOD AB, 1984, MED CARE, V22, P98, DOI 10.1097/00005650-198402000-00002; Gould W., 1993, STATA TECHNICAL B, P13; GREENBAUM DM, 1984, CRIT CARE MED, V12, P1073, DOI 10.1097/00003246-198412000-00016; GROEGER JS, 1992, CRIT CARE MED, V20, P846, DOI 10.1097/00003246-199206000-00024; HANNON EL, 1992, HEALTH SERV RES, V27, P527; Iezzoni LI, 2013, RISK ADJUSTMENT MEAS, V4th; Jiang HJ, 1997, CRIT CARE MED, V25, P773, DOI 10.1097/00003246-199705000-00011; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Norman PE, 1998, BMJ-BRIT MED J, V317, P852, DOI 10.1136/bmj.317.7162.852; Paterson L, 1991, BRIT EDUC RES J, V17, P387, DOI [DOI 10.1080/0141192910170408, 10.1080/0141192910170408]; POLLACK MM, 1988, CRIT CARE MED, V16, P11, DOI 10.1097/00003246-198801000-00003; Pollack MM, 1997, CRIT CARE MED, V25, P1637, DOI 10.1097/00003246-199710000-00011; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; Romano P S, 1993, Med Care Rev, V50, P451, DOI 10.1177/002570879305000404; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; SHORTELL SM, 1991, MED CARE, V29, P709, DOI 10.1097/00005650-199108000-00004; STEINER CA, 1994, NEW ENGL J MED, V330, P403, DOI 10.1056/NEJM199402103300607; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; VEITH FJ, 1991, J VASC SURG, V13, P523, DOI 10.1016/0741-5214(91)90313-J; WACKSMAN R, 1996, CRIT CARE MED, V24, pA21; WAGNER DP, 1987, CHEST, V92, P423, DOI 10.1378/chest.92.3.423; Wennberg DE, 1998, JAMA-J AM MED ASSOC, V279, P1278, DOI 10.1001/jama.279.16.1278; ZIMMERMAN JE, 1993, CRIT CARE MED, V21, P1443, DOI 10.1097/00003246-199310000-00010; [No title captured]	40	484	490	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1310	1317		10.1001/jama.281.14.1310	http://dx.doi.org/10.1001/jama.281.14.1310			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208147	Bronze			2022-12-01	WOS:000079628700036
J	Villar, RG; Shapiro, RL; Busto, S; Riva-Posse, C; Verdejo, G; Farace, MI; Rosetti, F; San Juan, JA; Julia, CM; Becher, J; Maslanka, SE; Swerdlow, DL				Villar, RG; Shapiro, RL; Busto, S; Riva-Posse, C; Verdejo, G; Farace, MI; Rosetti, F; San Juan, JA; Julia, CM; Becher, J; Maslanka, SE; Swerdlow, DL			Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHROTROPHIC CLOSTRIDIUM; FOODBORNE BOTULISM; UNITED-STATES; SPOILAGE; GROWTH	Context Botulism is an important public health problem in Argentina, but obtaining antitoxin rapidly has been difficult because global supplies are limited. in January 1998, a botulism outbreak occurred in Buenos Aires. Objectives To determine the source of the outbreak, improve botulism surveillance, and establish an antitoxin supply and release system in Argentina. Design, Setting, and Participants Cohort study in January 1998 of 21 drivers of a specific bus route in urban Buenos Aires. Main Outcome Measure Occurrence of botulism and implication of a particular food as the vehicle causing this outbreak. Results Nine (43%) of 21 bus drivers developed botulism; presenting with gastroenteritis, symptoms of acute cranial nerve dysfunction including ptosis, dysphagia, blurred vision, and motor weakness. One driver experienced respiratory failure. Type A toxin was detected from 3 of 9 patients' serum samples. All drivers received botulism antitoxin; there were no fatalities. Consumption of matambre (Argentine meat roll) was significantly associated with illness. Among 11 persons who ate matambre, 9 developed illness, compared with none of those who did not eat it (P < .001). The matambre had been cooked in water at 78 degrees C to 80 degrees C for 4 hours, sealed in heat-shrinked plastic wrap, and stored in refrigerators that did not cool adequately. Subsequently, a botulism surveillance and antitoxin release system was established. Conclusions Insufficient cooking time and temperatures, storage in heat-shrinked plastic wrap, and inadequate refrigeration likely contributed to Clostridium botulinum spore survival, germination, and toxin production. A rapid-response botulism surveillance and antitoxin release system in Argentina should provide more timely distribution of antitoxin to patients and may serve as a model for other nations.	Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Sci Resources Program, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Minist Salud Reg 5, Buenos Aires, DF, Argentina; Minist Salud & Acc Social, Buenos Aires, DF, Argentina; Med Sanitaria, Buenos Aires, DF, Argentina; Direcc Epidemiol, Buenos Aires, DF, Argentina; Pan Amer Hlth Org, Buenos Aires, DF, Argentina; ANLIS Carlos G Malbran, Inst Nacl Enfermedades Infecc, Dept Bacteriol, Buenos Aires, DF, Argentina; Hosp FJ Muniz, Buenos Aires, DF, Argentina	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Pan American Health Organization; University of Buenos Aires	Swerdlow, DL (corresponding author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA.							Aureli P, 1996, LANCET, V348, P1594, DOI 10.1016/S0140-6736(05)66220-4; Broda DM, 1996, INT J FOOD MICROBIOL, V29, P335, DOI 10.1016/0168-1605(95)00070-4; Broda DM, 1996, INT J FOOD MICROBIOL, V29, P371, DOI 10.1016/0168-1605(95)00071-2; *CDCP, 1995, MMWR-MORBID MORTAL W, V43, P22; Centers for Disease Control and Prevention, 1998, BOT US 1899 1996 HDB; *CHILL FOOD ASS, 1997, GUID GOOD HYG PRACT; Conner D. E., 1989, Journal of Food Safety, V10, P131; DOYLE M, 1991, FOOD TECHNOL, V44, P154; Graham AF, 1996, APPL ENVIRON MICROB, V62, P2664, DOI 10.1128/AEM.62.7.2664-2668.1996; HATHEWAY CL, 1998, INFECT DIS, P1919; Hauschild AHW, 1993, CLOSTRIDIUM BOTULINU, P69; HUGHES J, 1981, ANN INTERN MED, V95, P422; Juneja VK, 1996, INT J FOOD MICROBIOL, V32, P115, DOI 10.1016/0168-1605(96)01111-7; LECOUR H, 1988, ARCH INTERN MED, V148, P578, DOI 10.1001/archinte.148.3.578; MARTIN D, 1996, EPIDEMIOLOGY, V7, P2933; ROBOLOT P, 1994, J MED MICROBIOL, V40, P379; Shapiro RL, 1998, ANN INTERN MED, V129, P221, DOI 10.7326/0003-4819-129-3-199808010-00011; Shapiro RL, 1997, JAMA-J AM MED ASSOC, V278, P433, DOI 10.1001/jama.278.5.433; STLOUIS ME, 1991, BACTERIAL INFECT HUM, P115; TACKET CO, 1984, AM J MED, V76, P794, DOI 10.1016/0002-9343(84)90988-4; TROILLET N, 1995, SCHWEIZ MED WSCHR, V125, P1805; *USDA EXT SERV, 1994, USDA EXT SERV AGR B, V539; WEBER JT, 1993, J INFECT DIS, V167, P451, DOI 10.1093/infdis/167.2.451; Weber JT, 1994, INFECT DIS, P1185; WILCOX P, 1989, AM REV RESPIR DIS, V139, P157, DOI 10.1164/ajrccm/139.1.157; WOODRUFF BA, 1992, J INFECT DIS, V166, P1281, DOI 10.1093/infdis/166.6.1281	26	29	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1334	+		10.1001/jama.281.14.1334	http://dx.doi.org/10.1001/jama.281.14.1334			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208152				2022-12-01	WOS:000079628700041
J	Wheeler, MH				Wheeler, MH			Total thyroidectomy for benign thyroid disease	LANCET			English	Editorial Material							CANCER		Univ Wales Hosp, Dept Endocrine Surg, Cardiff CF4 4XW, S Glam, Wales	Cardiff University	Wheeler, MH (corresponding author), Univ Wales Hosp, Dept Endocrine Surg, Cardiff CF4 4XW, S Glam, Wales.							BEAHRS OH, 1963, SURG GYNECOL OBSTET, V117, P535; CADY B, 1979, CANCER, V43, P810, DOI 10.1002/1097-0142(197903)43:3<810::AID-CNCR2820430306>3.0.CO;2-B; CADY B, 1986, WORLD J SURG, V10, P786; CATZ B, 1969, AM J SURG, V118, P434, DOI 10.1016/0002-9610(69)90151-2; CLARK OH, 1982, ANN SURG, V196, P361, DOI 10.1097/00000658-198209000-00016; DEGROOT L, 1973, JAMA-J AM MED ASSOC, V225, P487, DOI 10.1001/jama.225.5.487; GOUGH IR, 1992, AUST NZ J SURG, V62, P87; HARNESS JK, 1986, WORLD J SURG, V10, P781, DOI 10.1007/BF01655238; KHADRA M, 1992, AUST NZ J SURG, V62, P91; Kocher T, 1903, TXB OPERATIVE SURG, P133; Liu Q, 1998, SURGERY, V123, P2, DOI 10.1016/S0039-6060(98)70221-1; REEVE TS, 1987, ANN SURG, V206, P782, DOI 10.1097/00000658-198712000-00016; SMEDS S, 1997, TXB ENDOCRINE SURG, P205; Stephenson B M, 1994, Curr Opin Gen Surg, P53; WINSA B, 1995, EUR J ENDOCRINOL, V132, P406, DOI 10.1530/eje.0.1320406	15	44	47	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1998	351	9115					1526	1527		10.1016/S0140-6736(05)61116-6	http://dx.doi.org/10.1016/S0140-6736(05)61116-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326531				2022-12-01	WOS:000073868000004
J	Roux, B; MacKinnon, R				Roux, B; MacKinnon, R			The cavity and pore helices the KcsA K+ channel: Electrostatic stabilization of monovalent cations	SCIENCE			English	Article							MOLECULAR-DYNAMICS; POTASSIUM CHANNEL; PROTEINS; DIPOLES; ENERGY	The electrostatic influence of the central cavity and pore alpha helices in the potassium ion channel from Streptomyces lividans (KcsA K+ channel) was analyzed by solving the finite difference Poisson equation. The cavity and helices overcome the destabilizing influence of the membrane and stabilize a cation at the membrane center. The electrostatic effect of the pore helices is large compared to that described for water-soluble proteins because of the low dielectric membrane environment. The combined contributions of the ion self-energy and the helix electrostatic field give rise to selectivity for monovalent cations in the water-filled cavity. Thus, the K+ channel uses simple electrostatic principles to solve the fundamental problem of ion destabilization by the cell membrane lipid bilayer.	Univ Montreal, Dept Phys, GRTM, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Chim, GRTM, Montreal, PQ H3C 3J7, Canada; Rockefeller Univ, Lab Mol Neurobiol & Biophys, Howard Hughes Med Inst, New York, NY 10021 USA	Universite de Montreal; Universite de Montreal; Howard Hughes Medical Institute; Rockefeller University	Roux, B (corresponding author), Univ Montreal, Dept Phys, GRTM, Case Postal 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; *CCP4 PROGR, 1994, ACTA CRYSTALLOGR D, V50, P60; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; HE JJ, 1993, PROTEIN SCI, V2, P1643, DOI 10.1002/pro.5560021010; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOL WGJ, 1978, NATURE, V273, P5662; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Nina M, 1997, J PHYS CHEM B, V101, P5239, DOI 10.1021/jp970736r; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; Simonson T, 1996, J AM CHEM SOC, V118, P8452, DOI 10.1021/ja960884f; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WIBBLE BA, 1994, NATURE, V371, P246	17	371	379	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					100	102		10.1126/science.285.5424.100	http://dx.doi.org/10.1126/science.285.5424.100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390357				2022-12-01	WOS:000081199800039
J	Kahana, MJ; Sekuler, R; Caplan, JB; Kirschen, M; Madsen, JR				Kahana, MJ; Sekuler, R; Caplan, JB; Kirschen, M; Madsen, JR			Human theta oscillations exhibit task dependence during virtual maze navigation	NATURE			English	Article							HUMAN HIPPOCAMPAL-FORMATION; RHYTHM; MODULATION; RAT	Theta oscillations (electroencephalographic activity with a frequency of 4-8 Hz) have long been implicated in spatial navigation in rodents(1-3); however, the role of theta oscillators in human spatial navigation has not been explored. Here we describe subdural recordings from epileptic patients learning to navigate computer-generated mazes. Visual inspection of the raw intracranial signal revealed striking episodes of high-amplitude slow-wave oscillations at a number of areas of the cortex, including temporal cortex. Spectral analysis showed that these oscillations were in the theta band. These episodes of theta activity, which typically last several cycles, are dependent on task characteristics. Theta oscillations occur more frequently in more complex mazes; they are also more frequent during recall trials than during learning trials.	Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA; Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	Brandeis University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Kahana, MJ (corresponding author), Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA.							Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; [Anonymous], 1983, CANADIAN PSYCHOL; ARNOLDS DEAT, 1980, ELECTROEN CLIN NEURO, V50, P324, DOI 10.1016/0013-4694(80)90160-1; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BORST JGG, 1987, BRAIN RES, V407, P81, DOI 10.1016/0006-8993(87)91221-2; Buzsaki G, 1996, CEREB CORTEX, V6, P81, DOI 10.1093/cercor/6.2.81; Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; GROSSMANN A, 1985, MATH PLUS PHYSICS, V1; HALGREN E, 1978, ELECTROEN CLIN NEURO, V44, P778, DOI 10.1016/0013-4694(78)90212-2; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; Jensen O, 1998, J NEUROSCI, V18, P10688; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1997, J NEUROSCI, V17, P7103; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; ROUTTENBERG A, 1973, BEHAV BIOL, V8, P801, DOI 10.1016/S0091-6773(73)80122-1; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; SLAWINSKA U, 1995, BRAIN RES, V678, P117, DOI 10.1016/0006-8993(95)00174-O; Sohal VS, 1998, HIPPOCAMPUS, V8, P171, DOI 10.1002/(SICI)1098-1063(1998)8:2<171::AID-HIPO9>3.0.CO;2-O; Sperling MR, 1997, EPILEPSIA, V38, pS6, DOI 10.1111/j.1528-1157.1997.tb04541.x; STEWART M, 1991, BRAIN RES, V538, P59, DOI 10.1016/0006-8993(91)90376-7; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; Tesche CD, 1997, BRAIN RES, V749, P53, DOI 10.1016/S0006-8993(96)01286-3; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646	27	452	458	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					781	784		10.1038/21645	http://dx.doi.org/10.1038/21645			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391243				2022-12-01	WOS:000081101600053
J	Whiten, A; Goodall, J; McGrew, WC; Nishida, T; Reynolds, V; Sugiyama, Y; Tutin, CEG; Wrangham, RW; Boesch, C				Whiten, A; Goodall, J; McGrew, WC; Nishida, T; Reynolds, V; Sugiyama, Y; Tutin, CEG; Wrangham, RW; Boesch, C			Cultures in chimpanzees	NATURE			English	Article							CHILDREN HOMO-SAPIENS; PAN-TROGLODYTES; WILD CHIMPANZEES; EVOLUTION; IMITATION	As an increasing number of field studies of chimpanzees (Pan troglodytes) have achieved long-term status across Africa, differences in the behavioural repertoires described have become apparent that suggest there is significant cultural variation(1-7). Here we present a systematic synthesis of this information from the seven most long-term studies, which together have accumulated 151 years of chimpanzee observation. This comprehensive analysis reveals patterns of variation that are far more extensive than have previously been documented for any animal species except humans(8-11). We find that 39 different behaviour patterns, including tool usage, grooming and courtship behaviours, are customary or habitual in some communities but are absent in others where ecological explanations have been discounted. Among mammalian and avian species, cultural variation has previously been identified only for single behaviour patterns, such as the local dialects of song-birds(12,13). The extensive, multiple variations now documented for chimpanzees are thus without parallel. Moreover, the combined repertoire of these behaviour patterns in each chimpanzee community is itself highly distinctive, a phenomenon characteristic of human cultures(14) but previously unrecognised in non-human species.	Univ St Andrews, Scottish Primate Res Grp, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland; Gombe Stream Res Ctr, Kigoma, Tanzania; Miami Univ, Dept Zool, Oxford, OH 45056 USA; Miami Univ, Dept Sociol Gerontol & Anthropol, Oxford, OH 45056 USA; Kyoto Univ, Human Evolut Studies Lab, Kyoto 60601, Japan; Univ Oxford, Inst Biol Anthropol, Oxford OX2 6QS, England; Kyoto Univ, Primate Res Inst, Inuyama, Aichi 4848506, Japan; Ctr Int Rech Med Franceville, Franceville, Gabon; Univ Stirling, Dept Biol Sci, Stirling FK9 4LA, Scotland; Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA; Max Planck Inst Evolutionary Anthropol, D-04301 Leipzig, Germany	University of St Andrews; University System of Ohio; Miami University; University System of Ohio; Miami University; Kyoto University; University of Oxford; Kyoto University; University of Stirling; Harvard University; Max Planck Society	Whiten, A (corresponding author), Univ St Andrews, Scottish Primate Res Grp, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland.							BLOCH M, 1991, MAN, V26, P183, DOI 10.2307/2803828; BOESCH C, 1994, J HUM EVOL, V26, P325, DOI 10.1006/jhev.1994.1020; Boesch Christophe, 1996, Proceedings of the British Academy, V88, P251; BONNER JT, 1980, EVOLUTION CULTURE AN; Galef B G, 1992, Hum Nat, V3, P157, DOI 10.1007/BF02692251; Goodall J., 1986, CHIMPANZEES GOMBE PA; Huffman Michael A., 1996, P267, DOI 10.1016/B978-012273965-1/50014-5; Imanishi K., 1957, Primates, V1, P1, DOI 10.1007/BF01667196; Kroeber A.L., 1963, CULTURE; Lefebvre L., 1988, P141; MARLER P, 1964, SCIENCE, V146, P1483, DOI 10.1126/science.146.3650.1483; McGrew WC, 1998, ANNU REV ANTHROPOL, V27, P301, DOI 10.1146/annurev.anthro.27.1.301; MCGREW WC, 1978, MAN, V13, P234, DOI 10.2307/2800247; McGrew WC, 1992, CHIMPANZEE MAT CULTU; MUNDINGER PC, 1980, ETHOL SOCIOBIOL, V1, P183, DOI 10.1016/0162-3095(80)90008-4; Murdock G.P., 1967, ETHNOGRAPHIC ATLAS; NAGELL K, 1993, J COMP PSYCHOL, V107, P174, DOI 10.1037/0735-7036.107.2.174; Nishida T., 1987, P462; Nishida T., 1990, CHIMPANZEES MAHALE M; Paquette D., 1992, Human Evolution, V7, P17, DOI 10.1007/BF02436257; Slater T.L.B., 1995, BIRD SONG THEMES VAR; Spence KW, 1937, PSYCHOL BULL, V34, P806, DOI 10.1037/h0061498; Sugiyama Yukimaru, 1993, P175; SUMITA K, 1985, Primates, V26, P168, DOI 10.1007/BF02382016; TOMASELLO M, 1993, BEHAV BRAIN SCI, V16, P495, DOI 10.1017/S0140525X0003123X; Tomasello M., 1987, HUM EVOL, V2, P175, DOI DOI 10.1007/BF02436405; WHITEN A, 1992, ADV STUD BEHAV, V21, P239, DOI 10.1016/S0065-3454(08)60146-1; Whiten A, 1998, J COMP PSYCHOL, V112, P270, DOI 10.1037/0735-7036.112.3.270; Whiten A, 1996, J COMP PSYCHOL, V110, P3, DOI 10.1037/0735-7036.110.1.3; Wrangham R. W., 1994, CHIMPANZEE CULTURES	30	1407	1457	6	429	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					682	685		10.1038/21415	http://dx.doi.org/10.1038/21415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	207JB	10385119				2022-12-01	WOS:000080932800058
J	Sibert, JR; Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, FDJ				Sibert, JR; Mott, A; Rolfe, K; James, R; Evans, R; Kemp, A; Dunstan, FDJ			Preventing injuries in public playgrounds through partnership between health services and local authority: community intervention study	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Coll Med, Acad Ctr, Llandough Hosp, Dept Child Hlth, Penarth CF64 2XX, S Glam, Wales; Cardiff Cty Council, Sports & Leisure Dept, Cardiff CF14 4EP, S Glam, Wales; Univ Wales Hosp, Dept Accid & Emergency, Cardiff CF4 4XW, S Glam, Wales	Cardiff University; Cardiff University	Sibert, JR (corresponding author), Univ Wales Coll Med, Acad Ctr, Llandough Hosp, Dept Child Hlth, Penarth CF64 2XX, S Glam, Wales.							HESELTINE P, 1989, PLAYGROUND MANAGEMEN; MOTT A, 1994, ARCH DIS CHILD, V71, P328, DOI 10.1136/adc.71.4.328; Mott A, 1997, LANCET, V349, P1874, DOI 10.1016/S0140-6736(96)10343-3; Stone DH, 1998, ARCH DIS CHILD, V78, P108, DOI 10.1136/adc.78.2.108	4	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1595	1595		10.1136/bmj.318.7198.1595	http://dx.doi.org/10.1136/bmj.318.7198.1595			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364118	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000080913100030
J	Li, XY; Virbasius, A; Zhu, XC; Green, MR				Li, XY; Virbasius, A; Zhu, XC; Green, MR			Enhancement of TBP binding by activators and general transcription factors	NATURE			English	Article							RNA-POLYMERASE-II; IN-VIVO; SACCHAROMYCES-CEREVISIAE; PROMOTER SELECTIVITY; TATA-ELEMENT; YEAST; PROTEIN; COMPLEX; MOT1; CORE	Eukaryotic transcriptional activators function, at least in part, by promoting assembly of the preinitiation complex(1-3), which comprises RNA polymerase II and its general transcription factors (GTFs). Activator-mediated stimulation of the assembly of the preinitiation complex has been studied in vitro but has been relatively refractory to in vivo analysis, Here we use a DNA-crosslinking/immunoprecipitation assay to study in living cells the first step in the assembly of the preinitiation complex, the interaction between the TATA-box-binding protein (TBP) and its binding site, the TATA box. Analysis of a variety of endogenous yeast genes, and of a series of activators of differing strength, reveals a general correlation between TBP binding and transcriptional activity. Using mutant yeast strains, we show that Mot1 prevents the binding of TBP to inactive promoters and that activator-mediated stimulation of TBP binding requires additional GTFs, including TFIIB and Srb4. Taken together, our results indicate that TBP binding in vivo is stringently controlled, and that the ability of activators to stimulate this step in the assembly of the preinitiation complex is a highly cooperative process involving multiple transcription factors.	Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, 373 Plantat St,Suite 309, Worcester, MA 01605 USA.	michael.green@ummed.edu						AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Collart MA, 1996, MOL CELL BIOL, V16, P6668; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Lee M, 1997, MOL CELL BIOL, V17, P1336, DOI 10.1128/MCB.17.3.1336; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; SELLECK SB, 1988, P NATL ACAD SCI USA, V85, P5399, DOI 10.1073/pnas.85.15.5399; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X	28	201	203	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					605	609		10.1038/21232	http://dx.doi.org/10.1038/21232			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376604				2022-12-01	WOS:000080778400061
J	Wilcox, AJ; Baird, DD; Wenberg, CR				Wilcox, AJ; Baird, DD; Wenberg, CR			Time of implantation of the conceptus and loss of pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; URINARY ESTROGEN; PROGESTERONE METABOLITES; INVITRO FERTILIZATION; RADIOIMMUNOASSAY; BLASTOCYST; OVULATION; SECRETION; WINDOW; WOMEN	Background Implantation of the conceptus is a key step in pregnancy, but little is known about the time of implantation or the relation between the time of implantation and the outcome of pregnancy. Methods We collected daily urine samples for up to six months from 221 women attempting to conceive after ceasing to use contraception. Ovulation was identified on the basis of the ratio of urinary estrogen metabolites to progesterone metabolites, which changes rapidly with luteinization of the ovarian follicle, The time of implantation was defined by the appearance of chorionic gonadotropin in maternal urine. Results There were 199 conceptions, for 95 percent of which (189) we had sufficient data for analysis. Of these 189 pregnancies, 141 (75 percent) lasted at least six weeks past the last menstrual period, and the remaining 48 pregnancies (25 percent) ended in early loss. Among the pregnancies that lasted 6 weeks or more, the first appearance of chorionic gonadotropin occurred 6 to 12 days after ovulation; 118 women (84 percent) had implantation on day 8, 9, or 10, The risk of early pregnancy loss increased with later implantation (P < 0.001), Among the 102 conceptuses that implanted by the ninth day, 13 percent ended in early loss. This proportion rose to 26 percent with implantation on day 10, to 52 percent on day 11, and to 82 percent after day 11. Conclusions In most successful human pregnancies, the conceptus implants 8 to 10 days after ovulation, The risk of early pregnancy loss increases with later implantation. (N Engl J Med 1999;340:1796-9,) (C) 1999, Massachusetts Medical Society.	NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilcox, AJ (corresponding author), NIEHS, Epidemiol Branch, MD A3-05, Res Triangle Pk, NC 27709 USA.		Baird, Donna D/D-5214-2017; Wilcox, Allen J/C-7723-2019	Baird, Donna D/0000-0002-5544-2653; Wilcox, Allen J/0000-0002-3376-1311; Weinberg, Clarice/0000-0002-7713-8556	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES044003, ZIAES049003, Z01ES044003, Z01ES049003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG EG, 1984, J CLIN ENDOCR METAB, V59, P867, DOI 10.1210/jcem-59-5-867; BAIRD DD, 1991, J CLIN ENDOCR METAB, V72, P793, DOI 10.1210/jcem-72-4-793; BAIRD DD, 1991, STAT MED, V10, P255, DOI 10.1002/sim.4780100209; BAIRD DD, 1995, EPIDEMIOLOGY, V6, P547, DOI 10.1097/00001648-199509000-00015; BEIER HM, 1994, HUM REPROD, V9, P98, DOI 10.1093/humrep/9.suppl_1.98; BOLTON VN, 1989, J IN VITRO FERTIL EM, V6, P30, DOI 10.1007/BF01134578; BONDUELLE ML, 1988, HUM REPROD, V3, P909, DOI 10.1093/oxfordjournals.humrep.a136808; CANFIELD RE, 1976, B WORLD HEALTH ORGAN, V54, P463; COLLINS WP, 1983, CURRENT TOPICS REPRO, V3, P49; England M.A., 1996, LIFE BIRTH; HEARN JP, 1991, J REPROD FERTIL, V92, P497; HERTIG AT, 1959, PEDIATRICS, V23, P202; Klentzeris Lucas D., 1997, Human Reproduction (Oxford), V12, P170; LENTON EA, 1991, J REPROD FERTIL, V92, P555; Lessey BA, 1996, AM J REPROD IMMUNOL, V35, P195; LIU HC, 1993, FERTIL STERIL, V60, P871; LIU HC, 1991, J IN VITRO FERTIL EM, V8, P65, DOI 10.1007/BF01138657; NORMAN RJ, 1987, OBSTET GYNECOL, V69, P590; Psychoyos A, 1976, J Reprod Fertil Suppl, P17; RINGLER GE, 1990, CURR OPIN OBSTET GYN, V2, P703; Rogers PAW, 1995, REPROD FERT DEVELOP, V7, P1395, DOI 10.1071/RD9951395; ROYSTON JP, 1983, CURRENT TOPICS REPRO, V3, P19; SAMARAJEEWA P, 1979, J STEROID BIOCHEM, V11, P1165, DOI 10.1016/0022-4731(79)90169-9; Speroff L, 1994, CLIN GYNECOLOGIC END, V5th; STEWART DR, 1993, CLIN ENDOCRINOL, V38, P379, DOI 10.1111/j.1365-2265.1993.tb00518.x; TURKASPA I, 1990, FERTIL STERIL, V53, P859; Wilcox A J, 1990, Epidemiology, V1, P382, DOI 10.1097/00001648-199009000-00008; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; WILCOX AJ, 1985, FERTIL STERIL, V44, P366; WOODWARD AJ, 1992, J CLIN ENDOCR METAB, V74, P999, DOI 10.1210/jc.74.5.999; WOODWARD BJ, 1993, HUM REPROD, V8, P1463, DOI 10.1093/oxfordjournals.humrep.a138280; WRIGHT K, 1978, STEROIDS, V31, P407, DOI 10.1016/0039-128X(78)90053-3; YOSHINAGA K, 1988, ANN NY ACAD SCI, V541, P424, DOI 10.1111/j.1749-6632.1988.tb22279.x; Younis JS, 1996, FERTIL STERIL, V66, P873	34	650	681	2	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1796	1799		10.1056/NEJM199906103402304	http://dx.doi.org/10.1056/NEJM199906103402304			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362823				2022-12-01	WOS:000080726800004
J	Bammer, G; Dobler-Mikola, A; Fleming, PM; Strang, J; Uchtenhagen, A				Bammer, G; Dobler-Mikola, A; Fleming, PM; Strang, J; Uchtenhagen, A			Drug abuse - The heroin prescribing debate: Integrating science and politics	SCIENCE			English	Editorial Material							PRESCRIPTION; MAINTENANCE; PROGRAM; ENGLAND; TRIAL; WALES		Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; Res Inst Addict, CH-8005 Zurich, Switzerland; Portsmouth City Drugs & Alcohol Serv, Portsmouth PO5 1LR, Hants, England; Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England	Australian National University; University of London; King's College London	Bammer, G (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Bammer, Gabriele/0000-0001-9098-0951				Bammer G, 1996, MED J AUSTRALIA, V164, P690, DOI 10.5694/j.1326-5377.1996.tb122243.x; Bammer G, 1999, CNS DRUGS, V11, P253, DOI 10.2165/00023210-199911040-00002; BAMMER G, 1994, 9 AUSTR NAT U AUSTR; BAMMER G, 1995, REPORT RECOMMENDATIO; *CENTR COMM TREATM, 1997, INV MED PRESCR HER R; DOBLERMIKOLA A, IN PRESS HEROIN METH; FLEMING PM, 1997, FEASIBILITY RES CONT, P1; HARTNOLL RL, 1980, ARCH GEN PSYCHIAT, V37, P877; *INT COMMD RUG ADD, 1965, DRUG ADD 2 REP; Metrebian N, 1998, MED J AUSTRALIA, V168, P596, DOI 10.5694/j.1326-5377.1998.tb141444.x; Minist. Health, 1926, ROLL REP DEP COMM MO; Perneger TV, 1998, BMJ-BRIT MED J, V317, P13, DOI 10.1136/bmj.317.7150.13; Sell L, 1997, DRUG ALCOHOL REV, V16, P221, DOI 10.1080/09595239800187401; SPEAR HB, 1994, HEROIN ADDICTION DRU, P3; Strang J, 1997, DRUG ALCOHOL REV, V16, P7, DOI 10.1080/09595239700186281; THORLEY A, 1981, DRUG PROBLEMS BRITAI, P117; Uchtenhagen A, 1997, EUR ADDICT RES, V3, P160, DOI 10.1159/000259173; UCHTENHAGEN A, IN PRESS PRESCRIPTIO; United Nations International Drug Control Programme, 1997, WORLD DRUG REP; Ward J., 1998, METHADONE MAINTENANC; 1977, SINGL CONV NARC DRUG, P19	21	57	57	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1277	1278		10.1126/science.284.5418.1277	http://dx.doi.org/10.1126/science.284.5418.1277			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	198NN	10383306				2022-12-01	WOS:000080430600024
J	Butterworth, B				Butterworth, B			Perspectives: Neuroscience - A head for figures	SCIENCE			English	Editorial Material							HUMAN INFANTS; SKILLS		UCL, Inst Cognit Neurosci, London WC1N 3AR, England	University of London; University College London	Butterworth, B (corresponding author), UCL, Inst Cognit Neurosci, London WC1N 3AR, England.	ucjtsbb@ucl.ac.uk						Butterworth B., 1999, MATH BRAIN; BUTTERWORTH B, IN PRESS DEV ARITHME; Dehaene S, 1997, CORTEX, V33, P219, DOI 10.1016/S0010-9452(08)70002-9; Dehaene S, 1999, SCIENCE, V284, P970, DOI 10.1126/science.284.5416.970; Delazer M, 1997, CORTEX, V33, P697, DOI 10.1016/S0010-9452(08)70727-5; JACKSON M, 1986, CORTEX, V22, P611, DOI 10.1016/S0010-9452(86)80020-X; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; LeFevre J, 1996, J EXP PSYCHOL LEARN, V22, P216, DOI 10.1037/0278-7393.22.1.216; Piaget J., 1952, CHILDS CONCEPT NUMB; STARKEY P, 1980, SCIENCE, V210, P1033, DOI 10.1126/science.7434014; WARRINGTON EK, 1982, Q J EXP PSYCHOL-A, V34, P31, DOI 10.1080/14640748208400856; WYNN K, 1992, NATURE, V358, P749, DOI 10.1038/358749a0; Wynn K, 1995, MATH COGNITION, V1, P35, DOI DOI 10.1016/S0010-0277(99)00066-9	13	62	62	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1999	284	5416					928	929		10.1126/science.284.5416.928	http://dx.doi.org/10.1126/science.284.5416.928			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10357680				2022-12-01	WOS:000080198800035
J	Bobrow, CS; Soothill, PW				Bobrow, CS; Soothill, PW			Fetal growth velocity: a cautionary tale	LANCET			English	Editorial Material							RETARDATION		Univ Bristol, Dept Obstet, St Michaels Hosp, Fetal Med Res Unit, Bristol BS2 8EG, Avon, England	University of Bristol	Bobrow, CS (corresponding author), Univ Bristol, Dept Obstet, St Michaels Hosp, Fetal Med Res Unit, Bristol BS2 8EG, Avon, England.		Soothill, Peter/D-2814-2009					Campbell S., 1993, ULTRASOUND OBSTET GY, P1432; CHARD T, 1993, BRIT J OBSTET GYNAEC, V100, P1076, DOI 10.1111/j.1471-0528.1993.tb15169.x; Gardosi J, 1997, CLIN OBSTET GYNECOL, V40, P715, DOI 10.1097/00003081-199712000-00005; GEIRSSON RT, 1991, BRIT J OBSTET GYNAEC, V98, P108, DOI 10.1111/j.1471-0528.1991.tb10323.x; HECHER K, 1995, CIRCULATION, V91, P129, DOI 10.1161/01.CIR.91.1.129; Jahn A, 1998, ACTA OBSTET GYN SCAN, V77, P643, DOI 10.1034/j.1600-0412.1998.770611.x; Mongelli M, 1998, OBSTET GYNECOL, V92, P908, DOI 10.1016/S0029-7844(98)00349-4; PEARCE JM, 1987, BRIT J OBSTET GYNAEC, V94, P100, DOI 10.1111/j.1471-0528.1987.tb02333.x; SOOTHILL PW, 1995, EUR J OBSTET GYN R B, V59, P21, DOI 10.1016/0028-2243(94)02013-5	9	20	22	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1460	1460		10.1016/S0140-6736(98)00408-5	http://dx.doi.org/10.1016/S0140-6736(98)00408-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232308				2022-12-01	WOS:000080278200005
J	Filteau, SM; Tomkins, AM				Filteau, SM; Tomkins, AM			Promoting vitamin A status in low-income countries	LANCET			English	Editorial Material							LEAFY VEGETABLES; DARK-GREEN; A STATUS; CHILDREN; IMPROVEMENT; INDONESIA		Inst Child Hlth, Ctr Int Child Hlth, London WC1 1EH, England	University of London; University College London	Filteau, SM (corresponding author), Inst Child Hlth, Ctr Int Child Hlth, London WC1 1EH, England.							ARROYAVE G, 1981, AM J CLIN NUTR, V34, P41, DOI 10.1093/ajcn/34.1.41; de Pee S, 1998, AM J CLIN NUTR, V68, P1058, DOI 10.1093/ajcn/68.5.1058; de Pee S, 1998, AM J CLIN NUTR, V68, P1068, DOI 10.1093/ajcn/68.5.1068; DEPEE S, 1995, LANCET, V346, P75, DOI 10.1016/S0140-6736(95)92111-7; English RM, 1997, BRIT MED J, V315, P1122, DOI 10.1136/bmj.315.7116.1122; FAWZI WW, 1995, J NUTR, V125, P1211; Hume EM, 1949, 264 MED RES COUNC; Hussain A, 1996, ACTA PAEDIATR, V85, P971, DOI 10.1111/j.1651-2227.1996.tb14196.x; MUHILAL M A, 1988, American Journal of Clinical Nutrition, V48, P1265; SOMMER A, 1996, VITAMIN A DEFICIENCY; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570; *WHO UN CHILDR FUN, 1982, CONTR VIT A DEF XER	12	11	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1458	1459		10.1016/S0140-6736(98)00391-2	http://dx.doi.org/10.1016/S0140-6736(98)00391-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232307				2022-12-01	WOS:000080278200004
J	Lye, M				Lye, M			Rhythm of life and vicissitudes of old age	LANCET			English	Editorial Material							CIRCADIAN-RHYTHMS; PEOPLE		Univ Liverpool, Dept Geriatr Med, Liverpool L69 3GA, Merseyside, England	University of Liverpool	Lye, M (corresponding author), Univ Liverpool, Dept Geriatr Med, Liverpool L69 3GA, Merseyside, England.							ASPLUND R, 1992, Scandinavian Journal of Primary Health Care, V10, P98, DOI 10.3109/02813439209014044; Asplund R, 1998, BRIT J UROL, V82, P642; Bodo G, 1998, SCAND J UROL NEPHROL, V32, P320; Carrier J, 1996, CHRONOBIOL INT, V13, P373, DOI 10.3109/07420529609012661; Friedler E, 1996, BUILD ENVIRON, V31, P385, DOI 10.1016/0360-1323(96)00008-X; JACK CIA, 1995, GERONTOLOGY, V41, P280; Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253; Nyberg L, 1996, J AM GERIATR SOC, V44, P156, DOI 10.1111/j.1532-5415.1996.tb02432.x; Ouslander JG, 1998, J AM GERIATR SOC, V46, P1274, DOI 10.1111/j.1532-5415.1998.tb04545.x; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Ralph MR, 1996, SEMIN CELL DEV BIOL, V7, P821, DOI 10.1006/scdb.1996.0100; Reilly T, 1997, OCCUP ENVIRON MED, V54, P812, DOI 10.1136/oem.54.11.812; Rivkees SA, 1997, PEDIATR CLIN N AM, V44, P467, DOI 10.1016/S0031-3955(05)70486-7; ROBERTS W, 1859, EDINBURGH MED J, V5, P817; Rosato E, 1997, BIOESSAYS, V19, P1075, DOI 10.1002/bies.950191206; VISWANATHAN N, 1995, BRAIN RES, V686, P10, DOI 10.1016/0006-8993(95)00423-N; WATERHOUSE JM, 1996, REV CLIN GERONTOL, V6, P11	17	4	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1461	1462		10.1016/S0140-6736(98)00367-5	http://dx.doi.org/10.1016/S0140-6736(98)00367-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232309				2022-12-01	WOS:000080278200006
J	Takeuchi, JK; Koshiba-Takeuchi, K; Matsumoto, K; Vogel-Hopker, A; Naitoh-Matsuo, M; Ogura, K; Takahashi, N; Yasuda, K; Ogura, T				Takeuchi, JK; Koshiba-Takeuchi, K; Matsumoto, K; Vogel-Hopker, A; Naitoh-Matsuo, M; Ogura, K; Takahashi, N; Yasuda, K; Ogura, T			Tbx5 and Tbx4 genes determine the wing/leg identity of limb buds	NATURE			English	Article							T-BOX GENES; VERTEBRATE LIMB; OPTOMOTOR-BLIND; EXPRESSION; SPECIFICATION; EVOLUTION; INVOLVEMENT; INITIATION; FAMILY; SYSTEM	Much progress has been made in understanding limb development(1-3). Most genes are expressed equally and in the same pattern in the fore- and hindlimbs, which nevertheless develop into distinct structures(3-8). The T-box genes Tbx5 and Tbx4 on the other hand, are expressed differently in chick wing (Tbx5) and leg (Tbx4) buds(9-12). Molecular analysis of the optomotor blind gene(13), which belongs to the same family of transcription factors, has revealed that this gene is involved in the transdetermination of Drosophila wing and leg imaginal discs(14). In addition, expression of Tbx5 and Tbx4 correlates well with the identity of ectopic limb buds induced by fibroblast growth factor(4,5,15-19). Thus, it is thought that Tbx5 and Tbx4 might be involved in determining limb identity. Another candidate is the Pitx1 gene, which encodes a bicoid-type homeodomain transcription factor that is expressed in leg buds(20,21). Here we determine the importance of these factors in establishing limb identity.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Max Planck Inst Brain Res, D-60528 Frankfurt, Germany	Nara Institute of Science & Technology; Max Planck Society	Ogura, T (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	ogura@bs.aist-nara.ac.jp						Carroll RL, 1997, PATTERNS PROCESSES V; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Coates MI, 1998, BIOESSAYS, V20, P371, DOI 10.1002/(SICI)1521-1878(199805)20:5<371::AID-BIES4>3.0.CO;2-R; Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Isaac A, 1998, DEVELOPMENT, V125, P1867; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Logan M, 1998, DEVELOPMENT, V125, P2825; MOMOSE T, IN PRESS DEV GROWTH, V41; MOTGAN BA, 1996, METHOD CELL BIOL, V51, P185; Nelson CE, 1996, DEVELOPMENT, V122, P1449; OGURA T, 1995, P NATL ACAD SCI USA, V92, P392, DOI 10.1073/pnas.92.2.392; OGURA T, 1995, P NATL ACAD SCI USA, V92, P387, DOI 10.1073/pnas.92.2.387; Ohuchi H, 1998, DEVELOPMENT, V125, P51; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; PETERSON RL, 1994, MECH DEVELOP, V47, P253, DOI 10.1016/0925-4773(94)90043-4; POECK B, 1993, DEVELOPMENT, V117, P1017; Shang J, 1997, GENOMICS, V40, P108, DOI 10.1006/geno.1996.4558; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; STEPHENS TD, 1993, DEV DYNAM, V197, P157, DOI 10.1002/aja.1001970302; STEPHENS TD, 1989, DEV BIOL, V133, P1, DOI 10.1016/0012-1606(89)90290-X; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; Vogel A, 1996, DEVELOPMENT, V122, P1737; Wessells NK, 1977, TISSUE INTERACTION D; WILKINSON DG, 1993, IN SITU HYBRIDIZATIO, P75	30	198	207	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					810	814		10.1038/19762	http://dx.doi.org/10.1038/19762			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235263				2022-12-01	WOS:000080058100059
J	Cobleigh, MA; Norlock, FE; Oleske, DM; Starr, A				Cobleigh, MA; Norlock, FE; Oleske, DM; Starr, A			Hormone replacement therapy and high S phase in breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DNA FLOW-CYTOMETRY; ESTROGEN-RECEPTOR STATUS; PROGNOSTIC FACTORS; RISK-FACTORS; WOMEN; CARCINOMA; PLOIDY; TUMOR; REGRESSION	Context Prolonged postmenopausal hormone replacement therapy (HRT) is associated with increased incidence of breast cancer and, paradoxically, reduced breast cancer mortality, The biological rationale for this discrepancy has not been explored. Objective To compare the prognostic characteristics of cancers arising in women who have used HRT with those in women who never have used HRT. Design Prospective cohort study from December 1989 to November 1996. Setting Teaching hospital in a large midwestern metropolitan area. Patients Cohort of 331 postmenopausal women who presented consecutively with 349 invasive breast cancers. Main outcome Measures Estrogen receptor (ER) status (ER positive vs ER negative) and S phase (low vs high) for current HRT users vs never users. Results The frequency of high S-phase fraction among cancers in women who were using HRT was markedly increased com pared with that in women who had never used HRT (adjusted odds ratio [OR], 2.82; 95% confidence interval [CI], 1.04-7.66). However, the greater frequency of high S-phase fraction was limited to women with ER-positive cancers (for HRT users vs never Users, OR, 5.25; 95% CI, 1.36-20.28; for ER-negative cancers in HRT users vs never users, OR, 1.08; 95% CI, 0.20-5.86). Conclusions Use of HRT appears to stimulate growth of ER-positive but not ER-negative breast cancer as measured by S-phase fraction. The prognostic significance of high S-phase fraction in current HRT users who have ER-positive tumors is unknown.	Rush Presbyterian St Lukes Med Ctr, Sect Med Oncol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Med, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA	Rush University; Rush University; Rush University	Cobleigh, MA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Sect Med Oncol, 1725 W Harrison St,Suite 821, Chicago, IL 60612 USA.							BALSLEV I, 1994, INT J CANCER, V56, P16; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BONNIER P, 1995, OBSTET GYNECOL, V85, P11, DOI 10.1016/0029-7844(94)00324-7; BOSARI S, 1992, CANCER-AM CANCER SOC, V70, P1943, DOI 10.1002/1097-0142(19921001)70:7<1943::AID-CNCR2820700722>3.0.CO;2-Y; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COBLEIGH MA, 1998, CANC TREAT RES, V94, P210; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COOPER JA, 1989, BRIT J CANCER, V59, P119, DOI 10.1038/bjc.1989.24; DHODAPKAR MV, 1995, CANCER-AM CANCER SOC, V75, P43, DOI 10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#; EWERS SB, 1992, BREAST CANCER RES TR, V24, P115, DOI 10.1007/BF01961244; FUQUA SAW, 1996, DIS BREAST, P262; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Harvey SC, 1996, AM J ROENTGENOL, V167, P394, DOI 10.2214/ajr.167.2.8686614; HILDRETH NG, 1983, J NATL CANCER I, V70, P1027; Holli K, 1998, J CLIN ONCOL, V16, P3115, DOI 10.1200/JCO.1998.16.9.3115; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; HULKA BS, 1984, AM J EPIDEMIOL, V119, P692, DOI 10.1093/oxfordjournals.aje.a113790; JONES C, 1994, MED J AUSTRALIA, V161, P106, DOI 10.5694/j.1326-5377.1994.tb127340.x; LESSER ML, 1981, CANCER, V48, P299, DOI 10.1002/1097-0142(19810715)48:2<299::AID-CNCR2820480215>3.0.CO;2-2; LIPPMAN M, 1976, CANCER RES, V36, P4595; Magnusson C, 1996, BREAST CANCER RES TR, V38, P325, DOI 10.1007/BF01806152; MERKEL DE, 1993, CANCER, V72, P1926, DOI 10.1002/1097-0142(19930915)72:6<1926::AID-CNCR2820720622>3.0.CO;2-I; MUSS HB, 1989, CANCER, V64, P1894, DOI 10.1002/1097-0142(19891101)64:9<1894::AID-CNCR2820640923>3.0.CO;2-K; OREILLY SM, 1990, J CLIN ONCOL, V8, P2040, DOI 10.1200/JCO.1990.8.12.2040; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; SQUITIERI R, 1994, J AM COLL SURGEONS, V178, P167; STAL O, 1993, J CLIN ONCOL, V11, P1717, DOI 10.1200/JCO.1993.11.9.1717; STANFORD JL, 1987, AM J EPIDEMIOL, V125, P184, DOI 10.1093/oxfordjournals.aje.a114519; TOIKKANEN S, 1989, BRIT J CANCER, V60, P693, DOI 10.1038/bjc.1989.342; WENGER CR, 1993, BREAST CANCER RES TR, V28, P9, DOI 10.1007/BF00666351; WINCHESTER DJ, 1990, ARCH SURG-CHICAGO, V125, P886; WITZIG TE, 1994, CANCER, V74, P1752, DOI 10.1002/1097-0142(19940915)74:6<1752::AID-CNCR2820740618>3.0.CO;2-5	32	34	35	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1528	1530		10.1001/jama.281.16.1528	http://dx.doi.org/10.1001/jama.281.16.1528			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227323				2022-12-01	WOS:000079857400035
J	Ballestas, ME; Chatis, PA; Kaye, KM				Ballestas, ME; Chatis, PA; Kaye, KM			Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen	SCIENCE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; PERMITS STABLE REPLICATION; KAPOSIS-SARCOMA; CELL-LINES; INFECTED-CELLS; LYMPHOMA; IDENTIFICATION; SEQUENCES; BINDING; PROTEIN	Primary effusion Lymphoma (PEL) cells harbor Kaposi's sarcoma-associated herpesvirus (KSHV) episomes and express a KSHV-encoded Latency-associated nuclear antigen (LANA). In PEL cells, LANA and KSHV DNA colocalized in dots in interphase nuclei and along mitotic chromosomes. In the absence of KSHV DNA, LANA was diffusely distributed in the nucleus or on mitotic chromosomes. In Lymphoblasts, LANA was necessary and sufficient for the persistence of episomes containing a specific KSHV DNA fragment. Furthermore, LANA colocalized with the artificial KSHV DNA episomes in nuclei and along mitotic chromosomes. These results support a model in which LANA tethers KSHV DNA to chromosomes during mitosis to enable the efficient segregation of KSHV episomes to progeny cells.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; NEN Life Sci Prod, Boston, MA 02118 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kaye, KM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.			Ballestas, Mary/0000-0003-0660-9477	NCI NIH HHS [CA67380-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067380] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Decker LL, 1996, J EXP MED, V184, P283, DOI 10.1084/jem.184.1.283; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; GARDELLA T, 1984, J VIROL, V50, P248, DOI 10.1128/JVI.50.1.248-254.1984; GROGAN EA, 1983, P NATL ACAD SCI-BIOL, V80, P7650, DOI 10.1073/pnas.80.24.7650; HARRIS A, 1985, J VIROL, V56, P328, DOI 10.1128/JVI.56.1.328-332.1985; Jones D, 1998, NEW ENGL J MED, V339, P444, DOI 10.1056/NEJM199808133390705; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kellam P, 1997, J Hum Virol, V1, P19; Kung SH, 1996, J VIROL, V70, P1738, DOI 10.1128/JVI.70.3.1738-1744.1996; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; Renne R, 1996, J VIROL, V70, P8151, DOI 10.1128/JVI.70.11.8151-8154.1996; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; Szekely L, 1998, J GEN VIROL, V79, P1445, DOI 10.1099/0022-1317-79-6-1445; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	34	569	589	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					641	644		10.1126/science.284.5414.641	http://dx.doi.org/10.1126/science.284.5414.641			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213686				2022-12-01	WOS:000079951100044
J	Mosterd, A; D'Agostino, RB; Silbershatz, H; Sytkowski, PA; Kannel, WB; Grobbee, DE; Levy, D				Mosterd, A; D'Agostino, RB; Silbershatz, H; Sytkowski, PA; Kannel, WB; Grobbee, DE; Levy, D			Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; NATIONAL-HEALTH; ARTERY DISEASE; SECULAR TRENDS; SERIAL CHANGES; RISK-FACTORS; MORTALITY; CRITERIA; DECLINE	Background Men and women with hypertension are at increased risk for cardiovascular disease, especially when left ventricular hypertrophy is present. We examined temporal trends in the use of antihypertensive medications and studied the relation between their use, the prevalence of high blood pressure, and the presence of electrocardiographic evidence of left ventricular hypertrophy. Methods A total of 10,333 participants in the Framingham Heart Study who were 45 to 74 years of age underwent a total of 51,756 examinations from 1950 to 1989. Data were obtained on blood pressure and the use of antihypertensive medications, and electrocardiograms were assessed for left ventricular hypertrophy. The generalized-estimating-equation method was used to test for trends over time. Results From 1950 to 1989, the rate of use of antihypertensive medications increased from 2.3 percent to 24.6 percent among men and from 5.7 percent to 27.7 percent among women. The age-adjusted prevalence of systolic blood pressure of at least 160 mm Hg or diastolic blood pressure of at least 100 mm Hg declined from 18.5 percent to 9.2 percent among men and from 28.0 percent to 7.7 percent among women. This decline was accompanied by age-adjusted reductions in the prevalence of electrocardiographic evidence of left ventricular hypertrophy, from 4.5 percent to 2.5 percent among men and from 3.6 percent to 1.1 percent among women. Conclusions Our findings support the notion that the increasing use of antihypertensive medication has resulted in a reduced prevalence of high blood pressure and a concomitant decline in left ventricular hypertrophy in the general population. Our observations may in part explain the considerable decline in mortality from cardiovascular disease observed since the late 1960s. (N Engl J Med 1999;340:1221-7) (C) 1999, Massachusetts Medical Society.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Thoraxctr, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Div Cardiol, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Julius Ctr Patient Oriented Res, Utrecht, Netherlands; NHLBI, Bethesda, MD 20892 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Epidemiol, Boston, MA USA; Boston Univ, Sch Med, Dept Math, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Epidemiol & Prevent Med, Boston, MA 02118 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Utrecht University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boston University; Boston University	Levy, D (corresponding author), NHLBI, Framingham Heart Study, 5 Thurber St, Framingham, MA 01702 USA.		Levy, Daniel/ABF-6873-2021; Grobbee, Diederick/C-7651-2014; Levy, Daniel/ABB-2752-2021	Levy, Daniel/0000-0003-1843-8724; Grobbee, Diederick/0000-0003-4472-4468; 	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASHIZAWA N, 1989, J AM COLL CARDIOL, V13, P165, DOI 10.1016/0735-1097(89)90566-4; Black HR, 1998, ARCH INTERN MED, V158, P573; Black HR, 1997, ARCH INTERN MED, V157, P2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; CASALE PN, 1985, J AM COLL CARDIOL, V6, P572, DOI 10.1016/S0735-1097(85)80115-7; CHAMBERS J, 1995, BRIT MED J, V311, P273, DOI 10.1136/bmj.311.7000.273; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; FEINLEIB M, 1992, MONOGRAPHS EPIDEMIOL, V16, P261; FROHLICH ED, 1992, NEW ENGL J MED, V327, P1768; GHALI JK, 1991, J AM COLL CARDIOL, V17, P1277, DOI 10.1016/S0735-1097(10)80135-4; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1992, AM J PUBLIC HEALTH, V82, P1593, DOI 10.2105/AJPH.82.12.1593; KNUTSEN R, 1988, J CLIN EPIDEMIOL, V41, P293, DOI 10.1016/0895-4356(88)90134-5; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LANTI M, 1990, AM J CARDIOL, V66, P1181, DOI 10.1016/0002-9149(90)91095-N; LEE DK, 1992, JAMA-J AM MED ASSOC, V268, P3201; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; Levy D, 1998, NEW ENGL J MED, V339, P915, DOI 10.1056/NEJM199809243391309; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MACMAHON S, 1989, AM J CARDIOL, V63, P202, DOI 10.1016/0002-9149(89)90286-5; MCLENACHAN JM, 1987, NEW ENGL J MED, V317, P787, DOI 10.1056/NEJM198709243171302; *NAT HEART LUNG BL, 1998, MORB MORT 1998 CHART; PRINGLE SD, 1989, J AM COLL CARDIOL, V13, P1377, DOI 10.1016/0735-1097(89)90314-8; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Sullivan JM, 1993, J AM COLL CARDIOL, V22, P508, DOI 10.1016/0735-1097(93)90057-8; Sytkowski PA, 1996, AM J EPIDEMIOL, V143, P338, DOI 10.1093/oxfordjournals.aje.a008748; Sytkowski PA, 1996, CIRCULATION, V93, P697, DOI 10.1161/01.CIR.93.4.697; VANHOOF R, 1991, AM J MED, V90, pS55, DOI 10.1016/0002-9343(91)90438-4; Verdecchia P, 1998, CIRCULATION, V97, P48, DOI 10.1161/01.CIR.97.1.48; 1985, HYPERTENSION, V7, P105	39	205	213	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 22	1999	340	16					1221	1227		10.1056/NEJM199904223401601	http://dx.doi.org/10.1056/NEJM199904223401601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188EL	10210704				2022-12-01	WOS:000079833800001
J	Williamson, LM; Lowe, S; Love, EM; Cohen, H; Soldan, K; McClelland, DBL; Skacel, P; Barbara, JAJ				Williamson, LM; Lowe, S; Love, EM; Cohen, H; Soldan, K; McClelland, DBL; Skacel, P; Barbara, JAJ			Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-TRANSFUSION; SYSTEM; RISK	Objective To receive and collate reports of death or major complications of transfusion of blood or components. Design Haematologists were invited confidentially to report deaths and major complications after blood transfusion during October 1996 to September 1998. S etting Hospitals in United Kingdom and Ireland. Subjects Patients who died or experienced serious complications, as defined below; associated with transfusion of red cells, platelets, fresh frozen plasma or cryoprecipitate. Main outcome measures Death, "wrong" blood transfused to patient acute and delayed transfusion reactions, transfusion related acute lung injury, transfusion associated graft versus host disease, post-transfusion purpura, and infection transmitted by transfusion. Circumstances relating to these cases and relative frequency of complications. Results Over 24 months, 366 cases were reported of which 191 (52%) were "wrong blood to patient" episodes. Analysis of these revealed multiple errors of identification, often beginning when blood was collected from the blood bank. There were 22 deaths from all causes, including three from ABO incompatibility. There were 12 infections: four bacterial (one fatal), seven viral, and one fatal case of malaria. During die second 12 months, 164/424 hospitals (39%) submitted a "nil to report" return. Conclusions Transfusion is now extremely safe, but vigilance is needed to ensure correct identification of blood and patient Staff education should include an awareness of ABO incompatibility and bacterial contamination as causes of life threatening reactions to blood.	Univ E Anglia, Natl Blood Serv, Div Transfus Med, Cambridge CB2 2PT, England; Natl Blood Serv Manchester, Manchester M13 9LL, Lancs, England; UCL Hosp, London WC1E 6DB, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Natl Blood Serv, London NW9 5EQ, England; Royal Infirm, Dept Transfus Med, Edinburgh & South East Scotland Blood Transfus Se, Edinburgh EH3 9HB, Midlothian, Scotland; Hammersmith Hosp, Royal Postgrad Med Sch, London W12 0HS, England; Natl Blood Serv, London NW9 5BG, England	University of East Anglia; University College London Hospitals NHS Foundation Trust; University of London; University College London; Public Health England; Royal Infirmary of Edinburgh; Imperial College London	Williamson, LM (corresponding author), Univ E Anglia, Natl Blood Serv, Div Transfus Med, Cambridge CB2 2PT, England.	lorna.williamson@nbs.nhs.uk		Soldan, Kate/0000-0002-0361-3174				AuBuchon JP, 1997, TRANSFUSION, V37, P1211, DOI 10.1046/j.1537-2995.1997.37111298088055.x; BLAJCHMAN MA, 1994, VOX SANG, V67, P25, DOI 10.1111/j.1423-0410.1994.tb04540.x; Calman KC, 1996, BRIT MED J, V313, P799; Chapman JF, 1996, TRANSFUSION MED, V6, P273, DOI 10.1111/j.1365-3148.1996.tb00079.x; *CTR NAT HEM, 1999, HEM ACT DOSS LETT IN; Ingrand P, 1998, TRANSFUSION, V38, P1030, DOI 10.1046/j.1537-2995.1998.38111299056312.x; Kaplan HS, 1998, TRANSFUSION, V38, P1071, DOI 10.1046/j.1537-2995.1998.38111299056319.x; Lumadue JA, 1997, TRANSFUSION, V37, P1169, DOI 10.1046/j.1537-2995.1997.37111298088047.x; MCCLELLAND DBL, 1994, BRIT MED J, V308, P1205, DOI 10.1136/bmj.308.6938.1205; McClelland DBL, 1998, TRANSFUSION, V38, P999, DOI 10.1046/j.1537-2995.1998.38111299056306.x; *NHS EX, 1999, BETT BLOOD TRANSF; SAZAMA K, 1985, TRANSFUSION, V30, P583; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Shiba M, 1997, TRANSFUSION, V37, P457, DOI 10.1046/j.1537-2995.1997.37597293873.x; Williamson LM, 1996, BRIT MED J, V313, P1221, DOI 10.1136/bmj.313.7067.1221; WILLIAMSON LM, 1999, SHOT ANN REPORT 1997; WILLIAMSON LM, 1998, SHOT ANN REPORT 1996	17	233	241	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					16	19		10.1136/bmj.319.7201.16	http://dx.doi.org/10.1136/bmj.319.7201.16			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390452	Bronze, Green Published			2022-12-01	WOS:000081326500023
J	Chen, DG; Ma, H; Hong, H; Koh, SS; Huang, SM; Schurter, BT; Aswad, DW; Stallcup, MR				Chen, DG; Ma, H; Hong, H; Koh, SS; Huang, SM; Schurter, BT; Aswad, DW; Stallcup, MR			Regulation of transcription by a protein methyltransferase	SCIENCE			English	Article							ARGININE N-METHYLTRANSFERASE; HORMONE RECEPTORS; STEROID-RECEPTORS; COACTIVATOR; BINDING; DOMAINS; ACETYLTRANSFERASE; TRANSACTIVATION; ACETYLATION; SPECIFICITY	The p160 family of coactivators, SRC-1, GRIP1/TIF2, and p/CIP, mediate transcriptional activation by nuclear hormone receptors. Coactivator-associated arginine methyltransferase 1 (CARM1), a previously unidentified protein that binds to the carboxyl-terminal region of p160 coactivators, enhanced transcriptional activation by nuclear receptors, but only when GRIP1 or SRC-1a was coexpressed. Thus, CARM1 functions as a secondary coactivator through its association with p160 coactivators. CARM1 can methylate histone H3 in vitro, and a mutation in the putative S-adenosylmethionine binding domain of CARM 1 substantially reduced both methyltransferase and coactivator activities. Thus, coactivator-mediated methylation of proteins in the transcription machinery may contribute to transcriptional regulation.	Univ So Calif, Dept Pathol HMR 301, Los Angeles, CA 90033 USA; Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA USA	University of Southern California; University of California System; University of California Irvine	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol HMR 301, 2011 Zonal Ave, Los Angeles, CA 90033 USA.				NIA NIH HHS [AG00093] Funding Source: Medline; NIDDK NIH HHS [DK43093] Funding Source: Medline; NINDS NIH HHS [NS17269] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ASWAD DW, UNPUB; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CHAMBERLIN JP, 1978, ANAL BIOCHEM, V98, P132; Chen D.-Y., UNPUB; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GARY JD, 1996, J BIOL CHEM, V271, P11585; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MA H, IN PRESS MOL CELL BI; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	32	955	994	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2174	2177		10.1126/science.284.5423.2174	http://dx.doi.org/10.1126/science.284.5423.2174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381882				2022-12-01	WOS:000081099300051
J	Choudhry, NK; Etchells, EE				Choudhry, NK; Etchells, EE			Does this patient have aortic regurgitation?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PULSED DOPPLER ECHOCARDIOGRAPHY; M-MODE ECHOCARDIOGRAPHY; HEALTH-CARE FACILITY; VALVULAR REGURGITATION; MITRAL-STENOSIS; BLOOD-PRESSURE; INSUFFICIENCY; MURMURS; DIAGNOSIS; PREVALENCE	Objective To review evidence as to the precision and accuracy of clinical examination for aortic regurgitation (AR), Methods We conducted a structured MEDLINE search of English-language articles (January 1966-July 1997), manually reviewed all reference lists of potentially relevant articles, and contacted authors of relevant studies for additional information. Each study (n = 16) was independently reviewed by both authors and graded for methodological quality. Results Most studies assessed cardiologists as examiners. Cardiologists' precision for detecting diastolic murmurs was moderate using audiotapes (kappa = 0.51) and was good in the clinical setting (simple agreement, 94%), The most useful finding for ruling in AR is the presence of an early diastolic murmur (positive likelihood ratio [LR], 8.8-32.0 [95% confidence interval {CI}, 2.8-32 to 16-63] for detecting mild or greater AR and 4.0-8.3 [95% CI, 2.5-6.9 to 6.2-11] for detecting moderate or greater AR) (2 grade A studies). The most useful finding for ruling out AR is the absence of early diastolic murmur (negative LR, 0.2-0.3 [95% CI, 0.1-0.3 to 0.2-0.4) for mild or greater AR and 0.1 [95% CI, 0.0-0.3] for moderate or greater AR) (2 grade A studies). Except for a test evaluating the response to transient arterial occlusion (positive LR, 8.4 [95% CI, 1.3-81.0]; negative LR, 0.3 [95% CI, 0.1-0.8]), most signs display poor sensitivity and specificity for AR. Conclusion Clinical examination by cardiologists is accurate for detecting AR, but not enough is known about the examinations of less-expert clinicians.	Univ Toronto, Dept Med, Div Gen Internal Med & Clin Epidemiol, Toronto, ON, Canada; Univ Hlth Network, Toronto, ON M5G 2C4, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Etchells, EE (corresponding author), Univ Hlth Network, 200 Elizabeth St,Eng-248, Toronto, ON M5G 2C4, Canada.							ABBAS F, 1987, SOUTHERN MED J, V80, P1051, DOI 10.1097/00007611-198708000-00027; ALEXANDER WD, 1977, BRIT HEART J, V39, P900; ARONOW WS, 1987, AM J CARDIOL, V59, P181, DOI 10.1016/S0002-9149(87)80105-4; ARONOW WS, 1989, AM J CARDIOL, V63, P128, DOI 10.1016/0002-9149(89)91098-9; Ballard D J, 1989, Int J Technol Assess Health Care, V5, P249; BETHEL CS, 1963, AM J CARDIOL, V11, P763, DOI 10.1016/0002-9149(63)90104-8; Blumgart HL, 1933, J AMER MED ASSOC, V100, P173, DOI 10.1001/jama.1933.02740030021007; CENTOR R, 1992, 2 2 ANAL; COHN LH, 1967, AM J CARDIOL, V19, P177, DOI 10.1016/0002-9149(67)90530-9; COME PC, 1986, J AM COLL CARDIOL, V8, P1355, DOI 10.1016/S0735-1097(86)80308-4; CONSTANT J, 1985, BEDSIDE CARDIOLOGY; CONSTANT J, 1965, AM HEART J, V70, P322; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; Desjardins VA, 1996, AM J MED, V100, P149, DOI 10.1016/S0002-9343(97)89452-1; DITTMANN H, 1987, EUR HEART J, V8, P53, DOI 10.1093/eurheartj/8.suppl_C.53; DUBROW RJ, 1964, MED ANN DIST COLUMBI, V33, P305; ESPER RJ, 1982, AM J CARDIOL, V50, P1037, DOI 10.1016/0002-9149(82)90414-3; Etchells E, 1997, JAMA-J AM MED ASSOC, V277, P564, DOI 10.1001/jama.277.7.564; FEINSTEIN AR, 1959, NEW ENGL J MED, V260, P1331, DOI 10.1056/NEJM195906252602608; FLINT A, 1862, AM J MED SCI, V44, P29; FRANK MJ, 1965, ARCH INTERN MED, V116, P357, DOI 10.1001/archinte.1965.03870030037008; Freeman AR, 1933, ANN INTERN MED, V6, P1371, DOI 10.7326/0003-4819-6-11-1371; GRAYBURN PA, 1986, ANN INTERN MED, V104, P599, DOI 10.7326/0003-4819-104-5-599; HARVEY WP, 1994, DIS MON, V40, P43; HEGGLIN R, 1968, CIRCULATION S5, V37, P77; Hill L, 1909, HEART-J STUD CIRC, V1, P73; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; KOOPMAN PAR, 1984, BIOMETRICS, V40, P513, DOI 10.2307/2531405; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LANDZBERG JS, 1992, J AM COLL CARDIOL, V20, P408, DOI 10.1016/0735-1097(92)90110-9; LEE D, 1995, CHIN MED J, V56, P152; LEMBO NJ, 1986, ANN INTERN MED, V105, P368, DOI 10.7326/0003-4819-105-3-368; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; Linhart J W, 1971, Ann Thorac Surg, V11, P27; Mangione S, 1997, JAMA-J AM MED ASSOC, V278, P717, DOI 10.1001/jama.278.9.717; MEYERS DG, 1982, SOUTHERN MED J, V75, P1192, DOI 10.1097/00007611-198210000-00009; MEYERS DG, 1985, AM J CARDIOL, V56, P811, DOI 10.1016/0002-9149(85)91151-8; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; PEREZ JE, 1985, ANN INTERN MED, V103, P497, DOI 10.7326/0003-4819-103-4-497; RAFTERY EB, 1967, AM J EPIDEMIOL, V85, P438, DOI 10.1093/oxfordjournals.aje.a120705; RAHKO PS, 1989, ANN INTERN MED, V111, P466, DOI 10.7326/0003-4819-111-6-466; REEVES RA, 1995, JAMA-J AM MED ASSOC, V273, P1211, DOI 10.1001/jama.1995.03520390071036; Roldan CA, 1996, AM J CARDIOL, V77, P1327, DOI 10.1016/S0002-9149(96)00200-7; RUSHMER RF, 1952, AMA AM J DIS CHILD, V83, P740, DOI 10.1001/archpedi.1952.02040100038003; SAAL AK, 1985, J AM COLL CARDIOL, V5, P176; SAPIRA JD, 1981, SOUTHERN MED J, V74, P459, DOI 10.1097/00007611-198104000-00022; Sapira JD, 1990, ART SCI BEDSIDE DIAG; SCOGNAMIGLIO R, 1994, NEW ENGL J MED, V331, P689, DOI 10.1056/NEJM199409153311101; SHARMA R S, 1981, Lancet, V2, P612; SHAVER JA, 1995, CURR PROB CARDIOLOGY, V20, P445; SOFFER A, 1967, AM J CARDIOL, V20, P285; STCLAIR EW, 1992, ANN INTERN MED, V117, P751, DOI 10.7326/0003-4819-117-9-751; WARD JM, 1977, J CLIN ULTRASOUND, V5, P5, DOI 10.1002/jcu.1870050103; WARNES CA, 1983, AM J CARDIOL, V51, P1551, DOI 10.1016/0002-9149(83)90675-6	54	17	17	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2231	2238		10.1001/jama.281.23.2231	http://dx.doi.org/10.1001/jama.281.23.2231			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376577				2022-12-01	WOS:000080777000038
J	Iribarren, C; Tekawa, IS; Sidney, S; Friedman, GD				Iribarren, C; Tekawa, IS; Sidney, S; Friedman, GD			Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Epidemiological-Research	JUN 24-26, 1998	CHICAGO, ILLINOIS	Soc Epidemiol Res			PASSIVE SMOKING; MYOCARDIAL-INFARCTION; TOBACCO-SMOKE; PIPE SMOKERS; LUNG-CANCER; MORTALITY; EXPOSURE; PHARYNX; ALCOHOL; LARYNX	Background The sale of cigars in the United States has been increasing since 1993. Cigar smoking is a known risk factor for certain cancers and for chronic obstructive pulmonary disease (COPD). However, unlike the relation between cigarette smoking and cardiovascular disease, the association between cigar smoking and cardiovascular disease has not been clearly established. Methods We performed a cohort study among 17,774 men 30 to 85 years of age at base line (from 1964 through 1973) who were enrolled in the Kaiser Permanente health plan and who reported that they had never smoked cigarettes and did not currently smoke a pipe. Those who smoked cigars (1546 men) and those who did not (16,228) were followed from 1971 through the end of 1995 for a first hospitalization for or death from a major cardiovascular disease or COPD, and through the end of 1996 for a diagnosis of cancer. Results In multivariate analyses, cigar smokers, as compared with nonsmokers, were at higher risk for coronary heart disease (relative risk, 1.27; 95 percent confidence interval, 1.12 to 1.45), COPD (relative risk, 1.45; 95 percent confidence interval, 1.10 to 1.91), and cancers of the upper aerodigestive tract (relative risk, 2.02; 95 percent confidence interval, 1.01 to 4.06) and lung (relative risk, 2.14; 95 percent confidence interval, 1.12 to 4.11), with evidence of dose-response effects. There appeared to be a synergistic relation between cigar smoking and alcohol consumption with respect to the risk of oropharyngeal cancers and cancers of the upper aerodigestive tract. Conclusions Independently of other risk factors, regular cigar smoking can increase the risk of coronary heart disease, COPD, and cancers of the upper aerodigestive tract and lung. (N Engl J Med 1999;340: 1773-80.) (C) 1999, Massachusetts Medical Society.	Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA	Kaiser Permanente	Iribarren, C (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3505 Broadway, Oakland, CA 94611 USA.				NATIONAL CANCER INSTITUTE [R35CA049761] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA 49761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPEL BR, 1990, AM J PUBLIC HEALTH, V80, P560, DOI 10.2105/AJPH.80.5.560; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; ARMITAGE A, 1978, CLIN PHARMACOL THER, V23, P143; BROWN CA, 1993, THORAX, V48, P1163, DOI 10.1136/thx.48.11.1163; BRUNNEMANN KD, 1974, J CHROMATOGR SCI, V12, P70, DOI 10.1093/chromsci/12.2.70; Cendon SP, 1997, BRAZ J MED BIOL RES, V30, P1241, DOI 10.1590/S0100-879X1997001000017; Cohen MF, 1978, MULTIPHASIC HLTH TES; COLLEN MF, 1969, JOM-J OCCUP MED, V11, P355; COX DR, 1972, J R STAT SOC B, V34, P187; DALHAMN T, 1970, ARCH ENVIRON HEALTH, V20, P252, DOI 10.1080/00039896.1970.10665581; *DEP AGR, 1997, EC RES SERV SER; *DEP HHS, 1989, DHHS PHS PUBL; *DEP HLTH HUM SERV, 1982, DHHS PHS PUBL; DIEZROUX AV, 1995, PREV MED, V24, P48, DOI 10.1006/pmed.1995.1007; FRANCESCHI S, 1990, CANCER RES, V50, P6502; FRIEDMAN GD, 1972, AM J EPIDEMIOL, V96, P23, DOI 10.1093/oxfordjournals.aje.a121429; FRIEDMAN GD, 1997, SMOKING TOBACCO CONT, V8, P477; GOLDMAN AL, 1977, CHEST, V72, P33, DOI 10.1378/chest.72.1.33; GYNTELBERG F, 1981, LANCET, V1, P987; HAMMOND EC, 1958, JAMA-J AM MED ASSOC, V166, P1294, DOI 10.1001/jama.1958.02990110030007; Henningfield JE, 1996, JAMA-J AM MED ASSOC, V276, P1857, DOI 10.1001/jama.1996.03540230007003; HICKEY N, 1983, BRIT HEART J, V49, P423, DOI 10.1136/hrt.49.5.423; HIGGINS ITT, 1988, PREV MED, V17, P116, DOI 10.1016/0091-7435(88)90077-1; HUBER GL, 1977, B EUR PHYSIOPATH RES, V13, P513; *INT AG RES CANC, 1986, IARC MON EV CARC RIS, V38; Iribarren C, 1998, CIRCULATION, V97, P822; KAUFMAN DW, 1987, BRIT MED J, V294, P1315, DOI 10.1136/bmj.294.6583.1315; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; LANGE P, 1992, EUR RESPIR J, V5, P1111; LUBIN JH, 1984, J NATL CANCER I, V73, P377, DOI 10.1093/jnci/73.2.377; MUSCAT JE, 1992, CANCER, V69, P2244, DOI 10.1002/1097-0142(19920501)69:9&lt;2244::AID-CNCR2820690906&gt;3.0.CO;2-O; *NCI, 1998, SMOK TOB CONTR MON, V9; *OFF SMOK HLTH, 1992, PUBL HLTH SERV BIBL, V46; PECHACEK TF, 1985, JAMA-J AM MED ASSOC, V254, P3330, DOI 10.1001/jama.254.23.3330; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; ROTHMAN K, 1972, J CHRON DIS, V25, P711, DOI 10.1016/0021-9681(72)90006-9; Schmid P, 1996, THROMB RES, V81, P451, DOI 10.1016/0049-3848(96)00017-5; Selby JV, 1996, NEW ENGL J MED, V335, P1888, DOI 10.1056/NEJM199612193352506; SINZINGER H, 1989, WIEN KLIN WOCHENSCHR, V101, P694; Slattery ML, 1997, INT J CANCER, V71, P706; Steenland K, 1996, CIRCULATION, V94, P622, DOI 10.1161/01.CIR.94.4.622; STRACHAN DP, 1991, BRIT J SURG, V78, P401, DOI 10.1002/bjs.1800780407; Terry MB, 1998, AM J EPIDEMIOL, V147, P903; Valkonen M, 1998, CIRCULATION, V97, P2012, DOI 10.1161/01.CIR.97.20.2012; WYNDER EL, 1976, CANCER-AM CANCER SOC, V38, P1591, DOI 10.1002/1097-0142(197610)38:4<1591::AID-CNCR2820380425>3.0.CO;2-R; 1997, MMWR MORB MORTAL WKL, V46, P433; [No title captured]	47	144	154	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1773	1780		10.1056/NEJM199906103402301	http://dx.doi.org/10.1056/NEJM199906103402301			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362820	Bronze			2022-12-01	WOS:000080726800001
J	Leonardo, A; Konishi, M				Leonardo, A; Konishi, M			Decrystallization of adult birdsong by perturbation of auditory feedback	NATURE			English	Article							SONG; FINCHES; MAINTENANCE; SYRINX	Young birds learn to sing by using auditory feedback to compare their own vocalizations to a memorized or innate song pattern; if they are deafened as juveniles, they will not develop normal songs(1,2). The completion of song development is called crystallization. After this stage, song shows little variation in its temporal or spectral properties. However, the mechanisms underlying this stability are largely unknown. Here we present evidence that auditory feedback is actively used in adulthood to maintain the stability of song structure. We found that perturbing auditory feedback during singing in adult zebra finches caused their song to deteriorate slowly. This 'decrystallization' consisted of a marked loss of the spectral and temporal stereotypy seen in crystallized song, including stuttering, creation, deletion and distortion of song syllables. After normal feedback was restored, these deviations gradually disappeared and the original song was recovered. Thus, adult birds that do not learn new songs nevertheless retain a significant amount of plasticity in the brain.	CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Leonardo, A (corresponding author), CALTECH, Computat & Neural Syst Program, MC 216-76, Pasadena, CA 91125 USA.	leonardo@cns.caltech.edu						Bradley E, 1993, INTRO BOOTSTRAP; Cover T.M., 1991, ELEMENTS INFORM THEO, DOI [10.1002/047174882X, DOI 10.1002/047174882X, DOI 10.1002/047174882X.CH11]; Fee MS, 1998, NATURE, V395, P67, DOI 10.1038/25725; FELLER W, 1971, INTRO PROBABILITY TH, V1; Ho C, 1998, P JOINT S NEUR COMP, V5, P76; Houde JF, 1998, SCIENCE, V279, P1213, DOI 10.1126/science.279.5354.1213; Konishi M., 1965, Zeitschrift fuer Tierpsychologie, V22, P770; MARLER P, 1987, ETHOLOGY, V76, P89; NORDEEN KW, 1992, BEHAV NEURAL BIOL, V57, P58, DOI 10.1016/0163-1047(92)90757-U; NOTTEBOH.F, 1968, IBIS, V110, P549, DOI 10.1111/j.1474-919X.1968.tb00063.x; Okanoya K, 1997, J NEUROBIOL, V33, P343; SELIM SZ, 1984, IEEE T PATTERN ANAL, V6, P81, DOI 10.1109/TPAMI.1984.4767478; SOSSINKA R, 1980, Z TIERPSYCHOL, V53, P123; SUTHERS RA, 1990, NATURE, V347, P473, DOI 10.1038/347473a0; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Woolley SMN, 1997, J NEUROSCI, V17, P6380	16	252	257	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1999	399	6735					466	470		10.1038/20933	http://dx.doi.org/10.1038/20933			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365958				2022-12-01	WOS:000080667900048
J	Pattyn, A; Morin, X; Cremer, H; Goridis, C; Brunet, JF				Pattyn, A; Morin, X; Cremer, H; Goridis, C; Brunet, JF			The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives	NATURE			English	Article							MICE LACKING GDNF; ENTERIC NERVOUS-SYSTEM; MOUSE MODEL; EXPRESSION; KIDNEY; NEURONS; DEFECTS; SOX10; RET; PRECURSORS	The sympathetic, parasympathetic and enteric ganglia are the main components of the peripheral autonomic nervous system(1), and are all derived from the neural crest(2). The factors needed for these structures to develop include the transcription factor Mash 1 (refs 3-5), the glial-derived neurotrophic factor GNDF (refs 6-8) and its receptor subunits(9-12), and the neuregulin signalling system(13), each of which is essential for the differentiation and survival of subsets of autonomic neurons. Here we show that all autonomic ganglia fail to form properly and degenerate in mice lacking the homeodomain transcription factor Phox2b, as do the three cranial sensory ganglia that are part of the autonomic reflex circuits. in the anlagen of the enteric nervous system and the sympathetic ganglia, Phox2b is needed for the expression of the GDNF-receptor subunit Ret and for maintaining Mash1 expression. Mutant ganglionic anlagen also fail to switch on the genes that encode two enzymes needed for the biosynthesis of the neurotransmitter noradrenaline, dopamine-beta-hydroxylase and tyrosine hydroxylase, demonstrating that Phox2b regulates the noradrenergic phenotype in vertebrates.	Univ Meditterranee, AP Marseille, INSERM, CNRS,Dev Biol Inst Marseille,Lab Genet & Physiol, F-13288 Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Brunet, JF (corresponding author), Univ Meditterranee, AP Marseille, INSERM, CNRS,Dev Biol Inst Marseille,Lab Genet & Physiol, Luminy Case 907, F-13288 Marseille 9, France.		morin, xavier/AAI-3306-2020; Alexandre, Pattyn/ABF-1346-2020	Brunet, Jean-Francois/0000-0002-1985-6103; Morin, Xavier/0000-0001-9999-0355; Pattyn, Alexandre/0000-0003-1215-1482; Cremer, Harold/0000-0002-8673-5176				Blaugrund E, 1996, DEVELOPMENT, V122, P309; BLESSING WW, 1997, LOWER BRAINSTEM BODI, P1; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Durbec PL, 1996, DEVELOPMENT, V122, P349; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; Hirsch MR, 1998, DEVELOPMENT, V125, P599; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KNITTEL T, 1995, DEVELOPMENT, V121, P1077; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; LANGLEY JN, 1921, AUTONOMIC NEVOUS SYS; Le Douarin N.M., 1982, NEURAL CREST; Lo LC, 1998, DEVELOPMENT, V125, P609; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Tiveron MC, 1996, J NEUROSCI, V16, P7649; Young HM, 1998, DEV BIOL, V202, P67, DOI 10.1006/dbio.1998.8987	27	628	645	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1999	399	6734					366	370		10.1038/20700	http://dx.doi.org/10.1038/20700			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360575				2022-12-01	WOS:000080547800062
J	Stewart, AL; Rifkin, L; Amess, PN; Kirkbride, V; Townsend, JP; Miller, DH; Lewis, SW; Kingsley, DPE; Moseley, IF; Foster, O; Murray, RM				Stewart, AL; Rifkin, L; Amess, PN; Kirkbride, V; Townsend, JP; Miller, DH; Lewis, SW; Kingsley, DPE; Moseley, IF; Foster, O; Murray, RM			Brain structure and neurocognitive and behavioural function in adolescents who were born very preterm	LANCET			English	Article							ULTRASOUND APPEARANCE; NEURODEVELOPMENTAL IMPAIRMENT; INFANTS; PREDICTION	Background Infants born very preterm (<33 weeks) are at increased risk of neurocognitive deficits. Their neurodevelopmental outcome up to age 8 years can be predicted by neonatal ultrasonography, but little is known of their later function. We investigated the effect of very preterm birth on brain structure and neurocognitive and behavioural functioning in adolescence. Methods A cohort of 105 infants born before 33 weeks of gestation in 1979-80 had ultrasonographic scans at University College Hospital, London, and were prospectively examined at 1, 4, and 8 years. At age 14-15 years, 72 of those who remained in UK (cases) and 21 age-matched full-term controls underwent brain magnetic resonance imaging (MRI), as well as neurological, cognitive, and behavioural assessment. MRI images were assessed by two neuroradiologists unaware of ultrasonographic findings or case or control status. Findings Of the 72 cases, 40 had unequivocally abnormal MRI and 15 had equivocal scans. Of the 21 controls, one had abnormal and five equivocal MRI. Abnormalities of ventricles, corpus callosum, and white matter were especially common in cases. More brain lesions were identified by MRI than by neonatal ultrasonography. The cases had significantly more reading, adjustment, and neurological impairments than controls, but their behaviour was significantly related to MRI abnormality. Interpretation Individuals born very preterm show an excess of neurocognitive and behavioural problems in adolescence, and more than half have abnormal MRI brain scans.	UCL, Sch Med, Rayne Inst, Dept Pediat,Perinatal Brain Res Grp, London WC1E 6JJ, England; Kings Coll London, Inst Psychiat, London WC2R 2LS, England; UCL, Inst Neurol, London WC1E 6JJ, England; Univ Manchester, Sch Psychiat & Behav Sci, Manchester, Lancs, England	University of London; King's College London; University College London; UCL Medical School; University of London; King's College London; University of London; University College London; University of Manchester	Stewart, AL (corresponding author), UCL, Sch Med, Rayne Inst, Dept Pediat,Perinatal Brain Res Grp, London WC1E 6JJ, England.	ann@arlingtonave.demon.co.uk	Townsend, Jeffrey/H-2747-2019; Murray, Robin M/F-8658-2012	Townsend, Jeffrey/0000-0002-9890-3907; Murray, Robin M/0000-0003-0829-0519; Lewis, Shon/0000-0003-1861-4652; Rifkin, Larry/0000-0003-2590-9010	Multiple Sclerosis Society [491] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		Beery K. E, 1989, DEV TEST VISUAL MOTO, V3rd; CANNONSPOOR HE, 1982, SCHIZOPHRENIA BULL, V8, P470, DOI 10.1093/schbul/8.3.470; COSTELLO AMD, 1988, DEV MED CHILD NEUROL, V30, P711; FAIRWEATHER DVI, 1983, REIDS CONTROVERSY OB, V3, P154; FRANSELLA F, 1965, BRIT J EDUC PSYCHOL, V35, P86, DOI 10.1111/j.2044-8279.1965.tb01791.x; Giedd JN, 1996, DEV BRAIN RES, V91, P274; HOPE PL, 1988, DEV MED CHILD NEUROL, V30, P457; KIRKBRIDE V, 1994, PEDIATR RES, V36, pA20; LEVENE MI, 1981, ARCH DIS CHILD, V56, P900, DOI 10.1136/adc.56.12.900; PANETH N, 1994, BRAIN DAMAGE PRETERM, P99; PAPE KE, 1979, LANCET, V1, P1261; ROTH SC, 1994, DEV MED CHILD NEUROL, V36, P1049; ROTH SC, 1993, DEV MED CHILD NEUROL, V35, P755; Rutter M, 1981, ED HLTH BEHAV; SCHONNEL FJ, 1960, DIAGNOSTIC ATTAINMEN; STEWART AL, 1987, DEV MED CHILD NEUROL, V29, P3; STEWART AL, 1983, ARCH DIS CHILD, V58, P598, DOI 10.1136/adc.58.8.598; THORBURN RJ, 1981, LANCET, V1, P1119; THORBURN RJ, 1982, EARLY HUM DEV, V6, P31, DOI 10.1016/0378-3782(82)90055-X	19	297	305	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1653	1657		10.1016/S0140-6736(98)07130-X	http://dx.doi.org/10.1016/S0140-6736(98)07130-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335784				2022-12-01	WOS:000080408000009
J	Prehoda, KE; Lee, DJ; Lim, WA				Prehoda, KE; Lee, DJ; Lim, WA			Structure of the enabled VASP homology 1 domain-peptide complex: A key component in the spatial control of actin assembly	CELL			English	Article							ALDRICH-SYNDROME PROTEIN; METABOTROPIC GLUTAMATE RECEPTORS; MULTIPLE ISOMORPHOUS REPLACEMENT; PROLINE-RICH MOTIF; LISTERIA-MONOCYTOGENES; PTB DOMAIN; PHOSPHOINOSITIDE BINDING; PHOSPHOTYROSINE-BINDING; SIGNAL-TRANSDUCTION; FOCAL ADHESION	The Enabled/VASP homology 1 (EVH1;also called WH1) domain is an interaction module found in several proteins implicated in actin-based cell motility. EVH1 domains bind the consensus proline-rich motif FPPPP and are required for targeting the actin assembly machinery to sites of cytoskeletal remodeling. The crystal structure of the mammalian Enabled (Mena) EVH1 domain complexed with a peptide ligand reveals a mechanism of recognition distinct from that used by other proline-binding modules. The EVH1 domain fold is unexpectedly similar to that of the pleckstrin homology domain, a membrane localization module. This finding demonstrates the functional plasticity of the pleckstrin homology fold as a binding scaffold and suggests that membrane association may play an auxiliary role in EVH1 targeting.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu		Prehoda, Ken/0000-0003-4214-6158				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Finan PM, 1996, J BIOL CHEM, V271, P26291, DOI 10.1074/jbc.271.42.26291; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Machesky LM, 1997, CURR BIOL, V7, pR164, DOI 10.1016/S0960-9822(97)70079-4; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; Ponting CP, 1997, J MOL MED-JMM, V75, P769, DOI 10.1007/s001090050166; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; Zhou MM, 1995, PROG BIOPHYS MOL BIO, V64, P221, DOI 10.1016/S0079-6107(96)00005-3; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	54	203	211	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					471	480		10.1016/S0092-8674(00)80757-6	http://dx.doi.org/10.1016/S0092-8674(00)80757-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338211	Bronze			2022-12-01	WOS:000080299100008
J	Nelson, JE				Nelson, JE			Saving lives and saving deaths	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									CUNY Mt Sinai Sch Med, Med Intens Care Unit, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Nelson, JE (corresponding author), CUNY Mt Sinai Sch Med, Med Intens Care Unit, Box 1232,1 Gustave L Levy Pl, New York, NY 10029 USA.	jnelson@smtplink.mssm.edu							0	18	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					776	777		10.7326/0003-4819-130-9-199905040-00020	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357699				2022-12-01	WOS:000080062300011
J	Hickman, AB; Namboodiri, MAA; Klein, DC; Dyda, F				Hickman, AB; Namboodiri, MAA; Klein, DC; Dyda, F			The structural basis of ordered substrate binding by serotonin N-acetyltransferase: Enzyme complex at 1.8 angstrom resolution with a bisubstrate analog	CELL			English	Article							CATALYTIC MECHANISM; CRYSTAL-STRUCTURES; WATER-MOLECULES; PINEAL-GLAND; REFINEMENT; SUPERFAMILY; PARAMETERS; PROTEINS	Serotonin N-acetyltransferase, a member of the GNAT acetyltransferase superfamily, is the penultimate enzyme in the conversion of serotonin to melatonin, the circadian neurohormone. Comparison of the structures of the substrate-free enzyme and the complex with a bisubstrate analog, coenzyme A-S-acetyltryptamine, demonstrates that acetyl coenzyme A (AcCoA) binding is accompanied by a large conformational change that in turn leads to the formation of the serotonin-binding site. The structure of the complex also provides insight into how the enzyme may facilitate acetyl transfer. A water-filled channel leading from the active site to the surface provides a pathway for proton removal following amine deprotonation. Furthermore, structural and mutagenesis results indicate an important role for Tyr-168 in catalysis.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Dev Neurobiol Lab, NICHHD, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Physiol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Uniformed Services University of the Health Sciences - USA	Dyda, F (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	dyda@ulti.niddk.nih.gov		Klein, David/0000-0002-1792-5806	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000095, ZIAHD000095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIHDK034002, Z01DK034002, ZIADK034002] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P6689, DOI 10.1021/bi980106v; Bonhomme N, 1998, J CLIN PSYCHOPHARM, V18, P447, DOI 10.1097/00004714-199812000-00005; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; Kohen A, 1998, ACCOUNTS CHEM RES, V31, P397, DOI 10.1021/ar9701225; Kordik CP, 1999, J MED CHEM, V42, P181, DOI 10.1021/jm980521l; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; Marx D, 1999, NATURE, V397, P601, DOI 10.1038/17579; *MERCK CO, 1976, MERCK IND, P1095; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; Modis Y, 1998, STRUCTURE, V6, P1345, DOI 10.1016/S0969-2126(98)00134-8; NAMBOODIRI MAA, 1987, METHOD ENZYMOL, V142, P583; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; POMES R, 1995, CHEM PHYS LETT, V234, P416, DOI 10.1016/0009-2614(95)00071-B; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Tronrud DE, 1996, J APPL CRYSTALLOGR, V29, P100, DOI 10.1107/S002188989501421X; Wirz-Justice Anna, 1995, P999; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8	37	146	149	3	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					361	369		10.1016/S0092-8674(00)80745-X	http://dx.doi.org/10.1016/S0092-8674(00)80745-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319816	Bronze			2022-12-01	WOS:000080100500009
J	Antman, K; Shea, S				Antman, K; Shea, S			Screening mammography under age 50	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-CANCER DETECTION; YOUNG-WOMEN; DEATH RATES; TRIALS; PERSPECTIVE; MORTALITY; RISK		Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY USA; Columbia Univ, Coll Phys & Surg, Div Gen Med, New York, NY USA	Columbia University; Columbia University	Antman, K (corresponding author), MHB 6N 435,177 Ft Washington Ave, New York, NY 10032 USA.	kha@columbia.edu		/0000-0002-1093-8356	NCI NIH HHS [P01CA-40053, P20CA66244-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053, F32CA066244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson I, 1997, J Natl Cancer Inst Monogr, P63; Bjurstam N, 1997, J Natl Cancer Inst Monogr, P53; Dolan NC, 1997, CANCER, V80, P413; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; Elwood JM, 1993, ONLINE J CURR CLIN T; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; Frisell J, 1997, BREAST CANCER RES TR, V45, P263, DOI 10.1023/A:1005872617944; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Larsson L G, 1996, J Med Screen, V3, P129; Larsson L G, 1997, J Natl Cancer Inst Monogr, P57; Margolese R, 1996, LANCET, V347, P881, DOI 10.1016/S0140-6736(96)91352-5; Miller A B, 1997, J Natl Cancer Inst Monogr, P37; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; Narod SA, 1997, LANCET, V349, P1846, DOI 10.1016/S0140-6736(05)61736-9; NEUGUT AI, 1995, AM J PUBLIC HEALTH, V85, P832, DOI 10.2105/AJPH.85.6.832; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OSUCH JR, 1994, CANCER, V74, P271, DOI 10.1002/cncr.2820741311; ROBERTS MM, 1990, LANCET, V335, P241; Shapiro S, 1997, J Natl Cancer Inst Monogr, P27; SICKLES EA, 1995, ANN INTERN MED, V122, P534, DOI 10.7326/0003-4819-122-7-199504010-00010; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; Tabar L, 1997, J Natl Cancer Inst Monogr, P43; TARONE RE, 1995, CANCER, V75, P997, DOI 10.1002/1097-0142(19950215)75:4<997::AID-CNCR2820750415>3.0.CO;2-M; Taubes G, 1997, SCIENCE, V275, P1056, DOI 10.1126/science.275.5303.1056; WRIGHT CJ, 1995, LANCET, V346, P29, DOI 10.1016/S0140-6736(95)92655-0	27	20	22	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1470	1472		10.1001/jama.281.16.1470	http://dx.doi.org/10.1001/jama.281.16.1470			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227298				2022-12-01	WOS:000079857400001
J	Bender, R; Jockel, KH; Trautner, C; Spraul, M; Berger, M				Bender, R; Jockel, KH; Trautner, C; Spraul, M; Berger, M			Effect of age on excess mortality in obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; 26-YEAR RISK; WEIGHT; WOMEN; POPULATION; MEN	Context The effect of age on excess mortality from all causes associated with obesity is controversial. Few studies have investigated the association between body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters), age, and mortality, with sufficient numbers of subjects at all levels of obesity. Objective To assess the effect of age on the excess mortality associated with all degrees of obesity. Design Prospective cohort study. Setting and Participants A total of 6193 obese patients with mean (SD) BMI of 36.6 (6.1) kg/m(2) and mean (SD) age of 40.4 (12.9) years who had been referred to the obesity clinic of Heinrich-Heine University, Dusseldorf, Germany, between 1961 and 1994. Median follow-up time was 14.8 years. Main Outcome Measure All-cause mortality through 1994 among 6053 patients for whom follow-up data were available (1028 deaths) analyzed as standardized mortality ratios (SMRs) using the male-female population of the geographic region (North Rhine Westphalia) as reference. Results The cohort was grouped into approximate quartiles according to age (18-29, 30-39, 40-49, and 50-74 years) and BMI (25 to <32, 32 to <36, 36 to <40, and greater than or equal to 40 kg/m(2)) at baseline. The SMRs showed a significant excess mortality with an SMR for men of 1.67 (95% confidence interval, 1.51-1.85; P<.001) and an SMR for women of 1.45 (95% confidence interval, 1.34-1.57; P<.001), The excess mortality associated with obesity declined with age. For men, the SMRs of the 4 age groups were 2.46, 2.30, 1.99, and 1.31, respectively; for women, they were 1.81, 2.10, 1.70, and 1.26, respectively (Poisson trend test, P<.001). The SMRs increased with BMI but, within each BMI group, the SMRs decreased with age. The lowest SMRs (for men, 1.01; for women, 0.91) were obtained for patients older than 50 years with BMIs of 25 to less than 32 kg/m(2). Thus, older men and women at a BMI range of 25 to less than 32 kg/m(2) had no excess mortality. The highest SMRs (for men, 4.22; for women, 3.79) were calculated for the patients aged 18 to 29 years with a BMI of 40 kg/m(2) or higher. Conclusions In this large cohort of obese persons, risk of death increased with body weight, but obesity-related excess mortality declined with age at all levels of obesity.	Univ Dusseldorf, Dept Metab Dis & Nutr, WHO, Collaborating Ctr Diabet, D-40001 Dusseldorf, Germany; Biometry & Epidemiol Univ Clin, Inst Med Informat, Essen, Germany; Humboldt Univ, Inst Occupat & Social Med & Epidemiol, Berlin, Germany	Heinrich Heine University Dusseldorf; World Health Organization; University of Duisburg Essen; Humboldt University of Berlin	Bender, R (corresponding author), Univ Dusseldorf, Dept Metab Dis & Nutr, WHO, Collaborating Ctr Diabet, POB 101007, D-40001 Dusseldorf, Germany.	bender@uni-duesseldorf.de						Allison DB, 1997, INT J OBESITY, V21, P424, DOI 10.1038/sj.ijo.0800423; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; Bender R, 1998, AM J EPIDEMIOL, V147, P42; BERCHTOLD P, 1981, INT J OBESITY, V5, P1; BERGER M, 1976, INTERNIST, V17, P494; BERGER M, 1981, RECENT ADV OBESITY R, P1; Breslow NE, 1987, STAT METHODS CANC RE, VII; DRENICK EJ, 1980, JAMA-J AM MED ASSOC, V243, P443, DOI 10.1001/jama.243.5.443; Durazo-Arvizu RA, 1998, AM J EPIDEMIOL, V147, P739, DOI 10.1093/oxfordjournals.aje.a009518; Forschungsverbund DHP, 1998, DTSCH HERZ KREISL PR; Jones ME, 1998, AM J EPIDEMIOL, V148, P1012; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; KUSHNER RF, 1993, NUTR REV, V51, P127, DOI 10.1111/j.1753-4887.1993.tb03089.x; LARSSON B, 1981, INT J OBESITY, V5, P97; Lindsted KD, 1997, AM J EPIDEMIOL, V146, P1, DOI 10.1093/oxfordjournals.aje.a009185; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MATTILA K, 1986, BRIT MED J, V292, P867, DOI 10.1136/bmj.292.6524.867-a; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; RISSANEN A, 1991, J CLIN EPIDEMIOL, V44, P787, DOI 10.1016/0895-4356(91)90131-R; SAS, 1987, SAS STAT GUID PERS C; *SAS I INC, 1985, SAS PROC GUID PERS C; *SAS I INC, 1985, SAS IML US GUID VERS; Singh PN, 1998, EPIDEMIOLOGY, V9, P246, DOI 10.1097/00001648-199805000-00007; SJOSTROM L V, 1992, American Journal of Clinical Nutrition, V55, p516S, DOI 10.1093/ajcn/55.2.516s; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; STOLZENBERG H, 1995, NATL HLTH SURVEY GER; Troiano RP, 1996, INT J OBESITY, V20, P63	28	192	196	2	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1498	1504		10.1001/jama.281.16.1498	http://dx.doi.org/10.1001/jama.281.16.1498			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227319	Bronze			2022-12-01	WOS:000079857400031
J	Preiser, PR; Jarra, W; Capiod, T; Snounou, G				Preiser, PR; Jarra, W; Capiod, T; Snounou, G			A rhoptry-protein-associated mechanism of clonal phenotypic variation in rodent malaria	NATURE			English	Article							PLASMODIUM-YOELII; MULTIGENE FAMILY; GENE; ERYTHROCYTES; FALCIPARUM; EXPRESSION; MEROZOITES; PARASITE; INVASION; VIVAX	The recognition and invasion of host cells are mediated by components of the apical complex of the ookinete, sporozoite and merozoite stages of Plasmodium parasites'. The paired rhoptries (organelles involved in host-cell recognition) in the epical complex contain many proteins of as-yet unknown function. In the rodent malaria agent P, yoelii yoelii, a multigene family codes for merozoite rhoptry proteins of relative molecular mass 235,000 (p235 proteins)(2,3); these proteins are thought to determine the subset of erythrocytes that the parasites invade(4,5). Further support for this idea came from the identification of a region in p235 with weak but significant homology to reticulocyte-binding protein-2 of P. vivax(6-8) and the demonstration that at least one p235 member binds to the erythrocyte surface membrane(9). Here, using single, micromanipulated P.y.yoelii parasites, we describe a new mechanism of gene expression by which the merozoites originating from a single schizont each express a distinct member of this multigene family. We propose that this nerv type of clonal phenotypic variation provides the parasite with a survival strategy in the mammalian host; this strategy contributes to the observed chronicity of malarial infections. This phenomenon is genetically and functionally distinct from classical antigenic variation, which is mediated by the var multigene family of P. falciparum(10-13).	Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Natl Inst Med Res, Dept Neurophysiol & Neuropharmacol, London NW7 1AA, England; Northwick Pk Hosp, Imperial Coll Sch Med, Dept Infect & Trop Med, Lister Unit, Harrow HA1 3UJ, Middx, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research; Imperial College London	Preiser, PR (corresponding author), Natl Inst Med Res, Div Parasitol, Mill Hill, London NW7 1AA, England.		Preiser, Peter R/A-2201-2011; Snounou, Georges/F-3352-2011; CAPIOD, Thierry/K-4234-2017	Snounou, Georges/0000-0002-6133-6398; CAPIOD, Thierry/0000-0002-8448-7041; , Peter/0000-0003-4331-7000				BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; BORRE MB, 1995, MOL BIOCHEM PARASIT, V70, P149, DOI 10.1016/0166-6851(95)00025-V; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; FREEMAN RR, 1980, NATURE, V284, P366, DOI 10.1038/284366a0; GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P; Galinski MR, 1996, PARASITOL TODAY, V12, P20, DOI 10.1016/0169-4758(96)80641-7; Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0; JARRA W, 1989, PARASITE IMMUNOL, V11, P1, DOI 10.1111/j.1365-3024.1989.tb00644.x; KEEN J, 1990, MOL BIOCHEM PARASIT, V42, P241, DOI 10.1016/0166-6851(90)90167-K; KEEN JK, 1994, MOL BIOCHEM PARASIT, V65, P171, DOI 10.1016/0166-6851(94)90125-2; Ogun SA, 1996, MOL BIOCHEM PARASIT, V76, P321, DOI 10.1016/0166-6851(95)02540-5; Preiser PR, 1998, EXP PARASITOL, V89, P50, DOI 10.1006/expr.1998.4259; SamYellowe TY, 1996, PARASITOL TODAY, V12, P308, DOI 10.1016/0169-4758(96)10030-2; Sinha KA, 1996, MOL BIOCHEM PARASIT, V76, P329, DOI 10.1016/0166-6851(95)02546-4; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1	17	111	112	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 15	1999	398	6728					618	622		10.1038/19309	http://dx.doi.org/10.1038/19309			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217144				2022-12-01	WOS:000079754700057
J	Smith, O				Smith, O			Medicine - Fear of flying	SCIENCE			English	Editorial Material																		Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 2	1999	284	5411					61	61		10.1126/science.284.5411.61	http://dx.doi.org/10.1126/science.284.5411.61			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182QE	10215531				2022-12-01	WOS:000079509000027
J	Hughes, PM; Turton, P; Evans, CDH				Hughes, PM; Turton, P; Evans, CDH			Stillbirth as risk factor for depression and anxiety in the subsequent pregnancy: cohort study	BRITISH MEDICAL JOURNAL			English	Article							POSTNATAL DEPRESSION; PERINATAL DEATH	Objective To assess women's symptoms of depression and anxiety during pregnancy and the postpartum year in the pregnancy after stillbirth; to assess relevance of time since loss. Design Cohort study with four assessments: in third trimester and 6 weeks, 6 months, and 12 months after birth. Setting Outpatient departments of three district general hospitals; subjects' homes. Subjects 60 women whose previous pregnancy ended in stillbirth after 18 weeks' gestation; 60 matched controls. Main outcome measures Depression and anxiety measured by Edinburgh postnatal depression scale, Beck depression inventory, and Spielberger state-trait anxiety scale. Results In the third trimester women whose previous pregnancy had ended in stillbirth were significantly more depressed than control women (10.8 v 8.2; P = 0.004) and had greater state anxiety (39.8 v 32.8, P = 0.003) The difference was accounted for by those women who conceived less than 12 months after the stillbirth, who were also more depressed at 1 year. Results in those who conceived 12 months or more after stillbirth were similar to those in their controls at all points and showed lower trait anxiety 1 year post partum. One year after the birth 8% of control women and 19% of subjects scored high for depression (P = 0.39), with most of the depression among the more recently bereaved (28% v 11%; P = 0.18). In the women who had experienced stillbirth, depression in the third trimester was highly predictive of depression 1 year after subsequent birth (P less than or equal to 0.0005). Conclusion Vulnerability to depression and anxiety in the next pregnancy and puerperium is related to time since stillbirth, with more recently bereaved women at significantly greater risk than controls. As there are problems for mother and infant associated with high anxiety and depression during and after pregnancy, there may be advantage in waiting 12 months before the next conception.	St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England; Tavistock & Portman NHS Trust, Tavistock Clin, London NW3 5BA, England	St Georges University London	Hughes, PM (corresponding author), St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England.		Evans, Chris/E-7526-2011	Evans, Chris/0000-0002-4197-4202				BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOURNE S, 1984, BRIT MED J, V289, P147, DOI 10.1136/bmj.289.6438.147; Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; DAVIS DL, 1989, J AM ACAD CHILD PSY, V28, P481, DOI 10.1097/00004583-198907000-00002; FORREST CG, 1982, BRIT MED J, V285, P1475; Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0; Hunfeld JAM, 1997, PRENATAL DIAG, V17, P843, DOI 10.1002/(SICI)1097-0223(199709)17:9<843::AID-PD147>3.0.CO;2-Q; LEWIS E, 1979, BRIT MED J, V2, P27, DOI 10.1136/bmj.2.6181.27; LOU HC, 1994, DEV MED CHILD NEUROL, V36, P826; Murray D, 1990, J REPROD INFANT PSYC, V8, P99, DOI DOI 10.1080/02646839008403615; MURRAY L, 1992, J CHILD PSYCHOL PSYC, V33, P543, DOI 10.1111/j.1469-7610.1992.tb00890.x; *OFF NAT STAT, 1998, SER FMI, V15, P1; PHIPPS S, 1985, INT J PSYCHIAT MED, V15, P243, DOI 10.2190/GDC5-KA60-JPNH-PND2; ROWE J, 1978, PEDIATRICS, V62, P166; SPIELBERGER CD, 1970, TEST STATE TRAIT ANX; SROUFE LA, 1983, MINN SYM CHILD PSYCH, V16, P41; TEIXEIRA JMA, IN PRESS BMJ; THEUT SK, 1988, J AM ACAD CHILD PSY, V27, P289, DOI 10.1097/00004583-198805000-00004; WADWA PD, 1993, AM J OBSTET GYNECOL, V169, P858; ZUCKERMAN B, 1989, AM J OBSTET GYNECOL, V160, P1107, DOI 10.1016/0002-9378(89)90170-1	21	159	161	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1721	1724		10.1136/bmj.318.7200.1721	http://dx.doi.org/10.1136/bmj.318.7200.1721			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381705	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000081216900022
J	de Rosa, R; Grenier, JK; Andreeva, T; Cook, CE; Adoutte, A; Akam, M; Carroll, SB; Balavoine, G				de Rosa, R; Grenier, JK; Andreeva, T; Cook, CE; Adoutte, A; Akam, M; Carroll, SB; Balavoine, G			Hox genes in brachiopods and priapulids and protostome evolution	NATURE			English	Article							HOMEOBOX GENES; CLUSTER; IDENTIFICATION; ARTHROPODS; ANNELIDA; ANIMALS; ELEGANS; ORIGIN; CLADE	Understanding the early evolution of animal body plans requires knowledge both of metazoan phylogeny and of the genetic and developmental changes involved in the emergence of particular forms. Recent 18S ribosomal RNA phylogenies suggest a three-branched tree for the Bilateria comprising the deuterostomes and two great protostome clades, the lophotrochozoans(1) and ecdysozoans(2). Here, we show that the complement of Nor genes in critical protostome phyla reflects these phylogenetic relationships and reveals the early evolution of developmental regulatory potential in bilaterians. We have identified Hox genes that are shared by subsets of protostome phyla. These include a diverged pair of posterior (Abdominal-B-like) genes in both a brachiopod and a polychaete annelid, which supports the lophotrochozoan assemblage, and a distinct posterior Hox gene shared by a priapulid, a nematode and the arthropods, which supports the ecdysozoan dade. The ancestors of each of these two major protostome lineages had a minimum of eight to ten Hox genes. The major period of Hox gene expansion and diversification thus occurred before the radiation of each of the three great bilaterian clades.	Univ Paris Sud, CNRS, UPRESA Q8080, Lab Biol Cellulaire 4, F-91405 Orsay, France; Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; St Petersburg State Univ, Inst Biol, Dept Embryol, St Petersburg 199034, Russia; Univ Cambridge, Museum Zool, Dept Zool, Lab Dev & Evolut, Cambridge CB2 3EJ, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Saint Petersburg State University; University of Cambridge	Balavoine, G (corresponding author), CNRS, Ctr Genet Mol, UPR 9061, Ave Terrasse,Batiment 26, F-91198 Gif Sur Yvette, France.	Guillaume.Balavoine@cgm.cnrs-gif.fr		de Rosa, Renaud/0000-0002-3239-6324; Cook, Charles E/0000-0002-4145-8048	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adoutte A, 1999, TRENDS GENET, V15, P104, DOI 10.1016/S0168-9525(98)01671-0; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; Balavoine G, 1996, NUCLEIC ACIDS RES, V24, P1547, DOI 10.1093/nar/24.8.1547; Balavoine G, 1998, AM ZOOL, V38, P843; BOARDMANN RS, 1987, FOSSIL INVERTEBRATES; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Degnan Bernard M., 1993, Molecular Marine Biology and Biotechnology, V2, P1; DICK MH, 1994, MOL PHYLOGENET EVOL, V3, P146, DOI 10.1006/mpev.1994.1017; DUBOULE D, 1990, GENOMICS, V7, P458, DOI 10.1016/0888-7543(90)90185-W; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; Grenier JK, 1997, CURR BIOL, V7, P547, DOI 10.1016/S0960-9822(06)00253-3; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Kmita-Cunisse M, 1998, P NATL ACAD SCI USA, V95, P3030, DOI 10.1073/pnas.95.6.3030; Mackey LY, 1996, J MOL EVOL, V42, P552, DOI 10.1007/BF02352285; Martinez P, 1999, P NATL ACAD SCI USA, V96, P1469, DOI 10.1073/pnas.96.4.1469; Nielsen C., 1995, ANIMAL EVOLUTION; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SHANKLAND M, 1991, DEVELOPMENT, P29; SNOW P, 1994, MOL PHYLOGENET EVOL, V3, P360, DOI 10.1006/mpev.1994.1042; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Swofford DL, 2002, PAUP PHYLOGENETIC AN; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WONG VY, 1995, J NEUROSCI, V15, P5551; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0; [No title captured]	30	389	393	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					772	776						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391241				2022-12-01	WOS:000081101600051
J	Boulanger, L; Poo, MM				Boulanger, L; Poo, MM			Gating of BDNF-induced synaptic potentiation by cAMP	SCIENCE			English	Article							NERVE GROWTH-FACTOR; LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; NEUROTROPHIC FACTOR; CYCLIC-AMP; SIGNALING PATHWAY; CORTICAL-NEURONS; VISUAL-CORTEX; CA1 REGION; BRAIN	Neurotrophins have been implicated in activity-dependent synaptic plasticity, but the underlying intracellular mechanisms remain Largely unknown. Synaptic potentiation induced by brain-derived neurotrophic factor (BDNF), but not neurotrophin 3, was prevented by blockers of adenosine 3',5'-monophosphate (cAMP) signaling. Activators of cAMP signaling alone were ineffective in modifying synaptic efficacy but greatly enhanced the potentiation effect of BDNF. Blocking cAMP signaling abolished the facilitation of BDNF-induced potentiation by presynaptic activity. Thus synaptic actions of BDNF are gated by cAMP. Activity and other coincident signals that modulate cAMP concentrations may specify the action of secreted neurotrophins on developing nerve terminals.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.			Boulanger, Lisa/0000-0002-6578-7890	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037831] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 37831] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agnihotri N, 1997, J NEUROSCI RES, V47, P555, DOI 10.1002/(SICI)1097-4547(19970301)47:5<555::AID-JNR11>3.0.CO;2-X; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; Boulanger L, 1999, NAT NEUROSCI, V2, P346, DOI 10.1038/7258; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; CASTELLUCCI VF, 1982, J NEUROSCI, V2, P1673; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; CONDORELLI DF, 1994, J NEUROCHEM, V63, P509; CONNOLLY JL, 1985, J NEUROSCI RES, V13, P183, DOI 10.1002/jnr.490130113; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FERRENDELLI JA, 1980, BRAIN RES, V200, P93, DOI 10.1016/0006-8993(80)91097-5; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Gottschalk W, 1998, J NEUROSCI, V18, P6830; Hempel CM, 1996, NATURE, V384, P166, DOI 10.1038/384166a0; Heumann Rolf, 1994, Current Opinion in Neurobiology, V4, P668, DOI 10.1016/0959-4388(94)90008-6; Heymach JV, 1996, J BIOL CHEM, V271, P25430, DOI 10.1074/jbc.271.41.25430; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; Iyengar R, 1996, SCIENCE, V271, P461, DOI 10.1126/science.271.5248.461; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KIM HG, 1994, P NATL ACAD SCI USA, V91, P12341, DOI 10.1073/pnas.91.25.12341; KNIPPER M, 1993, FEBS LETT, V324, P147, DOI 10.1016/0014-5793(93)81382-A; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Korte M, 1996, J PHYSIOLOGY-PARIS, V90, P157, DOI 10.1016/S0928-4257(97)81415-5; Korte M, 1996, P NATL ACAD SCI USA, V93, P12547, DOI 10.1073/pnas.93.22.12547; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; LESSMANN V, 1994, NEUROREPORT, V6, P21; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; LU B, 1993, NATURE, V363, P76, DOI 10.1038/363076a0; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Ming GL, 1997, J NEUROSCI, V17, P7860; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; REDDY R, 1995, J BIOL CHEM, V270, P14340, DOI 10.1074/jbc.270.24.14340; Sala R, 1998, EUR J NEUROSCI, V10, P2185, DOI 10.1046/j.1460-9568.1998.00227.x; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Stoop R, 1996, J NEUROSCI, V16, P3256; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Wang Q, 1998, J NEUROSCI, V18, P4973; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	60	103	105	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1982	1984		10.1126/science.284.5422.1982	http://dx.doi.org/10.1126/science.284.5422.1982			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373115				2022-12-01	WOS:000080932700045
J	Eisenhofer, G; Lenders, JWM; Linehan, WM; Walther, MM; Goldstein, DS; Keiser, HR				Eisenhofer, G; Lenders, JWM; Linehan, WM; Walther, MM; Goldstein, DS; Keiser, HR			Plasma normetanephrine and metanephrine for detecting pheochromocytoma in Von Hippel-Lindau disease and multiple endocrine neoplasia type 2	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIQUID-CHROMATOGRAPHY; DIAGNOSIS; URINARY; CATECHOLAMINES; METABOLISM	Background. The detection of pheochromocytomas in patients at risk for these tumors, such as patients with von Hippel-Lindau disease or multiple endocrine neoplasia type 2 (MEN-2), is hindered by the inadequate sensitivity of commonly available biochemical tests. In this study we evaluated measurements of plasma normetanephrine and metanephrine for detecting pheochromocytomas in patients with von Hippel-Lindau disease or MEN-2. Methods. We studied 26 patients with von Hippel-Lindau disease and 9 patients with MEN-2 who had histologically verified pheochromocytomas and 50 patients with von Hippel-Lindau disease or MEN-2 who had no radiologic evidence of pheochromocytoma. Von Hippel-Lindau disease and MEN-2 were diagnosed on the basis of germ-line mutations of the appropriate genes. The plasma concentrations of normetanephrine and metanephrine were compared with the plasma concentrations of catecholamines (norepinephrine and epinephrine) and urinary excretion of catecholamines, metanephrines, and vanillylmandelic acid. Results. The sensitivity of measurements of plasma normetanephrine and metanephrine for the detection of tumors was 97 percent, whereas the other biochemical tests had a sensitivity of only 47 to 74 percent. All patients with MEN-2 had high plasma concentrations of metanephrine, whereas the patients with von Hippel-Lindau disease had almost exclusively high plasma concentrations of only normetanephrine. One patient with von Hippel-Lindau disease had a normal plasma normetanephrine concentration; this patient had a very small adrenal tumor (< 1 cm). The high sensitivity of measurements of plasma normetanephrine and metanephrine was accompanied by a high level of specificity (96 percent). Conclusions. Measurements of plasma normetanephrine and metanephrine are useful in screening for pheochromocytomas in patients with a familiar predisposition to these tumors. (N Engl J Med 1999; 340:1872-9.) (C) 1999, Massachusetts Medical Society.	NINDS, Clin Neurosci Branch, NIH, Bethesda, MD 20892 USA; NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA; NHLBI, Hypertens Endocrine Branch, NIH, Bethesda, MD 20892 USA; Univ Nijmegen St Radboud Hosp, Dept Gen Internal Med, NL-6500 HB Nijmegen, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Radboud University Nijmegen	Eisenhofer, G (corresponding author), NINDS, Clin Neurosci Branch, NIH, Bldg 10,Rm 6N252,10 Ctr Dr,MSC-1620, Bethesda, MD 20892 USA.		Eisenhofer, Graeme/AAU-9829-2021; Lenders, J.W.M./L-4487-2015	Eisenhofer, Graeme/0000-0002-8601-9903; Lenders, J.W.M./0000-0002-7658-4466	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002979] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APRILL BS, 1994, ANN INTERN MED, V120, P485, DOI 10.7326/0003-4819-120-6-199403150-00006; BRAVO EL, 1994, ENDOCR REV, V15, P356, DOI 10.1210/er.15.3.356; CALMETTES C, 1992, EUR J CLIN INVEST, V22, P755, DOI 10.1111/j.1365-2362.1992.tb01441.x; EISENHOFER G, 1995, CLIN SCI, V88, P533, DOI 10.1042/cs0880533; EISENHOFER G, 1995, J CLIN ENDOCR METAB, V80, P3009, DOI 10.1210/jc.80.10.3009; Eisenhofer G, 1998, J CLIN ENDOCR METAB, V83, P2175, DOI 10.1210/jc.83.6.2175; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; EISENHOFER G, 1994, J AUTONOM NERV SYST, V50, P93, DOI 10.1016/0165-1838(94)90127-9; Eisenhofer G, 1996, J NEUROCHEM, V66, P1565; EISENHOFER G, IN PRESS CLIN EXP PH; GAGEL RF, 1988, NEW ENGL J MED, V318, P478, DOI 10.1056/NEJM198802253180804; GERLO EAM, 1994, CLIN CHEM, V40, P250; HAMILTON BP, 1978, AM J MED, V65, P1027, DOI 10.1016/0002-9343(78)90757-X; Heron E, 1996, ANN INTERN MED, V125, P300, DOI 10.7326/0003-4819-125-4-199608150-00008; HSIAO RJ, 1990, AM J MED, V88, P607, DOI 10.1016/0002-9343(90)90526-J; KARSDORP N, 1994, AM J MED, V97, P158, DOI 10.1016/0002-9343(94)90026-4; LENDERS JWM, 1995, ANN INTERN MED, V123, P101, DOI 10.7326/0003-4819-123-2-199507150-00004; LENDERS JWM, 1993, CLIN CHEM, V39, P97; MANGER WM, 1993, CLEV CLIN J MED, V60, P365; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; MOYER TP, 1979, CLIN CHEM, V25, P256; NEUMANN HPH, 1993, NEW ENGL J MED, V329, P1531, DOI 10.1056/NEJM199311183292103; NEUMANN HPH, 1994, NEW ENGL J MED, V331, P1535; PEASTON RT, 1993, J CLIN PATHOL, V46, P734, DOI 10.1136/jcp.46.8.734; SATO T, 1975, TOHOKU J EXP MED, V115, P15, DOI 10.1620/tjem.115.15; Shawar L, 1996, J La State Med Soc, V148, P535; SINCLAIR D, 1991, ANN CLIN BIOCHEM, V28, P417, DOI 10.1177/000456329102800420; STEWART MF, 1993, J CLIN PATHOL, V46, P280, DOI 10.1136/jcp.46.3.280; VISTELLE R, 1991, CLIN ENDOCRINOL, V34, P133, DOI 10.1111/j.1365-2265.1991.tb00283.x	29	224	232	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1872	1879		10.1056/NEJM199906173402404	http://dx.doi.org/10.1056/NEJM199906173402404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369850	Bronze			2022-12-01	WOS:000080863500004
J	Joo, H; Lin, ZL; Arnold, FH				Joo, H; Lin, ZL; Arnold, FH			Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation	NATURE			English	Article							DIRECTED EVOLUTION; HYDROGEN-PEROXIDE; GENE; CRYSTALLOGRAPHY; SUPERFAMILY; OXIDATION; ESTERASE; OXYGEN; H2O2	Enzyme-based chemical transformations typically proceed with high selectivity under mild conditions, and are;becoming increasingly important in the pharmaceutical and chemical industries. Cytochrome P450 monooxygenases (P450s) constitute a large family(1) of enzymes of particular interest in this regard. Their biological functions, such as detoxification of xenobiotics and steroidogenesis(2-5), are based on the ability to catalyse the insertion of oxygen into:a wide variety of compounds(6). Such a catalytic transformation might find technological applications in areas ranging from gene therapy and environmental remediation to the selective synthesis of pharmaceuticals and chemicals(7-10). But relatively low turnover rates (particularly towards non-natural substrates), low stability and the need for electron-donating cofactors prohibit the practical use of P450s as isolated enzymes. Here we report the directed evolution(11) of the P450 from Pseudomonas putida to create mutants that hydroxylate naphthalene in the absence of cofactors through the 'peroxide shunt' pathway(12,13) with more than 20-fold higher activity than the native enzyme. We are able to screen efficiently for improved mutants by coexpressing them with horseradish peroxidase, which converts the products of the P450 reaction into fluorescent compounds amenable to digital imaging screening. This system should allow us to select and develop mono- and di-oxygenases into practically useful biocatalysts for the hydroxylation of a wide range of aromatic compounds.	CALTECH, Div Chem & Chem Engn 210 41, Pasadena, CA 91125 USA	California Institute of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn 210 41, Pasadena, CA 91125 USA.		Lin, Zhanglin/A-7232-2011	Arnold, Frances H./0000-0002-4027-364X				Arnold FH, 1998, ACCOUNTS CHEM RES, V31, P125, DOI 10.1021/ar960017f; Cerniglia Carl E., 1992, Biodegradation, V3, P351, DOI 10.1007/BF00129093; Cook DL, 1997, BIOCHEMISTRY-US, V36, P10801, DOI 10.1021/bi971284b; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Duport C, 1998, NAT BIOTECHNOL, V16, P186, DOI 10.1038/nbt0298-186; England PA, 1998, FEBS LETT, V424, P271, DOI 10.1016/S0014-5793(98)00189-6; FABER K, 1997, BIOTRANSFORMATIONS O, P208; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; HRYCAY EG, 1975, BIOCHEM BIOPH RES CO, V66, P209, DOI 10.1016/S0006-291X(75)80315-9; HUMMEL W, 1989, EUR J BIOCHEM, V184, P1, DOI 10.1111/j.1432-1033.1989.tb14983.x; Jounaidi Y, 1998, CANCER RES, V58, P4391; Lin ZL, 1999, BIOTECHNOL PROGR, V15, P467, DOI 10.1021/bp990037r; MCKAY CP, 1991, ORIGINS LIFE EVOL B, V21, P157, DOI 10.1007/BF01809444; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; Samuilov VD, 1997, BIOCHEMISTRY-MOSCOW+, V62, P451; Seelbach K, 1996, TETRAHEDRON LETT, V37, P1377, DOI 10.1016/0040-4039(96)00010-X; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; UNGER BP, 1986, J BIOL CHEM, V261, P1158; vanDeurzen MPJ, 1997, TETRAHEDRON, V53, P13183, DOI 10.1016/S0040-4020(97)00477-8; WACKETT LP, 1994, NATURE, V368, P627, DOI 10.1038/368627a0; Waxman David J., 1995, P391; Zhao H., 1999, MANUAL IND MICROBIOL, P597; Zhao HM, 1999, PROTEIN ENG, V12, P47, DOI 10.1093/protein/12.1.47; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	32	336	400	2	119	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					670	673		10.1038/21395	http://dx.doi.org/10.1038/21395			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385118				2022-12-01	WOS:000080932800054
J	Gaidos, EJ; Nealson, KH; Kirschvink, JL				Gaidos, EJ; Nealson, KH; Kirschvink, JL			Biogeochemistry - Life in ice-covered oceans	SCIENCE			English	Editorial Material							EARLY EARTH; HYDROTHERMAL SYSTEMS; SNC METEORITES; LIQUID WATER; EUROPA; MARS; SURFACE; SATELLITES; REDUCTION; JUPITER		CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Wisconsin, Ctr Great Lakes Studies, Milwaukee, WI 53204 USA	California Institute of Technology; University of Wisconsin System; University of Wisconsin Milwaukee	Gaidos, EJ (corresponding author), CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA.	gaidos@gps.caltech.edu		Gaidos, Eric/0000-0002-5258-6846				Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; BALLHAUS C, 1990, NATURE, V348, P437, DOI 10.1038/348437a0; Carlson RW, 1999, SCIENCE, V283, P2062, DOI 10.1126/science.283.5410.2062; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; CHANG S, 1993, NATO ADV SCI INST SE, V416, P259; CRAWFORD GD, 1988, ICARUS, V73, P66, DOI 10.1016/0019-1035(88)90085-1; Delitsky ML, 1997, J GEOPHYS RES-PLANET, V102, P16385, DOI 10.1029/97JE01250; DICHRISTINA TJ, 1988, WATER SCI TECHNOL, V20, P69, DOI 10.2166/wst.1988.0268; DSON FJ, 1997, ATL MON, V280, P71; Elderfield H, 1996, ANNU REV EARTH PL SC, V24, P191, DOI 10.1146/annurev.earth.24.1.191; Greeley R, 1998, ICARUS, V135, P4, DOI 10.1006/icar.1998.5969; GREELEY R, 1991, SCIENCE, V254, P996, DOI 10.1126/science.254.5034.996; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HOBBS PV, 1974, ICE PHYSICS; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; Jakosky BM, 1998, J GEOPHYS RES-PLANET, V103, P19359, DOI 10.1029/98JE01892; Jean-Baptiste P, 1998, EARTH PLANET SC LETT, V158, P81, DOI 10.1016/S0012-821X(98)00045-4; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; Kirschvink J.L., 1992, PROTEROZOIC BIOSPHER, P51; KNAUER GA, 1993, BIOGEOCHEMICAL CYCLE, P211; LOVLEY DR, 1986, APPL ENVIRON MICROB, V51, P683, DOI 10.1128/AEM.51.4.683-689.1986; MAHER KA, 1988, NATURE, V331, P612, DOI 10.1038/331612a0; McCollom TM, 1997, GEOCHIM COSMOCHIM AC, V61, P4375, DOI 10.1016/S0016-7037(97)00241-X; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MOOD S, 1983, ASTRONOMY, V11, P16; Moore JM, 1998, ICARUS, V135, P127, DOI 10.1006/icar.1998.5973; MURRELL JC, 1992, FEMS MICROBIOL LETT, V88, P233, DOI 10.1016/0378-1097(92)90805-X; MYERS CR, 1990, J BACTERIOL, V172, P6232, DOI 10.1128/jb.172.11.6232-6238.1990; Navarro-Gonzalez R, 1998, GEOPHYS RES LETT, V25, P3123, DOI 10.1029/98GL02423; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Orton GS, 1996, SCIENCE, V274, P389, DOI 10.1126/science.274.5286.389; OVERMANN J, 1992, LIMNOL OCEANOGR, V37, P150, DOI 10.4319/lo.1992.37.1.0150; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; Powell CS, 1997, SCI AM, V276, P28, DOI 10.1038/scientificamerican0497-28; Priscu JC, 1998, SCIENCE, V280, P2095, DOI 10.1126/science.280.5372.2095; Rathbun JA, 1998, GEOPHYS RES LETT, V25, P4157, DOI 10.1029/1998GL900135; Reynolds R T, 1987, Adv Space Res, V7, P125, DOI 10.1016/0273-1177(87)90364-4; REYNOLDS RT, 1983, ICARUS, V56, P246, DOI 10.1016/0019-1035(83)90037-4; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; Shock EL, 1997, J GEOPHYS RES-PLANET, V102, P23687, DOI 10.1029/97JE01087; Shock EL, 1996, CIBA F SYMP, V202, P40; SLEEP NH, 1989, NATURE, V342, P139, DOI 10.1038/342139a0; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; Spaun NA, 1998, GEOPHYS RES LETT, V25, P4277, DOI 10.1029/1998GL900176; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; Stumm W., 1981, AQUAT CHEM; Sullivan R, 1998, NATURE, V391, P371, DOI 10.1038/34874; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; YUNG YL, 1996, AM ASTR SOC DIV PLAN; Zahnle K, 1998, ICARUS, V136, P202, DOI 10.1006/icar.1998.6015	55	132	138	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1631	1633		10.1126/science.284.5420.1631	http://dx.doi.org/10.1126/science.284.5420.1631			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10383341				2022-12-01	WOS:000080668300031
J	Smith, DE; Zuber, MT; Solomon, SC; Phillips, RJ; Head, JW; Garvin, JB; Banerdt, WB; Muhleman, DO; Pettengill, GH; Neumann, GA; Lemoine, FG; Abshire, JB; Aharonson, O; Brown, CD; Hauck, SA; Ivanov, AB; McGovern, PJ; Zwally, HJ; Duxbury, TC				Smith, DE; Zuber, MT; Solomon, SC; Phillips, RJ; Head, JW; Garvin, JB; Banerdt, WB; Muhleman, DO; Pettengill, GH; Neumann, GA; Lemoine, FG; Abshire, JB; Aharonson, O; Brown, CD; Hauck, SA; Ivanov, AB; McGovern, PJ; Zwally, HJ; Duxbury, TC			The global topography of Mars and implications for surface evolution	SCIENCE			English	Article							RADIO OCCULTATION MEASUREMENTS; MARTIAN MANTLE CONVECTION; IMPACT BASINS; HEMISPHERIC DICHOTOMY; PHASE-TRANSITIONS; CRUSTAL DICHOTOMY; GIANT IMPACT; POLAR-REGION; MARINER-9; THARSIS	Elevations measured by the Mars Orbiter Laser Altimeter have yielded a high-accuracy global map of the topography of Mars. Dominant features include the low northern hemisphere, the Tharsis province, and the Hellas impact basin. The northern hemisphere depression is primarily a long-wavelength effect that has been shaped by an internal mechanism. The topography of Tharsis consists of two broad rises. Material excavated from Hellas contributes to the high elevation of the southern hemisphere and to the scarp along the hemispheric boundary. The present topography has three major drainage centers, with the northern Lowlands being the largest. The two polar cap volumes yield an upper limit of the present surface water inventory of 3.2 to 4.7 million cubic kilometers.	NASA, Goddard Space Flight Ctr, Earth Sci Directorate, Greenbelt, MD 20771 USA; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Carnegie Institution for Science; Washington University (WUSTL); Brown University; California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Smith, DE (corresponding author), NASA, Goddard Space Flight Ctr, Earth Sci Directorate, Greenbelt, MD 20771 USA.		Neumann, Gregory A/I-5591-2013; Hauck, Steven A/A-7865-2008; Abshire, James/I-2800-2013; Banerdt, William/Q-7324-2019; Ivanov, Anton B/C-8944-2014; Lemoine, Frank/D-1215-2013	Neumann, Gregory A/0000-0003-0644-9944; Hauck, Steven A/0000-0001-8245-146X; Banerdt, William/0000-0003-3125-1542; Ivanov, Anton B/0000-0001-8376-8581; Aharonson, Oded/0000-0001-9930-2495; McGovern, Patrick/0000-0001-9647-3096; Garvin, James/0000-0003-1606-5645; Lemoine, Frank G./0000-0002-3051-1456				Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BANERDT WB, 1982, J GEOPHYS RES, V87, P9723, DOI 10.1029/JB087iB12p09723; BANERDT WB, 1992, MARS, P249; Breuer D, 1998, GEOPHYS RES LETT, V25, P229, DOI 10.1029/97GL03767; Carr M., 1981, SURFACE MARS; Carr M.H, 1996, WATER MARS; CARR MH, 1981, ICARUS, V48, P91, DOI 10.1016/0019-1035(81)90156-1; CLIFFORD SM, 1987, J GEOPHYS RES-SOLID, V92, P9135, DOI 10.1029/JB092iB09p09135; Connerney JEP, 1999, SCIENCE, V284, P794, DOI 10.1126/science.284.5415.794; CONRATH B, 1973, J GEOPHYS RES, V78, P4267, DOI 10.1029/JB078i020p04267; Dohm JM, 1999, PLANET SPACE SCI, V47, P411, DOI 10.1016/S0032-0633(98)00141-X; DOWNS GS, 1982, J GEOPHYS RES, V87, P9747, DOI 10.1029/JB087iB12p09747; DURHAM WB, 1999, LUNAR PLANET SCI, V30, P2017; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; FREY H, 1988, GEOPHYS RES LETT, V15, P229, DOI 10.1029/GL015i003p00229; Frey H, 1998, GEOPHYS RES LETT, V25, P4409, DOI 10.1029/1998GL900095; FREY HV, 1998, EOS T AM GEOPHYS UNI, V79; GARVIN JB, UNPUB; Harder H, 1998, J GEOPHYS RES-PLANET, V103, P16775, DOI 10.1029/98JE01543; Harder H, 1996, NATURE, V380, P507, DOI 10.1038/380507a0; Head JW, 1998, GEOPHYS RES LETT, V25, P4401, DOI 10.1029/1998GL900116; HORD CW, 1972, ICARUS, V17, P443, DOI 10.1016/0019-1035(72)90010-3; Johnson C., UNPUB; KARGEL JS, 1992, GEOLOGY, V20, P3, DOI 10.1130/0091-7613(1992)020<0003:AGOM>2.3.CO;2; KIEFFER HH, 1979, J GEOPHYS RES, V84, P8263, DOI 10.1029/JB084iB14p08263; KLIORE AJ, 1972, ICARUS, V17, P484, DOI 10.1016/0019-1035(72)90014-0; LEMOINE FG, 1999, AIAA SPAC FLIGHT MEC; LINDAL GF, 1979, J GEOPHYS RES, V84, P8443, DOI 10.1029/JB084iB14p08443; Lingenfelter R. E., 1973, Moon, V7, P172, DOI 10.1007/BF00578814; LUCHITTA BK, 1992, MARS, P453; Malin MC, 1999, NATURE, V397, P589, DOI 10.1038/17551; MCEWEN A, 1999, LUNAR PLANET SCI, V30, P1829; MCGILL GE, 1989, J GEOPHYS RES-SOLID, V94, P2753, DOI 10.1029/JB094iB03p02753; MCGILL GE, 1991, ICARUS, V93, P386, DOI 10.1016/0019-1035(91)90221-E; MCGILL GE, 1990, J GEOPHYS RES-SOLID, V95, P12595, DOI 10.1029/JB095iB08p12595; MOORE JM, 1993, GEOPHYS RES LETT, V20, P1599, DOI 10.1029/93GL01302; Mutch T.A., 1976, GEOLOGY MARS; NEUMANN GA, 1995, MAR GEOPHYS RES, V17, P221, DOI 10.1007/BF01203464; NYE JF, UNPUB; PAIGE DA, 1994, J GEOPHYS RES-PLANET, V99, P25993, DOI 10.1029/93JE03429; PARKER TJ, 1989, ICARUS, V82, P111, DOI 10.1016/0019-1035(89)90027-4; PARKER TJ, 1993, J GEOPHYS RES-PLANET, V98, P11061, DOI 10.1029/93JE00618; PHILLIPS RJ, 1990, J GEOPHYS RES-SOLID, V95, P5089, DOI 10.1029/JB095iB04p05089; ROTH LE, 1980, ICARUS, V42, P287, DOI 10.1016/0019-1035(80)90096-2; SCHENK PM, UNPUB; SCHULTZ RA, 1990, J GEOPHYS RES-SOLID, V95, P14175, DOI 10.1029/JB095iB09p14175; SCHULTZ RA, 1994, J GEOPHYS RES-PLANET, V99, P8371, DOI 10.1029/94JE00277; SHARP RP, 1971, J GEOPHYS RES, V76, P331, DOI 10.1029/JB076i002p00331; SHARP RP, 1973, J GEOPHYS RES, V78, P4073, DOI 10.1029/JB078i020p04073; SLEEP NH, 1994, J GEOPHYS RES-PLANET, V99, P5639, DOI 10.1029/94JE00216; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; Smith DE, 1996, SCIENCE, V271, P184, DOI 10.1126/science.271.5246.184; SMITH DE, IN PRESS EOS T AM GE; SODERBLOM LA, 1978, ICARUS, V34, P622, DOI 10.1016/0019-1035(78)90050-7; SOLOMON SC, 1982, J GEOPHYS RES, V87, P9755, DOI 10.1029/JB087iB12p09755; TANAKA KL, 1995, J GEOPHYS RES-PLANET, V100, P5407, DOI 10.1029/94JE02804; TURCOTTE DL, 1981, J GEOPHYS RES, V86, P3951, DOI 10.1029/JB086iB05p03951; WICHMAN RW, 1989, J GEOPHYS RES-SOLID, V94, P17333, DOI 10.1029/JB094iB12p17333; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0; WISE DU, 1979, J GEOPHYS RES, V84, P7934, DOI 10.1029/JB084iB14p07934; WISE DU, 1979, ICARUS, V38, P456, DOI 10.1016/0019-1035(79)90200-8; WU SSC, 1984, NATURE, V309, P432, DOI 10.1038/309432a0; ZHONG S, UNPUB; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839; ZUBER MT, 1992, J GEOPHYS RES-PLANET, V97, P7781, DOI 10.1029/92JE00341; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053; Zuber MT, 1998, GEOPHYS RES LETT, V25, P4393, DOI 10.1029/1998GL900129; ZUBER MT, 1998, 1 INT C MARS POL SCI	71	657	666	5	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1495	1503		10.1126/science.284.5419.1495	http://dx.doi.org/10.1126/science.284.5419.1495			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348732				2022-12-01	WOS:000080548100029
J	Blasius, B; Huppert, A; Stone, L				Blasius, B; Huppert, A; Stone, L			Complex dynamics and phase synchronization in spatially extended ecological systems	NATURE			English	Article							SNOWSHOE HARE CYCLE; POPULATION-DYNAMICS; SOLAR-ACTIVITY; CHAOS; MODELS; LYNX; OSCILLATORS; CANADA	Population cycles that persist in time and are synchronized over; space pervade ecological systems, but their underlying causes remain a long-standing enigma(1-11). Here we examine the synchronization of complex population oscillations in networks of model communities and in natural systems, where phenomena such as unusual '4- and 10-year cycle' of wildlife are often found. In the proposed spatial model, each local patch sustains a three-level trophic system composed of interacting predators, consumers and vegetation, Populations oscillate regularly and periodically in phase, but with irregular and chaotic peaks together in abundance-twin realistic features that are not found in standard ecological models. In a spatial lattice of patches, only small amounts of local migration are required to induce broad-scale 'phase synchronization,(12,13), with all populations in the lattice phase-locking to the same collective rhythm. Peak population abundances, however, remain chaotic and largely uncorrelated, Although synchronization is often perceived as being detrimental to spatially structured populations(14), phase synchronization leads to the emergence of complex chaotic travelling-wave structures which may be crucial for species persistence.	Tel Aviv Univ, Porter Super Ctr Ecol & Environm Studies, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Zool, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University	Stone, L (corresponding author), Tel Aviv Univ, Porter Super Ctr Ecol & Environm Studies, IL-69978 Tel Aviv, Israel.		Blasius, Bernd/GLU-4137-2022; Blasius, Bernd/AAH-1897-2019	Blasius, Bernd/0000-0002-6558-1462; Stone, Lewi/0000-0002-6465-579X				Blasius B, 1999, P ROY SOC B-BIOL SCI, V266, P93, DOI 10.1098/rspb.1999.0608; BULMER MG, 1974, J ANIM ECOL, V43, P701, DOI 10.2307/3532; COHEN AH, 1982, J MATH BIOL, V13, P345, DOI 10.1007/BF00276069; Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256; Elton C, 1942, J ANIM ECOL, V11, P215, DOI 10.2307/1358; GILPIN ME, 1979, AM NAT, V113, P306, DOI 10.1086/283389; Gotelli N.J., 1995, PRIMER ECOLOGY; GURNEY WSC, 1992, J MATH BIOL, V30, P251, DOI 10.1007/BF00176151; HANSKI I, 1993, NATURE, V364, P232, DOI 10.1038/364232a0; HASTINGS A, 1991, ECOLOGY, V72, P896, DOI 10.2307/1940591; KIETH LB, 1963, WILDLIFES 10 YEAR CY; Korpimaki E, 1996, BIOSCIENCE, V46, P754, DOI 10.2307/1312851; May R.M., 1973, STABILITY COMPLEXITY; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MORAN PAP, 1953, AUST J ZOOL, V1, P291, DOI 10.1071/ZO9530291; O'Donoghue M, 1998, ECOLOGY, V79, P1193, DOI 10.2307/176736; PECORA LM, 1990, PHYS REV LETT, V64, P821, DOI 10.1103/PhysRevLett.64.821; Ranta E, 1997, SCIENCE, V278, P1621, DOI 10.1126/science.278.5343.1621; Ranta E, 1997, AM NAT, V149, P765, DOI 10.1086/286019; Ranta E, 1997, NATURE, V390, P456, DOI 10.1038/37261; Rosenblum MG, 1996, PHYS REV LETT, V76, P1804, DOI 10.1103/PhysRevLett.76.1804; Royama T., 1992, ANAL POPULATION ECOL; Schafer C, 1998, NATURE, V392, P239, DOI 10.1038/32567; SCHAFFER WM, 1984, AM NAT, V124, P798, DOI 10.1086/284318; SINCLAIR ARE, 1993, AM NAT, V141, P173, DOI 10.1086/285468; Sinclair ARE, 1997, AM NAT, V149, P776, DOI 10.1086/286020; Stenseth NC, 1997, P NATL ACAD SCI USA, V94, P5147, DOI 10.1073/pnas.94.10.5147; STONE L, 1993, NATURE, V365, P617, DOI 10.1038/365617a0; VANDERMEER J, 1996, PROG THEOR PHYS, V71, P13; WOLF JB, 1982, PHYSICA D, V16, P285	30	722	733	2	169	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1999	399	6734					354	359		10.1038/20676	http://dx.doi.org/10.1038/20676			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360572				2022-12-01	WOS:000080547800059
J	Salomaa, V; Matei, C; Aleksic, N; Sansores-Garcia, L; Folsom, AR; Juneja, H; Chambless, LE; Wu, KK				Salomaa, V; Matei, C; Aleksic, N; Sansores-Garcia, L; Folsom, AR; Juneja, H; Chambless, LE; Wu, KK			Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study	LANCET			English	Article							DEPENDENT DIABETES-MELLITUS; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; HUMAN-PLASMA; FACTOR-VIII; E-SELECTIN; GENE; DESIGN; EXTENT	Background. Small amounts of soluble thrombomodulin in plasma are thought to reflect endothelial damage. In a case-cohort study, we examined whether soluble thrombomodulin is a predictor of incident coronary heart disease and carotid artery atherosclerosis. Methods. The study population consisted of 14170 black and white participants from the Atherosclerosis Risk in Communities (ARIC) study, who did not have cardiovascular disease at the start of the study and who we followed up for 6 years. After appropriate exclusions, we analysed 258 cases of incident coronary heart disease and 449 cases of carotid atherosclerosis. A stratified random sample of 753 individuals from the ARIC cohort was used as the comparison group. We used EIA to measure soluble thrombomodulin in plasma samples from both groups. For the analysis, we used quintiles of soluble thrombomodulin concentrations (< 24.7, 24.8-30 6, 30.7-40.2, 40.3-55.2, and greater than or equal to 55.3 ng/mL). Findings. Soluble thrombomodulin showed a strong, graded, inverse association with incident coronary heart disease (p = 0.005), The adjusted rate ratio of the highest quintile of soluble thrombomodulin compared with the lowest quintile was 0.29 (95% Cl 0.15-0.57), The association with carotid atherosclerosis, however, tended to be positive, especially among white participants (odds ratio 2.94 [1.15-7.51] for highest vs lowest quintile). The relation of soluble thrombomodulin to incident coronary heart disease and carotid atherosclerosis was dependent. on factor VIII coagulant activity (p = 0.06 and 0.003, respectively). Interpretation. The prospective association of soluble thrombomodulin with incident. coronary heart disease differs from its cross-sectional association with carotid atherosclerosis, In healthy people, plasma concentrations of soluble thrombomodulin may reflect endothelial expression of thrombomodulin. High concentration of soluble thrombomodulin may be associated with decreased risk of coronary heart disease.	Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, FIN-00300 Helsinki, Finland; Univ Texas, Sch Med, Div Haematol Oncol, Houston, TX USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Univ N Carolina, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA	Finland National Institute for Health & Welfare; University of Texas System; University of Minnesota System; University of Minnesota Twin Cities; University of North Carolina; University of North Carolina Chapel Hill	Salomaa, V (corresponding author), Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, FIN-00300 Helsinki, Finland.		Wu, Kenneth Kun-Yu/B-1070-2010	Sansores-Garcia, Leticia/0000-0003-2510-225X	NHLBI NIH HHS [N01-HC-55018, N01-HC-55015, N01-HC-55016] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055018, N01HC055015] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1991, J Neuroimaging, V1, P68; BARLOW WE, 1994, BIOMETRICS, V50, P1064, DOI 10.2307/2533444; Blann AD, 1997, EUR J HAEMATOL, V59, P115; Blann AD, 1997, EUR J CLIN INVEST, V27, P916, DOI 10.1046/j.1365-2362.1997.2180766.x; BRANDT JT, 1993, ARCH PATHOL LAB MED, V117, P48; CatellaLawson F, 1997, CORONARY ARTERY DIS, V8, P105, DOI 10.1097/00019501-199702000-00007; Doggen CJM, 1998, THROMB HAEMOSTASIS, V80, P743; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; Esmon CT, 1997, CIRCULATION, V96, P9; Folsom AR, 1997, CIRCULATION, V96, P1102, DOI 10.1161/01.CIR.96.4.1102; IBBOTSON SH, 1992, DIABETOLOGIA, V35, P863, DOI 10.1007/BF00399933; Inukai T, 1996, DIABETES RES CLIN PR, V33, P99, DOI 10.1016/0168-8227(96)01283-1; Ireland H, 1997, CIRCULATION, V96, P15; ISHII H, 1985, J CLIN INVEST, V76, P2178, DOI 10.1172/JCI112225; ISHII H, 1991, THROMB HAEMOSTASIS, V65, P618; Jansson JH, 1997, CIRCULATION, V96, P2938, DOI 10.1161/01.CIR.96.9.2938; Mohri M, 1998, THROMB HAEMOSTASIS, V80, P925; Norlund L, 1997, THROMB HAEMOSTASIS, V77, P248; Ohlin AK, 1997, THROMB HAEMOSTASIS, V78, P396; PAPP AC, 1989, THROMB HAEMOSTASIS, V61, P15; Peter K, 1997, ARTERIOSCL THROM VAS, V17, P505, DOI 10.1161/01.ATV.17.3.505; PIGNOLI P, 1986, CIRCULATION, V74, P1339; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; RILEY WA, 1991, J NEUROIMAGING, V1, P168; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Sadler JE, 1997, THROMB HAEMOSTASIS, V78, P392; *U N CAR NAT HEAT, 1987, ATH RISK COMM STUD M, V9; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184	29	201	210	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1729	1734		10.1016/S0140-6736(98)09057-6	http://dx.doi.org/10.1016/S0140-6736(98)09057-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347984				2022-12-01	WOS:000080667700009
J	Tweed, DB; Haslwanter, TP; Happe, V; Fetter, M				Tweed, DB; Haslwanter, TP; Happe, V; Fetter, M			Non-commutativity in the brain	NATURE			English	Article							TO-POSITION TRANSFORMATION; INVARIANT BODY KINEMATICS; VESTIBULOOCULAR REFLEX; DIRECTIONAL PLASTICITY; ROTATIONAL KINEMATICS; MUSCLE PULLEYS; 3 DIMENSIONS; SACCADES; MONKEY; SYSTEM	In non-commutative algebra, order makes a difference to multiplication, so that a x b not equal b x a (refs 1, 2). This feature is necessary for computing rotary motion, because order makes a difference to the combined effect of two rotations(3-6). It has therefore been proposed that there are non-commutative operators in the brain circuits that deal with rotations, including motor circuits that steer the eyes, head and limbs(4,5,7-15), and sensory circuits that handle spatial information(12,15). This idea is controversial(12,13,16-21): Studies of eye and head control have revealed behaviours that are consistent with non-commutativity in the brain(7-9,12-15), but none that clearly rules out all commutative models(17-20). Here we demonstrate noncommutative computation in the vestibule-ocular reflex. We show that subjects rotated in darkness can hold their gaze points stable in space, correctly computing different final eye-position commands when put through the same two rotations in different orders, in a way that is unattainable by any commutative system.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; ETH Honggerberg, Dept Phys, CH-8093 Zurich, Switzerland; Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany	University of Toronto; University of Toronto; University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Eberhard Karls University of Tubingen	Tweed, DB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.							Carpenter RHS, 1988, MOVEMENTS EYES; CRAWFORD JD, 1991, J NEUROPHYSIOL, V65, P407, DOI 10.1152/jn.1991.65.3.407; Demer JL, 1996, J PEDIATR OPHTHALMOL, V33, P208; HAMILTON WR, 1953, LECT QUATERNIONS; Henriques DYP, 1998, J NEUROSCI, V18, P1583; HESTENES D, 1994, NEURAL NETWORKS, V7, P65, DOI 10.1016/0893-6080(94)90056-6; HESTENES D, 1994, NEURAL NETWORKS, V7, P79, DOI 10.1016/0893-6080(94)90057-4; Koch Christof, 1999, P1; McCarthy J.M., 1990, INTRO THEORETICAL KI; MERFELD DM, 1995, EXP BRAIN RES, V106, P123; MILLER JM, 1993, OPHTHALMOLOGY, V100, P475; MINKEN AWH, 1993, EXP BRAIN RES, V93, P521, DOI 10.1007/BF00229367; Peng G C, 1994, J Vestib Res, V4, P453; Quaia C, 1998, J NEUROPHYSIOL, V79, P3197, DOI 10.1152/jn.1998.79.6.3197; Raphan T, 1998, J NEUROPHYSIOL, V79, P2653, DOI 10.1152/jn.1998.79.5.2653; RAPHAN T, 1997, 3 DIMENSIONAL KINEMA, P359; ROBINSON DA, 1970, J NEUROPHYSIOL, V33, P393, DOI 10.1152/jn.1970.33.3.393; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SCHNABOLK C, 1994, J NEUROPHYSIOL, V71, P623, DOI 10.1152/jn.1994.71.2.623; SCHULTHEIS LW, 1981, ANN NY ACAD SCI, V374, P504, DOI 10.1111/j.1749-6632.1981.tb30895.x; Schutz B.F., 1980, GEOMETRICAL METHODS; Smith MA, 1998, J NEUROPHYSIOL, V80, P2295, DOI 10.1152/jn.1998.80.5.2295; STRAUMANN D, 1995, VISION RES, V35, P3321, DOI 10.1016/0042-6989(95)00091-R; TWEED D, 1994, J NEUROPHYSIOL, V72, P1425, DOI 10.1152/jn.1994.72.3.1425; TWEED D, 1987, J NEUROPHYSIOL, V58, P832, DOI 10.1152/jn.1987.58.4.832; TWEED D, 1990, VISION RES, V30, P111, DOI 10.1016/0042-6989(90)90131-4; Tweed D, 1997, J NEUROPHYSIOL, V77, P654, DOI 10.1152/jn.1997.77.2.654; VANOPSTAL AJ, 1991, SCIENCE, V252, P1313, DOI 10.1126/science.1925545; WESTHEIMER G, 1957, J OPT SOC AM, V47, P967, DOI 10.1364/JOSA.47.000967	29	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					261	263		10.1038/20441	http://dx.doi.org/10.1038/20441			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353248				2022-12-01	WOS:000080427400056
J	Nicolson, RI; Fawcett, AJ; Berry, EL; Jenkins, IH; Dean, P; Brooks, DJ				Nicolson, RI; Fawcett, AJ; Berry, EL; Jenkins, IH; Dean, P; Brooks, DJ			Association of abnormal cerebellar activation with motor learning difficulties in dyslexic adults	LANCET			English	Article							DEVELOPMENTAL DYSLEXIA; INVOLVEMENT; CHILDREN; DEFICITS	Background In addition to their impairments in literacy-related skills, dyslexic children show characteristic difficulties in phonological skill, motor skill, and balance. There is behavioural and biochemical evidence that these difficulties may be attributable to mild cerebellar dysfunction. We wanted to find out whether there was abnormal brain activation when dyslexic adults undertook tasks known normally to involve cerebellar activation. Methods Brain activation was monitored by positron emission tomography in matched groups of six dyslexic adults and six control adults as they carried out either a prelearned sequence or learned a navel sequence of finger movements. Findings Brain activation was significantly lower (p<0.01) far the dyslexic adults than for the controls in the right cerebellar cortex and the left cingulate gyrus when executing the prelearned sequence,and in the right cerebellar cortex when learning the new sequence. Interpretation The results provided direct evidence that, for this group of dyslexic adults, the behavioural signs of cerebellar abnormality reflect underlying abnormalities in cerebellar activation.	Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England; Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0HS, England; Inst Neurol, London WC1N 3BG, England	University of Sheffield; Imperial College London; University of London; University College London	Nicolson, RI (corresponding author), Univ Sheffield, Dept Psychol, Western Bank, Sheffield S10 2TP, S Yorkshire, England.	r.nicolson@shef.ac.uk	Nicolson, Rod Ian/GQZ-4137-2022; Fawcett, Angela/AAA-6600-2021	Brooks, David/0000-0003-2602-2518				AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; Allen G, 1997, SCIENCE, V275, P1940, DOI 10.1126/science.275.5308.1940; American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU, V3rd; BRADLEY L, 1983, NATURE, V301, P419, DOI 10.1038/301419a0; Dow R. S., 1958, PHYSL PATHOLOGY CERE; Eccles J. C. M., 1967, CEREBELLUM NEURONAL; Eden GF, 1996, NATURE, V382, P66, DOI 10.1038/382066a0; Fawcett A., 1994, DYSLEXIA CHILDREN MU; Fawcett AJ, 1996, ANN DYSLEXIA, V46, P259, DOI 10.1007/BF02648179; Fawcett AJ, 1999, J MOTOR BEHAV, V31, P68, DOI 10.1080/00222899909601892; FRANK J, 1973, J AM ACAD CHILD PSY, V12, P690, DOI 10.1016/S0002-7138(09)61276-0; Friston KJ., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Holmes G, 1917, BRAIN, V40, P461, DOI 10.1093/brain/40.4.461; ITO M, 1990, REV NEUROL, V146, P564; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; JENKINS IH, 1994, J NEUROSCI, V14, P3775; JORM AF, 1986, J CHILD PSYCHOL PSYC, V27, P45, DOI 10.1111/j.1469-7610.1986.tb00620.x; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; NICOLSON RI, 1994, ANN DYSLEXIA, V44, P147, DOI 10.1007/BF02648159; NICOLSON RI, 1995, P ROY SOC B-BIOL SCI, V259, P43, DOI 10.1098/rspb.1995.0007; NICOLSON RI, 1994, Q J EXP PSYCHOL-A, V47, P29, DOI 10.1080/14640749408401142; NICOLSON RI, 1990, COGNITION, V35, P159, DOI 10.1016/0010-0277(90)90013-A; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Paulesu E, 1996, BRAIN, V119, P143, DOI 10.1093/brain/119.1.143; Rae C, 1998, LANCET, V351, P1849, DOI 10.1016/S0140-6736(97)99001-2; Rudel R. G., 1985, DYSLEXIA NEUROSCIENT, P33; SILVERI MC, 1994, NEUROLOGY, V44, P2047, DOI 10.1212/WNL.44.11.2047; STANOVICH KE, 1988, ANN DYSLEXIA, V38, P154, DOI 10.1007/BF02648254; Talairach J, 1988, COPLANAR STEROTAXIC; *WELLC DEP COGN NE, 1996, SPM96 WELLC I WELL D; WOLF M, 1991, READ RES QUART, V26, P123, DOI 10.2307/747978; WOLFF PH, 1990, DEV PSYCHOL, V26, P349, DOI 10.1037/0012-1649.26.3.349; World Federation of Neurology, 1968, REP RES GROUP DYSL W; YAP RL, 1994, J LEARN DISABIL, V27, P660, DOI 10.1177/002221949402701006; [No title captured]	35	241	249	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1662	1667		10.1016/S0140-6736(98)09165-X	http://dx.doi.org/10.1016/S0140-6736(98)09165-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198DT	10335786				2022-12-01	WOS:000080408000011
J	Discher, BM; Won, YY; Ege, DS; Lee, JCM; Bates, FS; Discher, DE; Hammer, DA				Discher, BM; Won, YY; Ege, DS; Lee, JCM; Bates, FS; Discher, DE; Hammer, DA			Polymersomes: Tough vesicles made from diblock copolymers	SCIENCE			English	Article							COMPLEX PHASE-BEHAVIOR; FLUID MEMBRANES; CURVATURE ELASTICITY; PHYSICAL-PROPERTIES; BILAYER-MEMBRANES; BLOCK-COPOLYMERS; SURFACTANT; COHESION	Vesicles were made from amphiphilic diblock copolymers and characterized by micromanipulation. The average molecular weight of the specific polymer studied, polyethyleneoxide-polyethylethylene (EO40-EE37), is several times greater than that of typical phospholipids in natural membranes. Both the membrane bending and area expansion moduli of electroformed polymersomes (polymer-based Liposomes) fell within the range of Lipid membrane measurements, but the giant polymersomes proved to be almost an order of magnitude tougher and sustained far greater areal strain before rupture. The polymersome membrane was also at Least 10 times Less permeable to water than common phospholipid bilayers. The results suggest a new class of synthetic thin-shelled capsules based on block copolymer chemistry.	Univ Penn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA; Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Minnesota System; University of Minnesota Twin Cities	Discher, DE (corresponding author), Univ Penn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA.			discher, dennis/0000-0001-6163-2229; Lee, James/0000-0002-7173-4875	NHLBI NIH HHS [P01-HL18208, R01-HL62352-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062352, P01HL018208] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELOVA MI, 1992, PROG COLL POL SCI S, V89, P127; BENSHAUL A, 1995, HDB PHYSICS BIOL SYS, V1, pCH7; BLOOM M, 1991, Q REV BIOPHYS, V24, P293, DOI 10.1017/S0033583500003735; Cevc G., 1995, HDB BIOL PHYSICS, V1; Chaieb S, 1998, PHYS REV E, V58, P7733, DOI 10.1103/PhysRevE.58.7733; Cornelissen JJLM, 1998, SCIENCE, V280, P1427, DOI 10.1126/science.280.5368.1427; DEULING HJ, 1976, J PHYS-PARIS, V37, P1335, DOI 10.1051/jphys:0197600370110133500; Dobereiner HG, 1997, PHYS REV E, V55, P4458, DOI 10.1103/PhysRevE.55.4458; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; Hajduk DA, 1998, J PHYS CHEM B, V102, P4269, DOI 10.1021/jp973323z; Harasym TO, 1997, CANCER CHEMOTH PHARM, V40, P309, DOI 10.1007/s002800050662; Harris J. M., 1997, POLYETHYLENE GLYCOL; HELFRICH W, 1984, NUOVO CIMENTO D, V3, P137, DOI 10.1007/BF02452208; Hillmyer MA, 1996, SCIENCE, V271, P976, DOI 10.1126/science.271.5251.976; ISRAELACHVILI J, 1991, INTERMOLECULAR SURFA; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Lasic D., 1995, HDB BIOL PHYS, V1; LIN Z, 1993, J PHYS CHEM-US, V97, P3571, DOI 10.1021/j100116a022; LONGO MI, 1994, SCIENCE, V266, P1032; Longo ML, 1997, BIOPHYS J, V73, P1430, DOI 10.1016/S0006-3495(97)78175-X; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; Needham D., 1996, VESICLES; Netz RR, 1996, PHYS REV E, V53, P3875, DOI 10.1103/PhysRevE.53.3875; PETROV AG, 1984, PROG SURF SCI, V16, P389, DOI 10.1016/0079-6816(84)90016-9; SACKMANN E, 1995, HDB BIOL PHYSICS A, V1; Seifert U., 1995, P403; SEIFERT U, 1991, PHYS REV A, V44, P1182, DOI 10.1103/PhysRevA.44.1182; SVETINA S, 1989, EUR BIOPHYS J BIOPHY, V17, P101, DOI 10.1007/BF00257107; SZLEIFER I, 1988, PHYS REV LETT, V60, P1966, DOI 10.1103/PhysRevLett.60.1966; WALTER A, 1991, BIOPHYS J, V60, P1315, DOI 10.1016/S0006-3495(91)82169-5; Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969; Won YY, 1999, SCIENCE, V283, P960, DOI 10.1126/science.283.5404.960; Yu K, 1998, MACROMOLECULES, V31, P3509, DOI 10.1021/ma971419l	34	2101	2181	21	962	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1999	284	5417					1143	1146		10.1126/science.284.5417.1143	http://dx.doi.org/10.1126/science.284.5417.1143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325219				2022-12-01	WOS:000080359100029
J	Belay, ED; Bresee, JS; Holman, RC; Khan, AS; Shahriari, A; Schonberger, LB				Belay, ED; Bresee, JS; Holman, RC; Khan, AS; Shahriari, A; Schonberger, LB			Reye's syndrome in the United States from 1981 through 1997	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC-HEALTH-SERVICE; ASPIRIN USE; CHILDREN; MEDICATIONS; PATTERN; RISK	Background Reye's syndrome is characterized by encephalopathy and fatty degeneration of the liver, usually after influenza or varicella. Beginning in 1980, warnings were issued about the use of salicylates in children with those viral infections because of the risk of Reye's syndrome. Methods To describe the pattern of Reye's syndrome in the United States, characteristics of the patients, and risk factors for poor outcomes, we analyzed national surveillance data collected from December 1980 through November 1997. The surveillance system is based on voluntary reporting with the use of a standard case-report form. Results From December 1980 through November 1997 (surveillance years 1981 through 1997), 1207 cases of Reye's syndrome were reported in patients less than 18 years of age. Among those for whom data on race and sex were available, 93 percent were white and 52 percent were girls. The number of reported cases of Reye's syndrome declined sharply after the association of Reye's syndrome with aspirin was reported. After a peak of 555 cases in children reported in 1980, there have been no more than 36 cases per year since 1987. Antecedent illnesses were reported in 93 percent of the children, and detectable blood salicylate levels in 82 percent. The overall case fatality rate was 31 percent. The case fatality rate was highest in children under five years of age (relative risk, 1.8; 95 percent confidence interval, 1.5 to 2.1) and in those with a serum ammonia level above 45 mu g per deciliter (26 mu mol per liter) (relative risk, 3.4; 95 percent confidence interval, 1.9 to 6.2). Conclusions Since 1980, when the association between Reye's syndrome and the use of aspirin during varicella or influenza-like illness was first reported, there has been a sharp decline in the number of infants and children reported to have Reye's syndrome. Because Reye's syndrome is now very rare, any infant or child suspected of having this disorder should undergo extensive investigation to rule out the treatable inborn metabolic disorders that can mimic Reye's syndrome. (N Engl J Med 1999;340:1377-82.) (C) 1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Belay, ED (corresponding author), Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Mailstop A-39,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	ebb8@cdc.gov	Belay, Ermias/A-8829-2013	Belay, Ermias/0000-0002-9837-0960				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; ARROWSMITH JB, 1987, PEDIATRICS, V79, P858; Brain WR, 1929, LANCET, V1, P221; Centers for Disease Control and Prevention, 1980, MMWR-MORBID MORTAL W, V29, P537; Centers for Disease Control and Prevention, 1980, MMWR-MORBID MORTAL W, V29, P532; COREY L, 1976, AM J MED, V61, P615, DOI 10.1016/0002-9343(76)90139-X; DAVIS DL, 1992, LANCET, V340, P1042; FORSYTH BW, 1991, AM J DIS CHILD, V145, P964, DOI 10.1001/archpedi.1991.02160090014005; GREEN A, 1992, ARCH DIS CHILD, V67, P1313, DOI 10.1136/adc.67.10.1313; HALPIN TJ, 1982, JAMA-J AM MED ASSOC, V248, P687, DOI 10.1001/jama.248.6.687; Hardie RM, 1996, ARCH DIS CHILD, V74, P400, DOI 10.1136/adc.74.5.400; HURWITZ ES, 1987, JAMA-J AM MED ASSOC, V257, P3366; HURWITZ ES, 1985, NEW ENGL J MED, V313, P849, DOI 10.1056/NEJM198510033131403; HURWITZ ES, 1987, JAMA-J AM MED ASSOC, V257, P1905, DOI 10.1001/jama.257.14.1905; JOHNSON G M, 1963, N C Med J, V24, P464; Kleinbaum D.G., 1988, APPL REGRESSION ANAL; *NAT SURV REY SYND, 1982, MMWR-MORBID MORTAL W, V31, P53; NELSON DB, 1979, REYES SYNDROME, V2, P33; PARTIN JS, 1984, HEPATOLOGY, V4, P687, DOI 10.1002/hep.1840040421; PINSKY PF, 1988, JAMA-J AM MED ASSOC, V260, P657, DOI 10.1001/jama.260.5.657; REMINGTON PL, 1986, PEDIATRICS, V77, P93; REMINGTON PL, 1985, AM J DIS CHILD, V139, P870, DOI 10.1001/archpedi.1985.02140110024021; RENNEBOHM RM, 1985, J PEDIATR-US, V107, P877, DOI 10.1016/S0022-3476(85)80179-7; REYE RDK, 1963, LANCET, V2, P749; ROE CR, 1986, J PEDIATR-US, V108, P13, DOI 10.1016/S0022-3476(86)80762-4; ROWE PC, 1988, JAMA-J AM MED ASSOC, V260, P3167, DOI 10.1001/jama.260.21.3167; STARKO KM, 1980, PEDIATRICS, V66, P859; *SURG GEN, 1982, MMWR-MORBID MORTAL W, V31, P289; TAYLOR JP, 1985, AM J DIS CHILD, V139, P486, DOI 10.1001/archpedi.1985.02140070060034; WALDMAN RJ, 1982, JAMA-J AM MED ASSOC, V247, P3089, DOI 10.1001/jama.247.22.3089; 1997, MMWR MORB MORTAL WKL, V46, P750; 1980, MMWR MORB MORTAL WKL, V29, P321	32	186	202	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1377	1382		10.1056/NEJM199905063401801	http://dx.doi.org/10.1056/NEJM199905063401801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228187				2022-12-01	WOS:000080090600001
J	Clark, WW; Bohne, BA				Clark, WW; Bohne, BA			Effects of noise on hearing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPOSURE		Cent Inst Deaf, St Louis, MO 63110 USA		Clark, WW (corresponding author), Cent Inst Deaf, St Louis, MO 63110 USA.		Bohne, Barbara/A-9113-2008	Bohne, Barbara/0000-0003-3874-7620				AXELSSON A, 1995, OCCUPATIONAL MED STA, P657; CLARK WW, 1987, J ACOUST SOC AM, V82, P1253, DOI 10.1121/1.395261; CLARK WW, 1991, J ACOUST SOC AM, V90, P175, DOI 10.1121/1.401285; *NAT RIFL ASS, 1999, 1999 FACT CARD; Toynbee J., 1860, DIS EAR THEIR NATURE; WATKINS D, 1998, SPECTRUM-J STATE GOV, V15, P1	6	74	77	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1658	1659		10.1001/jama.281.17.1658	http://dx.doi.org/10.1001/jama.281.17.1658			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235164				2022-12-01	WOS:000080025900035
J	Nightingale, SL				Nightingale, SL			Regularly updated drug product safety information on the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1580	1580		10.1001/jama.281.17.1580	http://dx.doi.org/10.1001/jama.281.17.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235141				2022-12-01	WOS:000080025900007
J	Kondo, T; Duboule, D				Kondo, T; Duboule, D			Breaking colinearity in the mouse HoxD complex	CELL			English	Article							IN-VIVO; GENE-EXPRESSION; POLYCOMB GROUP; MURINE; MICE; CHROMATIN; DROSOPHILA; SPECIFICATION; ORGANIZATION; HIERARCHY	Vertebrate Hox genes are activated in a spatiotemporal sequence that reflects their clustered organization. While this colinear relationship is a property of most metazoans with an anterior to posterior polarity, the underlying molecular mechanisms are unknown. Previous work suggested that Hox genes were made progressively available for transcription in the course of gastrulation, implying the existence of an element capable of initiating a repressive conformation, subsequently relieved from the clusters sequentially. We searched for this element by combining a genomic walk with successive transgene insertions upstream of the HoxD complex followed by a series of deletions. The largest deficiency induced posterior homeotic transformations coincidentally with an earlier activation of Herd genes. These data suggest that a regulatory element located upstream of the complex is necessary for setting up the early pattern of Hox gene colinear activation.	Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Duboule, D (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.			jin teng, long/0000-0002-1948-9331; duboule, denis/0000-0001-9961-2960				AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Beckers J, 1998, DEV DYNAM, V213, P1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Core N, 1997, DEVELOPMENT, V124, P721; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1994, DEVELOPMENT, P143; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1998, CURR OPIN GENET DEV, V8, P514, DOI 10.1016/S0959-437X(98)80004-X; Dupe V, 1997, DEVELOPMENT, V124, P399; DUSH MK, 1992, DEV BIOL, V151, P273, DOI 10.1016/0012-1606(92)90232-6; FAIELLA A, 1991, NUCLEIC ACIDS RES, V19, P6541, DOI 10.1093/nar/19.23.6541; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FROHMAN MA, 1992, MECH DEVELOP, V38, P55, DOI 10.1016/0925-4773(92)90038-L; GAUNT SJ, 1988, DEVELOPMENT S, P71; Gerard M, 1996, GENE DEV, V10, P2326, DOI 10.1101/gad.10.18.2326; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Herault Y, 1998, NAT GENET, V20, P381, DOI 10.1038/3861; Herault Y, 1999, DEV BIOL, V208, P157, DOI 10.1006/dbio.1998.9179; Herault Y, 1996, EMBO J, V15, P6727, DOI 10.1002/j.1460-2075.1996.tb01062.x; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; INOUYE M, 1976, Congenital Anomalies, V16, P171; IZPISUABELMONTE.JC, 1990, DEVELOPMENT, V119, P733; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Kondo T, 1998, MOL CELL, V1, P289, DOI 10.1016/S1097-2765(00)80029-5; Kondo T, 1997, NATURE, V390, P29, DOI 10.1038/36234; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Mann RS, 1997, BIOESSAYS, V19, P661, DOI 10.1002/bies.950190804; MULLER J, 1995, DEVELOPMENT, V121, P2847; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; RENUCCI A, 1992, EMBO J, V11, P1459, DOI 10.1002/j.1460-2075.1992.tb05190.x; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; Sordino P, 1996, MECH DEVELOP, V59, P165, DOI 10.1016/0925-4773(96)00587-4; SPYROPOULOS DD, 1994, GENE DEV, V8, P1949, DOI 10.1101/gad.8.16.1949; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Zakany J, 1997, EMBO J, V16, P4393, DOI 10.1093/emboj/16.14.4393; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0	47	121	123	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					407	417		10.1016/S0092-8674(00)80749-7	http://dx.doi.org/10.1016/S0092-8674(00)80749-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319820	Bronze			2022-12-01	WOS:000080100500013
J	Visintin, R; Hwang, ES; Amon, A				Visintin, R; Hwang, ES; Amon, A			Cfi1 prevents premature exit from mitosis by anchoring Cdc14 phosphatase in the nucleolus	NATURE			English	Article							ANAPHASE PROMOTING COMPLEX; SISTER-CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; MULTICOPY SUPPRESSOR; PROTEIN PHOSPHATASE; PROTEOLYSIS; TRANSITION; METAPHASE	In eukaryotes, the activation of mitotic cyclin-dependent kinases (CDKs) induces mitosis, and their inactivation causes cells to leave mitosis(1). In budding yeast, two redundant mechanisms induce the inactivation of mitotic CDKs. In one mechanism, a specialized ubiquitin-dependent proteolytic system (called the APC-dependent proteolysis machinery) degrades the mitotic (Clb) cyclin subunit. In the other, the kinase-inhibitor Sic1 binds to mitotic CDKs and inhibits their kinase activity(1,2). The highly conserved protein phosphatase Cdc14 promotes both Clb degradation and Sic1 accumulation. Cdc14 promotes SIC1 transcription and the stabilization of Sic1 protein by dephosphorylating Sic1 and its transcription factor Swi5. Cdc14 activates the degradation of Clb cyclins by dephosphorylating the APC-specificity factor Cdh1 (refs 3, 4). So how is Cdc14 regulated? Here we show that Cdc14 is sequestered in the nucleolus for most of the cell cycle. During nuclear division, Cdc14 is released from the nucleolus, allowing it to reach its targets. A highly conserved signalling cascade, critical for the exit from mitosis, is required for this movement of Cdc14 during anaphase. Furthermore, we have identified a negative regulator of Cdc14 Cfi1, that anchors Cdc14 in the nucleolus.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Amon, A (corresponding author), MIT, Ctr Canc Res, Bldg E17,40 Ames St, Cambridge, MA 02139 USA.		Visintin, Rosella/J-9690-2012	Amon, Angelika/0000-0001-9837-0314; Visintin, Rosella/0000-0001-6758-9946				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; James P, 1996, GENETICS, V144, P1425; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; Smith JS, 1998, GENETICS, V149, P1205; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	28	487	490	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 29	1999	398	6730					818	823		10.1038/19775	http://dx.doi.org/10.1038/19775			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235265				2022-12-01	WOS:000080058100061
J	Karpinski, S; Reynolds, H; Karpinska, B; Wingsle, G; Creissen, G; Mullineaux, P				Karpinski, S; Reynolds, H; Karpinska, B; Wingsle, G; Creissen, G; Mullineaux, P			Systemic signaling and acclimation in response to excess excitation energy in Arabidopsis	SCIENCE			English	Article							CYTOSOLIC ASCORBATE PEROXIDASE; LIGHT; PHOTOINHIBITION; PROTEIN; STRESS; TRANSFORMATION; PHOTOSYNTHESIS; EXPRESSION	Land plants are sessile and have developed sophisticated mechanisms that allow for both immediate and-acclimatory responses to changing environments. Partial exposure of Low light-adapted Arabidopsis plants to excess light results in a systemic acclimation to excess excitation energy and consequent photooxidative stress in unexposed leaves. Thus, plants possess a mechanism to communicate excess excitation energy systemically, allowing them to mount a defense against further episodes of such stress. Systemic redox changes in the proximity of photosystem II, hydrogen peroxide, and the induction of antioxidant defenses are key determinants of this mechanism of systemic acquired acclimation.	Swedish Univ Agr Sci, Fac Forestry, Dept Forest Genet & Plant Physiol, SE-90183 Umea, Sweden; John Innes Ctr Plant Sci Res, Dept Appl Genet, Norwich NR4 7UH, Norfolk, England	Swedish University of Agricultural Sciences; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Karpinski, S (corresponding author), Swedish Univ Agr Sci, Fac Forestry, Dept Forest Genet & Plant Physiol, SE-90183 Umea, Sweden.		Mullineaux, Philip M/F-7723-2012; Creissen, Gary P/C-7481-2009; Karpinski, Stanislaw/ABD-9543-2021	Mullineaux, Philip M/0000-0002-1998-3540; Creissen, Gary P/0000-0003-4992-8056; Karpinski, Stanislaw/0000-0002-4328-1207				ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; Baker N. R., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P127; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Edwards A, 1996, PLANT PHYSIOL, V112, P89, DOI 10.1104/pp.112.1.89; ESCOUBAS JM, 1995, P NATL ACAD SCI USA, V92, P10237, DOI 10.1073/pnas.92.22.10237; Foyer CH., 1997, OXIDATIVE STRESS MOL, P587; GUERINEAU F, 1992, PLANT MOL BIOL, V18, P815, DOI 10.1007/BF00020027; Huner NPA, 1998, TRENDS PLANT SCI, V3, P224, DOI 10.1016/S1360-1385(98)01248-5; KARPINSKI S, 1993, PLANT PHYSIOL, V103, P1385, DOI 10.1104/pp.103.4.1385; Karpinski S, 1997, PLANT CELL, V9, P627, DOI 10.1105/tpc.9.4.627; Krause G. H., 1994, Causes of photooxidative stress and amelioration of defense systems in plants., P43; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P691; KUBO GH, 1992, FEBS LETT, V315, P313; LONG SP, 1994, ANNU REV PLANT PHYS, V45, P633, DOI 10.1146/annurev.pp.45.060194.003221; Lopez-Delgado H, 1998, J EXP BOT, V49, P713, DOI 10.1093/jexbot/49.321.713; MAXWELL DP, 1995, PLANT PHYSIOL, V109, P787, DOI 10.1104/pp.109.3.787; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; PRASAD TK, 1994, PLANT CELL, V6, P65, DOI 10.1105/tpc.6.1.65; RUSSELL AW, 1995, PLANT PHYSIOL, V107, P943, DOI 10.1104/pp.107.3.943; Santos M, 1996, PLANTA, V198, P64, DOI 10.1007/BF00197587; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	21	698	751	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					654	657		10.1126/science.284.5414.654	http://dx.doi.org/10.1126/science.284.5414.654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213690				2022-12-01	WOS:000079951100048
J	Stamey, TA; McNeal, JE; Yemoto, CM; Sigal, BM; Johnstone, IM				Stamey, TA; McNeal, JE; Yemoto, CM; Sigal, BM; Johnstone, IM			Biological determinants of cancer progression in men with prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESIDUAL CANCER; ANTIGEN ASSAYS; ADENOCARCINOMA; METASTASIS; VOLUME	Context The recent increase in ability to diagnose prostatic adenocarcinoma has created a dilemma for treatment decisions, Objective To determine whether prostate cancer progression is associated with a modified version of the Gleason grading system together with selected morphologic and clinical variables. Design Retrospective analysis of a cohort of patients with peripheral zone prostate cancers who underwent surgery between August 1983 and July 1992. Setting University hospital. Patients Radical prostatectomy specimens from 379 men treated only by surgical excision were prospectively studied for 8 morphologic variables using previously standardized techniques. Variables were percentage of each cancer occupied by Gleason grade 4/5 (% Gleason grade 4/5, the Stanford modified Gleason scale), cancer volume, vascular invasion, lymph node involvement, seminal vesicle invasion, capsular penetration, positive surgical margin, prostate weight, and preoperative prostate-specific antigen (PSA) level, Main Outcome Measure Biochemical progression of prostate cancer as indicated by serum PSA level of 0.07 ng/mL and increasing. Results Cancer grade expressed as % Gleason grade 4/5 and cancer volume were highly predictive of disease progression, In a Cox proportional hazards model that included % Gleason grade 4/5, the traditional Gleason score was not an independent predictor of treatment failure. Positive lymph node findings and intraprostatic vascular invasion were the only other variables that remained significant at the .01 level. Conclusion The % Gleason grade 4/5, cancer volume, positive lymph node findings, and intraprostatic vascular invasion were independently associated with prostate cancer progression, defined by an increasing PSA level. Techniques to accurately measure cancer volume and % Gleason grade 4/5 are needed to better predict which patient will experience cancer progression. The commonly accepted predictors of progression-capsular penetration and positive surgical margins-were not independently predictive of failure after radical prostatectomy.	Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA	Stanford University; Stanford University	Stamey, TA (corresponding author), Stanford Univ, Med Ctr, Dept Urol, 300 Pasteur Dr, Stanford, CA 94305 USA.							BABAIAN RJ, 1995, J UROLOGY, V154, P1808, DOI 10.1016/S0022-5347(01)66790-9; Cox D.R., 1989, MONOGRAPHS STAT APPL, V2nd ed.; Cox DR., 1984, ANAL SURVIVAL DATA; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Isaacs JT, 1997, AM J PATHOL, V150, P1511; MCNEAL JE, 1990, AM J SURG PATHOL, V14, P240, DOI 10.1097/00000478-199003000-00005; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; McNeal JE, 1996, AM J SURG PATHOL, V20, P1351, DOI 10.1097/00000478-199611000-00006; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; MCNEAL JE, 1991, ANN PATHOL, V11, P263; PRESTIGIACOMO AF, 1994, J UROLOGY, V152, P1515, DOI 10.1016/S0022-5347(17)32459-X; STAMEY TA, 1995, UROLOGY, V45, P2, DOI 10.1016/S0090-4295(95)96168-2; Stamey TA, 1996, CLIN CHEM, V42, P849; VENABLES WN, 1997, MODERN APPL STAT S P, P357; VILLERS A, 1992, CANCER, V70, P2313, DOI 10.1002/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T	15	512	533	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1395	1400		10.1001/jama.281.15.1395	http://dx.doi.org/10.1001/jama.281.15.1395			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217055	Bronze			2022-12-01	WOS:000079701000029
J	Staessen, JA; Roels, HA; Emelianov, D; Kuznetsova, T; Thijs, L; Vangronsveld, J; Fagard, R				Staessen, JA; Roels, HA; Emelianov, D; Kuznetsova, T; Thijs, L; Vangronsveld, J; Fagard, R		PheeCad Study Grp	Environmental exposure to cadmium, forearm bone density, and risk of fractures: prospective population study	LANCET			English	Article							DUAL-PHOTON ABSORPTIOMETRY; AMBULATORY BLOOD-PRESSURE; TOTAL-BODY CALCIUM; OSTEOPOROSIS; LEAD; RAT	Background Chronic low-level exposure to cadmium may promote calcium loss via urinary excretion. We undertook a prospective population study to investigate whether environmental exposure to cadmium lowers bone density and increases risk of fractures. Methods We measured urinary cadmium excretion, a biomarker of lifetime exposure, in people from ten districts of Belgium, of which six districts bordered on three zinc smelters. We also measured cadmium in soil and in vegetables from the districts, and collected data on incidence of fractures and height loss. Bone density was measured at the forearm just above the wrist by single photon absorptiometry, and calculated as the mean of six proximal and four distal scans. Findings Mean cadmium excretion at baseline was 8.7 nmol dairy. Across the ten districts, mean cadmium concentration in soil ranged from 0.8 to 14.7 mg/kg, and from 0.1 to 4.0 mg/kg dry weight in vegetables. Median follow-up was 6.6 years. Mean forearm bane density in proximal and distal scans was 0.54 g/cm(2) and 0.43 g/cm(2) in men, and 0.44 g/cm(2) and 0.34 g/cm(2) in women, in postmenopausal women, a twofold increase in urinary cadmium correlated with 0.01 g/cm(2) decrease in bone density (p < 0.02). The relative risks associated with doubted urinary cadmium were 1.73 (95% CI 1.16-2.57; p = 0.007) for fractures in women and 1.60 (0.94-2.72, p = 0.08) for height toss in men. Cadmium excretion in districts near smelters was 22.8% higher (p = 0.001) than in other districts, with fracture rates of 16.0 end 10.3 cases per 1000 person-years, respectively, and a population-attributable risk of 35.0%. Interpretation Even at a low degree of environmental exposure, cadmium may promote skeletal demineralisation, which may lead to increased bone fragility and raised risk of fractures.	Katholieke Univ Leuven, Dept Mol & Cardiovasc Res, Hypertens & Cardiovasc Rehabil Unit, B-3000 Leuven, Belgium; Catholic Univ Louvain, Unite Toxicol Ind & Med Travail, Brussels, Belgium; Limburgs Univ Ctr, Diepenbeek, Belgium	KU Leuven; Universite Catholique Louvain; Hasselt University	Staessen, JA (corresponding author), Katholieke Univ Leuven, Dept Mol & Cardiovasc Res, Hypertens & Cardiovasc Rehabil Unit, Campus Gasthuisberg,Herestr 49, B-3000 Leuven, Belgium.	jan.staessen@med.kuleuven.ac.be	Vangronsveld, Jaco/ABE-5907-2020; Staessen, Jan A/A-1065-2011; Kuznetsova, Tatiana/ABI-5662-2020	Vangronsveld, Jaco/0000-0003-4423-8363; Staessen, Jan A/0000-0002-3026-1637; Kuznetsova, Tatiana/0000-0003-4293-4576; Thijs, Lutgarde/0000-0002-8108-2356				BHATTACHARYYA MH, 1988, P NATL ACAD SCI USA, V85, P8761, DOI 10.1073/pnas.85.22.8761; BRONNER F, 1989, AM J PHYSIOL, V257, pF707, DOI 10.1152/ajprenal.1989.257.5.F707; BRONNER F, 1986, AM J PHYSIOL, V250, pG561, DOI 10.1152/ajpgi.1986.250.5.G561; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; Chalkley SR, 1998, OCCUP ENVIRON MED, V55, P446, DOI 10.1136/oem.55.7.446; CHRISTIANSEN C, 1975, SCAND J CLIN LAB INV, V35, P425, DOI 10.3109/00365517509095763; CLAEYS F, 1992, CADMIUM HUMAN ENV TO, P83; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; HOJIMA Y, 1994, MATRIX BIOL, V14, P113, DOI 10.1016/0945-053X(94)90001-9; Jarup L, 1998, OCCUP ENVIRON MED, V55, P435, DOI 10.1136/oem.55.7.435; Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1; JAWOROWSKI Z, 1985, SCI TOTAL ENVIRON, V43, P103, DOI 10.1016/0048-9697(85)90034-8; JIN T, 1987, TOXICOLOGY, V45, P307, DOI 10.1016/0300-483X(87)90020-5; Kjellstrom T., 1985, CADMIUM HLTH TOXICOL, VII, P257; Kjellstrom T., 1986, CADMIUM HLTH TOXICOL, V2, P111; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; LORENTZON R, 1977, CLIN SCI MOL MED, V53, P439, DOI 10.1042/cs0530439; MAZESS RB, 1981, CALCIFIED TISSUE INT, V33, P361; MCARDLE WD, 1991, EXERCISE PHYSL ENERG, P804; MIYAHARA T, 1988, TOXICOL APPL PHARM, V96, P52, DOI 10.1016/0041-008X(88)90246-3; NILAS L, 1985, J NUCL MED, V26, P1257; Nordberg GF, 1985, CADMIUM HLTH TOXICOL, VI, P103; Office of Population Censuses and Surveys, 1980, CLASS OCC COD IND; SHERLOCK JC, 1983, CADMIUM 83, P107; STAESSEN J, 1991, BRIT J IND MED, V48, P710; STAESSEN JA, 1994, LANCET, V343, P1523, DOI 10.1016/S0140-6736(94)92936-X; Staessen JA, 1997, J HUM HYPERTENS, V11, P507, DOI 10.1038/sj.jhh.1000476; Staessen JA, 1996, JAMA-J AM MED ASSOC, V275, P1563, DOI 10.1001/jama.275.20.1563; VALKEMA R, 1989, EUR J NUCL MED, V15, P269, DOI 10.1007/BF00257547	29	317	333	0	47	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 3	1999	353	9159					1140	1144		10.1016/S0140-6736(98)09356-8	http://dx.doi.org/10.1016/S0140-6736(98)09356-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209978				2022-12-01	WOS:000079858400012
J	Elstein, D; Klutstein, MW; Lahad, A; Abrahamov, A; Hadas-Halpern, I; Zimran, A				Elstein, D; Klutstein, MW; Lahad, A; Abrahamov, A; Hadas-Halpern, I; Zimran, A			Echocardiographic assessment of pulmonary hypertension in Gaucher's disease	LANCET			English	Article							REPLACEMENT THERAPY	Background Enzyme therapy has been shown to decrease the signs and symptoms of Gaucher's disease. A few patients, however, develop pulmonary hypertension on such treatment. We investigated the frequency of pulmonary hypertension in Gaucher's disease. Methods We studied 134 adults with type 1 Gaucher's disease, including 73 patients on enzyme replacement, with echocardiography. We measured tricuspid incompetence (TI) with continuous-wave doppler. Pulmonary hypertension was indicated by a TI gradient of more than 30 mm Hg. Findings Nine (7%) patients had pulmonary hypertension: all were treated and six had undergone splenectomy. Chest radiographs confirmed the presence of pulmonary hypertension in these patients as well as in most patients with TI gradients of 25-29 mm Hg. Interpretation The confounding effects of disease severity and splenectomy in many treated patients precluded definitive conclusion of cause and effect. Nonetheless, we found an unexpectedly high rate of pulmonary hypertension and recommended routine echocardiographic monitoring of all treated and untreated patients with type 1 Gaucher's disease. We also suggest consideration of treatment withdrawal if the TI gradient progresses to more than 30 mm Hg.	Shaare Zedek Med Ctr, Gaucher Clin, IL-91031 Jerusalem, Israel; Shaare Zedek Med Ctr, Dept Med, IL-91031 Jerusalem, Israel; Shaare Zedek Med Ctr, Dept Cardiol, IL-91031 Jerusalem, Israel; Shaare Zedek Med Ctr, Dept Pediat, IL-91031 Jerusalem, Israel; Shaare Zedek Med Ctr, Dept Diagnost Radiol, IL-91031 Jerusalem, Israel	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Elstein, D (corresponding author), Shaare Zedek Med Ctr, Gaucher Clin, POB 3235, IL-91031 Jerusalem, Israel.							Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; DAWSON A, 1995, CLIN RES, V43, P277; GOLDSMITH GH, 1988, ANN INTERN MED, V108, P797, DOI 10.7326/0003-4819-108-6-797; Harats D, 1997, ACTA HAEMATOL-BASEL, V98, P47; Kerem E, 1996, EUR RESPIR J, V9, P340, DOI 10.1183/09031936.96.09020340; LEE RE, 1988, LAB INVEST, V58, pA54; Rich S, 1997, HEART DIS TXB CARDIO, P780; ROBERTS WC, 1967, CIRCULATION, V35, P783, DOI 10.1161/01.CIR.35.4.783; Ross DJ, 1997, NEW ENGL J MED, V336, P379, DOI 10.1056/NEJM199701303360516; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; THEISE ND, 1990, AM J PEDIAT HEMATOL, V12, P74; ZIMRAN A, 1994, AM J MED, V97, P3, DOI 10.1016/0002-9343(94)90042-6	13	75	80	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1544	1546		10.1016/S0140-6736(98)10194-0	http://dx.doi.org/10.1016/S0140-6736(98)10194-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326537				2022-12-01	WOS:000073868000010
J	Dormann, P; Balbo, I; Benning, C				Dormann, P; Balbo, I; Benning, C			Arabidopsis galactolipid biosynthesis and lipid trafficking mediated by DGD1	SCIENCE			English	Article							CHLOROPLAST ENVELOPES; MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE; MUTANT DEFICIENT; OUTER-MEMBRANE; THALIANA; DIGALACTOSYLDIACYLGLYCEROL; PLANTS; GALACTOSYLTRANSFERASE; DIACYLGLYCEROL; CLONING	The photosynthetic apparatus in plant cells is associated with membranes of the thylakoids within the chloroplast and is embedded into a highly specialized Lipid matrix. Diacylglycerol galactolipids are common in thylakoid membranes but are excluded from all others. Isolation of the gene DGD1, encoding a galactosyltransferase-like protein, now provides insights into assembly of the thylakoid Lipid matrix and subcellular Lipid trafficking in Arabidopsis thaliana.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Max Planck Inst Mol Pflanzenphysiol, D-14476 Golm, Germany	Michigan State University; Max Planck Society	Benning, C (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	benning@pilot.msu.edu	Benning, Christoph/Y-2528-2019	Benning, Christoph/0000-0001-8585-3667				ANDERSSON L, 1995, J LIPID RES, V36, P1392; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; BROWSE J, 1994, ARABIDOPSIS, P881; Camilleri C, 1998, PLANT J, V14, P633, DOI 10.1046/j.1365-313X.1998.00159.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Chen LJ, 1998, PLANT J, V16, P33, DOI 10.1046/j.1365-313x.1998.00270.x; CLINE K, 1983, PLANT PHYSIOL, V71, P366, DOI 10.1104/pp.71.2.366; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Hartel H, 1998, PLANT PHYSIOL BIOCH, V36, P407, DOI 10.1016/S0981-9428(98)80204-0; Hartel H, 1997, PLANT PHYSIOL, V115, P1175, DOI 10.1104/pp.115.3.1175; HEEMSKERK JWM, 1990, PLANT PHYSIOL, V93, P1286, DOI 10.1104/pp.93.4.1286; HEINZ E, 1983, PLANT PHYSIOL, V72, P273, DOI 10.1104/pp.72.2.273; Joyard J, 1998, PLANT PHYSIOL, V118, P715, DOI 10.1104/pp.118.3.715; KUNST L, 1988, P NATL ACAD SCI USA, V85, P4143, DOI 10.1073/pnas.85.12.4143; MARECHAL E, 1994, J BIOL CHEM, V269, P5788; MEYER K, 1996, GENOME MAPPING PLANT, P137; Mongrand S, 1998, PHYTOCHEMISTRY, V49, P1049, DOI 10.1016/S0031-9422(98)00243-X; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; Ohlsson L, 1998, J NUTR, V128, P239, DOI 10.1093/jn/128.2.239; Reifarth F, 1997, BIOCHEMISTRY-US, V36, P11769, DOI 10.1021/bi9709654; Shimojima M, 1997, P NATL ACAD SCI USA, V94, P333, DOI 10.1073/pnas.94.1.333; TEUCHER T, 1991, PLANTA, V184, P319, DOI 10.1007/BF00195332; Uwer U, 1998, PLANT CELL, V10, P1277, DOI 10.1105/tpc.10.8.1277; VANBESOUW A, 1978, BIOCHIM BIOPHYS ACTA, V529, P44, DOI 10.1016/0005-2760(78)90102-9; VONSCHAEVEN A, 1989, THESIS FREIE U BERLI	32	162	168	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2181	2184		10.1126/science.284.5423.2181	http://dx.doi.org/10.1126/science.284.5423.2181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381884				2022-12-01	WOS:000081099300053
J	Franc, NC; Heitzler, P; Ezekowitz, RAB; White, K				Franc, NC; Heitzler, P; Ezekowitz, RAB; White, K			Requirement for croquemort in phagocytosis of apoptotic cells in Drosophila	SCIENCE			English	Article							MONOCYTE-DERIVED MACROPHAGES; GENE-EXPRESSION; C-ELEGANS; VITRONECTIN RECEPTOR; SCAVENGER RECEPTOR; DEATH; PROTEIN; CD36; RECOGNITION; MELANOGASTER	Macrophages in the Drosophila embryo are responsible for the phagocytosis of apoptotic cells and are competent to engulf bacteria. Croquemort (CRQ) is a CD36-related receptor expressed exclusively on these macrophages. Genetic evidence showed that crq was essential for efficient phagocytosis of apoptotic corpses but was not required for the engulfment of bacteria. The expression of CRQ was regulated by the amount of apoptosis. These data define distinct pathways for the phagocytosis of corpses and bacteria in Drosophila.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lab Dev Immunol, Charlestown, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Charlestown, MA 02129 USA; Univ Strasbourg 1, CNRS, INSERM, IGBMC, F-67404 Illkirch Graffenstaden, France	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	White, K (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.		White, Kristin/D-7936-2013; Franc, Nathalie/C-2208-2009	Franc, Nathalie/0000-0002-1617-385X	NIGMS NIH HHS [R01 GM055568] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS JM, 1992, P NATL ACAD SCI USA, V89, P10375, DOI 10.1073/pnas.89.21.10375; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Dimarcq JL, 1997, INSECT BIOCHEM MOLEC, V27, P877, DOI 10.1016/S0965-1748(97)00072-6; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Franc NC, 1999, CURR OPIN IMMUNOL, V11, P47, DOI 10.1016/S0952-7915(99)80009-0; Frank LH, 1996, DEVELOPMENT, V122, P1343; Gateff E., 1980, INVERTEBRATE SYSTEMS, P517; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; HEITZLER P, UNPUB; Hortsch M, 1998, INT J DEV BIOL, V42, P33; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NELSON RE, 1994, EMBO J, V13, P3438, DOI 10.1002/j.1460-2075.1994.tb06649.x; NICHOLSON A, 1995, THROMB VASC BIOL, V15, P269; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Ryeom SW, 1996, J CELL SCI, V109, P387; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Savill J, 1997, BRIT MED BULL, V53, P491; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SCHNEITZ K, 1993, GENE DEV, V7, P114, DOI 10.1101/gad.7.1.114; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TEPASS U, 1994, DEVELOPMENT, V120, P1829; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5	38	294	301	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1991	1994		10.1126/science.284.5422.1991	http://dx.doi.org/10.1126/science.284.5422.1991			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373118				2022-12-01	WOS:000080932700048
J	Clarkson, MJ; Wells, JRE; Gibson, F; Saint, R; Tremethick, DJ				Clarkson, MJ; Wells, JRE; Gibson, F; Saint, R; Tremethick, DJ			Regions of variant histone His2AvD required for Drosophila development	NATURE			English	Article							NUCLEOSOME	One way in which a distinct chromosomal domain could be established to carry out a specialized function is by the localized incorporation of specific histone variants into nucleosomes. H2AZ, one such variant of the histone protein H2A, is required for the survival of Drosophila melanogaster(1), Tetrahymena thermophila(2) and mice (R. Faast et al., in preparation). To search for the unique features of Drosophila H2AZ (His2AvD, also referred to as H2AvD) that are required for its essential function, we have performed amino-acid swap experiments in which residues unique to Drosophila His2AvD were replaced with equivalently positioned Drosophila H2A.1 residues. Mutated His2AvD genes encoding modified versions of this histone were transformed into Drosophila and tested for their ability to rescue null-mutant lethality. We show that the unique feature of His2AvD does not reside in its histone fold but in its carboxy-terminal domain. This C-terminal region maps to a short alpha-helix in H2A that is buried deep inside the nuceleosome core.	Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Genet, Adelaide, SA 5005, Australia	Australian National University; John Curtin School of Medical Research; University of Adelaide; University of Adelaide	Tremethick, DJ (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, POB 334, Canberra, ACT 2601, Australia.		Saint, Robert/A-4190-2008	Saint, Robert/0000-0002-7989-6043; Tremethick, David/0000-0001-5274-8078				HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Liu XW, 1996, MOL CELL BIOL, V16, P4305; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ng KW, 1997, EMBO J, V16, P2072, DOI 10.1093/emboj/16.8.2072; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593	8	158	163	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					694	697		10.1038/21436	http://dx.doi.org/10.1038/21436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385122				2022-12-01	WOS:000080932800062
J	Das, A; Gilbert, CD				Das, A; Gilbert, CD			Topography of contextual modulations mediated by short-range interactions in primary visual cortex	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONALLY CHARACTERIZED SITES; CROSS-CORRELATION ANALYSIS; HORIZONTAL CONNECTIONS; ORIENTATION SELECTIVITY; DIRECTION SELECTIVITY; INTRINSIC CONNECTIONS; CORTICAL DYNAMICS; CAT; SENSITIVITY	Neurons in primary visual cortex (V1) respond differently to a simple visual element presented in isolation from when it is embedded within a complex image. This difference, a specific modulation by surrounding elements in the image, is mediated by short- and long-range connections within V1 and by feedback from other areas. Here we study the role of short-range connections in this process, and relate it to the layout of local inhomogeneities in the cortical maps of orientation and space. By measuring correlation between neuron pairs located in optically imaged maps of V1 orientation columns we show that the strength of local connections between cells is a graded function of lateral separation across cortex, largely radially symmetrical and relatively independent of orientation preferences. We then show the contextual influence of flanking visual elements on neuronal responses varies systematically with a neuron's position within the cortical orientation map. The strength of this contextual influence on a neuron can be predicted from a model of local connections based on simple overlap with particular features of the orientation map. This Indicates that local Intracortical circuitry could endow neurons with a graded specialization for processing angular visual features such as corners and T functions, and this specialization could have its own functional cortical map, linked with the orientation map.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Gilbert, CD (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	gilbert@rockvax.rockefeller.edu						AERTSEN AMHJ, 1985, BRAIN RES, V340, P341, DOI 10.1016/0006-8993(85)90931-X; Bauer U, 1999, VISION RES, V39, P613, DOI 10.1016/S0042-6989(98)00172-2; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bosking WH, 1997, J NEUROSCI, V17, P2112; CRIST RE, 1997, ABSTR SOC NEUROSCI, V23, P1543; Crook JM, 1997, VISUAL NEUROSCI, V14, P141, DOI 10.1017/S095252380000883X; Crook JM, 1998, EUR J NEUROSCI, V10, P2056, DOI 10.1046/j.1460-9568.1998.00218.x; DAS A, 1995, J NEUROPHYSIOL, V74, P779, DOI 10.1152/jn.1995.74.2.779; Das A, 1997, NATURE, V387, P594, DOI 10.1038/42461; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Gawne TJ, 1996, CEREB CORTEX, V6, P482, DOI 10.1093/cercor/6.3.482; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HATA Y, 1991, J PHYSIOL-LONDON, V441, P593, DOI 10.1113/jphysiol.1991.sp018769; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; HUBENER M, 1992, J COMP NEUROL, V324, P67, DOI 10.1002/cne.903240106; Ito M, 1999, NEURON, V22, P593, DOI 10.1016/S0896-6273(00)80713-8; Ito M, 1998, NEURON, V20, P1191, DOI 10.1016/S0896-6273(00)80499-7; KAPADIA MK, 1995, NEURON, V15, P843, DOI 10.1016/0896-6273(95)90175-2; KATZ LC, 1989, J NEUROSCI, V9, P1389; KISVARDAY ZF, 1986, EXP BRAIN RES, V64, P541, DOI 10.1007/BF00340492; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MALACH R, 1994, TRENDS NEUROSCI, V17, P101, DOI 10.1016/0166-2236(94)90113-9; MALACH R, 1992, J COMP NEUROL, V315, P303, DOI 10.1002/cne.903150306; MCGUIRE BA, 1991, J COMP NEUROL, V305, P370, DOI 10.1002/cne.903050303; MELSSEN WJ, 1987, BIOL CYBERN, V57, P403, DOI 10.1007/BF00354985; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; Polat U, 1998, NATURE, V391, P580, DOI 10.1038/35372; Shevelev IA, 1998, NEUROSCIENCE, V84, P713, DOI 10.1016/S0306-4522(97)00393-X; SHEVELEV IA, 1995, NEUROSCIENCE, V69, P51, DOI 10.1016/0306-4522(95)00188-O; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; Sompolinsky H, 1997, CURR OPIN NEUROBIOL, V7, P514, DOI 10.1016/S0959-4388(97)80031-1; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; TSO DY, 1989, J NEUROSCI, V9, P2432; ULLMAN S, 1990, COLD SH Q B, V55, P889; Wertheimer M., 1938, SOURCE BOOK GESTALT, P71, DOI https://doi.org/10.1037/11496-005	45	238	241	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1999	399	6737					655	661		10.1038/21371	http://dx.doi.org/10.1038/21371			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385116				2022-12-01	WOS:000080932800050
J	Fambrough, D; McClure, K; Kazlauskas, A; Lander, ES				Fambrough, D; McClure, K; Kazlauskas, A; Lander, ES			Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; FACTOR-BETA-RECEPTOR; PHOSPHORYLATION SITES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; AUTOPHOSPHORYLATION SITES; SERINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; INTERFERON-GAMMA	We sought to explore the relationship between receptor tyrosine kinase (RTK) activated signaling pathways and the transcriptional induction of immediate early genes (IEGs). Using global expression monitoring, we identified 66 fibroblast IEGs induced by platelet-derived growth factor beta receptor (PDGFR beta) signaling. Mutant receptors lacking binding sites for activation of the PLC gamma, PI3K, SHP2, and RasGAP pathways still retain partial ability to induce 64 of these IEGs. Removal of the Grb2-binding site further broadly reduces induction. These results suggest that the diverse pathways exert broadly overlapping effects on IEG induction. Interestingly, a mutant receptor that restores the RasGAP-binding site promotes induction of an independent group of genes, normally induced by interferons. Finally, we compare the PDGFR beta and fibroblast growth factor receptor 1; each induces essentially identical IEGs in fibroblasts.	Schepens Eye Res Inst, Boston, MA 02114 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Schepens Eye Research Institute; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA.	lander@wi.mit.edu						ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM L, 1995, MOL CELL BIOL, V15, P4553; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; STJOHNSTON D, 1992, CELL, V68, P201; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; TAMAYO P, 1999, IN PRESS P NATL ACAD; TAVERSE S, 1994, CURR BIOL, V4, P694; UENO H, 1993, J BIOL CHEM, V268, P22814; Vaillancourt RR, 1996, ONCOGENE, V13, P151; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618; ZUBIAUR M, 1995, J BIOL CHEM, V270, P17221, DOI 10.1074/jbc.270.29.17221	59	380	394	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					727	741		10.1016/S0092-8674(00)80785-0	http://dx.doi.org/10.1016/S0092-8674(00)80785-0			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380925	Bronze			2022-12-01	WOS:000080886300011
J	Shi, SH; Hayashi, Y; Petralia, RS; Zaman, SH; Wenthold, RJ; Svoboda, K; Malinow, R				Shi, SH; Hayashi, Y; Petralia, RS; Zaman, SH; Wenthold, RJ; Svoboda, K; Malinow, R			Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation	SCIENCE			English	Article							LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; EVOKED DENDRITIC EXOCYTOSIS; GLUTAMATE RECEPTORS; SILENT SYNAPSES; PHOSPHORYLATION; CA1; LTP; TRANSMISSION; EXPRESSION	To monitor changes in alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor distribution in living neurons, the AMPA receptor subunit GluR1 was tagged with green fluorescent protein (GFP), This protein (GluR1-GFP) was functional and was transiently expressed in hippocampal CA1 neurons, in dendrites visualized with two-photon Laser scanning microscopy or electron microscopy, most of the GluR1-GFP was intracellular, mimicking endogenous GluR1 distribution. Tetanic synaptic stimulation induced a rapid delivery of tagged receptors into dendritic spines as well as clusters in dendrites. These postsynaptic trafficking events required synaptic N-methyl-D-aspartate (NMDA) receptor activation and may contribute to the enhanced AMPA receptor-mediated transmission observed during long-term potentiation and activity-dependent synaptic maturation.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; NIDODS, Neurochem Lab, NIH, Bethesda, MD 20892 USA	Cold Spring Harbor Laboratory; National Institutes of Health (NIH) - USA	Malinow, R (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	malinow@cshl.org	Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019	Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004; Zaman, Shahid/0000-0003-1639-6014	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000003, Z01DC000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BenAri Y, 1997, TRENDS NEUROSCI, V20, P523, DOI 10.1016/S0166-2236(97)01147-8; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; Denk W, 1997, NEURON, V18, P351, DOI 10.1016/S0896-6273(00)81237-4; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hayashi Y, 1997, MOL BRAIN RES, V46, P338, DOI 10.1016/S0169-328X(97)00073-9; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; MAINEN ZF, IN PRESS METHODS; Maletic-Savatic M, 1998, J NEUROSCI, V18, P6814; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Maletic-Savatic M, 1998, J NEUROSCI, V18, P6803; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, IN PRESS IMAGING LIV; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MULLER D, 1988, P NATL ACAD SCI USA, V85, P9346, DOI 10.1073/pnas.85.23.9346; Musleh W, 1997, P NATL ACAD SCI USA, V94, P9451, DOI 10.1073/pnas.94.17.9451; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Nusser Z, 1998, NEURON, V21, P545, DOI 10.1016/S0896-6273(00)80565-6; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Petralia RS, 1997, J COMP NEUROL, V385, P456, DOI 10.1002/(SICI)1096-9861(19970901)385:3<456::AID-CNE9>3.0.CO;2-2; Petralia RS, 1999, NAT NEUROSCI, V2, P31, DOI 10.1038/4532; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Takechi H, 1998, NATURE, V396, P757, DOI 10.1038/25547; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Worley P, 1998, NEURON, V21, P936, DOI 10.1016/S0896-6273(00)80609-1; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	42	972	1005	0	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1999	284	5421					1811	1816		10.1126/science.284.5421.1811	http://dx.doi.org/10.1126/science.284.5421.1811			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364548				2022-12-01	WOS:000080809000042
J	Wu, Q; Maniatis, T				Wu, Q; Maniatis, T			A striking organization of a large family of human neural cadherin-like cell adhesion genes	CELL			English	Article							CLASSIC CADHERINS; STRUCTURAL BASIS; NERVOUS-SYSTEM; N-CADHERIN; EXPRESSION; SUPERFAMILY; MOLECULES; PROTEIN; PROTOCADHERINS; COMPLEX	We have identified 52 novel human cadherin-like genes organized into three closely linked clusters. Comparison of the genomic DNA sequences with those of representative cDNAs reveals a striking genomic organization similar to that of immunoglobulin and T cell receptor gene clusters. The N-terminal extracellular and transmembrane domains of each cadherin protein are encoded by a distinct and unusually large exon. These exons are organized in a tandem array. By contrast, the C-terminal cytoplasmic domain of each protein is identical and is encoded by three small exons located downstream from the cluster of N-terminal exons. This unusual organization has interesting implications regarding the molecular code required to establish complex networks of neuronal connections in the brain and the mechanisms of cell-specific cadherin-like gene expression.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Maniatis, T (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.		Wu, Qiang/A-6751-2009	Wu, Qiang/0000-0003-3841-3591	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arndt K, 1998, MOL CELL NEUROSCI, V10, P211, DOI 10.1006/mcne.1998.0665; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Bradley RS, 1998, CURR BIOL, V8, P325, DOI 10.1016/S0960-9822(98)70132-0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Chun J, 1999, NEURON, V22, P7, DOI 10.1016/S0896-6273(00)80671-6; Colman DR, 1997, MOL CELL NEUROSCI, V10, P1, DOI 10.1006/mcne.1997.0648; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hagler DJ, 1998, NEURON, V20, P1059, DOI 10.1016/S0896-6273(00)80486-9; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Hirano S, 1999, J NEUROSCI, V19, P995; Inoue A, 1997, SCIENCE, V276, P1428, DOI 10.1126/science.276.5317.1428; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Matsunami H, 1995, DEV BIOL, V172, P466, DOI 10.1006/dbio.1995.8029; MISHKEVICH F, 1998, MOL CELL NEUROSCI, V12, P240; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OBATA S, 1995, J CELL SCI, V108, P3765; Obata S, 1998, CELL ADHES COMMUN, V6, P323, DOI 10.3109/15419069809010791; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; SAGO H, 1995, GENOMICS, V29, P631, DOI 10.1006/geno.1995.9956; Sanes JR, 1999, CURR OPIN NEUROBIOL, V9, P79, DOI 10.1016/S0959-4388(99)80010-5; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Serafini T, 1997, TRENDS NEUROSCI, V20, P322; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1998, CURR OPIN NEUROBIOL, V8, P593, DOI 10.1016/S0959-4388(98)80086-X; Strehl S, 1998, GENOMICS, V53, P81, DOI 10.1006/geno.1998.5467; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Suzuki ST, 1996, J CELL BIOCHEM, V61, P531, DOI 10.1002/(SICI)1097-4644(19960616)61:4<531::AID-JCB6>3.0.CO;2-P; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	55	543	618	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					779	790		10.1016/S0092-8674(00)80789-8	http://dx.doi.org/10.1016/S0092-8674(00)80789-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380929	Bronze			2022-12-01	WOS:000080886300015
J	Oda, R; Huc, I; Schmutz, M; Candau, SJ; MacKintosh, FC				Oda, R; Huc, I; Schmutz, M; Candau, SJ; MacKintosh, FC			Tuning bilayer twist using chiral counterions	NATURE			English	Article							LIPID TUBULES; HELICAL CRYSTALLIZATION; SURFACTANTS; MORPHOLOGY; DEPENDENCE; MEMBRANES; RIBBONS	From seashells to DNA, chirality is expressed at every level of biological structures. In self-assembled structures it may emerge cooperatively from chirality at the molecular scale. Amphiphilic molecules, for example, can form a variety of aggregates and mesophases that express the chirality of their constituent molecules at a supramolecular scale of micrometres (refs 1-3), Quantitative prediction of the large-scale chirality based on that at the molecular scale remains a largely unsolved problem. Furthermore, experimental control over the expression of chirality at the supramolecular level is difficult to achieve(4-7): mixing of different enantiomers usually results in phase separation(18). Here we present an experimental and theoretical description of a system in which chirality can be varied continuously and controllably ('tuned') in micrometre-scale structures. we observe the formation of twisted ribbons consisting of bilayers of gemini surfactants (two surfactant molecules covalently linked at their charged head groups). We find that the degree of twist and the pitch of the ribbons can be tuned by the introduction of opposite-handed chiral counterions in various proportions. This degree of control might be of practical value; for example, in the use of the helical structures as templates for helical crystallization of macromolecules(8,9).	ENSCPB, Inst Europeen Chim & Biol, F-33402 Talence, France; Lab Dynam Fluides Complexes, F-67000 Strasbourg, France; ULP, Inst Genet & Biol Mol & Cellulaire, INSERM, CNRS, F-67404 Illkirch, France; Univ Michigan, Dept Phys, Ann Arbor, MI 48109 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Michigan System; University of Michigan	Oda, R (corresponding author), ENSCPB, Inst Europeen Chim & Biol, Av Pey Berland,BP 108, F-33402 Talence, France.		Schmutz, Marc/A-4953-2012; oda, reiko/B-2214-2013; Oda, Reiko/AAE-4185-2021; MacKintosh, Fred C/A-9450-2008; MacKintosh, Frederick/AAB-9332-2021	Schmutz, Marc/0000-0003-4059-7609; MacKintosh, Fred C/0000-0002-2607-9541; MacKintosh, Frederick/0000-0002-2607-9541; oda, reiko/0000-0003-3273-8635				CHUNG DS, 1993, P NATL ACAD SCI USA, V90, P11341, DOI 10.1073/pnas.90.23.11341; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; FUHRHOP JH, 1993, CHEM REV, V93, P1565, DOI 10.1021/cr00020a008; HELFRICH W, 1988, PHYS REV A, V38, P3065, DOI 10.1103/PhysRevA.38.3065; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; Oda R, 1998, ANGEW CHEM INT EDIT, V37, P2689, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2689::AID-ANIE2689>3.0.CO;2-Z; Oda R, 1999, LANGMUIR, V15, P2384, DOI 10.1021/la9814889; Prins LJ, 1999, NATURE, V398, P498, DOI 10.1038/19053; Ringler P, 1997, CHEM-EUR J, V3, P620, DOI 10.1002/chem.19970030419; Rowan AE, 1998, ANGEW CHEM INT EDIT, V37, P63, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<63::AID-ANIE63>3.0.CO;2-4; SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669; Selinger JV, 1996, PHYS REV E, V53, P3804, DOI 10.1103/PhysRevE.53.3804; SINGH A, 1988, CHEM PHYS LIPIDS, V47, P135, DOI 10.1016/0009-3084(88)90083-7; Spector MS, 1998, LANGMUIR, V14, P3493, DOI 10.1021/la980086y; THOMAS BN, 1995, SCIENCE, V267, P1635, DOI 10.1126/science.267.5204.1635; Wilson-Kubalek EM, 1998, P NATL ACAD SCI USA, V95, P8040, DOI 10.1073/pnas.95.14.8040; Yashima E, 1999, NATURE, V399, P449, DOI 10.1038/20900; ZANA R, 1993, NATURE, V362, P228, DOI 10.1038/362228a0	18	562	563	3	222	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					566	569		10.1038/21154	http://dx.doi.org/10.1038/21154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376596	Green Published			2022-12-01	WOS:000080778400050
J	Sugiura, R; Toda, T; Dhut, S; Shuntoh, H; Kuno, T				Sugiura, R; Toda, T; Dhut, S; Shuntoh, H; Kuno, T			The MAPK kinase Pek1 acts as a phosphorylation-dependent molecular switch	NATURE			English	Article							FISSION YEAST; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; GENE; PATHWAY; GROWTH; STRESS; MEK; INTEGRITY; POLARITY	The mitogen-activated protein kinase (MAPK) pathway is a highly conserved eukaryotic signalling: cascade that converts extracellular signals into various outputs, such as cell growth and differentiation(1-3), MAPK is phosphorylated and activated by a specific MAPK kinase (MAPKK)(4): MAPKK is therefore considered to be an activating regulator of MAPK. Pmk1 is a MAPK that regulates cell integrity(5) and which, with calcineurin phosphatase, antagonizes chloride homeostasis(6) in fission yeast. We have now identified Pek1, a MAPKK for Pmk1 MAPK. We show here that Pek1, in its unphosphorylated form, acts as a potent negative regulator of Pmk1 MAPK sig-nailing. Mkh1(7), an upstream MAPKK kinase (MAPKKK), converts Pek1 from being an inhibitor to an activator. Our results indicate that Pek1 has a dual stimulatory and inhibitory function which depends on its phosphorylation state. This switch-like mechanism could contribute to the all-or-none physiological response mediated by the MAPK signalling pathway.	Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, Kobe, Hyogo 6500017, Japan; Imperial Canc Res Fund, Cell Regulat Lab, London WC2A 3PX, England; Kobe Univ, Sch Med, Fac Hlth Sci, Suma Ku, Kobe, Hyogo 6500142, Japan	Kobe University; Cancer Research UK; Kobe University	Kuno, T (corresponding author), Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tkuno@kobe-u.ac.jp						BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BEACH D, 1982, MOL GEN GENET, V187, P326, DOI 10.1007/BF00331138; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murray AW, 1998, CELL, V92, P157, DOI 10.1016/S0092-8674(00)80910-1; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sengar AS, 1997, MOL CELL BIOL, V17, P3508, DOI 10.1128/MCB.17.7.3508; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toda T, 1996, MOL CELL BIOL, V16, P6752; YOSHIDA T, 1994, J CELL SCI, V107, P1725; ZaitsevskayaCarter T, 1997, EMBO J, V16, P1318, DOI 10.1093/emboj/16.6.1318; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	27	67	72	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 3	1999	399	6735					479	483		10.1038/20951	http://dx.doi.org/10.1038/20951			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365961				2022-12-01	WOS:000080667900051
J	Sharp, TG; El Goresy, A; Wopenka, B; Chen, M				Sharp, TG; El Goresy, A; Wopenka, B; Chen, M			A post-stishovite SiO2 polymorph in the meteorite Shergotty: Implications for impact events	SCIENCE			English	Article							LOWER-MANTLE PRESSURES; ELNES SPECTROSCOPY; PEROVSKITE MGSIO3; PHASE-TRANSITION; SILICA; TRANSFORMATIONS; DISSOCIATION; TEMPERATURE; CHONDRITES	Transmission electron microscopy and electron diffraction show that the martian meteorite Shergotty, a shocked achondrite, contains a dense orthorhombic SiO2 phase similar to post-stishovite SiO2 with the alpha-PbO2 structure. If an SiO2 mineral exists in Earth's Lower mantle, it would probably occur in a post-stishovite SiO2 structure, The presence of such a high-density polymorph in a shocked sample indicates that post-stishovite SiO2 structures may be used as indicators of extreme shock pressures.	Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Max Planck Inst Kernphys, D-69029 Heidelberg, Germany; Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; Acad Sinica, Guangzhou Inst Geochem, Guangzhou 510640, Peoples R China	Arizona State University; Arizona State University-Tempe; Max Planck Society; Washington University (WUSTL); Chinese Academy of Sciences; Guangzhou Institute of Geochemistry, CAS	Sharp, TG (corresponding author), Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA.							AHRENS TJ, 1996, ADV MAT 96 NEW TREND, P1; Belonoshko AB, 1996, AM MINERAL, V81, P785; BOGARD D, 1987, GEOCHIM COSMOCHIM AC, V51, P2035, DOI 10.1016/0016-7037(87)90192-X; CHAO ECT, 1962, J GEOPHYS RES, V67, P419, DOI 10.1029/JZ067i001p00419; Dubrovinsky LS, 1997, NATURE, V388, P362, DOI 10.1038/41066; ElGoresy A, 1997, METEORIT PLANET SCI, V32, pA38; ELGORESY A, 1998, LUNAR PLANET SCI C, V29, P1707; GALEENER FL, 1982, J NON-CRYST SOLIDS, V49, P53, DOI 10.1016/0022-3093(82)90108-9; German V. N., 1973, Soviet Physics - JETP, V37; GILLET P, 1984, EARTH PLANET SC LETT, V70, P426, DOI 10.1016/0012-821X(84)90026-8; HEANEY PJ, 1994, REV MINERAL, V29, P1; HEMLEY RJ, 1994, REV MINERAL, V29, P41; HEMLEY RJ, 1986, PHYS REV LETT, V57, P747, DOI 10.1103/PhysRevLett.57.747; Karki BB, 1997, PHYS REV B, V55, P3465, DOI 10.1103/PhysRevB.55.3465; KINGMA KJ, 1995, NATURE, V374, P243, DOI 10.1038/374243a0; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; LIU LG, 1978, J GEOPHYS RES, V83, P2301, DOI 10.1029/JB083iB05p02301; MCMILLAN P, 1984, J CHEM PHYS, V81, P4234, DOI 10.1063/1.447455; MEADE C, 1995, SCIENCE, V268, P1743, DOI 10.1126/science.268.5218.1743; Poe B, 1997, PHYS CHEM MINER, V24, P477, DOI 10.1007/s002690050062; Saxena SK, 1998, EUR J MINERAL, V10, P1275; Saxena SK, 1996, SCIENCE, V274, P1357, DOI 10.1126/science.274.5291.1357; SCHMITT RT, 1995, METEORITICS, V30, P574; SEKINE T, 1987, GEOCHIM COSMOCHIM AC, V51, P379, DOI 10.1016/0016-7037(87)90250-X; Sharp T, 1996, PHYS CHEM MINER, V23, P17, DOI 10.1007/BF00202989; Sharp TG, 1998, METEORIT PLANET SCI, V33, pA144; Sharp TG, 1997, SCIENCE, V277, P352, DOI 10.1126/science.277.5324.352; SMITH JV, 1979, METEORITICS, V14, P121, DOI 10.1111/j.1945-5100.1979.tb00486.x; Stishov S., 1961, GEOCHEMISTRY-USSR, P837; STOFFLER D, 1986, GEOCHIM COSMOCHIM AC, V50, P889, DOI 10.1016/0016-7037(86)90371-6; Stoffler D., 1988, METEORITES EARLY SOL, P165; STOLPER EM, 1979, GEOCHIM COSMOCHIM AC, V43, P598; Teter DM, 1998, PHYS REV LETT, V80, P2145, DOI 10.1103/PhysRevLett.80.2145; Tomioka N, 1997, SCIENCE, V277, P1084, DOI 10.1126/science.277.5329.1084; TSCHERMAK MG, 1872, SITZUNGSBERICHTE MAT, V65, P122; TSUCHIDA Y, 1990, NATURE, V347, P267, DOI 10.1038/347267a0; TSUCHIDA Y, 1989, NATURE, V339, P209; Xie X, 1997, METEORIT PLANET SCI, V32, pA143	38	109	121	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1511	1513		10.1126/science.284.5419.1511	http://dx.doi.org/10.1126/science.284.5419.1511			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348735				2022-12-01	WOS:000080548100032
J	Voisine, C; Craig, EA; Zufall, N; von Ahsen, O; Pfanner, N; Voos, W				Voisine, C; Craig, EA; Zufall, N; von Ahsen, O; Pfanner, N; Voos, W			The protein import motor of mitochondria: Unfolding and trapping of preproteins ave distinct and separable functions of matrix Hsp70	CELL			English	Article							HEAT-SHOCK PROTEIN-70; INTERMEMBRANE SPACE; PRECURSOR PROTEINS; INNER MEMBRANE; SORTING SIGNAL; ATP HYDROLYSIS; TRANSLOCATION; COMPLEX; BINDING; REQUIREMENT	Mitochondrial heat shock protein 70 (mtHsp70) functions in unfolding, translocation, and folding of imported proteins. Controversial models of mtHsp70 action have been discussed: (1) physical trapping of preproteins is sufficient to explain the various mtHsp70 functions, and (2) unfolding of preproteins requires an active motor function of mtHsp70 ("pulling"). Intragenic suppressors of a mutant mtHsp70 separate two functions: a nonlethal folding defect caused by enhanced trapping of preproteins, and a conditionally lethal unfolding defect caused by an impaired interaction of mtHsp70 with the membrane anchor Tim44. Even enhanced trapping in wild-type mitochondria does not generate a pulling force. The motor function of mtHsp70 cannot be explained by passive trapping alone but includes an essential ATP-dependent interaction with Tim44 to generate a pulling force and unfold preproteins.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Freiburg	Craig, EA (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.		Pfanner, Nikolaus/AAV-7878-2021; Voisine, Cindy/AAG-9045-2019	Voisine, Cindy/0000-0001-7165-9636	NIGMS NIH HHS [GM27870, 5T32GM08349] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870, T32GM008349] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bomer U, 1997, EMBO J, V16, P2205, DOI 10.1093/emboj/16.9.2205; Bomer U, 1998, EMBO J, V17, P4226, DOI 10.1093/emboj/17.15.4226; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; Chauwin JF, 1998, BIOPHYS J, V74, P1732, DOI 10.1016/S0006-3495(98)77884-1; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; GARTNER F, 1995, EMBO J, V14, P6043, DOI 10.1002/j.1460-2075.1995.tb00293.x; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Horst M, 1996, PROTEIN SCI, V5, P759; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; ORRWEAVER TL, 1988, MOL CELL BIOL, V8, P5292, DOI 10.1128/MCB.8.12.5292; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PFANNER N, 1995, CURR BIOL, V5, P132; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; VONAHSEN O, 1995, J BIOL CHEM, V270, P29848; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	40	205	214	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					565	574		10.1016/S0092-8674(00)80768-0	http://dx.doi.org/10.1016/S0092-8674(00)80768-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367886	Bronze			2022-12-01	WOS:000080672100006
J	Ybe, JA; Brodsky, FM; Hofmann, K; Lin, K; Liu, SH; Chen, L; Earnest, TN; Fletterick, RJ; Hwang, PK				Ybe, JA; Brodsky, FM; Hofmann, K; Lin, K; Liu, SH; Chen, L; Earnest, TN; Fletterick, RJ; Hwang, PK			Clathrin self-assembly is mediated by a tandemly repeated superhelix	NATURE			English	Article							PROTEIN COMPLEX; TRIMERIZATION; RESOLUTION; PROGRAM; ALPHA; CHAIN	Clathrin is a triskelion-shaped cytoplasmic protein that polymerizes into a polyhedral lattice on intracellular membranes to form protein-coated membrane vesicles. Lattice formation induces the sorting of membrane proteins during endocytosis and organelle biogenesis by interacting with membrane-associated adaptor molecules(1). The clathrin triskelion is a trimer of heavy-chain subunits (1,675 residues), each binding a single light-chain subunit, in the hub domain (residues 1,074-1,675), Light chains negatively modulate polymerization so that intracellular clathrin assembly is adaptor-dependent(2). Here we report the atomic structure, to 2.6 Angstrom resolution, of hub residues 1,210-1,516 involved in mediating spontaneous clathrin heavy-chain polymerization and light-chain association(3,4), The hub fragment folds into an elongated coil of alpha-helices, and alignment analyses reveal a 145-residue motif that is repeated seven times along the filamentous leg and appears in other proteins involved in vacuolar protein sorting. The resulting model provides a three-dimensional framework for understanding clathrin heavy-chain self-assembly, light-chain binding and trimerization.	Univ Calif San Francisco, Dept Microbiol & Immunol, GW Hooper Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; MEMOREC Stoffel Gmbh, Bioinformat Grp, D-50829 Cologne, Germany; Lawrence Berkeley Natl Lab, Phys Biosci Div, Adv Light Source, Macromol Crystallog Facil, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Brodsky, FM (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, GW Hooper Fdn, San Francisco, CA 94143 USA.	fmarbro@itsa.ucsf.edu	Hofmann, Kay/D-6714-2011	Hofmann, Kay/0000-0002-2289-9083; Brodsky, Frances/0000-0002-1334-9258				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bucher P, 1996, COMPUT CHEM, V20, P3, DOI 10.1016/S0097-8485(96)80003-9; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CONIBEAR E, 1996, BIOCHIM BIOPHYS ACTA, V1404, P211; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; Kleywegt G.J., 1994, PROTEIN CRYSTALLOGR, V31, P9; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nakamura N, 1997, J BIOL CHEM, V272, P11344; NATHKE IS, 1992, CELL, V68, P899, DOI 10.1016/0092-8674(92)90033-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peters JW, 1996, NAT STRUCT BIOL, V3, P991, DOI 10.1038/nsb1296-991; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; Terwilliger TC, 1997, METHOD ENZYMOL, V276, P530; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297	30	126	127	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					371	375		10.1038/20708	http://dx.doi.org/10.1038/20708			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360576				2022-12-01	WOS:000080547800063
J	Kannus, P; Parkkari, J; Koskinen, S; Niemi, S; Palvanen, M; Jarvinen, M; Vuori, I				Kannus, P; Parkkari, J; Koskinen, S; Niemi, S; Palvanen, M; Jarvinen, M; Vuori, I			Fall-induced injuries and deaths among older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OSTEOPOROTIC FRACTURES; ELDERLY PEOPLE; RISK; PREVENTION; COMMUNITY; EXERCISE; HOME	Context Although various fall-induced injuries and deaths among older adults are increasing, little is known about the epidemiology of these events. Objective To determine the trends in the number and incidence of fall-induced injuries and deaths of older adults in a well-defined white population. Design and Setting Secular trend analysis of the population of Finland, using the Finnish National Hospital Discharge Register and the Official Cause-of-Death Statistics of Finland. Participants All persons aged 50 years or older who were admitted to hospitals in Finland for primary treatment of a first fall-induced injury from the years of 1970 to 1995, and for com parison, all fall-induced deaths in the same age group from the years 1971 to 1995. Main Outcome Measure The number and the age-specific and age-adjusted incidence rate (per 100 000 persons) of fall-induced injuries and deaths in each year of the study. Results For the study period, both the total and population-adjusted number (per 100 000 persons) of Finns aged 50 years or older with fall-induced injury increased substantially. Total fall-induced injuries increased from 5622 in 1970 to 21 574 in 1995, a 284% increase, and the rate increased from 494 to 1398 per 100 000 persons, a 183% increase. The age-adjusted incidence also increased in both women (from 648 in 1970 to 1469 in 1995, a 127% increase) and men (from 434 in 1970 to 972 in 1995, a 124% increase), Moreover, the number of deaths due to falls in the overall population increased from 441 in 1971 to 793 in 1995, an 80% increase, and the rate increased from 38 in 1971 to 51 in 1995, a 34% increase. However, after age adjustment the incidence of fall-induced death did not show a clear upward trend, Conclusions In a well-defined white population, the number of older persons with fall-induced injuries is increasing at a rate that cannot be explained simply by demographic changes. Preventive measures should be adopted to control the increasing burden of these injuries. Fortunately, the age-adjusted incidence of the fall-induced deaths shows no increasing trend over time.	Tampere Univ, Sch Med, Tampere, Finland; Tampere Univ, Dept Surg, Tampere, Finland; Tampere Univ Hosp, Tampere, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Urho Kaleva Kekkonen Inst Hlth Promot Res, Accident & Trauma Res Ctr, Tampere, Finland; Urho Kaleva Kekkonen Inst Hlth Promot Res, Tampere Res Ctr Sports Med, Tampere, Finland	Tampere University; Tampere University; Tampere University; Tampere University Hospital; Finland National Institute for Health & Welfare	Kannus, P (corresponding author), UKK Inst, Kaupinpuistonkatu 1, FIN-33500 Tampere, Finland.							Campbell AJ, 1997, BMJ-BRIT MED J, V315, P1065, DOI 10.1136/bmj.315.7115.1065; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; GRUNDY E, 1997, OFFICE NATL STAT S, V13, P182; HONKONEN R, 1990, HOSP DUE INJURIES FI, V1; Kannus P, 1996, BRIT MED J, V313, P1051; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; KANNUS P, 1995, LANCET, V346, P50, DOI 10.1016/S0140-6736(95)92679-8; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; KIVELA SL, 1986, SCAND J SOC MED, V14, P31, DOI 10.1177/140349488601400106; LAHTI R, 1996, FINN MED J, V51, P64; LAURITZEN JB, 1993, OSTEOPOROSIS INT, V3, P127, DOI 10.1007/BF01623273; LIIMATTA M, 1994, PUBLICATIONS NATL PU; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; Manton KG, 1997, DEMOGRAPHY, V34, P135, DOI 10.2307/2061664; MELTON LJ, 1993, BONE, V14, pS1; OAKLEY A, 1996, EFFECTIVE HLTH CARE, V2, P1; *OFF STAT FINL, 1996, OFF CAUS OF DEATH ST; *OFF STAT FINL, 1996, STRUCT POP VIT STAT; POHJOLAINEN P, 1997, SCAND J SOC MED, V52, pS1; PROVINCE MA, 1995, JAMA-J AM MED ASSOC, V273, P1341, DOI 10.1001/jama.1995.03520410035023; Rivara FP, 1997, NEW ENGL J MED, V337, P543, DOI 10.1056/NEJM199708213370807; ROMANOV K, 1994, PSYCHOSOM MED, V56, P328, DOI 10.1097/00006842-199407000-00008; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; Salmela R, 1987, SAIRAALA, V49, P480; SATTIN RW, 1998, 4 WORLD C INJ PREV C, P529; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2354; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VANWEEL C, 1995, LANCET, V345, P1549, DOI 10.1016/S0140-6736(95)91091-3	31	381	393	4	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1895	1899		10.1001/jama.281.20.1895	http://dx.doi.org/10.1001/jama.281.20.1895			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198ME	10349892	Bronze			2022-12-01	WOS:000080427300028
J	Schuckit, MA				Schuckit, MA			New findings in the genetics of alcoholism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEN; ASSOCIATION; DEPENDENCE; SAMPLE; ABUSE; TWINS; RISK		Univ Calif San Diego, Sch Med, Dept Psychiat, San Diego, CA 92161 USA; San Diego Vet Affairs Med Ctr, Alcohol & Drug Treatment Program, San Diego, CA USA	University of California System; University of California San Diego	Schuckit, MA (corresponding author), Univ Calif San Diego, Sch Med, Dept Psychiat, 3350 LaJolla Village Dr, San Diego, CA 92161 USA.	mschuckit@ucsd.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA005526, U10AA008403] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA05526, 5U10AA08403] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BAUMEISTER M, 1999, BIOL PSYCHIAT, V45, P522; Begleiter H, 1998, EVOKED POTENTIAL, V108, P244, DOI 10.1016/S0168-5597(98)00002-1; Bierut LJ, 1998, ARCH GEN PSYCHIAT, V55, P982, DOI 10.1001/archpsyc.55.11.982; CHAO HM, 1995, ALCOHOL CLIN EXP RES, V19, P104, DOI 10.1111/j.1530-0277.1995.tb01477.x; Edenberg HJ, 1998, ALCOHOL CLIN EXP RES, V22, P505, DOI 10.1111/j.1530-0277.1998.tb03680.x; Ehlers CL, 1999, BIOL PSYCHIAT, V45, P776, DOI 10.1016/S0006-3223(98)00113-9; GOODWIN DW, 1973, ARCH GEN PSYCHIAT, V28, P238; Heath AC, 1997, PSYCHOL MED, V27, P1381, DOI 10.1017/S0033291797005643; Kendler KS, 1997, ARCH GEN PSYCHIAT, V54, P178; Malhotra AK, 1999, BIOL PSYCHIAT, V45, P544, DOI 10.1016/S0006-3223(98)00365-5; Murayama M, 1998, ALCOHOL CLIN EXP RES, V22, P524, DOI 10.1097/00000374-199804000-00033; Neumark YD, 1998, J STUD ALCOHOL, V59, P133, DOI 10.15288/jsa.1998.59.133; PICKENS RW, 1991, ARCH GEN PSYCHIAT, V48, P19; Prescott CA, 1999, AM J PSYCHIAT, V156, P34, DOI 10.1176/ajp.156.1.34; Sander T, 1998, ALCOHOL CLIN EXP RES, V22, P2108, DOI 10.1097/00000374-199812000-00030; Schuckit MA, 1996, ARCH GEN PSYCHIAT, V53, P202; Schuckit MA, 1998, J STUD ALCOHOL, V59, P485, DOI 10.15288/jsa.1998.59.485; Schuckit MA, 1999, BIOL PSYCHIAT, V45, P647, DOI 10.1016/S0006-3223(98)00248-0; SCHUCKIT MA, 1972, AM J PSYCHIAT, V128, P1132, DOI 10.1176/ajp.128.9.1132; Tsuang MT, 1998, ARCH GEN PSYCHIAT, V55, P967, DOI 10.1001/archpsyc.55.11.967; Wall TL, 1995, ALCOHOL HEALTH RES W, V19, P184	21	51	51	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1875	1876		10.1001/jama.281.20.1875	http://dx.doi.org/10.1001/jama.281.20.1875			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198ME	10349877				2022-12-01	WOS:000080427300001
J	Ohba, T; Nakamura, M; Nishitani, H; Nishimoto, T				Ohba, T; Nakamura, M; Nishitani, H; Nishimoto, T			Self-organization of microtubule asters induced in Xenopus egg extracts by GTP-bound Ran	SCIENCE			English	Article							GAMMA-TUBULIN; NUCLEOTIDE EXCHANGE; CYTOPLASMIC DYNEIN; RING COMPLEX; RCC1; CENTROSOME; PROTEIN; NUCLEATION; REGULATOR; TRANSPORT	The nucleotide exchange activity of RCC1,the only known nucleotide exchange factor for Ran, a Ras-like small guanosine triphosphatase, was required for microtubule aster formation with or without demembranated sperm in Xenopus egg extracts arrested in meiosis II. Consistently, in the RCC1-depleted egg extracts, Ran guanosine triphosphate (RanGTP), but not Ran guanosine diphosphate (RanGDP), induced self-organization of microtubule asters, and the process required the activity of dynein. Thus, Ran was shown to regulate formation of the microtubule network.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Maidashi Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Nishimoto, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Maidashi Higashi Ku, Fukuoka 8128582, Japan.		Oba, Tomoyuki/ABT-2152-2022	Oba, Tomoyuki/0000-0002-6715-7892; Nishitani, Hideo/0000-0001-5907-9380				Azuma Y, 1996, J BIOCHEM-TOKYO, V120, P82; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; Martin OC, 1998, J CELL BIOL, V141, P675, DOI 10.1083/jcb.141.3.675; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Oki M, 1998, MOL GEN GENET, V257, P624; Pereira G, 1997, J CELL SCI, V110, P295; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; Seki T, 1996, J BIOCHEM, V120, P207; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	28	247	250	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1356	1358		10.1126/science.284.5418.1356	http://dx.doi.org/10.1126/science.284.5418.1356			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334990				2022-12-01	WOS:000080430600053
J	Greenberg, RA; Chin, L; Femino, A; Lee, KH; Gottlieb, GJ; Singer, RH; Greider, CW; DePinho, RA				Greenberg, RA; Chin, L; Femino, A; Lee, KH; Gottlieb, GJ; Singer, RH; Greider, CW; DePinho, RA			Short dysfunctional telomeres impair tumorigenesis in the INK4a(Delta 2/3) cancer-prone mouse	CELL			English	Article							ARF TUMOR-SUPPRESSOR; IMMORTAL HUMAN-CELLS; LIFE-SPAN; P53-DEPENDENT APOPTOSIS; CELLULAR SENESCENCE; LACKING TELOMERASE; HUMAN FIBROBLASTS; FISSION YEAST; INK4A LOCUS; P53	Maintenance of telomere length is predicted to be essential for bypass of senescence and crisis checkpoints in cancer cells. The impact of telomere dysfunction on tumorigenesis was assessed in successive generations of mice doubly null for the telomerase RNA (mTR) and the INK4a tumor suppressor genes. Significant reductions in tumor formation in vivo and oncogenic potential in vitro were observed in late generations of telomerase deficiency, coincident with severe telomere shortening and associated dysfunction. Reintroduction of mTR into cells significantly restored the oncogenic potential, indicating telomerase activation is a cooperating event in the malignant transformation of cells containing critically short telomeres. The results described here demonstrate that loss of telomere function in a cancer-prone mouse model possessing intact DNA damage responses impairs, but does not prevent, tumor formation.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Struct Biol & Anat, Bronx, NY 10461 USA; Quest Diagnost Inc, Anat Pathol, Teterboro, NJ USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CA16519] Funding Source: Medline; NICHD NIH HHS [HD348880, HD28317] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bacchetti S, 1996, CANCER SURV, V28, P197; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bednarek AK, 1997, MOL CARCINOGEN, V20, P329, DOI 10.1002/(SICI)1098-2744(199712)20:4<329::AID-MC1>3.0.CO;2-E; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, ONCOGENE, V11, P893; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Conzen SD, 1995, ONCOGENE, V11, P2295; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DYKHUIZEN D, 1974, NATURE, V251, P616, DOI 10.1038/251616a0; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1991, GENOMICS, V11, P235, DOI 10.1016/0888-7543(91)90128-2; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; PALERMO I, 1998, NATURE, V395, P125; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	57	316	329	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					515	525		10.1016/S0092-8674(00)80761-8	http://dx.doi.org/10.1016/S0092-8674(00)80761-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338215	Bronze			2022-12-01	WOS:000080299100012
J	Yoon, JW; Yoon, CS; Lim, HW; Huang, QQ; Kang, Y; Pyun, KH; Hirasawa, K; Sherwin, RS; Jun, HS				Yoon, JW; Yoon, CS; Lim, HW; Huang, QQ; Kang, Y; Pyun, KH; Hirasawa, K; Sherwin, RS; Jun, HS			Control of autoimmune diabetes in NOD mice by CAD expression or suppression in beta cells	SCIENCE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; T-CELLS; TRANSGENIC MICE; LYMPHOCYTES; DESTRUCTION; MELLITUS; MOUSE; CD4+; IDENTIFICATION; PREVENTION	Glutamic acid decarboxylase (GAD) is a pancreatic beta cell autoantigen in humans and nonobese diabetic (NOD) mice. beta Cell-specific suppression of GAD expression in two Lines of antisense CAD transgenic NOD mice prevented autoimmune diabetes, whereas persistent GAD expression in the beta cells in the other four Lines of antisense CAD transgenic NOD mice resulted in diabetes, similar to that seen in transgene-negative NOD mice. Complete suppression of beta cell GAD expression blocked the generation of diabetogenic T cells and protected islet grafts from autoimmune injury. Thus, beta cell-specific CAD expression is required for the development of autoimmune diabetes in NOD mice, and modulation of GAD might, therefore, have therapeutic value in type 1 diabetes.	Univ Calgary, Fac Med, Julia McFarlane Diabet Res Ctr, Lab Viral & Immunopathogenesis Diabet, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Ajou Univ, Sch Med, Dept Endocrinol & Metab, Lab Endocrinol,Inst Med Sci, Suwon 442749, South Korea; Yale Univ, Sch Med, Diabet Endocrinol Res Ctr, New Haven, CT 06520 USA; Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea	University of Calgary; University of Calgary; Ajou University; Yale University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Yoon, JW (corresponding author), Univ Calgary, Fac Med, Julia McFarlane Diabet Res Ctr, Lab Viral & Immunopathogenesis Diabet, Calgary, AB T2N 4N1, Canada.			Jun, Hee-Sook/0000-0002-1166-4932	NIDDK NIH HHS [DK 53015-01, DK 45735] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, P01DK053015] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; ELLIOTT JF, 1994, DIABETES, V43, P1494, DOI 10.2337/diabetes.43.12.1494; Endl J, 1997, J CLIN INVEST, V99, P2405, DOI 10.1172/JCI119423; GILON P, 1991, HISTOCHEMISTRY, V96, P355, DOI 10.1007/BF00271357; GORDON JW, 1993, METHOD ENZYMOL, V225, P747; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; KANG YK, UNPUB; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KAWAMURA T, 1993, J IMMUNOL, V151, P4362; NAGATA M, 1992, DIABETES, V41, P998, DOI 10.2337/diabetes.41.8.998; NAGATA M, 1994, J IMMUNOL, V152, P2042; Rossini A.A., 1993, DIABETES REV ALEX, V1, P43; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; UTSUGI T, 1994, TRANSPLANTATION, V57, P1799, DOI 10.1097/00007890-199406270-00020; Wong FS, 1997, RES IMMUNOL, V148, P327, DOI 10.1016/S0923-2494(97)87242-2; YOON JW, 1982, NATURE, V296, P566, DOI 10.1038/296566a0; YOON JW, 1976, NATURE, V264, P178, DOI 10.1038/264178a0; Yoon JW, 1998, AUTOIMMUNITY, V27, P109, DOI 10.3109/08916939809008041; Zekzer D, 1998, J CLIN INVEST, V101, P68, DOI 10.1172/JCI119878	23	210	224	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1183	1187		10.1126/science.284.5417.1183	http://dx.doi.org/10.1126/science.284.5417.1183			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325232				2022-12-01	WOS:000080359100042
J	Lee, A; Wong, ST; Gallagher, D; Li, B; Storm, DR; Scheuer, T; Catterall, WA				Lee, A; Wong, ST; Gallagher, D; Li, B; Storm, DR; Scheuer, T; Catterall, WA			Ca2+/calmodulin binds to and modulates P/Q-type calcium channels	NATURE			English	Article							BETA-GAMMA-SUBUNITS; RAT BRAIN-STEM; CA2+ CHANNELS; CALMODULIN-BINDING; SUBCELLULAR-DISTRIBUTION; ALPHA(1A) SUBUNITS; PROTEIN; INACTIVATION; MECHANISM; SYNAPSE	Neurotransmitter release at many central synapses is initiated by an influx of calcium ions through P/Q-type calcium channels(1,2), which are densely localized in nerve terminals(3). Because neurotransmitter release is proportional to the fourth power of calcium concentration(4,5), regulation of its entry can profoundly influence neurotransmission. N- and P/Q-type calcium channels are inhibited by G proteins(6,7), and recent evidence indicates feedback regulation of P/Q-type channels by calcium(8). Although calcium-dependent inactivation of L-type channels is well documented(9-11), little is known about how calcium modulates P/Q-type channels. Here we report a calcium-dependent interaction between calmodulin and a novel site in the carboxy-terminal domain of the cu,A subunit of P/Q-type channels. In the presence of low concentrations of intracellular calcium chelators, calcium influx through P/Q-type channels enhances channel inactivation, increases recovery from inactivation and produces a long-lasting facilitation of the calcium current. These effects are prevented by overexpression of a calmodulin-binding inhibitor peptide and by deletion of the calmodulin-binding domain. Our results reveal an unexpected association of Ca2+/calmodulin with P/Q-type calcium channels that may contribute to calcium-dependent synaptic plasticity.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	wcatt@u.washington.edu		Lee, Amy/0000-0001-8021-0443				Borst JGG, 1998, J PHYSIOL-LONDON, V513, P149, DOI 10.1111/j.1469-7793.1998.149by.x; Cuttle MF, 1998, J PHYSIOL-LONDON, V512, P723, DOI 10.1111/j.1469-7793.1998.723bd.x; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Forsythe ID, 1998, NEURON, V20, P797, DOI 10.1016/S0896-6273(00)81017-X; HARPER JW, 1993, CELL, V75, P805; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Hofer GF, 1997, BIOPHYS J, V73, P1857, DOI 10.1016/S0006-3495(97)78216-X; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; Peterson BZ, 1999, BIOPHYS J, V76, pA340; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; Sakurai T, 1996, J CELL BIOL, V134, P511, DOI 10.1083/jcb.134.2.511; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TEO TS, 1973, J BIOL CHEM, V248, P5950; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; vonGersdorff H, 1996, J NEUROSCI, V16, P115; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WU ZL, 1993, J BIOL CHEM, V268, P23766; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zuhlke RD, 1999, BIOPHYS J, V76, pA343	30	395	403	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1999	399	6732					155	159		10.1038/20194	http://dx.doi.org/10.1038/20194			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335845				2022-12-01	WOS:000080335700051
J	Manos, MM; Kinney, WK; Hurley, LB; Sherman, ME; Shieh-Ngai, J; Kurman, RJ; Ransley, JE; Fetterman, BJ; Hartinger, JS; McIntosh, KM; Pawlick, GF; Hiatt, RA				Manos, MM; Kinney, WK; Hurley, LB; Sherman, ME; Shieh-Ngai, J; Kurman, RJ; Ransley, JE; Fetterman, BJ; Hartinger, JS; McIntosh, KM; Pawlick, GF; Hiatt, RA			Identifying women with cervical neoplasia - Using human papillomavirus DNA testing for equivocal Papanicolaou results	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THINPREP PAP TEST; ATYPICAL SQUAMOUS CELLS; UNDETERMINED SIGNIFICANCE; QUALITY ASSURANCE; SMEAR REPORTS; MANAGEMENT; EXPERIENCE; DIAGNOSES; CYTOLOGY; RISK	Context A Papanicolaou (Pap) test result of atypical squamous cells of undetermined significance (ASCUS) presents a clinical challenge. Only 5% to 10% of women with ASCUS harbor serious cervical disease, but more than one third of the high-grade squamous intraepithelial lesions (HSILs) in screening populations are identified from ASCUS Pap test results. Objective To determine whether human papillomavirus (HPV) DNA testing of residual material from liquid-based Pap tests and referral of cases found to be HPV-positive directly to colposcopy could provide sensitive detection of underlying HSILs in women with ASCUS Pap results, compared with repeat Pap testing. Design and Setting Natural history of women with ASCUS Pap smear results, all of whom had liquid-based cytology, HPV testing, and subsequent repeat Pap tests and colposcopy with histologic evaluation, conducted at 12 gynecology clinics in a targe managed care organization between October 1995 and June 1996. Participants From a cohort of 46 009 women who had routine cervical examinations, 995 women with Pap test results of ASCUS who consented to participate were identified. Main Outcome Measures Cervical histology, HPV test results, and repeat Pap smear results, and sensitivity of HPV testing to identify patients found to have HSIL+ histology. Results Of 995 participants with ASCUS Pap test results, 973 had both a definitive histologic diagnosis and HPV result. Sixty-five (6.7%) had histologic HSIL or cancer. For women with histologic HSIL+, the HPV test was positive in 89.2% (95% confidence interval [CI], 78.4%-95.2%), and the specificity was 64.1% (95% CI, 60.9%-67.2%). The repeat Pap smear result was abnormal in 76.2% (95% CI, 63.5%-85.7%). Triage based on HPV testing only or on repeat Pap testing only would refer similar proportions (approximately 39%) to colposcopy. The sensitivity of HPV DNA testing for HSIL was equivalent to, if not greater than, that of the repeat Pap test. We further estimated that an HPV-based algorithm including the immediate colposcopy of HPV-positive women, and then repeat Pap testing of all others, would provide an overall sensitivity of 96.9% (95% CI, 88.3%-99.5%). Conclusions For women with ASCUS Pap tests, HPV DNA testing of residual specimens collected for routine cervical cytology can help identify those who have underlying HSIL. By testing the specimen collected at initial screening, the majority of highrisk cases can be identified and referred for colposcopy based on a single screening.	No Calif Kaiser Permanente Med Grp, Div Res, Oakland, CA USA; No Calif Kaiser Permanente Med Grp, Div Gynecol Oncol, Oakland, CA USA; No Calif Kaiser Permanente Med Grp, Dept Pathol, Oakland, CA USA; No Calif Kaiser Permanente Med Grp, Reg Lab, Oakland, CA USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Obstet & Gynecol, Baltimore, MD 21205 USA	Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Manos, MM (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3505 Broadway, Oakland, CA 94611 USA.		Hiatt, Robert/AAQ-1537-2021					Bishop JW, 1997, ACTA CYTOL, V41, P269, DOI 10.1159/000332511; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Corkill M, 1998, J Low Genit Tract Dis, V2, P12, DOI 10.1097/00128360-199801000-00003; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; COX JT, 1996, HUMAN PAPILLOMAVIRUS, V2, P811; *CYT SOFTW CORP, 1996, STATX 3 WIND US MAN; DAVEY DD, 1994, DIAGN CYTOPATHOL, V11, P390, DOI 10.1002/dc.2840110416; Dupree WB, 1998, CANCER CYTOPATHOL, V84, P202, DOI 10.1002/(SICI)1097-0142(19980825)84:4<202::AID-CNCR4>3.0.CO;2-O; Ferenczy A, 1996, AM J OBSTET GYNECOL, V175, P651; FERENCZY A, 1995, INT J GYNECOL CANCER, V5, P321, DOI 10.1046/j.1525-1438.1995.05050321.x; Ferris DG, 1998, J FAM PRACTICE, V46, P125; Ferris DG, 1998, J FAM PRACTICE, V46, P136; Fleiss J.L., 1981, STAT METHODS RATES P; Kinney WK, 1998, OBSTET GYNECOL, V91, P973, DOI 10.1016/S0029-7844(98)00080-5; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; Lee KR, 1997, OBSTET GYNECOL, V90, P278, DOI 10.1016/S0029-7844(97)00228-7; Linder J, 1997, ACTA CYTOL, V41, P30, DOI 10.1159/000332302; LORINCZ A, 1996, PAPILLOMAVIRUS REPOR, V7, P1; Papillo JL, 1998, ACTA CYTOL, V42, P203, DOI 10.1159/000331547; Roberts JM, 1997, MED J AUSTRALIA, V167, P466, DOI 10.5694/j.1326-5377.1997.tb126672.x; RONNETT BM, IN PRESS HUM PATHOL; *SAS I INC, 1977, SAS STAT SOFTW CHANG; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SHERMAN ME, 1994, AM J CLIN PATHOL, V102, P182, DOI 10.1093/ajcp/102.2.182; Sherman ME, 1997, CANCER CYTOPATHOL, V81, P89; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; Wright TC, 1998, AM J OBSTET GYNECOL, V178, P962, DOI 10.1016/S0002-9378(98)70531-9; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L	29	435	460	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1605	1610		10.1001/jama.281.17.1605	http://dx.doi.org/10.1001/jama.281.17.1605			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235153	Bronze			2022-12-01	WOS:000080025900024
J	Rosenthal, E; Pradier, C; Keita-Perse, O; Altare, J; Dellamonica, P; Cassuto, JP				Rosenthal, E; Pradier, C; Keita-Perse, O; Altare, J; Dellamonica, P; Cassuto, JP			Needlestick injuries among French medical students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPOSURE		Nice Sophia Antipolis Univ, Archet Hop 1, Dept Internal Med & Hematol, Serv Med Interne 2, F-06202 Nice 3, France; Nice Sophia Antipolis Univ, Archet Hop 1, Ctr Informat & Soins Immunodeficience Humaine, F-06202 Nice, France	CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur	Rosenthal, E (corresponding author), Nice Sophia Antipolis Univ, Archet Hop 1, Dept Internal Med & Hematol, Serv Med Interne 2, 151 Route St Antoine Ginestiere,BP 3079, F-06202 Nice 3, France.		Pradier, Christian/AAE-9669-2022; Pradier, Christian/AFE-8255-2022					Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P929; DEVRIES B, 1994, MED J AUSTRALIA, V160, P398; KOENIG S, 1995, AM J INFECT CONTROL, V23, P40, DOI 10.1016/0196-6553(95)90007-1; ONEILL TM, 1992, ARCH INTERN MED, V152, P1451, DOI 10.1001/archinte.152.7.1451; RESNIC FS, 1995, ARCH INTERN MED, V155, P75, DOI 10.1001/archinte.155.1.75; TERESKERZ P, 1995, ADV EXPOSURE PREV, V1, P10; WATERMAN J, 1994, J HOSP INFECT, V26, P149, DOI 10.1016/0195-6701(94)90058-2; 1996, MMWR MORB MORTAL WKL, V45, P468	9	22	24	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1660	1660		10.1001/jama.281.17.1660	http://dx.doi.org/10.1001/jama.281.17.1660			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10336348				2022-12-01	WOS:000080025900036
J	Zhang, SM; Hunter, DJ; Hankinson, SE; Giovannucci, EL; Rosner, BA; Colditz, GA; Speizer, FE; Willett, WC				Zhang, SM; Hunter, DJ; Hankinson, SE; Giovannucci, EL; Rosner, BA; Colditz, GA; Speizer, FE; Willett, WC			A prospective study of folate intake and the risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMA HOMOCYSTEINE; ALCOHOL-CONSUMPTION; WOMEN; QUESTIONNAIRE; METHIONINE; DISEASE; COLON; DIET	Context Folate is involved in DNA synthesis and methylation and may reduce breast cancer risk, particularly among women with greater alcohol consumption. Objectives To assess the association between folate intake and risk of breast cancer and whether higher folate intake may reduce excess risk among women who consume alcohol. Design Prospective cohort study performed in 1980, with 16 years of follow-up, Setting and Participants A total of 88 818 women who completed the dietary questionnaire section of the Nurses' Health Study in 1980. Main Outcome Measure Incidence of invasive breast cancer by levels of folate and alcohol intake, Results A total of 3483 cases of breast cancer were documented. Total folate intake was not associated with overall risk of breast cancer. However, among women who consumed at least 15 g/d of alcohol, the risk of breast cancer was highest among those with low folate intake. For total folate intake of at least 600 mu g/d compared with 150 to 299 mu g/d, the multivariate relative risk (RR) was 0.55 (95% confidence interval [CI], 0.39-0.76; P for trend = .001). This association was only slightly attenuated after additional adjustment for intake of beta carotene, lutein/zeaxanthin, preformed vitamin A, and total vitamins C and E. The risk of breast cancer associated with alcohol intake was strongest among women with total folate intake of less than 300 mu g/d (for alcohol intake greater than or equal to 15 g/d vs <15 g/d, multivariate RR, 1.32; 95% CI, 1.15-1.50). For women who consumed at least 300 mu g/d of total folate, the multivariate RR for intake of at least 15 g/d of alcohol vs less than 15 g/d was 1.05 (95% CI, 0.92-1.20), Current use of multivitamin supplements, the major source of folate, was associated with lower breast cancer risk among women who consumed at least 15 g/d of alcohol (for current users of supplements vs never users, RR, 0.74; 95% CI, 0.59-0.93). Conclusions Our findings suggest that the excess risk of breast cancer associated with alcohol consumption may be reduced by adequate folate intake.	Channing Lab, Boston, MA 02115 USA; Harvard Univ, Ctr Canc Prevent, Dept Epidemiol, Cambridge, MA 02138 USA; Harvard Univ, Ctr Canc Prevent, Dept Nutr, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Brigham & Women's Hospital	Zhang, SM (corresponding author), Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; FREUDENHEIM JL, 1991, INT J EPIDEMIOL, V20, P368, DOI 10.1093/ije/20.2.368; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GRAHAM S, 1991, AM J EPIDEMIOL, V134, P552, DOI 10.1093/oxfordjournals.aje.a116129; Hankinson SE, 1997, CANCER CAUSE CONTROL, V8, P65, DOI 10.1023/A:1018435205695; HILLMAN RS, 1982, ANNU REV MED, V33, P345, DOI 10.1146/annurev.me.33.020182.002021; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Mason J B, 1996, Oncology (Williston Park), V10, P1727; Mason JB, 1996, ONCOLOGY, V10, P1742; Michels KB, 1996, LANCET, V347, P431, DOI 10.1016/S0140-6736(96)90010-0; *NAT RES COUNC, 1989, REC DIET ALL, P150; Oakley GP, 1998, NEW ENGL J MED, V338, P1060, DOI 10.1056/NEJM199804093381509; Rayburn WF, 1996, J AM COLL NUTR, V15, P121; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SCHATZKIN A, 1994, CANCER, V74, P1101, DOI 10.1002/1097-0142(19940801)74:3+<1101::AID-CNCR2820741519>3.0.CO;2-X; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Swanson CA, 1997, EPIDEMIOLOGY, V8, P231, DOI 10.1097/00001648-199705000-00001; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1973, FED REG         0802, V38, P20725	32	313	327	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1632	1637		10.1001/jama.281.17.1632	http://dx.doi.org/10.1001/jama.281.17.1632			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235158				2022-12-01	WOS:000080025900029
J	Kuntz, KM; Fleischmann, KE; Hunink, MGM; Douglas, PS				Kuntz, KM; Fleischmann, KE; Hunink, MGM; Douglas, PS			Cost-effectiveness of diagnostic strategies for patients with chest pain	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; chest pain; exercise test; tomography, emission-computed, single-photon; coronary angiography	CORONARY-ARTERY DISEASE; CHRONIC STABLE ANGINA; LONG-TERM SURVIVAL; BYPASS-SURGERY; HEART-DISEASE; ARTERIOGRAPHY 1984-1987; CARDIAC ANGIOGRAPHY; RANDOMIZED TRIALS; ANGIOPLASTY; REGISTRY	Background: Many noninvasive tests exist to determine whether patients should undergo coronary angiography. The routine use of coronary angiography without previous noninvasive testing is typically not advocated. Objective: To determine the cost-effectiveness of diagnostic strategies for patients with chest pain. Design: Cost-effectiveness analysis, Data Sources: Published data. Target Population: Patients who present with chest pain, have no history of myocardial infarction, and are able to perform an exercise stress test. Time Horizon: Lifetime. Perspective: Societal. Interventions: No testing, exercise electrocardiography, exercise echocardiography, exercise single-photon emission computed tomography (SPECT), and coronary angiography alone. Outcome Measures: quality-adjusted life expectancy, lifetime cost, and incremental cost-effectiveness. Results of Base-Case Analysis: The incremental cost-effectiveness ratio of routine coronary angiography compared with exercise echocardiography was $36 400 per quality-adjusted life-year (QALY) saved for 55-year-old men with typical angina. For 55-year-old men with atypical angina, exercise echocardiography compared with exercise electrocardiography cost $41 900 per QALY saved. If adequate exercise echocardiography was not available, exercise SPECT cost $54 800 per QALY saved compared with exercise electrocardiography for these patients. For 55-year-old men with nonspecific chest pain, the incremental cost-effectiveness ratio of exercise electrocardiography compared with no testing was $57 700 per QALY saved. Results of Sensitivity Analysis: On the basis of a probabilistic sensitivity analysis, there is a 75% chance that exercise echocardiography costs less than $50 900 per QALY saved for 55-year-old men with atypical angina. Conclusions: Exercise electrocardiography or exercise echocardiography resulted in reasonable cost-effectiveness ratios for patients at mild to moderate risk for coronary artery disease in terms of age, sex, and type of chest pain. Coronary angiography without previous noninvasive testing resulted in reasonable cost-effectiveness ratios for patients with a high pretest probability of coronary artery disease.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA USA; Univ Groningen, Groningen, Netherlands	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Groningen	Kuntz, KM (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, 718 Huntington Ave, Boston, MA 02115 USA.	kmk@hsph.harvard.edu		Douglas, Pamela/0000-0001-9876-4049	PHS HHS [1K08H102964-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADLER DS, 1986, AM J CARDIOL, V58, P195, DOI 10.1016/0002-9149(86)90046-9; BRUNELLI C, 1989, EUR HEART J, V10, P292, DOI 10.1093/oxfordjournals.eurheartj.a059486; CALIFF RM, 1988, J AM COLL CARDIOL, V11, P20, DOI 10.1016/0735-1097(88)90160-X; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; CHAITMAN BR, 1990, J AM COLL CARDIOL, V16, P1071, DOI 10.1016/0735-1097(90)90534-V; DESERVI S, 1989, INT J CARDIOL, V22, P43, DOI 10.1016/0167-5273(89)90134-4; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Doubilet P, 1985, Med Decis Making, V5, P293, DOI 10.1177/0272989X8500500305; ELVEBACK LR, 1981, MAYO CLIN PROC, V56, P665; FISHER L, 1984, NEW ENGL J MED, V310, P750; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FISHER L, 1983, CIRCULATION, V68, P951; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; HILBORNE LH, 1991, PERCUTANEOUS TRANSLU; HOLMES DR, 1988, J AM COLL CARDIOL, V12, P1149, DOI 10.1016/0735-1097(88)92593-4; JOHNSON LW, 1989, CATHETER CARDIO DIAG, V17, P5, DOI 10.1002/ccd.1810170103; KATZ DA, 1994, J VASC SURG, V19, P980, DOI 10.1016/S0741-5214(94)70209-8; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; LAVE JR, 1932, MED CARE S, V32, pJS77; LAWRIE GM, 1987, ANN THORAC SURG, V44, P180, DOI 10.1016/S0003-4975(10)62037-1; LEE TH, 1988, MED DECIS MAKING, V8, P268, DOI 10.1177/0272989X8800800408; LOZNER EC, 1989, CATHETER CARDIO DIAG, V17, P11, DOI 10.1002/ccd.1810170104; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MIRANDA CP, 1991, ANN INTERN MED, V114, P649, DOI 10.7326/0003-4819-114-8-649; MYERS WO, 1987, ANN THORAC SURG, V43, P599, DOI 10.1016/S0003-4975(10)60230-5; *NAT CTR HLTH STAT, 1991, VIT STAT US 1988 A, V1; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; NWASOKWA ON, 1991, ANN INTERN MED, V114, P1035, DOI 10.7326/0003-4819-114-12-1035; PALMAS W, 1995, J AM COLL CARDIOL, V25, P1024, DOI 10.1016/0735-1097(94)00523-S; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RODRIGUEZ A, 1993, J AM COLL CARDIOL, V22, P1060, DOI 10.1016/0735-1097(93)90416-X; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Ryan T, 1993, J Am Soc Echocardiogr, V6, P186; SOLOT G, 1993, NUCL MED COMMUN, V14, P23, DOI 10.1097/00006231-199301000-00006; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Stinnett AAMM, 1996, COST EFFECTIVENESS H, P349; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; Yusuf S, 1994, ONLINE J CURR CLIN T	47	127	127	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					709	+		10.7326/0003-4819-130-9-199905040-00002	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357689				2022-12-01	WOS:000080062300001
J	Ridgway, WM; Fasso, M; Fathman, CG				Ridgway, WM; Fasso, M; Fathman, CG			Immunology - A new look at MHC and autoimmune disease	SCIENCE			English	Editorial Material							NONOBESE DIABETIC MICE; GLUTAMIC-ACID DECARBOXYLASE; ANTIGEN PRESENTATION; POSITIVE SELECTION; NOD MOUSE; T-CELLS; TOLERANCE; INSULITIS; PEPTIDE; AUTOREACTIVITY		Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA	Stanford University	Ridgway, WM (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA.							ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; CARRASCOMARIN E, 1996, J IMMUNOL, V156, P50; Costagliola S, 1996, ENDOCRINOLOGY, V137, P4637, DOI 10.1210/en.137.11.4637; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; HUMPHREYSBEHER MG, 1994, ADV EXP MED BIOL, V350, P631; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.immunol.13.1.93; Kanagawa O, 1998, P NATL ACAD SCI USA, V95, P1721, DOI 10.1073/pnas.95.4.1721; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; Kim DT, 1996, J IMMUNOL, V156, P2737; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; LIU GY, 1995, IMMUNITY, V3, P407, DOI 10.1016/1074-7613(95)90170-1; MAKINO S, 1985, EXP ANIM TOKYO, V34, P425, DOI 10.1538/expanim1978.34.4_425; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; Ridgway WM, 1998, CLIN IMMUNOL IMMUNOP, V86, P3, DOI 10.1006/clin.1997.4449; Ridgway WM, 1996, J EXP MED, V183, P1657, DOI 10.1084/jem.183.4.1657; Ridgway WM, 1998, J EXP MED, V188, P2267, DOI 10.1084/jem.188.12.2267; RIDGWAY WM, 1998, CAN J DIAB CARE S, V3, P6; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639	24	74	78	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					749	+		10.1126/science.284.5415.749	http://dx.doi.org/10.1126/science.284.5415.749			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10336398				2022-12-01	WOS:000080056200028
J	Imai, Y; Kimura, T; Murakami, A; Yajima, N; Sakamaki, K; Yonehara, S				Imai, Y; Kimura, T; Murakami, A; Yajima, N; Sakamaki, K; Yonehara, S			The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis	NATURE			English	Article							DOMAIN-CONTAINING PROTEIN; SIGNALING COMPLEX DISC; DEATH-EFFECTOR DOMAIN; CYTOCHROME-C; MOLECULAR-CLONING; ANTIGEN FAS; CELL-DEATH; CED-4; MITOCHONDRIA; RELEASE	Fas is a cell-surface receptor molecule that relays apoptotic (cell death) signals into cells. When Fas is activated by binding of its ligand, the proteolytic: protein caspase-8 is recruited to a signalling complex known as DISC by binding to a Fas-associated adapter protein. A large new protein, FLASH, has now been identified by cloning of its complementary DNA. This protein contains a motif with oligomerizing activity whose sequence is similar to that of the Caenorhabditis elegans protein CED-4, and another domain (DRD domain) that interacts with a death-effector domain in caspase-8 or in the adapter protein. Stimulated Fas binds FLASH, so FLASH is probably a component of the DISC signalling complex. Transient expression of FLASH activates caspase-8, whereas overexpression of a truncated form of FLASH containing only one of its DRD or CED-4-like domains does not allow activation of caspase-8 and Fas-mediated apoptosis to occur, Overexpression of full-length FLASH blocks the anti-apoptotic effect of the adenovirus protein E1B19K. FLASH is therefore necessary for the activation of caspase-8 in Fas-mediated apoptosis.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Yonehara, S (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	syonehar@virus.kyoto-u.ac.jp	Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231; Sakamaki, Kazuhiro/0000-0002-7072-9628				BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHIMURA Y, 1995, J IMMUNOL, V154, P4395; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakamaki K, 1998, EUR J BIOCHEM, V253, P399, DOI 10.1046/j.1432-1327.1998.2530399.x; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YONCHARA S, 1989, J EXP MED, V169, P1747; YONEHARA S, 1994, INT IMMUNOL, V6, P1849, DOI 10.1093/intimm/6.12.1849; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	47	210	226	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					777	785		10.1038/19709	http://dx.doi.org/10.1038/19709			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235259				2022-12-01	WOS:000080058100050
J	Jordan, BA; Devi, LA				Jordan, BA; Devi, LA			G-protein-coupled receptor heterodimerization modulates receptor function	NATURE			English	Article							DELTA-OPIOID RECEPTOR; SIGNAL-TRANSDUCTION; CROSS-TALK; INTERNALIZATION; DIMERIZATION; COEXPRESSION; PEPTIDES; SUBTYPES; AGONIST; POTENT	The opioid system modulates several physiological processes, including analgesia, the stress response, the immune response and neuroendocrine function(1). Pharmacological and molecular cloning studies have identified three opioid-receptor types, delta, kappa and mu, that mediate these diverse effects(2,3). Little is known about the ability of the receptors to interact to form new functional structures, the simplest of which would be a dimer, Structural and biochemical studies show that other G-protein-coupled receptors (GPCRs) interact to form homodimers(4,5), Moreover, two nonfunctional receptors heterodimerize to form a functional receptor, suggesting that dimerization is crucial for receptor function(6-11). However, heterodimerization between two fully functional receptors has not been documented. Here we provide biochemical and pharmacological evidence for the heterodimerization of two fully functional opioid receptors, kappa and delta. This results in a new receptor that exhibits ligand binding and functional properties that are distinct from those of either receptor. Furthermore, the kappa-delta heterodimer synergistically binds highly selective agonists and potentiates signal transduction. Thus, heterodimerization of these GPCRs represents a novel mechanism that modulates their function.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University	Devi, LA (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776; Jordan, Bryen/0000-0002-4967-444X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA019521, R01DA008863] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA008863-17, R01 DA008863, K05 DA019521, K05 DA019521-08] Funding Source: Medline; NINDS NIH HHS [R01 NS026880, R01 NS026880-22] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Herz A., 1993, OPIOIDS; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan B, 1998, BRIT J ANAESTH, V81, P12, DOI 10.1093/bja/81.1.12; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MIOTTO K, 1995, PHARM OPIOID PEPTIDE, P57; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Nock B.U., 1995, PHARM OPIOID PEPTIDE, P29; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; ROTH G, 1990, J MED CHEM, V258, P299; SCHILLER PW, 1993, J MED CHEM, V36, P3182, DOI 10.1021/jm00073a020; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zaki PA, 1996, ANNU REV PHARMACOL, V36, P379; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	30	915	984	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					697	700		10.1038/21441	http://dx.doi.org/10.1038/21441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385123	Green Accepted			2022-12-01	WOS:000080932800063
J	Oparka, KJ; Roberts, AG; Boevink, P; Santa Cruz, S; Roberts, L; Pradel, KS; Imlau, A; Kotlizky, G; Sauer, N; Epel, B				Oparka, KJ; Roberts, AG; Boevink, P; Santa Cruz, S; Roberts, L; Pradel, KS; Imlau, A; Kotlizky, G; Sauer, N; Epel, B			Simple, but not branched, plasmodesmata allow the nonspecific trafficking of proteins in developing tobacco leaves	CELL			English	Article							CELL-TO-CELL; GREEN FLUORESCENT PROTEIN; VIRUS MOVEMENT PROTEIN; SIZE-EXCLUSION LIMIT; MOSAIC-VIRUS; ENDOPLASMIC-RETICULUM; NICOTIANA-CLEVELANDII; SETCREASEA-PURPUREA; MOLECULAR-CLONING; SIEVE ELEMENTS	Leaves undergo a sink-source transition during which a physiological change occurs from carbon import to export. In sink leaves, biolistic bombardment of plasmids encoding GFP-fusion proteins demonstrated that proteins with an M-r up to 50 kDa could move freely through plasmodesmata. During the sink-source transition, the capacity to traffic proteins decreased substantially and was accompanied by a developmental switch from simple to branched forms of plasmodesmata. inoculation of sink leaves with a movement protein-defective virus showed that virally expressed GFP, but not viral RNA, was capable of trafficking between sink cells during infection. Contrary to dogma that plasmodesmata have a size exclusion limit below 1 kDa, the data demonstrate that nonspecific "macromolecular trafficking" is a general feature of simple plasmodesmata in sink leaves.	Scottish Crop Res Inst, Cell Biol Unit, Dundee DD2 5DA, Scotland; Univ Erlangen Nurnberg, Lehrstuhl Bot 2, D-91058 Erlangen, Germany; Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel	James Hutton Institute; University of Erlangen Nuremberg; Tel Aviv University	Oparka, KJ (corresponding author), Scottish Crop Res Inst, Cell Biol Unit, Dundee DD2 5DA, Scotland.	kopark@scri.sari.ac.uk	Roberts, Alison/G-6305-2012; Boevink, Petra/AAO-6498-2021	Boevink, Petra/0000-0002-7021-9097				Angell SM, 1996, VIROLOGY, V216, P197, DOI 10.1006/viro.1996.0046; Balachandran S, 1997, P NATL ACAD SCI USA, V94, P14150, DOI 10.1073/pnas.94.25.14150; BECK DL, 1991, VIROLOGY, V183, P695, DOI 10.1016/0042-6822(91)90998-Q; Blackman LM, 1998, PLANT CELL, V10, P525, DOI 10.1105/tpc.10.4.525; Boevink P, 1996, PLANT J, V10, P935, DOI 10.1046/j.1365-313X.1996.10050935.x; BOEVINK PB, 1999, IN PRESS PLANTA; BURNELL JN, 1988, J EXP BOT, V39, P1575, DOI 10.1093/jxb/39.11.1575; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; CLELAND RE, 1994, PROTOPLASMA, V178, P81, DOI 10.1007/BF01404123; Cook ME, 1997, AM J BOT, V84, P1169, DOI 10.2307/2446040; Cruz SS, 1998, PLANT CELL, V10, P495, DOI 10.1105/tpc.10.4.495; Cruz SS, 1996, P NATL ACAD SCI USA, V93, P6286, DOI 10.1073/pnas.93.13.6286; DEOM CM, 1990, P NATL ACAD SCI USA, V87, P3284, DOI 10.1073/pnas.87.9.3284; Ding B, 1996, PLANT J, V10, P157, DOI 10.1046/j.1365-313X.1996.10010157.x; DING B, 1992, PLANT CELL, V4, P915, DOI 10.1105/tpc.4.8.915; Ding B., 1996, MEMBRANES SPECIALIZE, P489; DING BA, 1995, VIROLOGY, V207, P345, DOI 10.1006/viro.1995.1093; Dopf J, 1996, GENE, V173, P39, DOI 10.1016/0378-1119(95)00692-3; Ehlers K, 1996, PLANTA, V199, P126; Epel BL, 1996, GENE, V173, P75, DOI 10.1016/0378-1119(95)00678-8; ERWEE MG, 1985, PLANTA, V163, P9, DOI 10.1007/BF00395891; FENCZIK CA, 1996, PLANT GEN R, P249; FRANCESCHI VR, 1994, PLANTA, V192, P347; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; GalOn A, 1997, J VIROL METHODS, V64, P103, DOI 10.1016/S0166-0934(96)02146-5; GAMALEI YV, 1994, PLANTA, V194, P443, DOI 10.1007/BF00714455; Gilbertson RL, 1996, TRENDS PLANT SCI, V1, P260; GOODWIN PB, 1983, PLANTA, V157, P124, DOI 10.1007/BF00393645; GUNNING BES, 1978, PLANTA, V143, P121, DOI 10.1007/BF00387786; HATTORI T, 1985, PLANT MOL BIOL, V5, P313, DOI 10.1007/BF00020629; HEPLER PK, 1982, PROTOPLASMA, V111, P121, DOI 10.1007/BF01282070; Imlau A, 1999, PLANT CELL, V11, P309, DOI 10.1105/tpc.11.3.309; Ishiwatari Y, 1998, PLANTA, V205, P12, DOI 10.1007/s004250050291; Itaya A, 1998, PLANT PHYSIOL, V118, P373, DOI 10.1104/pp.118.2.373; Itaya A, 1997, PLANT J, V12, P1223, DOI 10.1046/j.1365-313X.1997.12051223.x; Jackson D, 1997, CURR OPIN GENET DEV, V7, P495, DOI 10.1016/S0959-437X(97)80076-7; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; KIKUYAMA M, 1992, PLANT CELL PHYSIOL, V33, P413; KOLLMANN R, 1985, PROTOPLASMA, V126, P19, DOI 10.1007/BF01287669; KOLLMANN R, 1985, PROTOPLASMA, V124, P224, DOI 10.1007/BF01290774; Kragler F, 1998, ANN BOT-LONDON, V81, P1, DOI 10.1006/anbo.1997.0522; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; LUCAS WJ, 1995, CURR OPIN CELL BIOL, V7, P673, DOI 10.1016/0955-0674(95)80109-X; Mezitt LA, 1996, PLANT MOL BIOL, V32, P251, DOI 10.1007/BF00039385; MIZUHIRA V, 1972, ACTA HISTOCHEM CYTOC, V1, P233; OPARKA KJ, 1981, PLANTA, V151, P561, DOI 10.1007/BF00387436; Oparka KJ, 1997, PLANT J, V12, P781, DOI 10.1046/j.1365-313X.1997.12040781.x; Oparka KJ, 1996, TRENDS PLANT SCI, V1, P412, DOI 10.1016/S1360-1385(96)10043-1; OVERALL RL, 1982, PROTOPLASMA, V111, P134, DOI 10.1007/BF01282071; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; PETTY ITD, 1990, VIROLOGY, V179, P712, DOI 10.1016/0042-6822(90)90138-H; Raven JA, 1997, EUR J PHYCOL, V32, P95; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Roberts AG, 1997, PLANT CELL, V9, P1381, DOI 10.1105/tpc.9.8.1381; Ryabov EV, 1998, VIROLOGY, V242, P303, DOI 10.1006/viro.1997.9025; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHULZ A, 1995, PROTOPLASMA, V188, P22, DOI 10.1007/BF01276793; SEAGULL RW, 1983, PLANTA, V159, P497, DOI 10.1007/BF00409138; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; STIEKEMA WJ, 1988, PLANT MOL BIOL, V11, P255, DOI 10.1007/BF00027383; TERRY BR, 1987, PLANTA, V171, P145, DOI 10.1007/BF00391090; TILNEY LG, 1991, J CELL BIOL, V112, P739, DOI 10.1083/jcb.112.4.739; TOMENIUS K, 1987, VIROLOGY, V160, P363, DOI 10.1016/0042-6822(87)90007-9; TUCKER EB, 1993, PROTOPLASMA, V174, P45, DOI 10.1007/BF01404041; TUCKER EB, 1982, PROTOPLASMA, V113, P193, DOI 10.1007/BF01280907; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; WAIGMANN E, 1994, P NATL ACAD SCI USA, V91, P1433, DOI 10.1073/pnas.91.4.1433; WANG HL, 1995, PLANT CELL ENVIRON, V18, P373, DOI 10.1111/j.1365-3040.1995.tb00373.x; WANG N, 1994, PLANT PHYSIOL, V104, P17, DOI 10.1104/pp.104.1.17; WOLF S, 1989, SCIENCE, V246, P377, DOI 10.1126/science.246.4928.377; WOLF S, 1991, PLANT CELL, V3, P593, DOI 10.1105/tpc.3.6.593; Wright KM, 1997, J EXP BOT, V48, P1807, DOI 10.1093/jexbot/48.315.1807; Zhu T, 1998, PROTOPLASMA, V203, P35, DOI 10.1007/BF01280585	77	342	356	1	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					743	754		10.1016/S0092-8674(00)80786-2	http://dx.doi.org/10.1016/S0092-8674(00)80786-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380926	Bronze			2022-12-01	WOS:000080886300012
J	LeDuc, P; Haber, C; Bao, G; Wirtz, D				LeDuc, P; Haber, C; Bao, G; Wirtz, D			Dynamics of individual flexible polymers in a shear flow	NATURE			English	Article							SINGLE DNA MOLECULE; STAINING METHOD; MICROSCOPY	Polymer dynamics are of central importance in materials science, mechanical engineering, biology and medicine(1,2). The dynamics of macromolecular solutions and melts in shear flow are typically studied using bulk experimental methods such as light and neutron scattering and birefringence(3,4). But the effect of shear on the conformation and dynamics of individual polymers is still not well understood(5-7). Here we describe observations of the real-time dynamics of individual, flexible polymers (fluorescently labelled DNA molecules(8-15)) under a shear flow. The sheared polymers exhibit many types of extended conformation with an overall orientation ranging from parallel to perpendicular with respect to the flow direction. For shear rates much smaller than the inverse of the relaxation time of the molecule, the relative populations of these two main types of conformation are controlled by the rate of the shear flow. These results question the adequacy of assumptions made in standard models of polymer dynamics(5,6).	Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA.		Wirtz, Denis/A-3257-2010					ARCHER LA, 1995, J FLUID MECH, V301, P133, DOI 10.1017/S0022112095003831; de Gennes P. G., 1991, SCALING CONCEPTS POL; DEGENNES PG, 1997, SCIENCE, V276, P199; Doi M., 1986, THEORY POLYM DYNAMIC; FULLER GG, 1995, OPTICLA RHEOMETRY CO; HINCH EJ, 1977, PHYS FLUIDS, V20, pS22, DOI 10.1063/1.861735; HINCH EJ, 1976, J FLUID MECH, V75, P765, DOI 10.1017/S0022112076000529; HINCH EJ, 1976, J FLUID MECH, V74, P317, DOI 10.1017/S002211207600181X; HOFFMAN A, 1995, POLYM BIOMATERIALS; JANESCHITZKRIEG.H, 1983, POLYM MELT RHEOLOGY; Jeffery GB, 1922, P R SOC LOND A-CONTA, V102, P161, DOI 10.1098/rspa.1922.0078; LEAL LG, 1971, J FLUID MECH, V46, P685, DOI 10.1017/S0022112071000788; MATSUMOTO M, 1992, J POLYM SCI POL PHYS, V30, P779, DOI 10.1002/polb.1992.090300716; MATSUMOTO S, 1981, J MOL BIOL, V152, P501, DOI 10.1016/0022-2836(81)90255-2; MORIKAWA K, 1981, J BIOCHEM-TOKYO, V89, P693, DOI 10.1093/oxfordjournals.jbchem.a133247; MUNK P, 1989, INTRO MACROMOLECULAR; OSTAP EM, 1992, BIOPHYS J, V63, P966, DOI 10.1016/S0006-3495(92)81684-3; Perkins TT, 1997, SCIENCE, V276, P2016, DOI 10.1126/science.276.5321.2016; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SHIVASHANKAR G, 1997, APPL PHYS LETT, V7, P3727; Smith DE, 1996, MACROMOLECULES, V29, P1372, DOI 10.1021/ma951455p; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; WIRTZ D, 1995, PHYS REV LETT, V75, P2436, DOI 10.1103/PhysRevLett.75.2436; Xu JY, 1998, MACROMOLECULES, V31, P6486, DOI 10.1021/ma9717754	25	187	190	1	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					564	566		10.1038/21148	http://dx.doi.org/10.1038/21148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376595				2022-12-01	WOS:000080778400049
J	Qin, HX; Srinivasula, SM; Wu, G; Fernandes-Alnemri, T; Alnemri, ES; Shi, YG				Qin, HX; Srinivasula, SM; Wu, G; Fernandes-Alnemri, T; Alnemri, ES; Shi, YG			Structural basis of procaspase-9 recruitment by the apoptotic protease-activating factor 1	NATURE			English	Article							PROGRAMMED CELL-DEATH; ADAPTER MOLECULE; CYTOCHROME-C; CED-4; OLIGOMERIZATION; ASSOCIATION; CASPASE-2; APAF-1; RAIDD; CARD	Caspase-9-mediated apoptosis (programmed cell death) plays a central role in the development and homeostasis of all multicellular organisms. Mature caspase-9 is derived from its procaspase precursor as a result of recruitment by the activating factor Apaf-1. The crystal structures of the caspase-recruitment domain of Apaf-1 by itself and In complex with the prodomain of procaspase-9 have been determined at 1.6 and 2.5 Angstrom resolution, respectively. These structures and other evidence reveal that each molecule of Apaf-1 interacts with a molecule of procaspase-9 through two highly charged and complementary surfaces formed by non-conserved residues; these surfaces determine recognition specificity through networks of intermolecular hydrogen bonds and van der Waals interactions. Mutation of the important interface residues in procaspase-9 or Apaf-1 prevents or reduces activation of procaspase-9 In a cell-free system. Wild-type, but not mutant, prodomains of caspase-9 completely inhibit catalytic processing of procaspase-9. Furthermore, analysis of homologues from Caenorhabditis elegans indicates that recruitment of CED-3 by CED-4 is probably mediated by the same set of: conserved structural motifs, with a corresponding change in the specificity-determining residues.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Princeton University; Princeton University; Jefferson University	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Washington Rd, Princeton, NJ 08544 USA.	ygshi@princeto.edu	Alnemri, Emad S/B-4526-2010	Shi, Yigong/0000-0003-2030-168X				Ahmad M, 1997, CANCER RES, V57, P615; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; GREEN DR, 1995, CURR OPIN IMMUNOL, V7, P694, DOI 10.1016/0952-7915(95)80079-4; Hengartner MO, 1996, CURR OPIN GENET DEV, V6, P34, DOI 10.1016/S0959-437X(96)90007-6; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Horvitz HR, 1999, CANCER RES, V59, p1701S; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; SALEH A, IN PRESS J BIOL CHEM; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, CANCER RES, V59, P999; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	32	351	358	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					549	557		10.1038/21124	http://dx.doi.org/10.1038/21124			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376594				2022-12-01	WOS:000080778400046
J	Owerkowicz, T; Farmer, CG; Hicks, JW; Brainerd, EL				Owerkowicz, T; Farmer, CG; Hicks, JW; Brainerd, EL			Contribution of gular pumping to lung ventilation in monitor lizards	SCIENCE			English	Article							GAS-EXCHANGE; EVOLUTION; EXERCISE; VARANUS; CONSTRAINT; WALKING; IGUANA	A controversial hypothesis has proposed that Lizards are subject to a speed dependent axial constraint that prevents effective Lung ventilation during moderate- and high-speed Locomotion. This hypothesis has been challenged by results demonstrating that monitor lizards (genus Varanus) experience no axial constraint. Evidence presented here shows that, during locomotion, varanids use a positive pressure gular pump to assist Lung ventilation. Disabling the gular pump reveals that the axial constraint is present in varanids but it is masked by gular pumping under normal conditions. These findings support the prediction that the axial constraint may be found in other tetrapods that breathe by costal aspiration and locomote with a lateral undulatory gait.	Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA; Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Univ Massachusetts, Prod Organism & Evolutionary biol, Amherst, MA 01003 USA	Harvard University; University of California System; University of California Irvine; University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Owerkowicz, T (corresponding author), Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009796] Funding Source: NIH RePORTER; NHLBI NIH HHS [1F32-HL09796-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALGHAMDI MS, 1995, J PHYSIOL-LONDON, V483P, pP6; Auffenberg, 1981, BEHAV ECOLOGY KOMODO; BARTHOLOMEW G. A., 1964, PHYSIOL ZOOL, V37, P341; BELS VL, 1995, J ZOOL LOND, V235, P95; BENNETT AF, 1994, ADV VET SCI COMP MED, V38, P113; BENNETT AF, 1982, BIOL REPTILIA, V13, P153; BRAINERD EL, 1994, AM ZOOL, V34, P289; CARRIER D, 1990, J EXP BIOL, V152, P453; CARRIER DR, 1987, PALEOBIOLOGY, V13, P326; CARRIER DR, 1987, EXP BIOL, V47, P33; CARRIER DR, 1991, AM ZOOL, V31, P644; CHRISTIAN KA, 1994, AUST J ZOOL, V42, P185, DOI 10.1071/ZO9940185; DEBAN SM, 1994, J EXP ZOOL, V270, P451, DOI 10.1002/jez.1402700506; Dial BE, 1996, J EXP ZOOL, V276, P415, DOI 10.1002/(SICI)1097-010X(19961215)276:6<415::AID-JEZ5>3.0.CO;2-Q; Estes R., 1988, P119; GANS C, 1970, Forma et Functio, V3, P61; GANS C, 1970, Evolution, V24, P723, DOI 10.1111/j.1558-5646.1970.tb01807.x; GLEESON TT, 1980, AM J PHYSIOL, V239, pR174, DOI 10.1152/ajpregu.1980.239.1.R174; Hicks James W., 1998, V19, P425; HOPKINS SR, 1995, J EXP BIOL, V198, P1783; JOHNALDER HB, 1981, AM J PHYSIOL, V241, pR342, DOI 10.1152/ajpregu.1981.241.5.R342; KING D, 1993, GOANNA BIOL VARANID; Liem K.F., 1985, P185; MITCHELL GS, 1981, RESP PHYSIOL, V43, P365, DOI 10.1016/0034-5687(81)90116-X; PARSONS TS, 1970, BIOLOGY REPTILIA, V2, P99; PERRY SF, 1983, ADV ANAT EMBRYOL CEL, V79, P1; PHILLIPS JA, 1995, J HERPETOL, V29, P407, DOI 10.2307/1564991; Ritter D, 1996, J EXP BIOL, V199, P2499; Wang T, 1997, J EXP BIOL, V200, P2629; WEBB G, 1971, J MORPHOL, V134, P335, DOI 10.1002/jmor.1051340306; WOOD SC, 1977, AM J PHYSIOL, V233, pR89, DOI 10.1152/ajpregu.1977.233.3.R89	31	93	95	3	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1661	1663		10.1126/science.284.5420.1661	http://dx.doi.org/10.1126/science.284.5420.1661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356394				2022-12-01	WOS:000080668300042
J	Law, M; Wald, N				Law, M; Wald, N			Why heart disease mortality is low in France: the time lag explanation	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; HIGH-DENSITY-LIPOPROTEIN; MALE BRITISH DOCTORS; SERUM-CHOLESTEROL; RED WINE; ALCOHOL-CONSUMPTION; HEALTHY-VOLUNTEERS; MYOCARDIAL-INFARCTION; MODERATE CONSUMPTION; HDL-CHOLESTEROL		St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Law, M (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					Arnetz BB, 1994, EUR J PUBLIC HEALTH, V4, P38; ARTAUDWILD SM, 1993, CIRCULATION, V88, P2771, DOI 10.1161/01.CIR.88.6.2771; BENNETT SA, 1994, MED J AUSTRALIA, V161, P519, DOI 10.5694/j.1326-5377.1994.tb127594.x; BLOT WJ, 1992, CANCER RES, V52, pS2119; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BONITHONKOPP C, 1993, ATHEROSCLEROSIS, V104, P173, DOI 10.1016/0021-9150(93)90188-Z; BUCK C, 1982, INT J EPIDEMIOL, V11, P294; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; deLorgeril M, 1997, EUR J CLIN NUTR, V51, P116, DOI 10.1038/sj.ejcn.1600374; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; Doll R., 1981, JNCI-J NATL CANCER I, V66, P1292; Duthie GG, 1998, EUR J CLIN NUTR, V52, P733, DOI 10.1038/sj.ejcn.1600635; FONNEBO V, 1992, AM J EPIDEMIOL, V135, P504, DOI 10.1093/oxfordjournals.aje.a116317; FORMAN MR, 1995, AM J CLIN NUTR, V62, P131, DOI 10.1093/ajcn/62.1.131; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; Hertog MGL, 1996, EUR J CLIN NUTR, V50, P63; HOLLINGSWORTH D, 1957, ENGLISHMANS FOOD; JACOBSEN BK, 1992, SCAND J SOC MED, V20, P184, DOI 10.1177/140349489202000309; JOLLIFFE N, 1959, J Chronic Dis, V9, P636, DOI 10.1016/0021-9681(59)90114-6; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KUZUYA F, 1995, ANN NY ACAD SCI, V748, P510; LAURIER D, 1992, EUR J EPIDEMIOL, V8, P693, DOI 10.1007/BF00145386; LAW MR, 1994, EUR J CLIN NUTR, V48, P305; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Law MR, 1998, J EPIDEMIOL COMMUN H, V52, P344, DOI 10.1136/jech.52.6.344; LINDEBERG S, 1994, J INTERN MED, V236, P331, DOI 10.1111/j.1365-2796.1994.tb00804.x; MALASPINA JP, 1981, ATHEROSCLEROSIS, V40, P373, DOI 10.1016/0021-9150(81)90149-0; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MarquesVidal P, 1996, AM J EPIDEMIOL, V143, P1089, DOI 10.1093/oxfordjournals.aje.a008683; MCMICHAEL J, 1979, LANCET, V1, P1186; *MIN AGR FISH FOOD, 1956, HOUS FOOD CONS EXP 1; *MIN AGR FISH FOOD, 1982, HOUS FOOD CONS EXP 1; *MIN AGR FISH FOOD, 1973, HOUS FOOD CONS EXP 1; *MIN AGR FISH FOOD, 1962, HOUS FOOD CONS EXP 1; Muldoon MF, 1996, BRIT MED J, V312, P458, DOI 10.1136/bmj.312.7029.458; Neil HAW, 1996, J ROY COLL PHYS LOND, V30, P329; NICOLAIDESBOUMA.A, 1993, INT SMOKING STAT; *OFF POP CENS SURV, 1993, HLTH SURV ENGL 1991; *OFF POP CENS SURV, 1996, LIV BRIT RES 1994 GE; *OFF POP CENS SURV, 1993, 1992 MORT STAT CAUS; *OFF POP CENS SURV, 1990, DIET NUTR SURV BRIT; OKAYAMA A, 1995, J CLIN EPIDEMIOL, V48, P329, DOI 10.1016/0895-4356(94)00146-H; PEKKANEN J, 1995, J EPIDEMIOL COMMUN H, V49, P144, DOI 10.1136/jech.49.2.144; Pellegrini N, 1996, EUR J CLIN NUTR, V50, P209; Pellegrini N, 1996, EUR J CLIN NUTR, V50, P535; PUJIA A, 1993, ATHEROSCLEROSIS, V102, P1, DOI 10.1016/0021-9150(93)90079-A; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; ROSE G, 1982, BRIT MED J, V284, P1600, DOI 10.1136/bmj.284.6329.1600; SCHLIENGER JL, 1991, PATHOL BIOL, V39, P195; *SENECA INV, 1991, EUR J CLIN NUTR S3, V45, P53; *SENECA INV, 1996, EUR J CLIN NUTR, V50, pS25; SHAPER AG, 1994, INT J EPIDEMIOL, V23, P482, DOI 10.1093/ije/23.3.482; SHELLEY E, 1995, EUR HEART J, V16, P752, DOI 10.1093/oxfordjournals.eurheartj.a060993; SIMONS LA, 1995, ATHEROSCLEROSIS, V113, P219, DOI 10.1016/0021-9150(94)05449-S; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; STRANDBERG TE, 1995, BRIT HEART J, V74, P449; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; TUNSTALLPEDOE H, 1988, BRIT MED J, V297, P1559, DOI 10.1136/bmj.297.6663.1559; VACCARINO V, 1995, EUR HEART J, V16, P761, DOI 10.1093/oxfordjournals.eurheartj.a060994; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; VERSCHUREN WMM, 1994, INT J EPIDEMIOL, V23, P948, DOI 10.1093/ije/23.5.948; Wald N, 1991, UK SMOKING STAT; *WHO, 1986, WORLD HLTH STAT ANN; *WHO, 1990, WHO MONICA PROJ WORL; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; [No title captured]	74	119	122	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1471	1476		10.1136/bmj.318.7196.1471	http://dx.doi.org/10.1136/bmj.318.7196.1471			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10346778	Green Published			2022-12-01	WOS:000080668200028
J	Hsin, H; Kenyon, C				Hsin, H; Kenyon, C			Signals from the reproductive system regulate the lifespan of C-elegans	NATURE			English	Article							CAENORHABDITIS-ELEGANS; FAMILY MEMBER; LONGEVITY; GENE; DAF-2; HERMAPHRODITE; BEHAVIOR; MUTATION; DIAPAUSE; AGE-1	Understanding hew the ageing process is regulated is a fascinating and fundamental problem in biology. Here we demonstrate that signals from the reproductive system influence the Lifespan of the nematode Cacnorhabditis elegans. If the cells that give rise to the germ line are killed with a laser microbeam, the lifespan of the animal is extended. Our findings suggest that germline signals act by modulating the activity of an insulin/IGF-1 (insulin-like growth factor) pathway that is known to regulate the ageing of this organism. Mutants with reduced activity of the insulin/IGF-1-receptor homologue DAF-2 have been shown to live twice as long as normal(1-3), and their longevity requires the activity of DAF-16, a member of the forkhead/winged-helix family of transcriptional regulators(1,2,4,5). We find that, in order for germline ablation to extend lifespan, DAF-16 is required, as well as a putative nuclear hormone receptor, DAF-12 (refs 6, 7). In addition, our findings suggest that signals from the somatic gonad also influence ageing, and that this effect requires DAF-2 activity. Together, our findings imply that the C. elegans insulin/IGF-1 system integrates multiple signals to define the animal's rate of ageing. This study demonstrates an inherent relationship between the reproductive state of this animal and its lifespan, and may have implications for the co-evolution of reproductive capability and longevity.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			Hsin, Honor/0000-0002-0510-7494				AUSTIN J, 1994, DEVELOPMENT, V120, P313; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; DORMAN JB, 1995, GENETICS, V141, P1399; Eizinger A, 1997, SCIENCE, V278, P452, DOI 10.1126/science.278.5337.452; FRIEDMAN DB, 1988, GENETICS, V118, P75; Gems D, 1998, GENETICS, V150, P129; Gregoire FM, 1998, BIOCHEM BIOPH RES CO, V249, P385, DOI 10.1006/bbrc.1998.9164; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LARSEN PL, 1995, GENETICS, V139, P1567; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Riddle DL, 1997, C ELEGANS, P739; YEH WH, 1991, THESIS U MISSOURI	17	655	680	6	74	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1999	399	6734					362	366		10.1038/20694	http://dx.doi.org/10.1038/20694			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360574				2022-12-01	WOS:000080547800061
J	Zhao, HB; Santos-Sacchi, J				Zhao, HB; Santos-Sacchi, J			Auditory collusion and a coupled couple of outer hair cells	NATURE			English	Article							MOTILITY VOLTAGE SENSOR; GUINEA-PIG; MECHANICAL RESPONSES; MEMBRANE CAPACITANCE; COCHLEAR AMPLIFIER; BASILAR-MEMBRANE; FREQUENCY LIMIT; CHARGE; DEPENDENCE	The discrepancies between measured frequency responses of the basilar membrane in the inner ear and the frequency tuning found in psychophysical experiments led to Bekesy's idea of lateral inhibition in the auditory nervous system(1). We now know that basilar membrane tuning can account for neural tuning(2), and that sharpening of the passive travelling wave depends on the mechanical activity of outer hair cells (OHCs)(3), but the mechanism by which OHCs enhance tuning remains unclear. OHCs generate voltage-dependent length changes at acoustic rates(4-8), which deform the cochlear partition(9-11). Here we use an electrical correlate of OHC mechanical activity, the motility-related gating current, to investigate mechano-electrical interactions among adjacent OHCs. We show that the motility caused by voltage stimulation of one cell in a group evokes gating currents in adjacent OHCs. The resulting polarization in adjacent cells is opposite to that within the stimulated cell, which may be indicative of lateral inhibition. Also such interactions promote distortion and suppression in the electrical and, consequently, the mechanical activity of OHCs. Lateral interactions may provide a basis for enhanced frequency selectivity in the basilar membrane of mammals.	Yale Univ, Sch Med, Otolaryngol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA	Yale University; Yale University	Santos-Sacchi, J (corresponding author), Yale Univ, Sch Med, Otolaryngol Sect, 333 Cedar St, New Haven, CT 06510 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000273] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC000273] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ASHMORE JF, 1990, NEUROSCI RES       S, V12, P39; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; DALLOS P, 1992, J NEUROSCI, V12, P4575; DALLOS P, 1995, SCIENCE, V267, P2006, DOI 10.1126/science.7701325; DALLOS P, 1980, PSYCHOPHYSICAL PHYSL, P242; DALLOS P, 1977, PSYCHOPHYSICS PHYSL, P147; Gale JE, 1997, NATURE, V389, P63, DOI 10.1038/37968; GALE JE, 1994, P ROY SOC B-BIOL SCI, V255, P243, DOI 10.1098/rspb.1994.0035; GOLDSTEI.JL, 1968, PR INST ELECTR ELECT, V56, P981, DOI 10.1109/PROC.1968.6449; GOLDSTEIN JL, 1967, J ACOUST SOC AM, V41, P676, DOI 10.1121/1.1910396; HUANG GJ, 1994, P NATL ACAD SCI USA, V91, P12268, DOI 10.1073/pnas.91.25.12268; HUANG GJ, 1993, BIOPHYS J, V65, P2228, DOI 10.1016/S0006-3495(93)81248-7; IWASA KH, 1993, BIOPHYS J, V65, P492, DOI 10.1016/S0006-3495(93)81053-1; JARAMILLO F, 1993, NATURE, V364, P527, DOI 10.1038/364527a0; KAKEHATA S, 1995, BIOPHYS J, V68, P2190, DOI 10.1016/S0006-3495(95)80401-7; KAKEHATA S, 1967, J ACOUST SOC AM, V41, P676; MAMMANO F, 1993, NATURE, V365, P838, DOI 10.1038/365838a0; Narayan SS, 1998, SCIENCE, V282, P1882, DOI 10.1126/science.282.5395.1882; Nuttall AL, 1995, HEARING RES, V92, P170, DOI 10.1016/0378-5955(95)00216-2; SANTOS-SACCHI J, 1988, HEARING RES, V35, P143, DOI 10.1016/0378-5955(88)90113-X; SANTOS-SACCHI J, 1993, BIOPHYS J, V65, P2217, DOI 10.1016/S0006-3495(93)81247-5; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; Santos-Sacchi J, 1998, J PHYSIOL-LONDON, V510, P225, DOI 10.1111/j.1469-7793.1998.225bz.x; SANTOS-SACCHI J, 1992, J NEUROSCI, V12, P1906; TAKAHASHI S, IN PRESS J MEMBR BIO; TUNSTALL MJ, 1995, J PHYSIOL-LONDON, V485, P739, DOI 10.1113/jphysiol.1995.sp020765; VATER M, 1992, J COMP NEUROL, V318, P380, DOI 10.1002/cne.903180404; von Bekesy G., 1960, EXPT HEARING; XUE SW, 1995, J ACOUST SOC AM, V97, P3030, DOI 10.1121/1.413103	30	69	73	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 27	1999	399	6734					359	362		10.1038/20686	http://dx.doi.org/10.1038/20686			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360573				2022-12-01	WOS:000080547800060
J	Geddes, DM; Shah, PL				Geddes, DM; Shah, PL			Where we are now with rhDNase	LANCET			English	Editorial Material							RECOMBINANT HUMAN DNASE; CYSTIC-FIBROSIS		Royal Brompton Hosp, London SW3 6NP, England	Royal Brompton Hospital	Geddes, DM (corresponding author), Royal Brompton Hosp, London SW3 6NP, England.		Shah, Pallav L/AAB-2758-2019	Shah, Pallav L/0000-0002-9052-4638				Davies J, 1997, PEDIATR PULM, V23, P243, DOI 10.1002/(SICI)1099-0496(199704)23:4<243::AID-PPUL1>3.0.CO;2-N; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.3.CO;2-R; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; Milla CE, 1998, THORAX, V53, P1014, DOI 10.1136/thx.53.12.1014; SHAH PL, 1995, RESP MED, V89, P499, DOI 10.1016/0954-6111(95)90126-4	5	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1727	1727		10.1016/S0140-6736(98)00411-5	http://dx.doi.org/10.1016/S0140-6736(98)00411-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347981				2022-12-01	WOS:000080667700006
J	Cesar, JA; Victora, CG; Barros, FC; Santos, IS; Flores, JA				Cesar, JA; Victora, CG; Barros, FC; Santos, IS; Flores, JA			Impact of breast feeding on admission for pneumonia during postneonatal period in Brazil: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							SOUTHERN BRAZIL; DISEASES; CHILDREN; DIARRHEAL	Objective To determine whether breast feeding protects infants against pneumonia and whether the protection varies with age. Design Nested case-control study. Setting Pelotas, southern Brazil. Subjects Cases were 152 infants aged 28-364 days who had been admitted to hospital for pneumonia. Controls were 2391 cases in a population based case-control study Main outcome measure Odds ratio of admission for pneumonia according to type of milk consumed (breast milk alone, breast and formula milk, or formula milk and other fluids only), use of fluid supplements apart from formula milk, and use of solid supplements. Results Infants who were not being breast fed were 17 times more likely than those being breast fed without formula milli to be admitted to hospital for pneumonia (95% confidence interval 7.7 to 36.0). This relative risk was 61 (19.0 to 195.5) for children under 3 months old, decreasing to 10 (2.8 to 36.2) thereafter. Supplementation with solids was associated with a relative risk of 13.4 (7.6 to 23.5) for all infants and 175 (21.8 to 1405.1) for those under 3 months old. Conclusion Breast feeding protects young children against pneumonia, especially in the first months of life. These results may be used for targeting intervention campaigns at the most vulnerable age groups.	Fdn Univ Rio Grande, Dept Materno Infantil, Rio Grande Sol, Brazil; Univ Fed Pelotas, Dept Social Med, Rio Grande Sol, Brazil; Hosp Pediat Santo Antonio, Rio Grande Sol, Brazil	Universidade Federal do Rio Grande; Universidade Federal de Pelotas	Cesar, JA (corresponding author), Univ London London Sch Hyg & Trop Med, Maternal & Child Epidemiol Unit, 49-51 Bedford Sq, London WC1B 3DP, England.		Victora, Cesar G/D-4476-2013; Barros, Fernando C/D-4857-2013; Santos, Ina S/C-2001-2009; Victora, Cesar Gomes/Y-2455-2019	Victora, Cesar G/0000-0002-2465-2180; Victora, Cesar Gomes/0000-0002-2465-2180				BARROS FC, 1986, ACTA PAEDIATR SCAND, V75, P558, DOI 10.1111/j.1651-2227.1986.tb10250.x; BROWN KH, 1989, PEDIATRICS, V83, P31; CERQUEIRO MC, 1990, REV INFECT DIS, V12, pS1021; Cesar JA, 1997, REV SAUDE PUBL, V31, P53, DOI 10.1590/S0034-89101997000100008; CHEN Y, 1988, PEDIATRICS, V81, P58; Dean A.G., 1994, EPI INFO VERSION 6 W; ELLESTADSAYED J, 1979, CAN MED ASSOC J, V120, P295; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; Jelliffe D.B., 1978, HUMAN MILK MODERN WO, P84, DOI 10.1136/bmj.2.6151.1573; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; LOMBARDI C, 1988, REV SAUDE PUBL, V22, P253, DOI 10.1590/S0034-89101988000400001; MORRIS SS, 1995, RISK FACTORS ACUTE L, P2; Norussis NJ, 1993, STAT PACKAGE SOCIAL; PIO A, 1985, ACUTE RESP INFECT CH, P100; RODRIGUES L, 1990, INT J EPIDEMIOL, V13, P87; ROSSNER B, 1995, FUNDAMENTALS BIOSTAT, P345; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P27; SCHWARTZ B, 1994, AETIOLOGY ACUTE LOWE; SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356; *STAT RES CORP, 1988, EP GRAPH EST TEST PA; Victora CG, 1996, REV SAUDE PUBL, V30, P34, DOI 10.1590/S0034-89101996000100005; VICTORA CG, 1994, PEDIATRICS, V93, P977; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224; VICTORA CG, 1987, LANCET, V2, P319; VICTORA CG, 1990, BREASTFEEDING NUTR I, P405; VICTORA CG, 1992, MEASUREMENT MATERNAL, P85; VICTORA CG, IN PRESS AM J CLIN N	27	141	168	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1316	1320		10.1136/bmj.318.7194.1316	http://dx.doi.org/10.1136/bmj.318.7194.1316			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198HR	10323815	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000080418400024
J	Gouet, P; Diprose, JM; Grimes, JM; Malby, R; Burroughs, JN; Zientara, S; Stuart, DI; Mertens, PPC				Gouet, P; Diprose, JM; Grimes, JM; Malby, R; Burroughs, JN; Zientara, S; Stuart, DI; Mertens, PPC			The highly ordered double-stranded RNA genome of bluetongue virus revealed by crystallography	CELL			English	Article							TOBACCO MOSAIC-VIRUS; MOLECULAR REPLACEMENT; ICOSAHEDRAL VIRUS; REOVIRUS GENOME; MESSENGER-RNA; VISUALIZATION; RESOLUTION; PARTICLES; PROTEIN; CORES	The concentration of double-stranded RNA within the bluetongue virus core renders the genome segments liquid crystalline. Powder diffraction rings confirm this local ordering with a 30 Angstrom separation between strands. Determination of the structure of the bluetongue virus core serotype 10 and comparison with that of serotype 1 reveals most of the gc nomic double-stranded RNA, packaged as well-ordered layers surrounding putative transcription complexes at the apices of the particle. The outer layer of RNA is sufficiently well ordered by interaction with the capsid that a model can be built and extended to the less-ordered inner layers, providing a structural framework for understanding the mechanism of this complex transcriptional machine. We show that the genome segments maintain local order during transcription.	Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; AFRC, Inst Anim Hlth, Pirbright Lab, Woking GU24 0NF, Surrey, England; Ctr Natl Etud Vet & Alimentaires Alfort, Lab Cent Rech Vet, F-94703 Maisons Alfort, France; Oxford Ctr Mol Sci, Oxford OX1 3QT, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; Ecole Nationale Veterinaire d'Alfort (ENVA); University of Oxford	Stuart, DI (corresponding author), Univ Oxford, Mol Biophys Lab, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.	dave@biop.ox.ac.uk	Zientara, Stephan/A-5336-2016; Zientara, Stephan/AAA-7661-2021	Zientara, Stephan/0000-0003-0089-8175; Zientara, Stephan/0000-0002-6733-8503; Stuart, David/0000-0002-3426-4210; Mertens, Peter/0000-0002-3438-3738; Grimes, Jonathan Mark/0000-0001-9698-0389; gouet, patrice/0000-0001-9485-6157				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARTLETT NM, 1974, J VIROL, V14, P315, DOI 10.1128/JVI.14.2.315-326.1974; Bourgeois D, 1998, J APPL CRYSTALLOGR, V31, P22, DOI 10.1107/S0021889897006730; BRUNGER AT, 1992, XPLOR VERSION 3 1; BURROUGHS JN, 1995, VIROLOGY, V210, P217, DOI 10.1006/viro.1995.1335; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; DELANO WL, 1995, ACTA CRYSTALLOGR D, V51, P740, DOI 10.1107/S0907444995001284; Dryden KA, 1998, VIROLOGY, V245, P33, DOI 10.1006/viro.1998.9146; EATON BT, 1990, CURR TOP MICROBIOL, V162, P89; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; Foulser D., 1995, Computer Graphics, V29, P13, DOI 10.1145/204362.204365; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GILLIES S, 1971, SCIENCE, V174, P694, DOI 10.1126/science.174.4010.694; GRIME GW, 1991, NUCL INSTRUM METH B, V54, P52, DOI 10.1016/0168-583X(91)95490-5; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Joklik WK, 1996, PROG NUCLEIC ACID RE, V53, P249, DOI 10.1016/S0079-6603(08)60147-6; JOKLIK WK, 1983, REOVIRIDAE, P9; LARSON SB, 1993, NATURE, V361, P179, DOI 10.1038/361179a0; Lawton JA, 1997, NAT STRUCT BIOL, V4, P118, DOI 10.1038/nsb0297-118; Livolant F, 1996, PROG POLYM SCI, V21, P1115, DOI 10.1016/S0079-6700(96)00016-0; MACFARLANE SA, 1991, VIROLOGY, V183, P405, DOI 10.1016/0042-6822(91)90155-5; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mertens P. P. C., 1992, Bluetongue, African horse sickness, and related orbiviruses: Proceedings of the Second International Symposium., P404; MERTENS PPC, 1987, VIROLOGY, V157, P375, DOI 10.1016/0042-6822(87)90280-7; Millward S, 1983, REOVIRIDAE, P107; NAMBA K, 1989, J MOL BIOL, V208, P307, DOI 10.1016/0022-2836(89)90391-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payne C.C., 1983, P425; Prasad BVV, 1996, NATURE, V382, P471, DOI 10.1038/382471a0; Qiao XY, 1997, P NATL ACAD SCI USA, V94, P4074, DOI 10.1073/pnas.94.8.4074; Ramadevi N, 1998, P NATL ACAD SCI USA, V95, P13537, DOI 10.1073/pnas.95.23.13537; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; Roner MR, 1995, P NATL ACAD SCI USA, V92, P12362, DOI 10.1073/pnas.92.26.12362; RONER MR, 1990, VIROLOGY, V179, P845, DOI 10.1016/0042-6822(90)90153-I; ROUSSEL A, 1991, TURBO FRODO; ROY P, 1992, J GEN VIROL, V73, P3051, DOI 10.1099/0022-1317-73-12-3051; ROY P, 1989, VIRUS RES, V13, P179, DOI 10.1016/0168-1702(89)90015-4; Shaw AL, 1996, STRUCTURE, V4, P957, DOI 10.1016/S0969-2126(96)00102-5; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; Stuart DI, 1998, ARCH VIROL, P235; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; Tsuruta H, 1998, J MOL BIOL, V284, P1439, DOI 10.1006/jmbi.1998.2231; WANG BC, 1985, DIFFRACTION METHODS, P90; WHITE CK, 1976, VIROLOGY, V70, P171, DOI 10.1016/0042-6822(76)90247-6; YAZAKI K, 1980, VIROLOGY, V105, P467, DOI 10.1016/0042-6822(80)90047-1	50	147	156	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					481	490		10.1016/S0092-8674(00)80758-8	http://dx.doi.org/10.1016/S0092-8674(00)80758-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338212	Bronze			2022-12-01	WOS:000080299100009
J	Griffith, JD; Comeau, L; Rosenfield, S; Stansel, RM; Bianchi, A; Moss, H; de Lange, T				Griffith, JD; Comeau, L; Rosenfield, S; Stansel, RM; Bianchi, A; Moss, H; de Lange, T			Mammalian telomeres end in a large duplex loop	CELL			English	Article							ESCHERICHIA-COLI; BINDING-PROTEIN; DNA; TRF1; MOUSE; YEAST; CELL; TETRAHYMENA; POLYMERASE; SEQUENCES	Mammalian telomeres contain a duplex array of telomeric repeats bound to the telomeric repeat-binding factors TRF1 and TRF2. Inhibition of TRF2 results in immediate deprotection of chromosome ends, manifested by loss of the telomeric 3' overhang, activation of p53, and end-to-end chromosome fusions. Electron microscopy reported here demonstrated that TRF2 can remodel linear telomeric DNA into large duplex loops (t loops) in vitro. Electron microscopy analysis of psoralen cross-linked telomeric DNA purified from human and mouse cells revealed abundant large t loops with a size distribution consistent with their telomeric origin. Binding of TRF1 and single strand binding protein suggested that t loops are formed by invasion of the 3' telomeric overhang into the duplex telomeric repeat array. T loops may provide a general mechanism for the protection and replication of telomeres.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Rockefeller Univ, New York, NY 10021 USA	University of North Carolina; University of North Carolina Chapel Hill; Rockefeller University	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.		de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X; Bianchi, Alessandro/0000-0001-6583-1671	NCI NIH HHS [CA19043] Funding Source: Medline; NIGMS NIH HHS [GM31819, GM49046] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049046, R01GM031819, R01GM049046] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; BIANCHI A, 1999, THESIS ROCKEFELLER U; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; CECH TR, 1976, P NATL ACAD SCI USA, V73, P2644, DOI 10.1073/pnas.73.8.2644; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; de Lange T, 1999, SCIENCE, V283, P947, DOI 10.1126/science.283.5404.947; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; deLange T, 1996, SEMIN CELL DEV BIOL, V7, P23, DOI 10.1006/scdb.1996.0005; DELANGE T, 1995, TELOMERES, P265; Gall J. G., 1995, TELOMERES, P1; GOLDBACH RW, 1979, BIOCHIM BIOPHYS ACTA, V562, P400, DOI 10.1016/0005-2787(79)90104-7; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HANSON CV, 1976, SCIENCE, V193, P62, DOI 10.1126/science.935855; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KLEINSCHMIDT A., 1959, ZEIT NATURFORSCH, V14b, P770; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KREUZER KN, 1994, MOL BIOL BACTERIOP T, V4, P28; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; McClintock B, 1941, GENETICS, V26, P234; MORIN GB, 1988, CELL, V52, P367, DOI 10.1016/S0092-8674(88)80029-1; Muller HJ., 1938, COLLECT NET, V13, P181; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Price C, 1999, NATURE, V397, P213, DOI 10.1038/16598; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	52	1826	1905	10	139	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					503	514		10.1016/S0092-8674(00)80760-6	http://dx.doi.org/10.1016/S0092-8674(00)80760-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338214	Bronze			2022-12-01	WOS:000080299100011
J	Pestano, GA; Zhou, YL; Trimble, LA; Daley, J; Weber, GF; Cantor, H				Pestano, GA; Zhou, YL; Trimble, LA; Daley, J; Weber, GF; Cantor, H			Inactivation of misselected CD8 T cells by CD8 gene methylation and cell death	SCIENCE			English	Article							MHC CLASS-I; IMMATURE THYMOCYTES; POSITIVE SELECTION; THYMIC SELECTION; DEFICIENT MICE; LPR MICE; RECEPTOR; LYMPHOCYTES; ANTIGEN; SPECIFICITY	Misselected CD8 cells that express T cell receptors (TCRs) that do not recognize class I major histocompatibility complex (MHC) protein can emerge from thymic selection. A postthymic quality control mechanism that purges these cells from the repertoire is defined here. The failure of mature CD8 cells to simultaneously engage their TCR and CD8 coreceptor triggers an activation process that begins with inhibition of CD8 gene expression through remethylation and concludes with up-regulation of surface Fas and pas Ligand and cellular apoptosis. Thus, inhibition of a death signal through continued TCR-CD8 coengagement of MHC molecules is a key checkpoint for the continued survival of correctly selected T cells. Molecular defects that prevent delivery of the death signal to mistakenly selected T cells underlie the expansion of double-negative T cells, which is the cellular signature of a subset of systemic autoimmune diseases.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Cantor, H (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA76176] Funding Source: Medline; NIAID NIH HHS [AI 13600, AI 37833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037833, R01AI013600] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APASOV SG, 1994, J IMMUNOL, V152, P2087; Basson MA, 1998, J EXP MED, V187, P1249; BENEDIKT K, 1998, J IMMUNOL, V161, P6939; CARBONE AM, 1988, SCIENCE, V242, P1174, DOI 10.1126/science.2460926; CARBONE AM, 1988, J IMMUNOL, V141, P1369; Cho BK, 1999, P NATL ACAD SCI USA, V96, P2976, DOI 10.1073/pnas.96.6.2976; Chung DH, 1996, HUM IMMUNOL, V45, P124, DOI 10.1016/0198-8859(95)00168-9; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; CRUMP AL, 1993, P NATL ACAD SCI USA, V90, P10739, DOI 10.1073/pnas.90.22.10739; Devi BS, 1998, J AUTOIMMUN, V11, P471, DOI 10.1006/jaut.1998.0213; EBNET K, 1991, INT IMMUNOL, V3, P9, DOI 10.1093/intimm/3.1.9; Fehling HJ, 1997, CURR OPIN IMMUNOL, V9, P263, DOI 10.1016/S0952-7915(97)80146-X; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Hertz M, 1998, NATURE, V394, P292, DOI 10.1038/28419; IWABUCHI K, 1992, P NATL ACAD SCI USA, V89, P9000, DOI 10.1073/pnas.89.19.9000; Jameson SC, 1998, CURR OPIN IMMUNOL, V10, P214, DOI 10.1016/S0952-7915(98)80251-3; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOH DR, 1995, EUR J IMMUNOL, V25, P2558, DOI 10.1002/eji.1830250923; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; LeDeist F, 1996, LANCET, V348, P719, DOI 10.1016/S0140-6736(96)02293-3; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MALDONADO MA, 1995, J EXP MED, V181, P64; Maniatis T., 1982, MOL CLONING LAB MANU; Marrack P, 1997, CURR OPIN IMMUNOL, V9, P250, DOI 10.1016/S0952-7915(97)80144-6; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nesic D, 1998, J IMMUNOL, V160, P3705; PATARCA R, 1990, J EXP MED, V172, P1177, DOI 10.1084/jem.172.4.1177; Perkins DL, 1996, J IMMUNOL, V156, P4961; PESTANO GA, UNPUB; Preckel T, 1998, EUR J IMMUNOL, V28, P3706, DOI 10.1002/(SICI)1521-4141(199811)28:11<3706::AID-IMMU3706>3.0.CO;2-7; RAO A, 1983, IMMUNOGENETICS, V17, P147, DOI 10.1007/BF00364755; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Schulz RJ, 1996, J IMMUNOL, V157, P4379; SOBEL ES, 1995, CLIN IMMUNOL IMMUNOP, V74, P177, DOI 10.1006/clin.1995.1026; SUZUKI H, 1994, J IMMUNOL, V153, P4496; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Volkmann A, 1998, J EXP MED, V188, P1083, DOI 10.1084/jem.188.6.1083; VONBOEHMER H, 1997, IMMUNOLOGIST, V5, P185; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2	49	72	78	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1187	1191		10.1126/science.284.5417.1187	http://dx.doi.org/10.1126/science.284.5417.1187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325233				2022-12-01	WOS:000080359100043
J	San-Segundo, PA; Roeder, GS				San-Segundo, PA; Roeder, GS			Pch2 links chromatin silencing to meiotic checkpoint control	CELL			English	Article							SYNAPTONEMAL COMPLEX PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; GENE-EXPRESSION; RIBOSOMAL DNA; YEAST; RECOMBINATION; MEIOSIS; NUCLEOLUS; MUTANTS	The PCH2 gene of Saccharomyces cerevisiae is required for the meiotic checkpoint that prevents chromosome segregation when recombination and chromosome synapsis are defective. Mutation of PCH2 relieves the checkpoint-induced pachytene arrest of the zip1, zip2, and dmc1 mutants, resulting in chromosome missegregation and low spore viability. Most of the Pch2 protein localizes to the nucleolus, where it represses meiotic interhomolog recombination in the ribosomal DNA, apparently by excluding the meiosis-specific Hop1 protein. Nucleolar localization of Pch2 depends on the silencing factor Sir2, and mutation of SIR2 also bypasses the zip1 pachytene arrest. Under certain circumstances, Sir3-dependent localization of Pch2 to telomeres also provides checkpoint function. These unexpected findings link the nucleolus, chromatin silencing, and the pachytene checkpoint.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Roeder, GS (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.		San-Segundo, Pedro A/L-4539-2014	San-Segundo, Pedro A/0000-0002-5616-574X	NIGMS NIH HHS [GM28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beyer A, 1997, PROTEIN SCI, V6, P2043; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; ENGEBRECHT JA, 1989, GENETICS, V121, P237; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; McKee AHZ, 1997, GENETICS, V146, P817; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; Nierras CR, 1997, CHROMOSOMA, V105, P444; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PETES TD, 1977, P NATL ACAD SCI USA, V74, P5091, DOI 10.1073/pnas.74.11.5091; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Santos B, 1997, J CELL BIOL, V136, P95, DOI 10.1083/jcb.136.1.95; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Singer MS, 1998, GENETICS, V150, P613; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tung KS, 1998, GENETICS, V149, P817; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2	48	207	210	3	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					313	324		10.1016/S0092-8674(00)80741-2	http://dx.doi.org/10.1016/S0092-8674(00)80741-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319812	Bronze			2022-12-01	WOS:000080100500005
J	Emerson, PM; Lindsay, SW; Walraven, GEL; Faal, H; Bogh, C; Lowe, K; Bailey, RL				Emerson, PM; Lindsay, SW; Walraven, GEL; Faal, H; Bogh, C; Lowe, K; Bailey, RL			Effect of fly control on trachoma and diarrhoea	LANCET			English	Article							GAMBIAN VILLAGE; MUSCA-DOMESTICA; TRANSMISSION; IMPACT	Background Domestic flies are accepted vectors of diarrhoea, but their role in trachoma transmission has never been quantified and no study has shown that fly control decreases the prevalence of trachoma. We assessed the effect of fly control on public health in a pilot study in Gambian villages. Methods We studied two pairs of villages-one pair in the 1997 wet season, and one pair in the 1998 dry season. For each pair, deltamethrin was sprayed for 3 months to control flies in one village whilst the other was used as a control. Fly populations were monitored with traps. We surveyed trachoma at baseline and at 3 months, and collected daily data on diarrhoea in children aged between 3 months and 5 years. Findings Fly control decreased numbers of muscid flies by around 75% in the intervention villages compared with controls. Trachoma prevalence was similar at baseline (wet season, prevalence in intervention village 8.8% vs control 12.2%; dry season, 18.0% vs 16.0%), but after 3 months of fly control there were 75% fewer new cases of trachoma in the intervention villages (wet season 3.7% vs 13.7%; dry season 10.0% vs 18.9%; rate ratio and relative risk of pooled data 0.25 [adjusted 95% CI 0.09-0.64], p=0.003). There was 22% less childhood diarrhoea in the wet season (14% vs 19%, period prevalence ratio 0.78 [0.64-0.95], p=0.01), and 26% less diarrhoea in the dry season (6% vs 8%; 0.74 [0.34-1.59], p=0.60) compared with controls. Interpretation Muscid flies are important vectors of trachoma and childhood diarrhoea in The Gambia. Deltamethrin spray is effective for fly control and may be useful for reducing trachoma and diarrhoea in some situations, but further research on sustainable fly-control methods is needed.	MRC, Banjul, Gambia; Univ Durham, Durham DH1 3HP, England; Danish Bilharziasis Lab, Charlottenlund, Denmark; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; Durham University; University of London; London School of Hygiene & Tropical Medicine	Emerson, PM (corresponding author), MRC Labs, POB 273, Banjul, Gambia.			Emerson, Paul/0000-0002-6478-8816				BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944; BAILEY RL, 1994, J INFECT DIS, V170, P709, DOI 10.1093/infdis/170.3.709; BENN C, 1992, B WORLD HEALTH ORGAN, V70, P705; COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N; DOLIN PJ, 1997, LANCET, V349, P151; FORSEY T, 1981, BRIT J OPHTHALMOL, V65, P147, DOI 10.1136/bjo.65.2.147; FOTEDAR R, 1992, J HOSP INFECT, V20, P209, DOI 10.1016/0195-6701(92)90089-5; GREENWOOD BM, 1993, T R SOC TROP MED S2, V87, pS2; MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295, DOI 10.1080/02724936.1991.11747518; Maccallan A F, 1931, Br J Ophthalmol, V15, P369, DOI 10.1136/bjo.15.7.369; MONZON R B, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P222; REINHARD.J, 1968, B WORLD HEALTH ORGAN, V39, P497; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P145; TAYLOR HR, 1988, AM J TROP MED HYG, V38, P623, DOI 10.4269/ajtmh.1988.38.623; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088; WRIGHT EP, 1983, J HYG-CAMBRIDGE, V91, P223, DOI 10.1017/S0022172400060228	19	136	139	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1401	1403		10.1016/S0140-6736(98)09158-2	http://dx.doi.org/10.1016/S0140-6736(98)09158-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227221				2022-12-01	WOS:000080020800013
J	Goldhaber, SZ; Visani, L; De Rosa, M				Goldhaber, SZ; Visani, L; De Rosa, M		ICOPER	Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)	LANCET			English	Article							RANDOMIZED TRIAL; ALTEPLASE; HEPARIN; ECHOCARDIOGRAPHY; RECURRENCE; THERAPY	Background Pulmonary embolism (PE) remains poorly understood. Rates of clinical outcomes such as death and recurrence vary widely among trials. We therefore establish the International Cooperative Pulmonary Embolism Registry (ICOPER), with the aim of identifying factors associated with death. Methods 2454 consecutive eligible patients with acute PE were registered from 52 hospitals in seven countries in Europe and North America. The primary outcome measure was all-cause mortality at 3 months. The prognostic effect of baseline factors on survival was assessed with multivariate analyses, Findings 2110 (86.0%) patients had PE proven by necropsy, high-probability lung scan, pulmonary angiography, or venous ultrasonography plus high clinical suspicion; ICOPER accepted without independent review diagnoses and interpretation of imaging provided by participating centres; 3-month follow-up was completed in 98.0% of patients. The overall crude mortality rate at 3 months was 17.4% (426 of 2454 deaths, including 52 patients lost to follow-up): 179 of 397 (45.1%) deaths were ascribed to PE and 70 of 397 (17.6%) to cancer, and no information on the cause of death was available for 29 patients. After exclusion of 61 patients in whom PE was first discovered at necropsy, the mortality rate at 3 months was 15.3% (365 of 2393 deaths). On multiple-regression modelling, age over 70 years (hazard ratio 1.6 [95% CI 1.1-2.3]), cancer (2.3 [1.5-3.5]), congestive heart failure (2.4 [1.5-3.7]), chronic obstructive pulmonary disease (1.8 [1.2-2.7]), systolic arterial hypotension (2.9 [1.7-5.0]) tachypnoea (2.0 [1.2-3.2]), and right-ventricular hypokinesis on echocardiography (2.0 [1.3-2.9]) were identified as significant prognostic factors. Interpretation PE remains an important clinical problem with a high mortality rate. Data from ICOPER provide rates and highlight adverse prognostic categories that will help in planning of future trials of high-risk PE patients.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Boehringer Ingelheim Italia, Milan, Italy; CINECA, Bologna, Italy	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boehringer Ingelheim; CINECA, Italy	Goldhaber, SZ (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.							Cannon CP, 1996, AM J CARDIOL, V78, P1149, DOI 10.1016/S0002-9149(96)90069-7; DALLAVOLTA S, 1992, J AM COLL CARDIOL, V20, P520, DOI 10.1016/0735-1097(92)90002-5; GIRARD P, 1987, THORAX, V42, P481, DOI 10.1136/thx.42.7.481; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; GOLDHABER SZ, 1994, CHEST, V106, P718, DOI 10.1378/chest.106.3.718; HIRSCH DR, 1995, JAMA-J AM MED ASSOC, V274, P335, DOI 10.1001/jama.274.4.335; Hull RD, 1997, ARCH INTERN MED, V157, P2317, DOI 10.1001/archinte.157.20.2317; Kanter DS, 1997, CHEST, V111, P1241, DOI 10.1378/chest.111.5.1241; Kasper W, 1997, J AM COLL CARDIOL, V30, P1165, DOI 10.1016/S0735-1097(97)00319-7; Kasper W, 1997, HEART, V77, P346, DOI 10.1136/hrt.77.4.346; *NAT COOP STUD, 1973, CIRCULATION S2, V47, P1; Ribeiro A, 1997, AM HEART J, V134, P479, DOI 10.1016/S0002-8703(97)70085-1	12	1969	2100	0	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1386	1389		10.1016/S0140-6736(98)07534-5	http://dx.doi.org/10.1016/S0140-6736(98)07534-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227218				2022-12-01	WOS:000080020800010
J	Denoyelle, F; Marlin, S; Weil, D; Moatti, L; Chauvin, P; Garabedian, EN; Petit, C				Denoyelle, F; Marlin, S; Weil, D; Moatti, L; Chauvin, P; Garabedian, EN; Petit, C			Clinical features of the prevalent form of childhood deafness, DFNB1, due to a connexin-26 gene defect: implications for genetic counselling	LANCET			English	Article							SYNDROMIC RECESSIVE DEAFNESS; NONSYNDROMIC HEARING-LOSS; MYOSIN-VIIA GENE; SENSORINEURAL DEAFNESS; MUTATIONS; IDENTIFICATION	Background DFNB1, the locus of an autosomal recessive form of deafness due to mutations in the connexin-26 gene (CX26 or GJB2) is one of the most frequent hereditary defects in human beings. To date, no clinical characterisation of the DFNB1 inner-ear defects has been reported, which precludes the provision of prognostic information and genetic counselling. Methods We enrolled, in a prospective study, 140 children from 104 families affected by sensorineural deafness with various degrees of hearing loss. The children either belonged to a family affected by autosomal recessive deafness (DFNB family) or represented sporadic cases. We searched for mutations in the 5' non-coding exon and in the coding region of CX26. Audiometric and radiological features were investigated and compared in deaf children with and without CX26 mutations. Findings CX26 mutations were present in 43 (49%) of the 88 families with cases of prelingual deafness versus none of;the 16 families with postlingual forms of deafness (p < 0 . 01). The inner-ear defects of 54 prelingually deaf children with biallelic CX26 mutations were compared with the defects in 57 prelingually deaf children without CX26 mutations. DFNB1 deafness varied from mild to profound, associated with sloping or flat audiometric curves and a radiologically normal inner ear. Hearing loss was not progressive in 11 of 16 cases tested, and variations in the severity of deafness between siblings were common. Interpretation The characteristic audiometric and radiological features of DFNB1 should be the reference used to guide the investigation,by CX26 molecular diagnostic tests,of deaf children with a compatible phenotype. Prognostic information can now be given to families: the hearing loss in DFNB1 deafness is non-progressive in most cases, at least up to young adulthood. An important element for genetic counselling is that the severity of hearing loss due to DFNB1 is extremely variable and cannot be predicted, even within families.	Inst Pasteur, Unite Genet Deficits Sensoriels, CNRS, URA 1968, F-75724 Paris 15, France; Hop Enfants Armand Trousseau, Serv ORL, Paris, France; Univ Paris 06, Fac Med St Antoine, INSERM,U444, Unite Rech Epidemiol & Sci Informat, Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Petit, C (corresponding author), Inst Pasteur, Unite Genet Deficits Sensoriels, CNRS, URA 1968, F-75724 Paris 15, France.		Chauvin, Pierre/G-1095-2015; Chauvin, Pierre/S-2981-2019	Chauvin, Pierre/0000-0002-9183-6406; Chauvin, Pierre/0000-0002-9183-6406; Denoyelle, Francoise/0000-0003-4338-9258; Petit, Christine/0000-0002-9069-002X; marlin, sandrine/0000-0002-4115-9806				BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; Cystic Fibrosis Genetic Anal Consortium, 1990, AM J HUM GENET, V47, P354; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Denoyelle F, 1998, NATURE, V393, P319, DOI 10.1038/30639; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; FISHER NA, 1994, OTOLARYNG CLIN N AM, V27, P511; FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003; GORLIN RJ, 1995, HEREDITARY HEARING L, V28, P43; HUYGEN PLM, 1993, INT J PEDIATR OTORHI, V25, P39, DOI 10.1016/0165-5876(93)90008-Q; Jackler RK, 1987, LARYNGOSCOPE 2 S40, V3, P2; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; Kelley PM, 1998, AM J HUM GENET, V62, P792, DOI 10.1086/301807; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Lench N, 1998, LANCET, V351, P415, DOI 10.1016/S0140-6736(98)24006-2; Li XC, 1998, NAT GENET, V18, P215, DOI 10.1038/ng0398-215; LIU XZ, 1994, ANN OTO RHINOL LARYN, V103, P428, DOI 10.1177/000348949410300602; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; PABLA HS, 1991, INT J PEDIATR OTORHI, V22, P161, DOI 10.1016/0165-5876(91)90035-A; PARVING A, 1985, INT J PEDIATR OTORHI, V9, P31, DOI 10.1016/S0165-5876(85)80003-3; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; Ressot C, 1998, J NEUROSCI, V18, P4063; Scott DA, 1998, HUM MUTAT, V11, P387, DOI 10.1002/(SICI)1098-1004(1998)11:5<387::AID-HUMU6>3.0.CO;2-8; Vartiainen E, 1997, INT J PEDIATR OTORHI, V41, P175, DOI 10.1016/S0165-5876(97)00080-3; Wang AH, 1998, SCIENCE, V280, P1447, DOI 10.1126/science.280.5368.1447; Weil D, 1997, NAT GENET, V16, P191, DOI 10.1038/ng0697-191; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	27	331	358	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 17	1999	353	9161					1298	1303		10.1016/S0140-6736(98)11071-1	http://dx.doi.org/10.1016/S0140-6736(98)11071-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XU	10218527				2022-12-01	WOS:000080278100009
J	LaRusso, N				LaRusso, N			Search for medical treatment for primary biliary cirrhosis	LANCET			English	Editorial Material											LaRusso, N (corresponding author), MAYO CLIN & MAYO FDN,DIV GASTROENTEROL,ROCHESTER,MN 55905, USA.							BERK PD, 1997, SEM LIV DIS 1 FEB, V17; Kaplan MM, 1997, ANN INTERN MED, V126, P682, DOI 10.7326/0003-4819-126-9-199705010-00002; Neuberger J, 1997, LANCET, V350, P875, DOI 10.1016/S0140-6736(97)05419-6	3	2	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1046	1046		10.1016/S0140-6736(05)70452-9	http://dx.doi.org/10.1016/S0140-6736(05)70452-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213545				2022-12-01	WOS:A1997YA73400006
J	Franklyn, JA; Maisonneuve, P; Sheppard, M; Betteridge, J; Boyle, P				Franklyn, JA; Maisonneuve, P; Sheppard, M; Betteridge, J; Boyle, P			Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study	LANCET			English	Article							I-131 THERAPY; FOLLOW-UP; RADIOACTIVE IODINE; BREAST-CANCER; THYROTOXICOSIS; RISK	Background Radioiodine is used increasingly as first-line treatment for hyperthyroidism, but concerns remain about subsequent risk of cancer, especially in those treated at a young age, We investigated cancer incidence and mortality in patients treated with radioiodine for hyperthyroidism, Methods We did a population-based study in 7417 patients treated in Birmingham, UK, between 1950 and 1991. We compared details of all cancer diagnoses and deaths in 1971-91 from the UK Office for National Statistics with data on cancer incidence and mortality for England and Wales specific for age, sex, and period. Findings During 72 073 person-years of follow-up, 634 cancer diagnoses were made, compared with an expected number of 761 (standardised incidence ratio [SIR] 0.83 [95% CI 0.77-0.90]), The relative risk of cancer mortality was also decreased (observed cancer deaths 448, expected 499; standardised mortality ratio [SMR] 0.90 [0.82-0.98]). Incidence of cancers of the pancreas, bronchus, trachea, bladder, and lymphatic and haemopoietic systems was lowered. Mortality from cancers at all these sites was also reduced but findings were significant only for bronchus and trachea. There were significant increases in incidence and mortality for cancers of the small bowel (SIR 4.81 [2.16-10.72], SMR 7.03 [3.16-15.66]) and thyroid (SIR 3.25 [1.69-6.25], SMR 2.78 [1.16- 6.77]), although absolute risk of these cancers was small. Interpretation The decrease in overall cancer incidence and mortality in those treated for hyperthyroidism with radioiodine is reassuring. The absolute risk of cancers of the small bower and thyroid remain low, but the increased relative risk shows the need for long-term vigilance in those receiving radioiodine.	Univ Birmingham, Dept Med, Birmingham, W Midlands, England; European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy	University of Birmingham; IRCCS European Institute of Oncology (IEO)	Franklyn, JA (corresponding author), Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England.		Boyle, Peter/A-4380-2014; Maisonneuve, Patrick/U-9789-2018	Boyle, Peter/0000-0001-6251-0610; Maisonneuve, Patrick/0000-0002-5309-4704				BARBER SG, 1977, LANCET, V2, P967; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BAXTER MA, 1993, Q J MED, V86, P495, DOI 10.1093/qjmed/86.8.495; Boyle P, 1997, LUNG CANCER, V17, P1, DOI 10.1016/S0169-5002(97)00648-X; DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem-38-6-976; FRANKLYN JA, 1991, CLIN ENDOCRINOL, V34, P71, DOI 10.1111/j.1365-2265.1991.tb01738.x; Franklyn JA, 1998, NEW ENGL J MED, V338, P712, DOI 10.1056/NEJM199803123381103; FRANKLYN JA, 1994, NEW ENGL J MED, V330, P1731; GOLDMAN MB, 1988, AM J EPIDEMIOL, V127, P969, DOI 10.1093/oxfordjournals.aje.a114900; HALL P, 1992, LANCET, V340, P1; HALL P, 1992, INT J CANCER, V50, P886, DOI 10.1002/ijc.2910500611; HOFFMAN DA, 1982, AM J EPIDEMIOL, V115, P243, DOI 10.1093/oxfordjournals.aje.a113296; HOFFMAN DA, 1982, INT J EPIDEMIOL, V11, P218, DOI 10.1093/ije/11.3.218; HOFFMAN DA, 1983, J NATL CANCER I, V70, P63; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; KERBER RA, 1993, JAMA-J AM MED ASSOC, V270, P2076; MUIR C, 1987, IARC SCI PUBLICATION, V88; Pacini F, 1997, J CLIN ENDOCR METAB, V82, P3563, DOI 10.1210/jc.82.11.3563; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; Ron E, 1998, JAMA-J AM MED ASSOC, V280, P347, DOI 10.1001/jama.280.4.347; SHORE RE, 1985, J NATL CANCER I, V74, P1177; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; Waterhouse J., 1976, IARC SCI PUBLICATION, V15; Waterhouse JA, 1982, IARC SCI PUBLICATION, VIV; *WHO, 1977, INT CLASS DIS MAN IN, V1	26	165	172	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2111	2115		10.1016/S0140-6736(98)12295-X	http://dx.doi.org/10.1016/S0140-6736(98)12295-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382695				2022-12-01	WOS:000080969300011
J	Blelloch, R; Kimble, J				Blelloch, R; Kimble, J			Control of organ shape by a secreted metalloprotease in the nematode Caenorhabditis elegans	NATURE			English	Article							SEQUENCE-TAGGED SITES; I N-PROTEINASE; PROGELATINASE-A; GENE; SUPERFAMILY; EXPRESSION; ACTIVATION; CLONING	The molecular controls governing organ shape are poorly understood. In the nematode Caenorhabditis elegans, the gonad acquires a U-shape by the directed migration of a specialized 'leader' cell, which is located at the tip of the growing gonadal 'arm'(1). The gon-1 gene is essential for gonadal morphogenesis: in gon-1 mutants, no arm elongation occurs and somatic gonadal structures are severely malformed(2). Here we report that gon-1 encodes a secreted protein with a metalloprotease domain and multiple thrombospondin type-1-like repeats. This motif architecture is typical of a small family of genes that include bovine procollagen I N-protease (P1NP), which cleaves collagen(3), and murine ADAMTS-1, the expression of which correlates with tumour cell progression(4). We find that gon-1 is expressed in two sites, leader cells and muscle, and that expression in each site has a unique role in forming the gonad. We speculate that GON-1 controls morphogenesis by remodelling basement membranes and that regulation of its activity is crucial for achieving organ shape.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Cell & Mol Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kimble, J (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA.	jekimble@facstaff.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams J. C., 1995, THROMBOSPONDIN GENE; BLELLOCH R, GON 1 GENE REGULATES; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cha J, 1997, BIOCHEMISTRY-US, V36, P16019, DOI 10.1021/bi972223g; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; KIMBLE JE, 1981, DEV BIOL, V81, P208, DOI 10.1016/0012-1606(81)90284-0; Korswagen HC, 1996, P NATL ACAD SCI USA, V93, P14680, DOI 10.1073/pnas.93.25.14680; KRAUSE M, 1995, CAENORHABDITIS ELEGA, P513; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; Mello C, 1995, CAENORHABDITIS ELEGA, P451; OKKEMA PG, 1993, GENETICS, V135, P385; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SCHEDL T, 1997, C ELEGANS, V2, P241; STOCKER W, 1995, PROTEIN SCI, V4, P823; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMS BD, 1992, GENETICS, V131, P609; [No title captured]	24	159	166	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					586	590		10.1038/21196	http://dx.doi.org/10.1038/21196			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376599				2022-12-01	WOS:000080778400056
J	Voltz, R; Gultekin, SH; Rosenfeld, MR; Gerstner, E; Eichen, J; Posner, JB; Dalmau, J				Voltz, R; Gultekin, SH; Rosenfeld, MR; Gerstner, E; Eichen, J; Posner, JB; Dalmau, J			A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENCEPHALOMYELITIS SENSORY NEURONOPATHY; ANTIGENS; EXPRESSION; CARCINOMA; ANTIBODY; TISSUE	Background In patients with cancer, symptoms of limbic and brain-stem dysfunction may result from a paraneoplastic disorder. Paraneoplastic limbic or brain-stem encephalitis occurs more frequently with testicular cancer than with most other cancers. We sought antineuronal antibodies that might be used in a diagnostic test for this syndrome. Methods Immunohistochemical and immunoblotting techniques were used to detect serum and cerebrospinal fluid antibodies. Serologic screening of a complementary DNA library and Northern blotting were used to clone the target antigen and determine which tissues expressed it. RESULTS Of 13 patients with testicular cancer and paraneoplastic limbic or brain-stem encephalitis (or both), 10 had antibodies in serum and cerebrospinal fluid against a 40-kd neuronal protein. These antibodies were used to clone a gene that we call Ma2, which codes for a protein (Ma2) that was recognized by serum from the 10 patients, but not by serum from 344 control subjects. Ma2 was selectively expressed by normal brain tissue and by the testicular tumors of the patients. Ma2 shares homology with Ma?, a "brain-testis-cancer" gene related to other paraneoplastic syndromes and tumors. Conclusions The serum of patients with subacute limbic and brain-stem dysfunction and testicular cancer contains antibodies against a protein found in normal brain and in testicular tumors. Detection of these antibodies supports the paraneoplastic origin of the neurologic disorder and could be of diagnostic importance. (N Engl J Med 1999;340:1788-95.) (C) 1999, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cotzias Lab Neurooncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Dalmau, J (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA.			Dalmau, Josep/0000-0001-5856-2813	NINDS NIH HHS [NS-26064] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026064] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHERN GL, 1994, NEUROLOGY, V44, P1270, DOI 10.1212/WNL.44.7.1270; Alamowitch S, 1997, BRAIN, V120, P923, DOI 10.1093/brain/120.6.923; BAKHEIT AMO, 1990, J NEUROL NEUROSUR PS, V53, P1084, DOI 10.1136/jnnp.53.12.1084; Bennett JL, 1999, NEUROLOGY, V52, P864, DOI 10.1212/WNL.52.4.864; BURTON GV, 1988, CANCER, V62, P2248, DOI 10.1002/1097-0142(19881115)62:10<2248::AID-CNCR2820621029>3.0.CO;2-X; CATTORETTI G, 1993, J PATHOL, V171, P83, DOI 10.1002/path.1711710205; Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919; CORSELLIS JA, 1968, BRAIN, V91, P481, DOI 10.1093/brain/91.3.481; Dalmau J, 1999, BRAIN, V122, P27, DOI 10.1093/brain/122.1.27; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; DALMAU J, 1992, AM J PATHOL, V141, P881; Dalmau JO, 1997, SEMIN ONCOL, V24, P318; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DIRR LY, 1990, NEUROLOGY, V40, P1304, DOI 10.1212/WNL.40.8.1304; DROPCHO EJ, 1994, ANN NEUROL, V36, P200, DOI 10.1002/ana.410360212; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; Henson RA., 1982, CANC NERVOUS SYSTEM, P314; LEE LG, 1992, NUCLEIC ACIDS RES, V20, P2471, DOI 10.1093/nar/20.10.2471; POSNER JB, 1995, NEUROLOGIC COMPLICAT, P353; SCHULLER E, 1990, TRENDS IN NEUROIMMUNOLOGY, P3; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z	22	247	262	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1999	340	23					1788	1795		10.1056/NEJM199906103402303	http://dx.doi.org/10.1056/NEJM199906103402303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	203UU	10362822				2022-12-01	WOS:000080726800003
J	Marston, A				Marston, A			Gut rot	LANCET			English	Editorial Material											Marston, A (corresponding author), 4 Hereford Sq, London SW7 4TT, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1875	1877		10.1016/S0140-6736(98)11456-3	http://dx.doi.org/10.1016/S0140-6736(98)11456-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359430				2022-12-01	WOS:000080667800048
J	Ridker, PM; Manson, JE; Buring, JE; Shih, J; Matias, M; Hennekens, CH				Ridker, PM; Manson, JE; Buring, JE; Shih, J; Matias, M; Hennekens, CH			Homocysteine and risk of cardiovascular disease among postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; SERUM TOTAL HOMOCYSTEINE; PLASMA HOMOCYST(E)INE; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; US PHYSICIANS; FOLIC-ACID; POPULATION; MUTATION	Context Individuals with elevated levels of homocysteine tend to have higher prevalence of cardiovascular disease. However, prospective studies of homocysteine are inconsistent and data among women are limited. Objective To determine whether elevated homocysteine levels in healthy postmenopausal women predict risk of developing cardiovascular disease. Design Prospective, nested case-control study with a mean 3-year follow-up. Setting The Women's Health Study, an ongoing US primary prevention trial initiated in 1993. Participants From a total cohort of 28 263 postmenopausal women with no history of cardiovascular disease or cancer at baseline, 122 women who subsequently experienced cardiovascular events were defined as cases, and 244 age- and smoking status-matched women who remained free of disease during follow-up were defined as controls. Main Outcome Measures Incidence of death due to cardiovascular disease, nonfatal myocardial infarction (MI), stroke, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft by baseline homocysteine level, Results Of the 122 cases, there were 85 events of MI or stroke and 37 coronary revascularizations. Case subjects had significantly higher baseline homocysteine levels than controls (14.1 vs 12.4 mu mol/L; P = .02). Subjects with homocysteine levels in the highest quartile had a 2-fold increase in risk of any cardiovascular event (relative risk [RR], 2.0; 95% confidence interval [CI], 1.1-3.8). This effect was largely due to an excess of cases with high levels of homocysteine; the RR for those with homocysteine levels at or higher than the 95th percentile (20.7 mu mol/L) was 2.6 (95% CI, 1.1-5.7), Risk estimates were independent of traditional risk factors and were greatest for the end points of MI and stroke (RR for those with baseline homocysteine levels in the top quartile, 2.2; 95% CI, 1.1-4.6). Self-reported multivitamin supplement use at study entry was associated with significantly reduced levels of homocysteine (P<.001). However, the association between increasing quartile of homocysteine level and risk of MI or stroke remained significant in analyses controlling for baseline multivitamin supplement use (P = .003 for trend), and subgroup analyses limited to women who were (P = .02 for trend) or were not (P = .04 for trend) taking multivitamin supplements. Conclusions Among healthy postmenopausal US women, elevated levels of homocysteine moderately increased the risk of future cardiovascular disease. Whether lowering the homocysteine level reduces risk of cardiovascular events requires testing in randomized controlled trials.	Brigham & Womens Hosp, Div Cardiovasc Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Abbott Labs, Abbott Pk, IL 60064 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Abbott Laboratories	Ridker, PM (corresponding author), Brigham & Womens Hosp, Div Cardiovasc Dis, 75 Francis St, Boston, MA 02115 USA.	pmridker@bics.bwh.harvard.edu						Alfheim I, 1998, CLIN CHEM, V44, pA170; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; Ma J, 1996, CIRCULATION, V94, P2410, DOI 10.1161/01.CIR.94.10.2410; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SHIPCHANDLER MT, 1995, CLIN CHEM, V41, P991; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAYLOR LM, 1991, J VASC SURG, V13, P128, DOI 10.1016/0741-5214(91)90020-U; Verhoef P, 1997, AM J CARDIOL, V79, P799, DOI 10.1016/S0002-9149(96)00874-0; Verhoef P, 1998, J AM COLL CARDIOL, V32, P353, DOI 10.1016/S0735-1097(98)00244-7; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; WILLETT WC, 1994, STROKE, V25, P1924	26	188	197	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1817	1821		10.1001/jama.281.19.1817	http://dx.doi.org/10.1001/jama.281.19.1817			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340369	Bronze			2022-12-01	WOS:000080288800035
J	Conn, GL; Draper, DE; Lattman, EE; Gittis, AG				Conn, GL; Draper, DE; Lattman, EE; Gittis, AG			Crystal structure of a conserved ribosomal protein-RNA complex	SCIENCE			English	Article							FACTOR EF-G; TERTIARY STRUCTURE; ESCHERICHIA-COLI; GTPASE CENTER; THIOSTREPTON INTERACT; SUBUNIT; BINDING; DOMAIN; L11; THERMODYNAMICS	The structure of a highly conserved complex between a 58-nucleotide domain of Large subunit ribosomal RNA and the RNA-binding domain of ribosomal protein L11 has been solved at 2.8 angstrom resolution. It reveals a precisely folded RNA structure that is stabilized by extensive tertiary contacts and contains an unusually Large core of stacked bases. A bulge Loop base from one hairpin of the RNA is intercalated into the distorted major groove of another helix; the protein Locks this tertiary interaction into place by binding to the intercalated base from the minor groove side. This direct interaction with a key ribosomal RNA tertiary interaction suggests that part of the role of L11 is to stabilize an unusual RNA fold within the ribosome.	Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Draper, DE (corresponding author), Johns Hopkins Univ, Dept Chem, Charles & 34Th St, Baltimore, MD 21218 USA.	draper@jhunix.hcf.jhu.edu; lattman@jhu.edu	Lattman, Eaton/D-6681-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029048] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM29048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Bukhman YV, 1997, J MOL BIOL, V273, P1020, DOI 10.1006/jmbi.1997.1383; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Conn GL, 1998, BIOCHEMISTRY-US, V37, P11980, DOI 10.1021/bi980825+; CUNDLIFFE E, 1979, NATURE, V278, P859, DOI 10.1038/278859a0; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; DRAPER DE, 1995, J MOL BIOL, V249, P231, DOI 10.1006/jmbi.1995.0291; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fountain MA, 1996, BIOCHEMISTRY-US, V35, P6539, DOI 10.1021/bi952697k; Gopalan V, 1997, J MOL BIOL, V267, P765, DOI 10.1006/jmbi.1997.0907; GuhaThakurta D, 1999, BIOCHEMISTRY-US, V38, P3633, DOI 10.1021/bi9826411; GUTELL R, COMMUNICATION; Hinck AP, 1997, J MOL BIOL, V274, P101, DOI 10.1006/jmbi.1997.1379; Huang SG, 1996, J MOL BIOL, V258, P308, DOI 10.1006/jmbi.1996.0252; HUMMEL H, 1987, BIOCHIMIE, V69, P857, DOI 10.1016/0300-9084(87)90212-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUCKER FM, 1995, RNA, V1, P219; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAING LG, 1994, J MOL BIOL, V237, P560, DOI 10.1006/jmbi.1994.1255; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; LU M, 1994, J MOL BIOL, V244, P572, DOI 10.1006/jmbi.1994.1753; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSENDAHL G, 1994, NUCLEIC ACIDS RES, V22, P357, DOI 10.1093/nar/22.3.357; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; Terwilliger TC, 1997, METHOD ENZYMOL, V276, P530; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; XING YY, 1995, J MOL BIOL, V249, P319, DOI 10.1006/jmbi.1995.0299; Xing YY, 1997, NAT STRUCT BIOL, V4, P24, DOI 10.1038/nsb0197-24; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o	41	242	247	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1999	284	5417					1171	1174		10.1126/science.284.5417.1171	http://dx.doi.org/10.1126/science.284.5417.1171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325228				2022-12-01	WOS:000080359100038
J	Zheng, WM; Knudsen, EI				Zheng, WM; Knudsen, EI			Functional selection of adaptive auditory space map by GABA(A)-mediated inhibition	SCIENCE			English	Article							EXPERIENCE-DEPENDENT PLASTICITY; BARN OWL; VISUAL CALIBRATION; OPTIC TECTUM; CORTICAL-NEURONS; NEURAL MAP; CORTEX; LOCALIZATION; MIDBRAIN; BLOCKADE	The external nucleus of the inferior colliculus in the barn owl contains an auditory map of space that is based on the tuning of neurons for interaural differences in the timing of sound. In juvenile owls, this region of the brain can acquire alternative maps of interaural time difference as a result of abnormal experience. It has been found that, in an external nucleus that is expressing a learned, abnormal map, the circuitry underlying the normal map still exists but is functionally inactivated by inhibition mediated by gamma-aminobutyric acid type A (GABA(A)) receptors. This inactivation results from disproportionately strong inhibition of specific input channels to the network. Thus, experience-driven changes in patterns of inhibition, as well as adjustments in patterns of excitation, can contribute critically to adaptive plasticity in the central nervous system.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Zheng, WM (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Fairchild Sci Bldg, Stanford, CA 94305 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F32DC000307, R01DC000155] Funding Source: NIH RePORTER; NIDCD NIH HHS [5 R01 DC00155-18, F32 DC00307-01] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Brainard MS, 1998, J NEUROSCI, V18, P3929; BRAINARD MS, 1993, J NEUROSCI, V13, P4589; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; DULAC S, 1990, J NEUROPHYSIOL, V63, P131, DOI 10.1152/jn.1990.63.1.131; Feldman DE, 1997, J NEUROSCI, V17, P6820; Galarreta M, 1998, NAT NEUROSCI, V1, P587, DOI 10.1038/2822; Hensch TK, 1996, SCIENCE, V272, P554, DOI 10.1126/science.272.5261.554; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KNUDSEN EI, 1978, SCIENCE, V200, P795, DOI 10.1126/science.644324; KNUDSEN EI, 1991, SCIENCE, V253, P85, DOI 10.1126/science.2063209; KNUDSEN EI, 1993, J NEUROSCI, V13, P2837; KOCH C, 1983, P NATL ACAD SCI-BIOL, V80, P2799, DOI 10.1073/pnas.80.9.2799; Lane RD, 1997, J NEUROPHYSIOL, V77, P2723, DOI 10.1152/jn.1997.77.5.2723; MOISEFF A, 1981, J NEUROSCI, V1, P40, DOI 10.1523/JNEUROSCI.01-01-00040.1981; MOWER GD, 1984, BRAIN RES, V309, P168, DOI 10.1016/0006-8993(84)91024-2; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; Shadlen MN, 1998, J NEUROSCI, V18, P3870; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724	21	102	103	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					962	965		10.1126/science.284.5416.962	http://dx.doi.org/10.1126/science.284.5416.962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320376				2022-12-01	WOS:000080198800045
J	McLaughlin, VV; Genthner, DE; Panella, MM; Hess, DM; Rich, S				McLaughlin, VV; Genthner, DE; Panella, MM; Hess, DM; Rich, S			Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: A case series	ANNALS OF INTERNAL MEDICINE			English	Article							EPOPROSTENOL PROSTACYCLIN; VASCULAR-DISEASE; THERAPY; REDUCTION; INFUSION; VESSELS	Background: Treatment of patients with secondary pulmonary hypertension has been unsatisfactory. Objective: To describe exercise capacity, functional class, and hemodynamic variables after long-term intravenous infusion of prostacyclin in patients with secondary pulmonary hypertension. Design: Case series. Setting: Academic referral center. Patients: 33 patients with secondary, precapillary pulmonary hypertension (New York Heart Association class III or IV). Intervention: Continuous intravenous prostacyclin administered by portable infusion pump on a compassionate-use basis. Measurements: Functional class, treadmill time, and hemodynamic variables. Results: Patients were followed for an average of 12.7 +/- 5.6 months. Exercise tolerance and New York Heart Association class improved in each patient. The duration of treadmill exercise increased from 186 seconds to 491 seconds, an increase of 305 seconds (95% CI, 194 to 417 seconds; P < 0.001). Mean pulmonary artery pressure decreased from 60 mm Hg to 46 mm Hg. a decrease of 14 mm Hg (Cl, 9 to 19 mm Hg; P < 0.001). Cardiac output increased from 3.90 L/min to 6.30 L/min, an increase of 2.40 L/min (CI, 1.56 to 3.25 L/min; P < 0.001). The pulmonary vascular resistance decreased from 1143 dynes . s/cm(5) to 575 dynes . s/cm(5), a decrease of 567 dynes s/cm(5) (CI, 407 to 727 dynes . s/cm(5); P < 0.001). Patients with collagen vascular disease, congenital heart disease, and portopulmonary hypertension were analyzed with other patients and separately. All groups had a statistically significant reduction in mean pulmonary artery pressure and a statistically significant increase in cardiac output. Conclusion: Intravenous prostacyclin may be effective in the treatment of patients with certain types of secondary pulmonary hypertension.	Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA	Rush University	McLaughlin, VV (corresponding author), Rush Heart Inst, Ctr Pulm Heart Dis, 1725 W Harrison St,Suite 020, Chicago, IL 60612 USA.							Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BERMANROSENZWEI.E, 1998, AM J RESP, V157, pA596; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; HAWORTH SG, 1984, BRIT HEART J, V52, P557; Higenbottam TW, 1998, HEART, V79, P175, DOI 10.1136/hrt.79.2.175; Humbert M, 1998, CHEST, V114, p80S, DOI 10.1378/chest.114.1_Supplement.80S; Koh ET, 1996, BRIT J RHEUMATOL, V35, P989; Kuo PC, 1997, TRANSPLANTATION, V63, P604, DOI 10.1097/00007890-199702270-00020; Mandell MS, 1996, CLIN CHEST MED, V17, P17, DOI 10.1016/S0272-5231(05)70296-3; McLaughlin VV, 1998, NEW ENGL J MED, V338, P273, DOI 10.1056/NEJM199801293380501; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; RABINOVITCH M, 1984, CIRCULATION, V69, P655, DOI 10.1161/01.CIR.69.4.655; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; RICH S, 1998, WORLD S PRIM PULM HY; WAGENVOORT CA, 1970, CIRCULATION, V42, P1163, DOI 10.1161/01.CIR.42.6.1163; WAGENVOORT CA, 1985, MINN MED, V68, P45; YAMAKI S, 1985, BRIT HEART J, V54, P428; YOUNG RH, 1978, AM J MED, V64, P998, DOI 10.1016/0002-9343(78)90455-2	20	156	159	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	1999	130	9					740	743		10.7326/0003-4819-130-9-199905040-00014	http://dx.doi.org/10.7326/0003-4819-130-9-199905040-00014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192DE	10357693				2022-12-01	WOS:000080062300005
J	Rae, TD; Schmidt, PJ; Pufahl, RA; Culotta, VC; O'Halloran, TV				Rae, TD; Schmidt, PJ; Pufahl, RA; Culotta, VC; O'Halloran, TV			Undetectable intracellular free copper: The requirement of a copper chaperone for superoxide dismutase	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; SACCHAROMYCES-CEREVISIAE; YEAST; GENE; TRAFFICKING; ENCODES; PROTEIN; ATX1	The topper chaperone for the superoxide dismutase (CCS) gene is necessary for expression of an active, copper-bound form of superoxide dismutase (SOD1) in vivo in spite of the high affinity of SOD1 for copper (dissociation constant = 6 fM) and the high intracellular concentrations of both SOD1 (10 mu M in yeast) and copper (70 mu M in yeast), In vitro studies demonstrated that purified Cu(I)-yCCS protein is sufficient for direct copper activation of apo-ySOD1 but is necessary only when the concentration of free copper ions ([Cu](free)) is strictly limited. Moreover, the physiological requirement for yCCS in vivo was readily bypassed by elevated copper concentrations and abrogation of intracellular copper-scavenging systems such as the metallothioneins, This metallochaperone protein activates the target enzyme through direct insertion of the copper cofactor and apparently functions to protect the metal ion from binding to intracellular copper scavengers. These results indicate that intracellular [Cu](free) is Limited to less than one free copper ion per cell and suggest that a pool of free copper ions is not used in physiological activation of metalloenzymes.	Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Baltimore, MD 21205 USA	Northwestern University; Northwestern University; Johns Hopkins University	Culotta, VC (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	vculotta@jhsph.edu; t-ohalloran@nwu.edu	O'Halloran, Thomas/ABE-6125-2021; Johnson, Michael D. L./B-4352-2012	O'Halloran, Thomas/0000-0001-8732-5059; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111, R01GM050016, R37GM050016, F32GM019457] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54111, R01 GM054111, GM 50016, F32 GM19457] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; CIRIOLO MR, 1990, J BIOL CHEM, V265, P11030; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; CULOTTA VC, 1995, J BIOL CHEM, V270, P29991; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRIDOVICH I, 1985, CRC HDB METHODS OXYG, P213; GOSCIN SA, 1972, BIOCHIM BIOPHYS ACTA, V289, P276, DOI 10.1016/0005-2744(72)90078-2; HAWKINS CJ, 1963, J CHEM SOC, P2996, DOI 10.1039/jr9630002996; HIROSE J, 1982, ARCH BIOCHEM BIOPHYS, V218, P179, DOI 10.1016/0003-9861(82)90334-4; HORECKA J, 1995, GENE, V162, P87, DOI 10.1016/0378-1119(95)00325-Z; KARIN M, 1984, P NATL ACAD SCI-BIOL, V81, P337, DOI 10.1073/pnas.81.2.337; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lyons TJ, 1998, J BIOL INORG CHEM, V3, P650, DOI 10.1007/s007750050279; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Schmidt P., UNPUB; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1978, METHODS YEAST GENETI; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VALENTINE JS, 1982, COPPER PROTEINS, P292	27	1286	1323	4	160	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1999	284	5415					805	808		10.1126/science.284.5415.805	http://dx.doi.org/10.1126/science.284.5415.805			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221913				2022-12-01	WOS:000080056200047
J	Ray, LB				Ray, LB			The science of signal transduction	SCIENCE			English	Editorial Material																			0	13	14	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					755	756		10.1126/science.284.5415.755	http://dx.doi.org/10.1126/science.284.5415.755			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10336400				2022-12-01	WOS:000080056200031
J	Daniel, R; Katz, RA; Skalka, AM				Daniel, R; Katz, RA; Skalka, AM			A role for DNA-PK in retroviral DNA integration	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; MURINE LEUKEMIA-VIRUS; HAMSTER OVARY CELL; MAMMALIAN-CELLS; V(D)J RECOMBINATION; AVIAN-SARCOMA; LIGASE-IV; IN-VIVO; MUTATION	Retroviral DNA integration is catalyzed by the viral protein integrase. Here, it is shown that DNA-dependent protein kinase (DNA-PK), a host cell protein, also participates in the reaction. DNA-PK-deficient murine scid cells infected with three different retroviruses showed a substantial reduction in retroviral DNA integration and died by apoptosis. Scid cell killing was not observed after infection with an integrase-defective virus. suggesting that abortive integration is the trigger for death in these DNA repair-deficient cells. These results suggest that the initial events in retroviral integration are detected as DNA damage by the host cell and that completion of;the integration process requires the DNA-PK-mediated repair pathway.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Skalka, AM (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			Daniel, Rene/0000-0002-3876-6242	NATIONAL CANCER INSTITUTE [R01CA071515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI040721] Funding Source: NIH RePORTER; NCI NIH HHS [CA71515] Funding Source: Medline; NIAID NIH HHS [AI40721, AI40835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Barsov EV, 1996, J VIROL, V70, P3922, DOI 10.1128/JVI.70.6.3922-3929.1996; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BROWN PO, 1998, RETROVIRUSES, P161; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; DANIEL R, UNPUB; Danska JS, 1996, MOL CELL BIOL, V16, P5507; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Gaken JA, 1996, J VIROL, V70, P3992; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; STAMATO TD, 1983, SOMAT CELL GENET, V9, P165, DOI 10.1007/BF01543175; STOKER AW, 1988, J VIROL, V62, P1008, DOI 10.1128/JVI.62.3.1008-1015.1988; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	35	211	233	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					644	647		10.1126/science.284.5414.644	http://dx.doi.org/10.1126/science.284.5414.644			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213687				2022-12-01	WOS:000079951100045
J	Belgrader, P; Benett, W; Hadley, D; Richards, J; Stratton, P; Mariella, R; Milanovich, F				Belgrader, P; Benett, W; Hadley, D; Richards, J; Stratton, P; Mariella, R; Milanovich, F			Infectious disease - PCR detection of bacteria in seven minutes	SCIENCE			English	Article							MICROCHIP PCR; INSTRUMENT		Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Belgrader, P (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, POB 808, Livermore, CA 94551 USA.							Belgrader P, 1998, CLIN CHEM, V44, P2191; Cheng J, 1998, TOP CURR CHEM, V194, P215; Christel LA, 1999, J BIOMECH ENG-T ASME, V121, P22, DOI 10.1115/1.2798037; FOSTER FK, 1998, P S MICR SYST ASME I; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Ibrahim MS, 1998, ANAL CHEM, V70, P2013, DOI 10.1021/ac971091u; Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Niemeyer DM, 1998, MIL MED, V163, P226, DOI 10.1093/milmed/163.4.226; Northrup M.A., 1996, United States Patent, Patent No. 5589136; Northrup MA, 1998, ANAL CHEM, V70, P918, DOI 10.1021/ac970486a; Tang YW, 1997, CLIN CHEM, V43, P2021	12	307	364	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					449	450		10.1126/science.284.5413.449	http://dx.doi.org/10.1126/science.284.5413.449			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10232992				2022-12-01	WOS:000079792200033
J	Wong, ZYH; Stebbing, M; Ellis, JA; Lamantia, A; Harrap, SB				Wong, ZYH; Stebbing, M; Ellis, JA; Lamantia, A; Harrap, SB			Genetic linkage of beta and gamma subunits of epithelial sodium channel to systolic blood pressure	LANCET			English	Article							HUMAN HYPERTENSION; PSEUDOHYPOALDOSTERONISM TYPE-1; CARDIOVASCULAR-DISEASE; MUTATIONS; POPULATION; LESSONS; TRAITS	Background Mutations in the genes on chromosome 16p12 that encode the beta and gamma subunits of the epithelial sodium channel (SCNNIB and SCNNIG, respectively) have been linked with rare sodium-dependent forms of low and high blood pressure. Other DNA variants in or around these genes may contribute to variation in blood pressure and the risk of coronary heart disease and stroke. Methods We studied 286 white families from the general population in Victoria, Australia. Each family comprised both parents and two natural children. All participants were genotyped at chromosome 16p12 by use of four highly polymorphic microsatellite markers. Quantitative phonotype measurements were correlated with genotype in identity-by-descent sibling-pair linkage analyses. Findings We found significant linkage between systolic blood pressure and chromosome 16p12 after parametric analyses (p=0.0003) and non-parametric analyses (p=0.001). The mean difference in systolic blood pressure between siblings identical-by-descent at these loci was half as large (7.1 mm Hg) as the difference between siblings non-identical at these loci (14.0 mm Hg, p=0.001). No linkage between chromosome 16p12 and diastolic blood pressure or body-mass index was observed. Interpretation Chromosome 16p12 and the SCNNIB and SCNNIG genes are implicated in the physiological variation of systolic blood pressure. Our findings are important in explaining individual cardiovascular risk within the general population.	Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia	University of Melbourne	Harrap, SB (corresponding author), Univ Melbourne, Dept Physiol, Parkville, Vic 3052, Australia.		Ellis, Justine A/G-5006-2011	Ellis, Justine/0000-0003-4103-4445; Harrap, Stephen/0000-0003-2907-6714				Antikainen R, 1998, J HYPERTENS, V16, P577, DOI 10.1097/00004872-199816050-00004; Baker EH, 1998, LANCET, V351, P1388, DOI 10.1016/S0140-6736(97)07306-6; Brownstein MJ, 1996, BIOTECHNIQUES, V20, P1004, DOI 10.2144/96206st01; Chang HG, 1996, J HYPERTENS, V14, P1417, DOI 10.1097/00004872-199612000-00005; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Fuller PJ, 1996, J HYPERTENS, V14, P1383, DOI 10.1097/00004872-199612000-00001; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HARRAP SB, 1994, LANCET, V344, P169, DOI 10.1016/S0140-6736(94)92762-6; KANNEL WB, 1976, AM J CARDIOL, V37, P269, DOI 10.1016/0002-9149(76)90323-4; Kreutz R, 1997, HYPERTENSION, V29, P131, DOI 10.1161/01.HYP.29.1.131; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Luft Friedrich C., 1997, American Journal of Clinical Nutrition, V65, p612S, DOI 10.1093/ajcn/65.2.612S; MESSERLI FH, 1997, ARCH INTERN MED, V157, P2407; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460; Persu A, 1998, HYPERTENSION, V32, P129, DOI 10.1161/01.HYP.32.1.129; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; SAFAR ME, 1994, AM J MED SCI, V307, pS3; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; WATT GCM, 1988, J CARDIOVASC PHARM, V12, pS21; White PC, 1996, HYPERTENSION, V28, P927, DOI 10.1161/01.HYP.28.6.927	26	51	52	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1222	1225		10.1016/S0140-6736(98)10118-6	http://dx.doi.org/10.1016/S0140-6736(98)10118-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217082				2022-12-01	WOS:000079744100010
J	Veigel, C; Coluccio, LM; Jontes, JD; Sparrow, JC; Milligan, RA; Molloy, JE				Veigel, C; Coluccio, LM; Jontes, JD; Sparrow, JC; Milligan, RA; Molloy, JE			The motor protein myosin-I produces its working stroke in two steps	NATURE			English	Article							ACTIN-FILAMENTS; FORCE GENERATION; LIVER; SUBFRAGMENT-1; MECHANISM; INVITRO; RELEASE; MUSCLE; MOVE	Many types of cellular motility including muscle contraction, are driven by the cyclical interaction of the motor protein myosin with actin filaments, coupled to the breakdown of ATP. It is thought that myosin binds to actin and then produces force and movement as it 'tilts' or 'rocks' into one or more subsequent, stable conformations(1,2). Here we use an optical-tweezers transducer to measure the mechanical transitions made by a single myosin head while it is attached to actin We find that two members of the myosin-I family, rat liver myosin-I of relative molecular mass 130,000 (M-r 130K) and chick intestinal brush-border myosin-I, produce movement in two distinct steps. The initial movement (of roughly 6 nanometres) is produced within 10 milliseconds of actomyosin binding, and the second step (of roughly 5.5 nanometres) occurs after a variable time delay The duration of the period following the second step is also variable and depends on the concentration of ATP. At the highest time resolution possible (about I millisecond), we cannot detect this second step when studying the single-headed subfragment-1 of fast skeletal muscle myosin II. The slower kinetics of myosin-I have allowed us to observe the separate mechanical states that contribute to its working stroke.	Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Boston Biomed Res Inst, Boston, MA 02114 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of York - UK; Boston Biomedical Research Institute; Scripps Research Institute	Molloy, JE (corresponding author), Univ York, Dept Biol, POB 373, York YO10 5YW, N Yorkshire, England.	jeml@york.ac.uk		Molloy, Justin/0000-0002-8307-2450				COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; Colquhoun David, 1995, P483; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; COLUCCIO LM, 1993, CELL MOTIL CYTOSKEL, V24, P189, DOI 10.1002/cm.970240306; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; Iwane AH, 1997, BIOCHEM BIOPH RES CO, V230, P76, DOI 10.1006/bbrc.1996.5861; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Molloy J. E., 1995, Biophysical Journal, V68, P298; MOLLOY JE, 1987, NATURE, V328, P449, DOI 10.1038/328449a0; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; Veigel C, 1998, BIOPHYS J, V75, P1424, DOI 10.1016/S0006-3495(98)74061-5; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WILLIAMS R, 1994, CELL MOTIL CYTOSKEL, V27, P41, DOI 10.1002/cm.970270105	24	243	245	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 8	1999	398	6727					530	533		10.1038/19104	http://dx.doi.org/10.1038/19104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206648				2022-12-01	WOS:000079662800052
J	Solter, D; Gearhart, J				Solter, D; Gearhart, J			Biomedicine - Putting stem cells to work	SCIENCE			English	Editorial Material									Max Planck Inst Immunol, Dept Dev Biol, Freiburg, Germany; Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA	Max Planck Society; Johns Hopkins University	Solter, D (corresponding author), Max Planck Inst Immunol, Dept Dev Biol, Freiburg, Germany.	solter@immunbio.mpg.de; gearhart@jhmi.edu	Solter, Davor/Q-5476-2019					Gearhart J, 1998, SCIENCE, V282, P1061, DOI 10.1126/science.282.5391.1061; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kolata Gina, 1999, N Y Times Web, pF2; LIPSICH LA, 1979, NATURE, V281, P74, DOI 10.1038/281074a0; Marshall E, 1998, SCIENCE, V282, P1390, DOI 10.1126/science.282.5393.1390; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Rossant J, 1999, NAT BIOTECHNOL, V17, P23, DOI 10.1038/5194; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Smith A, 1998, CURR BIOL, V8, pR802, DOI 10.1016/S0960-9822(07)00504-0; Solter D, 1998, NATURE, V394, P315, DOI 10.1038/28485; SOLTER D, 1985, COLD SPRING HARB SYM, V50, P45, DOI 10.1101/SQB.1985.050.01.008; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145	12	90	106	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1999	283	5407					1468	1470		10.1126/science.283.5407.1468	http://dx.doi.org/10.1126/science.283.5407.1468			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173AR	10206877				2022-12-01	WOS:000078959200030
J	Horton, R				Horton, R			ICRF: from mayhem to meltdown	LANCET			English	Editorial Material																			0	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 11	1997	350	9084					1043	1044		10.1016/S0140-6736(05)70449-9	http://dx.doi.org/10.1016/S0140-6736(05)70449-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YA734	10213542				2022-12-01	WOS:A1997YA73400003
J	Schwartz, T; Rould, MA; Lowenhaupt, K; Herbert, A; Rich, A				Schwartz, T; Rould, MA; Lowenhaupt, K; Herbert, A; Rich, A			Crystal structure of the Z alpha domain of the human editing enzyme ADAR1 bound to left-handed Z-DNA	SCIENCE			English	Article							RNA ADENOSINE-DEAMINASE; DOUBLE HELICAL DNA; MOLECULAR-STRUCTURE; ATOMIC RESOLUTION; BINDING DOMAIN; TRANSCRIPTION; RECOGNITION; PROTEINS; COMPLEX; NUCLEI	The editing enzyme double-stranded RNA adenosine deaminase includes a DNA binding domain, Z alpha, which is specific for Left-handed Z-DNA, The 2.1 angstrom crystal structure of Z alpha complexed to DNA reveals that the substrate is in the left-handed Z conformation. The contacts between Z alpha and Z-DNA are made primarily with the "zigzag" sugar-phosphate backbone, which provides a basis for the specificity for the Z conformation. A single base contact is observed to guanine in the syn conformation, characteristic of Z-DNA. Intriguingly, the helix-turn-helix motif, frequently used to recognize B-DNA, is used by Z alpha to contact Z-DNA.	MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	Massachusetts Institute of Technology (MIT); University of Vermont	Rich, A (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Herbert, Alan/AAY-4286-2020; Schwartz, Thomas/ABA-1770-2021	Schwartz, Thomas/0000-0001-8012-1512; Herbert, Alan/0000-0002-0093-1572; /0000-0002-8187-6498				Berger I, 1998, BIOCHEMISTRY-US, V37, P13313, DOI 10.1021/bi9813126; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Draper DE, 1999, NUCLEIC ACIDS RES, V27, P381, DOI 10.1093/nar/27.2.381; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fraenkel E, 1998, J MOL BIOL, V284, P351, DOI 10.1006/jmbi.1998.2147; GESSNER RV, 1989, J BIOL CHEM, V264, P7921; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; Herbert A, 1998, NUCLEIC ACIDS RES, V26, P3486, DOI 10.1093/nar/26.15.3486; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; HERBERT AG, 1993, NUCLEIC ACIDS RES, V21, P2669, DOI 10.1093/nar/21.11.2669; Herbert JM, 1996, J BIOL CHEM, V271, P25928; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lilley D. M. J., 1995, DNA PROTEIN STRUCTUR; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Schade M, 1999, EMBO J, V18, P470, DOI 10.1093/emboj/18.2.470; SCHADE M, UNPUB; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; Schwartz T, 1999, J BIOL CHEM, V274, P2899, DOI 10.1074/jbc.274.5.2899; SCHWARTZ T, IN PRESS ACTA CRYSTA; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WANG AHJ, 1981, SCIENCE, V211, P171, DOI 10.1126/science.7444458; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; XU HE, IN PRESS GENES DEV	41	282	296	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1999	284	5421					1841	1845		10.1126/science.284.5421.1841	http://dx.doi.org/10.1126/science.284.5421.1841			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364558				2022-12-01	WOS:000080809000052
J	Merrow, M; Brunner, M; Roenneberg, T				Merrow, M; Brunner, M; Roenneberg, T			Assignment of circadian function for the Neurospora clock gene frequency	NATURE			English	Article							TEMPERATURE COMPENSATION; BLUE-LIGHT; CRYPTOCHROME; RHYTHM; PHOTORESPONSES; PHOTORECEPTOR; DROSOPHILA; CRASSA; SYSTEM	Circadian clocks consist of three elements: entrainment pathways (inputs), the mechanism generating the rhthmicity (oscillator), and the output pathways that control the circadian rhythms. It is difficult to assign molecular clock components to any one of these elements. Experiments show that inputs can be circadianly regulated(1-3) and outputs can feed back on the oscillator(4,5), Mathematical simulations indicate that under- or overexpression of a gene product can result in arrhythmicity, whether the protein is part of the oscillator or substantially Dart of a rhythmically expressed input pathway(6). To distinguish between these two possibilities, we used traditional circadian entrainment protocols(7,8) on a genetic model system, Neurospora crassa.	Univ Munich, Inst Med Psychol, D-80336 Munich, Germany; Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	University of Munich; University of Munich	Merrow, M (corresponding author), Univ Munich, Inst Med Psychol, Goethestr 31-33, D-80336 Munich, Germany.			Brunner, Michael/0000-0001-9798-3047				ARONSON BD, 1994, P NATL ACAD SCI USA, V91, P7683, DOI 10.1073/pnas.91.16.7683; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; ARPAIA G, 1993, PLANT PHYSIOL, V102, P1299, DOI 10.1104/pp.102.4.1299; ASCHOFF J, 1981, P 13 INT C SOC CHRON, P105; Aschoff J, 1981, BIOL RHYTHMS; BLOCK G, 1995, CELLULAR ANAL MOLLUS, P51; BRUCE VG, 1960, COLD SPRING HARB SYM, V25, P29, DOI 10.1101/SQB.1960.025.01.005; Chang B, 1997, J PLANT RES, V110, P449, DOI 10.1007/BF02506805; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DHARMANANDA S, 1980, STUDIES CIRCADIAN CL; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FELDMAN J F, 1973, Genetics, V75, P605; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Lakin-Thomas PL, 1998, J BIOL RHYTHM, V13, P268, DOI 10.1177/074873098129000101; Liu Y, 1998, SCIENCE, V281, P825, DOI 10.1126/science.281.5378.825; Loros J J, 1986, J Biol Rhythms, V1, P187, DOI 10.1177/074873048600100302; Merrow MW, 1997, P NATL ACAD SCI USA, V94, P3877, DOI 10.1073/pnas.94.8.3877; MERROW MW, 1994, EMBO J, V13, P2257, DOI 10.1002/j.1460-2075.1994.tb06507.x; MROSOVSKY N, 1992, J BIOL RHYTHM, V7, P41, DOI 10.1177/074873049200700104; Roenneberg T, 1997, PLANTA, V202, P494, DOI 10.1007/s004250050154; Roenneberg T, 1998, J BIOL RHYTHM, V13, P167, DOI 10.1177/074873098129000011; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; ROENNEBERG T, IN PRESS METHODS ENZ, V305; RUSSO VEA, 1988, J PHOTOCH PHOTOBIO B, V2, P59, DOI 10.1016/1011-1344(88)85037-1; SARGENT ML, 1966, PLANT PHYSIOL, V41, P1343, DOI 10.1104/pp.41.8.1343; Somers DE, 1998, DEVELOPMENT, V125, P485; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; WINFREE AT, 1974, SCIENCE, V183, P970, DOI 10.1126/science.183.4128.970	30	185	185	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					584	586		10.1038/21190	http://dx.doi.org/10.1038/21190			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376598	Green Published			2022-12-01	WOS:000080778400055
J	Ahmed, T; Ali, M; Choudhary, IA; Haque, ME; Salam, MA; Rabbani, GH; Suskind, RM; Fuchs, GJ				Ahmed, T; Ali, M; Choudhary, IA; Haque, ME; Salam, MA; Rabbani, GH; Suskind, RM; Fuchs, GJ			Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol	LANCET			English	Article							MALNUTRITION	Background. Severely malnourished children have high mortality rates. Death commonly occurs during the first 48 h after hospital admission, and has been attributed to faulty case-management. We developed a standardised protocol for acute-phase treatment of children with severe malnutrition and diarrhoea, with the aim of reducing mortality. Methods. We compared severely malnourished children with diarrhoea aged 0-5 years managed by non protocol conventional treatment, and those treated by our standardised protocol that included slow rehydration with an emphasis on oral rehydration. The standardised-protocol group included children admitted to the ICDDR,B Hospital, Dhaka between Jan 1, 1997, and June 30, 1997, while those admitted between Jan 1, 1996, and June 30, 1996, before the protocol was implemented, were the non-protocol group. Findings. Characteristics on admission of children on standardised protocol (n = 334) and non-protocol children (n = 293) were similar except that more children on standardised protocol had oedema, acidosis, and Vibrio cholerae isolated from stools. 199 (59.9%) of children on standardised protocol were successfully rehydrated with oral rehydration solution, compared with 85 (29%) in the nonprotocol group (p < 0.0001). Use of expensive antibiotics was less frequent in children on standardised protocol than in the other group (p < 0.0001). Children on standardised protocol had fewer episodes of hypoglycaemia than non-protocol children (15 vs 30, p = 0.005). 49 (17%) of children on nonprotocol treatment died, compared with 30 (9%) children on standardised protocol (odds ratio for mortality, 0.49, 95% CI 0.3-0.8, p = 0.003). Interpretation. Compared with non-protocol management, our standardised protocol resulted in fewer episodes of hypoglycaemia, less need for intravenous fluids, and a 47% reduction in mortality. This standardised protocol should be considered in all children with diarrhoea and severe malnutrition.	Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Clin Sci, Dhaka 1000, Bangladesh; Louisiana State Univ, Dept Paediat, Sch Med, New Orleans, LA 70112 USA	International Centre for Diarrhoeal Disease Research (ICDDR); Louisiana State University System	Fuchs, GJ (corresponding author), Int Ctr Diarrhoeal Dis Res, Ctr Hlth & Populat Res, Div Clin Sci, GPO Box 128, Dhaka 1000, Bangladesh.	gfuchs@icddrb.org	Fuchs, George/GLV-1285-2022	Fuchs, George/0000-0002-8679-8265				BRIEND A, 1993, EUR J CLIN NUTR, V47, P750; ELMOUGI M, 1988, J PEDIATR GASTR NUTR, V7, P572, DOI 10.1097/00005176-198807000-00016; Friedman LM, 1985, FUNDAMENTALS CLIN TR; GEHAN EA, 1974, NEW ENGL J MED, V290, P198, DOI 10.1056/NEJM197401242900405; GERSONY WM, 1987, NELSON TXB PEDIAT, P1018; Hennekens C., 1987, EPIDEMIOLOGY MED; Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223; SUSKIND D, 1990, NESTLE NUTR WORKS SE, V19, P1; *WHO, 1992, MAN PAT DIARRH PROGR; World Health Organization, 1990, AC RESP INF CHILDR C; World Health Organization, 1997, STRAT PREV BLINDN NA; World Health Organization, 1999, MAN SEV MALN MAN PHY	12	186	189	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1919	1922		10.1016/S0140-6736(98)07499-6	http://dx.doi.org/10.1016/S0140-6736(98)07499-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371570				2022-12-01	WOS:000080668500011
J	Matlack, KES; Misselwitz, B; Plath, K; Rapoport, TA				Matlack, KES; Misselwitz, B; Plath, K; Rapoport, TA			BiP acts as a molecular ratchet during posttranslational transport of prepro-alpha factor across the ER membrane	CELL			English	Article							MITOCHONDRIAL PROTEIN IMPORT; ENDOPLASMIC-RETICULUM; INNER MEMBRANE; SECRETORY PROTEINS; SEC PROTEINS; TRANSLOCATION; YEAST; COMPLEX; HSP70; INSERTION	We have addressed the mechanism by which proteins are posttranslationally transported across the membrane of the yeast endoplasmic reticulum (ER). We demonstrate that BiP (Kar2p), a member of the Hsp70 family resident in the ER lumen, acts as a molecular ratchet during translocation of the secretory protein prepro-cu factor through the channel formed by the Sec complex. Multiple BiP molecules associate with each translocation substrate following interaction with the J domain of the Sec63p component of the Sec complex. Bound BiP minimizes passive backward movements of the substrate through the channel, and BiP's subsequent dissociation results in a free polypeptide in the ER lumen. Antibodies against the substrate can replace BiP, indicating that a Brownian ratchet is sufficient to achieve translocation.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Cell Biol, Boston, MA 02115 USA.		Misselwitz, Benjamin/L-7193-2016	Misselwitz, Benjamin/0000-0002-8719-5175; Plath, Kathrin/0000-0001-7796-3372	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054238] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54238] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bomer U, 1998, EMBO J, V17, P4226, DOI 10.1093/emboj/17.15.4226; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	31	309	310	3	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					553	564		10.1016/S0092-8674(00)80767-9	http://dx.doi.org/10.1016/S0092-8674(00)80767-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367885	Bronze			2022-12-01	WOS:000080672100005
J	Nicoll, A; Catchpole, M; Cliffe, S; Hughes, G; Simms, I; Thomas, D				Nicoll, A; Catchpole, M; Cliffe, S; Hughes, G; Simms, I; Thomas, D			Sexual health of teenagers in England and Wales: analysis of national data	BRITISH MEDICAL JOURNAL			English	Article									Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, HIV & Sexually Transmitted Dis Div, London NW9 5EQ, England; Ctr Communicable Dis Surveillance, Lab Serv, Welsh Unit, Cardiff CF4 3QX, S Glam, Wales	Public Health England	Nicoll, A (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, HIV & Sexually Transmitted Dis Div, London NW9 5EQ, England.		Simms, Ian/P-1454-2019; Simms, Ian/AAA-8740-2019	Simms, Ian/0000-0003-4519-5684; Hughes, Gwenda/0000-0003-2090-7702				COWAN FM, 1993, GENITOURIN MED, V69, P141; DICKSON R, 1997, EFFECTIVE HLTH CARE, V3, P1; HUGHES G, 1997, NEW CASES GENITOURIN; Simms I., 1998, CDR Weekly, V8, pS1; 1998, MMWR, V47, P749	5	52	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1321	1322		10.1136/bmj.318.7194.1321	http://dx.doi.org/10.1136/bmj.318.7194.1321			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323816	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000080418400025
J	Ren, JH; Kachel, K; Kim, H; Malenbaum, SE; Collier, RJ; London, E				Ren, JH; Kachel, K; Kim, H; Malenbaum, SE; Collier, RJ; London, E			Interaction of diphtheria toxin T domain with molten globule-like proteins and its implications for translocation	SCIENCE			English	Article							PARTIALLY FOLDED STATE; MEMBRANE TRANSLOCATION; SERUM-ALBUMIN; A-FRAGMENT; CONFORMATIONS; APOMYOGLOBIN; INTERMEDIATE; BILAYERS; MUTANTS; PH	The transmembrane (T) domain of diphtheria toxin has a critical role in the Low pH-induced translocation of the catalytic domain (A chain) of the toxin across membranes. Here it is shown that at Low pH, addition of proteins in a partly unfolded, molten globule-like conformation converted the T domain from a shallow membrane-inserted form to its transmembrane form. Fluorescence energy transfer demonstrated that molten globule-like proteins bound to the T domain. Thus, the T domain recognizes proteins that are partly unfolded and may function in translocation of the A chain as a transmembrane chaperone.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; Harvard University; Harvard Medical School	London, E (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Collier, R John/0000-0002-2427-4239	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022021, R37AI022021] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22021] Funding Source: Medline; NIGMS NIH HHS [GM 39186] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1979, BIOCHIM BIOPHYS ACTA, V576, P333, DOI 10.1016/0005-2795(79)90408-2; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FALNES PO, 1995, J BIOL CHEM, V270, P20787, DOI 10.1074/jbc.270.35.20787; FALNES PO, 1994, J BIOL CHEM, V269, P8402; HAEZEBROUCK P, 1995, J MOL BIOL, V246, P382, DOI 10.1006/jmbi.1994.0093; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; KACHEL K, 1998, NATURE, V273, P22950; LEE JW, 1992, ARCH BIOCHEM BIOPHYS, V297, P354, DOI 10.1016/0003-9861(92)90684-O; LEE JY, 1992, J BIOL CHEM, V267, P14753; Liu LP, 1996, BIOPOLYMERS, V39, P465, DOI 10.1002/(SICI)1097-0282(199609)39:3<465::AID-BIP17>3.0.CO;2-A; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Ren JH, 1999, BIOCHEMISTRY-US, V38, P976, DOI 10.1021/bi981576s; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; SADLER PJ, 1993, EUR J BIOCHEM, V212, P811, DOI 10.1111/j.1432-1033.1993.tb17722.x; Wang Y, 1997, J BIOL CHEM, V272, P25091, DOI 10.1074/jbc.272.40.25091; WEIDLOCHA A, 1992, EMBO J, V11, P4835; ZHAO JM, 1988, J BIOL CHEM, V263, P15369	22	105	107	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					955	957		10.1126/science.284.5416.955	http://dx.doi.org/10.1126/science.284.5416.955			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320374				2022-12-01	WOS:000080198800043
J	Shtilerman, M; Lorimer, GH; Englander, SW				Shtilerman, M; Lorimer, GH; Englander, SW			Chaperonin function: Folding by forced unfolding	SCIENCE			English	Article							HYDROGEN-EXCHANGE; CONFORMATIONAL STATES; RIBULOSEBISPHOSPHATE CARBOXYLASE; POLYPEPTIDE BINDING; CRYSTAL-STRUCTURE; CYTOCHROME-C; GROEL; PROTEIN; MECHANISM; PATHWAYS	The ability of the GroEL chaperonin to unfold a protein trapped in a misfolded condition was detected and studied by hydrogen exchange. The GroEL-induced unfolding of its substrate protein is only partial, requires the complete chaperonin system, and is accomplished within the 13 seconds required for a single system turnover. The binding of nucleoside triphosphate provides the energy for a single unfolding event; multiple turnovers require adenosine triphosphate hydrolysis. The substrate protein is released on each turnover even if it has not yet refolded to the native state. These results suggest that GroEL helps partly folded but blocked proteins to fold by causing them first to partially unfold. The structure of GroEL seems well suited to generate the nonspecific mechanical stretching force required for forceful protein unfolding.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA	University System of Maryland; University of Maryland College Park; University of Pennsylvania	Lorimer, GH (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	GL48@umail.umd.edu			NIGMS NIH HHS [R01 GM031847, GM31847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; BAL Y, 1993, PROTEIN-STRUCT FUNCT, V17, P75; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Braig K, 1998, CURR OPIN STRUC BIOL, V8, P159, DOI 10.1016/S0959-440X(98)80033-X; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; Burston SG, 1996, NATURE, V383, P96, DOI 10.1038/383096a0; Burton RE, 1998, BIOCHEMISTRY-US, V37, P5337, DOI 10.1021/bi980245c; Chamberlain AK, 1996, NAT STRUCT BIOL, V3, P782, DOI 10.1038/nsb0996-782; Clark AC, 1998, METHOD ENZYMOL, V290, P100; Clark AC, 1999, J MOL BIOL, V285, P1777, DOI 10.1006/jmbi.1998.2403; CONNELLY GP, 1993, PROTEINS, V17, P87, DOI 10.1002/prot.340170111; Corrales FJ, 1996, P NATL ACAD SCI USA, V93, P4509, DOI 10.1073/pnas.93.9.4509; Coyle JE, 1997, FOLD DES, V2, pR93, DOI 10.1016/S1359-0278(97)00046-1; DILL KA, 1995, PROTEIN SCI, V4, P561; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ENGLANDER SW, 1983, Q REV BIOPHYS, V16, P521, DOI 10.1017/S0033583500005217; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; ENGTANDER SW, 1906, CURR OPIN STRUC BIOL, V6, P18; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; Freund C, 1998, FOLD DES, V3, P39, DOI 10.1016/S1359-0278(98)00007-8; Fuentes EJ, 1998, BIOCHEMISTRY-US, V37, P3687, DOI 10.1021/bi972579s; Gervasoni P, 1998, J MOL BIOL, V275, P663, DOI 10.1006/jmbi.1997.1481; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Gross M, 1996, PROTEIN SCI, V5, P2506, DOI 10.1002/pro.5560051213; GUO ZY, 1995, BIOPOLYMERS, V36, P83, DOI 10.1002/bip.360360108; HAMMACK B, 1998, BIOCHEMISTRY-US, V275, P719; Hiller R, 1997, P NATL ACAD SCI USA, V94, P11329, DOI 10.1073/pnas.94.21.11329; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; JENNINGS PA, 1993, BIOCHEMISTRY-US, V32, P3783, DOI 10.1021/bi00065a034; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Konermann L, 1997, BIOCHEMISTRY-US, V36, P5554, DOI 10.1021/bi970046d; Llorca O, 1997, FEBS LETT, V405, P195, DOI 10.1016/S0014-5793(97)00186-5; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; Matagne A, 1997, J MOL BIOL, V267, P1068, DOI 10.1006/jmbi.1997.0963; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; ROSEN BP, 1996, BIOMEMBR, V5, P241; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SCHLOSS JV, 1984, METHOD ENZYMOL, V90, P522; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; SHASTRY MCR, 1995, J MOL BIOL, V247, P1013, DOI 10.1006/jmbi.1994.0196; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Sparrer H, 1996, J MOL BIOL, V258, P74, DOI 10.1006/jmbi.1996.0235; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; THIRUMALAI D, 1994, STAT MECH, P15; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Todd MJ, 1996, P NATL ACAD SCI USA, V93, P4030, DOI 10.1073/pnas.93.9.4030; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; XU Z, COMMUNICATION; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; Zahn R, 1996, J MOL BIOL, V261, P43, DOI 10.1006/jmbi.1996.0440; ZAHN R, 1994, NATURE, V368, P261, DOI 10.1038/368261a0	74	252	254	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 30	1999	284	5415					822	825		10.1126/science.284.5415.822	http://dx.doi.org/10.1126/science.284.5415.822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221918	Green Accepted, Green Submitted			2022-12-01	WOS:000080056200052
J	Mills, AA; Zheng, BH; Wang, XJ; Vogel, H; Roop, DR; Bradley, A				Mills, AA; Zheng, BH; Wang, XJ; Vogel, H; Roop, DR; Bradley, A			p63 is a p53 homologue required for limb and epidermal morphogenesis	NATURE			English	Article							GENE-EXPRESSION; CHICK; MICE; DIFFERENTIATION; PATTERN; DEATH; BUD	The p53 tumour suppressor is a transcription factor that regulates the progression of the cell through its cycle and cell death (apoptosis) in response to environmental stimuli such as DNA damage and hypoxia(1,2). Even though p53 modulates these critical cellular processes, mice that lack p53 are developmentally normal(3), suggesting that p53-related proteins might compensate for the functions of p53 during embryogenesis. Two p53 homologues, p63 and p73, are known(4,5) and here we describe the function of p63 in vivo. Mice lacking p63 are born alive but have striking developmental defects. Their limbs are absent or truncated, defects that are caused by a failure of the apical ectodermal ridge to differentiate. The skin of p63-deficient mice does not progress past an early developmental stage: it lacks stratification and does not express differentiation markers. Structures dependent upon epidermal-mesenchymal interactions during embryonic development, such as hair follicles, teeth and mammary glands, are absent in p63-deficient mice. Thus, in contrast to p53, p63 is essential for several aspects of ectodermal differentiation during embryogenesis.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA; Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Bradley, A (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.	abradley@bcm.tmc.edu		Vogel, Otto Hannes/0000-0002-0960-3508; Bradley, Allan/0000-0002-2349-8839				BICKENBACH JR, 1995, J INVEST DERMATOL, V104, P405, DOI 10.1111/1523-1747.ep12665896; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Cygan JA, 1997, DEVELOPMENT, V124, P5021; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Grieshammer U, 1996, DEVELOPMENT, V122, P3851; Hardy MH, 1996, ACTA ANAT, V157, P169; HINCHLIFFE JR, 1973, J EMBRYOL EXP MORPH, V30, P753; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Liu PT, 1998, GENETICS, V150, P1155; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCNEISH JD, 1988, SCIENCE, V241, P837, DOI 10.1126/science.3406741; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; PRAHLAD KV, 1979, J EXP ZOOL, V209, P427, DOI 10.1002/jez.1402090308; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; VALANCIUS V, 1991, MOL CELL BIOL, V11, P4389, DOI 10.1128/MCB.11.9.4389; Vogel A, 1996, DEVELOPMENT, V122, P1737; WANG XJ, 1995, ONCOGENE, V10, P279; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; Wilkinson DG, 1992, SITU HYBRIDIZATION P; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZHENG B, IN PRESS NUCL ACIDS; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	31	1641	1685	1	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 22	1999	398	6729					708	713		10.1038/19531	http://dx.doi.org/10.1038/19531			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227293				2022-12-01	WOS:000079920100051
J	Van Dyck, E; Stasiak, AZ; Stasiak, A; West, SC				Van Dyck, E; Stasiak, AZ; Stasiak, A; West, SC			Binding of double-strand breaks in DNA by human Rad52 protein	NATURE			English	Article							HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; VERTEBRATE CELLS; MAMMALIAN-CELLS; REPAIR; YEAST; SACCHAROMYCES; RESISTANCE; COMPLEXES; EXCHANGE	Double-strand breaks (DSBs) in DNA are caused by ionizing radiation. These chromosomal breaks can kill the cell unless repaired efficiently, and inefficient or inappropriate repair can lead to mutation, gene translocation and cancer(1), Two proteins that participate in the repair of DSBs are Rad52 and Ku: in lower eukaryotes such as yeast, DSBs are repaired by Rad52-dependent homologous recombination, whereas vertebrates repair DSBs primarily by Ku-dependent non-homologous end-joining(2). The contribution of homologous recombination to vertebrate DSB repair, however, is important(3,4). Biochemical studies indicate that Ku binds to DNA ends and facilitates end-joining(5). Here we show that human Rad52, like Ku, binds directly to DSBs, protects them from exonuclease attack and facilitates end-to-end interactions. A model for repair is proposed in which either Ku or Rad52 binds the DSB. Ku directs DSBs into the non-homologous end-joining repair pathway, whereas Rad52 initiates repair by homologous recombination. Ku and Rad52, therefore, direct entry into alternative pathways for the repair of DNA breaks.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Univ Lausanne, Lab Anal Ultrastruct, CH-1015 Lausanne, Switzerland	University of Lausanne	West, SC (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.		Stasiak, Andrzej/E-5551-2010	Stasiak, Andrzej/0000-0002-0398-1989; West, Stephen/0000-0001-8848-9418; Van Dyck, Eric/0000-0001-8614-2402				ANDERSON CW, 1996, MOL ANAL DNA REARRAN, P91; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Friedberg EC, 1995, DNA REPAIR MUTAGENES; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Johnson BL, 1996, MUTAT RES-DNA REPAIR, V363, P179, DOI 10.1016/0921-8777(96)00007-9; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Reddy MP, 1997, GERIATRICS, V52, P59; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Shen ZY, 1996, MUTAT RES-DNA REPAIR, V364, P81, DOI 10.1016/0921-8777(96)00025-0; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; SUBRAMANI S, 1988, GENETIC RECOMBINATIO, P549; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	30	254	259	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					728	731		10.1038/43942	http://dx.doi.org/10.1038/43942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227297	Bronze			2022-12-01	WOS:000079920100055
J	Alonso, JM; Hirayama, T; Roman, G; Nourizadeh, S; Ecker, JR				Alonso, JM; Hirayama, T; Roman, G; Nourizadeh, S; Ecker, JR			EIN2, a bifunctional transducer of ethylene and stress responses in Arabidopsis	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; SIGNAL-TRANSDUCTION; SACCHAROMYCES-CEREVISIAE; GENETIC-ANALYSIS; PROTEIN-KINASES; ROOT-GROWTH; THALIANA; YEAST; PATHWAY; TRANSPORTER	Ethylene regulates plant growth, development, and responsiveness to a variety of stresses. Cloning of the Arabidopsis EIN2 gene identifies a central component: of the ethylene signaling pathway. The amino-terminal integral membrane domain of EIN2 shows similarity to the disease-related Nramp family of metal-ion transporters. Expression of the EIN2 CEND is sufficient to constitutively activate ethylene responses and restores responsiveness to jasmonic acid and paraquat-induced oxygen radicals to mutant plants. EIN2 is thus recognized as a molecular link between previously distinct hormone response pathways. plants may use a combinatorial mechanism for assessing various stresses by enlisting a common set of signaling molecules.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Ecker, JR (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.		HIRAYAMA, Takashi/B-2496-2011; Ecker, Joseph R/B-9144-2008; Bruening, Stefan/B-8505-2011; Roman, Gregg/W-1586-2019; Alonso, Jose M/K-6826-2014	HIRAYAMA, Takashi/0000-0002-3868-2380; Ecker, Joseph R/0000-0001-5799-5895; Roman, Gregg/0000-0003-1519-4699; Alonso, Jose M/0000-0001-7087-1571				BALCOMBE D, 1986, NATURE, V321, P446; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; Coons DM, 1997, YEAST, V13, P9, DOI 10.1002/(SICI)1097-0061(199701)13:1<9::AID-YEA51>3.0.CO;2-U; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; Fleet JC, 1998, NUTR REV, V56, P88, DOI 10.1111/j.1753-4887.1998.tb01701.x; Fujita H, 1996, PLANT CELL PHYSIOL, V37, P1094, DOI 10.1093/oxfordjournals.pcp.a029059; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; Johnson PR, 1998, ANNU REV GENET, V32, P227, DOI 10.1146/annurev.genet.32.1.227; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)10052-9; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Matallana E., 1992, Methods in Arabidopsis research., P144; NOURIZADEH S, UNPUB; Oh SA, 1997, PLANT J, V12, P527, DOI 10.1046/j.1365-313X.1997.00527.x; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; Penninckx IAMA, 1998, PLANT CELL, V10, P2103, DOI 10.1105/tpc.10.12.2103; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; ROMAN G, 1995, GENETICS, V139, P1393; ROTHENBERG M, UNPUB SCIENCE; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; Sambrook J., 1989, MOL CLONING LAB MANU; Smalle J, 1997, P NATL ACAD SCI USA, V94, P2756, DOI 10.1073/pnas.94.6.2756; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; SU WP, 1992, PLANT PHYSIOL, V99, P1569, DOI 10.1104/pp.99.4.1569; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WEST AH, 1992, J BIOL CHEM, V267, P24625	43	925	994	14	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2148	2152		10.1126/science.284.5423.2148	http://dx.doi.org/10.1126/science.284.5423.2148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381874				2022-12-01	WOS:000081099300043
J	Jablonski, D				Jablonski, D			The future of the fossil record	SCIENCE			English	Editorial Material							MASS EXTINCTION; EVOLUTION; DIVERSITY; REORGANIZATION; LIMBS	The fossil record provides a powerful basis for analyzing the controlling factors and impact of biological evolution over a wide range of temporal and spacial scales and in the context of an evolving Earth. An increasingly interdisciplinary paleontology has begun to formulate the next generation of questions, drawing on a wealth of new data, and on methodological advances ranging from high-resolution geochronology to simulation of morphological evolution. Key issues related to evolutionary biology include the biotic and physical factors that govern biodiversity dynamics, the developmental and ecological basis for the nonrandom introduction of evolutionary innovations in time and space, rules of biotic response to environmental perturbations, and the dynamic feedbacks between life and the Earth's surface processes. The sensitivity of evolutionary processes to rates, magnitudes, and spatial scales of change in the physical and biotic environment will be important in all these areas.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Jablonski, D (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	djablons@midway.uchicago.edu						Benton Michael J., 1996, P185; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; Coates MI, 1998, BIOESSAYS, V20, P371, DOI 10.1002/(SICI)1521-1878(199805)20:5<371::AID-BIES4>3.0.CO;2-R; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; Droser ML, 1997, GEOLOGY, V25, P167, DOI 10.1130/0091-7613(1997)025<0167:ETEAOM>2.3.CO;2; FLESSE KW, 1999, GEOBIOLOGY EARTH SCI; Foote M, 1997, ANNU REV ECOL SYST, V28, P129, DOI 10.1146/annurev.ecolsys.28.1.129; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; Gould SJ, 1998, PHILOS T R SOC B, V353, P307, DOI 10.1098/rstb.1998.0211; Holland SM, 1999, GEOLOGY, V27, P491, DOI 10.1130/0091-7613(1999)027<0491:MFSTFR>2.3.CO;2; Jablonski D, 1998, SCIENCE, V279, P1327, DOI 10.1126/science.279.5355.1327; Jackson JBC, 1999, TRENDS ECOL EVOL, V14, P72, DOI 10.1016/S0169-5347(98)01504-3; Kidwell Susan M., 1996, P290; Kirschvink JL, 1997, SCIENCE, V277, P541, DOI 10.1126/science.277.5325.541; LANE HR, 1997, PALEONTOLOGY 21 CENT, V25, P1; LOGAN GA, 1995, NATURE, V376, P53, DOI 10.1038/376053a0; Lupia R, 1999, PALEOBIOLOGY, V25, P1, DOI 10.1666/0094-8373(1999)25[1:MDITER]2.0.CO;2; MALEY C, 1997, GEOL SOC AM ABSTR, V29, pA31; Marshall CR, 1996, SCIENCE, V274, P1360, DOI 10.1126/science.274.5291.1360; McGhee GR, 1999, PERS PALEOB; McKinney ML, 1997, ANNU REV ECOL SYST, V28, P495, DOI 10.1146/annurev.ecolsys.28.1.495; Miller AI, 1998, SCIENCE, V281, P1157, DOI 10.1126/science.281.5380.1157; Morris SC, 1998, PHILOS T R SOC B, V353, P327, DOI 10.1098/rstb.1998.0213; Roy K, 1996, PALEOBIOLOGY, V22, P436, DOI 10.1017/S0094837300016389; Sepkoski J. John Jr, 1996, P211; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P168, DOI 10.1017/S0094837300015852; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Stanley SM, 1998, PALAEOGEOGR PALAEOCL, V144, P3, DOI 10.1016/S0031-0182(98)00109-6; STANLEY SM, 1997, GEOBIOLOGY CRITICAL; Valentine JW, 1999, DEVELOPMENT, V126, P851; VANVALEN L, 1973, SCIENCE, V180, P516	32	36	38	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2114	2116		10.1126/science.284.5423.2114	http://dx.doi.org/10.1126/science.284.5423.2114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381868				2022-12-01	WOS:000081099300037
J	Sattler, R; Xiang, ZG; Lu, WY; Hafner, M; MacDonald, JF; Tymianski, M				Sattler, R; Xiang, ZG; Lu, WY; Hafner, M; MacDonald, JF; Tymianski, M			Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein	SCIENCE			English	Article							LONG-TERM POTENTIATION; CALCIUM NEUROTOXICITY; POSTSYNAPTIC PROTEIN; SYNTHASE; NEURONS; BRAIN; HIPPOCAMPUS; MECHANISMS; CHANNELS; PATHWAYS	The efficiency with which N-methyl-D-aspartate receptors (NMDARs) trigger intracellular signaling pathways governs neuronal plasticity, development, senescence, and disease. In cultured cortical neurons, suppressing the expression of the NM DAR scaffolding protein PSD-95 (postsynaptic density-95) selectively attenuated excitotoxicity triggered via NMDARs, but not by other glutamate or calcium ion (Ca2+) channels. NMDAR function was unaffected, because receptor expression, NMDA currents, and Ca-45(2+) loading were unchanged. Suppressing PSD-95 blocked Ca2+-activated nitric oxide production by NMDARs selectively, without affecting neuronal nitric oxide synthase expression or function. Thus, PSD-95 is required for efficient coupling of NMDAR activity to nitric oxide toxicity, and imparts specificity to excitotoxic Ca2+ signaling.	Univ Toronto, Toronto Western Hosp, Lab 11 416, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada; Mannheim Univ Appl Sci, D-68163 Mannheim, Germany	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Tymianski, M (corresponding author), Univ Toronto, Toronto Western Hosp, Lab 11 416, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Lu, Wei-Yang/K-4404-2013	Tymianski, Mike/0000-0002-6311-9565	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039060] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 39060] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Brorson JR, 1999, J NEUROSCI, V19, P147, DOI 10.1523/JNEUROSCI.19-01-00147.1999; BURNASHEV N, 1995, J PHYSIOL-LONDON, V485, P403, DOI 10.1113/jphysiol.1995.sp020738; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; JAFFE DA, 1995, LEONARDO MUSIC J, V5, P11, DOI 10.2307/1513155; Jones OT, 1997, J NEUROSCI, V17, P6152; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KOMAU HC, 1995, SCIENCE, V269, P1737; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Olney J.W., 1978, KAINIC ACID TOOL NEU, P95; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 1997, J CEREBR BLOOD F MET, V17, P455, DOI 10.1097/00004647-199704000-00011; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; TYMIANSKI M, UNPUB; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; Yamada Y, 1999, J BIOL CHEM, V274, P6647, DOI 10.1074/jbc.274.10.6647	32	673	706	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1845	1848		10.1126/science.284.5421.1845	http://dx.doi.org/10.1126/science.284.5421.1845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364559				2022-12-01	WOS:000080809000053
J	Dimmeler, S; Fleming, I; Fisslthaler, B; Hermann, C; Busse, R; Zeiher, AM				Dimmeler, S; Fleming, I; Fisslthaler, B; Hermann, C; Busse, R; Zeiher, AM			Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation	NATURE			English	Article							PROTEIN-KINASE-B; FLUID SHEAR-STRESS; SIGNAL-TRANSDUCTION; CALCIUM; SUPPRESSION; EXPRESSION; APOPTOSIS; PATHWAY; ANGIOGENESIS; CALMODULIN	Nitric oxide (NO) produced by the endothelial NO synthase (eNOS) is a fundamental determinant of cardiovascular homesotasis: it regulates systemic blood pressure, vascular remodelling and angiogenesis(1-3). Physiologically, the most important stimulus for the continuous formation of NO is the viscous drag (shear stress) generated by the streaming blood on the endothelial layer(4-8). Although shear-stress-mediated phosphorylation of eNOS is thought to regulate enzyme activity(9,10), the mechanism of activation of eNOS is not yet known. Here we demonstrate that the serine/threonine protein kinase Akt/PKB (11-13) mediates the activation of eNOS, leading to increased NO production. Inhibition of the phosphatidylinositol-3-OH kinase/Akt pathway or mutation of the Akt site on eNOS protein (at serine 1177) attenuates the serine phosphorylation and prevents the activation of eNOS, Mimicking the phosphorylation of Ser1177 directly enhances enzyme activity and alters the sensitivity of the enzyme to Ca2+, rendering its activity maximal at sub-physiological concentrations of Ca2+. Thus, phosphorylation of eNOS by Akt represents a novel Ca2+-independent regulatory mechanism for activation of eNOS.	Univ Frankfurt, Dept Internal Med 4, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Zeiher, AM (corresponding author), Univ Frankfurt, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Fleming, Ingrid/L-1225-2014; Fleming, Ingrid/AAB-6123-2022	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Dimmeler, Stefanie/0000-0002-1045-2436				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Busse R, 1998, J VASC RES, V35, P73, DOI 10.1159/000025568; COPPER JA, 1983, METHOD ENZYMOL, V99, P387; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; FLEMING L, 1996, CIRC RES, V79, P984; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; vanderZee R, 1997, CIRCULATION, V95, P1030; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeiher AM, 1996, LANCET, V348, pS10, DOI 10.1016/S0140-6736(96)98004-6; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	29	2893	2981	8	207	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					601	605		10.1038/21224	http://dx.doi.org/10.1038/21224			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376603				2022-12-01	WOS:000080778400060
J	Smith, O				Smith, O			Biomedicine - Pain-killer genes	SCIENCE			English	Editorial Material																		FINEGOLD AA, IN PRESS HUM GENE TH; Wilson SP, 1999, P NATL ACAD SCI USA, V96, P3211, DOI 10.1073/pnas.96.6.3211	2	2	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1634	1634		10.1126/science.284.5420.1634	http://dx.doi.org/10.1126/science.284.5420.1634			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10383343				2022-12-01	WOS:000080668300033
J	Shimizu, S; Narita, M; Tsujimoto, Y				Shimizu, S; Narita, M; Tsujimoto, Y			Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC	NATURE			English	Article							PERMEABILITY TRANSITION PORE; ION-CHANNEL; BAX; APOPTOSIS; MEMBRANE; YEAST; INHIBITION; BCL-X(L); FORMS	During transduction of an apoptotic (death) signal into the cell, there is an alteration in the permeability of the membranes of the cell's mitochondria, which causes the translocation of the apoptogenic protein cytochrome c into the cytoplasm, which in turn activates death-driving proteolytic proteins known as caspases(1,2). The Bcl-2 family of proteins, whose members may be anti-apoptotic or pro-apoptotic, regulates cell death by controlling this mitochondrial membrane permeability during apoptosis(3-5), but how that is achieved is unclear. Here we create liposomes that carry the mitochondrial porin channel (also called the voltage-dependent anion channel, or VDAC) to show that the recombinant pro-apoptotic proteins Bax and Bak accelerate the opening of VDAC, whereas the anti-apoptotic protein Bd-x(L) doses VDAC by binding to it directly. pax and Bak allow cytochrome c to pass through VDAC out of liposomes, but passage is prevented by Bcl-X-L. In agreement with this, VDAC1-deficient mitochondria from a mutant yeast did not exhibit a Bax/Bak-induced loss in membrane potential and cytochrome c release, both of which were inhibited by Bcl-x(L). Our results indicate that the Bcl-2 family of proteins bind to the VDAC in order to regulate the mitochondrial membrane potential and the release of cytochrome c during apoptosis.	Japan Sci & Technol Corp, CREST, Osaka 5650871, Japan; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University	Tsujimoto, Y (corresponding author), Japan Sci & Technol Corp, CREST, 2-2 Yamadaoka, Osaka 5650871, Japan.			Narita, Masashi/0000-0001-7764-577X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BATHORI G, 1993, BIOCHIM BIOPHYS ACTA, V1145, P168, DOI 10.1016/0005-2736(93)90394-F; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KELVIN H, 1990, CURRENT PROTOCOLS IM; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; Mannella CA, 1998, J STRUCT BIOL, V121, P207, DOI 10.1006/jsbi.1997.3954; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	28	1820	1930	1	96	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					483	487		10.1038/20959	http://dx.doi.org/10.1038/20959			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365962				2022-12-01	WOS:000080667900052
J	McLafferty, FW; Fridriksson, EK; Horn, DM; Lewis, MA; Zubarev, RA				McLafferty, FW; Fridriksson, EK; Horn, DM; Lewis, MA; Zubarev, RA			Biochemistry - Biomolecule mass spectrometry	SCIENCE			English	Article							PROTEIN CHARACTERIZATION; ELECTROPHORESIS; IDENTIFICATION; PEPTIDE		Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	McLafferty, FW (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.		Zubarev, Roman A/W-7891-2018	Zubarev, Roman A/0000-0001-9839-2089; Lewis Ph.D., Mark/0000-0002-2273-3729				BIEMANN K, 1995, PROTEIN SCI, V4, P1920, DOI 10.1002/pro.5560040926; CHAIT BT, UNPUB; CHENG XH, 1995, J AM CHEM SOC, V117, P8859, DOI 10.1021/ja00139a023; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; FORET F, 1995, J CHROMATOGR A, V716, P157, DOI 10.1016/0021-9673(95)00621-S; HORN D, UNPUB; Jensen ON, 1997, ANAL CHEM, V69, P1706, DOI 10.1021/ac961189t; Jensen ON, 1998, PROTEINS, P74; Jorgensen TJD, 1998, ANAL CHEM, V70, P4427, DOI 10.1021/ac980563h; Kelleher NL, 1998, PROTEIN SCI, V7, P1796, DOI 10.1002/pro.5560070815; Kelleher NL, 1999, J AM CHEM SOC, V121, P806, DOI 10.1021/ja973655h; Kelleher NL, 1997, J BIOL CHEM, V272, P32215, DOI 10.1074/jbc.272.51.32215; KELLEHER NL, UNPUB; Little DP, 1996, J AM CHEM SOC, V118, P9352, DOI 10.1021/ja9533611; McLafferty FW, 1998, J AM CHEM SOC, V120, P4732, DOI 10.1021/ja9728076; McLafferty FW, 1997, INT J MASS SPECTROM, V165, P457, DOI 10.1016/S0168-1176(97)00171-7; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; Schnier PD, 1998, J AM CHEM SOC, V120, P9605, DOI 10.1021/ja973534h; Schuhmacher M, 1996, ELECTROPHORESIS, V17, P848, DOI 10.1002/elps.1150170506; Senko MW, 1997, J AM SOC MASS SPECTR, V8, P970, DOI 10.1016/S1044-0305(97)00126-8; SHABANOWITZ J, 1999, MASS SPECTROMETRY BI; Valaskovic GA, 1996, SCIENCE, V273, P1199, DOI 10.1126/science.273.5279.1199; Yang LY, 1998, ANAL CHEM, V70, P3235, DOI 10.1021/ac980224o; Zubarev RA, 1999, J AM CHEM SOC, V121, P2857, DOI 10.1021/ja981948k	24	168	184	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1289	1290		10.1126/science.284.5418.1289	http://dx.doi.org/10.1126/science.284.5418.1289			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383309				2022-12-01	WOS:000080430600031
J	Relman, DA				Relman, DA			The search for unrecognized pathogens	SCIENCE			English	Editorial Material							KAPOSIS-SARCOMA; MICROBIAL PATHOGENS; INFECTIOUS AGENTS; WHIPPLES-DISEASE; IDENTIFICATION; HERPESVIRUS; VIEW; BIODIVERSITY; SEQUENCES; ECOSYSTEM	The distribution and diversity of microorganisms in the world are far greater than have been previously appreciated. Molecular, cultivation-independent methods have played a key role in this insight. To what extent do humans remain ignorant of microbial diversity within the human body and the settings in which microorganisms cause human disease? In addition to implicating microbial agents in nontraditional infectious diseases, the use of methods such as broad-range polymerase chain reaction, representational difference analysis, expression Library screening, and host gene expression profiling may force a reassessment of the concepts of microbial disease causation.	Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Relman, DA (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA.			Relman, David A./0000-0001-8331-1354				AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Brown PO, 1998, NAT GENET, V18, P91, DOI 10.1038/ng0298-91; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18; Fredricks DN, 1998, CURR CLIN TOPICS INF, V18, P180; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gao SJ, 1996, EMERG INFECT DIS, V2, P159, DOI 10.3201/eid0203.960301; Hahn AF, 1998, LANCET, V352, P635, DOI 10.1016/S0140-6736(97)12308-X; Hoerauf A, 1999, J CLIN INVEST, V103, P11, DOI 10.1172/JCI4768; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KOLENBRANDER PE, 1993, J BACTERIOL, V175, P3247, DOI 10.1128/jb.175.11.3247-3252.1993; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; MARSHALL BJ, 1995, JAMA-J AM MED ASSOC, V274, P1064, DOI 10.1001/jama.274.13.1064; MARSHALL BJ, 1984, LANCET, V1, P1311; Moore PS, 1998, AM J EPIDEMIOL, V147, P217, DOI 10.1093/oxfordjournals.aje.a009440; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Perkins BK, 1996, EMERG INFECT DIS, V2, P47, DOI 10.3201/eid0201.960106; Relman DA, 1998, EMERG INFECT DIS, V4, P382, DOI 10.3201/eid0403.980310; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; Ward DM, 1998, MICROBIOL MOL BIOL R, V62, P1353, DOI 10.1128/MMBR.62.4.1353-1370.1998; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; Wilson M, 1998, INFECT IMMUN, V66, P2401, DOI 10.1128/IAI.66.6.2401-2409.1998; Woese C, 1998, P NATL ACAD SCI USA, V95, P6854, DOI 10.1073/pnas.95.12.6854; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	42	154	168	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1308	1310		10.1126/science.284.5418.1308	http://dx.doi.org/10.1126/science.284.5418.1308			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334977	Green Submitted			2022-12-01	WOS:000080430600040
J	Zuhlke, RD; Pitt, GS; Deisseroth, K; Tsien, RW; Reuter, H				Zuhlke, RD; Pitt, GS; Deisseroth, K; Tsien, RW; Reuter, H			Calmodulin supports both inactivation and facilitation of L-type calcium channels	NATURE			English	Article							CA2+ CHANNELS; CA2+-SENSITIVE INACTIVATION; ALPHA(1C) SUBUNIT; DEPENDENT INACTIVATION; INHIBITION; VOLTAGE; CELLS; MOTIF; MODULATION; MECHANISM	L-type Ca2+ channels support Ca2+ entry into cells, which triggers cardiac contraction(1), controls hormone secretion from endocrine cells(2) and initiates transcriptional events that support learning and memory(3). These channels are examples of molecular signal-transduction units that regulate themselves through their own activity. Among the many types of voltage-gated Ca2+ channel, L-type Ca2+ channels particularly display inactivation and facilitation, both of which are closely linked to the earlier entry of Ca2+ ions(4-10). Both forms of autoregulation have a significant impact on the amount of Ca2+ that enters the cell during repetitive activity, with major consequences downstream. Despite extensive biophysical analysis(9), the molecular basis of autoregulation remains unclear, although a putative Ca2+-binding EF-hand motif(11,12) and a nearby consensus calmodulin-binding isoleucine-glutamine ('IQ') motif(13,14) in the carboxy terminus of the alpha(1C) channel subunit have been implicated(12,14-16). Here we show that calmodulin is a critical Ca2+ sensor for both inactivation and facilitation, and that the nature of the modulatory effect depends on residues within the IQ motif important for calmodulin binding. Replacement of the native isoleucine by alanine removed Ca2+-dependent inactivation and unmasked a strong facilitation; conversion of the same residue to glutamate eliminated both forms of autoregulation. These results indicate that the same calmodulin molecule may act as a Ca2+ sensor for both positive and negative modulation.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	University of Bern; Stanford University; Stanford University	Reuter, H (corresponding author), Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland.		Tuluc, Petronel/C-2527-2011; Pitt, Geoffrey/L-4927-2019					ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; Bernatchez G, 1998, BIOPHYS J, V75, P1727, DOI 10.1016/S0006-3495(98)77614-3; BERS DM, 1991, EXCITATION CONTRACTI; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HAACK JA, 1994, BIOPHYS J, V66, P1051, DOI 10.1016/S0006-3495(94)80886-0; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; Hofer GF, 1997, BIOPHYS J, V73, P1857, DOI 10.1016/S0006-3495(97)78216-X; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; KINCAID RL, 1982, J BIOL CHEM, V257, P638; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NOBLE S, 1981, J PHYSIOL-LONDON, V310, P57, DOI 10.1113/jphysiol.1981.sp013537; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1998, FEBS LETT, V427, P220, DOI 10.1016/S0014-5793(98)00425-6; ZYGMUNT AC, 1990, J PHYSIOL-LONDON, V428, P653, DOI 10.1113/jphysiol.1990.sp018233	29	689	707	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	1999	399	6732					159	162		10.1038/20200	http://dx.doi.org/10.1038/20200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335846				2022-12-01	WOS:000080335700052
J	Henderson, J; North, K; Griffiths, M; Harvey, I; Golding, J				Henderson, J; North, K; Griffiths, M; Harvey, I; Golding, J		Avon Longitudinal Study Pregnancy Childhood Tea	Pertussis vaccination and wheezing illnesses in young children: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							ASTHMA; INFECTION; SYMPTOMS; ALLERGY; ADULTS; IGE	Objectives To examine the relation between pertussis vaccination and the prevalence of wheezing illnesses in young children. Design Prospective cohort study. Setting Three former health districts comprising Avon Health Authority. Subjects 9444 of 14 138 children enrolled in the Avon longitudinal study of pregnancy and childhood and for whom data on wheezing symptoms, vaccination status, and 15 environmental and biological variables were available. Main outcome measures Episodes of wheezing from birth to 6 months, 7-18 months, 19-30 months, and 31-42 months. These time periods were used to derive five categories of wheezing illness: early wheezing (not after 18 months); late onset wheezing (after 18 months); persistent wheezing (at every time period); recurrent wheezing (any combination of two or more episodes for each period); and intermittent wheezing (any combination of single episodes of reported wheezing). These categories were stratified according to parental self reported asthma or allergy. Results Unadjusted comparisons of the defined wheezing illnesses in vaccinated and non-vaccinated children showed no significant association between pertussis vaccination and any of the wheezing outcomes regardless of stratification for parental asthma or allergy. Wheeze was more common in non-vaccinated children at 18 months, and there was a tendency for late onset wheezing to be associated with non-vaccination in children whose parents did not have asthma, but this was not significant. After adjustment for environmental and biological variables, logistic regression analyses showed no significant increased relative risk for any of the wheezing outcomes in vaccinated children: early wheezing (0.99, 95% confidence interval 0.80 to 1.23), late onset wheezing (0.85, 0.69 to 1.05), persistent wheezing (0.91, 0.41 to 1.79), recurrent wheezing (0.96, 0.72 to 1.26), and intermittent wheezing (1.06, 0.81 to 1.37). Conclusions No evidence was found that pertussis vaccination increases the risk of wheezing illnesses in young children. Further follow up of this population with objective measurement of allergy and bronchial responsiveness is planned to confirm these observations.	Univ Bristol, Fdn Study Infant Death Unit, Inst Child Hlth, Bristol BS2 8BJ, Avon, England; Unit Paediat & Perinatal Epidemiol, Bristol BS2 1TQ, Avon, England; St Michaels Hosp, Dept Ear Nose & Throat, Bristol BS2 8EG, Avon, England; Univ E Anglia, Sch Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England	University of Bristol; University of East Anglia	Henderson, J (corresponding author), Univ Bristol, Fdn Study Infant Death Unit, Inst Child Hlth, Bristol BS2 8BJ, Avon, England.		Northstone, Kate/A-8165-2011	Northstone, Kate/0000-0002-0602-1983; Golding, Jean/0000-0003-2826-3307	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abramson M, 1996, J ASTHMA, V33, P189, DOI 10.3109/02770909609054551; ATMAR RL, 1990, VACCINE, V8, P217, DOI 10.1016/0264-410X(90)90049-R; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Feeney M, 1997, LANCET, V350, P764, DOI 10.1016/S0140-6736(97)03192-9; GOLDING J, 1996, CONT REV OBSTET GYNA, V8, P89; HAUS M, 1988, LANCET, V1, P711; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MUNOZ JJ, 1990, CELL IMMUNOL, V127, P327, DOI 10.1016/0008-8749(90)90136-F; Nilsson L, 1996, JAMA-J AM MED ASSOC, V275, P760, DOI 10.1001/jama.275.10.760; ODENT MR, 1994, JAMA-J AM MED ASSOC, V272, P592, DOI 10.1001/jama.1994.03520080034035; SALISBURY D, 1996, IMMUNISATION INFECT; SCHUSTER A, 1993, CLIN INVESTIGATOR, V71, P208; Silverman M, 1997, THORAX, V52, P936, DOI 10.1136/thx.52.11.936; WJST M, 1994, ANN ALLERGY, V73, P450	15	73	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1173	1176						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10221941	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000080277900028
J	Sessions, SK; Franssen, RA; Horner, VL				Sessions, SK; Franssen, RA; Horner, VL			Morphological clues from multilegged frogs: Are retinoids to blame?	SCIENCE			English	Article							REGENERATING AXOLOTL LIMBS; VITAMIN-A; POSITIONAL MEMORY; RANA-TEMPORARIA; ACID; PATTERN; DEFORMITIES; AXIS	Morphological analysis was performed on multilegged deformed frogs representing five species from 12 different Localities in California, Oregon, Arizona, and New York. The pattern of duplicated Limbs was consistent with mechanical perturbation by trematode infestation but not with the effects of retinoids.	Hartwick Coll, Dept Biol, Oneonta, NY 13820 USA		Sessions, SK (corresponding author), Hartwick Coll, Dept Biol, Oneonta, NY 13820 USA.							Blaustein AR, 1997, P NATL ACAD SCI USA, V94, P13735, DOI 10.1073/pnas.94.25.13735; BRYANT SV, 1992, DEV BIOL, V152, P1, DOI 10.1016/0012-1606(92)90152-7; BRYANT SV, 1987, AM ZOOL, V27, P675; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; GARDINER DM, 1989, J EXP ZOOL, V251, P47, DOI 10.1002/jez.1402510107; Gardiner DM, 1996, INT J DEV BIOL, V40, P797; GARDINER DM, 1995, DEVELOPMENT, V121, P1731; HARMON MA, 1995, P NATL ACAD SCI USA, V92, P6157, DOI 10.1073/pnas.92.13.6157; Harrison R, 1969, HARRISON STAGE DESCR; Helgen Judy, 1998, P288; HONIG LS, 1985, J EMBRYOL EXP MORPH, V87, P163; JOHNSON PT, 1998, THESIS STANFORD U; Johnson PTJ, 1999, SCIENCE, V284, P802, DOI 10.1126/science.284.5415.802; KIM WS, 1986, DEV BIOL, V114, P170, DOI 10.1016/0012-1606(86)90393-3; LUDOLPH DC, 1990, DEV BIOL, V140, P41, DOI 10.1016/0012-1606(90)90051-J; MADEN M, 1993, DEV BIOL, V159, P379, DOI 10.1006/dbio.1993.1249; MADEN M, 1981, J EMBRYOL EXP MORPH, V63, P243; MADEN M, 1983, DEV BIOL, V98, P409, DOI 10.1016/0012-1606(83)90370-6; Ouellet M, 1997, J WILDLIFE DIS, V33, P95, DOI 10.7589/0090-3558-33.1.95; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P35; SCADDING SR, 1986, J EMBRYOL EXP MORPH, V91, P19; SESSIONS SK, 1990, J EXP ZOOL, V254, P38, DOI 10.1002/jez.1402540107; SESSIONS SK, 1989, AM ZOOL, V29, pA73; SESSIONS SK, UNPUB; STOCUM DL, 1991, CELL, V67, P5, DOI 10.1016/0092-8674(91)90565-G; THOMS SD, 1984, DEV BIOL, V103, P319, DOI 10.1016/0012-1606(84)90320-8; Van Valen L., 1974, Journal Herpet, V8, P109; VOLPE EP, 1981, UNDERSTANDING EVOLUT	30	77	86	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					800	802		10.1126/science.284.5415.800	http://dx.doi.org/10.1126/science.284.5415.800			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221911				2022-12-01	WOS:000080056200045
J	Lu, QX; Gore, M; Zhang, Q; Camenisch, T; Boast, S; Casagranda, F; Lai, C; Skinner, MK; Klein, R; Matsushima, GK; Earp, HS; Goff, SP; Lemke, G				Lu, QX; Gore, M; Zhang, Q; Camenisch, T; Boast, S; Casagranda, F; Lai, C; Skinner, MK; Klein, R; Matsushima, GK; Earp, HS; Goff, SP; Lemke, G			Tyro-3 family receptors are essential regulators of mammalian spermatogenesis	NATURE			English	Article							TYROSINE KINASE RECEPTOR; PROTEIN-S; GENOMIC STRUCTURE; SERTOLI CELLS; GAS6; IDENTIFICATION; EXPRESSION; GROWTH; MER; AXL	We have generated and analysed null mutations in the mouse genes encoding three structurally related receptors with tyrosine kinase activity: Tyro 3, Axl, and Mer(1-4). Mice lacking any single receptor, or any combination of two receptors, are viable and fertile, but male animals that lack all three receptors produce no mature sperm, owing to the progressive death of differentiating germ cells. This degenerative phenotype appears to result from a failure of the tropic support that is normally provided by Sertoli cells of thc seminiferous tubules, whose function depends on testosterone and additional factors produced by Leydig cells(5-7). Tyro 3, Axl and Mer are all normally expressed by Sertoli cells during postnatal development, whereas their ligands, Gas6 and protein S, are produced by Leydig cells before sexual maturity, and by both Leydig and Sertoli cells thereafter. Here we show that the concerted activation of Tyro 3, Axl and Mer in Sertoli cells is critical to the role that these cells play as nurturers of developing germ cells. Additional observations indicate that these receptors may also be essential for the tropic maintenance of diverse cell types in the mature nervous, immune and reproductive systems.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Columbia Univ, Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Washington State Univ, Ctr Reprod Biol, Dept Genet & Cell Biol, Pullman, WA 99164 USA	Salk Institute; Columbia University; Howard Hughes Medical Institute; Columbia University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; European Molecular Biology Laboratory (EMBL); Scripps Research Institute; Washington State University	Lemke, G (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.		Klein, Ruediger/C-6147-2008; Goff, Stephen P/K-6337-2014	Klein, Ruediger/0000-0002-3109-0163; Goff, Stephen P/0000-0003-0693-5547; Camenisch, Todd/0000-0002-7797-9822				Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BIESECKER LG, 1995, ONCOGENE, V10, P2239; Camenisch TD, 1999, J IMMUNOL, V162, P3498; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRISWOLD MD, 1995, BIOL REPROD, V52, P211, DOI 10.1095/biolreprod52.2.211; HENRIKSEN K, 1995, ENDOCRINOLOGY, V136, P3285, DOI 10.1210/en.136.8.3285; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; Joseph DR, 1997, STEROIDS, V62, P578, DOI 10.1016/S0039-128X(97)00045-7; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; Lewis PM, 1996, GENOMICS, V31, P13, DOI 10.1006/geno.1996.0003; MARK MR, 1994, J BIOL CHEM, V269, P10720; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SCHULZ AS, 1993, ONCOGENE, V8, P509; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SKINNER MK, 1993, SERTOLI CELL, P237; Smiley ST, 1997, CELL IMMUNOL, V181, P120, DOI 10.1006/cimm.1997.1210; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUN YT, 1990, ENDOCRINOLOGY, V127, P1215, DOI 10.1210/endo-127-3-1215; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; WONG V, 1983, AM J ANAT, V167, P143, DOI 10.1002/aja.1001670202; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759	30	368	390	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					723	728		10.1038/19554	http://dx.doi.org/10.1038/19554			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227296				2022-12-01	WOS:000079920100054
J	Davis, KL; Mohs, RC; Marin, D; Purohit, DP; Perl, DP; Lantz, M; Austin, G; Haroutunian, V				Davis, KL; Mohs, RC; Marin, D; Purohit, DP; Perl, DP; Lantz, M; Austin, G; Haroutunian, V			Cholinergic markers in elderly patients with early signs of Alzheimer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACETYLTRANSFERASE ACTIVITY; NUCLEUS BASALIS; CORTICAL BIOPSY; SENILE DEMENTIA; DEFICITS; PHYSOSTIGMINE; RECOVERY; PLAQUES; SCALE; RISK	Context A central tenet of Alzheimer disease (AD) is the loss of cortical cholinergic function and cholinergic markers in postmortem brain specimens. Whether these profound deficits in cholinergic markers found in end-stage patients are also found in patients with much earlier disease is not known. Objective To determine whether cholinergic deficits in AD precede, follow, or occur in synchrony with the earliest signs of cognitive deterioration. Design, Setting, and Patients Postmortem study of nursing home residents with Clinical Dementia Rating (CDR) Scale scores of 0.0 to 2.0 and 4.0 to 5.0 who underwent autopsy between 1986 and 1997, comparing the activity of the cholinergic marker enzymes in the cortices of 66 elderly subjects with no (CDR score = 0.0; n = 18), questionable (CDR score = 0.5; n = 11), mild (CDR score = 1.0; n = 22), or moderate (CDR score = 2.0; n = 15) dementia vs subjects with severe dementia (CDR score = 4.0-5.0; n = 15). Main Outcome Measures Activity of the cholinergic marker enzymes choline acetyltransferase and acetylcholinesterase in 9 neocortical brain regions. Results The activity of choline acetyltransferase and acetylcholinesterase in 9 neocortical brain regions did not differ significantly in subjects with CDR scores of 0.0 to 2.0, but was significantly lower in subjects with severe dementia (CDR score = 4.0-5.0), Choline acetyltransferase levels were significantly correlated with severity of neuropathological lesions of AD, as measured by density of neuritic plaques and neurofibrillary tangles. Conclusions Although neocortical cholinergic deficits are characteristic of severely demented AD patients, in this study, cholinergic deficits were not apparent in individuals with mild AD and were not present until relatively late in the course of the disease. These results suggest that patients with more severe disease should be a target for cholinergic treatment.	CUNY Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; Jewish Home & Hosp, New York, NY USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Davis, KL (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl, New York, NY 10029 USA.		Perl, Daniel/GPS-9879-2022		NATIONAL INSTITUTE ON AGING [P01AG002219] Funding Source: NIH RePORTER; NIA NIH HHS [AG02219, AG05138] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARTUS RT, 1986, PHARMACOL BIOCHEM BE, V24, P1287, DOI 10.1016/0091-3057(86)90186-3; BIERER LM, 1995, J NEUROCHEM, V64, P749; BOWEN DM, 1982, J NEUROL SCI, V57, P191, DOI 10.1016/0022-510X(82)90026-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTMAN CW, 1979, MECH AGEING DEV, V9, P103, DOI 10.1016/0047-6374(79)90124-6; DAMASIO H, 1989, LESION ANAL NEUROPSY, P184; DAVIES P, 1976, LANCET, V2, P1403; DAVIS KL, 1978, SCIENCE, V201, P272, DOI 10.1126/science.351807; DAVIS KL, 1992, NEW ENGL J MED, V327, P1253, DOI 10.1056/NEJM199210293271801; DEKOSKY ST, 1992, ANN NEUROL, V32, P625; FARLOW MR, 1995, RES ADV ALZHEIMERS D, P284; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; HAROUTUNIAN V, 1994, SCHIZOPHR RES, V12, P137, DOI 10.1016/0920-9964(94)90071-X; Haroutunian V, 1998, ARCH NEUROL-CHICAGO, V55, P1185, DOI 10.1001/archneur.55.9.1185; HAROUTUNIAN V, IN PRESS ARCH NEUROL; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; LI G, 1995, AM J PSYCHIAT, V152, P424; MARTIN EM, 1987, NEUROLOGY, V37, P1201, DOI 10.1212/WNL.37.7.1201; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MOHS RC, 1985, AM J PSYCHIAT, V142, P28; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; PERRY EK, 1977, LANCET, V1, P189; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; SANTUCCI AC, 1989, PROGR CLIN BIOL RES, P1111; SILVERMAN JM, 1994, ARCH GEN PSYCHIAT, V51, P577; WENK GL, 1984, BRAIN RES, V293, P184, DOI 10.1016/0006-8993(84)91468-9	30	406	422	1	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1401	1406		10.1001/jama.281.15.1401	http://dx.doi.org/10.1001/jama.281.15.1401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217056	Bronze			2022-12-01	WOS:000079701000030
J	Briscoe, J; Sussel, L; Serup, P; Hartigan-O'Connor, D; Jessell, TM; Rubenstein, JLR; Ericson, J				Briscoe, J; Sussel, L; Serup, P; Hartigan-O'Connor, D; Jessell, TM; Rubenstein, JLR; Ericson, J			Homeobox gene Nkx2.2 and specification of neuronal identity by graded Sonic hedgehog signalling	NATURE			English	Article							HOMEODOMAIN TRANSCRIPTION FACTOR; MOTOR-NEURONS; MICE LACKING; NERVOUS-SYSTEM; FLOOR PLATE; NEURAL-TUBE; EXPRESSION; CNS; DIFFERENTIATION; RAT	During vertebrate development, the specification of distinct cell types is thought to be controlled by inductive signals acting at different concentration thresholds(1). The degree of receptor activation in response to these signals is a known determinant of cell fate(2), but the later steps at which graded signals are converted into all-or-none distinctions in cell identity remain poorly resolved. In the ventral neural tube, motor neuron and interneuron generation depends on the graded activity of the signalling protein Sonic hedgehog (Shh)(3-5). These neuronal subtypes derive from distinct progenitor cell populations that express the homeodomain proteins Nkx2.2 or Pax6 in response to graded Shh signalling(6,7). In mice lacking Pax6, progenitor cells generate neurons characteristic of exposure to greater Shh activity(6,8). However, Nkx2.2 expression expands dosally in Pax6 mutants(6), raising the possibility that Pax6 controls neuronal pattern indirectly. Here we provide evidence that Nkx2.2 has a primary role in ventral neuronal patterning. In Nkx2.2 mutants, Pax6 expression is unchanged but cells undergo a ventral-to-dorsal transformation in fate and generate motor neurons rather than interneurons. Thus, Nkx2.2 has an essential role in interpreting graded Shh signals and selecting neuronal identity.	Univ Calif San Francisco, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA; Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	University of California System; University of California San Francisco; Columbia University; Howard Hughes Medical Institute	Rubenstein, JLR (corresponding author), Univ Calif San Francisco, Nina Ireland Lab Dev Neurobiol, 402 Parnassus Ave,LPP1 Box 0984, San Francisco, CA 94143 USA.		Serup, Palle/A-7407-2011	Serup, Palle/0000-0002-0858-590X; Briscoe, James/0000-0002-1020-5240; Ericson, Johan/0000-0002-8019-7127				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; BARTH KA, 1995, DEVELOPMENT, V121, P1755; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; Fan CM, 1996, MOL CELL NEUROSCI, V7, P519, DOI 10.1006/mcne.1996.0037; GEISERT EE, 1989, NEUROSCI LETT, V102, P137, DOI 10.1016/0304-3940(89)90068-2; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Hartigan DJ, 1996, GENE, V168, P271, DOI 10.1016/0378-1119(95)00745-8; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; JIMENEZ F, 1995, EMBO J, V14, P3487, DOI 10.1002/j.1460-2075.1995.tb07355.x; LAUDER JM, 1974, J COMP NEUROL, V155, P469, DOI 10.1002/cne.901550407; LEBER SM, 1995, J NEUROSCI, V15, P1236; MACDONALD R, 1995, DEVELOPMENT, V121, P2397; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; McDonald JA, 1998, GENE DEV, V12, P3603, DOI 10.1101/gad.12.22.3603; Osumi N, 1997, DEVELOPMENT, V124, P2961; Pabst O, 1998, MECH DEVELOP, V73, P85, DOI 10.1016/S0925-4773(98)00035-5; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Qiu MS, 1998, MECH DEVELOP, V72, P77, DOI 10.1016/S0925-4773(98)00018-5; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tanabe Y, 1998, CELL, V95, P67, DOI 10.1016/S0092-8674(00)81783-3; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	30	573	590	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 15	1999	398	6728					622	627		10.1038/19315	http://dx.doi.org/10.1038/19315			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217145				2022-12-01	WOS:000079754700058
J	Reddel, H; Jenkins, C; Woolcock, A				Reddel, H; Jenkins, C; Woolcock, A			Diurnal variability - time to change asthma guidelines?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PEAK EXPIRATORY FLOW; SELF-MANAGEMENT PLANS; BRONCHIAL RESPONSIVENESS; POPULATION-SAMPLE; OBSTRUCTION		Royal Prince Alfred Hosp, Inst Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Camperdown, NSW 2050, Australia	University of Sydney; University of Sydney	Reddel, H (corresponding author), Royal Prince Alfred Hosp, Inst Resp Med, POB M77, Camperdown, NSW 2050, Australia.	hkr@mail.med.usyd.edu.au	Reddel, Helen/AAC-3394-2020; Reddel, Helen/ABD-6338-2021	Reddel, Helen/0000-0002-6695-6350; Jenkins, Christine/0000-0003-2717-5647				Brand PLP, 1997, EUR RESPIR J, V10, P1242, DOI 10.1183/09031936.97.10061242; CLARK TJH, 1977, BRIT J DIS CHEST, V71, P87, DOI 10.1016/0007-0971(77)90087-0; CONNOLLY CK, 1994, RESP MED, V88, P453, DOI 10.1016/S0954-6111(05)80049-6; CONNOLLY CK, 1981, BRIT J DIS CHEST, V75, P197, DOI 10.1016/0007-0971(81)90053-X; COTE J, 1993, THORAX, V48, P48, DOI 10.1136/thx.48.1.48; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; CROSS D, 1991, J ALLERGY CLIN IMMUN, V87, P120, DOI 10.1016/0091-6749(91)90223-B; DAHL R, 1991, EUR RESPIR J, V4, P1178; DALONZO GE, 1995, AM J RESP CRIT CARE, V152, P1097, DOI 10.1164/ajrccm.152.3.7663789; Fishwick D, 1996, EUR RESPIR J, V9, P861, DOI 10.1183/09031936.96.09050861; Gannon PFG, 1998, THORAX, V53, P790, DOI 10.1136/thx.53.9.790; *GLOB IN ASTHM, 1995, NIH PUBL; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; HIGGINS BG, 1992, AM REV RESPIR DIS, V145, P588, DOI 10.1164/ajrccm/145.3.588; Lebowitz MD, 1997, EUR RESPIR J, V10, pS49; Meijer RJ, 1997, EUR RESPIR J, V10, P1163, DOI 10.1183/09031936.97.10051163; *NAT ASHM ED PREV, 1997, NIH PUBL; *NAT ASTHM CAMP AU, 1998, ASTHM MAN HDB; NEUKIRCH F, 1992, AM REV RESPIR DIS, V146, P71, DOI 10.1164/ajrccm/146.1.71; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Reddel H, 1999, LANCET, V353, P758; REDDEL HK, 1995, AM J RESP CRIT CARE, V151, P1320, DOI 10.1164/ajrccm.151.5.7735580; Reddel HK, 1998, EUR RESPIR J, V12, P309, DOI 10.1183/09031936.98.12020309; Reddel HK, 1998, EUR RESPIR J, V12, P853, DOI 10.1183/09031936.98.12040853; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SALOME C, 1998, AM J RESP CRIT CARE, V157, pA631; SIERSTED HC, 1994, AM J RESP CRIT CARE, V149, P598, DOI 10.1164/ajrccm.149.3.8118624; Toogood JH, 1996, J ALLERGY CLIN IMMUN, V98, P555, DOI 10.1016/S0091-6749(96)70089-1; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; WALLS AF, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb00106.x; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	34	34	35	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					45	47		10.1136/bmj.319.7201.45	http://dx.doi.org/10.1136/bmj.319.7201.45			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390464	Green Published			2022-12-01	WOS:000081326500037
J	Brugnara, C; Zurakowski, D; DiCanzio, J; Boyd, T; Platt, O				Brugnara, C; Zurakowski, D; DiCanzio, J; Boyd, T; Platt, O			Reticulocyte hemoglobin content to diagnose iron deficiency in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; SOLUBLE TRANSFERRIN RECEPTOR; HEMODIALYSIS-PATIENTS; ZINC PROTOPORPHYRIN; CELLULAR INDEXES; CLINICAL UTILITY; LABORATORY TESTS; SERUM FERRITIN; MICROCYTOSIS; DISORDERS	Context Early identification of iron deficiency in children is essential to prevent the damaging long-term consequences of this disease. However, it is not clear which indices should be included in a diagnostic panel for iron deficiency and iron deficiency anemia in children. Objective To develop an effective approach for the diagnosis of iron deficiency and iron deficiency anemia in young children. Design and Setting Retrospective laboratory analysis, carried out over 7 weeks in 1996, using blood samples ordered by pediatricians and sent to a large metropolitan hospital for analysis. Patients A total of 210 children (mean [SD] age, 2.9 [2.0] years; 120 were male) who had a lead screening test (complete blood cell count and plasma lead level) ordered by a primary care pediatrician. Main Outcome Measures Levels of hemoglobin (Hb), iron, transferrin, transferrin saturation (Tfsat), ferritin, and circulating transferrin receptor and reticulocyte Hb content (CHr) among patients with and without iron deficiency, defined as Tfsat of less than 20%, and iron deficiency anemia, defined as Tfsat of less than 20% and Hb level of less than 110 g/L. Results Of the 210 subjects, 43 (20.5%) were iron deficient; 24 of these had iron deficiency anemia. Reticulocyte Hb content and Hb levels were the only significant predictors of iron deficiency (likelihood ratio test [LRT] = 15.96; P<.001 for CHr, and LRT=6.59; P=.01 for Hb), and CHr was the only significant multivariate predictor of iron deficiency anemia (LRT = 30.43; P<.001). Plasma ferritin level had no predictive value (P=.97), Subjects with CHr of less than 26 pg (optimal cutoff value based on sensitivity/specificity analysis) had lower Hb level, mean corpuscular volume, mean corpuscular Hb level, serum iron level, and Tfsat, and increased red blood cell distribution width vs those with CHr of 26 pg or more (P<.001 for all). Conclusions Reticulocyte Hb content level was the strongest predictor of iron deficiency and iron deficiency anemia in children. It holds promise as an alternative to biochemical iron studies in diagnosis.	Harvard Univ, Childrens Hosp, Sch Med, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Biostat, Boston, MA 02115 USA; Baystate Med Ctr, Springfield, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Baystate Medical Center	Brugnara, C (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Lab Med, 300 Longwood Ave,Bader 760, Boston, MA 02115 USA.		Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713				Bhandari S, 1997, AM J KIDNEY DIS, V30, P814, DOI 10.1016/S0272-6386(97)90087-1; BRUGNARA C, 1994, J LAB CLIN MED, V123, P660; BRUGNARA C, 1994, BLOOD, V83, P3100, DOI 10.1182/blood.V83.10.3100.3100; BRUGNARA C, 1994, AM J CLIN PATHOL, V102, P623, DOI 10.1093/ajcp/102.5.623; Brugnara C, 1998, INT J CLIN LAB RES, V28, P1, DOI 10.1007/s005990050011; Bruner AB, 1996, LANCET, V348, P992, DOI 10.1016/S0140-6736(96)02341-0; BURNS ER, 1990, AM J CLIN PATHOL, V93, P240, DOI 10.1093/ajcp/93.2.240; Buttarello M, 1995, ARCH PATHOL LAB MED, V119, P1141; Cazzola M, 1997, BLOOD, V89, P4248, DOI 10.1182/blood.V89.12.4248; DALLMAN PR, 1981, J PEDIATR, V98, P376; DONOFRIO G, 1992, ARCH PATHOL LAB MED, V116, P84; DONOFRIO G, 1995, BLOOD, V85, P818, DOI 10.1182/blood.V85.3.818.bloodjournal853818; FAIRBANKS VF, 1991, HOSP PRACT, V26, P17; FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385; Fishbane S, 1997, KIDNEY INT, V52, P217, DOI 10.1038/ki.1997.323; GREEN R, 1991, HOSP PRACT, V26, P25; HALLBERG L, 1993, BRIT J HAEMATOL, V85, P787, DOI 10.1111/j.1365-2141.1993.tb03225.x; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hastka J, 1996, CLIN CHEM, V42, P718; HASTKA J, 1994, CLIN CHEM, V40, P768; KAIRISTO V, 1995, SCAND J CLIN LAB INV, V55, P43, DOI 10.3109/00365519509088450; Lafferty JD, 1996, AM J CLIN PATHOL, V106, P201; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; Mast AE, 1998, CLIN CHEM, V44, P45; Mittman N, 1997, AM J KIDNEY DIS, V30, P912, DOI 10.1016/S0272-6386(97)90104-9; OSKI FA, 1993, NEW ENGL J MED, V329, P190, DOI 10.1056/NEJM199307153290308; osmer D. W, 1989, APPL LOGISTIC REGRES, P38; PIZARRO F, 1991, J PEDIATR-US, V118, P687, DOI 10.1016/S0022-3476(05)80027-7; ROOT CB, 1998, CODEMAP 98 LAB PATHO; SIEGEL RM, 1994, CLIN PEDIATR, V33, P473, DOI 10.1177/000992289403300805; SKIKNE BS, 1990, BLOOD, V75, P1870; Suominen P, 1997, CLIN CHEM, V43, P1641; ZAR JH, 1996, BIOSTAT ANAL, P474	34	164	177	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 16	1999	281	23					2225	2230		10.1001/jama.281.23.2225	http://dx.doi.org/10.1001/jama.281.23.2225			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	204RB	10376576	Bronze			2022-12-01	WOS:000080777000037
J	Doetsch, F; Caille, I; Lim, DA; Garcia-Verdugo, JM; Alvarez-Buylla, A				Doetsch, F; Caille, I; Lim, DA; Garcia-Verdugo, JM; Alvarez-Buylla, A			Subventricular zone astrocytes are neural stem cells in the adult mammalian brain	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FIBRILLARY ACIDIC PROTEIN; MEDIATED GENE-TRANSFER; RAT CEREBRAL-CORTEX; NEURONAL PRECURSORS; VENTRICULAR ZONE; RADIAL GLIA; RECEPTOR IMMUNOREACTIVITY; RECOMBINANT RETROVIRUS; MONOCLONAL-ANTIBODY	Neural stem cells reside in the subventricular zone (SVZ) of the adult mammalian brain. This germinal region, which continually generates new neurons destined for the olfactory bulb, is composed of four cell types: migrating neuroblasts, immature precursors, astrocytes, and ependymal cells. Here we show that SVZ astrocytes, and not ependymal cells, remain labeled with proliferation markers after long survivals in adult mice. After elimination of immature precursors and neuroblasts by an antimitotic treatment, SVZ astrocytes divide to generate immature precursors and neuroblasts. Furthermore, in untreated mice, SVZ astrocytes specifically infected with a retrovirus give rise to new neurons in the olfactory bulb. Finally, we show that SVZ astrocytes give rise to cells that grow into multipotent neurospheres in vitro. We conclude that SVZ astrocytes act as neural stem cells in both the normal and regenerating brain.	Rockefeller Univ, New York, NY 10021 USA; Univ Valencia, E-46100 Burjassot, Spain	Rockefeller University; University of Valencia	Alvarez-Buylla, A (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	alvarez@rockvax.rockefeller.edu	Caillé, Isabelle/AAC-9575-2021; García-Verdugo, José Manuel/L-8421-2017	García-Verdugo, José Manuel/0000-0001-9872-6499; Alvarez-Buylla, Arturo/0000-0003-4426-8925; Caille, Isabelle/0000-0002-9054-2641; Lim, Daniel/0000-0001-7221-3425	NICHD NIH HHS [HD32116] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; NINDS NIH HHS [NS28478] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028478, R01NS028478, R37NS028478] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; Alvarez-Buylla A, 1998, J NEUROSCI, V18, P1020; ALVAREZBUYLLA A, 1990, NEURON, V5, P101, DOI 10.1016/0896-6273(90)90038-H; ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; Baba H, 1997, DEV NEUROSCI-BASEL, V19, P49, DOI 10.1159/000111185; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Blasco-Ibanez JM, 1998, EUR J NEUROSCI, V10, P1784, DOI 10.1046/j.1460-9568.1998.00190.x; Caille I, 1996, BRAIN RES, V730, P17, DOI 10.1016/0006-8993(96)00424-6; Calaora V, 1996, NEUROSCIENCE, V73, P581, DOI 10.1016/0306-4522(96)00042-5; CAVANAGH JB, 1970, J ANAT, V106, P471; CEPKO CL, 1992, CURRENT PROTOCOLS MO; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DIDIER M, 1986, CELL TISSUE RES, V245, P343; Doetsch F, 1997, J NEUROSCI, V17, P5046; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; ECKENHOFF MF, 1988, J NEUROSCI, V8, P2729; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021, DOI 10.1523/JNEUROSCI.15-03-02021.1995; GRAY GE, 1992, DEVELOPMENT, V114, P271; GRITTI A, 1995, NEUROSCI LETT, V185, P151, DOI 10.1016/0304-3940(95)11247-T; Gritti A, 1999, J NEUROSCI, V19, P3287; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; HUNTER KE, 1995, P NATL ACAD SCI USA, V92, P2061, DOI 10.1073/pnas.92.6.2061; Jacobson M., 1991, DEV NEUROBIOLOGY; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KISHI K, 1987, J COMP NEUROL, V258, P112, DOI 10.1002/cne.902580109; KORR H, 1973, J COMP NEUROL, V150, P169, DOI 10.1002/cne.901500205; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MESSIER B, 1958, EXP CELL RES, V14, P224, DOI 10.1016/0014-4827(58)90235-0; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V91, P276, DOI 10.1016/0304-3940(88)90693-3; Okada A, 1999, EXP NEUROL, V156, P394, DOI 10.1006/exnr.1999.7033; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; PATERSON JA, 1973, J COMP NEUROL, V149, P83, DOI 10.1002/cne.901490106; Peters A., 1978, FINE STRUCTURE NERVO, V4, P588; POTTEN CS, 1988, J CELL SCI, P45; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Qian XM, 1998, DEVELOPMENT, V125, P3143; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; Shi JY, 1998, J NEUROSCI, V18, P4627; SMART I, 1961, J COMP NEUROL, V116, P325, DOI 10.1002/cne.901160306; SOTELO JR, 1958, Z ZELLFORSCH MIK ANA, V49, P1, DOI 10.1007/BF00335059; SPRANGRUDE GJ, 1988, SCIENCE, V241, P58; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Weiss S, 1996, J NEUROSCI, V16, P7599; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131; WILKIN GP, 1990, TRENDS NEUROSCI, V13, P43, DOI 10.1016/0166-2236(90)90065-I; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403; Yoon SO, 1996, P NATL ACAD SCI USA, V93, P11974, DOI 10.1073/pnas.93.21.11974; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	73	2990	3135	5	171	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					703	716		10.1016/S0092-8674(00)80783-7	http://dx.doi.org/10.1016/S0092-8674(00)80783-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380923	Bronze			2022-12-01	WOS:000080886300009
J	Stewart, P				Stewart, P			Exposure assessment in community-based epidemiological studies	LANCET			English	Editorial Material									NCI, Occupat Epidemiol Branch, Rockville, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stewart, P (corresponding author), NCI, Occupat Epidemiol Branch, Rockville, MD 20892 USA.							Benke G, 1997, INT J EPIDEMIOL, V26, P635, DOI 10.1093/ije/26.3.635; KROMHOUT H, 1987, AM J IND MED, V12, P551, DOI 10.1002/ajim.4700120509; STEWART WF, 1994, AM J IND MED, V26, P297, DOI 10.1002/ajim.4700260304; Tielemans E, 1999, OCCUP ENVIRON MED, V56, P145, DOI 10.1136/oem.56.3.145	4	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1816	1817		10.1016/S0140-6736(99)90075-2	http://dx.doi.org/10.1016/S0140-6736(99)90075-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359403				2022-12-01	WOS:000080667800006
J	Stringer, JSA; Rouse, DJ; Goldenberg, RL				Stringer, JSA; Rouse, DJ; Goldenberg, RL			Prophylactic cesarean delivery for the prevention of perinatal human immunodeficiency virus transmission - The case for restraint	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MOTHER-TO-CHILD; ANTIRETROVIRAL THERAPY; CONTROLLED TRIALS; HIV-INFECTION; ZIDOVUDINE; PREECLAMPSIA; INDINAVIR; MORTALITY; CALCIUM; SECTION		Univ Alabama Birmingham, Ctr Res Womens Hlth, Dept Obstet & Gynecol, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham	Stringer, JSA (corresponding author), Univ Alabama Birmingham, Ctr Res Womens Hlth, Dept Obstet & Gynecol, 618 S 20th St,340 OHB, Birmingham, AL 35233 USA.	uabobgyn@aol.com	Stringer, Jeffrey S. A./AAU-2342-2021	Stringer, Jeffrey/0000-0002-9590-7216				Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Bailar JC, 1999, NEW ENGL J MED, V340, P958, DOI 10.1056/NEJM199903253401211; BEROYZ G, 1994, LANCET, V343, P619; Birchard K, 1998, LANCET, V352, P796, DOI 10.1016/S0140-6736(05)60698-8; BROSSARD Y, 1995, AIDS, V9, P359, DOI 10.1097/00002030-199509040-00007; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1113, DOI 10.1001/jama.275.14.1113; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599; DUNN J, 1994, PROF ENG, V7, P10; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HAVERKAMP AD, 1979, AM J OBSTET GYNECOL, V134, P399, DOI 10.1016/S0002-9378(16)33082-4; IMPERIALE T F, 1991, Journal of the American Medical Association, V266, P260, DOI 10.1001/jama.266.2.260; KIND C, 1995, EUR J PEDIATR, V154, P542, DOI 10.1007/s004310050339; Landesman SH, 1996, NEW ENGL J MED, V334, P1617, DOI 10.1056/NEJM199606203342501; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Levine RJ, 1997, NEW ENGL J MED, V337, P69, DOI 10.1056/NEJM199707103370201; Mandelbrot L, 1996, AM J OBSTET GYNECOL, V175, P661; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; MORRIS A, 1999, 6 C RETR OPP INF JAN; MSELLATI P, 1995, J ACQ IMMUN DEF SYND, V8, P506; NEWELL ML, 1994, LANCET, V343, P1464; O'Sullivan M. J., 1999, American Journal of Obstetrics and Gynecology, V180, pS105; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; READ J, 1999, 6 C RETR OPP INF JAN; Schuitemaker N, 1997, ACTA OBSTET GYN SCAN, V76, P332, DOI 10.1111/j.1600-0412.1997.tb07987.x; SEMPRINI AE, 1995, AIDS, V9, P913, DOI 10.1097/00002030-199508000-00013; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; STEK A, 1999, AM J OBSTET GYNECOL, V180, pS6; THACKER SB, 1995, OBSTET GYNECOL, V86, P613, DOI 10.1016/0029-7844(95)00232-G; THOMAS PA, 1994, PEDIATR INFECT DIS J, V13, P489, DOI 10.1097/00006454-199406000-00005; Tovo PA, 1996, J ACQ IMMUN DEF SYND, V11, P88, DOI 10.1097/00042560-199601010-00012; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV; WATTS H, 1999, 6 C RETR OPP INF JAN; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	41	35	35	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	1999	281	20					1946	1949		10.1001/jama.281.20.1946	http://dx.doi.org/10.1001/jama.281.20.1946			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198ME	10349900				2022-12-01	WOS:000080427300036
J	Kogevinas, M; Anto, JM; Sunyer, J; Tobias, A; Kromhout, H; Burney, P				Kogevinas, M; Anto, JM; Sunyer, J; Tobias, A; Kromhout, H; Burney, P		European Community Resp Hlth Survey Study Grp	Occupational asthma in Europe and other industrialised areas: a population-based study	LANCET			English	Article							RESPIRATORY-HEALTH-SURVEY; BRONCHIAL RESPONSIVENESS; GENERAL-POPULATION; EXPOSURE; QUESTIONNAIRE; CHLORINE; SYMPTOMS; SPAIN; RISK	Background. There are no large population-based studies on occupational asthma, and few estimates of the proportion of asthma attributed to occupation, even though asthma is the most common occupational respiratory disorder in industrialised countries. Methods. We assessed data on 15637 people aged 20-44, randomly selected from the general population of 26 areas in 12 industrialised countries. Asthma was assessed by methacholine challenge test and by questionnaire data on respiratory symptoms and use of medication. Occupation was defined by job-titles and a job exposure matrix was constructed. Findings. Highest risk of asthma, defined as bronchial hyperresponsiveness and reported asthma symptoms or medication, was shown for farmers (odds ratio 2.62 [95% Cl 1.29-5.35]), painters (2.34 [1.04-5.28]), plastic workers (2.20 [0.59-8.29]), cleaners (1.97 [1.33-2.92]), spray painters (1.96 [0.72-5.34]), and agricultural workers (1.79 [1.02-3.16]). Similar risks were shown for asthma defined as reported asthma symptoms or medication. The most consistent results across countries were shown for farmers and cleaners. Excess asthma risk was associated with high exposure to biological dusts, mineral dusts, and gases and fumes. The proportion of asthma among young adults attributed to occupation was 5%-10%. Interpretation. The prevalence of occupational asthma in women and in specific occupations has been underestimated. Given a mean prevalence of asthma of about 5%, about 0.2%-0.5% of young adults become asthmatics or have their asthma exacerbated because of their occupations.	Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, Barcelona 08003, Spain; Agr Univ Wageningen, Environm & Occupat Hlth Grp, Wageningen, Netherlands; Guys & St Thomass Med & Dent Sch, Dept Publ Hlth Med, London, England	Wageningen University & Research; University of London; King's College London	Kogevinas, M (corresponding author), Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, 80 Doctor Aiguador Rd, Barcelona 08003, Spain.		Kogevinas, Manolis/C-3918-2017; Sunyer, Jordi/G-6909-2014; Kromhout, Hans/A-9159-2008; Tobias, Aurelio/ABE-5682-2020; Anto, J M/H-2676-2014	Kogevinas, Manolis/0000-0002-9605-0461; Sunyer, Jordi/0000-0002-2602-4110; Kromhout, Hans/0000-0002-4233-1890; Tobias, Aurelio/0000-0001-6428-6755; Anto, J M/0000-0002-4736-8529; Burney, Peter/0000-0001-8635-5678	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER; NCRR NIH HHS [2 S07 RR05521-28] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bernstein David I., 1993, P103; BERNSTEIN JA, 1994, J ALLERGY CLIN IMMUN, V94, P257, DOI 10.1016/0091-6749(94)90048-5; BHERER L, 1994, OCCUP ENVIRON MED, V51, P225, DOI 10.1136/oem.51.4.225; BLANC P, 1987, CHEST, V92, P613, DOI 10.1378/chest.92.4.613; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; BURGE PS, 1994, THORAX, V49, P842, DOI 10.1136/thx.49.8.842; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676, DOI 10.1164/ajrccm.149.6.8004329; Checkoway H, 1989, RES METHODS OCCUPATI; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; DAVID AP, 1976, BIOMETRICS, V32, P647; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301, DOI 10.1136/oem.54.5.301; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; KOBAYASHI S, 1974, ALLERGOLOGIE, P124; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137, DOI 10.1164/ajrccm.154.1.8680669; KRZYZANOWSKI M, 1988, INT J EPIDEMIOL, V17, P397, DOI 10.1093/ije/17.2.397; Leroyer C, 1998, OCCUP ENVIRON MED, V55, P356, DOI 10.1136/oem.55.5.356; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; NEMERY B, 1996, EUR RESPIR J, V10, P1977; NG TP, 1994, AM J IND MED, V25, P709, DOI 10.1002/ajim.4700250510; Nielsen J, 1996, CONTACT DERMATITIS, V34, P284, DOI 10.1111/j.1600-0536.1996.tb02201.x; REILLY MJ, 1995, ARCH ENVIRON HEALTH, V50, P26, DOI 10.1080/00039896.1995.9955009; STINGENI L, 1995, CONTACT DERMATITIS, V33, P172, DOI 10.1111/j.1600-0536.1995.tb00540.x; Sunyer J, 1998, AM J RESP CRIT CARE, V157, P512, DOI 10.1164/ajrccm.157.2.9705029; VENABLES KM, 1987, BRIT J IND MED, V44, P73; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; VIEGI G, 1991, AM REV RESPIR DIS, V143, P510, DOI 10.1164/ajrccm/143.3.510; XU XP, 1993, CHEST, V104, P1364, DOI 10.1378/chest.104.5.1364	30	329	335	0	22	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1750	1754		10.1016/S0140-6736(98)07397-8	http://dx.doi.org/10.1016/S0140-6736(98)07397-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347988				2022-12-01	WOS:000080667700013
J	Coffman, RL; Reiner, SL				Coffman, RL; Reiner, SL			Immunology - Instruction, selection, or tampering with the odds?	SCIENCE			English	Editorial Material							T-LYMPHOCYTES; EXPRESSION; CELLS; ACTIVATION; MECHANISM; ALLELES; LINEAGE		DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA; Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Chicago	Coffman, RL (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, 901 Calif Ave, Palo Alto, CA 94304 USA.	Coffman@dnax.org; sreiner@midway.uchicago.edu						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Chess A, 1998, ADV IMMUNOL, V69, P437, DOI 10.1016/S0065-2776(08)60613-6; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Fitzpatrick DR, 1998, J EXP MED, V188, P103, DOI 10.1084/jem.188.1.103; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Naramura M, 1998, IMMUNITY, V9, P209, DOI 10.1016/S1074-7613(00)80603-2; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; WEINTRAUB H, 1977, COLD SPRING HARB SYM, V42, P401, DOI 10.1101/SQB.1978.042.01.042; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	17	47	48	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1283	+		10.1126/science.284.5418.1283	http://dx.doi.org/10.1126/science.284.5418.1283			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383307				2022-12-01	WOS:000080430600029
J	Xu, QL; Mellitzer, G; Robinson, V; Wilkinson, DG				Xu, QL; Mellitzer, G; Robinson, V; Wilkinson, DG			In vivo cell sorting in complementary segmental domains mediated by Eph receptors and ephrins	NATURE			English	Article							CHICK-EMBRYO HINDBRAIN; TYROSINE KINASE; TRANSMEMBRANE LIGANDS; ADHESION MOLECULES; GENE-EXPRESSION; SEK-1; PHOSPHORYLATION; SPECIFICITY; RESTRICTION; KROX-20	The restriction of intermingling between specific cell populations is crucial for the maintenance of organized patterns during development. A striking example is the restriction of cell mixing between segments in the insect epidermis' and the vertebrate hindbrain(2) that may enable each segment to maintain a distinct identity. In the hindbrain, this is a result of different adhesive properties of odd- and even-numbered segments (rhombomeres)(3,4), but an adhesion molecule with alternating segmental expression has not been found. However, blocking experiments suggest that Eph-receptor tyrosine kinases may be required for the segmental restriction of cells(5). Eph receptors and their membrane-bound ligands, ephrins, are expressed in complementary rhombomeres(6) and, by analogy with their roles in axon pathfinding(7,8), could mediate cell repulsion at boundaries. Remarkably, transmembrane ephrins can themselves transduce signals(9,10), raising the possibility that bi-directional signalling occurs between adjacent ephrin- and Eph-receptor-expressing cells. We report here that mosaic activation of Eph receptors leads to sorting of cells to boundaries in odd-numbered rhombomeres, whereas mosaic activation of ephrins results in sorting to boundaries in even-numbered rhombomeres. These data implicate Eph receptors and ephrins in the segmental restriction of cell intermingling.	Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England	MRC National Institute for Medical Research	Wilkinson, DG (corresponding author), Natl Inst Med Res, Div Dev Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.		Georg, Mellitzer/R-4180-2016	Georg, Mellitzer/0000-0003-4467-0789; Wilkinson, David/0000-0001-6757-7080				Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Ellis C, 1996, ONCOGENE, V12, P1727; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; Gonzalez-Reyes A, 1998, DEVELOPMENT, V125, P3635; GUTHRIE S, 1993, DEVELOPMENT, V118, P527; HEYMAN I, 1993, DEV DYNAM, V198, P241, DOI 10.1002/aja.1001980402; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Irving C, 1996, DEV BIOL, V173, P26, DOI 10.1006/dbio.1996.0004; LAWRENCE PA, 1981, CELL, V26, P3, DOI 10.1016/0092-8674(81)90027-1; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Meima L, 1997, EUR J NEUROSCI, V9, P177, DOI 10.1111/j.1460-9568.1997.tb01365.x; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; STEINBERG MS, 1970, J EXP ZOOL, V173, P395, DOI 10.1002/jez.1401730406; Theil T, 1998, DEVELOPMENT, V125, P443; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Wizenmann A, 1997, MOL CELL NEUROSCI, V9, P448, DOI 10.1006/mcne.1997.0642; WOO K, 1995, DEVELOPMENT, V121, P2595; XU QL, 1994, DEVELOPMENT, V120, P287; Xu QL, 1997, J MOL MED-JMM, V75, P576, DOI 10.1007/s001090050142; Xu QL, 1995, DEVELOPMENT, V121, P4005; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U	27	363	364	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	1999	399	6733					267	271		10.1038/20452	http://dx.doi.org/10.1038/20452			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353250				2022-12-01	WOS:000080427400058
J	Silberberg, J				Silberberg, J			Better coronary risk assessment in women	LANCET			English	Editorial Material							HEART-DISEASE; FAMILY-HISTORY; HYPERTENSION; PREVENTION; MEN		John Hunter Hosp, Cardiovasc Unit, Newcastle, NSW 2320, Australia	John Hunter Hospital	Silberberg, J (corresponding author), John Hunter Hosp, Cardiovasc Unit, Newcastle, NSW 2320, Australia.							[Anonymous], 1996, J Am Coll Cardiol, V27, P957; BERWICK DM, 1980, CHOLESTEROL CHILDREN, P357; De Bacquer D, 1998, HEART, V80, P570, DOI 10.1136/hrt.80.6.570; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; HUNT SC, 1986, J CHRON DIS, V39, P809, DOI 10.1016/0021-9681(86)90083-4; KULLER LH, 1986, CIRCULATION, V73, P114, DOI 10.1161/01.CIR.73.1.114; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; Newnham HH, 1997, LANCET, V349, pS3, DOI 10.1016/S0140-6736(97)90002-7; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, ATHEROSCLEROSIS, V110, P121, DOI 10.1016/0021-9150(94)90200-3; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Silberberg JS, 1998, AM J EPIDEMIOL, V147, P1133; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	15	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1637	1638		10.1016/S0140-6736(98)00382-1	http://dx.doi.org/10.1016/S0140-6736(98)00382-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335779				2022-12-01	WOS:000080408000004
J	Wimberly, BT; Guymon, R; McCutcheon, JP; White, SW; Ramakrishnan, V				Wimberly, BT; Guymon, R; McCutcheon, JP; White, SW; Ramakrishnan, V			A detailed view of a ribosomal active site: The structure of the L11-RNA complex	CELL			English	Article							RNA TERTIARY STRUCTURE; FACTOR EF-G; CRYSTAL-STRUCTURE; PROTEIN L11; ESCHERICHIA-COLI; GTPASE CENTER; ANOMALOUS DIFFRACTION; THIOSTREPTON INTERACT; SECONDARY STRUCTURE; BINDING	We report the crystal structure of a 58 nucleotide fragment of 23S ribosomal RNA bound to ribosomal protein L11. This highly conserved ribonucleoprotein domain is the target for the thiostrepton family of antibiotics that disrupt elongation factor function. The highly compact RNA has both familiar and novel structural motifs. While the C-terminal domain of L11 binds RNA tightly, the N-terminal domain makes only limited contacts with RNA and is proposed to function as a switch that reversibly associates with an adjacent region of RNA. The sites of mutations conferring resistance to thiostrepton and micrococcin line a narrow cleft between the RNA and the N-terminal domain. These antibiotics are proposed to bind in this cleft, locking the putative switch and interfering with the function of elongation factors.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Tennessee, St Jude Childrens Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38105 USA	Utah System of Higher Education; University of Utah; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Ramakrishnan, V (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.	stephen.white@stjude.org; v.ramakrishnan@m.cc.utah.edu	White, Stephen W/N-8164-2018	Ramakrishnan, V/0000-0002-4699-2194; McCutcheon, John/0000-0002-5489-6039	NIGMS NIH HHS [GM 44973] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Briones E, 1998, J BIOL CHEM, V273, P31956, DOI 10.1074/jbc.273.48.31956; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Bukhman YV, 1997, J MOL BIOL, V273, P1020, DOI 10.1006/jmbi.1997.1383; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Conn GL, 1998, BIOCHEMISTRY-US, V37, P11980, DOI 10.1021/bi980825+; CUNDLIFFE E, 1981, EUR J BIOCHEM, V118, P47, DOI 10.1111/j.1432-1033.1981.tb05484.x; CUNDLIFFE E, 1979, NATURE, V278, P859, DOI 10.1038/278859a0; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DONNER D, 1978, P NATL ACAD SCI USA, V75, P3192, DOI 10.1073/pnas.75.7.3192; DRAPER DE, 1995, NUCL ACIDS S SER, V33, P5; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Fountain MA, 1996, BIOCHEMISTRY-US, V35, P6539, DOI 10.1021/bi952697k; GLOTZ C, 1981, NUCLEIC ACIDS RES, V9, P3287, DOI 10.1093/nar/9.14.3287; GRUENWEDEL DW, 1967, BIOPOLYMERS, V5, P847, DOI 10.1002/bip.1967.360050907; GRUENWEDEL DW, 1966, J MOL BIOL, V21, P129, DOI 10.1016/0022-2836(66)90084-2; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hinck AP, 1997, J MOL BIOL, V274, P101, DOI 10.1006/jmbi.1997.1379; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KOSTURKO LD, 1974, BIOCHEMISTRY-US, V13, P3949, DOI 10.1021/bi00716a020; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LU M, 1994, J MOL BIOL, V244, P572, DOI 10.1006/jmbi.1994.1753; LU M, 1995, NUCLEIC ACIDS RES, V23, P3426, DOI 10.1093/nar/23.17.3426; Markus MA, 1997, NAT STRUCT BIOL, V4, P70, DOI 10.1038/nsb0197-70; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1981, NUCLEIC ACIDS RES, V9, P6167, DOI 10.1093/nar/9.22.6167; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PESTKA S, 1970, BIOCHEM BIOPH RES CO, V40, P667, DOI 10.1016/0006-291X(70)90956-3; Porse BT, 1999, J MOL BIOL, V287, P33, DOI 10.1006/jmbi.1999.2600; Porse BT, 1998, J MOL BIOL, V276, P391, DOI 10.1006/jmbi.1997.1541; PRICE SR, 1995, J MOL BIOL, V249, P398, DOI 10.1006/jmbi.1995.0305; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; ROSENDAHL G, 1994, NUCLEIC ACIDS RES, V22, P357, DOI 10.1093/nar/22.3.357; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; SCHMIDT FJ, 1981, J BIOL CHEM, V256, P2301; SOPORI ML, 1972, BIOCHEM BIOPH RES CO, V46, P238, DOI 10.1016/0006-291X(72)90655-9; Spahn CMT, 1998, BIOL CHEM, V379, P753; STOFFLER G, 1980, J BIOL CHEM, V255, P517; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON J, 1979, EUR J BIOCHEM, V98, P261, DOI 10.1111/j.1432-1033.1979.tb13184.x; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; WANG YX, 1993, BIOCHEMISTRY-US, V32, P12279, DOI 10.1021/bi00097a002; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; WIMBERLY B, 1994, NAT STRUCT BIOL, V1, P820, DOI 10.1038/nsb1194-820; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Wimberly BT, 1997, STRUCTURE, V5, P1187, DOI 10.1016/S0969-2126(97)00269-4; XING YY, 1995, J MOL BIOL, V249, P319, DOI 10.1006/jmbi.1995.0299; Xing YY, 1997, NAT STRUCT BIOL, V4, P24, DOI 10.1038/nsb0197-24; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o	62	297	307	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					491	502		10.1016/S0092-8674(00)80759-X	http://dx.doi.org/10.1016/S0092-8674(00)80759-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338213	Bronze			2022-12-01	WOS:000080299100010
J	Kamura, T; Koepp, DM; Conrad, MN; Skowyra, D; Moreland, RJ; Iliopoulos, O; Lane, WS; Kaelin, WG; Elledge, SJ; Conaway, RC; Harper, JW; Conway, JW				Kamura, T; Koepp, DM; Conrad, MN; Skowyra, D; Moreland, RJ; Iliopoulos, O; Lane, WS; Kaelin, WG; Elledge, SJ; Conaway, RC; Harper, JW; Conway, JW			Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-CYCLE EXIT; F-BOX; SACCHAROMYCES-CEREVISIAE; PROTEIN; GENE; IDENTIFICATION; PATHWAY; CDC53; PROTEOLYSIS	The von Hippel-Lindau (VHL) tumor suppressor gene is mutated in most human kidney cancers. The VHL protein is part of a complex that includes Elongin B, Elongin C, and Cullin-2, proteins associated with transcriptional elongation and ubiquitination. Here it is shown that the endogenous VHL complex in rat liver also includes Rbx1, an evolutionarily conserved protein that contains a RING-H2 fingerlike motif and that interacts with Cullins. The yeast homolog of Rbx1 is a subunit and potent activator of the Cdc53-containing SCFCdc4 ubiquitin ligase required for ubiquitination of the cyclin-dependent kinase inhibitor Sic1 and for the G(1) to S cell cycle transition. These findings provide a further Link between VHL and the cellular ubiquitination machinery.	Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Howard Hughes Med Inst, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; Baylor College of Medicine; Baylor College of Medicine; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Conway, JW (corresponding author), Oklahoma Med Res Fdn, Howard Hughes Med Inst, 825 NE 13th St, Oklahoma City, OK 73104 USA.			Harper, Jeffrey/0000-0002-6944-7236; Conaway, Joan/0000-0002-2786-0663	NIA NIH HHS [AG-11085] Funding Source: Medline; NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINEHAN WM, 1995, JAMA-J AM MED ASSOC, V273, P564; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Siemeister G, 1996, CANCER RES, V56, P2299; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	31	635	661	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					657	661		10.1126/science.284.5414.657	http://dx.doi.org/10.1126/science.284.5414.657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213691				2022-12-01	WOS:000079951100049
J	Rohatgi, R; Ma, L; Miki, H; Lopez, M; Kirchhausen, T; Takenawa, T; Kirschner, MW				Rohatgi, R; Ma, L; Miki, H; Lopez, M; Kirchhausen, T; Takenawa, T; Kirschner, MW			The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly	CELL			English	Article							ALDRICH-SYNDROME PROTEIN; DEPOLYMERIZING PROTEIN; LISTERIA-MONOCYTOGENES; BINDING; RAC; CYTOSKELETON; MOTILITY; RHO; PHOSPHORYLATION; REORGANIZATION	Although small GTP-binding proteins of the Rho family have been implicated in signaling to the actin cytoskeleton, the exact nature of the linkage has remained obscure. We describe a novel mechanism that links one Rho family member, Cdc42, to actin polymerization. N-WASP, a ubiquitously expressed Cdc42-interacting protein, is required for Cdc42-stimulated actin polymerization in Xenopus egg extracts. The C terminus of N-WASP binds to the Arp2/3 complex and dramatically stimulates its ability to nucleate actin polymerization. Although full-length N-WASP is less effective, its activity can be greatly enhanced by Cdc42 and phosphatidylinositol (4,5) bisphosphate. Therefore, N-WASP and the Arp2/3 complex comprise a core mechanism that directly connects signal transduction pathways to the stimulation of actin polymerization.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 108, Japan	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of Tokyo	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Ma, Le/A-3733-2013	Ma, Le/0000-0003-2769-9416	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875] Funding Source: NIH RePORTER; NHLBI NIH HHS [5PO1 HL 59561-02] Funding Source: Medline; NIGMS NIH HHS [GM26875] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Fukuoka M, 1997, GENE, V196, P43, DOI 10.1016/S0378-1119(97)00184-4; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALROW E, 1988, ANTIBODIES LAB MANUA, P283; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; NOBES CD, 1995, J CELL SCI, V108, P225; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VAN AL, 1997, GENE DEV, V11, P2295; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zigmond SH, 1998, CURR BIOL, V8, pR654, DOI 10.1016/S0960-9822(07)00415-0	37	1044	1057	0	62	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 16	1999	97	2					221	231		10.1016/S0092-8674(00)80732-1	http://dx.doi.org/10.1016/S0092-8674(00)80732-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219243	Bronze			2022-12-01	WOS:000079779800011
J	Shou, WY; Seol, JH; Shevchenko, A; Baskerville, C; Moazed, D; Chen, ZWS; Jang, J; Shevchenko, A; Charbonneau, H; Deshaies, RJ				Shou, WY; Seol, JH; Shevchenko, A; Baskerville, C; Moazed, D; Chen, ZWS; Jang, J; Shevchenko, A; Charbonneau, H; Deshaies, RJ			Exit from mitosis is triggered by Tem1-dependent release of the protein phosphatase Cdc14 from nucleolar RENT complex	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MULTICOPY SUPPRESSOR; POLYACRYLAMIDE GELS; MASS-SPECTROMETRY; CDK-INHIBITOR; BUDDING YEAST; M-PHASE; KINASE; GENE	Exit from mitosis in budding yeast requires a group of essential proteins-including the GTPase Tem1 and the protein phosphatase Cdc14-that downregulate cyclin-dependent kinase activity. We identified a mutation, net1-1, that bypasses the lethality of tem 1 Delta. NEM encodes a novel protein, and mass spectrometric analysis reveals that it is a key component of a multifunctional complex, denoted RENT (for regulator of nucleolar silencing and telophase), that also contains Cdc14 and the silencing regulator Sir2. From G1 through anaphase, RENT localizes to the nucleolus, and Cdc14 activity is inhibited by Net1. In late anaphase, Cdc14 dissociates from RENT, disperses throughout the cell in a Tem1-dependent manner, and ultimately triggers mitotic exit. Nucleolar sequestration may be a general mechanism for the regulation of diverse biological processes.	CALTECH, Div Biol, Pasadena, CA 91125 USA; European Mol Biol Lab, Peptide & Prot Grp, D-69012 Heidelberg, Germany; Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	California Institute of Technology; European Molecular Biology Laboratory (EMBL); Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; Harvard Medical School	Deshaies, RJ (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	deshaies@cco.caltech.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354; Shou, Wenying/0000-0001-5693-381X	NCI NIH HHS [CA59935] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059935, R01CA059935] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; CULOTTI J, 1971, EXP CELL RES, V67, P389, DOI 10.1016/0014-4827(71)90424-1; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; Hardy CFJ, 1996, MOL CELL BIOL, V16, P6775; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; IMIGER S, 1995, CELL, V81, P269; INO H, 1993, BRAIN RES, V614, P131, DOI 10.1016/0006-8993(93)91026-O; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Komarnitsky SI, 1998, MOL CELL BIOL, V18, P2100, DOI 10.1128/MCB.18.4.2100; Li LW, 1997, J BIOL CHEM, V272, P29403, DOI 10.1074/jbc.272.47.29403; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Oakes M, 1998, J CELL BIOL, V143, P23, DOI 10.1083/jcb.143.1.23; PARKES V, 1992, NUCLEIC ACIDS RES, V20, P5617, DOI 10.1093/nar/20.21.5617; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Schmidt S, 1997, GENE DEV, V11, P1519, DOI 10.1101/gad.11.12.1519; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cellbio.11.1.93; SHENOLIKAR S, 1995, SEMIN CANCER BIOL, V6, P219, DOI 10.1006/scbi.1995.0029; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; Shirayama M, 1996, MOL GEN GENET, V251, P176; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Toyn JH, 1997, GENETICS, V145, P85; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.0.CO;2-K; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	54	594	605	1	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					233	244		10.1016/S0092-8674(00)80733-3	http://dx.doi.org/10.1016/S0092-8674(00)80733-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219244	Bronze			2022-12-01	WOS:000079779800012
J	Thorogood, M				Thorogood, M			Risk of stroke in users of oral contraceptives	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Thorogood, M (corresponding author), London Sch Hyg & Trop Med, London WC1, England.	m.thorogood@lshtm.ac.uk						Chang CL, 1999, BMJ-BRIT MED J, V318, P13; Poulter NR, 1996, LANCET, V348, P505; Poulter NR, 1996, LANCET, V348, P498; Schwartz SM, 1998, STROKE, V29, P2277, DOI 10.1161/01.STR.29.11.2277	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1999	281	14					1255	1256		10.1001/jama.281.14.1255	http://dx.doi.org/10.1001/jama.281.14.1255			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	184TC	10208126				2022-12-01	WOS:000079628700002
J	Ye, YH; Lukinova, N; Fortini, ME				Ye, YH; Lukinova, N; Fortini, ME			Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants	NATURE			English	Article							CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE; VESTIGIAL GENE; WING FORMATION; IN-VIVO; EXPRESSION; RECEPTOR; PROTEIN; SIGNAL; DELTA	Presenilin proteins have been implicated both in developmental signalling by the cell-surface protein Notch and in the pathogenesis of Alzheimer's disease. Loss of presenilin function leads to Notch/lin-12-like mutant phenotypes in Caenorhabditis elegans(1,2) and to reduced Notch1 expression in the mouse paraxial mesoderm(3). In humans, presenilins that are associated with Alzheimer's disease stimulate overproduction of the neurotoxic 42-amino-acid beta-amyloid derivative (A beta 42) of the amyloid-precursor protein APP(4). Here we describe loss-of-function mutations in the Drosophila Presenilin gene that cause lethal Notch-like phenotypes such as maternal neurogenic effects during embryogenesis, loss of lateral inhibition within proneural cell dusters, and absence of wing margin formation. We show that presenilin is required for the normal proteolytic production of carboxy-terminal Notch fragments that are needed for receptor maturation and signalling, and that genetically it acts upstream of both the membrane-bound form and the activated nuclear form of Notch. Our findings provide evidence for the existence of distinct processing sites or modifications in the extracellular domain of Notch. They also link the role of presenilin in Notch signalling to its effect on amyloid production in Alzheimer's disease.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Fortini, ME (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	fortini@mail.med.upenn.edu						Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Kidd S, 1998, GENE DEV, V12, P3728, DOI 10.1101/gad.12.23.3728; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; KOOH PJ, 1993, DEVELOPMENT, V117, P493; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Levitan D, 1998, DEVELOPMENT, V125, P3599; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Luo B, 1997, MOL CELL BIOL, V17, P6057, DOI 10.1128/MCB.17.10.6057; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SCHWEISGUTH F, 1994, DEVELOPMENT, V120, P1433; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0	30	444	469	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 8	1999	398	6727					525	529		10.1038/19096	http://dx.doi.org/10.1038/19096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206647				2022-12-01	WOS:000079662800051
J	Sanchez, LM; Chirino, AJ; Bjorkman, PJ				Sanchez, LM; Chirino, AJ; Bjorkman, PJ			Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules	SCIENCE			English	Article							T-CELL RECEPTOR; 3-DIMENSIONAL STRUCTURE; EXPRESSION ANALYSIS; FC RECEPTOR; MOUSE CD1; COMPLEX; PEPTIDE; ZN-ALPHA(2)-GLYCOPROTEIN; ANTIGENS; PROTEIN	Zn-alpha(2)-glycoprotein (ZAC) is a soluble protein that is present in serum and other body fluids. ZAG stimulates lipid degradation in adipocytes and causes the extensive fat tosses associated with some advanced cancers. The 2.8 angstrom crystal structure of ZAC resembles a class I major histocompatibility complex (MHC) heavy chain, but ZAG does not bind the class I light chain beta(2)-microglobutin. The ZAG structure includes a large groove analogous to class I MHC peptide binding grooves. Instead of a peptide, the ZAG groove contains a nonpeptidic compound that may be implicated in lipid catabolism under normal or pathological conditions.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Bjorkman, PJ (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.	bjorkman@cco.caltech.edu						Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ARAKI T, 1988, P NATL ACAD SCI USA, V85, P679, DOI 10.1073/pnas.85.3.679; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bairoch A, 1998, NUCLEIC ACIDS RES, V26, P38, DOI 10.1093/nar/26.1.38; Bauer A, 1997, EUR J IMMUNOL, V27, P1366, DOI 10.1002/eji.1830270611; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.biochem.59.1.253; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUERGI W, 1961, J BIOL CHEM, V236, P1066; BUNDRED NJ, 1987, HISTOPATHOLOGY, V11, P603, DOI 10.1111/j.1365-2559.1987.tb02670.x; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; COLLINS EJ, 1994, NATURE, V371, P626, DOI 10.1038/371626a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIEZITZA I, 1993, EUR J CANCER, V29A, P1256, DOI 10.1016/0959-8049(93)90068-Q; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; FREIJE JP, 1991, FEBS LETT, V290, P247, DOI 10.1016/0014-5793(91)81271-9; FUEYO A, 1994, GENE, V145, P245, DOI 10.1016/0378-1119(94)90014-0; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; Hirai K, 1998, CANCER RES, V58, P2359; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANCET D, 1979, P NATL ACAD SCI USA, V76, P3844, DOI 10.1073/pnas.76.8.3844; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Li P, COMMUNICATION; LOPEZBOADO YS, 1994, BREAST CANCER RES TR, V29, P247, DOI 10.1007/BF00666478; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Ogikubo O, 1998, BIOCHEM BIOPH RES CO, V252, P257, DOI 10.1006/bbrc.1998.9614; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfaff M., 1997, INTEGRIN LIGAND INTE, P101, DOI [10.1007/978-1-4757-4064-6_4, DOI 10.1007/978-1-4757-4064-6_4]; Plaksin D, 1997, J IMMUNOL, V159, P4408; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SANCHEZ LM, 1992, CANCER RES, V52, P95; Sanchez LM, 1997, P NATL ACAD SCI USA, V94, P4626, DOI 10.1073/pnas.94.9.4626; SANCHEZ LM, UNPUB; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SHIBATA S, 1982, NEPHRON, V31, P170, DOI 10.1159/000182638; Simister NE, 1997, BIOCHEM SOC T, V25, P481, DOI 10.1042/bst0250481; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; TAKAGAKI M, 1994, BIOCHEM BIOPH RES CO, V201, P1339, DOI 10.1006/bbrc.1994.1851; Todorov PT, 1998, CANCER RES, V58, P2353; TYSOECALNON VA, 1991, BIOCHEM J, V277, P359, DOI 10.1042/bj2770359; UEYAMA H, 1994, J BIOCHEM, V116, P677, DOI 10.1093/oxfordjournals.jbchem.a124579; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	60	109	114	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 19	1999	283	5409					1914	1919		10.1126/science.283.5409.1914	http://dx.doi.org/10.1126/science.283.5409.1914			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10206894				2022-12-01	WOS:000079228600048
J	Delehanty, JM; Ling, FS; Berk, BC				Delehanty, JM; Ling, FS; Berk, BC			If I had an acute coronary syndrome ...	LANCET			English	Article							UNSTABLE ANGINA; DISEASE; TRIAL		Univ Rochester, Med Ctr, Cardiol Unit, Rochester, NY 14642 USA	University of Rochester	Berk, BC (corresponding author), Univ Rochester, Med Ctr, Cardiol Unit, Rochester, NY 14642 USA.	bradford_berk@urmc.rochester.edu		Berk, Bradford/0000-0002-2767-4115				Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; BRAUNWALD E, 1994, CIRCULATION, V90, P613, DOI 10.1161/01.CIR.90.1.613; Cannon CP, 1998, AM J CARDIOL, V82, P731, DOI 10.1016/S0002-9149(98)00540-2; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Simoons ML, 1997, LANCET, V349, P1429; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1	12	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet		1999	353			2			SII24	SII26						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GJ	10374763				2022-12-01	WOS:000080812700006
J	Simon, JA; Hudes, ES				Simon, JA; Hudes, ES			Relationship of ascorbic acid to blood lead levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-C	Context Some animal studies suggest that orally administered ascorbic acid may chelate lead and decrease the risk of the toxic effects of lead. However, results from. several small studies in humans have yielded inconclusive evidence of a beneficial effect of ascorbic acid on lead toxicity. Objective To examine the relationship between serum ascorbic acid levels and prevalence of elevated blood lead levels. Design, Setting, and Participants Cross-sectional analysis of a probability sample of the US population enrolled in the Third National Health and Nutrition Examination Survey, 1988-1994 (4213 youths aged 6-16 years and 15 365 adults aged greater than or equal to 17 years) without a history of lead poisoning. Main Outcome Measures Elevated and log blood lead levels by serum ascorbic acid level. Results A total of 22 youths (0.5%) and 57 adults (0.4%) had elevated blood lead levels (defined as greater than or equal to 0.72 mu mol/L [15 mu g/dL]) and greater than or equal to 0.97 mu mol/L [20 mu g/dL], respectively). After controlling for the effects of age, race, sex, income level, and dietary energy, fat, calcium, iron, and zinc intake, youths in the highest serum ascorbic acid tertile had an 89% decreased prevalence of elevated blood lead levels compared with youths in the lowest serum ascorbic acid tertile (odds ratio, 0.11; 95% confidence interval, 0.04-0.35; P for trend =.002), Adults in the highest 2 serum ascorbic acid tertiles had a 65% to 68% decreased prevalence of elevated blood lead levels compared with adults in the lowest serum ascorbic acid tertile (P for trend =.03). As a continuous predictor, serum ascorbic acid level was independently associated with decreased log blood lead levels among adults (P<.001), but not among youths (P=.14). Conclusions Our data suggest that high serum levels of ascorbic acid are independently associated with a decreased prevalence of elevated blood lead levels. If these associations are related causally, ascorbic acid intake may have public health implications for control of lead toxicity.	San Francisco VA Med Ctr, Med Serv, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco	Simon, JA (corresponding author), San Francisco VA Med Ctr, Med Serv, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	jasimon@itsa.ucsf.edu			NHLBI NIH HHS [HL53479] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1994, VITAL HLTH STAT, V1, P1; BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; CALABRESE EJ, 1987, ANN NY ACAD SCI, V498, P347, DOI 10.1111/j.1749-6632.1987.tb23773.x; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DAWSON EB, 1997, J AM COLL NUTR, V16, P480; FLANAGAN PR, 1982, AM J CLIN NUTR, V36, P823, DOI 10.1093/ajcn/36.5.823; GEY KF, 1994, BIBL NUTR DIET, P84; GOYER RA, 1979, LIFE SCI, V24, P433, DOI 10.1016/0024-3205(79)90215-7; Gunter E.W., 1996, LAB PROCEDURES USED; Holmes HN, 1939, J LAB CLIN MED, V24, P1119; JACOB RA, 1987, AM J CLIN NUTR, V46, P818, DOI 10.1093/ajcn/46.5.818; JACOB RA, 1992, J NUTR, V122, P1111, DOI 10.1093/jn/122.5.1111; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; LAUWERYS R, 1983, J OCCUP ENVIRON MED, V25, P668, DOI 10.1097/00043764-198309000-00015; MARCHMONTROBINS.SW, 1940, J LAB CLIN MED, V26, P1478; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; SASIENI P, 1995, STATA TECHNICAL B, V24; SASIENI P, 1998, STATA TECHNICAL B, V41; SIMON JA, 1992, J AM COLL NUTR, V11, P107; SOHLER A, 1977, J ORTHOMOL MED, V6, P272; *STATA STAT SOFTW, 1996, REL 5 0; SUZUKI T, 1979, J NUTR, V109, P1974, DOI 10.1093/jn/109.11.1974; SUZUKI T, 1979, J NUTR, V109, P982, DOI 10.1093/jn/109.6.982; Tukey J.W., 1977, EXPLORATORY DATA ANA, P61, DOI 10.1007/978-0-387-32833-1_136; U.S. Department of Health and Human Services Public Health Service Agency for Toxic Substances and Disease Registry, 1988, NAT EXT LEAD POIS CH; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV	26	83	91	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2289	2293		10.1001/jama.281.24.2289	http://dx.doi.org/10.1001/jama.281.24.2289			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386552				2022-12-01	WOS:000080925600027
J	Xu, L; Furukawa, S; Middlebrooks, JC				Xu, L; Furukawa, S; Middlebrooks, JC			Auditory cortical responses in the cat to sounds that produce spatial illusions	NATURE			English	Article							HUMAN LISTENERS; SPECTRAL CUES; MEDIAN PLANE; LOCALIZATION; CORTEX	Humans and cats can localize a sound source accurately if its spectrum is fairly broad and flat(1-3), as is typical of most natural sounds. However, if sounds are filtered to reduce the width of the spectrum, they result:in illusions of sources that are very different from the actual locations, particularly in the up/down and front/back dimensions(4-6). Such illusions reveal that the auditory system relies on specific characteristics of sound spectra to obtain cues for localization(7). In the-auditory cortex of cats, temporal firing patterns of neurons can signal the locations of broad-band sounds(8-9). Here we show that such spike patterns systematically mislocalize sounds that have been passed through a narrow-band filter. Both correct and incorrect locations signalled by neurons can be predicted quantitatively by a model of spectral processing that also predicts correct and incorrect localization judgements by human listeners(6). Similar cortical mechanisms, if present in humans, could underlie human auditory spatial perception.	Univ Michigan, Kresge Hearing Res Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Middlebrooks, JC (corresponding author), Univ Michigan, Kresge Hearing Res Inst, 1301 E Ann St, Ann Arbor, MI 48109 USA.		Xu, Li/C-5908-2008	Xu, Li/0000-0002-0988-7934; Furukawa, Shigeto/0000-0002-5833-7891				BLAUERT J, 1969, ACUSTICA, V22, P205; HEBRANK J, 1974, J ACOUST SOC AM, V56, P1829, DOI 10.1121/1.1903520; Huang AY, 1996, J ACOUST SOC AM, V100, P1070, DOI 10.1121/1.416293; MAKOUS JC, 1990, J ACOUST SOC AM, V87, P2188, DOI 10.1121/1.399186; MIDDLEBROOKS JC, 1990, J ACOUST SOC AM, V87, P2149, DOI 10.1121/1.399183; MIDDLEBROOKS JC, 1992, J ACOUST SOC AM, V92, P2607, DOI 10.1121/1.404400; Middlebrooks JC, 1998, J NEUROPHYSIOL, V80, P863, DOI 10.1152/jn.1998.80.2.863; MIDDLEBROOKS JC, 1991, ANNU REV PSYCHOL, V42, P135, DOI 10.1146/annurev.ps.42.020191.001031; MIDDLEBROOKS JC, IN PRESS J ACOUST SO; NAJAFI K, 1985, IEEE T ELECTRON DEV, V32, P1206, DOI 10.1109/T-ED.1985.22102; Populin LC, 1998, J NEUROSCI, V18, P2147; Xu L, 1998, J NEUROPHYSIOL, V80, P882, DOI 10.1152/jn.1998.80.2.882	12	22	23	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					688	691		10.1038/21424	http://dx.doi.org/10.1038/21424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385120	Green Published			2022-12-01	WOS:000080932800060
J	Siegal, FP; Kadowaki, N; Shodell, M; Fitzgerald-Bocarsly, PA; Shah, K; Ho, S; Antonenko, S; Liu, YJ				Siegal, FP; Kadowaki, N; Shodell, M; Fitzgerald-Bocarsly, PA; Shah, K; Ho, S; Antonenko, S; Liu, YJ			The nature of the principal type 1 interferon-producing cells in human blood	SCIENCE			English	Article							ALPHA-PRODUCING CELLS; IMMUNE-DEFICIENCY SYNDROME; HERPES-SIMPLEX VIRUS; DENDRITIC CELLS; OPPORTUNISTIC INFECTIONS; HIV-1 INFECTION; IN-VITRO; PHENOTYPE; MATURE	Interferons (IFNs) are the most important cytokines in antiviral immune responses, "Natural IFN-producing cells" (IPCs) in human blood express CD4 and major histocompatibility complex class II proteins, but have not been isolated and further characterized because of their rarity, rapid apoptosis, and lack of Lineage markers. Purified IPCs are here shown to be the CD4(+)CD11c(-) type 2 dendritic cell precursors (pDC2s), which produce 200 to 1000 times more IFN than other blood cells after microbial challenge. pDC2s are thus an effector cell type of the immune system, critical for antiviral and antitumor immune responses.	St Vincents Hosp & Med Ctr, New York, NY 10011 USA; Long Isl Jewish Med Ctr, Albert Einstein Coll Med, New Hyde Pk, NY 11042 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Long Isl Univ, Brookville, NY 11548 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA	Saint Vincents Hospital Manhattan; Northwell Health; Yeshiva University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Rutgers State University New Brunswick; Rutgers State University Medical Center	Siegal, FP (corresponding author), St Vincents Hosp & Med Ctr, New York, NY 10011 USA.		Yang, Chen/G-1379-2010					ABB J, 1983, CLIN EXP IMMUNOL, V52, P179; CHEHIMI J, 1989, IMMUNOLOGY, V68, P486; FELDMAN M, 1990, J INTERFERON RES, V10, P435, DOI 10.1089/jir.1990.10.435; FERBAS J, 1995, CLIN DIAGN LAB IMMUN, V2, P138, DOI 10.1128/CDLI.2.2.138-142.1995; FERBAS JJ, 1994, J IMMUNOL, V152, P4649; FITZGERALDBOCARSLY P, 1993, PHARMACOL THERAPEUT, V60, P39, DOI 10.1016/0163-7258(93)90021-5; Ghanekar S, 1996, J IMMUNOL, V157, P4028; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; HOWELL DM, 1994, CLIN IMMUNOL IMMUNOP, V71, P223, DOI 10.1006/clin.1994.1076; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; KIRCHNER H, 1979, Z IMMUNITATSFORSCH, V156, P65; LOPEZ C, 1983, J INFECT DIS, V148, P962, DOI 10.1093/infdis/148.6.962; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; PERUSSIA B, 1985, Natural Immunity and Cell Growth Regulation, V4, P120; PETER HH, 1980, EUR J IMMUNOL, V10, P547, DOI 10.1002/eji.1830100712; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; SANDBERG K, 1991, SCAND J IMMUNOL, V34, P565, DOI 10.1111/j.1365-3083.1991.tb01580.x; SIEGAL FP, 1994, LEUKEMIA, V8, P1474; SIEGAL FP, 1986, J CLIN INVEST, V78, P115, DOI 10.1172/JCI112539; STARR SE, 1993, ADV EXP MED BIOL, V329, P173; Sun SQ, 1998, J EXP MED, V188, P2335, DOI 10.1084/jem.188.12.2335; Svensson H, 1996, SCAND J IMMUNOL, V44, P164, DOI 10.1046/j.1365-3083.1996.d01-289.x	25	1739	1845	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1999	284	5421					1835	1837		10.1126/science.284.5421.1835	http://dx.doi.org/10.1126/science.284.5421.1835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364556				2022-12-01	WOS:000080809000050
J	Trommsdorff, M; Gotthardt, M; Hiesberger, T; Shelton, J; Stockinger, W; Nimpf, J; Hammer, RE; Richardson, JA; Herz, J				Trommsdorff, M; Gotthardt, M; Hiesberger, T; Shelton, J; Stockinger, W; Nimpf, J; Hammer, RE; Richardson, JA; Herz, J			Reeler/disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN-E RECEPTOR-2; REELER-LIKE PHENOTYPE; LAMINAR ORGANIZATION; TARGETED DISRUPTION; ADAPTER PROTEINS; CEREBRAL-CORTEX; MOUSE; GENE; SCRAMBLER	Layering of neurons in the cerebral cortex and cerebellum requires Reelin, an extracellular matrix protein, and mammalian Disabled (mDab1), a cytosolic protein that activates tyrosine kinases. Here, we report the requirement for two other proteins, cell surface receptors termed very low density lipoprotein receptor (VLDLR) and apolipoprotein E receptor 2 (ApoER2). Both receptors can bind mDab1 on their cytoplasmic tails and are expressed in cortical and cerebellar layers adjacent to layers that express Reelin. mDab1 expression is upregulated in knockout mice that lack both VLDLR and ApoER2. Inversion of cortical layers and absence of cerebellar foliation in these animals precisely mimic the phenotype of mice lacking Reelin or mDab1. These findings suggest that VLDLR and ApoER2 participate in transmitting the extracellular Reelin signal to intracellular signaling processes initiated by mDab1.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vienna	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	herz@utsw.swmed.edu	Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Nimpf, Johannes/0000-0002-9273-3492	NHLBI NIH HHS [HL20948, R37 HL063762] Funding Source: Medline; NIA NIH HHS [AG12300] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG012300] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; Brandes C, 1997, GENOMICS, V42, P185, DOI 10.1006/geno.1997.4702; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; Gallagher E, 1998, J COMP NEUROL, V402, P238; Goldowitz D, 1997, J NEUROSCI, V17, P8767; Gonzalez JL, 1997, J NEUROSCI, V17, P9204; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; HOWELL BW, 1999, IN PRESS MOL CELL BI; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Janz R, 1998, J NEUROSCI, V18, P9269; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Komuro H, 1998, J NEUROSCI, V18, P1478; KORNACK DR, 1995, NEURON, V15, P311, DOI 10.1016/0896-6273(95)90036-5; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Miyata T, 1997, J NEUROSCI, V17, P3599; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; NOVAK S, 1996, J BIOL CHEM, V271; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OROURKE NA, 1995, DEVELOPMENT, V121, P2165; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pearlman AL, 1998, CURR OPIN NEUROBIOL, V8, P45, DOI 10.1016/S0959-4388(98)80007-X; Rice DS, 1998, DEVELOPMENT, V125, P3719; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sweet HO, 1996, MAMM GENOME, V7, P798, DOI 10.1007/s003359900240; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; WILLNOW TE, 1994, METHOD CELL BIOL, V43, P305	45	1025	1057	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					689	701		10.1016/S0092-8674(00)80782-5	http://dx.doi.org/10.1016/S0092-8674(00)80782-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380922	Bronze			2022-12-01	WOS:000080886300008
J	Fulton, D; Gratton, JP; McCabe, TJ; Fontana, J; Fujio, Y; Walsh, K; Franke, TF; Papapetropoulos, A; Sessa, WC				Fulton, D; Gratton, JP; McCabe, TJ; Fontana, J; Fujio, Y; Walsh, K; Franke, TF; Papapetropoulos, A; Sessa, WC			Regulation of endothelium-derived nitric oxide production by the protein kinase Akt	NATURE			English	Article							FLUID SHEAR-STRESS; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; CELL-SURVIVAL; MICE LACKING; SYNTHASE; ACTIVATION; CALCIUM; CAVEOLAE; PALMITOYLATION	Endothelial nitric oxide synthase (eNOS) is the nitric oxide synthase isoform responsible for maintaining systemic blood pressure, vascular remodelling and angiogenesis(1-4), eNOS is phosphorylated in response to various forms of cellular stimulation(5-7), but the role of phosphorylation in the regulation of nitric oxide (NO) production and the kinase(s) responsible are not known. Here we show that the serine/threonine protein kinase Akt (protein kinase B) can directly phosphorylate eNOS on serine 1179 and activate the enzyme, leading to NO production, whereas mutant eNOS (S1179A) is resistant to phosphorylation and activation by Akt. Moreover, using adenovirus-mediated gene transfer, activated Akt increases basal NO release from endothelial cells, and activation-deficient Akt attenuates NO production stimulated by vascular endothelial growth factor. Thus, eNOS is a newly described Akt substrate linking signal transduction by Akt to the release of the gaseous second messenger NO.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Mol Cardiobiol Program, Boyer Ctr Mol Med, New Haven, CT 06536 USA; St Elizabeths Med Ctr, Boston, MA 02135 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Yale University; Yale University; St. Elizabeth's Medical Center; Columbia University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Fujio, Yasushi/H-3421-2017; Andreas, Papapetropoulos/AAJ-3089-2020; Sessa, William C/B-6844-2011	Fujio, Yasushi/0000-0003-0828-2930; Sessa, William C/0000-0001-5759-1938; Walsh, Kenneth/0000-0001-7580-2276; Papapetropoulos, Andreas/0000-0002-4253-5930; Gratton, Jean-Philippe/0000-0001-9877-8520	NIAMS NIH HHS [R01 AR040197] Funding Source: Medline; NIA NIH HHS [R01 AG015052] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Coffer PJ, 1998, BIOCHEM J, V335, P1; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	30	2133	2195	1	89	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					597	601		10.1038/21218	http://dx.doi.org/10.1038/21218			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376602	Green Accepted			2022-12-01	WOS:000080778400059
J	Wilde, A; Zheng, YX				Wilde, A; Zheng, YX			Stimulation of microtubule aster formation and spindle assembly by the small GTPase Ran	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; GAMMA-TUBULIN; SELF-ORGANIZATION; RING COMPLEX; PROTEIN; CHROMOSOMES; CENTROSOMES; MUTATIONS; NUCLEATION; DYNAMICS	Ran, a small guanosine triphosphatase, is suggested to have additional functions beyond its well-characterized role in nuclear trafficking, Guanosine triphosphate-bound Ran, but not guanosine biphosphate-bound Ran, stimulated polymerization of astral microtubules from centrosomes assembled on Xenopus sperm, Moreover, a Ran allele with a mutation in the effector domain (RanL43E) induced the formation of microtubule asters and spindle assembly, in the absence of sperm nuclei, in a gamma TuRC (gamma-tubulin ring complex)- and XMAP215 (Xenopus microtubule associated protein)-dependent manner. Therefore, Ran could be a key signaling molecule regulating microtubule polymerization during mitosis.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Carnegie Institution for Science	Zheng, YX (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.			Wilde, Andrew/0000-0002-9812-3847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056312] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56312-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dasso M, 1995, Prog Cell Cycle Res, V1, P163; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KIRKPATRICK D, 1994, GENETICS, V137, P381; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Martin OC, 1998, J CELL BIOL, V141, P675, DOI 10.1083/jcb.141.3.675; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; SAWIN KE, 1994, MOL BIOL CELL, V5, P217, DOI 10.1091/mbc.5.2.217; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WILDE A, UNPUB; ZHANG DH, 1995, J CELL BIOL, V131, P1125, DOI 10.1083/jcb.131.5.1125; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	25	318	323	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1359	1362		10.1126/science.284.5418.1359	http://dx.doi.org/10.1126/science.284.5418.1359			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334991				2022-12-01	WOS:000080430600054
J	Arsuaga, JL; Lorenzo, C; Carretero, JM; Gracia, A; Martinez, I; Garcia, N; de Castro, JMB; Carbonell, E				Arsuaga, JL; Lorenzo, C; Carretero, JM; Gracia, A; Martinez, I; Garcia, N; de Castro, JMB; Carbonell, E			A complete human pelvis from the Middle Pleistocene of Spain	NATURE			English	Article							SIERRA-DE-ATAPUERCA; LOS-HUESOS; SEXUAL DIMORPHISM; SIZE VARIATION; SIMA; SITE; HOMINIDS; PATTERNS	The Middle Pleistocene site of Sima de los Huesos in Sierra de Atapuerca, Spain, has yielded around 2,500 fossils from at least 33 different hominid individuals'. These have been dated at more than 200,000 years ago(2-4) and have been classified as ancestors of Neanderthals(5,6), An almost complete human male pelvis (labelled Pelvis 1) has been found, which we associate with two fragmentary femora. Pelvis 1 is robust and very broad with avery long superior pubic ramus, marked iliac flare, and a long femoral neck. This pattern is probably the primitive condition from which modern humans departed. A modern human newborn would pass through the birth canal of Pelvis 1 and this would be even larger in a female individual. We estimate the body mass of this individual at 95 kg or more. Using the cranial capacities of three specimens from Sima de los Huesos, the encephalization quotients are substantially smaller than in Neanderthals and modern humans.	Univ Complutense Madrid, Fac Ciencias Geol, Inst Geol Econ, Dept Paleontol, E-28040 Madrid, Spain; Univ Burgos, Fac Humanidades & Educ, Dept Ciencias Hist & Geog, Burgos 09071, Spain; CSIC, Museo Nacl Ciencias Nat, E-28006 Madrid, Spain; Univ Rovira & Virgili, Lab Arqueol, Tarragona 43005, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UCM - Instituto de Geologia Economica (IGE); Universidad de Burgos; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); Universitat Rovira i Virgili	Arsuaga, JL (corresponding author), Univ Complutense Madrid, Fac Ciencias Geol, Inst Geol Econ, Dept Paleontol, E-28040 Madrid, Spain.		Lorenzo, Carlos/E-4290-2015; Carbonell, Eudald/G-3003-2015; Carretero, José-Miguel/AAN-1926-2020; Díaz, José-Miguel Carretero/L-1703-2018	Lorenzo, Carlos/0000-0001-5706-293X; Carretero, José-Miguel/0000-0003-0409-8087; Díaz, José-Miguel Carretero/0000-0003-0409-8087; martinez, ignacio/0000-0002-1835-9199; Arsuaga, Juan Luis/0000-0001-5361-2295; Bermudez de Castro, Jose Maria/0000-0003-1314-3273				Abitbol M.M., 1996, BIRTH HUMAN EVOLUTIO; Arsuaga JL, 1997, J HUM EVOL, V33, P109, DOI 10.1006/jhev.1997.0132; ARSUAGA JL, 1993, NATURE, V362, P534, DOI 10.1038/362534a0; Arsuaga JL, 1997, J HUM EVOL, V33, P219, DOI 10.1006/jhev.1997.0133; Arsuaga JL, 1997, SCIENCE, V277, P1086, DOI 10.1126/science.277.5329.1086; ARSUAGA JL, 1994, AM J PHYS ANTHROPOL, V93, P241, DOI 10.1002/ajpa.1330930208; Bischoff JL, 1997, J HUM EVOL, V33, P129, DOI 10.1006/jhev.1997.0130; CuencaBescos G, 1997, J HUM EVOL, V33, P175, DOI 10.1006/jhev.1997.0153; FELDESMAN MR, 1990, AM J PHYS ANTHROPOL, V83, P359, DOI 10.1002/ajpa.1330830309; Garcia N, 1997, J HUM EVOL, V33, P155, DOI 10.1006/jhev.1997.0154; Kappelman J, 1997, NATURE, V387, P126, DOI 10.1038/387126a0; Lorenzo C, 1998, AM J PHYS ANTHROPOL, V106, P19; Rak Y., 1991, SQUELETTE MOUSTERIEN, P147; Rak Yoel, 1993, P523; Rosenberg KR, 1998, NEANDERTALS AND MODERN HUMANS IN WESTERN ASIA, P367; Ruff CB, 1997, NATURE, V387, P173, DOI 10.1038/387173a0; Ruff Christopher B., 1993, P234; SERRA JA, 1998, CONTRIB ESTUDO ANTHR, V15, P1; TAGUE RG, 1991, J HUM EVOL, V21, P153, DOI 10.1016/0047-2484(91)90059-5; TAGUE RG, 1992, AM J PHYS ANTHROPOL, V88, P1, DOI 10.1002/ajpa.1330880102; TRINKAUS E, 1995, J ARCHAEOL SCI, V22, P121, DOI 10.1016/S0305-4403(95)80170-7; Trotter M, 1952, AM J PHYS ANTHROP-NE, V10, P463, DOI 10.1002/ajpa.1330100407; Walrath DE, 1996, AM J PHYS ANTHROPOL, V100, P89, DOI 10.1002/(SICI)1096-8644(199605)100:1<89::AID-AJPA9>3.0.CO;2-8	23	141	148	0	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 20	1999	399	6733					255	258		10.1038/20430	http://dx.doi.org/10.1038/20430			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	198MF	10353247				2022-12-01	WOS:000080427400054
J	Boyer, TG; Martin, MED; Lees, E; Ricciardi, RP; Berk, AJ				Boyer, TG; Martin, MED; Lees, E; Ricciardi, RP; Berk, AJ			Mammalian Srb Mediator complex is targeted by adenovirus E1A protein	NATURE			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL REGULATION; ACTIVATED TRANSCRIPTION; KINASE; GENE; HOLOENZYME; PATHWAY; FAMILY; DOMAIN; CELLS	Adenovirus E1A proteins prepare the host cell for viral replication, stimulating cell cycling and viral transcription through interactions with critical cellular regulatory proteins such as RB1,2 and CBP3. Here we show that the E1A zinc-finger domain that is required to activate transcription of viral early genes binds to a host-cell multiprotein complex containing homologues of yeast Srb/Mediator proteins(4,5). This occurs through a stable interaction with the human homologue of Caenorhabditis elegans SUR-2, a protein required for many developmental processes in the nematode(6). This human Srb/Mediator complex stimulates transcription in vitro in response to both the E1A zinc-finger and the herpes simplex virus VP16 activation domains. Interaction with human Sur-2 is also required for transcription to be activated by the activation domain of a transcription factor of the ETS-family in response to activated mitogen-activated protein (MAP) kinase.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Univ Penn, Sch Dent Med, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem Biophys, Philadelphia, PA 19104 USA	University of California System; University of California Los Angeles; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Pennsylvania; University of Pennsylvania	Berk, AJ (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.		BERK, ARNOLD/AAF-7052-2020					ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; BRAUER AW, 1984, ANAL BIOCHEM, V137, P134, DOI 10.1016/0003-2697(84)90359-2; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Cho H, 1998, MOL CELL BIOL, V18, P5355, DOI 10.1128/MCB.18.9.5355; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/0968-0004(96)10043-8; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; Myer VE, 1998, J BIOL CHEM, V273, P27757, DOI 10.1074/jbc.273.43.27757; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Rickert P, 1996, ONCOGENE, V12, P2631; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SINGH N, 1995, GENE DEV, V9, P2251, DOI 10.1101/gad.9.18.2251; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011	28	249	257	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					276	279		10.1038/20466	http://dx.doi.org/10.1038/20466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353252				2022-12-01	WOS:000080427400060
J	Schmidt, MI; Duncan, BB; Sharrett, AR; Lindberg, G; Savage, PJ; Offenbacher, S; Azambuja, MI; Tracy, RP; Heiss, G				Schmidt, MI; Duncan, BB; Sharrett, AR; Lindberg, G; Savage, PJ; Offenbacher, S; Azambuja, MI; Tracy, RP; Heiss, G		ARIC Investigators	Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study	LANCET			English	Article							INDUCED INSULIN-RESISTANCE; NECROSIS-FACTOR-ALPHA; INNATE IMMUNE-SYSTEM; CARDIOVASCULAR-DISEASE; OBESITY; ASSOCIATION; EXPRESSION; LEPTIN; NIDDM	Background Type 2 diabetes mellitus and atherosclerotic cardiovascular disease have common antecedents. Since markers of inflammation predict coronary heart disease and are raised in patients with type 2 diabetes, we investigated whether they predict whether people will develop type 2 diabetes. Methods 12 330 men and women, aged 45-64 years, were followed up for a mean of 7 years. We analysed the association between different markers of acute inflammation and subsequent diagnosis of diabetes. In a subgroup of 610 individuals selected originally for an unrelated atherosclerosis case-control study, we also investigated diabetes associations with total sialic acid and orosomucoid, haptoglobin, and alpha(1)-antitrypsin. Findings 1335 individuals had a new diagnosis of diabetes. Adjusted odds ratios for developing diabetes for quartile extremes were 1.9 (95% CI 1.6-2.3) for raised white-cell count, 1.3 (1.0-1.5) for low serum albumin, and 1.2 (1.0-1.5) for raised fibrinogen. In the subgroup analysis, individuals with concentrations of orosomucoid and sialic acid of more than the median had odds ratios of 7.9 (2.6-23.7) and 3.7 (1.4-9.8), respectively. Adjustment for body-mass index and waist-to-hip ratio lessened the associations; those for white-cell count (1.5 [1.3-1.8]), orosomucoid (7.1 [2.1-23.7]), and sialic acid (2.8 [1.0-8.1]) remained significant. Interpretation Markers of inflammation are associated with the development of diabetes in middle-aged adults. Although autoimmunity may partly explain these associations, they probably reflect the pathogenesis of type 2 diabetes.	UFRGS, Sch Med, Dept Social Med, BR-90035003 Porto Alegre, RS, Brazil; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Sch Dent, Dent Res Ctr, Chapel Hill, NC USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Malmo Hosp, NEPI Fdn, Malmo, Sweden; Univ Vermont, Dept Pathol & Biochem, Colchester, VT USA	Universidade Federal do Rio Grande do Sul; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Vermont	Schmidt, MI (corresponding author), UFRGS, Sch Med, Dept Social Med, Rua Barcelos 2600-414, BR-90035003 Porto Alegre, RS, Brazil.		Schmidt, Maria/V-3196-2019; Schmidt, Maria Inês/AGT-5691-2022; Duncan, Bruce B/L-4140-2016; Schmidt, Maria Inês/AGP-6441-2022	Duncan, Bruce B/0000-0002-7491-2630; Schmidt, Maria Inês/0000-0002-3837-0731	NHLBI NIH HHS [N01-HC-55015, N01-HC-55016, N01-HC-55018] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055015, N01HC055018, N01HC055016] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; Chambless L E, 1992, Ann Epidemiol, V2, P723; Corbett J, 1997, DIABETOLOGIA, V40, pB27, DOI 10.1007/BF03168183; Gavin JR, 1997, DIABETES CARE, V20, P1183; Girard J, 1997, DIABETES METAB, V23, P16; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; Kushner I, 1993, ACUTE PHASE PROTEINS, P4; LINDBERG G, 1993, ATHEROSCLEROSIS, V103, P123, DOI 10.1016/0021-9150(93)90255-S; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Matson C.A., 1996, DIABETES REV, V4, P488; Memon RA, 1997, CYTOKINES HLTH DIS, P381; *NAT HEART LUNG BL, 1987, ATH RISK COMM ARIC S, P1; NIETO FJ, 1992, AM J EPIDEMIOL, V136, P525, DOI 10.1093/oxfordjournals.aje.a116530; Nilsson J, 1998, ARTERIOSCL THROM VAS, V18, P1199, DOI 10.1161/01.ATV.18.8.1199; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SALHANICK AI, 1988, AM J PHYSIOL, V255, P173; Schmidt MI, 1996, METABOLISM, V45, P699, DOI 10.1016/S0026-0495(96)90134-1; SIM E, 1993, HUMORAL FACTORS, P1; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VANDERPOLL T, 1998, AM J PHYSIOL, V24, pE457; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Yudkin JS, 1997, DIABETOLOGIA, V40, pS140	30	790	820	3	44	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	1999	353	9165					1649	1652		10.1016/S0140-6736(99)01046-6	http://dx.doi.org/10.1016/S0140-6736(99)01046-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335783				2022-12-01	WOS:000080408000008
J	Sury, MRJ; Hatch, DJ; Deeley, T; Dicks-Mireaux, C; Chong, WK				Sury, MRJ; Hatch, DJ; Deeley, T; Dicks-Mireaux, C; Chong, WK			Development of a nurse-led sedation service for paediatric magnetic resonance imaging	LANCET			English	Article							CHLORAL HYDRATE; ADVERSE EVENTS; PEDIATRIC MRI; CHILDREN; PROPOFOL; GUIDELINES; TOMOGRAPHY; ANESTHESIA; PROGRAM; SAFETY	Background Children generally lie still enough for magnetic resonance imaging (MRI) only if they are asleep, either under sedation, which is deeper than conscious sedation, or under anaesthesia. Anaesthesia resources, however, are limited, and non-anaesthetists must use sedation frequently. Demand for MRI has increased and the failure of our sedation regimen led to an impractical demand for anaesthesia and unacceptable waiting times for scanning. We have therefore developed a nurse-led sedation service in a designated unit next to the scanner. This study assessed the safety and efficacy of this approach. Methods Children who required MRI were sedated in the unit by designated sedationist nurses, who used an oral drug regimen (according to weight and age from conception: weight <5 hg, 50 mg/kg chloral hydrate; 5-10 kg, 100 mg/hg chloral hydrate; 10-20 hg, 1 mg/kg temazepam plus 0.25 mg/kg droperidol; >20 kg temazepam and droperidol as directed by radiologist; maximum doses 20 mg and 5 mg respectively). Nurses checked patients for their suitability, charted and administered the drugs according to a protocol, and monitored the children throughout the sedation. We prospectively audited failure and complications of sedation. Findings During the 30 month study, there were 1155 sedations. 61 (5%) were unsuccessful, and there were no adverse events relating to the airway or breathing. After scanning had finished all children, in response to gently pinching the nose, could open their mouths to maintain their airway. Interpretation This study suggests that it is possible to have a nurse-led sedation service for MRI of children that is both successful and safe.	Great Ormond St Hosp Children NHS Trust, Dept Anaesthesia, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, Dept Radiol, London WC1N 3JH, England; Inst Child Hlth, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Sury, MRJ (corresponding author), Great Ormond St Hosp Children NHS Trust, Dept Anaesthesia, Great Ormond St, London WC1N 3JH, England.							BARST SM, 1994, PAEDIATR ANAESTH, V4, P243; BLOOMFIELD EL, 1993, RADIOLOGY, V186, P93, DOI 10.1148/radiology.186.1.8416594; COTE CJ, 1995, AM J ROENTGENOL, V165, P910, DOI 10.2214/ajr.165.4.7676991; Egelhoff JC, 1997, AM J ROENTGENOL, V168, P1259, DOI 10.2214/ajr.168.5.9129423; FRUSH DP, 1995, AM J ROENTGENOL, V165, P913, DOI 10.2214/ajr.165.4.7676992; GLAISIER CM, 1995, AM J NEURORADIOL, V16, P111; HOLLMAN GA, 1995, CLIN PEDIATR, V34, P300, DOI 10.1177/000992289503400602; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Malviya S, 1997, ANESTH ANALG, V85, P1207, DOI 10.1097/00000539-199712000-00005; MartiBonmati L, 1995, NEURORADIOLOGY, V37, P687; MEROLA C, 1995, PAEDIATR ANAESTH, V5, P375, DOI 10.1111/j.1460-9592.1995.tb00330.x; Murphy MS, 1997, ARCH DIS CHILD, V77, P281, DOI 10.1136/adc.77.4.281; NEUMAN GG, 1992, ANESTH ANALG, V74, P931; *ROY COLL AN ROY C, 1992, SED AN RAD REP JOINT; SHEPHERD JK, 1990, BRIT J RADIOL, V63, P794, DOI 10.1259/0007-1285-63-754-794; SPEAR RM, 1993, PAEDIATR ANAESTH, V3, P325; SURY MRJ, 1994, ANAESTHESIA, V49, P174, DOI 10.1111/j.1365-2044.1994.tb03394.x; SURY MRJ, 1993, PAEDIATR ANAESTH, V3, P329; VADE A, 1995, AM J ROENTGENOL, V165, P905, DOI 10.2214/ajr.165.4.7676990; VALTONEN M, 1989, ACTA ANAESTH SCAND, V33, P170, DOI 10.1111/j.1399-6576.1989.tb02884.x; VANGERVEN M, 1992, ANAESTHESIA, V47, P706, DOI 10.1111/j.1365-2044.1992.tb02397.x; Wouters PF, 1997, EUR J ANAESTH, V14, P236, DOI 10.1046/j.1365-2346.1997.00071.x	22	84	85	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	1999	353	9165					1667	1671		10.1016/S0140-6736(98)08383-4	http://dx.doi.org/10.1016/S0140-6736(98)08383-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335787				2022-12-01	WOS:000080408000012
J	Lee, SH; Blake, R				Lee, SH; Blake, R			Visual form created solely from temporal structure	SCIENCE			English	Article							MOTION PERCEPTION; DISCRIMINATION; SEGMENTATION; INFORMATION; FIGURE; CORTEX; COHERENCE; PATTERNS; NEURONS; CONNECTIVITY	In several experiments, it was found that global perception of spatial form can arise exclusively from unpredictable but synchronized changes among Local features. Within an array of nonoverlapping apertures, contours move in one of two directions, with direction reversing randomly over time. When contours within a region of the array reverse directions in synchrony, they stand out conspicuously from the rest of the array where direction reversals are unsynchronized. Clarity of spatial structure from synchronized change depends on the rate of motion reversal and on the proportion of elements reversing direction in synchrony. Evidently, human vision is sensitive to the rich temporal structure in these stochastic events.	Vanderbilt Univ, Vanderbilt Vis Res Ctr, Nashville, TN 37240 USA	Vanderbilt University	Blake, R (corresponding author), Vanderbilt Univ, Vanderbilt Vis Res Ctr, 221 Kirkland Hall, Nashville, TN 37240 USA.		Lee, Sang-Hun/B-9898-2008		NATIONAL EYE INSTITUTE [R01EY007760] Funding Source: NIH RePORTER; NEI NIH HHS [EY07760, EY01826] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANSTIS SM, 1995, ARTFUL EYE, P232; BIALEK W, 1992, TRENDS NEUROSCI, V15, P428, DOI 10.1016/0166-2236(92)90005-S; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; Brainard D. H., 1997, SPATIAL VISION, V10, P443, DOI DOI 10.1163/156856897X00357; BRAVO MJ, 1992, VISION RES, V32, P1793, DOI 10.1016/0042-6989(92)90174-H; BRILLINGER DR, 1994, CAN J STAT, V22, P177, DOI 10.2307/3315583; Buracas GT, 1998, NEURON, V20, P959, DOI 10.1016/S0896-6273(00)80477-8; CAVANAGH P, 1992, SCIENCE, V257, P1563, DOI 10.1126/science.1523411; Chey J, 1997, J OPT SOC AM A, V14, P2570, DOI 10.1364/JOSAA.14.002570; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FAHLE M, 1995, VISION RES, V35, P491, DOI 10.1016/0042-6989(94)00126-7; FAHLE M, 1993, P ROY SOC B-BIOL SCI, V254, P199, DOI 10.1098/rspb.1993.0146; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; Garner W. R., 1962, UNCERTAINTY STRUCTUR; GILDEN D, 1995, PSYCHOL SCI, V6, P235, DOI 10.1111/j.1467-9280.1995.tb00598.x; GROSSBERG S, 1993, NEURAL NETWORKS, V6, P463, DOI 10.1016/S0893-6080(05)80052-8; GRZYWACZ NM, 1995, VISION RES, V35, P3183, DOI 10.1016/0042-6989(95)00102-6; JULESZ B, 1976, BIOL CYBERN, V23, P25, DOI 10.1007/BF00344148; Julesz B., 1971, FDN CYCLOPEAN PERCEP; Kiper DC, 1996, VISION RES, V36, P539, DOI 10.1016/0042-6989(95)00135-2; Koffka K, 1935, PRINCIPLES GESTALT P; Lee SH, 1999, INVEST OPHTH VIS SCI, V40, pS45; Leonards U, 1996, VISION RES, V36, P2689, DOI 10.1016/0042-6989(96)86829-5; LU ZL, 1995, NATURE, V377, P237, DOI 10.1038/377237a0; Mozer M., 1991, PERCEPTION MULTIPLE; PALMER SE, 1992, COGNITIVE PSYCHOL, V24, P436, DOI 10.1016/0010-0285(92)90014-S; PALMER SE, 1998, 39 ANN M PSYCH SOC D; RAMACHANDRAN VS, 1991, B PSYCHONOMIC SOC, V29, P391; REGAN D, 1991, PERCEPTION, V20, P315, DOI 10.1068/p200315; REGAN D, 1989, VISION RES, V29, P1389, DOI 10.1016/0042-6989(89)90194-6; Reiss R.D., 1993, COURSE POINT PROCESS; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P351, DOI 10.1152/jn.1990.64.2.351; ROCK I, 1986, HDB PERCEPTION HUMAN, V2; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Shannon C., 1964, MATH THEORY COMMUNIC; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Snider RK, 1998, J NEUROPHYSIOL, V80, P730, DOI 10.1152/jn.1998.80.2.730; THOMPSON WB, 1992, BIOL CYBERN, V66, P327, DOI 10.1007/BF00203669; Usher M, 1998, NATURE, V394, P179, DOI 10.1038/28166; Vecera SP, 1998, J EXP PSYCHOL HUMAN, V24, P441, DOI 10.1037/0096-1523.24.2.441; WILSON HR, 1994, VISUAL NEUROSCI, V11, P1205, DOI 10.1017/S0952523800007008	42	122	123	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1165	1168		10.1126/science.284.5417.1165	http://dx.doi.org/10.1126/science.284.5417.1165			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	197HJ	10325226				2022-12-01	WOS:000080359100036
J	Van der Stuyft, P; Gianella, A; Pirard, M; Cespedes, J; Lora, J; Peredo, C; Pelegrino, JL; Vorndam, V; Boelaert, M				Van der Stuyft, P; Gianella, A; Pirard, M; Cespedes, J; Lora, J; Peredo, C; Pelegrino, JL; Vorndam, V; Boelaert, M			Urbanisation of yellow fever in Santa Cruz, Bolivia	LANCET			English	Article							COST-EFFECTIVENESS; ENCEPHALITIS; INFECTIONS; DENGUE	Background Reinvasion by Aedes aegypti of cities in the Americas poses a threat of urbanisation of yellow fever. After detection of yellow-fever infection in a resident of the city of Santa Cruz, Bolivia, in December, 1997, we investigated all subsequent suspected cases. Methods We introduced active surveillance of yellow fever in the Santa Cruz area. Hospitals and selected urban and rural health centres reported all suspected cases. Patients were serologically screened for yellow fever, dengue, hepatitis A and B, and leptospirosis. We collected clinical and epidemiological information from patients' records and through interviews. We also carried out a population-based serosurvey in the neighbourhood of one case. Findings Between December, 1997, and June, 1998, symptomatic yellow-fever infection was confirmed in six residents of Santa Cruz, five of whom died. Five lived in the southern sector of the city. Two had not left the city during the incubation period, and one had visited only an area in which sylvatic transmission was deemed impossible. Of the 281 people covered in the serosurvey 16 (6%) were positive for IgM antibody to yellow fever. Among five people for whom this result could not be explained by recent vaccination, there were two pairs of neighbours. Interpretation Urban transmission of yellow fever in Santa Cruz was limited in space and time. Low yellow-fever immunisation coverage and high infestation with A aegypti in the city, and the existence of endemic areas in the region present a risk for future urban outbreaks. We recommend immediate large-scale immunisation of the urban population, as well as tightened surveillance and appropriate vector control.	Inst Trop Med, Epidemiol Unit, B-2000 Antwerp 1, Belgium; Ctr Nacl Enfermedades Trop, Santa Cruz, Bolivia; Belgian Agcy Dev Cooperat, CENETROP Project, Santa Cruz, Bolivia; Direcc Dept Salud, Secc Control Vectores, Santa Cruz, Bolivia; Inst Med Trop Pedro Kouri, La Havana, Cuba; Ctr Dis Control & Prevent, San Juan, PR USA	Institute of Tropical Medicine (ITM); Centers for Disease Control & Prevention - USA	Van der Stuyft, P (corresponding author), Inst Trop Med, Epidemiol Unit, B-2000 Antwerp 1, Belgium.		Boelaert, Marleen/E-2698-2012; Pelegrino Martinez de la Cotera, Jose Luis/F-9040-2016	Boelaert, Marleen/0000-0001-8051-6776; Pelegrino Martinez de la Cotera, Jose Luis/0000-0003-0833-653X				BRES PLJ, 1986, B WORLD HEALTH ORGAN, V64, P775; CHIPPAUX A, 1993, B SOC PATHOL EXOT, V86, P460; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; MONATH TP, 1993, AM J TROP MED HYG, V48, P274, DOI 10.4269/ajtmh.1993.48.274; MONATH TP, 1991, AM J TROP MED HYG, V45, P1; Pan American Health Organization, 1994, SCI PUBL, P1; PINHEIRO FP, 1986, B WORLD HEALTH ORGAN, V64, P511; ROBERTSON RL, 1992, HEALTH POLICY PLANN, V7, P111, DOI 10.1093/heapol/7.2.111; Robertson SE, 1996, JAMA-J AM MED ASSOC, V276, P1157, DOI 10.1001/jama.276.14.1157; SAGARNAGA RV, 1983, B CIENT CENETROP, V9, P13; SCHOFIELD CJ, 1984, B CIENTIFICO CENETRO, V10, P22; SOPER FL, 1952, AM J TROP MED HYG, V1, P361, DOI 10.4269/ajtmh.1952.1.361; Van der Stuyft P, 1998, TROP MED INT HEALTH, V3, P857; Watts DM, 1997, AM J TROP MED HYG, V56, P661, DOI 10.4269/ajtmh.1997.56.661; WHO Emerging and Other Communicable Diseases, 1998, WHOEPIGEN9809; 1998, WKLY EPIDEMIOL REC, V73, P370; 1998, WKLY EPIDEMIOL REC, V73, P354; 1999, LANCET, V353, P648; 1999, WKLY EPIDEMIOL REC, V74, P56; 1999, WKLY EPIDEMIOL REC, V74, P80	20	66	71	0	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1558	1562		10.1016/S0140-6736(99)03291-2	http://dx.doi.org/10.1016/S0140-6736(99)03291-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334253				2022-12-01	WOS:000080278300010
J	Cheetham, GMT; Jeruzalmi, D; Steitz, TA				Cheetham, GMT; Jeruzalmi, D; Steitz, TA			Structural basis for initiation of transcription from an RNA polymerase-promoter complex	NATURE			English	Article							CRYSTAL-STRUCTURE; DNA RECOGNITION; ANGSTROM RESOLUTION; BACTERIOPHAGE-T7; SUBSTITUTION; BINDING	Although the single-polypeptide-chain RNA polymerase from bacteriophage T7 (T7RNAP), like other RNA polymerases, uses the same mechanism of polymerization as the DNA polymerases, it can also recognize a specific promoter sequence, initiate new RNA chains from a single nucleotide, abortively cycle the synthesis of short transcripts, be regulated by a transcription inhibitor, and terminate transcription(1-3), As T7RNAP is homologous to the Pol I family of DNA polymerases(4), the differences between the structure of T7RNAP complexed to substrates and that of the corresponding DNA polymerase complex provides a structural basis for understanding many of these functional differences. T7RNAP initiates RNA synthesis at promoter sequences that are conserved from positions -17 to +6 relative to the start site of transcription. The crystal structure at 2.4 Angstrom resolution of T7RNAP complexed with a 17-base-pair promoter shows that the four base pairs closest to the catalytic active site have melted to form a transcription bubble. The T7 promoter sequence is recognized by interactions in the major groove between an antiparallel B-loop and bases. The amino-terminal domain is involved in promoter recognition and DNA melting. We have also used homology modelling of the priming and incoming nucleoside triphosphates from the T7 DNA-polymerase ternary complex structure to explain the specificity of T7RNAP for ribonucleotides, its ability to initiate from a single nucleotide, and the abortive cycling at the initiation of transcription.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEE SS, 1992, BIOCHEM INT, V26, P1; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MCALLISTER WT, 1978, P NATL ACAD SCI USA, V75, P804, DOI 10.1073/pnas.75.2.804; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RASKIN CA, 1992, J MOL BIOL, V228, P506, DOI 10.1016/0022-2836(92)90838-B; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; ROULD MA, 1992, NUCLEIC ACIDS MOL BI, V6, P225; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUZUKI M, 1995, PROTEIN ENG, V8, P1, DOI 10.1093/protein/8.1.1	30	259	276	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	1999	399	6731					80	83		10.1038/19999	http://dx.doi.org/10.1038/19999			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331394				2022-12-01	WOS:000080172100059
J	Diermayer, M; Hedberg, K; Hoesly, F; Fischer, M; Perkins, B; Reeves, M; Fleming, D				Diermayer, M; Hedberg, K; Hoesly, F; Fischer, M; Perkins, B; Reeves, M; Fleming, D			Epidemic serogroup B meningococcal disease in Oregon - The evolving epidemiology of the ET-5 strain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS; NEISSERIA-MENINGITIDIS; POPULATION-GENETICS; SAO-PAULO; INFLUENZA; OUTBREAK; CARRIAGE; VACCINE; COMPLEX; SMOKING	Context In 1993, Oregon's incidence of serogroup B meningococcal disease began to rise because of a highly clonal group of strains designated enzyme type 5 (ET-5), the first such increase observed in the United States. Objective To evaluate the impact that the ET-5 strain has had on the epidemiology of meningococcal disease in Oregon. Design and Setting Epidemiologic analysis of surveillance data on Oregon meningococcal disease cases from 1987 through 1996 and multilocus enzyme electrophoresis typing of serogroup B isolates from June 1993 through April 1995 and from April through June 1996. Patients A total of 836 persons with invasive meningococcal disease. Main Outcome Measures Disease frequency and clonality of strains. Results Serogroup B disease incidence rates more than doubled from the preepidemic period in 1987-1992 (1.0 case per 100 000 population) to the recent epidemic period in 1995-1996 (2.2 cases per 100 000), The age-specific incidence rate of serogroup B disease among those 15 through 19 years old increased 13-fold between the preepidemic period (0.5 case per 100 000) and 1995-1996 (6.4 cases per 100 000), However, the proportion of cases with meningococcemia and the case-fatality rate did not change. Of 99 Neisseria meningitidis isolates obtained from 1993-1995, 88 (89%) belonged to the ET-5 complex, Of these, 69 (78%) were a single clone, designated 301, Of 20 serogroup B isolates from 1996, 18 (90%) belonged to the ET-5 complex; 17 (94%) were the 301 clone. Conclusion Serogroup B meningococcal disease incidence continues at high levels in Oregon with increasing predominance of the ET-5 clonal strains.	Oregon Hlth Div, Portland, OR USA; Ctr Dis Control & Prevent, Div Field Epidemiol, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Div Bacterial & Mycot Dis, Atlanta, GA USA	Oregon Health & Science University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Hedberg, K (corresponding author), 800 NE Oregon St,Suite 772, Portland, OR 97232 USA.	katrina.hedberg@state.or.us			PHS HHS [U50/CCU011184] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARBONARE SB, 1995, PEDIATR INFECT DIS J, V14, P797, DOI 10.1097/00006454-199509000-00013; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P1010; DEAN A, 1995, EPI INFO VERSION 6 W; DEMORAES JC, 1992, LANCET, V340, P1074; Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015; FROHOLM L O, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P133; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; Jackson LA, 1996, PEDIATR INFECT DIS J, V15, P992, DOI 10.1097/00006454-199611000-00012; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; KREMASTINOU J, 1994, SCAND J INFECT DIS, V26, P719, DOI 10.3109/00365549409008641; LYSTAD A, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P57; MORROW HW, 1990, PEDIATR INFECT DIS J, V9, P394, DOI 10.1097/00006454-199006000-00005; PELTOLA H, 1982, LANCET, V2, P595; POOLMAN JT, 1986, LANCET, V2, P555; Racoosin JA, 1998, JAMA-J AM MED ASSOC, V280, P2094, DOI 10.1001/jama.280.24.2094; REEVES MW, 1995, EMERG INFECT DIS, V1, P53, DOI 10.3201/eid0102.950203; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SELANDER RK, 1987, MICROB PATHOGENESIS, V3, P1, DOI 10.1016/0882-4010(87)90032-5; STUART JM, 1989, LANCET, V2, P723, DOI 10.1016/S0140-6736(89)90781-2; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390; WYLE FA, 1972, J INFECT DIS, V126, P514, DOI 10.1093/infdis/126.5.514	27	79	82	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1493	1497		10.1001/jama.281.16.1493	http://dx.doi.org/10.1001/jama.281.16.1493			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227318	Bronze			2022-12-01	WOS:000079857400030
J	van der Horst, GTJ; Muijtjens, M; Kobayashi, K; Takano, R; Kanno, S; Takao, M; de Wit, J; Verkerk, A; Eker, APM; van Leenen, D; Buijs, R; Bootsma, D; Hoeijmakers, JHJ; Yasui, A				van der Horst, GTJ; Muijtjens, M; Kobayashi, K; Takano, R; Kanno, S; Takao, M; de Wit, J; Verkerk, A; Eker, APM; van Leenen, D; Buijs, R; Bootsma, D; Hoeijmakers, JHJ; Yasui, A			Mammalian Cry1 and Cry2 are essential for maintenance of circadian rhythms	NATURE			English	Article							BLUE-LIGHT PHOTORECEPTORS; HUMAN PHOTOLYASE HOMOLOG; DNA PHOTOLYASE; CLOCK GENE; DROSOPHILA; MOUSE; CRYPTOCHROME; SIMILARITY; TIMELESS; CLONING	Many biochemical, physiological and behavioural processes show circadian rhythms which are generated by an internal timekeeping mechanism referred to as the biological clock. According to rapidly developing. models, the core oscillator driving this clock is composed of an autoregulatory transcription-(post) translation-based feedback loop involving a set of 'clock' genes(1-6). Molecular docks do not oscillate with an exact 24-hour rhythmicity but are entrained to solar day/night rhythms by light. The mammalian proteins Cry1 and Cry2, which are members of the family of plant blue-light receptors (cryptochromes) and photolyases, have been proposed as candidate light receptors for photoentrainment of the biological clock(7-10). Here we show that mice lacking the Cry1 or Cry2 protein display accelerated and delayed free-running periodicity of locomotor activity, respectively. Strikingly, in the absence of both proteins, an instantaneous and complete loss of free-running rhythmicity is observed. This suggests that, in addition to a possible photoreceptor and antagonistic clock-adjusting function, both proteins are essential for the maintenance of circadian rhythmicity.	Erasmus Univ, Dept Cell Biol & Genet, MGC, NL-3000 DR Rotterdam, Netherlands; Tohoku Univ, Inst Dev Aging & Canc, Inst Dev, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Erasmus Univ, Dept Clin Genet, MGC, NL-3000 DR Rotterdam, Netherlands; Netherlands Inst Brain Res, NL-1105 AZ Amsterdam, Netherlands	Erasmus University Rotterdam; Tohoku University; Erasmus University Rotterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Dept Cell Biol & Genet, MGC, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Buijs, Rudolf/AAD-5707-2020; Weydahl, Andi/C-6391-2008; van der Horst, Gijsbertus TJ/E-3661-2015; Hoeijmakers, Jan/AAX-6972-2021; Kanno, Shin-ichiro/AAE-4549-2019	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Kobayashi-Nakamura, Kumiko/0000-0001-5579-3464				Ahmad M, 1998, PLANT CELL, V10, P197, DOI 10.1105/tpc.10.2.197; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRODY S, 1992, CHRONOBIOL INT, V9, P222, DOI 10.3109/07420529209064531; Dunlap J, 1998, SCIENCE, V280, P1548, DOI 10.1126/science.280.5369.1548; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Foster RG, 1998, NEURON, V20, P829, DOI 10.1016/S0896-6273(00)80464-X; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; HORTON RM, 1995, BIOTECHNIQUES, V19, P594; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; Millar AJ, 1997, CURR BIOL, V7, pR474, DOI 10.1016/S0960-9822(06)00240-5; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; NELSON RJ, 1981, COMP BIOCHEM PHYS A, V69, P145, DOI 10.1016/0300-9629(81)90651-4; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Sassone-Corsi P, 1998, NATURE, V392, P871, DOI 10.1038/31821; Schibler U, 1998, NATURE, V393, P620, DOI 10.1038/31337; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suarez-Lopez P, 1998, SCIENCE, V279, P1323, DOI 10.1126/science.279.5355.1323; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; vanderSpek PJ, 1996, GENOMICS, V37, P177, DOI 10.1006/geno.1996.0539; Whitmore D, 1998, CURR OPIN NEUROBIOL, V8, P635, DOI 10.1016/S0959-4388(98)80092-5; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; Yasui A, 1998, CONT CANC RES, P9; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5	30	1036	1059	2	132	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 15	1999	398	6728					627	630		10.1038/19323	http://dx.doi.org/10.1038/19323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217146				2022-12-01	WOS:000079754700059
J	Smith, SJ				Smith, SJ			Neurobiology - Dissecting dendrite dynamics	SCIENCE			English	Editorial Material							HIPPOCAMPAL SLICES; GROWTH; SPINES; SYNAPTOGENESIS; FILOPODIA; NEURONS		Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Smith, SJ (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.	sjsmith@leland.stanford.edu						BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; COOPER MW, 1992, J NEUROBIOL, V23, P814, DOI 10.1002/neu.480230704; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DAILEY ME, 1994, J NEUROSCI, V14, P1060, DOI 10.1523/JNEUROSCI.14-03-01060.1994; Dailey ME, 1996, J NEUROSCI, V16, P2983; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; HOSOKAWA T, 1995, J NEUROSCI, V15, P5560; Kater S. B., 1995, Current Opinion in Neurobiology, V5, P68, DOI 10.1016/0959-4388(95)80089-1; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Ludin B, 1998, TRENDS CELL BIOL, V8, P72, DOI 10.1016/S0962-8924(97)01169-0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; MATUS A, 1982, P NATL ACAD SCI-BIOL, V79, P7590, DOI 10.1073/pnas.79.23.7590; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; SMITH SJ, 1991, NERVE GROWTH CONE, P19; Vallano ML, 1998, CRIT REV NEUROBIOL, V12, P177, DOI 10.1615/CritRevNeurobiol.v12.i3.20; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	18	21	23	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 19	1999	283	5409					1860	1861		10.1126/science.283.5409.1860	http://dx.doi.org/10.1126/science.283.5409.1860			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177UC	10206891				2022-12-01	WOS:000079228600026
J	Trieman, N; Leff, J; Glover, G				Trieman, N; Leff, J; Glover, G			Outcome of long stay psychiatric patients resettled in the community: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TAPS PROJECT; FOLLOW-UP; POPULATIONS; HOSPITALS; DIFFICULT; CLOSURE	Objective To examine the outcome of a population of long stay psychiatric patients resettled in the community. Design Prospective study with 5 year follow up. Setting Over 140 residential settings in north London. Subjects 670 long stay patients from two London hospitals (Friern and Claybury) discharged to the community from 1985 to 1993. Main outcome measures Continuity and quality of residential care, readmission to hospital, mortality, crime, and vagrancy. Results Of the 523 patients who survived the 5 year follow up period, 469 (89.6%) were living in the community by the end of follow up, 310 (59.2%) in their original community placement A third (210) of all patients were readmitted at least once. Crime and homelessness presented few problems. Standardised mortality ratios for the group were comparable with those reported for similar populations. Conclusions When carefully planned and adequately resourced, community care for long star psychiatric patients is beneficial to most individuals and has minimal detrimental effects on society.	UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England; Inst Psychiat, Sect Community Psychiat, London SE5 8AF, England	University of London; University College London; UCL Medical School; University of London; King's College London	Trieman, N (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England.	n.trieman@fleet69.demon.co.uk						CLIFFORD P, 1991, BRIT J PSYCHIAT, V158, P190, DOI 10.1192/bjp.158.2.190; Gooch C, 1996, PSYCHOL MED, V26, P511, DOI 10.1017/S0033291700035595; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; HAUGLAND G, 1983, AM J PSYCHIAT, V140, P848; HAZEL M, 1998, BRIT J PSYCHIAT, V172, P35; JONES D, 1993, BRIT J PSYCHIAT, V162, P36, DOI 10.1192/S0007125000292234; *KINGS FUND, 1997, LOND MENT HLTH; LAMB HR, 1993, BRIT J PSYCHIAT, V162, P587, DOI 10.1192/bjp.162.5.587; Leff J, 1996, AM J PSYCHIAT, V153, P1318; LEFF J, 1994, BRIT J PSYCHIAT, V165, P13, DOI 10.1192/S000712500029315X; MODESTIN J, 1995, BRIT J PSYCHIAT, V166, P667, DOI 10.1192/bjp.166.5.667; ODRISCOLL C, 1993, BRIT J PSYCHIAT, V162, P30, DOI 10.1192/S0007125000292222; ODRISCOLL C, 1993, BRIT J PSYCHIAT, V162, P18, DOI 10.1192/S0007125000292209; Timms P W, 1989, Health Trends, V21, P70; Trieman N, 1998, ACTA PSYCHIAT SCAND, V98, P354, DOI 10.1111/j.1600-0447.1998.tb10098.x; Trieman N, 1996, BRIT J PSYCHIAT, V169, P289, DOI 10.1192/bjp.169.3.289; Trieman N, 1996, PSYCHOL MED, V26, P765, DOI 10.1017/S0033291700037788; WELLER MPI, 1989, NATURE, V339, P249, DOI 10.1038/339249a0	18	39	45	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					13	16		10.1136/bmj.319.7201.13	http://dx.doi.org/10.1136/bmj.319.7201.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214KE	10390451	Bronze, Green Published			2022-12-01	WOS:000081326500022
J	Bell, E; Wingate, RJT; Lumsden, A				Bell, E; Wingate, RJT; Lumsden, A			Homeotic transformation of rhombomere identity after localized Hoxb1 misexpression	SCIENCE			English	Article							TARGETED DISRUPTION; CHICK HINDBRAIN; CRANIAL NERVES; MOTOR-NEURONS; NEURAL CREST; MUTANT MICE; HOXA-1; EXPRESSION; MIGRATION; ALTERS	Segmentation of the hindbrain and branchial region is a conserved feature of head development, involving the nested expression of Hox genes. Although it is presumed that vertebrate Hox genes function as segment identifiers, responsible for mediating registration between elements of diverse embryonic origin, this assumption has remained untested. To assess this, retroviral misexpression was combined with orthotopic grafting in chick embryos to generate a mismatch in Hox coding between a specific rhombomere and its corresponding branchial arch. Rhombomere-restricted misexpression of a single gene, Hoxb1, resulted in the homeotic transformation of the rhombomere, revealed by reorganization of motor axon projections.	Kings Coll London, Guys Hosp, Dept Dev Neurobiol, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Lumsden, A (corresponding author), Kings Coll London, Guys Hosp, Dept Dev Neurobiol, London SE1 9RT, England.	andrew.lumsden@kcl.ac.uk	Wingate, Richard JT/C-5341-2009; Bell, Esther/C-5329-2009; Lumsden, Andrew/C-5146-2009	Wingate, Richard JT/0000-0002-1662-6097; 	NICHD NIH HHS [N01-HD-7-3263] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073263] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alexandre D, 1996, DEVELOPMENT, V122, P735; Bateson W., 1894, MAT STUDY VARIATION; BELL E, IN PRESS MECH DEV; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; Gavalas A, 1997, DEVELOPMENT, V124, P3693; Gavalas A, 1998, DEVELOPMENT, V125, P1123; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; Goddard JM, 1996, DEVELOPMENT, V122, P3217; Goulding M, 1998, NEURON, V21, P943, DOI 10.1016/S0896-6273(00)80612-1; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HILL J, 1995, MECH DEVELOP, V50, P3, DOI 10.1016/0925-4773(94)00321-D; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORGAN BA, 1996, METHOD CELL BIOL, V51, P186; PATA I, UNPUB; POURQUIE O, 1990, DEVELOPMENT, V109, P743; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; Tiret L, 1998, DEVELOPMENT, V125, P279; Wingate RJT, 1996, DEVELOPMENT, V122, P2143; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	28	121	121	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2168	2171		10.1126/science.284.5423.2168	http://dx.doi.org/10.1126/science.284.5423.2168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381880				2022-12-01	WOS:000081099300049
J	Hoogerwaard, EM; Bakker, E; Ippel, PF; Oosterwijk, JC; Majoor-Krakauer, DF; Leschot, NJ; Van Essen, AJ; Brunner, HG; van der Wouw, PA; Wilde, AAM; de Visser, M				Hoogerwaard, EM; Bakker, E; Ippel, PF; Oosterwijk, JC; Majoor-Krakauer, DF; Leschot, NJ; Van Essen, AJ; Brunner, HG; van der Wouw, PA; Wilde, AAM; de Visser, M			Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in the Netherlands: a cohort study	LANCET			English	Article							POLYMERASE CHAIN-REACTION; MANIFESTING CARRIERS; FEMALE CARRIERS; CARDIOMYOPATHY; INACTIVATION; DIAGNOSIS; GIRLS	Background Carriers of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) may show muscle weakness or dilated cardiomyopathy. Studies focusing on skeletal-muscle involvement were done before DNA analysis was possible. We undertook a cross-sectional study in a population of definite carriers to estimate the proportion and to assess the clinical profile of carriers with symptoms. We also assessed a possible correlation between genotype and phenotype. Methods Carriers of DMD and BMD, aged 18-60 years, were traced through the files of the central register kept at the Department of Human Genetics in Leiden, Netherlands. For each carrier who agreed to participate a medical history was taken, and muscle-strength assessment by hand-held dynamometry and manual muscle testing and cardiological assessment were done. Findings 129 carriers of muscular dystrophy (85 DMD, 44 BMD) participated in the study. In 90 women from 52 (70%) families, 37 different mutations were found. 28 (22%) women had symptoms. 22 (17%) had muscle weakness, varying from mild to moderately severe, Muscle weakness was found in carriers of DMD and BMD, but dilated cardiomyopathy was found only in seven (8%) carriers of DMD, of whom one had concomitant muscle weakness. There was an unexpectedly high proportion of left-ventricle dilation (18%). No genotype-phenotype correlation was found. Interpretation Clinical manifestation of muscle weakness, dilated cardiomyopathy, or both can be found in about a fifth of carriers of DMD and BMD. If left-ventricle dilation is taken into account, the proportion of carriers with symptoms is even higher, amounting to 40%.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Univ Utrecht, Dept Human Genet, Utrecht, Netherlands; Univ Rotterdam, Dept Human Genet, Rotterdam, Netherlands; Univ Groningen, Dept Human Genet, Groningen, Netherlands; Univ Nijmegen, Dept Human Genet, Nijmegen, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Utrecht University; Erasmus University Rotterdam; University of Groningen; Radboud University Nijmegen	Hoogerwaard, EM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Brunner, Han/C-9928-2013; Majoor-Krakauer, Danielle/AAC-3939-2020; Oosterwijk, Jan C./G-5770-2011; Bakker, Egbert/D-3525-2009	Bakker, Egbert/0000-0002-2843-7357				ABBADI N, 1994, AM J MED GENET, V52, P198, DOI 10.1002/ajmg.1320520215; AZOFEIFA J, 1995, HUM GENET, V96, P167, DOI 10.1007/BF00207374; BAKKER E, 1986, J MED GENET, V23, P573, DOI 10.1136/jmg.23.6.573; BEGGS AH, 1990, HUM GENET, V86, P45; BOYD Y, 1986, J MED GENET, V23, P484, DOI 10.1136/jmg.23.6.484; BUSHBY KMD, 1993, NEUROMUSCULAR DISORD, V3, P57, DOI 10.1016/0960-8966(93)90042-I; CARLQUIST JF, 1991, CIRCULATION, V83, P515, DOI 10.1161/01.CIR.83.2.515; CHAMBERLAIN JS, 1992, JAMA-J AM MED ASSOC, V267, P2609; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COMI LI, 1992, INT J CARDIOL, V34, P297, DOI 10.1016/0167-5273(92)90028-2; EMERY AEH, 1969, BMJ-BRIT MED J, V2, P418, DOI 10.1136/bmj.2.5654.418; FEIGENBAUM H, 1994, ECHOCARDIOGR-J CARD, P658; FROUHAR ZR, 1975, AM J HUM GENET, V27, P37; GLASS IA, 1992, J MED GENET, V29, P578, DOI 10.1136/jmg.29.8.578; HAGINOYA K, 1991, J NEUROL, V238, P375, DOI 10.1007/BF00319855; HORDER M, 1991, EUR J CLIN CHEM CLIN, V29, P435; IONASESCU VV, 1989, ACTA NEUROL SCAND, V79, P500, DOI 10.1111/j.1600-0404.1989.tb03821.x; MATTHEWS PM, 1995, NEUROMUSCULAR DISORD, V5, P209, DOI 10.1016/0960-8966(94)00057-G; MIRABELLA M, 1993, NEUROLOGY, V43, P2342, DOI 10.1212/WNL.43.11.2342; MOSER H, 1974, CLIN GENET, V5, P271; MOSER H, 1971, HUMANGENETIK, V11, P328, DOI 10.1007/BF00278661; *MRC, 1986, AIDS INV PER NERV SY; NORMAN A, 1989, CLIN GENET, V36, P31; PENN AS, 1970, NEUROLOGY, V20, P147, DOI 10.1212/WNL.20.2.147; PERLOFF JK, 1967, AM J MED, V42, P179, DOI 10.1016/0002-9343(67)90017-4; Politano L, 1996, JAMA-J AM MED ASSOC, V275, P1335, DOI 10.1001/jama.275.17.1335; REDDY BK, 1984, HUM GENET, V67, P460, DOI 10.1007/BF00291412; RICHARDS CS, 1990, AM J HUM GENET, V46, P672; SCHMIDTACHERT M, 1992, LANCET, V340, P1235, DOI 10.1016/0140-6736(92)92942-9; SEWRY CA, 1993, NEUROMUSCULAR DISORD, V3, P141, DOI 10.1016/0960-8966(93)90006-6; VANDERPLOEG RJO, 1991, J NEUROL NEUROSUR PS, V54, P244, DOI 10.1136/jnnp.54.3.244; vanEssen AJ, 1997, J MED GENET, V34, P805, DOI 10.1136/jmg.34.10.805; YOSHIOKA M, 1981, CLIN GENET, V20, P6	33	155	164	1	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2116	2119		10.1016/S0140-6736(98)10028-4	http://dx.doi.org/10.1016/S0140-6736(98)10028-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382696				2022-12-01	WOS:000080969300012
J	Simpson, WM; Johnstone, FD; Goldberg, DJ; Gormley, SM; Hart, GJ				Simpson, WM; Johnstone, FD; Goldberg, DJ; Gormley, SM; Hart, GJ			Antenatal HIV testing: assessment of a routine voluntary approach	BRITISH MEDICAL JOURNAL			English	Article							WOMEN		Univ Edinburgh, Ctr Reprod Biol, Dept Obstet & Gynaecol, Edinburgh EH3 9EW, Midlothian, Scotland; Scottish Ctr Infect & Environm Hlth, Glasgow G3 7LN, Lanark, Scotland; Univ Glasgow, MRC, Med Sociol Unit, Glasgow G12 8RZ, Lanark, Scotland	University of Edinburgh; University of Glasgow	Simpson, WM (corresponding author), 22 Lumsden Pk, Cupar KY15 5YL, Fife, Scotland.		Hart, Graham J/C-1591-2008	Hart, Graham/0000-0001-9676-6577				*INT CORK PART ENH, 1998, RED MOTH CHILD TRANS; Johnstone F, 1998, AIDS, V12, P911, DOI 10.1097/00002030-199808000-00014; MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Simpson WM, 1998, BRIT MED J, V316, P262, DOI 10.1136/bmj.316.7127.262	5	63	64	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1660	1661		10.1136/bmj.318.7199.1660	http://dx.doi.org/10.1136/bmj.318.7199.1660			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373168	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000081105600020
J	Soderlund, N; Zwi, K; Kinghorn, A; Gray, G				Soderlund, N; Zwi, K; Kinghorn, A; Gray, G			Prevention of vertical transmission of HIV: analysis of cost effectiveness of options available in South Africa	BRITISH MEDICAL JOURNAL			English	Article							TO-CHILD TRANSMISSION; HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; ZIDOVUDINE; INTERVENTION; TYPE-1; HEALTH; IMPACT; AIDS	Objective To assess the cost effectiveness of vertical transmission prevention strategies by using a mathematical simulation model, Design A Markov chain model was used to simulate the cost effectiveness of four formula feeding strategies, three antiretroviral interventions, and combined formula feeding and antiretroviral interventions on a cohort of 20 000 pregnancies, All children born to HIV positive mothers were followed up until age of likely death given current life expectancy and a cost per life year gained calculated fur each strategy. Setting Model of working class, urban South African population, Results Low cost antiretroviral regimens were almost as effective as high cost ones and more cost effective when formula feeding interventions were added, With or without formula feeding, low cost antiretroviral interventions were likely to save lives and money. Interventions that allowed breast feeding early on, to be replaced by formula feeding at 4 or 7 months, seemed likely to save fewer lives and offered poorer value for money Conclusions Antiretroviral interventions are probably cost effective across a wide range of settings, with or without formula feeding interventions, The appropriateness of formula feeding was highly cost effective only in settings with high seroprevalence and reasonable levels of child survival and dangerous where infant mortality was high or the protective effect of breast feeding substantial, Pilot projects are now needed to ensure the feasibility of implementation.	Univ Witwatersrand, Ctr Hlth Policy, ZA-2000 Johannesburg, South Africa; Chris Hani Baragwanath Hosp, Dept Paediat, Johannesburg, South Africa; Abt Associates S Africa, Johannesburg, South Africa; Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa	University of Witwatersrand; ABT Associates; University of Witwatersrand	Soderlund, N (corresponding author), Univ Witwatersrand, Ctr Hlth Policy, POB 1038, ZA-2000 Johannesburg, South Africa.		Zwi, Karen/S-4547-2016	Zwi, Karen/0000-0002-5561-5200				Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003; BROWN M, 1994, REPORT CONSULTANTS E; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P151; *CENTR STAT SERV, 1997, STAT BRIEF 1997; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CUNNINGHAM AS, 1991, J PEDIATR-US, V118, P659, DOI 10.1016/S0022-3476(05)80023-X; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; *DEP HLTH POP DEV, 1996, EPIDEMIOL COMMENTS, V23, P4; DUNN DT, 1994, J ACQ IMMUN DEF SYND, V7, P1064; Harrison D., 1995, S AFRICAN HLTH REV 1; KINGHORN A, 1998, PROJECTIONS COSTS AN; Mansergh G, 1996, JAMA-J AM MED ASSOC, V276, P139, DOI 10.1001/jama.276.2.139; Marseille E, 1998, AIDS, V12, P939, DOI 10.1097/00002030-199808000-00017; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Mofenson LM, 1997, ACTA PAEDIATR, V421, P1; *NAT DEP HLTH S AF, 1995, REG HLTH MAN INF SYS; NICOLL A, 1995, AIDS, V9, P107, DOI 10.1097/00002030-199509020-00001; Ratcliffe J, 1998, AIDS, V12, P1381, DOI 10.1097/00002030-199811000-00021; ROSS SM, 1983, S AFR MED J, V63, P23; Sculpher MJ, 1998, AIDS, V12, P1371, DOI 10.1097/00002030-199811000-00020; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SODERLUND N, 1998, MONOGRAPH CTR HLTH P, V52; SODERLUND N, 1997, LIKELY COSTS HOSP CA; Stover J, 1998, AIDS, V12, pS29; Tess BH, 1998, J ACQ IMMUN DEF SYND, V19, P189, DOI 10.1097/00042560-199810010-00014; *UNAIDS WHO, 1998, GUID MOD ANT TREATM; WAGSTAFF L, 1993, URBANISATION HLTH NE, V18, P9; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilkinson D, 1998, AIDS, V12, P1675, DOI 10.1097/00002030-199813000-00016; ZWI KJ, IN PRESS ANN TROP PA	33	71	73	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1999	318	7199					1650	1656		10.1136/bmj.318.7199.1650	http://dx.doi.org/10.1136/bmj.318.7199.1650			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373166	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000081105600018
J	Dickinson, MH; Lehmann, FO; Sane, SP				Dickinson, MH; Lehmann, FO; Sane, SP			Wing rotation and the aerodynamic basis of insect flight	SCIENCE			English	Article							LOW REYNOLDS-NUMBERS; DROSOPHILA-MELANOGASTER; LIFT PRODUCTION; MECHANISMS; KINEMATICS; PERFORMANCE; GENERATION; DYNAMICS; ANIMALS; FORCES	The enhanced aerodynamic performance of insects results from an interaction of three distinct yet interactive mechanisms: delayed stall,. rotational circulation, and wake capture. Delayed stall functions-during the translational portions of the stroke, when the wings sweep through the air with a Large angle of attack. In contrast, rotational circulation and wake capture generate aerodynamic forces during stroke reversals, when the wings rapidly rotate and change direction. In addition to contributing to the lift required to keep an insect aloft, these two rotational mechanisms provide a potent means by which the animal can modulate the direction and magnitude of flight forces during steering maneuvers. A comprehensive theory incorporating both translational and rotational mechanisms may explain the diverse patterns of wing motion displayed by different species of insects.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Wurzburg, Theodor Boveri Inst, Dept Behav Physiol & Sociobiol Zool, D-97074 Wurzburg, Germany	University of California System; University of California Berkeley; University of Wurzburg	Dickinson, MH (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.	flymanmd@socrates.berkeley.edu	Sikandar, Usama/F-6586-2016					ADAIR R, 1990, PHYSICS BASEBALL; CLOUPEAU M, 1979, J EXP BIOL, V80, P1; COLLETT TS, 1975, J COMP PHYSIOL, V99, P1, DOI 10.1007/BF01464710; Dalton S., 1975, BORNE WIND; Dickinson MH, 1996, AM ZOOL, V36, P537; Dickinson MH, 1996, J EXP BIOL, V199, P2085; DICKINSON MH, 1994, J EXP BIOL, V192, P179; DICKINSON MH, 1993, J EXP BIOL, V174, P45; DICKINSON MH, 1993, J EXP BIOL, V182, P173; Ellington C.P., 1995, Symposia of the Society for Experimental Biology, V49, P109; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P79, DOI 10.1098/rstb.1984.0052; Ellington CP, 1996, NATURE, V384, P626, DOI 10.1038/384626a0; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P1, DOI 10.1098/rstb.1984.0049; ELLINGTON CP, 1984, PHILOS T ROY SOC B, V305, P41, DOI 10.1098/rstb.1984.0051; ENNOS AR, 1989, J EXP BIOL, V142, P49; Fung Y.C., 1993, INTRO THEORY AEROELA; GOTZ KG, 1987, J EXP BIOL, V128, P35; GOTZ KG, 1984, BIOL CYBERN, V51, P135, DOI 10.1007/BF00357927; LEHMANN FO, 1994, THESIS EBERHAD KARLS; MARDEN JH, 1987, J EXP BIOL, V130, P235; MAXWORTHY T, 1981, ANNU REV FLUID MECH, V13, P329, DOI 10.1146/annurev.fl.13.010181.001553; MAY RM, 1978, S R ENTOMOL SOC LOND, V9, P188; Nachtigall W., 1974, INSECTS FLIGHT; RAYNER JMV, 1991, PHILOS T ROY SOC B, V334, P119, DOI 10.1098/rstb.1991.0101; SPEDDING GR, 1986, J FLUID MECH, V165, P247, DOI 10.1017/S0022112086003087; VandenBerg C, 1997, PHILOS T ROY SOC B, V352, P317, DOI 10.1098/rstb.1997.0023; Wagner H, 1925, Z ANGEW MATH MECH, V5, P17, DOI 10.1002/zamm.19250050103; WEISFOGH T, 1973, J EXP BIOL, V59, P169; WILKIN PJ, 1993, PHYSIOL ZOOL, V66, P1015, DOI 10.1086/physzool.66.6.30163752; Willmott AP, 1997, PHILOS T ROY SOC B, V352, P303, DOI 10.1098/rstb.1997.0022; ZANKER JM, 1990, PHILOS T ROY SOC B, V327, P1, DOI 10.1098/rstb.1990.0040	31	1677	1803	27	327	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 18	1999	284	5422					1954	1960		10.1126/science.284.5422.1954	http://dx.doi.org/10.1126/science.284.5422.1954			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373107				2022-12-01	WOS:000080932700037
J	Perrin, RM; DeRocher, AE; Bar-Peled, M; Zeng, WQ; Norambuena, L; Orellana, A; Raikhel, NV; Keegstra, K				Perrin, RM; DeRocher, AE; Bar-Peled, M; Zeng, WQ; Norambuena, L; Orellana, A; Raikhel, NV; Keegstra, K			Xyloglucan fucosyltransferase, an enzyme involved in plant cell wall biosynthesis	SCIENCE			English	Article							COMPLEX POLYSACCHARIDES; GOLGI-APPARATUS; ARABIDOPSIS; CELLULOSE; GLYCOSYLTRANSFERASES; OLIGOSACCHARIDES; GLYCOPROTEINS; FUCOSYLATION; LOCALIZATION; SIMULATIONS	Cell walls are crucial for development, signal transduction, and disease resistance in plants. Cell walls are made of cellulose, hemicelluloses, and pectins. Xyloglucan (XG), the principal load-bearing hemicellulose of dicotyledonous plants. has a terminal fucosyl residue. A 60-kilodalton fucosyltransferase (FTase) that adds this residue was purified from pea epicotyls. Peptide sequence information from the pea FTase allowed the cloning of a homologous gene, AtFT1, from Arabidopsis. Antibodies raised against recombinant AtFTase immunoprecipitate FTase enzyme activity from solubilized Arabidopsis membrane proteins, and AtFT1 expressed in mammalian COS cells results in the presence of XG FTase activity in these cells.	Michigan State Univ, US DOE, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Bot & Plant Pathol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Cell & Mol Biol Program, E Lansing, MI 48824 USA; Univ Chile, Fac Sci, Dept Biol, Santiago, Chile	Michigan State University; United States Department of Energy (DOE); Michigan State University; Michigan State University; Michigan State University; Universidad de Chile	Keegstra, K (corresponding author), Michigan State Univ, US DOE, Plant Res Lab, E Lansing, MI 48824 USA.		Zeng, Weiqing/AAA-7045-2019; Orellana, Ariel/E-2166-2014; Orellana, Ariel/AAE-4866-2021; Norambuena, Lorena/I-1248-2013	Orellana, Ariel/0000-0002-9243-808X; Orellana, Ariel/0000-0002-9243-808X; Norambuena, Lorena/0000-0002-6031-2394; Zeng, Weiqing/0000-0002-5466-8693				Arioli T, 1998, SCIENCE, V279, P717, DOI 10.1126/science.279.5351.717; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; CAMIRAND A, 1987, PLANT PHYSIOL, V84, P753, DOI 10.1104/pp.84.3.753; CARPITA N, 1997, PLANT METABOLISM, pCH9; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COSGROVE DJ, 1993, PLANT PHYSIOL, V102, P1, DOI 10.1104/pp.102.1.1; Creelman RA, 1997, PLANT CELL, V9, P1211, DOI 10.1105/tpc.9.7.1211; DRIOUICH A, 1993, TRENDS BIOCHEM SCI, V18, P210, DOI 10.1016/0968-0004(93)90191-O; FARKAS V, 1988, ARCH BIOCHEM BIOPHYS, V264, P48, DOI 10.1016/0003-9861(88)90568-1; FRY SC, 1993, PLANT PHYSIOL, V103, P1, DOI 10.1104/pp.103.1.1; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HAYASHI T, 1989, ANNU REV PLANT PHYS, V40, P139, DOI 10.1146/annurev.pp.40.060189.001035; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; LEVY S, 1991, PLANT J, V1, P195; Levy S, 1997, PLANT J, V11, P373, DOI 10.1046/j.1365-313X.1997.11030373.x; MCDOUGALL GJ, 1989, J EXP BOT, V40, P233, DOI 10.1093/jxb/40.2.233; MOORE PJ, 1991, J CELL BIOL, V112, P589, DOI 10.1083/jcb.112.4.589; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; PERRIN R, UNPUB; PUHLMANN J, 1994, PLANT PHYSIOL, V104, P699, DOI 10.1104/pp.104.2.699; Purugganan MM, 1997, PLANT PHYSIOL, V115, P181, DOI 10.1104/pp.115.1.181; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WHITNEY SEC, 1995, PLANT J, V8, P491, DOI 10.1046/j.1365-313X.1995.8040491.x; YORK WS, 1984, PLANT PHYSIOL, V75, P295, DOI 10.1104/pp.75.2.295; ZABLACKIS E, 1995, PLANT PHYSIOL, V107, P1129, DOI 10.1104/pp.107.4.1129	26	211	223	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1976	1979		10.1126/science.284.5422.1976	http://dx.doi.org/10.1126/science.284.5422.1976			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10373113				2022-12-01	WOS:000080932700043
J	Goodman, SN				Goodman, SN			Toward evidence-based medical statistics. 1: The P value fallacy	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; CONFIDENCE-INTERVALS; MULTIPLE COMPARISONS; JOURNALS; TESTS; HYPOTHESES; INFERENCE; TRENDS; FUTURE; DEBATE		Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Goodman, SN (corresponding author), Johns Hopkins Univ, Sch Med, 550 N Broadway,Suite 409, Baltimore, MD 21205 USA.	sgoodman@jhu.edu		Goodman, Steven/0000-0002-3872-5723				ALTMAN DG, 1994, JAMA-J AM MED ASSOC, V272, P129, DOI 10.1001/jama.272.2.129; ALTMAN DG, 1991, J R STAT SOC A STAT, V154, P223, DOI 10.2307/2983040; ANSCOMBE FJ, 1963, J AM STAT ASSOC, V58, P365, DOI 10.2307/2283272; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; Barnett ML, 1997, J DENT RES, V76, P534, DOI 10.1177/00220345970760010201; BARNETT V, 1982, COMP STAT INFERENCE; BEGG CB, 1990, BIOMETRIKA, V77, P467; Berger J.O., 1985, P BERKELEY C HONOR J, P15; Berkson J, 1942, J AM STAT ASSOC, V37, P325, DOI 10.2307/2279000; BERRY G, 1986, MED J AUSTRALIA, V144, P618, DOI 10.5694/j.1326-5377.1986.tb112339.x; BORAK J, 1982, SOC SCI MED, V16, P1939, DOI 10.1016/0277-9536(82)90393-8; BRAITMAN LE, 1988, ANN INTERN MED, V108, P296, DOI 10.7326/0003-4819-108-2-296; BROPHY JM, 1995, JAMA-J AM MED ASSOC, V273, P871, DOI 10.1001/jama.273.11.871; BROWNER WS, 1987, JAMA-J AM MED ASSOC, V257, P2459, DOI 10.1001/jama.257.18.2459; Carnap R., 1950, LOGICAL FDN PROBABIL; Carroll L, 1996, AM J CARDIOL, V78, P608, DOI 10.1016/S0002-9149(96)90531-7; Chia KS, 1997, SCAND J WORK ENV HEA, V23, P152, DOI 10.5271/sjweh.193; Clarke M, 1998, JAMA-J AM MED ASSOC, V280, P280, DOI 10.1001/jama.280.3.280; Colton T, 1974, STAT MED; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CORNFIELD J, 1966, AM STAT, V20, P18, DOI 10.2307/2682711; CORNFIELD J, 1969, BIOMETRICS, V25, P617, DOI 10.2307/2528565; COX DR, 1982, BRIT J CLIN PHARMACO, V14, P325, DOI 10.1111/j.1365-2125.1982.tb01987.x; Cox DR, 1979, THEORETICAL STAT; DAR R, 1994, J CONSULT CLIN PSYCH, V62, P75, DOI 10.1037/0022-006X.62.1.75; DIAMOND GA, 1983, ANN INTERN MED, V98, P385, DOI 10.7326/0003-4819-98-3-385; DUPONT WD, 1983, CONTROL CLIN TRIALS, V4, P3, DOI 10.1016/S0197-2456(83)80003-8; Edwards A.W.F., 1972, LIKELIHOOD; ETZIONI RD, 1995, ANNU REV PUBL HEALTH, V16, P23; EVANS SJW, 1988, BRIT HEART J, V60, P177; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; Feinstein AR, 1998, J CLIN EPIDEMIOL, V51, P355, DOI 10.1016/S0895-4356(97)00295-3; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; Fisher LD, 1999, CONTROL CLIN TRIALS, V20, P1, DOI 10.1016/S0197-2456(98)00052-X; Fisher LD, 1999, CONTROL CLIN TRIALS, V20, P16, DOI 10.1016/S0197-2456(98)00054-3; Fisher R.A., 1973, STAT METHODS SCI INF, V3rd ed.; Fisher RA, 1958, STAT METHODS RES WOR, P80; Freedman L, 1996, BMJ-BRIT MED J, V313, P569; FREEMAN PR, 1993, STAT MED, V12, P1443, DOI 10.1002/sim.4780121510; Gigerenzer G., 1989, EMPIRE CHANCE; Goodman SN, 1998, AM J EPIDEMIOL, V147, P807, DOI 10.1093/oxfordjournals.aje.a009531; GOODMAN SN, 1988, AM J PUBLIC HEALTH, V78, P1568, DOI 10.2105/AJPH.78.12.1568; GOODMAN SN, 1993, AM J EPIDEMIOL, V137, P485, DOI 10.1093/oxfordjournals.aje.a116700; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; GREENLAND S, 1991, EPIDEMIOLOGY, V2, P387, DOI 10.1097/00001648-199109000-00015; Hacking I., 1975, EMERGENCE PROBABILIT; HAYDEN GF, 1983, PEDIATRICS, V72, P84; Howson C., 1993, SCI REASONING BAYESI; KADANE JB, 1995, CONTROL CLIN TRIALS, V16, P313, DOI 10.1016/0197-2456(95)00072-0; Lang JM, 1998, EPIDEMIOLOGY, V9, P7, DOI 10.1097/00001648-199805000-00019; LEHMANN EL, 1993, J AM STAT ASSOC, V88, P1242; Lilford RJ, 1996, BRIT MED J, V313, P603; LUDBROOK J, 1994, AUST NZ J SURG, V64, P630, DOI 10.1111/j.1445-2197.1994.tb02308.x; MAINLAND D, 1963, CLIN PHARMACOL THER, V4, P580; MAINLAND D, 1984, BMJ-BRIT MED J, V288, P841, DOI 10.1136/bmj.288.6420.841; MAINLAND D, 1984, BMJ-BRIT MED J, V288, P920, DOI 10.1136/bmj.288.6421.920; Marks H., 1997, PROGR EXPT SCI THERA; Matthews JR., 1995, QUANTIFICATION QUEST, DOI 10.1515/9781400821808; McKenzie R, 1998, JAMA-J AM MED ASSOC, V280, P1061, DOI 10.1001/jama.280.12.1061; Morrison DE., 1970, SIGNIFICANCE TEST CO; Moye LA, 1999, CONTROL CLIN TRIALS, V20, P40, DOI 10.1016/S0197-2456(98)00051-8; Neyman J, 1933, PHILOS T R SOC LOND, V231, P289, DOI 10.1098/rsta.1933.0009; Oakes M. W., 1986, STAT INFERENCE COMME; PEARSON ES, 1962, ANN MATH STAT, V33, P394, DOI 10.1214/aoms/1177704566; PEARSON ES, 1938, BIOMETRIKA, V30, P210, DOI DOI 10.2307/2332648; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; POOLE C, 1987, AM J PUBLIC HEALTH, V77, P195, DOI 10.2105/AJPH.77.2.195; Porter Theodore M., 1996, TRUST NUMBERS PURSUI; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; Royall R, 1997, MONOGRAPHS STAT APPL, V71; ROZEBOOM WW, 1960, PSYCHOL BULL, V57, P416, DOI 10.1037/h0042040; Salmon WC., 1966, FDN SCI INFERENCE; SALSBURG DS, 1985, AM STAT, V39, P220, DOI 10.2307/2683942; SAVITZ DA, 1995, AM J EPIDEMIOL, V142, P904, DOI 10.1093/oxfordjournals.aje.a117737; SAVITZ DA, 1993, REPROD TOXICOL, V7, P95, DOI 10.1016/0890-6238(93)90242-Y; Seidenfeld T., 1979, PHILOS PROBLEMS STAT; SIMON R, 1994, BRIT J CANCER, V69, P979, DOI 10.1038/bjc.1994.192; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; SKELLAM JG, 1969, BIOMETRICS, V25, P457, DOI 10.2307/2528899; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; Stigler S.M., 1986, HIST STAT MEASUREMEN; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206; THOMAS DC, 1985, AM J EPIDEMIOL, V122, P1080, DOI 10.1093/oxfordjournals.aje.a114189; Tonelli MR, 1998, ACAD MED, V73, P1234, DOI 10.1097/00001888-199812000-00011; WULFF HR, 1987, STAT MED, V6, P3, DOI 10.1002/sim.4780060103; [No title captured]; [No title captured]; [No title captured]; [No title captured]	89	1032	1050	0	86	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					995	1004		10.7326/0003-4819-130-12-199906150-00008	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	206TE	10383371				2022-12-01	WOS:000080894700007
J	Treue, S; Trujillo, JCM				Treue, S; Trujillo, JCM			Feature-based attention influences motion processing gain in macaque visual cortex	NATURE			English	Article							AREA-MT; SELECTIVE ATTENTION; NEURAL MECHANISMS; MODULATION; V4; NEURONS; LESIONS; MONKEY; MST; V1	Changes in neural responses based on spatial attention have been demonstrated in many areas of visual cortex(1-4), indicating that the neural correlate of attention is an enhanced response to stimuli at an attended location and reduced responses to stimuli elsewhere. Here we demonstrate non-spatial, feature-based attentional modulation of visual motion processing, and show that attention increases the gain of direction-selective neurons in visual cortical area MT without narrowing the direction-tuning curves. These findings place important constraints on the neural mechanisms of attention and we propose to unify the effects of spatial location, direction of motion and other features of the attended stimuli in a 'feature similarity gain model' of attention.	Univ Tubingen, Dept Neurol, Cognit Neurosci Lab, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Treue, S (corresponding author), Univ Tubingen, Dept Neurol, Cognit Neurosci Lab, Morgenstelle 15, D-72076 Tubingen, Germany.		Martinez-Trujillo, Julio C/M-2146-2015	Martinez-Trujillo, Julio C/0000-0003-3338-578X				Beauchamp MS, 1997, J NEUROPHYSIOL, V78, P516, DOI 10.1152/jn.1997.78.1.516; Britten KH, 1996, VISUAL NEUROSCI, V13, P87, DOI 10.1017/S095252380000715X; CHELAZZI L, 1993, NATURE, V363, P345, DOI 10.1038/363345a0; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Duncan J, 1996, PERCEPT PSYCHOPHYS, V58, P1076, DOI 10.3758/BF03206834; ITTI L, IN PRESS NEURAL INFO; LANKHEET MJM, 1995, VISION RES, V35, P1401, DOI 10.1016/0042-6989(95)98720-T; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; Martinez J. C., 1998, Society for Neuroscience Abstracts, V24, P649; McAdams CJ, 1999, J NEUROSCI, V19, P431, DOI 10.1523/JNEUROSCI.19-01-00431.1999; MCADAMS CJ, 1996, NEUR ABSTR, V22, P1197; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1994, J NEUROSCI, V14, P2178; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; NEWSOME WT, 1988, J NEUROSCI, V8, P2201; NEWSOME WT, 1985, J NEUROSCI, V5, P825; OCraven KM, 1997, NEURON, V18, P591, DOI 10.1016/S0896-6273(00)80300-1; Reynolds J. H., 1997, Society for Neuroscience Abstracts, V23, P302; Reynolds JH, 1999, J NEUROSCI, V19, P1736; SNOWDEN RJ, 1992, EXP BRAIN RES, V88, P389, DOI 10.1007/BF02259114; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; Treue S., 1998, Society for Neuroscience Abstracts, V24, P1249; TREUE S, UNPUB J NEUROSCI; Valdes-Sosa M, 1998, J COGNITIVE NEUROSCI, V10, P137, DOI 10.1162/089892998563743	25	1005	1022	3	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					575	579		10.1038/21176	http://dx.doi.org/10.1038/21176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376597	Green Published			2022-12-01	WOS:000080778400053
J	Wolk, A; Manson, JE; Stampfer, MJ; Colditz, GA; Hu, FB; Speizer, FE; Hennekens, CH; Willett, WC				Wolk, A; Manson, JE; Stampfer, MJ; Colditz, GA; Hu, FB; Speizer, FE; Hennekens, CH; Willett, WC			Long-term intake of dietary fiber and decreased risk of coronary heart disease among women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; DIABETES-MELLITUS; MORTALITY; CHOLESTEROL; MEN; PRODUCTS; FAT; HEALTH; CONSUMPTION; COAGULATION	Context Epidemiological studies of men suggest that dietary fiber intake protects against coronary heart disease (CHD), but data on this association in women are sparse. Objective To examine the association between long-term intake of total dietary fiber as well as fiber from different sources and risk of CHD in women, Design and Setting The Nurses' Health Study, a large, prospective cohort study of US women followed up for 10 years from 1984, Dietary data were collected in 1984, 1986, and 1990, using a validated semiquantitative food frequency questionnaire. Participants A total of 68 782 women aged 37 to 64 years without previously diagnosed angina, myocardial infarction (MI), stroke, cancer, hypercholesterolemia, or diabetes at baseline. Main Outcome Measure Incidence of acute Anl or death due to CHD by amount of fiber intake. Results Response rate averaged 80% to 90% during the 10-year follow-up. We documented 591 major CHD events (429 nonfatal MIs and 162 CHD deaths). The age-adjusted relative risk (RR) for major CHD events was 0.53 (95% confidence interval [CI], 0.40-0.69) for women in the highest quintile of total dietary fiber intake (median, 22.9 g/d) compared with women in the lowest quintile (median, 11.5 g/d), After controlling for age, cardiovascular risk factors, dietary factors, and multivitamin supplement use, the RR was 0.77 (95% CI, 0.57-1.04). For a 10-g/d increase in total fiber intake (the difference between the lowest and highest quintiles), the multivariate RR of total CHD events was 0.81 (95% CI, 0.66-0.99), Among different sources of dietary fiber (eg, cereal, vegetables, fruit), only cereal fiber was strongly associated with a reduced risk of CHD (multivariate RR, 0.63; 95% CI, 0.49-0.81 for each 5-g/d increase in cereal fiber). Conclusions Our findings in women support the hypothesis that higher fiber intake, particularly from cereal sources, reduces the risk of CHD.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Environm Sci, Boston, MA USA; Harvard Univ, Sch Med, Dept Nutr, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA	Karolinska Institutet; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Wolk, A (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, S-17177 Stockholm, Sweden.	alicja.wolk@mep.ki.se	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL24074, HL0353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLERCREUTZ H, 1987, J STEROID BIOCHEM, V27, P1135, DOI 10.1016/0022-4731(87)90200-7; ANDERSON JW, 1979, AM J CLIN NUTR, V32, P346, DOI 10.1093/ajcn/32.2.346; ANDERSON JW, 1986, AM J GASTROENTEROL, V81, P907; ANDERSON JW, 1980, METABOLISM, V29, P551, DOI 10.1016/0026-0495(80)90081-5; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; *BRIT CARD SOC WOR, 1987, BRIT HEART J, V57, P188; BURR ML, 1982, AM J CLIN NUTR, V36, P873, DOI 10.1093/ajcn/36.5.873; CARA L, 1992, AM J CLIN NUTR, V55, P81, DOI 10.1093/ajcn/55.1.81; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; FEHILY AM, 1993, BRIT J NUTR, V69, P303, DOI 10.1079/BJN19930035; FESKENS EJM, 1994, AM J EPIDEMIOL, V140, P350, DOI 10.1093/oxfordjournals.aje.a117257; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HALLFRISCH J, 1995, AM J CLIN NUTR, V61, P379, DOI 10.1093/ajcn/61.2.379; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; HUNNINGHAKE DB, 1994, AM J CLIN NUTR, V59, P1050, DOI 10.1093/ajcn/59.5.1050; Jacobs DR, 1998, AM J CLIN NUTR, V68, P248, DOI 10.1093/ajcn/68.2.248; JENKINS DJA, 1993, NEW ENGL J MED, V329, P21, DOI 10.1056/NEJM199307013290104; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KROMHOUT D, 1982, LANCET, V2, P518; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MARCKMANN P, 1993, ARTERIOSCLER THROMB, V13, P505, DOI 10.1161/01.ATV.13.4.505; Mennen LI, 1997, AM J CLIN NUTR, V65, P732, DOI 10.1093/ajcn/65.3.732; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; *NAT CTR HLTH STAT, 1993, VIT STAT US 1989, V2; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; PROSKY L, 1985, J ASSOC OFF ANA CHEM, V68, P677; PROSKY L, 1984, J ASSOC OFF ANA CHEM, V67, P1044; PROSKY L, 1988, J ASSOC OFF ANA CHEM, V71, P1017; RICCARDI G, 1987, EUR HEART J, V8, P79, DOI 10.1093/eurheartj/8.suppl_E.79; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIPSIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317, DOI 10.1001/jama.267.24.3317; RIVELLESE A, 1980, LANCET, V2, P447; Rose GA., 1982, WHO MONOGRAPH SERIES, V58; SALDO BJ, 1985, MILBANK MEM FUND Q, V63, P286; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; Slavin J, 1997, NUTR CANCER, V27, P14, DOI 10.1080/01635589709514495; SMITH U, 1994, AM J CLIN NUTR, V59, p686S, DOI 10.1093/ajcn/59.3.686S; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; SUNDELL IB, 1993, HAEMOSTASIS, V23, P45; US Department of Health and Human Services, 1988, SURG GEN REP NUTR HL; *USDA, 1989, USDA AGR HDB SER, V8; VAHOUNY GV, 1980, LIPIDS, V15, P1012, DOI 10.1007/BF02534316; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wynder EL, 1996, JAMA-J AM MED ASSOC, V275, P486, DOI 10.1001/jama.275.6.486; 1989, CMAJ, V49, P629	58	278	298	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	1999	281	21					1998	2004		10.1001/jama.281.21.1998	http://dx.doi.org/10.1001/jama.281.21.1998			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200NN	10359388				2022-12-01	WOS:000080546700029
J	Niebauer, J; Volk, HD; Kemp, M; Dominguez, M; Schumann, RR; Rauchhaus, M; Poole-Wilson, PA; Coats, AJS; Anker, SD				Niebauer, J; Volk, HD; Kemp, M; Dominguez, M; Schumann, RR; Rauchhaus, M; Poole-Wilson, PA; Coats, AJS; Anker, SD			Endotoxin and immune activation in chronic heart failure: a prospective cohort study	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; IDIOPATHIC DILATED CARDIOMYOPATHY; FAILING HUMAN HEART; FACTOR-ALPHA; SEPTIC SHOCK; BLOOD-FLOW; LPS; CYTOKINES; BINDING; METABOLISM	Background. Immune activation in patients with chronic heart failure may be secondary to endotoxin (lipopolysaccharide) action. We investigated the hypothesis that altered gut permeability with bacterial translocation and endotoxaemia would be increased in patients with oedema secondary to congestive heart failure. Methods. We compared 20 patients who had chronic heart failure with recent-onset peripheral oedema (mean age 64 years [SD 10], New York Heart Association [NYHA] class 3.3 [0.7]), 20 stable non-oedematous patients with chronic heart failure (mean age 63 years [19], NYHA class 2.6 [0.7]), and 14 healthy volunteers (mean age 55 years [16]). Biochemical markers of endotoxaemia, inflammation, and immune activation were measured. Ten patients were studied within 1 week of complete resolution of oedema. Five patients survived longer than 6 months and were restudied again after remaining free of oedema for more than 3 months. Findings. Mean endotoxin concentrations were higher in oedematous patients with chronic heart failure than in stable patients with chronic heart failure (0.74 [SD 0.45] vs 0.37 EU/mL [0.23], p = 0.0009) and controls (0.46 EU/mL [0.21], p = 0.02). Oedematous patients had the highest concentrations of several cytokines. After short-term diuretic treatment, endotoxin concentrations decreased from 0.84 EU/mL [0.49] to 0.45 EU/mL [0.21], p < 0.05) but cytokines remained raised. After freedom of oedema for more than 3 months after oedema resolved, endotoxin concentrations remained unchanged from the previous visit (0.49 EU/mL [0.06], p = 0.45). Interpretation. Raised concentrations of endotoxin and cytokines are found in patients with chronic heart failure during acute oedematous exacerbation. Intensified diuretic treatment can normalise endotoxin concentrations. Our preliminary findings suggest that endotoxin may trigger immune activation in patients with chronic heart failure during oedematous episodes.	Natl Heart & Lung Inst, Imperial Coll Sch Med, London SW3 6LY, England; Univ Leipzig, Herzzentrum, Leipzig, Germany; Univ Klinikum Charite, Inst Med Immunol, Berlin, Germany; Harefield Hosp, Heart Sci Ctr, Harefield, Middx, England; Univ Klinikum Charite, Inst Mikrobiol & Hyg, Berlin, Germany; Max Delbruck Ctr Mol Med, Franz Volhard Klin, Berlin, Germany	Imperial College London; Heart Center Leipzig GMBH; Leipzig University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Anker, SD (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dovehouse St, London SW3 6LY, England.		volk, hans-dieter/AAV-8053-2021; Yen, Hsueh-Wei/A-1539-2010; Coats, Andrew J Stewart/E-4451-2012	volk, hans-dieter/0000-0002-7743-6668; Coats, Andrew J Stewart/0000-0002-2771-4260				Anker SD, 1997, J AM COLL CARDIOL, V30, P997, DOI 10.1016/S0735-1097(97)00262-3; Anker SD, 1998, QJM-MON J ASSOC PHYS, V91, P199, DOI 10.1093/qjmed/91.3.199; Anker SD, 1997, AM J CARDIOL, V79, P1426, DOI 10.1016/S0002-9149(97)00159-8; Anker SD, 1997, CIRCULATION, V96, P526; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Clark AL, 1996, J AM COLL CARDIOL, V28, P1092, DOI 10.1016/S0735-1097(96)00323-3; EGGESBO JB, 1994, CYTOKINE, V6, P521, DOI 10.1016/1043-4666(94)90080-9; GOMEZJIMENEZ J, 1995, CRIT CARE MED, V23, P253, DOI 10.1097/00003246-199502000-00009; Keel M, 1996, J TRAUMA, V41, P430, DOI 10.1097/00005373-199609000-00008; Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6; Lamping N, 1998, J CLIN INVEST, V101, P2065, DOI 10.1172/JCI2338; Lamping N, 1996, J IMMUNOL, V157, P4648; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Lew WYW, 1997, AM J PHYSIOL-HEART C, V272, pH2989, DOI 10.1152/ajpheart.1997.272.6.H2989; Munger MA, 1996, AM J CARDIOL, V77, P723, DOI 10.1016/S0002-9149(97)89206-5; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Sautner T, 1998, ANN SURG, V228, P239, DOI 10.1097/00000658-199808000-00014; SCHUMANN RR, 1990, SCIENCE, V249, P429; STARR RG, 1995, SHOCK, V3, P380; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TorreAmione G, 1996, CIRCULATION, V93, P704, DOI 10.1161/01.CIR.93.4.704; Vanderheyden M, 1998, EUR HEART J, V19, P747, DOI 10.1053/euhj.1997.0828; Vonhof S, 1998, INT J CARDIOL, V63, P237, DOI 10.1016/S0167-5273(97)00332-X; Wagner DR, 1998, CIRCULATION, V97, P521; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4	27	637	666	1	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1838	1842		10.1016/S0140-6736(98)09286-1	http://dx.doi.org/10.1016/S0140-6736(98)09286-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359409				2022-12-01	WOS:000080667800013
J	Marciano, DK; Russel, M; Simon, SM				Marciano, DK; Russel, M; Simon, SM			An aqueous channel for filamentous phage export	SCIENCE			English	Article							BACTERIAL OUTER MEMBRANES; PROTEIN SECRETION SYSTEMS; ESCHERICHIA-COLI; VIBRIO-CHOLERAE	Filamentous phage f1 exits its Escherichia coli host without killing the bacterial cell. It has been proposed that f1 is secreted through the outer membrane via a phage-encoded channel protein, pIV. A functional pIV mutant was isolated that allowed E. coli to grow on large maltodextrins and rendered E. coli sensitive to large hydrophilic antibiotics that normally do not penetrate the outer membrane. In planar lipid bilayers, both mutant and wild-type pIV formed highly conductive channels with similar permeability characteristics but different gating properties: the probability of the wild-type channel being open was much less than that of the mutant channel. The high conductivity of pIV channels suggests a large-diameter pore, thus implicating pIV as the outer membrane phage-conducting channel.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Russel, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.			Simon, Sanford/0000-0002-8615-4224; Marciano, Denise/0000-0003-0612-4664	NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULANGER P, 1988, J BIOL CHEM, V263, P9767; DELCOUR AH, 1991, J MEMBRANE BIOL, V119, P267, DOI 10.1007/BF01868731; EMR SD, 1982, J CELL BIOL, V95, P689, DOI 10.1083/jcb.95.3.689; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Linderoth NA, 1997, SCIENCE, V278, P1635, DOI 10.1126/science.278.5343.1635; MARCIANO DK, UNPUB; NIKAIDO H, 1992, MOL MICROBIOL, V6, P435, DOI 10.1111/j.1365-2958.1992.tb01487.x; Russel M, 1998, J MOL BIOL, V279, P485, DOI 10.1006/jmbi.1998.1791; Russel M, 1997, GENE, V192, P23, DOI 10.1016/S0378-1119(96)00801-3; SANDKVIST M, 1995, EMBO J, V14, P1664, DOI 10.1002/j.1460-2075.1995.tb07155.x; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STOCK JB, 1977, J BIOL CHEM, V252, P7850; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; WANDERSMAN C, 1979, J BACTERIOL, V140, P1; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x	16	84	91	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1516	1519		10.1126/science.284.5419.1516	http://dx.doi.org/10.1126/science.284.5419.1516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348737				2022-12-01	WOS:000080548100034
J	Karaolis, DKR; Somara, S; Maneval, DR; Johnson, JA; Kaper, JB				Karaolis, DKR; Somara, S; Maneval, DR; Johnson, JA; Kaper, JB			A bacteriophage encoding a pathogenicity island, a type-IV pilus and a phage receptor in cholera bacteria	NATURE			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; VIBRIO-CHOLERAE; FILAMENTOUS PHAGE; TOXR REGULON; PROTEIN; EVOLUTION; EXPRESSION; VIRULENCE; SECRETION; CLUSTER	The virulence properties of many pathogenic bacteria are due to proteins encoded by large gene clusters called pathogenicity islands(1,2), which are found in a variety of human pathogens including Escherichia coli, Salmonella, Shigella, Yersinia, Helicobacter pylori, Vibrio cholerae, and animal and plant pathogens such as Dichelobacter nodosus and Pseunomonas syringae(1-3). Although the presence of pathogenicity islands is a prerequisite for many bacterial diseases, little is known about their origins or mechanism of transfer into the bacterium. The bacterial agent of epidemic cholera, Vibrio cholerae, contains a bacteriophage known as cholera-toxin phage (CTX Phi)(4), which encodes the cholera toxin, and a large pathogenicity island called the VPI (for V. cholerae pathogenicity island)(5) which itself encodes a toxin-coregulated pilus that functions as a colonization factor(6) and as a CTX Phi receptor(4). We have now identified the VPI pathogenicity island as the genome of another filamentous bacteriophage, VPI Phi, We show that VPI Phi is transferred between V. cholerae strains and provide evidence that the TcpA subunit of the toxin-coregulated type IV pilus is in fact a coat protein of VPI Phi. Our results are the first description of a phage that encodes a receptor for another phage and of a virus-virus interaction that is necessary for bacterial pathogenicity.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Div Hosp Epidemiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; Maryland Hlth Care Syst, Dept Vet Affairs, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Karaolis, DKR (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA.	karaolis@umaryland.edu		Somara, Sita/0000-0001-7688-5560; Kaper, James/0000-0003-0715-2907				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Carroll PA, 1997, MOL MICROBIOL, V25, P1099, DOI 10.1046/j.1365-2958.1997.5371901.x; DALRYMPLE B, 1987, J MOL EVOL, V25, P261, DOI 10.1007/BF02100020; DIRITA VJ, 1991, P NATL ACAD SCI USA, V88, P5403, DOI 10.1073/pnas.88.12.5403; GIRON JA, 1991, SCIENCE, V254, P710, DOI 10.1126/science.1683004; Hacker J, 1997, MOL MICROBIOL, V23, P1089, DOI 10.1046/j.1365-2958.1997.3101672.x; Hase CC, 1998, P NATL ACAD SCI USA, V95, P730, DOI 10.1073/pnas.95.2.730; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hicks S, 1998, INFECT IMMUN, V66, P1570, DOI 10.1128/IAI.66.4.1570-1578.1998; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; HUANG HC, 1995, MOL PLANT MICROBE IN, V8, P733, DOI 10.1094/MPMI-8-0733; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; Karaolis DKR, 1998, P NATL ACAD SCI USA, V95, P3134, DOI 10.1073/pnas.95.6.3134; Kovach ME, 1996, MICROBIOL-SGM, V142, P2165, DOI 10.1099/13500872-142-8-2165; Lee CA, 1996, INFECT AGENT DIS, V5, P1; Maniatis T., 1982, MOL CLONING LAB MANU; MICHALSKI J, 1993, INFECT IMMUN, V61, P4462, DOI 10.1128/IAI.61.10.4462-4468.1993; PATEL P, 1991, INFECT IMMUN, V59, P4674, DOI 10.1128/IAI.59.12.4674-4676.1991; POLITZER R, 1959, MONOGR SER WHO, V43; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHAW CE, 1990, INFECT IMMUN, V58, P3042, DOI 10.1128/IAI.58.9.3042-3049.1990; TAYLOR R, 1988, VACCINE, V6, P151, DOI 10.1016/S0264-410X(88)80019-7; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910	24	285	309	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 27	1999	399	6734					375	379		10.1038/20715	http://dx.doi.org/10.1038/20715			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PA	10360577				2022-12-01	WOS:000080547800064
J	Goldie, SJ; Kuntz, KM; Weinstein, MC; Freedberg, KA; Welton, ML; Palefsky, JM				Goldie, SJ; Kuntz, KM; Weinstein, MC; Freedberg, KA; Welton, ML; Palefsky, JM			The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	12th World AIDS Conference	JUN 28-JUL 03, 1998	GENEVA, SWITZERLAND				HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-PAPILLOMAVIRUS INFECTION; CELL CARCINOMA; RISK-FACTORS; CYTOLOGIC ABNORMALITIES; ANTIRETROVIRAL THERAPY; CANCER INCIDENCE; NEOPLASIA; ASSOCIATION; DYSPLASIA	Context Homosexual and bisexual men infected with human immunodeficiency virus (HIV) are at increased risk for human papillomavirus-related anal neoplasia and anal squamous cell carcinoma (SCC). Objective To estimate the clinical benefits and cost-effectiveness of screening HIV-positive homosexual and bisexual men for anal squamous intraepithelial lesions (ASIL) and anal SCC. Design Cost-effectiveness analysis performed from a societal perspective that used reference case recommendations from the Panel on Cost-Effectiveness in Health and Medicine. A state-transition Markov model was developed to calculate lifetime costs, life expectancy, and quality-adjusted life expectancy for no screening vs several screening strategies for ASIL and anal SCC using anal Papanicolaou (Pap) testing at different intervals. Values for incidence, progression, and regression of anal neoplasia; efficacy of screening and treatment; natural history of HIV; health-related quality of life; and costs were obtained from the literature, Setting and Participants Hypothetical cohort of homosexual and bisexual HIV-positive men living in the United States. Main Outcome Measures Life expectancy, quality-adjusted life expectancy, quality-adjusted years of life saved, lifetime costs, and incremental cost-effectiveness ratio. Results Screening for ASIL increased quality-adjusted life expectancy at all stages of HIV disease. Screening with anal Pap tests every 2 years, beginning in early HIV disease (CD4 cell count >0.50 x 10(9)/L), resulted in a 2.7-month gain in quality-adjusted life expectancy for an incremental cost-effectiveness ratio of $13 000 per quality-adjusted life year saved. Screening with anal Pap tests yearly provided additional benefit at an incremental cost of $16 600 per quality-adjusted life year saved. If screening was not initiated until later in the course of HIV disease (CD4 cell count <0.50 x 10(9)/L), then yearly Pap test screening was preferred due to the greater amount of prevalent anal disease (cost-effectiveness ratio of less than $25 000 per quality-adjusted life year saved compared with no screening). Screening every 6 months provided little additional benefit over that of yearly screening. Results were most sensitive to the rate of progression of ASIL to anal SCC and the effectiveness of treatment of precancerous lesions. Conclusions Screening HIV-positive homosexual and bisexual men for ASIL and anal SCC with anal Pap tests offers quality-adjusted life expectancy benefits at a cost comparable with other accepted clinical preventive interventions.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Risk Anal, Boston, MA 02115 USA; Boston Univ, Sch Med, Gen Internal Med Sect, Clin Econ Res Unit, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Clin AIDS Program, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Epidemiol & Biostat, Boston Med Ctr,Evans Med Fdn, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med & Med, San Francisco, CA 94143 USA	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston University; Boston Medical Center; Boston University; Boston University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goldie, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Risk Anal, 718 Huntington Ave,Suite 2, Boston, MA 02115 USA.	sgoldie@hsph.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA054053] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000079] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA054053, R01-CA 54053] Funding Source: Medline; NCRR NIH HHS [5 M01-RR-00079] Funding Source: Medline; PHS HHS [U64/CCU114927-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AIDS, 1994, NAT TECHN INF SERV P; Aynaud O, 1998, SEX TRANSM INFECT, V74, P32, DOI 10.1136/sti.74.1.32; BERK ML, 1993, AHCPR PUBLICATION; Bottomley D M, 1996, Clin Oncol (R Coll Radiol), V8, P319, DOI 10.1016/S0936-6555(05)80720-4; CARDINALE V, 1997, DRUG TOPICS RED BOOK; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; CELENTANO D P, 1989, Public Health Reviews, V17, P173; CHADHA M, 1994, DIS COLON RECTUM, V37, P861, DOI 10.1007/BF02052589; Condra JH, 1998, ANN INTERN MED, V128, P951, DOI 10.7326/0003-4819-128-11-199806010-00017; Cornelius L, 1991, AHCPR PUBLICATION; CRITCHLOW CW, 1995, AIDS, V9, P1255, DOI 10.1097/00002030-199511000-00007; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; DANIEL GL, 1994, DIS COLON RECTUM, V37, P670, DOI 10.1007/BF02054410; DERUITER A, 1994, GENITOURIN MED, V70, P22; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FORTI RL, 1995, CLIN INFECT DIS, V21, P603, DOI 10.1093/clinids/21.3.603; FRAZER IH, 1986, LANCET, V2, P657; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Gold MR., 1996, COST EFFECTIVENESS H; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HAYE KR, 1988, GENITOURIN MED, V64, P378; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOLLAND JM, 1994, RADIOLOGY, V193, P251, DOI 10.1148/radiology.193.1.8090901; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HSIAO WC, 1988, JAMA-J AM MED ASSOC, V260, P2347, DOI 10.1001/jama.260.16.2347; Jay N, 1997, DIS COLON RECTUM, V40, P919, DOI 10.1007/BF02051199; KIVIAT NB, 1993, AIDS, V7, P43, DOI 10.1097/00002030-199301000-00007; Koblin BA, 1996, AM J EPIDEMIOL, V144, P916, DOI 10.1093/oxfordjournals.aje.a008861; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; LAW CLH, 1991, GENITOURIN MED, V67, P92; LONGINI IM, 1991, J ACQ IMMUN DEF SYND, V4, P1141; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; LONGO WE, 1994, ANN SURG, V220, P40, DOI 10.1097/00000658-199407000-00007; MELBYE M, 1994, AM J EPIDEMIOL, V139, P772, DOI 10.1093/oxfordjournals.aje.a117073; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; MENDENHALL WM, 1994, SURG ONCOL, V3, P135, DOI 10.1016/0960-7404(94)90042-6; *NAT CANC I, 1998, SEER CANC STAT REV; *NAT TECHN INF SER, 1995, MULT AIDS COH STUD M; Northfelt DW, 1996, HEMATOL ONCOL CLIN N, V10, P1177, DOI 10.1016/S0889-8588(05)70392-0; Palefsky JM, 1997, J ACQ IMMUN DEF SYND, V14, P415, DOI 10.1097/00042560-199704150-00004; PALEFSKY JM, 1994, J ACQ IMMUN DEF SYND, V7, P599; PALEFSKY JM, 1994, AIDS, V8, P283, DOI 10.1097/00002030-199403000-00001; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P314, DOI 10.1097/00042560-199804010-00004; PALEFSKY JM, 1995, CANCER EPIDEM BIOMAR, V4, P415; Palefsky JM, 1998, AIDS, V12, P495, DOI 10.1097/00002030-199805000-00011; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P320, DOI 10.1097/00042560-199804010-00005; PALEFSKY JM, 1992, J ACQ IMMUN DEF SYND, V5, P1258; Palefsky Joel, 1995, Current Opinion in Oncology, V7, P437, DOI 10.1097/00001622-199509000-00009; Peddada AV, 1997, INT J RADIAT ONCOL, V37, P1101, DOI 10.1016/S0360-3016(96)00596-2; Qualters J R, 1992, MMWR CDC Surveill Summ, V41, P1; Sayers SJ, 1998, INT J STD AIDS, V9, P37, DOI 10.1258/0956462981921017; SEGAL MJ, 1997, MED RBRVS PHYSICIANS; SHERMAN ME, 1995, MODERN PATHOL, V8, P270; SONNEX C, 1991, GENITOURIN MED, V67, P21; SURAWICZ CM, 1995, AM J GASTROENTEROL, V90, P1776; SURAWICZ CM, 1993, GASTROENTEROLOGY, V105, P658, DOI 10.1016/0016-5085(93)90880-L; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; Tsevat J, 1996, MED CARE, V34, P44, DOI 10.1097/00005650-199601000-00004; U.S. Bureau of the Census, 1997, STAT ABSTR US, V117th; Unger ER, 1997, ARCH PATHOL LAB MED, V121, P820; WEXNER SD, 1987, DIS COLON RECTUM, V30, P942, DOI 10.1007/BF02554281	68	282	293	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1822	1829		10.1001/jama.281.19.1822	http://dx.doi.org/10.1001/jama.281.19.1822			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	196BH	10340370	Bronze			2022-12-01	WOS:000080288800036
J	Levin, TR; Palitz, A; Grossman, S; Conell, C; Finkler, L; Ackerson, L; Rumore, G; Selby, JV				Levin, TR; Palitz, A; Grossman, S; Conell, C; Finkler, L; Ackerson, L; Rumore, G; Selby, JV			Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FECAL OCCULT BLOOD; COLORECTAL-CANCER; FLEXIBLE SIGMOIDOSCOPY; PATIENT PREFERENCES; HYPERPLASTIC POLYPS; COLONOSCOPY; ADENOMAS; RISK; MORTALITY; HISTORY	Context Indications are not well defined for follow-up colonoscopy for all patients with distal colonic tubular adenomas (TAs) found at screening sigmoidoscopy, Objective To determine whether distal adenoma size, number, and villous histology, along with family history and age, are predictors of advanced proximal colonic neoplasia, Design Cross-sectional analysis conducted between January 1, 1994, and December 31, 1995. Setting Large group-model hearth maintenance organization in northern California. Patients A total of 2972 asymptomatic subjects aged 50 years or older undergoing colonoscopy as follow-up to a screening sigmoidoscopy. Main Outcome Measure Based on sigmoidoscopy, colonoscopy, and pathology reports, occurrence of advanced proximal neoplasia, defined as adenocarcinoma or TAs 1 cm or larger or with villous features or severe dysplasia located beyond sigmoidoscopic view. Results The prevalence of advanced proximal neoplasia was similar among patients with no TAs at sigmoidoscopy, those with TAs less than 1 cm in diameter, and those with TAs 1 cm in diameter or larger (prevalence, 5.3%, 5.5%, and 5.6%, respectively). Of patients with a distal tubulovillous or villous adenoma, 12.1% had advanced proximal neoplasia. In multivariate analyses, having a distal tubulovillous adenoma or villous adenoma was the strongest predictor of advanced proximal neoplasia (odds ratio, 2.30; 95% confidence interval, 1.69-3.14). Age of 65 years or older, having more than 1 adenoma, and a positive family history of colorectal cancer were also significant predictors. Distal adenoma size was not a significant predictor in any multivariate analyses. Conclusions Advanced proximal neoplasia is not uncommon in subjects with or without distal TAs, but subjects with advanced distal histology and those older than 65 years are at increased risk. Age-specific screening using sigmoidoscopy starting at ages 50 to 55 years and colonoscopy after age 65 years may be justified.	Univ Calif San Francisco, Sch Med, GI Unit, Dept Med,Div Gastroenterol, San Francisco, CA 94143 USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Kaiser Permanente Med Ctr, Dept Pathol, Oakland, CA USA; Kaiser Permanente Med Ctr, Dept Med Gastroenterol, Martinez, CA USA	University of California System; University of California San Francisco; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Levin, TR (corresponding author), Univ Calif San Francisco, Sch Med, GI Unit, Dept Med,Div Gastroenterol, Room S-357,Box 0538, San Francisco, CA 94143 USA.							ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BRADY PG, 1993, GASTROINTEST ENDOSC, V39, P481, DOI 10.1016/S0016-5107(93)70155-8; CHURCH JM, 1988, DIS COLON RECTUM, V31, P50, DOI 10.1007/BF02552570; COOPER GS, 1995, CANCER, V75, P775, DOI 10.1002/1097-0142(19950201)75:3<775::AID-CNCR2820750305>3.0.CO;2-D; DINNING JP, 1994, ARCH INTERN MED, V154, P853, DOI 10.1001/archinte.154.8.853; Dominitz JA, 1997, AM J GASTROENTEROL, V92, P2171; Gopalswamy N, 1997, GASTROINTEST ENDOSC, V46, P497, DOI 10.1016/S0016-5107(97)70003-8; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; Jass JR, 1989, HISTOLOGICAL TYPING; KORETZ RL, 1993, ANN INTERN MED, V118, P63, DOI 10.7326/0003-4819-118-1-199301010-00011; Leard LE, 1997, J FAM PRACTICE, V45, P211; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; Marshall JR, 1996, GASTROENTEROLOGY, V111, P1411, DOI 10.1016/S0016-5085(96)70001-X; Mueller Astrid D., 1995, Archives of Internal Medicine, V155, P1741; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; Palitz A M, 1997, HMO Pract, V11, P5; PROVENZALE D, 1990, ANN INTERN MED, V113, P760, DOI 10.7326/0003-4819-113-10-760; Read TE, 1997, NEW ENGL J MED, V336, P8, DOI 10.1056/NEJM199701023360102; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; Schoen RE, 1997, GASTROINTEST ENDOSC, V46, P492, DOI 10.1016/S0016-5107(97)70002-6; Schoen RE, 1998, GASTROENTEROLOGY, V115, P533, DOI 10.1016/S0016-5085(98)70132-5; Sciallero S, 1997, GASTROINTEST ENDOSC, V46, P124, DOI 10.1016/S0016-5107(97)70059-2; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIMON JB, 1993, ANN INTERN MED, V118, P71, DOI 10.7326/0003-4819-118-1-199301010-00013; Slattery ML, 1996, CANCER, V78, P1666, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1666::AID-CNCR5>3.0.CO;2-C; Steinberg D, 1995, CART TREE STRUCTURED; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; Wagner JL, 1996, PREVENTION EARLY DET, P321; Wallace MB, 1998, ANN INTERN MED, V129, P273, DOI 10.7326/0003-4819-129-4-199808150-00002; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WOLF SH, 1996, US PREVENTIVE SERVIC, P89; ZARCHY TM, 1994, GASTROENTEROLOGY, V106, P1501, DOI 10.1016/0016-5085(94)90403-0	33	145	149	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1611	1617		10.1001/jama.281.17.1611	http://dx.doi.org/10.1001/jama.281.17.1611			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235154	Bronze			2022-12-01	WOS:000080025900025
J	Schmidt, G; Malik, M; Barthel, P; Schneider, R; Ulm, K; Rolnitzky, L; Camm, AJ; Bigger, JT; Schomig, A				Schmidt, G; Malik, M; Barthel, P; Schneider, R; Ulm, K; Rolnitzky, L; Camm, AJ; Bigger, JT; Schomig, A			Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction	LANCET			English	Article							RATE-VARIABILITY; EJECTION FRACTION; ARRHYTHMIC EVENTS; RISK; DYSFUNCTION; SURVIVORS	Background Identification of high-risk patients after acute myocardial infarction is essential for successful prophylactic therapy. The predictive accuracy of currently used risk predictors is modest even when several factors are combined. Thus, establishment of a new powerful method for risk prediction independent of the available stratifiers is of considerable practical value, Methods The study investigated fluctuations of sinus-rhythm cycle length after a single ventricular premature beat recorded in Holter electrocardiograms, and characterised the fluctuations (termed heart-rate turbulence) by two numerical parameters, termed turbulence onset and slope. The method was developed on a population of 100 patients with coronary heart disease and blindly applied to the population of the Multicentre Post-Infarction Program (MPIP; 577 survivors of acute infarction, 75 deaths during a median follow-up of 22 months) and to the placebo population of the European Myocardial Amiodarone Trial (EMIAT; 614 survivors of acute myocardial infarction, 87 deaths during median follow-up of 21 months). Multivariate risk stratification was done with the new parameters and conventional risk factors. Findings One of the new parameters (turbulence slope) was the most powerful stratifier of follow-up mortality in EMIAT and the second most powerful stratifier in MPIP: MPIP risk ratio 3.5 (95% CI 2.2-5.5, p<0.0001), EMIAT risk ratio 2.7 1.8-4.2, p<0.0001), In the multivariate analysis, low left-ventricular ejection fraction and turbulence slope were the only independent variables for mortality prediction in MPIP (p<0.001), whereas in EMIAT, five variables were independent mortality predictors: abnormal turbulence onset, abnormal turbulence slope, history of previous infarction, low left-ventricular ejection fraction, and high mean heart rate (p<0.001). In both MPIP and EMIAT, the combination of abnormal onset and slope was the most powerful multivariate risk stratifier: MPIP risk ratio 3.2 (1.7-6.0, p<0.0001), EMIAT risk ratio 3.2 (1.8-5.6, p<0.0001). Interpretation The absence of the heart rate turbulence after ventricular premature beats is a very potent postinfarction risk stratifier that is independent of other known risk factors and which is stronger than other presently available risk predictors.	Tech Univ Munich, Erste Med Klin, D-81675 Munich, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-81675 Munich, Germany; St George Hosp, Sch Med, Dept Cardiol Sci, London, England; Columbia Univ, Dept Med, Div Cardiol, New York, NY USA	Technical University of Munich; Technical University of Munich; St Georges University London; Columbia University	Schmidt, G (corresponding author), Tech Univ Munich, Erste Med Klin, Ismaniger Str 22, D-81675 Munich, Germany.	gschmidt@med1.med.tu-muenchen.de	Schneider, Raphaël/K-5446-2013; Schmidt, Georg/D-3711-2009	Schneider, Raphaël/0000-0002-6870-6902; Schmidt, Georg/0000-0003-3692-5243; Schneider, Raphael/0000-0001-7754-5840				[Anonymous], 1997, Ann Intern Med, V126, P556; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BREIMANN L, 1984, CLASSIFICATION REGRE; Camm AJ, 1996, CIRCULATION, V93, P1043; CHUNG EK, 1970, CARDIOLOGY, V55, P65, DOI 10.1159/000169268; Copie X, 1996, J AM COLL CARDIOL, V27, P270, DOI 10.1016/0735-1097(95)00454-8; Corr PB, 1986, HEART CARDIOVASCULAR, P1343; COX DR, 1972, J R STAT SOC B, V34, P187; DOHLEMANN C, 1979, Z KARDIOL, V68, P557; ERLANGER J, 1909, HEART, V1, P177; HASHIMOTO K, 1967, CIRC RES, V21, P297, DOI 10.1161/01.RES.21.3.297; HECHT AF, 1914, WIEN MED WCHNSCHR, V64, P178; JEDLICKA J, 1987, EUR HEART J, V8, P762, DOI 10.1093/eurheartj/8.7.762; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; KAPPAGODA CT, 1972, J PHYSIOL-LONDON, V225, P705, DOI 10.1113/jphysiol.1972.sp009965; KAPPAGODA CT, 1972, J PHYSIOL-LONDON, V220, P177, DOI 10.1113/jphysiol.1972.sp009700; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300; LOWN B, 1976, NEW ENGL J MED, V294, P1165; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MOSS AJ, 1977, AM J CARDIOL, V39, P635, DOI 10.1016/S0002-9149(77)80122-7; ODEMUYIWA O, 1991, AM J CARDIOL, V68, P434, DOI 10.1016/0002-9149(91)90774-F; Parsonnet AE, 1944, AM HEART J, V27, P676, DOI 10.1016/S0002-8703(44)90923-3; Redwood SR, 1997, EUR HEART J, V18, P1278; ROSENBAUM MB, 1955, CIRCULATION, V11, P240, DOI 10.1161/01.CIR.11.2.240; ROTH IR, 1948, AM HEART J, V36, P257, DOI 10.1016/0002-8703(48)90405-0; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; Schmidt G, 1996, PACE, V19, P976; SIMSON MB, 1981, CIRCULATION, V64, P235, DOI 10.1161/01.CIR.64.2.235; Skanes AC, 1998, CIRCULATION, V97, P2245, DOI 10.1161/01.CIR.97.22.2245; Wenckebach KF., 1927, UNREGELMASSIGE HERZT	32	566	641	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	1999	353	9162					1390	1396		10.1016/S0140-6736(98)08428-1	http://dx.doi.org/10.1016/S0140-6736(98)08428-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227219				2022-12-01	WOS:000080020800011
J	Wallace, EM; Baker, LS				Wallace, EM; Baker, LS			Effect of antenatal betamethasone administration on placental vascular resistance	LANCET			English	Article							CORTICOTROPIN-RELEASING HORMONE; DOPPLER WAVE-FORMS; UMBILICAL ARTERY; FLOW VELOCITY; FETAL SHEEP; PLASMA; PREGNANCY	Background High placental vascular resistance is an important cause of fetal growth restriction and subsequent perinatal mortality. Identification of affected pregnancies allows appropriate fetal surveillance and delivery, but there are no known therapeutic strategies to decrease resistance and improve blood flow. However, placental corticotropin-releasing hormone (CRH) is thought to be a potent fetoplacental vasodilator, and exogenous corticosteroids can increase placental CRH secretion. Therefore, we examined whether corticosteroids could improve fetoplacental blood flow in pregnancies with increased vascular resistance. Methods A retrospective review of umbilical-artery flow-velocity waveforms (FVWs) before and after betamethasone administration was undertaken in pregnancies with increased placental vascular resistance, as shown by umbilical-artery absent end-diastolic flow (AEDF). FVWs were obtained by pulsed-wave doppler ultrasonography. We studied all 28 pregnancies monitored at the maternal-fetal medicine unit of a university teaching hospital since 1995. Findings The median duration of gestation at presentation with AEDF was 27 weeks (range 23-33). In 19 (68% [95% CI 49-86]) pregnancies, umbilical-artery diastolic flow returned within 24 h after betamethasone administration, consistent with decreased resistance. The median duration of this effect was 3 days (range 2-7). There were no differences in duration of gestation at diagnosis or delivery, or in birthweight between fetuses showing a return of flow after betamethasone and those not showing a return of flow. Interpretation In pregnancies with umbilical-artery AEDF, betamethasone treatment is associated with decreased placental vascular resistance, possibly induced via increased placental CRH secretion. This study does not provide insights into whether this effect would be beneficial or harmful to the fetus.	Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; Monash Med Ctr, Maternal Fetal Med Unit, Clayton, Vic 3168, Australia	Monash University; Monash University	Wallace, EM (corresponding author), Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia.		Wallace, Euan M/K-6774-2015	Wallace, Euan M/0000-0002-4506-5233				BEATTIE RB, 1989, BRIT MED J, V298, P631, DOI 10.1136/bmj.298.6674.631; Bisits A, 1998, AM J OBSTET GYNECOL, V178, P862; Burns PN, 1987, DOPPLER ULTRASOUND M, P43; CHALLIS JRG, 1995, PLACENTA, V16, P481, DOI 10.1016/S0143-4004(05)80001-3; CLIFTON VL, 1995, J CLIN ENDOCR METAB, V80, P2888, DOI 10.1210/jc.80.10.2888; CLIFTON VL, 1994, J CLIN ENDOCR METAB, V79, P666, DOI 10.1210/jc.79.2.666; Cohlen BJ, 1996, ULTRASOUND OBST GYN, V8, P252, DOI 10.1046/j.1469-0705.1996.08040252.x; Derks JB, 1997, J PHYSIOL-LONDON, V499, P217, DOI 10.1113/jphysiol.1997.sp021922; Giles W, 1997, OBSTET GYNECOL, V89, P49, DOI 10.1016/S0029-7844(96)00371-7; GILES W, 1992, LANCET, V340, P856, DOI 10.1016/0140-6736(92)92737-Z; Giles WB, 1996, OBSTET GYNECOL, V87, P107, DOI 10.1016/0029-7844(95)00338-X; GILES WB, 1985, BRIT J OBSTET GYNAEC, V92, P31, DOI 10.1111/j.1471-0528.1985.tb01045.x; GOLAND RS, 1993, J CLIN ENDOCR METAB, V77, P1174, DOI 10.1210/jc.77.5.1174; GUARAN RL, 1994, AUST NZ J OBSTET GYN, V34, P39, DOI 10.1111/j.1479-828X.1994.tb01037.x; HARPER A, 1991, BRIT J OBSTET GYNAEC, V98, P453, DOI 10.1111/j.1471-0528.1991.tb10339.x; KARI MA, 1994, PEDIATRICS, V93, P730; KARSDORP VHM, 1994, LANCET, V344, P1164; Kingdom JCP, 1997, ULTRASOUND OBST GYN, V9, P271, DOI 10.1046/j.1469-0705.1997.09040271.x; Korebrits C, 1998, BRIT J OBSTET GYNAEC, V105, P556, DOI 10.1111/j.1471-0528.1998.tb10158.x; Krebs C, 1996, AM J OBSTET GYNECOL, V175, P1534, DOI 10.1016/S0002-9378(96)70103-5; Marinoni E, 1998, AM J OBSTET GYNECOL, V178, P770, DOI 10.1016/S0002-9378(98)70490-9; MCCOWAN LM, 1987, AM J OBSTET GYNECOL, V157, P900, DOI 10.1016/S0002-9378(87)80082-0; MORROW RJ, 1989, AM J OBSTET GYNECOL, V161, P1055, DOI 10.1016/0002-9378(89)90783-7; NEILSON JP, 1998, PREGNANCY CHILDBIRTH; NICOLAIDES KH, 1988, BRIT MED J, V297, P1026, DOI 10.1136/bmj.297.6655.1026; ROBINSON BG, 1988, P NATL ACAD SCI USA, V85, P5244, DOI 10.1073/pnas.85.14.5244; THOMPSON RS, 1988, BRIT J OBSTET GYNAEC, V95, P581, DOI 10.1111/j.1471-0528.1988.tb09487.x; WOLFE CDA, 1988, BRIT J OBSTET GYNAEC, V95, P1003, DOI 10.1111/j.1471-0528.1988.tb06504.x	28	93	94	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1404	1407		10.1016/S0140-6736(98)08229-4	http://dx.doi.org/10.1016/S0140-6736(98)08229-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227222				2022-12-01	WOS:000080020800014
J	Straight, AF; Shou, WY; Dowd, GJ; Turck, CW; Deshaies, RJ; Johnson, AD; Moazed, D				Straight, AF; Shou, WY; Dowd, GJ; Turck, CW; Deshaies, RJ; Johnson, AD; Moazed, D			Net1, a Sir2-associated nucleolar protein required for rDNA silencing and nucleolar integrity	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; TRANSCRIPTIONAL STATES; BINDING-PROTEIN; RIBOSOMAL DNA; BUDDING YEAST; COMPLEX; SIR2; EXPRESSION; LOCI	The Sir2 protein mediates gene silencing and repression of recombination at the rDNA repeats in budding yeast. Here we show that Sir2 executes these functions as a component of a nucleolar complex designated RENT (regulator of nucleolar silencing and telophase exit). Net1, a core subunit of this complex, preferentially cross-links to the rDNA repeats, but not to silent DNA regions near telomeres or to active genes, and tethers the RENT complex to rDNA. Net1 is furthermore required for rDNA silencing and nucleolar integrity. During interphase, Net1 and Sir2 colocalize to a subdomain within the nucleolus, but at the end of mitosis a fraction of Sir2 leaves the nucleolus and disperses as fool throughout the nucleus, suggesting that the structure of rDNA silent chromatin changes during the cell cycle. Our findings suggest that a protein complex shown to regulate exit from mitosis is also involved in gene silencing.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Calif San Francisco, Dept Microbiol, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Harvard University; Harvard Medical School; California Institute of Technology; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Moazed, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	danesh@hms.harvard.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354; Straight, Aaron/0000-0001-5885-7881; Shou, Wenying/0000-0001-5693-381X				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; DeRubertis F, 1996, NATURE, V384, P589; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GRANOT D, 1991, CELL MOTIL CYTOSKEL, V20, P47, DOI 10.1002/cm.970200106; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; HALFTER H, 1989, EMBO J, V8, P4265, DOI 10.1002/j.1460-2075.1989.tb08612.x; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KLAR AJS, 1979, GENETICS, V93, P37; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Park H, 1999, YEAST, V15, P35, DOI 10.1002/(SICI)1097-0061(19990115)15:1<35::AID-YEA340>3.3.CO;2-I; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; PRINGLE J R, 1991, P565; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RHODE PR, 1999, GENE DEV, V3, P1926; RINE J, 1987, GENETICS, V116, P9; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cellbio.11.1.93; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1998, GENETICS, V149, P1205; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; Woolford J. L., 1991, MOL CELLULAR BIOL YE, P587	49	323	327	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 16	1999	97	2					245	256		10.1016/S0092-8674(00)80734-5	http://dx.doi.org/10.1016/S0092-8674(00)80734-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	187GY	10219245	Bronze			2022-12-01	WOS:000079779800013
J	Westerman, AM; Entius, MM; de Baar, E; Boor, PPC; Koole, R; van Velthuysen, MLF; Offerhaus, GJA; Lindhout, D; de Rooij, FWM; Wilson, JHP				Westerman, AM; Entius, MM; de Baar, E; Boor, PPC; Koole, R; van Velthuysen, MLF; Offerhaus, GJA; Lindhout, D; de Rooij, FWM; Wilson, JHP			Peutz-Jeghers syndrome: 78-year follow-up of the original family	LANCET			English	Article							LOCALIZATION; KINASE	Background The association between heredity, gastrointestinal polyposis, and mucocutaneous pigmentation in Peutz-Jeghers syndrome (PJS) was first recognised in 1921 by Peutz in a Dutch family. This original family has now been followed-up for more than 78 years. We did mutation analysis in this family to test whether the recently identified LKB1 gene is indeed the PJS gene in this family. Methods The original family was retraced and the natural history of PJS was studied in six generations of this kindred by interview, physical examination, chart view, and histological review of tissue specimens. DNA-mutation analysis was done in all available descendants. Findings Clinical features in this family included gastrointestinal polyposis, mucocutaneous pigmentation, nasal polyposis, and rectal extrusion of polyps. Survival of affected family members was reduced by intestinal obstruction and by the development of malignant disease. A novel germline mutation in the LKB1 gene was found to cosegregate with the disease phenotype in the original family. The mutant LKB1 allele carried a T insertion at codon 66 in exon 1 resulting in frameshift and stop at codon 162 in exon 4. Interpretation The morbidity and mortality in this family suggest that PJS is not a benign disease. An inactivating germline mutation in the LKB1 gene is involved in the PJS phenotype in the original and oldest kindred known to be affected by PJS.	Univ Hosp Dijkzigt, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands; Erasmus Univ, MGC Dept Clin Genet, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Erasmus University Rotterdam	Wilson, JHP (corresponding author), Univ Hosp Dijkzigt, Dept Internal Med 2, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.		Lindhout, Dick/AAH-5765-2019; van Velthuysen, Marie-Louise/AAG-4895-2019	van Velthuysen, Marie-Louise/0000-0003-0435-9494; Lindhout, Dick/0000-0001-9580-624X				BARTHOLOMEW LG, 1957, GASTROENTEROLOGY, V32, P434; BARTHOLOMEW LG, 1962, SURG GYNECOL OBSTET, V115, P1; Cerqua N, 1993, Acta Otorhinolaryngol Ital, V13, P333; DEFACQ L, 1995, AM J GASTROENTEROL, V90, P1330; FARMER RG, 1963, AM J DIG DIS, V8, P953, DOI 10.1007/BF02232093; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; JANCU J, 1971, AM J GASTROENTEROL, V56, P545; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; LAMESCH AJ, 1983, DIS COLON RECTUM, V26, P452, DOI 10.1007/BF02556525; MANDEGOLD BC, 1969, MED WELT, V25, P1435; MORENS DM, 1975, AM J DIS CHILD, V129, P973, DOI 10.1001/archpedi.1975.02120450077019; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEARA MJF, 1995, J PEDIATR-US, V126, P965; TOVAR JA, 1983, J PEDIATR SURG, V18, P1, DOI 10.1016/S0022-3468(83)80262-0; van Wijk Th W, 1950, THESIS LEIDEN NETHER; Westerman AM, 1997, J CLIN GASTROENTEROL, V25, P387, DOI 10.1097/00004836-199707000-00023; YOUNG RH, 1982, CANCER, V50, P1384, DOI 10.1002/1097-0142(19821001)50:7<1384::AID-CNCR2820500726>3.0.CO;2-5	24	93	104	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1211	1215		10.1016/S0140-6736(98)08018-0	http://dx.doi.org/10.1016/S0140-6736(98)08018-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217080				2022-12-01	WOS:000079744100008
J	Berger, A				Berger, A			Rational drug design for Alzheimer's disease - Science commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																		Farlow MR, 1998, NEUROLOGY, V51, pS36, DOI 10.1212/WNL.51.1_Suppl_1.S36	1	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 6	1999	318	7184					639	640						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JD	10215361				2022-12-01	WOS:000079089200027
J	Emery, J; Walton, R; Coulson, A; Glasspool, D; Ziebland, S; Fox, J				Emery, J; Walton, R; Coulson, A; Glasspool, D; Ziebland, S; Fox, J			Computer support for recording and interpreting family histories of breast and ovarian cancer in primary care (RAGs): qualitative evaluation with simulated patients	BRITISH MEDICAL JOURNAL			English	Article							EXPERT-SYSTEMS; TECHNOLOGY; KNOWLEDGE; PROFORMA; GENETICS; SERVICES	Objectives To explore general practitioners' attitudes ton ards and use of a computer program for assessing genetic risk of cancer in primary care. Design Qualitative analysis of semistructured interviews and video recordings of simulated consultations. Participants Purposive sample of 15 general practitioners covering a range of computer literacy; interest in genetics, age, and sex. Interventions Each doctor used the program in two consultations in which an actor played a woman concerned about her family history of cancer. Consultations were videotaped and followed by interviews with the video as a prompt to questioning, Main outcome measures Use of computer program in the consultation. Results The program was viewed as an appropriate application of information technology because of the complexity of cancer genetics and a sense of "guideline chaos" in primary care. Doctors found the program easy to use, but it often affected their control of the consultation. They needed to balance their desire to share the computer screen with the patient, driven by their concerns about the effect of the computer on doctor-patient communication against the risk of premature disclosure of bad news. Conclusions This computer program could provide the necessary. support to assist assessment of genetic risk of cancer in primary care. The potential impact of computer software on the consultation should not be underestimated. This study highlights the need for careful evaluation when developing medical information systems.	Inst Hlth Sci, Div Publ Hlth & Primary Care, Gen Practice Res Grp, Imperial Canc Res Fund, Oxford OX3 7LF, England; Imperial Canc Res Fund, Adv Computat Lab, London WC2A 3PX, England	University of Oxford; Cancer Research UK	Emery, J (corresponding author), Inst Hlth Sci, Div Publ Hlth & Primary Care, Gen Practice Res Grp, Imperial Canc Res Fund, Oxford OX3 7LF, England.			Ziebland, Sue/0000-0002-6496-4859				ARBORELIUS E, 1991, Scandinavian Journal of Primary Health Care, V9, P71, DOI 10.3109/02813439109026587; *CANC RES CAMP, 1998, 1 CRC; EMERY J, IN PRESS BR J GEN PR; ERIKSON F, 1982, SOCIOL METHOD RES, V11, P213; Fischer C, 1996, HUM GENET, V97, P129, DOI 10.1007/BF02265253; Fox J, 1998, ARTIF INTELL MED, V14, P157, DOI 10.1016/S0933-3657(98)00021-9; Fox J, 1997, COMPUT METH PROG BIO, V54, P59, DOI 10.1016/S0169-2607(97)00034-5; Friedman C.P., 1997, EVALUATION METHODS M, P41; FRY A, IN PRESS FAM PRACT; GREATBATCH D, 1995, FAM PRACT, V12, P32, DOI 10.1093/fampra/12.1.32; Harris R, 1996, J MED GENET, V33, P346, DOI 10.1136/jmg.33.4.346; HARRIS R, 1995, BRIT MED J, V311, P275; Heathfield H, 1998, BRIT MED J, V316, P1959, DOI 10.1136/bmj.316.7149.1959; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kinmonth AL, 1998, BMJ-BRIT MED J, V316, P767, DOI 10.1136/bmj.316.7133.767; Mays N, 1996, QUALITATIVE RES HLTH; OHAGAN JJ, 1986, NEW ZEAL MED J, V99, P948; Patton M.Q., 1990, QUALITATIVE RES EVAL, V2nd ed.; Ridsdale L, 1997, SCAND J PRIM HEALTH, V15, P180, DOI 10.3109/02813439709035024; *ROYAL COLL GEN PR, 1998, 77 ROYAL COLL GEN PR; Silverman D., 2020, INTERPRETING QUALITA, V6th ed.; Strauss A., 1998, BASICS QUALITATIVE R; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; Timpka T, 1994, Artif Intell Med, V6, P501, DOI 10.1016/0933-3657(94)90027-2; Walton RT, 1997, BRIT MED J, V315, P791; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; 1997, QSR NUD IST PROGRAM	27	61	62	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					32	36		10.1136/bmj.319.7201.32	http://dx.doi.org/10.1136/bmj.319.7201.32			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390458	Green Published, Bronze			2022-12-01	WOS:000081326500032
J	Lohmann, V; Korner, F; Koch, JO; Herian, U; Theilmann, L; Bartenschlager, R				Lohmann, V; Korner, F; Koch, JO; Herian, U; Theilmann, L; Bartenschlager, R			Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line	SCIENCE			English	Article							CDNA CLONE; GENOME; IDENTIFICATION; 3'-TERMINUS; POLYMERASE; TRANSLATION; TRANSCRIPTS; CHIMPANZEE; GROWTH; REGION	An estimated 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease. Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems. A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons. Upon transfection into a human hepatoma cell line, these RNAs were found to replicate to high levels, permitting metabolic radiolabeling of viral RNA and proteins. This work defines the structure of HCV replicons functional in cell culture and provides the basis fora long-sought cellular system that should allow detailed molecular studies of HCV and the development of antiviral drugs.	Johannes Gutenberg Univ Mainz, Inst Virol, D-55131 Mainz, Germany; Stadt Klinikum Pforzheim, Med Klin 2, D-75116 Pforzheim, Germany	Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf	Bartenschlager, R (corresponding author), Johannes Gutenberg Univ Mainz, Inst Virol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	bartnsch@mail.uni-mainz.de	Lohmann, Volker/H-4211-2019; Bartenschlager, Ralf/L-2582-2015	Lohmann, Volker/0000-0001-8719-7608; Bartenschlager, Ralf/0000-0001-5601-9307				Bartenschlager R, 1997, INTERVIROLOGY, V40, P378, DOI 10.1159/000150570; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; Behrens SE, 1998, J VIROL, V72, P2364, DOI 10.1128/JVI.72.3.2364-2372.1998; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Fournier C, 1998, J GEN VIROL, V79, P2367, DOI 10.1099/0022-1317-79-10-2367; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gong YH, 1996, J GEN VIROL, V77, P2729, DOI 10.1099/0022-1317-77-11-2729; HOUGHTON M, 1996, FIELDS VIROLOGY, V1, P1035; Ikeda M, 1998, VIRUS RES, V56, P157, DOI 10.1016/S0168-1702(98)00063-X; KEDZIERSKI W, 1991, BIOTECHNIQUES, V10, P210; Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; LOHMANN V, UNPUB; Mizutani T, 1996, J VIROL, V70, P7219, DOI 10.1128/JVI.70.10.7219-7223.1996; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; Yamada N, 1996, VIROLOGY, V223, P255, DOI 10.1006/viro.1996.0476; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yanagi M, 1999, P NATL ACAD SCI USA, V96, P2291, DOI 10.1073/pnas.96.5.2291; YOO BJ, 1995, J VIROL, V69, P32, DOI 10.1128/JVI.69.1.32-38.1995	32	2325	2698	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	1999	285	5424					110	113		10.1126/science.285.5424.110	http://dx.doi.org/10.1126/science.285.5424.110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390360				2022-12-01	WOS:000081199800042
J	York, JD; Odom, AR; Murphy, R; Ives, EB; Wente, SR				York, JD; Odom, AR; Murphy, R; Ives, EB; Wente, SR			A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR EXPORT; SCHIZOSACCHAROMYCES-POMBE; PORE; HEXAKISPHOSPHATE; TRISPHOSPHATE; NUCLEOPORIN; METABOLISM; PHOSPHATES; TRANSPORT	In order to identify additional factors required for nuclear export of messenger RNA, a genetic screen was conducted with a yeast mutant deficient in a factor Gle1p, which associates with the nuclear pore complex (NPC). The three genes identified encode phospholipase C and two potential inositol polyphosphate kinases. Together, these constitute a signaling pathway from phosphatidylinositol 4,5-bisphosphate to inositol hexakisphosphate (IP6). The common downstream effects of mutations in each component were deficiencies in IP6 synthesis and messenger RNA export, indicating a role for IP6 in GLE7 function and messenger RNA export.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Duke University; Duke University; Washington University (WUSTL)	York, JD (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, DUMC 3813, Durham, NC 27710 USA.		John, Audrey Odom/AAF-1300-2019	John, Audrey Odom/0000-0001-8395-8537				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; DelPriore V, 1996, MOL BIOL CELL, V7, P1601, DOI 10.1091/mbc.7.10.1601; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; ESTEVEZ F, 1994, BIOCHEM J, V302, P709, DOI 10.1042/bj3020709; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; Lee MS, 1997, CURR OPIN GENET DEV, V7, P212, DOI 10.1016/S0959-437X(97)80131-1; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Ongusaha PP, 1998, BIOCHEM J, V335, P671, DOI 10.1042/bj3350671; PHILLIPPY B, 1994, J BIOL CHEM, V269, P28693; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STEPHENS L, 1990, NATURE, V326, P580; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275	29	429	447	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					96	100		10.1126/science.285.5424.96	http://dx.doi.org/10.1126/science.285.5424.96			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390371				2022-12-01	WOS:000081199800038
J	Sitas, F; Carrara, H; Beral, V; Newton, R; Reeves, G; Bull, D; Jentsch, U; Pacella-Norman, R; Bourboulia, D; Whitby, D; Boshoff, C; Weiss, R				Sitas, F; Carrara, H; Beral, V; Newton, R; Reeves, G; Bull, D; Jentsch, U; Pacella-Norman, R; Bourboulia, D; Whitby, D; Boshoff, C; Weiss, R			Antibodies against human herpesvirus 8 in black South African patients with cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; MULTIPLE-MYELOMA; SEXUAL TRANSMISSION; PERIPHERAL-BLOOD; NUCLEAR ANTIGEN; DNA-SEQUENCES; INFECTION; AIDS; HUMAN-HERPESVIRUS-8	Background. Infection with human herpesvirus 8 (HHV-8) has been consistently linked to Kaposi's sarcoma, but its mode of transmission, association with other cancers, and interaction with the human immunodeficiency virus type 1 (HIV-1) are largely unknown. Methods. Between January 1992 and December 1997, we interviewed 3591 black patients with cancer in Johannesburg and Soweto, South Africa. Blood was tested for antibodies against HIV-1 and HHV-8 in 3344 of the patients. Antibodies against HHV-8 were detected with an indirect immunofluorescence assay. The intensity of the fluorescent signal correlated well with the titers of antibodies (P < 0.001). The relations among the presence of anti-HHV-8 antibodies, sociodemographic and behavioral factors, type of cancer, and the presence or absence of coexistent HIV-1 infection were examined with the use of unconditional logistic-regression models. Results. Among the 3293 subjects with cancers other than Kaposi's sarcoma, the standardized seroprevalence of antibodies against HHV-8 was 32 percent, which did not differ significantly from the standardized seroprevalence among black blood donors. Among these 3293 patients, the prevalence of antibodies against HHV-8 increased with increasing age (P < 0.001) and an increasing number of sexual partners (P = 0.05) and decreased with increasing years of education (P = 0.007); it was not strongly associated with HIV-1 infection. Anti-HHV-8 antibodies were more frequent among black than white blood donors (P < 0.001). Among the 51 patients with Kaposi's sarcoma, the standardized seroprevalence of antibodies against HHV-8 was 83 percent, significantly higher than the prevalence among those without Kaposi's sarcoma (P < 0.001). For 16 other specific types of cancer, including multiple myeloma (108 cases) and prostate cancer (202 cases), the variation in the standardized seroprevalence of antibodies against HHV-8 was not remarkable. At a given intensity of fluorescence of anti-HHV-8 antibodies, Kaposi's sarcoma was more frequent among HIV-l-positive patients than among those who were HIV-l-negative (P < 0.001). Conclusions. Among black patients with cancer in South Africa, the seroprevalence of anti-HHV-8 antibodies is high and is specifically associated with Kaposi's sarcoma, particularly at high titers. (N Engl J Med 1999;340:1863-71.) (C) 1999, Massachusetts Medical Society.	S African Inst Med Res, Dept Anat Pathol, ZA-2000 Johannesburg, South Africa; Natl Canc Registry, S African Canc Epidemiol Unit, Johannesburg, South Africa; S African Inst Med Res, Dept Serol, ZA-2000 Johannesburg, South Africa; Univ Oxford, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford, England; UCL, Dept Oncol, London, England; UCL, Dept Mol Pathol, London, England	University of Oxford; University of London; University College London; University of London; University College London	Sitas, F (corresponding author), S African Inst Med Res, Dept Anat Pathol, POB 1038, ZA-2000 Johannesburg, South Africa.	freddys@mail.saimr.wits.ac.za	PACELLA, ROSANA E./F-2774-2010	PACELLA, ROSANA E./0000-0002-9742-1957; O'donnell, Colm/0000-0002-8004-450X; Sitas, Freddy/0000-0001-9679-1481				Ansari MQ, 1996, AM J CLIN PATHOL, V105, P221; BASSETT MT, 1995, INT J CANCER, V63, P29, DOI 10.1002/ijc.2910630107; BASSETT MT, 1995, INT J CANCER, V63, P763; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; Bourboulia D, 1998, JAMA-J AM MED ASSOC, V280, P31, DOI 10.1001/jama.280.1.31-a; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cook-Mozaffari P, 1998, BRIT J CANCER, V78, P1521, DOI 10.1038/bjc.1998.717; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; DETHE G, 1978, IARC SCI PUBLICATION, V20; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; Gaidano G, 1996, AIDS, V10, P941, DOI 10.1097/00002030-199610090-00003; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Kedes DH, 1996, NAT MED, V2, P1041; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kellam P, 1997, J Hum Virol, V1, P19; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Masood R, 1997, SCIENCE, V278, P1970; Moore PS, 1998, AM J EPIDEMIOL, V147, P217, DOI 10.1093/oxfordjournals.aje.a009440; Moore PS, 1996, AIDS, V10, P175, DOI 10.1097/00002030-199602000-00007; Munker R, 1997, PROSTATE, V33, P286, DOI 10.1002/(SICI)1097-0045(19971201)33:4&lt;286::AID-PROS10&gt;3.0.CO;2-F; Parravicini C, 1997, SCIENCE, V278, P1969, DOI 10.1126/science.278.5345.1969; Rabkin CS, 1998, J INFECT DIS, V178, P304, DOI 10.1086/515649; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Rettig MB, 1997, SCIENCE, V276, P1851, DOI 10.1126/science.276.5320.1851; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Sitas F, 1997, BRIT J CANCER, V75, P1704, DOI 10.1038/bjc.1997.290; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Whitby D, 1998, J NATL CANCER I, V90, P395, DOI 10.1093/jnci/90.5.395; Whitby D, 1997, SCIENCE, V278, P1971; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9	38	204	216	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 17	1999	340	24					1863	1871		10.1056/NEJM199906173402403	http://dx.doi.org/10.1056/NEJM199906173402403			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206EC	10369849				2022-12-01	WOS:000080863500003
J	Teter, SA; Houry, WA; Ang, D; Tradler, T; Rockabrand, D; Fischer, G; Blum, P; Georgopoulos, C; Hartl, FU				Teter, SA; Houry, WA; Ang, D; Tradler, T; Rockabrand, D; Fischer, G; Blum, P; Georgopoulos, C; Hartl, FU			Polypeptide flux through bacterial Hsp70: DnaK cooperates with trigger factor in chaperoning nascent chains	CELL			English	Article							HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; IN-VIVO; PRESECRETORY PROTEINS; CELLULAR DEFECTS; GENE; RECOGNITION; SYSTEM; TEMPERATURES	A role for DnaK, the major E. coli Hsp70, in chaperoning de novo protein folding has remained elusive. Here we show that under nonstress conditions DnaK transiently associates with a wide variety of nascent and newly synthesized polypeptides, with a preference for chains larger than 30 kDa. Deletion of the nonessential gene encoding trigger factor, a ribosome-associated chaperone, results in a doubling of the fraction of nascent polypeptides interacting with DnaK. Combined deletion of the trigger factor and DnaK genes is lethal under normal growth conditions. These findings indicate important, partially overlapping functions of DnaK and trigger factor in de novo protein folding and explain why the loss of either chaperone can be tolerated by E. coli.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva, Switzerland; Max Planck Gesell Forschungsstelle Enzymol Protei, D-06120 Halle, Germany; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	Max Planck Society; University of Geneva; Max Planck Society; University of Nebraska System; University of Nebraska Lincoln	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hartl, F. Ulrich/Y-8206-2019					ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Ayling A, 1996, PROTEIN SCI, V5, P478; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chattopadhyay S, 1999, BBA-PROTEIN STRUCT M, V1429, P293, DOI 10.1016/S0167-4838(98)00179-4; Checa SK, 1997, EUR J BIOCHEM, V248, P848, DOI 10.1111/j.1432-1033.1997.00848.x; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cellbio.9.1.601; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gothel SF, 1998, BIOCHEMISTRY-US, V37, P13392, DOI 10.1021/bi981253w; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kandror O, 1997, P NATL ACAD SCI USA, V94, P4978, DOI 10.1073/pnas.94.10.4978; Kandror O, 1997, J BIOL CHEM, V272, P1730, DOI 10.1074/jbc.272.3.1730; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; KRSKA J, 1993, J BACTERIOL, V175, P6433, DOI 10.1128/jb.175.20.6433-6440.1993; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; LLOYD RG, 1985, J BACTERIOL, V164, P836, DOI 10.1128/JB.164.2.836-844.1985; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Rockabrand D, 1998, J BACTERIOL, V180, P846, DOI 10.1128/JB.180.4.846-854.1998; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Yoshimune K, 1998, BIOCHEM BIOPH RES CO, V250, P115, DOI 10.1006/bbrc.1998.9255	49	335	340	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					755	765		10.1016/S0092-8674(00)80787-4	http://dx.doi.org/10.1016/S0092-8674(00)80787-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380927	Bronze			2022-12-01	WOS:000080886300013
J	Gapstur, SM; Morrow, M; Sellers, TA				Gapstur, SM; Morrow, M; Sellers, TA			Hormone replacement therapy and risk of breast cancer with a favorable histology - Results of the Iowa Women's Health Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; FAMILY HISTORY; UNITED-STATES; ESTROGEN; MORTALITY; QUESTIONNAIRE; CARCINOMA; SURVIVAL; DISEASE	Context. Long-term, postmenopausal use of hormone replacement therapy (HRT) appears to increase breast cancer risk. Whether the effect of HRT use on risk of breast cancer varies among histological types of invasive carcinoma is unknown. Objective. To determine associations between HRT use and risk of ductal carcinoma in situ (DCIS), invasive carcinoma with favorable histology, and invasive ductal or lobular carcinoma. Design. Prospective cohort study whose participants were followed up continuously for 11 years from January 1986 to December 1996. Setting and Participants. Iowa Women's Health Study, a population-based random sample of postmenopausal women aged 55 to 69 years in 1986. A total of 1520 incident breast cancer cases occurred in the at-risk cohort of 37105 women. Main outcome Measures. Multivariate-adjusted relative risk (RR) of tumor-specific breast cancers associated with duration of ever, current, or past HRT use. Results. Duration of ever HRT use was associated with risk of invasive carcinoma with a favorable histology, with an RR of 1.81 (95% confidence interval [Cl], 1.07-3.07) for those who used HRT 5 or fewer years vs an RR of 2.65 (95% CI, 1.34-5.23) for those who used HRT for more than 5 years (P for trend = .005) after adjustment for age and other breast cancer risk factors. There was no association between ever HRT use and the incidence of DCIS or invasive ductal or lobular carcinoma. Among current hormone users, after adjusting for age and other breast cancer risk factors, the RRs (95% Cls) of invasive carcinoma with a favorable histology were 4.42 (2.00-9.76) and 2.63 (1.18-5.89) for 5 or fewer years of use and for more than 5 years of use, respectively. Risk of invasive ductal or lobular carcinoma was associated with current use (less than or equal to 5 years) of HRT with an RR of 1.38 (95% Cl, 1.03-1.85). Conclusions. Exposure to HRT was associated most strongly with an increased risk of invasive breast cancer with a favorable prognosis. These data add important clinical information for assessing the risks and benefits of HRT use.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Surg, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lynn Sage Comprehens Breast Ctr, Chicago, IL 60611 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	Northwestern University; Northwestern University; Northwestern University; Mayo Clinic	Gapstur, SM (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BONNIER P, 1995, OBSTET GYNECOL, V85, P11, DOI 10.1016/0029-7844(94)00324-7; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CLAUS EB, 1993, CANCER, V71, P147, DOI 10.1002/1097-0142(19930101)71:1<147::AID-CNCR2820710124>3.0.CO;2-V; DUBIN N, 1986, AM J EPIDEMIOL, V123, P1101, DOI 10.1093/oxfordjournals.aje.a114338; EWERTZ M, 1991, INT J CANCER, V49, P526, DOI 10.1002/ijc.2910490409; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GAPSTUR SM, 1992, AM J EPIDEMIOL, V136, P1221, DOI 10.1093/oxfordjournals.aje.a116430; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Holli K, 1998, J CLIN ONCOL, V16, P3115, DOI 10.1200/JCO.1998.16.9.3115; JORDAN VC, 1998, P AM SOC CLIN ONCOL, V17, P46; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; Longnecker MP, 1996, CANCER EPIDEM BIOMAR, V5, P961; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; PEREZMESA CM, 1988, CANC BREAST, P206; Ries L, 1998, SEER CANC STAT REV 1; ROSEN PP, 1979, ANN CLIN LAB SCI, V9, P144; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491; SQUITIERI R, 1994, J AM COLL SURGEONS, V178, P167; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STRICKLAND DM, 1992, OBSTET GYNECOL, V80, P400; WEISS NS, 1978, ANN INTERN MED, V88, P410, DOI 10.7326/0003-4819-88-3-410; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; Willis DB, 1996, CANCER CAUSE CONTROL, V7, P449, DOI 10.1007/BF00052671; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F	34	174	177	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2091	2097		10.1001/jama.281.22.2091	http://dx.doi.org/10.1001/jama.281.22.2091			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367819				2022-12-01	WOS:000080668000031
J	Burstein, HJ; Gelber, S; Guadagnoli, E; Weeks, JC				Burstein, HJ; Gelber, S; Guadagnoli, E; Weeks, JC			Use of alternative medicine by women with early-stage breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; UNITED-STATES; COMPLEMENTARY THERAPIES; CONVENTIONAL TREATMENT; CONSERVING SURGERY; RISK; PREVALENCE; DISTRESS	Background We analyzed the use of alternative medicine by women who had received standard therapy for early-stage breast cancer diagnosed between September 1993 and September 1995. Methods A cohort of 480 patients with newly diagnosed early-stage breast cancer was recruited from a Massachusetts statewide cohort of women participating in a study of how women choose treatment for cancer. Alternative medical treatments, conventional therapies, and health-related quality of life were examined. Results New use of alternative medicine after surgery for breast cancer was common (reported by 28.1 percent of the women); such use was not associated with choices about standard medical therapies after we controlled for clinical and sociodemographic variables. A total of 10.6 percent of the women had used alternative medicine before they were given a diagnosis of breast cancer. Women who initiated the use of alternative medicine after surgery reported a worse quality of life than women who never used alternative medicine. Mental health scores were similar at base line among women who decided to use alternative medicine and those who did not, but three months after surgery the use of alternative medicine was independently associated with depression, fear of recurrence of cancer, lower scores for mental health and sexual satisfaction, and more physical symptoms as well as symptoms of greater intensity. All groups of women reported improving quality of life one year after surgery. Conclusions Among women with newly diagnosed early-stage breast cancer who had been treated with standard therapies, new use of alternative medicine was a marker of greater psychosocial distress and worse quality of life. (N Engl J Med 1999; 340:1733-9.) (C) 1999, Massachusetts Medical Society.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Weeks, JC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA059408] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN J, 1998, BOSTON GLOBE    0412, pE1; Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Cassileth BR, 1996, CANCER-AM CANCER SOC, V77, P1026, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1026::AID-CNCR4>3.3.CO;2-#; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Coppes MJ, 1998, NEW ENGL J MED, V339, P846, DOI 10.1056/NEJM199809173391213; Crocetti E, 1998, EUR J CANCER, V34, P324, DOI 10.1016/S0959-8049(97)10043-0; DANIELSON KJ, 1988, CAN MED ASSOC J, V138, P1005; DOWNER SM, 1994, BRIT MED J, V309, P86, DOI 10.1136/bmj.309.6947.86; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ganz PA, 1998, J CLIN ONCOL, V16, P501, DOI 10.1200/JCO.1998.16.2.501; GANZ PA, 1993, MED CARE, V31, P419, DOI 10.1097/00005650-199305000-00004; GANZ PA, 1995, JNCI-J NATL CANCER I, V87, P1372, DOI 10.1093/jnci/87.18.1372; Gevitz N, 1988, OTHER HEALERS UNORTH, P1; Guadagnoli E, 1998, J CLIN ONCOL, V16, P101, DOI 10.1200/JCO.1998.16.1.101; HARRIS L, 1987, HLTH INFORMATION USE; LASRY JCM, 1992, CANCER, V69, P2111, DOI 10.1002/1097-0142(19920415)69:8<2111::AID-CNCR2820690817>3.0.CO;2-T; LERNER IJ, 1984, CANCER, V53, P815, DOI 10.1002/1097-0142(19840201)53:3+<815::AID-CNCR2820531334>3.0.CO;2-U; LERNER IJ, 1992, CA-CANCER J CLIN, V42, P181, DOI 10.3322/canjclin.42.3.181; MAUNSELL E, 1992, CANCER-AM CANCER SOC, V70, P120, DOI 10.1002/1097-0142(19920701)70:1<120::AID-CNCR2820700120>3.0.CO;2-U; MEYEROWITZ BE, 1979, CANCER, V43, P1613, DOI 10.1002/1097-0142(197905)43:5<1613::AID-CNCR2820430508>3.0.CO;2-8; Mor V, 1994, J Natl Cancer Inst Monogr, P191; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6; ROWLAND JH, 1996, DIS BREAST, P919; S.A.S. Institute, 1990, SAS STAT US GUID; SCHAG CAC, 1993, J CLIN ONCOL, V11, P783, DOI 10.1200/JCO.1993.11.4.783; Sherbourne CD, 1992, MEASURING FUNCTIONIN, P194; SIEGEL A, 1998, P AM SOC CLIN ONCOL, V17, P667; TAYLOR SE, 1985, CANCER, V55, P2506, DOI 10.1002/1097-0142(19850515)55:10<2506::AID-CNCR2820551033>3.0.CO;2-0; VandeCreek L, 1999, ALTERN THER HEALTH M, V5, P71; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	33	458	464	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	1999	340	22					1733	1739		10.1056/NEJM199906033402206	http://dx.doi.org/10.1056/NEJM199906033402206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	201WQ	10352166				2022-12-01	WOS:000080620200006
J	Weiderpass, E; Baron, JA; Adami, HO; Magnusson, C; Lindgren, A; Bergstrom, R; Correia, N; Persson, I				Weiderpass, E; Baron, JA; Adami, HO; Magnusson, C; Lindgren, A; Bergstrom, R; Correia, N; Persson, I			Low-potency oestrogen and risk of endometrial cancer: a case-control study	LANCET			English	Article							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; HEART-DISEASE; ESTROGEN; ESTRIOL; PREVENTION; ESTRADIOL; MORTALITY	Background. Urogenital symptoms are common among postmenopausal women. Such symptoms may be alleviated by low-potency oestrogen formulations administered orally or vaginally. Although low-potency oestrogen formulations are assumed to have few, if any, adverse effects on the endometrium, risk of endometrial neoplasia has not been quantified. Methods. In a nationwide population-based case-control study in Sweden of endometrial cancer among postmenopausal women, we obtained detailed information on hormone replacement from 789 cases of endometrial cancer and 3368 population controls. In a histopathological review, 80 cases were reclassified as having endometrial atypical hyperplasia. Odds ratios and 95% Cl were calculated with unconditional logistic regression. Findings. After multivariate adjustment, oral use of oestriol 1-2 mg daily increased the relative risk of endometrial cancer and endometrial atypical hyperplasia: the odds ratios for at least 5 years of use compared with never use were 3.0 (95% Cl 2.0-4.4) and 8.3 (4.0-17.4), respectively. The association was stronger for well-differentiated cancers and those with limited invasion. The excess relative risk was lost rapidly after cessation of treatment. Only weak associations were observed between vaginal application of low-potency oestrogen formulations and relative risk of endometrial neoplasia. Interpretation. Oral, but not vaginal, treatment with low-potency oestrogen formulations increases the relative risk of endometrial neoplasia. Thus close surveillance of patients is needed, and addition of a progestagen should be considered.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Hanover, NH 03756 USA; Falun Hosp, Dept Pathol, Falun, Sweden; Harvard Univ, Sch Publ Hlth, Harvard Ctr Canc Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Karolinska Institutet; Dartmouth College; Falun Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Weiderpass, E (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.		Weiderpass, Elisabete/AAP-2747-2021; Weiderpass, Elisabete/M-4029-2016	Weiderpass, Elisabete/0000-0003-2237-0128; Weiderpass, Elisabete/0000-0003-2237-0128; Magnusson, Cecilia/0000-0002-8567-6725; Correia, Nestor/0000-0003-4852-9985	NCI NIH HHS [R01 CA58427] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058427] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; BORGLIN N E, 1959, Acta Obstet Gynecol Scand, V38, P157; BOTELLA J, 1995, J STEROID BIOCHEM, V55, P77, DOI 10.1016/0960-0760(95)00156-T; Bygdeman M, 1996, MATURITAS, V23, P259, DOI 10.1016/0378-5122(95)00955-8; Cardozo L, 1998, BRIT J OBSTET GYNAEC, V105, P403, DOI 10.1111/j.1471-0528.1998.tb10124.x; CLARK JH, 1977, ENDOCRINOLOGY, V100, P91, DOI 10.1210/endo-100-1-91; ENGLUND DE, 1980, ACTA OBSTET GYN SCAN, V59, P449, DOI 10.3109/00016348009155427; ESPOSITO G, 1991, GYNECOL ENDOCRINOL, V5, P131, DOI 10.3109/09513599109028436; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; GRADY D, 1996, CANC EPIDEMIOLOGY PR, P1058; Granberg S, 1997, MATURITAS, V27, P35, DOI 10.1016/S0378-5122(97)01107-9; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEIMER G, 1984, ACTA OBSTET GYN SCAN, V63, P563, DOI 10.3109/00016348409156720; Heimer G, 1996, Acta Obstet Gynecol Scand Suppl, V163, P1; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KELSEY JL, 1982, AM J EPIDEMIOL, V116, P333, DOI 10.1093/oxfordjournals.aje.a113417; KORACH K, 1980, ENDOCRINOLOGY, V106, P1900, DOI 10.1210/endo-106-6-1900; LAURITZEN C, 1961, ACTA ENDOCRINOL-COP, V38, P73, DOI 10.1530/acta.0.0380073; Minaguchi H, 1996, J Obstet Gynaecol Res, V22, P259; NILSSON K, 1992, MATURITAS, V15, P121, DOI 10.1016/0378-5122(92)90246-Z; PERSSON I, 1986, ACTA PATH MICRO IM A, V94, P187; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; Salmi T, 1980, Acta Endocrinol Suppl (Copenh), V233, P37; Schairer C, 1997, EPIDEMIOLOGY, V8, P59, DOI 10.1097/00001648-199701000-00010; SCHIFF I, 1980, AM J OBSTET GYNECOL, V138, P1137, DOI 10.1016/S0002-9378(16)32780-6; Speroff L., 1994, CLIN GYNECOLOGIC END, P583; ToozsHobson P, 1996, BMJ-BRIT MED J, V313, P350, DOI 10.1136/bmj.313.7053.350; VERMEULEN A, 1968, STEROIDS, V11, P609, DOI 10.1016/S0039-128X(68)80009-1	28	129	132	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1824	1828		10.1016/S0140-6736(98)10233-7	http://dx.doi.org/10.1016/S0140-6736(98)10233-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359406				2022-12-01	WOS:000080667800010
J	Kee, F; Wilson, RH; Harper, C; Patterson, CC; McCallion, K; Houston, RF; Moorehead, RJ; Sloan, JM; Rowlands, BJ				Kee, F; Wilson, RH; Harper, C; Patterson, CC; McCallion, K; Houston, RF; Moorehead, RJ; Sloan, JM; Rowlands, BJ			Influence of hospital and clinician workload on survival from colorectal cancer: cohort study	BRITISH MEDICAL JOURNAL			English	Article							SURGICAL-PROCEDURES; VOLUME; MORTALITY; SURGEONS; CARE; RISK	Objective To determine whether clinician or hospital caseload affects mortality from colorectal cancer. Design Cohort study of cases ascertained between 1990 and 1994 by a region-wide colorectal cancer register. Outcome measures Mortality within a median follow up period of 54 months after diagnosis. Results Of the 3217 new patients registered over the period, 1512 (48%) died before 31 December 1996. Strong predictors of survival both in a logistic repression (fixed follow up) and in a Cox's proportional hazards model (variable follow up) were Duke's stage, the degree of tumour differentiation, whether the liver was deemed clear of cancer by the surgeon at operation, and the type of intervention (elective or emergency and curative or palliative intent). In a multilevel model, surgeon's caseload had no significant effect on mortality at 2 years. Hospital workload, however, had a significant impact on survival. The odds ratio for death within 2 years for cases managed in a hospital with a caseload of between 33 and 46 cases per year, 47 and 54 cases per year, and greater than or equal to 55 cases per year (compared to one with less than or equal to 23 cases per year) were respectively 1.48 (95% confidence interval 1.03 to 2.13), 1.52 (1.08 to 2.19), and 1.18 (0.83 to 1.68). Conclusions There was no detectable caseload effect for surgeons managing colorectal cancer, but survival of patients treated in hospitals with caseloads above 33 cases per year was slightly worse than for those treated in hospitals With fewer caseloads. Imprecise measurement of clinician specific "events rates" and the lack of routinely collected case mix data present major challenges for clinical audit and governance in the years ahead.	Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland; Belvoir Pk Hosp, No Ireland Ctr Clin Oncol, Belfast BT8 8JR, Antrim, North Ireland; Belvoir Pk Hosp, No Ireland Canc Register, Belfast BT8 8JR, Antrim, North Ireland; Queens Univ Belfast, Dept Surg, Belfast BT12 6BJ, Antrim, North Ireland; N Down & Ards Hlth & Social Serv Trust, Belfast BT16 1RH, Antrim, North Ireland; Queens Univ Belfast, Dept Pathol, Belfast BT12 6BJ, Antrim, North Ireland; Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England	Queens University Belfast; Queens University Belfast; Queens University Belfast; University of Nottingham	Kee, F (corresponding author), Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland.							Christiansen CL, 1997, ANN INTERN MED, V127, P764, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00065; *DEP HLTH, 1997, GUID PURCH IMPR OUTC; *EXP ADV GROUP CAN, 1994, CONSULTATIVE DOCUMEN; FIELDING LP, 1978, LANCET, V2, P778; GOLDSTEIN H, 1996, J ROY STAT SOC A STA, V159, P1; GOLDSTEIN H, 1998, USERS GUIDE MLWINN; Hakama M, 1989, Int J Technol Assess Health Care, V5, P619; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; Holm T, 1997, BRIT J SURG, V84, P657, DOI 10.1002/bjs.1800840520; HOUGHTON A, 1994, BRIT J SURG, V81, P653, DOI 10.1002/bjs.1800810508; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; Kee F, 1996, J EPIDEMIOL COMMUN H, V50, P640, DOI 10.1136/jech.50.6.640; KEE F, 1992, BRIT MED J, V305, P158, DOI 10.1136/bmj.305.6846.158; Lovegrove J, 1997, LANCET, V350, P1128, DOI 10.1016/S0140-6736(97)06507-0; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Machin D., 1987, STAT TABLES DESIGN C; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; *NHS, 1997, EFFECTIVE HLTH CARE, V13, P11; PEARCE K, 1997, REV COLORECTAL CANC; *ROYAL COLL SURG E, 1996, GUID MAN COL CANC; Sagar PM, 1996, DIS COLON RECTUM, V39, P654, DOI 10.1007/BF02056945; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; Taylor I, 1996, EUR J SURG ONCOL, V22, P205, DOI 10.1016/S0748-7983(96)80001-1	23	86	87	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1381	1385		10.1136/bmj.318.7195.1381	http://dx.doi.org/10.1136/bmj.318.7195.1381			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334746	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000080524700023
J	Meyer, JE; Smith, DN; Lester, SC; Kaelin, C; DiPiro, PJ; Denison, CM; Christian, RL; Harvey, SC; Selland, DLG; Durfee, SM				Meyer, JE; Smith, DN; Lester, SC; Kaelin, C; DiPiro, PJ; Denison, CM; Christian, RL; Harvey, SC; Selland, DLG; Durfee, SM			Large-core needle biopsy of nonpalpable breast lesions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATYPICAL DUCTAL HYPERPLASIA; VACUUM-ASSISTED BIOPSY; MAMMOGRAPHIC FINDINGS; SURGICAL BIOPSY; 14-GAUGE; ABNORMALITIES; PLACEMENT; ACCURACY; IMPACT; CLIP	Context An increasing number of nonpalpable abnormalities requiring breast biopsy are being identified due to the widespread use of screening mammography, Large-cole needle biopsy (LCNB) has become an alternative to surgical excision, Objective To determine whether LCNB is a safe and accurate technique to evaluate nonpalpable abnormalities found on breast imaging studies. Design and Setting Case series at an institutional referral center from August 1, 1991, to December 31, 1997. Patients A total of 1643 women with 1 or more suspicious breast abnormalities received LCNBs (n = 1836 lesions). Intervention The LCNB of the breast uses a 14- or 11-gauge needle with stereotactic localization or ultrasound guidance, Main Outcome Measure Utility and potential limitations of LCNB compared with the criterion standard, surgical excision after wire localization. Results Of the 1836 breast lesions sampled, 444 (24%) were found to be malignant. a total of 412 (22%) were found to be malignant on the initial LCNB and 202 repeat biopsies yielded 32 additional malignancies, Complications were infrequent: 1 patient experienced a superficial infection and 1 developed a pneumothorax after LCNB. Conclusion Image-guided LCNB is a reliable diagnostic alternative to surgical excision of suspicious nonpalpable breast abnormalities.	Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Meyer, JE (corresponding author), Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.							Burbank F, 1997, RADIOLOGY, V204, P153, DOI 10.1148/radiology.204.1.9205238; Burbank F, 1996, AM SURGEON, V62, P738; Burbank F, 1997, RADIOLOGY, V202, P843, DOI 10.1148/radiology.202.3.9051043; Burbank F, 1997, RADIOLOGY, V205, P407, DOI 10.1148/radiology.205.2.9356621; ELVECROG EL, 1993, RADIOLOGY, V188, P453, DOI 10.1148/radiology.188.2.8327696; Jackman RJ, 1997, RADIOLOGY, V204, P485, DOI 10.1148/radiology.204.2.9240540; Jackman RJ, 1997, RADIOLOGY, V204, P677, DOI 10.1148/radiology.204.3.9280243; JACKMAN RJ, 1994, RADIOLOGY, V193, P91, DOI 10.1148/radiology.193.1.8090927; KOPANS DB, 1992, AM J ROENTGENOL, V158, P521, DOI 10.2214/ajr.158.3.1310825; Lee CH, 1997, RADIOLOGY, V202, P849, DOI 10.1148/radiology.202.3.9051045; LIBERMAN L, 1995, RADIOLOGY, V195, P633, DOI 10.1148/radiology.195.3.7753986; LIBERMAN L, 1995, AM J ROENTGENOL, V164, P1111, DOI 10.2214/ajr.164.5.7717215; Liberman L, 1997, RADIOLOGY, V203, P343, DOI 10.1148/radiology.203.2.9114086; Liberman L, 1998, RADIOLOGY, V208, P251, DOI 10.1148/radiology.208.1.9646821; Liberman L, 1997, RADIOLOGY, V205, P417, DOI 10.1148/radiology.205.2.9356622; MEYER JE, 1993, RADIOLOGY, V188, P581, DOI 10.1148/radiology.188.2.8327720; Meyer JE, 1997, RADIOLOGY, V204, P575, DOI 10.1148/radiology.204.2.9240556; Meyer JE, 1996, AM J ROENTGENOL, V167, P179, DOI 10.2214/ajr.167.1.8659367; Meyer JE, 1998, RADIOLOGY, V206, P717, DOI 10.1148/radiology.206.3.9494490; MEYER JE, 1990, JAMA-J AM MED ASSOC, V263, P2341, DOI 10.1001/jama.263.17.2341; PARKER SH, 1991, RADIOLOGY, V180, P403, DOI 10.1148/radiology.180.2.1648757; SICKLES EA, 1991, RADIOLOGY, V179, P463, DOI 10.1148/radiology.179.2.2014293; Smith DN, 1997, ARCH SURG-CHICAGO, V132, P256	23	187	192	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1638	1641		10.1001/jama.281.17.1638	http://dx.doi.org/10.1001/jama.281.17.1638			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235159				2022-12-01	WOS:000080025900030
J	Park, YC; Burkitt, V; Villa, AR; Tong, L; Wu, H				Park, YC; Burkitt, V; Villa, AR; Tong, L; Wu, H			Structural basis for self-association and receptor recognition of human TRAF2	NATURE			English	Article							NECROSIS-FACTOR RECEPTOR; FACTOR-KAPPA-B; CRYSTAL-STRUCTURE; BINDING-SITES; PROTEIN; DOMAIN; FAMILY; ACTIVATION; MEMBERS; COMPLEX	Tumour necrosis factor (TNF)-receptor-associated factors (TRAFs) form a family of cytoplasmic adapter proteins that mediate signal transduction from many members of the TNF-receptor superfamily and the interleukin-1 receptor(1). They are important in the regulation of cell survival and cell death. The carboxy-terminal region of TRAFs (the TRAF domain) is required for self-association and interaction with receptors. The domain contains a predicted coiled-coil region that is followed by a highly conserved TRAF-C domain(2). Here we report the crystal structure of the TRAF domain of human TRAF2, both alone and in complex with a peptide from TNF receptor-2 (TNF-R2). The structures reveal a trimeric self-association of the TRAF domain, which we confirm by studies in solution. The TRAF-C domain forms a new, eight-stranded antiparallel beta-sandwich structure. The TNF-R2 peptide binds to a conserved shallow surface depression on one TRAF-C domain and does not contact the other protomers of the trimer. The nature of the interaction indicates that an SXXE motif may be a TRAF2-binding consensus sequence. The trimeric structure of the TRAF domain provides an avidity-based explanation for the dependence of TRAF recruitment on the oligomerization of the receptors by their trimeric extracellular ligands.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Cornell University; Cornell University; Columbia University	Wu, H (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.			Tong, Liang/0000-0002-0563-6468				Arch RH, 1998, MOL CELL BIOL, V18, P558, DOI 10.1128/MCB.18.1.558; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1993, PHASES PROGRAM PACKA; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kuhne MR, 1997, J EXP MED, V186, P337, DOI 10.1084/jem.186.2.337; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pullen SS, 1998, BIOCHEMISTRY-US, V37, P11836, DOI 10.1021/bi981067q; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tong L, 1998, NAT STRUCT BIOL, V5, P819, DOI 10.1038/1860; TONG L, 1993, J APPL CRYSTALLOGR, V26, P15, DOI 10.1107/S0021889892007295; TONG L, 1993, J APPL CRYSTALLOGR, V26, P748, DOI 10.1107/S0021889893005631	30	283	294	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 8	1999	398	6727					533	538		10.1038/19110	http://dx.doi.org/10.1038/19110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	185HQ	10206649				2022-12-01	WOS:000079662800053
J	Perozo, E; Cortes, DM; Cuello, LG				Perozo, E; Cortes, DM; Cuello, LG			Structural rearrangements underlying K+-channel activation gating	SCIENCE			English	Article							PARAMAGNETIC-RESONANCE DATA; STREPTOMYCES-LIVIDANS; SECONDARY STRUCTURE; SPIN-LABELS; CIRCULAR-DICHROISM; POTASSIUM CHANNEL; PROTEIN-STRUCTURE; RECEPTOR CHANNEL; ION-CHANNEL; T4 LYSOZYME	The intramembrane molecular events underlying activation gating in the Streptomyces K+ channel were investigated by site-directed spin-labeling methods and electron paramagnetic resonance spectroscopy. A comparison of the closed and open conformations of the channel revealed periodic changes in spin-label mobility and intersubunit spin-spin interaction consistent with rigid-body movements of the two transmembrane helices TM1 and TM2. These changes involve translations and counterclockwise rotations of both helices relative to the center of symmetry of the channel. The movement of TM2 increases the diameter of the permeation pathway along the point of convergence of the four subunits, thus opening the pore, Although the extracellular residues flanking the selectivity filter remained immobile during gating, small movements were detected at the C-terminal end of the pore helix. with possible implications to the gating mechanism.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Ctr Struct Biol, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Perozo, E (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA.				NIGMS NIH HHS [GM57846, GM54690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057846, R01GM054690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Aidley D.J., 1996, ION CHANNELS MOL ACT; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chapman ML, 1997, BIOPHYS J, V72, P708, DOI 10.1016/S0006-3495(97)78707-1; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; CORTES DM, 1999, 43 ANN M BIOPH SOC B; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; CUELLO LG, 1999, 43 ANN M BIOPH SOC B; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; DONNELLY D, 1994, PROTEIN ENG, V7, P645, DOI 10.1093/protein/7.5.645; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EATON GR, 1989, SPIN LABELING THEORY; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Hille B., 1992, ION CHANNELS EXCITAB; Holmgren M, 1997, J GEN PHYSIOL, V109, P527, DOI 10.1085/jgp.109.5.527; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hustedt EJ, 1997, BIOPHYS J, V72, P1861, DOI 10.1016/S0006-3495(97)78832-5; le Coutre J, 1998, P NATL ACAD SCI USA, V95, P6114, DOI 10.1073/pnas.95.11.6114; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Steinhoff HJ, 1997, BIOPHYS J, V73, P3287, DOI 10.1016/S0006-3495(97)78353-X; Tatulian SA, 1998, FEBS LETT, V423, P205, DOI 10.1016/S0014-5793(98)00091-X; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; YELLEN G, IN PRESS Q REV BIOPH; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101	42	489	499	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					73	78		10.1126/science.285.5424.73	http://dx.doi.org/10.1126/science.285.5424.73			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390363				2022-12-01	WOS:000081199800030
J	Feneley, MR; Walsh, PC				Feneley, MR; Walsh, PC			Incontinence after radical prostatectomy	LANCET			English	Editorial Material							COLLAGEN INJECTION THERAPY; QUALITY-OF-LIFE; RETROPUBIC PROSTATECTOMY; URINARY-INCONTINENCE; FOLLOW-UP; CONTINENCE; SURGERY; CANCER		Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Feneley, MR (corresponding author), Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA.							APPELL RA, 1994, UROL CLIN N AM, V21, P177; Burnett AL, 1998, J UROLOGY, V160, P1301, DOI 10.1016/S0022-5347(01)62521-7; Eastham JA, 1996, J UROLOGY, V156, P1707, DOI 10.1016/S0022-5347(01)65488-0; Ficazzola MA, 1998, J UROLOGY, V160, P1317, DOI 10.1016/S0022-5347(01)62525-4; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; GEARY ES, 1995, UROLOGY, V45, P1000; Haab F, 1997, J UROLOGY, V158, P435, DOI 10.1016/S0022-5347(01)64496-3; MAATHEWSONCHAPM.M, 1997, J CANCER EDUC, V12, P218; SanchezOrtiz RF, 1997, J UROLOGY, V158, P2132, DOI 10.1016/S0022-5347(01)68177-1; STEINER MS, 1991, J UROLOGY, V145, P512, DOI 10.1016/S0022-5347(17)38382-9; Talcott JA, 1997, J NATL CANCER I, V89, P1117, DOI 10.1093/jnci/89.15.1117; Tefilli MV, 1998, UROLOGY, V52, P224, DOI 10.1016/S0090-4295(98)00151-4; Walsh Patrick C., 1999, Journal of Urology, V161, P387; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; Walsh PC, 1998, J UROLOGY, V160, P2418, DOI 10.1016/S0022-5347(01)62202-X; WEIN AJ, 1995, UROL CLIN N AM, V22, P557	16	12	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2091	2092		10.1016/S0140-6736(98)00355-9	http://dx.doi.org/10.1016/S0140-6736(98)00355-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382690				2022-12-01	WOS:000080969300006
J	Postma, MJ; Beck, EJ; Mandalia, S; Sherr, L; Walters, MDS; Houweling, H; Jager, JC				Postma, MJ; Beck, EJ; Mandalia, S; Sherr, L; Walters, MDS; Houweling, H; Jager, JC			Universal HIV screening of pregnant women in England: cost effectiveness analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ZIDOVUDINE PROPHYLAXIS; UNITED-KINGDOM; TRANSMISSION; TYPE-1	Objective To estimate the cost effectiveness of universal, voluntary HIV screening of pregnant women in England. Design Cost effectiveness analysis. Cost estimates of caring for HIV positive children were based on the stage of HIV infection and calculated using data obtained from a London hospital between 1986 and 1996. These were combined with estimates of the health benefits and costs of antenatal screening so that the cost effectiveness of universal, voluntary antenatal screening for HIV infection in England could be estimated. Main outcome measures Lifetime, direct costs of medical care of childhood HIV infection; life years gained as a result of the screening programme; net cost per life year gained fur different pretest counselling costs; and different prevalence rates of pregnant women who were unaware that they were HIV positive. Results Estimated direct lifetime medical and social care costs of childhood HIV infection were pound 178 300 using a 5% discount rate fur time preference (1995-6 prices). In high prevalence areas screening pregnant women for HIV is estimated to be a cost effective intervention with a net cost of less than pound 4000 for each life year gained. For areas with comparatively low prevalence rates, cost effectiveness could be less than pound 20 000 per life year gained, depending on the number of pregnant women who are unaware that they are infected and local screening costs. Conclusions Our results confirm recent recommendations that universal, voluntary antenatal HIV screening should be implemented in the London ar ea. Serious consideration of the policy should be given for other areas in England depending on local prevalence and screening costs.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Natl Inst Publ Hlth & Environm, Dept Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Dept Infect Dis & Epidemiol, NL-3720 BA Bilthoven, Netherlands; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Paediat, London W2 1PG, England; Royal Free Hosp, Sch Med, Dept Primary Care & Populat Sci, London NW3 2PF, England	Imperial College London; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Beck, EJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Epidemiol & Publ Hlth, St Marys Campus, London W2 1PG, England.	e.beck@ic.ac.uk		Postma, Maarten/0000-0002-6306-3653; Sherr, Lorraine/0000-0002-5902-8011				BECK EJ, 1997, HOSP COMMUNITY SERVI; BECK EJ, IN PRESS INT J STD A; Boer R, 1998, BRIT MED J, V317, P376; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P1; Centers for Disease Control (CDC), 1987, MMWR Morb Mortal Wkly Rep, V36, P225; CLUYSTIE IL, 1995, AIDS CARE, V7, P135; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; *INT WORK PART ENH, 1998, RED MOTH TO CHILD TR; JEFFERSON T, 1996, ELEMENTARY EC EVALUA; JORDAN R, 1997, J MED SCREEN, V3, P117; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; McIntosh K, 1998, NEW ENGL J MED, V339, P1467, DOI 10.1056/NEJM199811123392009; Mercey D, 1998, BMJ-BRIT MED J, V316, P241, DOI 10.1136/bmj.316.7127.241; MUGFORD M, 1996, THESIS U OXFORD OXFO; NEWELL ML, 1994, LANCET, V343, P1464; *NHS EX, 1997, HOSP COMM HLTH SERV; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Owens DK, 1998, J GEN INTERN MED, V13, P716, DOI 10.1046/j.1525-1497.1998.00211.x; Parsonage M, 1992, Health Econ, V1, P71, DOI 10.1002/hec.4730010110; *ROYAL COLL OBST G, 1997, NAT STUD HIV PREGN; SAVAGEKING F, 1998, BREAST FEEDING PROGR; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; 1997, J MED SCREENING, V4, P177	26	50	50	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	1999	318	7199					1656	1660		10.1136/bmj.318.7199.1656	http://dx.doi.org/10.1136/bmj.318.7199.1656			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210KY	10373167	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000081105600019
J	Dunn, N; Thorogood, M; Faragher, B; de Caestecker, L; MacDonald, TM; McCollum, C; Thomas, S; Mann, R				Dunn, N; Thorogood, M; Faragher, B; de Caestecker, L; MacDonald, TM; McCollum, C; Thomas, S; Mann, R			Oral contraceptives and myocardial infarction: results of the MICA case-control study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; YOUNG-WOMEN; RISK; HEALTH	Objectives To determine the association between myocardial infarction and use of different types of oral contraception in young women. Design Community based case-control study. Data from interviews and general practice records. Setting England, Scotland, and Wales. Participants Cases (n = 448) were recruited from women aged between 16 and 44 who had suffered an incident myocardial infarction between 1 October 1993 and 16 October 1995. Controls (n = 1728) were women without a diagnosis of myocardial infarction matched for age and general practice. Main outcome measures Odds ratios for myocardial infarction in current users of all combined oral contraceptives stratified by their progestagen content compared with non-users; current users of third generation versus second generation oral contraceptives. Results The adjusted odds ratio for myocardial infarction was 1.40 (95% confidence interval 0.78 to 2.52) for all combined oral contraceptive users, 1.10 (0.52 to 2.30) for second generation users, and 1.96 (0.87 to 4.39) for third generation users. Subgroup analysis by progestagen content did not show any significant difference from 1, and there was no effect of duration of use. The adjusted odds ratio for third generation users versus second generation users was 1.78 (0.66 to 4.83). 87% of cases were not exposed to an oral contraceptive, and 88% had clinical cardiovascular risk factors or were smokers, or both. Smoking was strongly associated with myocardial infarction: adjusted odds ratio 12.5 (7.29 to 21.5) for smoking 20 or more cigarettes a day. Conclusions There was no significant association between the use of oral contraceptives and myocardial infarction. The modest and non-significant point estimates for this association have wide confidence intervals. There was no significant difference between second and third generation products.	Drug Safety Res Unit, Southampton SO31 1AA, Hants, England; London Sch Hyg & Trop Med, London WC1 6FH, England; UMIST, Manchester Sch Management, Dept Org Psychol, Manchester M60 1QD, Lancs, England; Greater Glasgow Hlth Board, Dept Publ Hlth, Glasgow G3 8YU, Lanark, Scotland; Ninewells Hosp, Sch Med, Dept Clin Pharmacol & Therapeut, Med Monitoring Unit, Dundee DD1 9SY, Scotland; Univ S Manchester Hosp, Dept Surg, Manchester M20 8LR, Lancs, England; Univ Newcastle Upon Tyne, Wolfson Unit Clin Pharmacol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of London; London School of Hygiene & Tropical Medicine; University of Manchester; University of Dundee; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Newcastle University - UK	Dunn, N (corresponding author), Drug Safety Res Unit, Bursledon Hall, Southampton SO31 1AA, Hants, England.			MacDonald, Thomas/0000-0001-5189-6669				DebertRibeiro M, 1995, J CLIN EPIDEMIOL, V48, P1513; Dunn NR, 1997, PHARMACOEPIDEM DR S, V6, P283, DOI 10.1002/(SICI)1099-1557(199707)6:4<283::AID-PDS270>3.3.CO;2-6; Jick H, 1996, LANCET, V347, P627, DOI 10.1016/S0140-6736(96)91334-3; LAVECCHIA C, 1987, AM J EPIDEMIOL, V125, P832, DOI 10.1093/oxfordjournals.aje.a114599; Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; McAlpine R, 1998, PHARMACOEPIDEM DR S, V7, P311, DOI 10.1002/(SICI)1099-1557(199809/10)7:5<311::AID-PDS371>3.3.CO;2-F; OLIVER MF, 1986, MYOCARDIAL INFARCTIO, P215; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; ROSENBERG L, 1990, AM J EPIDEMIOL, V131, P1009, DOI 10.1093/oxfordjournals.aje.a115592; SYDNEY S, 1996, OBSTET GYNECOL, V88, P939; TunstallPedoe H, 1997, BRIT MED J, V315, P722, DOI 10.1136/bmj.315.7110.722	12	130	132	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1579	1583		10.1136/bmj.318.7198.1579	http://dx.doi.org/10.1136/bmj.318.7198.1579			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10364115	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000080913100019
J	Light, RW; Rogers, JT; Cheng, DS; Rodriguez, RM				Light, RW; Rogers, JT; Cheng, DS; Rodriguez, RM		Cardiovascular Surg Associates PC	Large pleural effusions occurring after coronary artery bypass grafting	ANNALS OF INTERNAL MEDICINE			English	Article						coronary artery bypass; pleural effusion; thoracenteses; thoracostomy; anti-inflammatory agents; sclerosing solutions	INTERNAL MAMMARY ARTERY; RESPIRATORY COMPLICATIONS; PULMONARY COMPLICATIONS; SAPHENOUS-VEIN; REVASCULARIZATION; SURGERY; INJURY	Background: Large pleural effusions sometimes occur after coronary artery bypass grafting (CABG), but their characteristics and clinical course are largely unknown. Objective: To describe the clinical course and pleural fluid findings in patients with large pleural effusions occurring after CABG. Design: Retrospective case series. Setting: Tertiary care, university-affiliated, nonprofit teaching hospital. Patients: 3707 patients who had CABC between 1 February 1996 and 1 August 1997. Measurements: Chest radiographs were reviewed, and information on pleural fluid findings, pleural effusion treatment, and cardiac surgery was obtained from medical records and a cardiac surgery database. Results: Pleural effusions that occupied more than 25% of the hemithorax were found in 29 patients (0.78%). Seven of the effusions were attributed to congestive heart failure, 2 were attributed to pericarditis, and 1 was attributed to pulmonary embolism. The explanation for the remaining 19 effusions was unclear. All but 2 effusions were predominantly left-sided. Of these 19 effusions, 8 were bloody and 11 were nonbloody. Bloody effusions usually occurred earlier, contained higher lactic acid dehydrogenase levels, and were frequently eosinophilic. Nonbloody effusions tended to be more difficult to manage. Conclusions: Large pleural effusions may develop in a small proportion of patients after CABG. The cause of many of these effusions is unclear. Most bloody effusions can be managed with one to three therapeutic thoracenteses. Resolution of nonbloody effusions may require antiinflammatory agents, tube thoracostomy, or intrapleural injection of sclerosing agents.	St Thomas Hosp, Pulm Dis Program, Nashville, TN 37202 USA; Vanderbilt Univ, Nashville, TN USA	Saint Thomas Hospital; Vanderbilt University	Light, RW (corresponding author), St Thomas Hosp, Pulm Dis Program, POB 380,4220 Harding Rd, Nashville, TN 37202 USA.	RLIGHT98@yahoo.com						AARNIO P, 1991, SCAND J THORAC CARD, V25, P175, DOI 10.3109/14017439109099035; Ali IM, 1996, CAN J SURG, V39, P42; COHEN ML, 1994, CHEST, V105, P1874, DOI 10.1378/chest.105.6.1874; Daganou M, 1998, CHEST, V113, P1285, DOI 10.1378/chest.113.5.1285; GALE GD, 1979, CAN ANAESTH SOC J, V26, P15, DOI 10.1007/BF03039447; HURLBUT D, 1990, ANN THORAC SURG, V50, P959, DOI 10.1016/0003-4975(90)91129-Y; KIM YK, 1988, AM HEART J, V115, P1077, DOI 10.1016/0002-8703(88)90079-8; KOLLEF MH, 1990, HEART LUNG, V19, P671; KOLLEF MH, 1990, CHEST, V97, P750, DOI 10.1378/chest.97.3.750; KOLLEF MH, 1993, SOUTHERN MED J, V86, P585, DOI 10.1097/00007611-199305000-00022; KOLLEF MH, 1988, CHEST, V94, P68, DOI 10.1378/chest.94.1.68; LANDYMORE RW, 1990, EUR J CARDIO-THORAC, V4, P156, DOI 10.1016/1010-7940(90)90187-5; Light R, 1995, PLEURAL DIS; Nikas DJ, 1998, ANN THORAC SURG, V65, P28, DOI 10.1016/S0003-4975(97)01261-7; PENG MJ, 1992, CHEST, V101, P327, DOI 10.1378/chest.101.2.327; ROLLA G, 1994, RESP MED, V88, P417, DOI 10.1016/S0954-6111(05)80043-5; SCHANDENE L, 1993, CLIN EXP IMMUNOL, V93, P115; WILSON JM, 1979, J THORAC CARDIOV SUR, V77, P489	18	68	70	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1999	130	11					891	+		10.7326/0003-4819-130-11-199906010-00004	http://dx.doi.org/10.7326/0003-4819-130-11-199906010-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200PB	10375337				2022-12-01	WOS:000080547900003
J	McIntosh, AR; Rajah, MN; Lobaugh, NJ				McIntosh, AR; Rajah, MN; Lobaugh, NJ			Interactions of prefrontal cortex in relation to awareness in sensory learning	SCIENCE			English	Article							FUNCTIONAL CONNECTIVITY; PET; EXPERIENCE; RESPONSES; CORTICES; PATTERN; SYSTEMS; HUMANS; IMAGES	In an associative Learning paradigm, human subjects could be divided based on whether they were aware that one tone predicted a visual event and another did not. Only aware subjects acquired a differential behavioral response to the tones, Regional cerebral blood flow in left prefrontal cortex showed learning-related changes only in aware subjects. Left prefrontal cortex also showed changes in functional connectivity with contralateral prefrontal cortex, sensory association cortices, and cerebellum. Several of the interacting areas correlated with aware subjects' behavior, These results suggest cerebral processes underlying awareness are mediated through interactions of large-scale neurocognitive systems.	Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada	University of Toronto; University Toronto Affiliates; Baycrest	McIntosh, AR (corresponding author), Baycrest Ctr Geriatr Care, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	mcintosh@psych.utoronto.ca	McIntosh, Anthony R/G-4955-2011; Rajah, Maria Natasha/AAE-8429-2019	Rajah, Maria Natasha/0000-0001-6177-7049; McIntosh, Anthony/0000-0002-1784-5662				Berns GS, 1997, SCIENCE, V276, P1272, DOI 10.1126/science.276.5316.1272; Braun AR, 1998, SCIENCE, V279, P91, DOI 10.1126/science.279.5347.91; Buchel C, 1999, SCIENCE, V283, P1538, DOI 10.1126/science.283.5407.1538; Clark RE, 1998, SCIENCE, V280, P77, DOI 10.1126/science.280.5360.77; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; Friston K. J., 1993, Human Brain Mapping, V1, P69, DOI 10.1002/hbm.460010108; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Friston KJ, 1997, NEUROIMAGE, V5, P213, DOI 10.1006/nimg.1997.0260; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; GRAFTON ST, 1995, J COGNITIVE NEUROSCI, V7, P497, DOI 10.1162/jocn.1995.7.4.497; KNIGHT RT, 1995, ADV NEUROL, V66, P21; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 1997, HUM BRAIN MAPP, V5, P323, DOI 10.1002/(SICI)1097-0193(1997)5:4<323::AID-HBM20>3.0.CO;2-D; McIntosh AR, 1998, J NEUROPHYSIOL, V80, P3148, DOI 10.1152/jn.1998.80.6.3148; McIntosh AR, 1998, CEREB CORTEX, V8, P648, DOI 10.1093/cercor/8.7.648; MCINTOSH AR, 1994, J NEUROSCI, V14, P655; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; MOLCHAN SE, 1994, P NATL ACAD SCI USA, V91, P8122, DOI 10.1073/pnas.91.17.8122; Morris JS, 1998, P ROY SOC B-BIOL SCI, V265, P649, DOI 10.1098/rspb.1998.0343; PETRIDES M, 1985, NEUROPSYCHOLOGIA, V23, P601, DOI 10.1016/0028-3932(85)90062-4; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PICTON TW, 1994, CURR OPIN NEUROBIOL, V4, P256, DOI 10.1016/0959-4388(94)90082-5; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; Sakai K, 1998, J NEUROSCI, V18, P1827; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; STUSS DT, IN PRESS FRONTAL LOB; STUSS DT, 1987, FRONTAL LOBES REVIS; Talairach J., 1988, COPLANAR STEREOTAXIC, P5; Thomas G., 1987, BIOL PSYCHOL, V25, P187, DOI [10.1016/0301-0511(87)90037-8, DOI 10.1016/0301-0511(87)90037-8]; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Wong PS, 1997, CONSCIOUS COGN, V6, P519, DOI 10.1006/ccog.1997.0322; WOODS RP, 1992, J COMPUT ASSIST TOMO, V16, P620, DOI 10.1097/00004728-199207000-00024	32	146	150	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 28	1999	284	5419					1531	1533		10.1126/science.284.5419.1531	http://dx.doi.org/10.1126/science.284.5419.1531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10348741				2022-12-01	WOS:000080548100038
J	Draper, ES; Kurinczuk, JJ; Abrams, KR; Clarke, M				Draper, ES; Kurinczuk, JJ; Abrams, KR; Clarke, M			Assessment of separate contributions to perinatal mortality of infertility history and treatment: a case-control analysis	LANCET			English	Article							INVITRO FERTILIZATION; MULTIPLE BIRTHS; PREGNANCIES	Background. Few studies have described the perinatal risks associated with infertility, other than for infertility treated by in-vitro fertilisation or gamete intrafallopian transfer, The aim of this analysis was to estimate the risks of perinatal death associated with treated and untreated infertility. Methods. A population-based case-control study of perinatal deaths was carried out in Leicestershire Health District over the period 1990-94, during which 60922 babies were delivered. Of these, 567 perinatal deaths were associated with 542 women. 972 mothers were randomly selected as controls. Medical. obstetric, and social data were collected for cases and controls from the medical notes and interviews with the women,The relative risks of perinatal death associated with treated and untreated infertility before the index pregnancy were estimated as odds ratios by means of unconditional logistic regression analysis. Findings. 65 (10%) of cases and 34 (3.5%) of the controls had infertility before the index pregnancy. History of infertility in the index pregnancy, irrespective of treatment, increased the risk of perinatal death (odds ratio 2.9 [95% Cl 1.8-4.5]). The population attributable risk fraction for perinatal death related to infertility was 62% (3.4-9.0). 45 (54%) of the deaths, even in the untreated group, were associated with immaturity. Compared with women without infertility, women with untreated infertility were at increased risk of perinatal death (3.3 [1.6-6.8]). The risk of perinatal death associated with multiple births did not explain this finding. Similarly, treated infertility also increased the risk of perinatal death (2.7 [1.5-4.7]); the risks associated with multiple births explained some, but not all, of this excess. In Leicestershire, the overall underlying risk of a mother experiencing at least one perinatal death over the study was 9.0 per 1000 women. For women who experience infertility, this risk increases by about 18 per 1000 (6-30). Interpretation. Counselling for women before any form of infertility treatment should include discussion of the risks of perinatal death. Our results would benefit from confirmation. However, we advocate that at antenatal booking a history of infertility, irrespective of treatment, should be sought, because these women have a significantly increased risk of perinatal death, particularly associated with prematurity.	Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; TVW Telethon Inst Child Hlth Res, W Perth, Australia	University of Leicester; Telethon Kids Institute; University of Western Australia	Draper, ES (corresponding author), Univ Leicester, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England.		Draper, Elizabeth/S-6874-2019; Draper, Elizabeth S/I-6304-2018; Abrams, Keith/AAA-2557-2020	Draper, Elizabeth/0000-0001-9340-8176; Draper, Elizabeth S/0000-0001-9340-8176; Abrams, Keith/0000-0002-7557-1567				BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; CLARKE M, 1988, BMJ-BRIT MED J, V297, P384, DOI 10.1136/bmj.297.6645.384; CLARKE M, 1993, BRIT MED J, V306, P824, DOI 10.1136/bmj.306.6881.824; CLARKE M, 1988, BRIT MED J, V296, P466, DOI 10.1136/bmj.296.6620.466; CLARKE M, 1981, AM J EPIDEMIOL, V113, P636, DOI 10.1093/oxfordjournals.aje.a113142; EZRA Y, 1993, EUR J OBSTET GYN R B, V48, P127, DOI 10.1016/0028-2243(93)90253-9; *HUM FERT EMBR AUT, 1996, 5 HFEA; KURINCZUK JJ, 1995, AUST NZ J OBSTET GYN, V35, P27, DOI 10.1111/j.1479-828X.1995.tb01825.x; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; MCFAUL PB, 1993, BRIT J OBSTET GYNAEC, V100, P820, DOI 10.1111/j.1471-0528.1993.tb14306.x; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; TAN SL, 1992, AM J OBSTET GYNECOL, V167, P778, DOI 10.1016/S0002-9378(11)91589-0; VENN A, 1993, AUST NZ J OBSTET GYN, V33, P379, DOI 10.1111/j.1479-828X.1993.tb02114.x; WIGGLESWORTH JS, 1980, LANCET, V2, P684; WILLIAMS MA, 1991, FERTIL STERIL, V56, P668	15	126	127	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1746	1749		10.1016/S0140-6736(98)08500-6	http://dx.doi.org/10.1016/S0140-6736(98)08500-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347987				2022-12-01	WOS:000080667700012
J	Makishima, M; Okamoto, AY; Repa, JJ; Tu, H; Learned, RM; Luk, A; Hull, MV; Lustig, KD; Mangelsdorf, DJ; Shan, B				Makishima, M; Okamoto, AY; Repa, JJ; Tu, H; Learned, RM; Luk, A; Hull, MV; Lustig, KD; Mangelsdorf, DJ; Shan, B			Identification of a nuclear receptor for bile acids	SCIENCE			English	Article							BINDING PROTEIN; RESPONSE PATHWAY; ORPHAN RECEPTORS; LXR-ALPHA; COACTIVATOR; ACTIVATION; SPECIFICITY; EXPRESSION; METABOLISM; TRANSPORT	Bile acids are essential for the solubilization and transport of dietary lipids and are the major products of cholesterol catabolism. Results presented here show that bile acids are physiological Ligands for the farnesoid X receptor (FXR), an orphan nuclear receptor. When bound to bile acids, FXR repressed transcription of the gene encoding cholesterol 7 alpha-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis, and activated the gene encoding intestinal bile acid-binding protein, which is a candidate bile acid transporter. These results demonstrate a mechanism by which bile acids transcriptionally regulate their biosynthesis and enterohepatic transport.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Tularik Inc, S San Francisco, CA 94080 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Mangelsdorf, David/0000-0002-4355-0796; Repa, Joyce/0000-0001-5740-1954; Hull, Mitchell/0000-0002-9364-1901				AKASHI Y, 1983, CLIN CHIM ACTA, V133, P125; CAREY MC, 1994, LIVER BIOL PATHOBIOL, pCH39; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; CROWTHER JR, 1995, METHODS MOL BIOL, V42; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GONG YZ, 1994, P NATL ACAD SCI USA, V91, P4741, DOI 10.1073/pnas.91.11.4741; HOFMANN AF, 1994, LIVER BIOL PATHOBIOL, pCH38; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; LARUSSO NF, 1975, GASTROENTEROLOGY, V69, P1301; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LUSTIG KD, UNPUB; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; ONATE SA, 1995, SCIENCE, V270, P1354; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; REPA JJ, UNPUB; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Sippel CJ, 1997, J BIOL CHEM, V272, P18290, DOI 10.1074/jbc.272.29.18290; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, pCH34; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	30	2062	2181	9	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1362	1365		10.1126/science.284.5418.1362	http://dx.doi.org/10.1126/science.284.5418.1362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334992				2022-12-01	WOS:000080430600055
J	Villar, RG; Macek, MD; Simons, S; Hayes, PS; Goldoft, MJ; Lewis, JH; Rowan, LL; Hursh, D; Patnode, M; Mead, PS				Villar, RG; Macek, MD; Simons, S; Hayes, PS; Goldoft, MJ; Lewis, JH; Rowan, LL; Hursh, D; Patnode, M; Mead, PS			Investigation of multidrug-resistant Salmonella serotype Typhimurium DT104 infections linked to raw-milk cheese in Washington State	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESCHERICHIA-COLI O157-H7; UNITED-STATES; MULTIRESISTANT STRAINS; SOFT CHEESE; OUTBREAK; CATTLE	Context Multidrug-resistant Salmonella Typhimurium DT104 has recently emerged as a cause of human and animal illness in Europe and North America. In early 1997, health officials in Yakima County, Washington, noted a 5-fold increase in salmonellosis among the county's Hispanic population. Objectives To characterize bacterial strains and identify risk factors for infection with Salmonella Typhimurium in Yakima County. Design Laboratory, case-control, and environmental investigations. Setting and Participants Patients with culture-confirmed Salmonella Typhimurium infection living in Yakima County and age- and neighborhood-matched control subjects. Main Outcome Measures Food vehicle implication based on case-control study and outbreak control. Results Between January 1 and May 5, 1997, 54 culture-confirmed cases of Salmonella Typhimurium were reported. The median age of patients was 4 years and 91% were Hispanic. Patients reported diarrhea (100%), abdominal cramps (93%), fever (93%), bloody stools (72%), and vomiting (53%); 5 patients (9%) were hospitalized. Twenty-two patients and 61 control subjects were enrolled in the case-control study. Seventeen case patients (77%) reported eating unpasteurized Mexican-style soft cheese in the 7 days before onset of illness compared with 17 control subjects (28%) (matched odds ratio, 32.3; 95% confidence interval, 3.0-874.6). All case-patient isolates were phage definitive type 104 (DT104) (n = 10) or DT104b (n = 12), and 20 (91%) were resistant to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline. The cheese produced and eaten by 2 unrelated patients was made with raw milk traced to the same local farm. Milk samples from nearby dairies yielded Salmonella Typhimurium DT104. The incidence of Salmonella Typhimurium infections in Yakima County returned to pre-1992 levels following interventions based on these findings. Conclusions Multidrug-resistant Salmonella Typhimurium DT104 emerged as a cause of salmonellosis in Yakima County, and Mexican-style soft cheese made with unpasteurized milk is an important vehicle for Salmonella Typhimurium DT104 transmission. We postulate that recent increases in human salmonellosis reflect the emergence of Salmonella Typhimurium DT104 among dairy cows in the region. Continued efforts are needed to discourage consumption of raw milk products, promote healthier alternatives, and study the ecology of multidrug-resistant Salmonella Typhimurium.	Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30333 USA; Natl Ctr Hlth Stat, Illness & Disabil Stat Branch, Div Hlth Interview Stat, Hyattsville, MD 20782 USA; Washington State Dept Hlth, Seattle, WA USA; Washington State Univ, Cooperat Extens, Pullman, WA 99164 USA; Yakima Cty Hlth Dist, Yakima, WA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Washington State University	Mead, PS (corresponding author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Natl Ctr Infect Dis, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA.			Macek, Mark/0000-0002-8677-2719				ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; Angulo FJ, 1997, AM J PUBLIC HEALTH, V87, P580, DOI 10.2105/AJPH.87.4.580; Ansay SE, 1997, LETT APPL MICROBIOL, V25, P131, DOI 10.1046/j.1472-765X.1997.00190.x; Barry AL., 1991, MANUAL CLIN MICROBIO, P117; Besser TE, 1997, VET REC, V140, P75; *CDCP, 1997, ANN TAB SALM SURV 19; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P308; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; Cody SH, 1999, JAMA-J AM MED ASSOC, V281, P1805, DOI 10.1001/jama.281.19.1805; Deschenes G, 1996, PEDIATR NEPHROL, V10, P203; Desenclos JC, 1996, BRIT MED J, V312, P91, DOI 10.1136/bmj.312.7023.91; Djuretic T, 1997, Commun Dis Rep CDR Rev, V7, pR41; Evans S, 1996, VET REC, V139, P557; FRIEDMAN CR, 1998, INT C EM INF DIS MAR; Gautom RK, 1997, J CLIN MICROBIOL, V35, P2977, DOI 10.1128/JCM.35.11.2977-2980.1997; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; Headrick ML, 1998, AM J PUBLIC HEALTH, V88, P1219, DOI 10.2105/AJPH.88.8.1219; KASRAZADEH M, 1994, INT J FOOD MICROBIOL, V22, P127, DOI 10.1016/0168-1605(94)90137-6; MARTIN D, 1996, EPIDEMIOLOGY, V7, P2933; Quinto EJ, 1997, LETT APPL MICROBIOL, V24, P291, DOI 10.1046/j.1472-765X.1997.00072.x; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; Slutsker L, 1997, ANN INTERN MED, V126, P505, DOI 10.7326/0003-4819-126-7-199704010-00002; TAUXE RV, 1991, J FOOD PROTECT, V54, P563, DOI 10.4315/0362-028X-54.7.563; Threlfall EJ, 1998, VET REC, V142, P255; Threlfall EJ, 1996, LANCET, V347, P1053, DOI 10.1016/S0140-6736(96)90199-3; WALL PG, 1995, VET REC, V136, P591, DOI 10.1136/vr.136.23.591; Wall PG, 1996, LANCET, V348, P471, DOI 10.1016/S0140-6736(96)24033-4; WALL PG, 1994, COMMUNICAB DIS REP, V4, P130; WRAY C, 1995, PUBLIC HLT LAB SERV, V13, P44	29	106	107	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1811	1816		10.1001/jama.281.19.1811	http://dx.doi.org/10.1001/jama.281.19.1811			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340368	Bronze			2022-12-01	WOS:000080288800034
J	Izaks, GJ; Westendorp, RGJ; Knook, DL				Izaks, GJ; Westendorp, RGJ; Knook, DL			The definition of anemia in older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE; RESIDENTS AGED 85; POPULATION; HEMOGLOBIN; PREVALENCE; MORTALITY	Context Whether hemoglobin concentrations defined as anemia by the World Health Organization (WHO) are associated with increased mortality in older persons is not known. Objective To investigate the association between hemoglobin concentration and cause-specific mortality in older persons. Design Community-based study conducted from 1986 to 1996 (follow-up period, 10 years). Setting Leiden, the Netherlands. Participants A total of 1016 community residents aged 85 years and older were eligible and 872 agreed to have a blood sample taken. Hemoglobin concentration was measured in 755 persons (74%), Main Outcome Measures Hemoglobin concentration, 10-year survival, and primary cause of death. According to the WHO criteria, anemia was defined as a hemoglobin concentration below 7.5 mmol/L (120 g/L) in women and below 8.1 mmol/L (130 g/L) in men. Results Compared with persons with a normal hemoglobin concentration, the mortality risk was 1.60 (95% confidence interval [CI], 1.24-2.06; P<.001) in women with anemia, and 2.29 (95% CI, 1.60-3.26; P<.001) in men with anemia. In both sexes, the mortality risk increased with lower hemoglobin concentrations. In persons without self-reported clinical disease at baseline, the mortality risk of anemia was 2.21 (95% CI, 1.37-3.57; P=.002). Mortality from malignant and infectious diseases was higher in persons with anemia. Conclusions Anemia defined by the WHO criteria was associated with an increased mortality risk in persons aged 85 years and older. The criteria are thus appropriate for older persons. A low hemoglobin concentration at old age signifies disease.	Leiden Univ, Med Ctr, Sect Gerontol & Geriat, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Izaks, GJ (corresponding author), Leiden Univ, Med Ctr, Sect Gerontol & Geriat, Dept Gen Internal Med, LUMC P3-Q,POB 9600, NL-2300 RC Leiden, Netherlands.		Izaks, Gerbrand/F-5089-2014	Izaks, Gerbrand/0000-0003-3213-7637	NATIONAL INSTITUTE ON AGING [R01AG006354] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06354] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ania BJ, 1997, J AM GERIATR SOC, V45, P825, DOI 10.1111/j.1532-5415.1997.tb01509.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; IZAKS GJ, 1995, PSYCHOL MED, V25, P841, DOI 10.1017/S0033291700035091; Izaks GJ, 1997, J AM GERIATR SOC, V45, P56, DOI 10.1111/j.1532-5415.1997.tb00978.x; JOOSTEN E, 1992, GERONTOLOGY, V38, P111, DOI 10.1159/000213315; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; NILSSONEHLE H, 1989, BRIT J HAEMATOL, V71, P437; SALIVE ME, 1992, J AM GERIATR SOC, V40, P489, DOI 10.1111/j.1532-5415.1992.tb02017.x; TIMIRAS ML, 1987, J AM GERIATR SOC, V35, P639, DOI 10.1111/j.1532-5415.1987.tb04340.x; WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9; *WHO, 1968, NUTR AN REP WHO SCI; *WHO, 1977, INT STAT CLASS DIS	12	323	334	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1714	1717		10.1001/jama.281.18.1714	http://dx.doi.org/10.1001/jama.281.18.1714			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328071				2022-12-01	WOS:000080161200028
J	Johnson, PTJ; Lunde, KB; Ritchie, EG; Launer, AE				Johnson, PTJ; Lunde, KB; Ritchie, EG; Launer, AE			The effect of trematode infection on amphibian limb development and survivorship	SCIENCE			English	Article							DEFORMITIES; BEHAVIOR	The causes of amphibian deformities and their role in widespread amphibian declines remain conjectural. Severe Limb abnormalities were induced at high frequencies in Pacific treefrogs (Hyla regilla) exposed to cercariae of a trematode parasite (Ribeiroia sp.). The abnormalities closely matched those observed at field sites, and an increase in parasite density caused an increase in abnormality frequency and a decline in tadpole survivorship. These findings call for further investigation of parasite infection as a cause of amphibian deformities in other sites and species.	Stanford Univ, Dept Biol Sci, Ctr Conservat Biol, Stanford, CA 94305 USA; James Cook Univ N Queensland, Dept Zool & Trop Ecol, Townsville, Qld 4811, Australia	Stanford University; James Cook University	Johnson, PTJ (corresponding author), Claremont McKenna Coll, WM Keck Sci Ctr, Roberts Environm Ctr, 925 N Mills Rd, Claremont, CA 91711 USA.		Ritchie, Euan/N-1088-2014; Lunde, Kevin/D-4202-2009	Ritchie, Euan/0000-0003-4410-8868; JOHNSON, PIETER/0000-0002-7997-5390				Bakker TCM, 1997, ECOLOGY, V78, P1098, DOI 10.1890/0012-9658(1997)078[1098:PICIBA]2.0.CO;2; Blaustein AR, 1997, P NATL ACAD SCI USA, V94, P13735, DOI 10.1073/pnas.94.25.13735; Gosner K. L., 1960, Herpetologica, V16, P183; HELGEN JC, 1998, STATUS CONSERVATION, pCH29; HELLUY S, 1990, CAN J ZOOL, V68, P1214, DOI 10.1139/z90-181; Kaiser J, 1997, SCIENCE, V278, P2051, DOI 10.1126/science.278.5346.2051; KUPFERBERG SJ, COMMUNICATION; La Clair JJ, 1998, ENVIRON SCI TECHNOL, V32, P1453, DOI 10.1021/es971024h; MUELLER JF, 1970, J PARASITOL, V56, P840, DOI 10.2307/3277738; Northcote Thomas G., 1992, Monographiae Biologicae, V68, P551; Ouellet M, 1997, J WILDLIFE DIS, V33, P95, DOI 10.7589/0090-3558-33.1.95; Schmidt CW, 1997, ENVIRON SCI TECHNOL, V31, pA324, DOI 10.1021/es9723693; SESSIONS SK, 1990, J EXP ZOOL, V254, P38, DOI 10.1002/jez.1402540107; Sessions SK, 1999, SCIENCE, V284, P800, DOI 10.1126/science.284.5415.800; Stauffer JR, 1997, BIOSCIENCE, V47, P41, DOI 10.2307/1313005; TIETGE JE, 1997, DISCUSSION FINDINGS; TYLER MJ, 1998, AUSTR FROGS NATURAL, P141; Wake DB, 1998, TRENDS ECOL EVOL, V13, P379, DOI 10.1016/S0169-5347(98)01428-1	18	270	289	0	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					802	804		10.1126/science.284.5415.802	http://dx.doi.org/10.1126/science.284.5415.802			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10221912				2022-12-01	WOS:000080056200046
J	Sankaranarayanan, R; Dock-Bregeon, AC; Romby, P; Caillet, J; Springer, M; Rees, B; Ehresmann, C; Ehresmann, B; Moras, D				Sankaranarayanan, R; Dock-Bregeon, AC; Romby, P; Caillet, J; Springer, M; Rees, B; Ehresmann, C; Ehresmann, B; Moras, D			The structure of threonyl-tRNA synthetase-tRNA(Thr) complex enlightens its repressor activity and reveals an essential zinc ion in the active site	CELL			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; TRANSLATIONAL CONTROL; MOLECULAR MIMICRY; CRYSTAL-STRUCTURE; PROTEIN-SYNTHESIS; IDENTITY RULES; AMINO-ACIDS; RECOGNITION; GENE	E. coli threonyl-tRNA synthetase (ThrRS) is a class II enzyme that represses the translation of its own mRNA. We report the crystal structure at 2.9 Angstrom resolution of the complex between tRNA(Thr) and ThrRS, whose structural features reveal novel strategies for providing specificity in tRNA selection. These include an aminoterminal domain containing a novel protein fold that makes minor groove contacts with the tRNA acceptor stem. The enzyme induces a large deformation of the anticodon loop, resulting in an interaction between two adjacent anticodon bases, which accounts for their prominent role in tRNA identity and translational regulation. A zinc ion found in the active site is implicated in amino acid recognition/discrimination.	ULP, INSERM, CNRS,UPR 9004 Biol Struct, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; CNRS, UPR 9002, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; CNRS, UPR 9073, Inst Biol Phys Chim, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Moras, D (corresponding author), ULP, INSERM, CNRS,UPR 9004 Biol Struct, Inst Genet & Biol Mol & Cellulaire, BP163, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	Sankaranarayanan, Rajan/AAI-9295-2020; ROMBY, Pascale/AGP-3328-2022	Dock-Bregeon, Anne-Catherine/0000-0002-6913-4061; Rajan, Sankaranarayanan/0000-0003-4524-9953				Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNEL C, 1993, BIOCHIMIE, V75, P1167, DOI 10.1016/0300-9084(93)90016-L; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BUECHTER DD, 1993, BIOCHEMISTRY-US, V32, P5267, DOI 10.1021/bi00070a039; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DELARUE M, 1993, BIOESSAYS, V15, P675, DOI 10.1002/bies.950151007; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FLORENTZ C, 1995, AMINOACYL TRNA SYNTH, P141; FREIST W, 1995, BIOL CHEM H-S, V376, P213; FREIST W, 1994, EUR J BIOCHEM, V220, P745, DOI 10.1111/j.1432-1033.1994.tb18675.x; Gabriel K, 1996, SCIENCE, V271, P195, DOI 10.1126/science.271.5246.195; GEISSLER S, 1993, GENE, V136, P253, DOI 10.1016/0378-1119(93)90474-H; GRAFFE M, 1992, SCIENCE, V255, P994, DOI 10.1126/science.1372129; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASEGAWA T, 1992, BIOCHEM BIOPH RES CO, V184, P478, DOI 10.1016/0006-291X(92)91219-G; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jovine L, 1996, STRUCTURE, V4, P621, DOI 10.1016/S0969-2126(96)00066-4; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; MEINNEL T, 1995, AMINOACYL TRNA SYNTH, P251; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOINE H, 1990, J MOL BIOL, V216, P299, DOI 10.1016/S0022-2836(05)80321-3; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NUREKI O, 1993, J BIOL CHEM, V268, P15368; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PARK SJ, 1988, J BIOL CHEM, V263, P16527; Romby P, 1996, EMBO J, V15, P5976, DOI 10.1002/j.1460-2075.1996.tb00984.x; ROMBY P, 1992, NUCLEIC ACIDS RES, V20, P5633, DOI 10.1093/nar/20.21.5633; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; SPRINGER M, 1985, J MOL BIOL, V185, P93, DOI 10.1016/0022-2836(85)90185-8; THEOBALD A, 1988, EUR J BIOCHEM, V175, P511, DOI 10.1111/j.1432-1033.1988.tb14223.x; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627	48	259	268	0	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					371	381		10.1016/S0092-8674(00)80746-1	http://dx.doi.org/10.1016/S0092-8674(00)80746-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319817	Bronze			2022-12-01	WOS:000080100500010
J	Hinrichs, KU; Hayes, JM; Sylva, SP; Brewer, PG; DeLong, EF				Hinrichs, KU; Hayes, JM; Sylva, SP; Brewer, PG; DeLong, EF			Methane-consuming archaebacteria in marine sediments	NATURE			English	Article							CARBON ISOTOPIC FRACTIONATION; METHANOGENIC BACTERIA; OXIDATION; DIVERSITY; ARCHAEA; SULFATE; SAMPLES; LIPIDS; FIELD	Large amounts of methane are produced in marine sediments but are then consumed before contacting aerobic waters or the atmosphere(1). Although no organism that can consume methane anaerobically has ever been isolated, biogeochemical evidence indicates that the overall process involves a transfer of electrons from methane to sulphate and is probably mediated by several organisms, including a methanogen (operating in reverse) and a sulphate-reducer (using an unknown intermediate substrate)(2). Here we describe studies of sediments related to a decomposing methane hydrate. These provide strong evidence that methane is being consumed by archaebacteria that are phylogenetically distinct from known methanogens, Specifically, lipid biomarkers that are commonly characteristic of archaea are so strongly depleted in carbon-13 that methane must be the carbon source, rather than the metabolic product, for the organisms that have produced them. Parallel gene surveys of small-subunit ribosomal RNA (16S rRNA) indicate the predominance of a new archael group which is peripherally related to the methanogenic orders Methanomicrobiales and Methanosarcinales.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA	Woods Hole Oceanographic Institution; Monterey Bay Aquarium Research Institute	Hayes, JM (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	jhayes@whoi.edu	Sylva, Sean/D-4400-2014; Hinrichs, Kai-Uwe/C-7675-2009	Sylva, Sean/0000-0002-4727-440X; Hinrichs, Kai-Uwe/0000-0002-0739-9291				BELYAEV SS, 1983, APPL ENVIRON MICROB, V45, P691, DOI 10.1128/AEM.45.2.691-697.1983; BIAN L, 1994, ISOTOPIC BIOGEOCHEMI; Boone David R., 1993, P35; BROOKS JM, 1991, MAR GEOL, V96, P103, DOI 10.1016/0025-3227(91)90204-H; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; FREEMAN KH, 1990, NATURE, V343, P254, DOI 10.1038/343254a0; Grosskopf R, 1998, APPL ENVIRON MICROB, V64, P4983; Hansen LB, 1998, AQUAT MICROB ECOL, V14, P195, DOI 10.3354/ame014195; Harder J, 1997, MAR GEOL, V137, P13, DOI 10.1016/S0025-3227(96)00075-8; HAYES JM, 1990, ORG GEOCHEM, V16, P1115, DOI 10.1016/0146-6380(90)90147-R; Hershberger KL, 1996, NATURE, V384, P420, DOI 10.1038/384420a0; Hoehler TM, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P326; HOEHLER TM, 1994, GLOBAL BIOGEOCHEM CY, V8, P451, DOI 10.1029/94GB01800; HOLZER G, 1979, J CHROMATOGR, V186, P795, DOI 10.1016/S0021-9673(00)95296-8; IRWIN H, 1977, NATURE, V269, P209, DOI 10.1038/269209a0; Kato C, 1997, EXTREMOPHILES, V1, P117, DOI 10.1007/s007920050024; Koga Y, 1998, BIOSCI BIOTECH BIOCH, V62, P230, DOI 10.1271/bbb.62.230; Kvenvolden KA, 1998, GEOL SOC SPEC PUBL, V137, P9, DOI 10.1144/GSL.SP.1998.137.01.02; MacGregor BJ, 1997, APPL ENVIRON MICROB, V63, P1178, DOI 10.1128/AEM.63.3.1178-1181.1997; Massana R, 1997, APPL ENVIRON MICROB, V63, P50, DOI 10.1128/AEM.63.1.50-56.1997; Munson MA, 1997, APPL ENVIRON MICROB, V63, P4729, DOI 10.1128/AEM.63.12.4729-4733.1997; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Reeburgh WS, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P334; SPROTT GD, 1993, APPL ENVIRON MICROB, V59, P912, DOI 10.1128/AEM.59.3.912-914.1993; SUMMONS RE, 1994, GEOCHIM COSMOCHIM AC, V58, P2853, DOI 10.1016/0016-7037(94)90119-8; Summons RE, 1998, ORG GEOCHEM, V28, P465, DOI 10.1016/S0146-6380(98)00011-4; TEIXIDOR P, 1992, J CHROMATOGR, V607, P253, DOI 10.1016/0021-9673(92)87083-K; TORNABENE TG, 1979, SCIENCE, V203, P51, DOI 10.1126/science.758677; Vetriani C, 1998, FEMS MICROBIOL LETT, V161, P83, DOI 10.1111/j.1574-6968.1998.tb12932.x; ZEHNDER AJB, 1979, J BACTERIOL, V137, P420, DOI 10.1128/JB.137.1.420-432.1979	30	903	991	11	316	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					802	805		10.1038/19751	http://dx.doi.org/10.1038/19751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235261				2022-12-01	WOS:000080058100057
J	Manian, FA				Manian, FA			Whither continuity of care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Infect Dis Consultants, St Louis, MO 63141 USA		Manian, FA (corresponding author), Infect Dis Consultants, St Louis, MO 63141 USA.								0	29	29	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 29	1999	340	17					1362	1363		10.1056/NEJM199904293401712	http://dx.doi.org/10.1056/NEJM199904293401712			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191BQ	10219075				2022-12-01	WOS:000080001700012
J	Ozonoff, D; Clapp, R				Ozonoff, D; Clapp, R			Cancer survival is no lottery	LANCET			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA	Boston University	Ozonoff, D (corresponding author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA.			Ozonoff, David/0000-0002-4281-4171; Clapp, Richard/0000-0001-8174-0825				Black JA, 1998, LANCET, V352, P50, DOI 10.1016/S0140-6736(98)02466-0; COLEMAN M, 1999, STUD MED POPUL SUBJ, V61; Geller AC, 1996, AM J PUBLIC HEALTH, V86, P538, DOI 10.2105/AJPH.86.4.538; Hert JT, 1998, LANCET, V352, P51; SAVAGE D, 1984, CANCER, V54, P3085, DOI 10.1002/1097-0142(19841215)54:12<3085::AID-CNCR2820541246>3.0.CO;2-Z	5	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	1999	353	9162					1379	1380		10.1016/S0140-6736(99)00109-9	http://dx.doi.org/10.1016/S0140-6736(99)00109-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227215				2022-12-01	WOS:000080020800006
J	Meneghini, MD; Ishitani, T; Carter, JC; Hisamoto, N; Ninomiya-Tsuji, J; Thorpe, CJ; Hamill, DR; Matsumoto, K; Bowerman, B				Meneghini, MD; Ishitani, T; Carter, JC; Hisamoto, N; Ninomiya-Tsuji, J; Thorpe, CJ; Hamill, DR; Matsumoto, K; Bowerman, B			MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in Caenorhabditis elegans	NATURE			English	Article							BETA SIGNAL-TRANSDUCTION; C-ELEGANS; GENE; SPECIFICATION; DROSOPHILA; WINGLESS; EMBRYOS; ACTIVATOR; MESODERM; ENDODERM	The signalling protein Wnt regulates transcription factors containing high-mobility-group (HMG) domains to direct decisions on cell fate during animal development(1). In Caenorhabditis elegans, the HMG-domain-containing repressor POP-1 distinguishes the fates of anterior daughter cells from their posterior sisters throughout development(2,3), and Wnt signalling downregulates POP-1 activity in one posterior daughter cell called E (refs 2, 4, 5). Here we show that the genes mom-4 and lit-1 are also required to downregulate POP-1, not only in E but also in other posterior daughter cells. Consistent with action in a common pathway, mom-4 and lit-1 exhibit similar mutant phenotypes and encode components of the mitogen-activated protein kinase (MAPK) pathway that are homologous to vertebrate transforming-growth-factor-beta-activated kinase (TAK1) and NEMO-like kinase (NLK), respectively. Furthermore, MOM-4 and TAK1 bind related proteins that promote their kinase activities. We conclude that: a MAPK-related pathway cooperates with Wnt signal transduction to downregulate POP-1 activity. These functions are likely to be conserved in vertebrates, as TAK1 and NLK can downregulate HMG-domain-containing proteins related to POP-1 (ref. 6).	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chkusa Ku, Nagoya, Aichi 4648602, Japan	University of Oregon; Nagoya University; Japan Science & Technology Agency (JST)	Bowerman, B (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	bbowerman@molbio.uoregon.edu	, Tohru/AAH-8979-2020; Ishitani, Tohru/E-9781-2014	, Tohru/0000-0002-6200-7043; Ninomiya-Tsuji, Jun/0000-0002-5584-0176	PHS HHS [R01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; BRENNER S, 1974, GENETICS, V77, P71; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; EPSTEIN HF, 1995, MODERN BIOL ANAL ORG; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1221; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kaletta T, 1997, NATURE, V390, P294, DOI 10.1038/36869; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PRIESS JR, 1987, CELL, V34, P85; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	28	231	243	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					793	797						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391246				2022-12-01	WOS:000081101600056
J	Wang, J; Smolyar, A; Tan, KM; Liu, J; Kim, MY; Sun, ZJ; Wagner, G; Reinherz, EL				Wang, J; Smolyar, A; Tan, KM; Liu, J; Kim, MY; Sun, ZJ; Wagner, G; Reinherz, EL			Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors	CELL			English	Article							T-CELL ACTIVATION; FUNCTION-ASSOCIATED ANTIGEN-3; PROTEIN-PROTEIN INTERFACES; CRYSTAL-STRUCTURE; MOLECULE CD2; IMMUNOGLOBULIN SUPERFAMILY; RECEPTOR CD2; MOUSE CHROMOSOME-1; GLYCOPROTEIN CD2; LIGAND-BINDING	Interaction between CD2 and its counterreceptor, CD58 (LFA-3), on opposing cells optimizes immune recognition, facilitating contacts between helper T lymphocytes and antigen-presenting cells as well as between cytolytic effecters and target cells. Here, we report the crystal structure of the heterophilic adhesion complex between the amino-terminal domains of human CD2 and CD58. A strikingly asymmetric, orthogonal, face-to-face interaction involving the major beta sheets of the respective immunoglobulin-like domains with poor shape complementarity is revealed. In the virtual absence of hydrophobic forces, interdigitating charged amino acid side chains form hydrogen bonds and salt links at the interface (similar to 1200 Angstrom(2)), imparting a high degree of specificity albeit with low affinity (K-D of similar to mu M). These features explain CD2-CD58 dynamic binding, offering insights into interactions of related immunoglobulin superfamily receptors.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wang, J (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	jwang@red.dfci.harvard.edu; ellis_reinherz@dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226, R01AI037581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056008] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21226, AI37581] Funding Source: Medline; NIGMS NIH HHS [GM56008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BOUSSIOTIS VA, 1994, J EXP MED, V180, P1665, DOI 10.1084/jem.180.5.1665; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; DAVIS SJ, 1995, J BIOL CHEM, V270, P369, DOI 10.1074/jbc.270.1.369; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; DENGLER TJ, 1992, EUR J IMMUNOL, V22, P2809, DOI 10.1002/eji.1830221109; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; Dustin ML, 1997, J BIOL CHEM, V272, P15782, DOI 10.1074/jbc.272.25.15782; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Freedman SJ, 1996, BIOCHEMISTRY-US, V35, P13733, DOI 10.1021/bi9610257; Garbe TR, 1996, MOL MED, V2, P134, DOI 10.1007/BF03402209; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GOLLOB JA, 1995, J EXP MED, V182, P721, DOI 10.1084/jem.182.3.721; Gollob JA, 1996, J IMMUNOL, V157, P1886; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRENSKY AM, 1983, J IMMUNOL, V131, P611; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lehninger A. L., 1975, BIOCH MOL BASIS CELL, V2nd; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MOINGEON PE, 1991, EUR J IMMUNOL, V21, P605, DOI 10.1002/eji.1830210311; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; MOSELEY WS, 1989, GENOMICS, V5, P899, DOI 10.1016/0888-7543(89)90132-8; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; OSBORN L, 1995, J EXP MED, V181, P429, DOI 10.1084/jem.181.1.429; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PARISH CR, 1988, J IMMUNOL, V141, P3498; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; RECNY MA, 1990, J BIOL CHEM, V265, P8542; RECNY MA, 1992, J BIOL CHEM, V267, P22428; REINHOLD BB, 1992, TECHNIQUES PROTEIN C, V3, P287; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SEWELL WA, 1988, IMMUNOGENETICS, V28, P278, DOI 10.1007/BF00345506; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; SHER PK, 1987, PEDIATR NEUROL, V3, P197; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUN ZYJ, 1999, IN PRESS EMBO J; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412	86	196	201	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					791	803		10.1016/S0092-8674(00)80790-4	http://dx.doi.org/10.1016/S0092-8674(00)80790-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380930	Bronze			2022-12-01	WOS:000080886300016
J	Zamanillo, D; Sprengel, R; Hvalby, O; Jensen, V; Burnashev, N; Rozov, A; Kaiser, KMM; Koster, HJ; Borchardt, T; Worley, P; Lubke, J; Frotscher, M; Kelly, PH; Sommer, B; Andersen, P; Seeburg, PH; Sakmann, B				Zamanillo, D; Sprengel, R; Hvalby, O; Jensen, V; Burnashev, N; Rozov, A; Kaiser, KMM; Koster, HJ; Borchardt, T; Worley, P; Lubke, J; Frotscher, M; Kelly, PH; Sommer, B; Andersen, P; Seeburg, PH; Sakmann, B			Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning	SCIENCE			English	Article							LONG-TERM POTENTIATION; NON-NMDA RECEPTORS; SUBUNIT GLUR-B; LASTING POTENTIATION; GLUTAMATE RECEPTORS; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; LTP; MEMORY; MICE	Gene-targeted mice lacking the L-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate (AM PA) receptor subunit GluR-A exhibited normal development, Life expectancy, and fine structure of neuronal dendrites and synapses. In hippocampal CA1 pyramidal neurons, GluR-A(-/-) mice showed a reduction in functional AMPA receptors, with the remaining receptors preferentially targeted to synapses. Thus, the CA1 soma-patch currents were strongly reduced, but glutamatergic synaptic currents were unaltered; and evoked dendritic and spinous Ca2+ transients, Ca2+-dependent gene activation, and hippocampal field potentials were as in the wild type, in adult GluR-A(-/-) mice, associative Long-term potentiation (LTP) was absent in CA3 to CA1 synapses, but spatial Learning in the water maze was not impaired. The results suggest that CA1 hippocampal LTP is controlled by the number or subunit composition of AMPA receptors and show a dichotomy between LTP in CA1 and acquisition of spatial memory.	Max Planck Inst Med Res, Dept Mol Neurosci, D-69120 Heidelberg, Germany; Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany; Univ Oslo, Dept Physiol, Inst Basic Med Sci, N-0316 Oslo, Norway; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Univ Freiburg, Dept Anat, D-79104 Freiburg, Germany; Novartis Pharma AG, NS Res, Basel, Switzerland	Max Planck Society; Max Planck Society; University of Oslo; Johns Hopkins University; Johns Hopkins University; University of Freiburg; Novartis	Sprengel, R (corresponding author), Max Planck Inst Med Res, Dept Mol Neurosci, Jahnstr 29, D-69120 Heidelberg, Germany.	sprengel@mpimf-heidelberg.mpg.de	Borchardt, Thilo/E-7844-2011; Rozov, Andrei/C-1997-2015; Burnashev, Nail/G-4056-2013; Lubke, Joachim/H-8762-2013	Borchardt, Thilo/0000-0002-2960-0267; Lubke, Joachim/0000-0002-4086-3199				ANDERSEN P, 1983, PROG BRAIN RES, V58, P419, DOI 10.1016/S0079-6123(08)60044-8; ANDERSEN P, 1960, ACTA PHYSIOL SCAND, V48, P178, DOI 10.1111/j.1748-1716.1960.tb01856.x; ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; BLAKE JF, 1988, NEUROSCI LETT, V89, P182, DOI 10.1016/0304-3940(88)90378-3; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Feldmeyer D, 1999, NAT NEUROSCI, V2, P57, DOI 10.1038/4561; FROTSCHER M, 1992, MICROSC RES TECHNIQ, V23, P306, DOI 10.1002/jemt.1070230406; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; Kask K, 1998, P NATL ACAD SCI USA, V95, P13777, DOI 10.1073/pnas.95.23.13777; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KELLY PH, 1993, CAN J PHYSIOL PHARM, V71, P352, DOI 10.1139/y93-055; Koester HJ, 1998, P NATL ACAD SCI USA, V95, P9596, DOI 10.1073/pnas.95.16.9596; KOHLER M, 1994, J BIOL CHEM, V269, P17367; KULLMANN DM, 1995, NEURON, V15, P997, DOI 10.1016/0896-6273(95)90089-6; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; Meiri N, 1998, P NATL ACAD SCI USA, V95, P15037, DOI 10.1073/pnas.95.25.15037; MOLNAR E, 1993, NEUROSCIENCE, V53, P307, DOI 10.1016/0306-4522(93)90198-O; Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; NostenBertrand M, 1996, NATURE, V379, P826, DOI 10.1038/379826a0; Okabe S, 1998, J NEUROSCI, V18, P4177; Petralia RS, 1997, J COMP NEUROL, V385, P456, DOI 10.1002/(SICI)1096-9861(19970901)385:3<456::AID-CNE9>3.0.CO;2-2; PHEND KD, 1992, J HISTOCHEM CYTOCHEM, V40, P1011, DOI 10.1177/40.7.1376741; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; Schurmans S, 1997, P NATL ACAD SCI USA, V94, P10415, DOI 10.1073/pnas.94.19.10415; Silver RA, 1996, J PHYSIOL-LONDON, V493, P167, DOI 10.1113/jphysiol.1996.sp021372; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; WIGSTROM H, 1985, ACTA PHYSIOL SCAND, V125, P159, DOI 10.1111/j.1748-1716.1985.tb07703.x; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0; WORLEY PF, 1990, COLD SPRING HARB SYM, V55, P213, DOI 10.1101/SQB.1990.055.01.023	52	608	619	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 11	1999	284	5421					1805	1811		10.1126/science.284.5421.1805	http://dx.doi.org/10.1126/science.284.5421.1805			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364547				2022-12-01	WOS:000080809000041
J	Leitzmann, MF; Willett, WC; Rimm, EB; Stampfer, MJ; Spiegelman, D; Colditz, GA; Giovannucci, E				Leitzmann, MF; Willett, WC; Rimm, EB; Stampfer, MJ; Spiegelman, D; Colditz, GA; Giovannucci, E			A prospective study of coffee consumption and the risk of symptomatic gallstone disease in men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; CHOLESTEROL-RAISING FACTOR; LOGISTIC-REGRESSION; LIPID-PEROXIDATION; PHYSICAL-ACTIVITY; BOILED COFFEE; CYCLIC-AMP; CAFFEINE; BILE; SMOKING	Context. Coffee has several metabolic effects that could reduce the risk of gallstone formation. Objective To examine the association between coffee consumption and the risk of symtomatic gallstone disease in men. Design and Setting The Health Professionals Follow-up Study, a prospective cohort study, in which the consumption of coffee and other caffeinated drinks was assessed starting in 1986 as part of the 131-item food frequency questionnaire given to US male health professionals with follow-up through 1996. Participants. A total of 46008 men, aged 40 to 75 years in 1986, without history of gallstone disease. Main Outcome Measures. Newly symptomatic gallstone disease (diagnosed by ultrasonography or x-ray) or a cholecystectomy. Results. During 404166 person-years of follow-up, 1081 subjects reported symptomatic gallstone disease, of whom 885 required cholecystectomy. After adjusting for other known or suspected risk factors, compared with men who did not: consume regular coffee in 1986 and 1990, the adjusted relative risk (RR) for those who consistently drank 2 to 3 cups of regular coffee per day was 0.60 (95% confidence interval [CI], 0.42-0.86) and far those who drank 4 or more cups per day the RR was 0.55 (95% CI, 0.33-0.92). All coffee brewing methods showed a decreased risk. The risk of symptomatic gallstone disease also declined with increasing caffeine intake (P for trend = .005). After controlling for known or suspected risk factors, the RR for men in the highest category of caffeine intake (>800 mg/d) compared with men in the lowest category (less than or equal to 25 mg/d) was 0.55 (95% CI, 0.35-0.87). In contrast, decaffeinated coffee was not associated with a decreased risk. Conclusions. In this cohort of US men, coffee consumption may have helped to prevent symptomatic gallstone disease.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Leitzmann, MF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	Michael.Leitzmann@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline; PHS HHS [T4509856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aeschbacher HU, 1991, MUTAGENS FOOD DETECT, P181; ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759; BARBARA L, 1995, AM J EPIDEMIOL, V141, P158, DOI 10.1093/oxfordjournals.aje.a117403; BASSO L, 1992, EUR J EPIDEMIOL, V8, P629, DOI 10.1007/BF00145375; BOTHAM KM, 1986, BIOCHIM BIOPHYS ACTA, V889, P382, DOI 10.1016/0167-4889(86)90202-8; Breslow NE, 1987, STAT METHODS CANC RE, VII; CONTER RL, 1986, AM J SURG, V151, P184, DOI 10.1016/0002-9610(86)90030-9; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; CURATOLO PW, 1983, ANN INTERN MED, V98, P641, DOI 10.7326/0003-4819-98-5-641; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Devasagayam TPA, 1996, BBA-BIOMEMBRANES, V1282, P63, DOI 10.1016/0005-2736(96)00040-5; DOUGLAS BR, 1990, AM J CLIN NUTR, V52, P553, DOI 10.1093/ajcn/52.3.553; Eder MI, 1996, FREE RADICAL BIO MED, V20, P743, DOI 10.1016/0891-5849(95)02154-X; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FRIEDMAN GD, 1989, J CLIN EPIDEMIOL, V42, P127, DOI 10.1016/0895-4356(89)90086-3; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; GIOVANNUCCI E, 1992, JNCI-J NATL CANCER I, V84, P91, DOI 10.1093/jnci/84.2.91; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; GULLESTAD L, 1992, ALCOHOL CLIN EXP RES, V16, P986, DOI 10.1111/j.1530-0277.1992.tb01906.x; HOLSTEGE A, 1993, J HEPATOL, V17, P67, DOI 10.1016/S0168-8278(05)80523-9; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; KALSER SC, 1993, AM J SURG, V165, P390; KANG JY, 1992, GUT, V33, P743, DOI 10.1136/gut.33.6.743; KATO H, 1995, ANGIOLOGY, V46, P169, DOI 10.1177/000331979504600212; Keiner F, 1965, Med Welt, V34, P1907; KLAPDOR R, 1978, ARZNEIMITTEL-FORSCH, V28-2, P1635; KNODELL RG, 1978, P SOC EXP BIOL MED, V157, P306; KONO S, 1991, DEV GASTRO, V12, P129; Kratzer W, 1997, SCAND J GASTROENTERO, V32, P953, DOI 10.3109/00365529709011208; LAVECCHIA C, 1991, INT J EPIDEMIOL, V20, P209, DOI 10.1093/ije/20.1.209; LILLEMOE KD, 1989, SURGERY, V106, P400; MAGNUSON T H, 1989, Current Surgery, V46, P477; MAURER KR, 1989, GASTROENTEROLOGY, V96, P487, DOI 10.1016/0016-5085(89)91575-8; Misciagna G, 1996, EUR J GASTROEN HEPAT, V8, P585, DOI 10.1097/00042737-199606000-00017; *NAT CTR HLTH STAT, 1994, NAT HOSP DISCH SURV; *NAT I DIAB DIG KI, 1995, NIH PUBL; Ortega RM, 1997, J AM COLL NUTR, V16, P88, DOI 10.1080/07315724.1997.10718655; PASTIDES H, 1990, ARCH INTERN MED, V150, P1409, DOI 10.1001/archinte.150.7.1409; Post SM, 1997, ARTERIOSCL THROM VAS, V17, P3064, DOI 10.1161/01.ATV.17.11.3064; Rao SSC, 1998, EUR J GASTROEN HEPAT, V10, P113, DOI 10.1097/00042737-199802000-00003; REYMANN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P158, DOI 10.1016/0167-4889(89)90203-6; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; Rustan AC, 1997, ARTERIOSCL THROM VAS, V17, P2140, DOI 10.1161/01.ATV.17.10.2140; SAHL T, 1998, AM J EPIDEMIOL, V147, P644; STAVRIC B, 1992, FOOD CHEM TOXICOL, V30, P533, DOI 10.1016/0278-6915(92)90106-U; *USDA, 1995, USDA NUTR DAT STAND; WEUSTENVANDERWOUW MPME, 1994, J LIPID RES, V35, P721	49	83	86	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1999	281	22					2106	2112		10.1001/jama.281.22.2106	http://dx.doi.org/10.1001/jama.281.22.2106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TJ	10367821	Bronze			2022-12-01	WOS:000080668000033
J	Margot, JL; Campbell, DB; Jurgens, RF; Slade, MA				Margot, JL; Campbell, DB; Jurgens, RF; Slade, MA			Topography of the lunar poles from radar interferometry: A survey of cold trap locations	SCIENCE			English	Article							POLAR ANOMALIES; MERCURY; ICE; MOON; CLEMENTINE; STABILITY; IMAGES; REGION	Detailed topographic maps of the lunar poles have been obtained by Earth-based radar-interferometry with the 3.5-centimeter wavelength Goldstone Solar System Radar. The interferometer provided maps 300 kilometers by 1000 kilometers of both polar regions at 150-meter spatial resolution and 50-meter height resolution. Using ray tracing, these digital elevation models were used to locate regions that are in permanent shadow from solar illumination and may harbor ice-deposits. Estimates of the total extent of shadowed areas poleward of 87.5 degrees latitude are 1030 and 2550 square kilometers for the north and south poles, respectively.	Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	Cornell University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Campbell, DB (corresponding author), Arecibo Observ, HC3 Box 53995, Arecibo, PR 00612 USA.		Margot, Jean-Luc/A-6154-2012	Margot, Jean-Luc/0000-0001-9798-1797				ARNOLD JR, 1979, J GEOPHYS RES, V84, P5659, DOI 10.1029/JB084iB10p05659; Butler BJ, 1997, J GEOPHYS RES-PLANET, V102, P19283, DOI 10.1029/97JE01347; BUTLER BJ, 1993, J GEOPHYS RES-PLANET, V98, P15003, DOI 10.1029/93JE01581; EVANS JV, 1968, RADAR ASTRONOMYU; Feldman WC, 1998, SCIENCE, V281, P1496, DOI 10.1126/science.281.5382.1496; HARMON JK, 1994, NATURE, V369, P213, DOI 10.1038/369213a0; HARMON JK, 1992, SCIENCE, V258, P640, DOI 10.1126/science.258.5082.640; HARMON JP, UNPUB; INGERSOLL AP, 1992, ICARUS, V100, P40, DOI 10.1016/0019-1035(92)90016-Z; LANZEROTTI LJ, 1981, J GEOPHYS RES, V86, P3949, DOI 10.1029/JB086iB05p03949; MARGOT JL, IN PRESS J GEOPHYS R; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; NOZETTE S, 1994, SCIENCE, V266, P1835, DOI 10.1126/science.266.5192.1835; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495; SALVAIL JR, 1994, ICARUS, V111, P441, DOI 10.1006/icar.1994.1155; SHAPIRO II, 1972, SCIENCE, V178, P939, DOI 10.1126/science.178.4064.939; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; Simpson RA, 1999, J GEOPHYS RES-PLANET, V104, P3845, DOI 10.1029/1998JE900038; SLADE MA, 1992, SCIENCE, V258, P635, DOI 10.1126/science.258.5082.635; Smith DE, 1997, J GEOPHYS RES-PLANET, V102, P1591, DOI 10.1029/96JE02940; Stacy NJS, 1997, SCIENCE, V276, P1527, DOI 10.1126/science.276.5318.1527; VASAVADA AR, UNPUB; WARD WR, 1975, SCIENCE, V189, P377, DOI 10.1126/science.189.4200.377; WATSON K, 1961, J GEOPHYS RES, V66, P3033, DOI 10.1029/JZ066i009p03033; Zuber MT, 1997, GEOPHYS RES LETT, V24, P2183, DOI 10.1029/97GL02111; [No title captured]	26	97	110	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1658	1660		10.1126/science.284.5420.1658	http://dx.doi.org/10.1126/science.284.5420.1658			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356393				2022-12-01	WOS:000080668300041
J	Lee, D; Sohn, H; Kalpana, GV; Choe, J				Lee, D; Sohn, H; Kalpana, GV; Choe, J			Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA	NATURE			English	Article							POLYMERASE ALPHA-PRIMASE; TRANSCRIPTIONAL ACTIVATOR; SACCHAROMYCES-CEREVISIAE; TRANSIENT REPLICATION; LARGE-T; E2; HELICASE; YEAST; GENES; SNF5	Mammalian viruses often use components of the host's cellular DNA replication machinery to carry out replication of their genomes, which enables these viruses to be used as tools for characterizing factors that are involved in cellular DNA replication. The human papillomavirus (HPV) E1 protein is essential for replication of the virus DNA(1-3). Here we identify the cellular factor that participates in viral DNA replication by using a two-hybrid assay(4) in the yeast Saccharomyces cerevisiae and E1 protein as bait. Using this assay, we isolated Ini1/hSNF5 (ref. 5), a component of the SWI/SNF complex which facilitates transcription by altering the structure of chromatin(6). In vitro binding and immunoprecipitation confirmed that E1 interacts directly with Ini1/hSNF5. Transient DNA-replication assay revealed that HPV DNA replication is stimulated in a dose-dependent manner by addition of Ini1/hSNF5, and that Ini1/hSNF5 antisense RNA blocks the replication of HPV DNA. Amino-acid substitution at residues that are conserved among E1 proteins prevented the E1-Ini1/hSNF5 interaction and reduced DNA replication of HPV in vivo. Our results indicate that Ini1/hSNF5 is required for the efficient replication of papillomavirus DNA and is therefore needed, either alone or in complex with SWI/SNF complex, for mammalian DNA replication as well.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Korea Advanced Institute of Science & Technology (KAIST); Yeshiva University; Albert Einstein College of Medicine	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Lee, Daeyoup/C-1653-2011; Choe, Joonho/F-3066-2011	Lee, Daeyoup/0000-0003-2006-1823; Kalpana, Ganjam/0000-0003-4111-0604				CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CLERTANT P, 1984, NATURE, V311, P276, DOI 10.1038/311276a0; DELVECCHIO AM, 1992, J VIROL, V66, P5949, DOI 10.1128/JVI.66.10.5949-5958.1992; Demeret C, 1995, NUCLEIC ACIDS RES, V23, P4777, DOI 10.1093/nar/23.23.4777; Gause William C., 1995, P293; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LAURENT BC, 1990, MOL CELL BIOL, V10, P5616, DOI 10.1128/MCB.10.11.5616; Lee D, 1997, VIRUS RES, V52, P97, DOI 10.1016/S0168-1702(97)00114-7; LI R, 1994, P NATL ACAD SCI USA, V91, P7051, DOI 10.1073/pnas.91.15.7051; Mansky KC, 1997, J VIROL, V71, P7600, DOI 10.1128/JVI.71.10.7600-7608.1997; Masterson PJ, 1998, J VIROL, V72, P7407, DOI 10.1128/JVI.72.9.7407-7419.1998; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Morozov A, 1998, P NATL ACAD SCI USA, V95, P1120, DOI 10.1073/pnas.95.3.1120; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; PARK P, 1994, P NATL ACAD SCI USA, V91, P8700, DOI 10.1073/pnas.91.18.8700; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; YANG L, 1993, P NATL ACAD SCI USA, V90, P5086, DOI 10.1073/pnas.90.11.5086; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Yasugi T, 1997, J VIROL, V71, P891, DOI 10.1128/JVI.71.2.891-899.1997; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	27	99	107	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					487	491		10.1038/20966	http://dx.doi.org/10.1038/20966			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365963				2022-12-01	WOS:000080667900053
J	Lebech, M; Andersen, O; Christensen, NC; Hertel, J; Nielsen, HE; Peitersen, B; Rechnitzer, C; Larsen, SO; Norgaard-Pedersen, B; Petersen, E				Lebech, M; Andersen, O; Christensen, NC; Hertel, J; Nielsen, HE; Peitersen, B; Rechnitzer, C; Larsen, SO; Norgaard-Pedersen, B; Petersen, E		Danish Congenital Toxoplasmosis Study Grp	Feasibility of neonatal screening for toxoplasma infection in the absence of prenatal treatment	LANCET			English	Article							IMMUNOGLOBULIN-M IGM; CONGENITAL TOXOPLASMOSIS; PREGNANT-WOMEN; FOLLOW-UP; ANTIBODIES; DIAGNOSIS; ASSAY	Background. The best method for prevention and control of congenital toxoplasma infection is uncertain. Prenatal screening is done in Austria and France, but the effect of treatment during pregnancy is not well documented. The aim of our study was to find out the maternofetal transmission rate and outcome in infants born to mothers who were not treated during pregnancy. Methods. We analysed 89873 eluates from phenylketonuria (PKU) cards from neonates and paired first-trimester serum samples from the mothers for specific IgG antibodies to Toxoplasma gondii. Children born to mothers who seroconverted during pregnancy were followed-up clinically and serologically to 12 months of age. In addition, 21144 PKU cards were analysed for toxoplasma-specific IgM antibodies during the last 12 months of the study. Findings. In 24989 (27.8%) cases both the PKU eluate and the first-trimester samples were IgG positive, which indicates previous maternal infection. 139 of the 64884 seronegative women acquired toxoplasma infection during pregnancy and gave birth to 141 infants (two sets of twins). 27 of these children were diagnosed with congenital toxoplasma infection. The transmission rate was 19.4% (95% Cl 13.2-27.0). Clinical signs and symptoms were found in four (15%) of the 27 children. The additional analysis for toxoplasma-specific IgM antibodies from the PKU card identified seven of nine children with congenital toxoplasma infection. The false-positive rate for the IgM test was 0.19 per 1000, and no false-negatives were found. Interpretation. The risks of transmission of infection and of disease in the infant are low in an area with a low risk of toxoplasma infection. A neonatal screening programme based on detection of toxoplasma-specific IgM antibodies alone will identify between 70% and 80% of cases of congenital toxoplasmosis.	Statens Serum Inst, Parasitol Lab, DK-2300 Copenhagen 5, Denmark; Statens Serum Inst, Dept Biostat, DK-2300 Copenhagen, Denmark; Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen 5, Denmark; Univ Hosp Rigshosp, Dept Paediat, Copenhagen, Denmark; Hillerod Cty Hosp, Dept Paediat, Hillerod, Denmark; Sonderborg Cty Hosp, Dept Paediat, Sonderborg, Denmark; Univ Hosp Gentofte, Dept Paediat, Gentofte, Denmark; Univ Hosp Glostrup, Dept Paediat, Glostrup, Denmark; Hvidovre Univ Hosp, Dept Paediat, Hvidovre, Denmark	Statens Serum Institut; Statens Serum Institut; Statens Serum Institut; Rigshospitalet; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; University of Copenhagen	Petersen, E (corresponding author), Statens Serum Inst, Parasitol Lab, Artillerivej 5, DK-2300 Copenhagen 5, Denmark.							ADES AE, 1993, AM J EPIDEMIOL, V137, P1022, DOI 10.1093/oxfordjournals.aje.a116758; Aspock H, 1990, Osterr Krankenpflegez, V43, P252; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; DESMONTS G, 1974, B NEW YORK ACAD MED, V50, P146; Desmonts G, 1985, Prog Clin Biol Res, V163B, P333; FORSGREN M, 1991, LANCET, V337, P1413, DOI 10.1016/0140-6736(91)93095-Q; FOULON W, 1984, BRIT J OBSTET GYNAEC, V91, P419, DOI 10.1111/j.1471-0528.1984.tb04777.x; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; Harning D, 1996, CLIN DIAGN LAB IMMUN, V3, P355, DOI 10.1128/CDLI.3.3.355-357.1996; HOHLFELD P, 1994, NEW ENGL J MED, V331, P695, DOI 10.1056/NEJM199409153311102; JEANNEL D, 1990, LANCET, V336, P359, DOI 10.1016/0140-6736(90)91890-M; KEMP DT, 1991, ACTA OTO-LARYNGOL, P73; KIMBALL AC, 1971, AM J OBSTET GYNECOL, V111, P211, DOI 10.1016/0002-9378(71)90892-1; KOPPE JG, 1989, INT OPHTHALMOL, V13, P387, DOI 10.1007/BF02306486; Lebech M, 1996, EUR J CLIN MICROBIOL, V15, P799, DOI 10.1007/BF01701522; LEBECH M, 1995, SCAND J INFECT DIS, V27, P259, DOI 10.3109/00365549509019019; MCAULEY J, 1994, CLIN INFECT DIS, V18, P38, DOI 10.1093/clinids/18.1.38; Pinon JM, 1996, J CLIN MICROBIOL, V34, P579, DOI 10.1128/JCM.34.3.579-583.1996; PRATLONG F, 1994, PRENATAL DIAG, V14, P191, DOI 10.1002/pd.1970140309; SHARMA SD, 1983, J IMMUNOL, V131, P977; Villena I, 1998, SCAND J INFECT DIS, V30, P295, DOI 10.1080/00365549850160963; WILSON CB, 1980, PEDIATRICS, V66, P767; ZUBER P, 1995, SCHWEIZ MED WOCHENSC, V125, P19	23	143	149	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1834	1837		10.1016/S0140-6736(98)11281-3	http://dx.doi.org/10.1016/S0140-6736(98)11281-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359408				2022-12-01	WOS:000080667800012
J	Dixon, JM; McDonald, C; Elton, RA; Miller, WR				Dixon, JM; McDonald, C; Elton, RA; Miller, WR		Edinburgh Breast Grp	Risk of breast cancer in women with palpable breast cysts: a prospective study	LANCET			English	Article							DISEASE; SUBSEQUENT; HISTORY	Background. 7% of women in the western world develop palpable breast cysts. Studies of the relation between cysts and breast cancer have conflicting results. There are two clearly defined types of cyst. We investigated whether one cyst type is associated with a higher rate of breast-cancer development than the other. Methods. We studied 1374 women with palpable breast cysts presenting between 1981 and 1987, who had cysts aspirated between 1981 and 1989. Cysts were classified as type I if the sodium/potassium (Na'/K') ratio in the cyst fluid was less than 3, or type II if the Na+/K+ ratio was 3 or more. Data on incidence of breast cancer were available until January, 1995, and we compared them with the expected numbers of cancers calculated from age-specific breast-cancer incidence in Scotland in 1988. Findings. 65 cancers developed during follow-up. The overall standardised incidence rate of breast cancer in patients with palpable cysts was 2.81 (95% Cl 2.17-3.59). The relative incidence rate was increased for all cyst types. The standardised incidence rate of developing breast cancer among women younger than 45 years was highest at 5.94 (2.97-10.63), with a significant trend for decreasing relative incidence rate with age (p < 0.05). Women older than 54 years had a standardised incidence rate of 1.73 (0.86-3.10). The standardised incidence rate of breast cancer was highest in the first year after aspiration (7.02 [3.73-12.00]) but the risk was still raised after 5 years (2.68 [1.84-3.76]). Interpretation. Women with breast cysts are at an increased risk of breast cancer, especially at younger ages. The type of cyst did not alter the associated relative incidence rate of breast-cancer development.	Western Gen Hosp, Edinburgh Breast Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Dixon, JM (corresponding author), Western Gen Hosp, Edinburgh Breast Unit, Edinburgh EH4 2XU, Midlothian, Scotland.		Miller, William/AAY-5398-2020					ARMITAGE P, 1994, STAT METHOS MED RES; BRADLOW HL, 1981, CLIN ONCOL, V7, P388; BRADLOW HL, 1983, ENDOCRINOLOGY CYSTIC, P59; BRISSAUD E, 1884, ARCH PHYSL, V3, P98; Bruzzi P, 1997, BMJ-BRIT MED J, V314, P925, DOI 10.1136/bmj.314.7085.925; BUNDRED NJ, 1991, BRIT J CANCER, V64, P953, DOI 10.1038/bjc.1991.433; CARSTAIRS V, 1991, DEPRIVATION HLTH SCO, P162; CHARDOT C, 1970, B CANCER, V57, P251; CIATTO S, 1990, EUR J CANCER, V26, P555, DOI 10.1016/0277-5379(90)90074-4; CONSTANTINI M, 1994, RECENT DEV STUDY BEN, P227; COOPER AP, 1829, DIS BREAST 1; DIXON JM, 1985, EUR J CANCER CLIN ON, V21, P1047, DOI 10.1016/0277-5379(85)90289-5; DIXON JM, 1983, BRIT J SURG, V70, P604, DOI 10.1002/bjs.1800701012; DIXON JM, 1985, BRIT J SURG, V72, P190, DOI 10.1002/bjs.1800720311; Dixon JM, 1997, BREAST, V6, P12, DOI 10.1016/S0960-9776(97)90536-1; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; Haagensen C., 1971, DIS BREAST; HAAGENSEN CD, 1981, BREAST CARCINOMA RIS; HARRINGTON LE, 1981, BREAST, V7, P113; HUGHES LE, 1987, LANCET, V2, P1316, DOI 10.1016/S0140-6736(87)91204-9; JOHNSON R, 1924, BRIT J SURG, V12, P630; JONES BM, 1980, BRIT J SURG, V67, P69; MILLER B, 1983, J ACAD LIBR, V9, P227; MILLER WR, 1983, ENDOCRINOLOGY CYSTIC, P77; PAGE DL, 1978, J NATL CANCER I, V61, P106; RECLUS P, 1883, REV CHIR, V3, P761; ROBERTS MM, 1984, BRIT MED J, V288, P275, DOI 10.1136/bmj.288.6413.275; SCHEURCH C, 1982, CANCER, V50, P1899; 1990, SCOTTISH HLTH STAT	29	76	80	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 22	1999	353	9166					1742	1745		10.1016/S0140-6736(98)06408-3	http://dx.doi.org/10.1016/S0140-6736(98)06408-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TF	10347986				2022-12-01	WOS:000080667700011
J	Cingolani, G; Petosa, C; Weis, K; Muller, CW				Cingolani, G; Petosa, C; Weis, K; Muller, CW			Structure of importin-beta bound to tbe IBB domain of importin-alpha	NATURE			English	Article							NUCLEAR-PROTEIN IMPORT; FACTOR P97; NUCLEOCYTOPLASMIC TRANSPORT; KARYOPHERIN-ALPHA; EXPORT RECEPTOR; PORE COMPLEXES; TRANSFER-RNA; IDENTIFICATION; SEQUENCE; BINDING	Cytosolic proteins bearing a classical nuclear localization signal enter the nucleus bound to a heterodimer of importin-alpha and importin-beta (also called karyopherin-alpha and -beta). The formation of this heterodimer involves the importin-beta-binding (IBB) domain of importin-alpha, a highly basic amino-terminal region of roughly 40 amino-acid residues. Here we report the crystal structure of human importin-beta bound to the IBB domain of importin-alpha, determined at 2.5 Angstrom and 2.3 Angstrom resolution in two crystal forms. Importin-beta consists of 19 tandemly repeated HEAT motifs and wraps intimately around the IBB domain. The association involves two separate regions of importin-beta, recognizing structurally distinct parts of the IBB domain: an amino-terminal extended moiety and a carboxy-terminal helix. The structure indicates that significant conformational changes occur when importin-beta binds or releases the IBB domain domain and suggests how dissociation of the importin-alpha/beta heterodimer may be achieved upon nuclear entry.	European Mol Biol Lab, Grenoble Outstn, ILL, F-38042 Grenoble 9, France; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL); University of California System; University of California Berkeley	Muller, CW (corresponding author), European Mol Biol Lab, Grenoble Outstn, ILL, BP 156, F-38042 Grenoble 9, France.	mueller@embl-grenoble.fr	Müller, Christoph W/I-7420-2012; Weis, Karsten/F-5719-2011	Müller, Christoph W/0000-0003-2176-8337; Weis, Karsten/0000-0001-7224-925X; Petosa, Carlo/0000-0002-9975-1167				ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Arts GJ, 1998, CURR BIOL, V8, P305, DOI 10.1016/S0960-9822(98)70130-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Bischoff FR, 1997, FEBS LETT, V419, P249, DOI 10.1016/S0014-5793(97)01467-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; Chi NC, 1997, J BIOL CHEM, V272, P6818, DOI 10.1074/jbc.272.10.6818; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Esnouf RM, 1998, ACTA CRYSTALLOGR D, V54, P938, DOI 10.1107/S0907444998004284; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.3.CO;2-I; Huber J, 1998, EMBO J, V17, P4114, DOI 10.1093/emboj/17.14.4114; IMAMOTO N, 1995, FEBS LETT, V368, P415; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kutay U, 1998, MOL CELL, V1, P359, DOI 10.1016/S1097-2765(00)80036-2; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Malik HS, 1997, P NATL ACAD SCI USA, V94, P13738, DOI 10.1073/pnas.94.25.13738; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; Truant R, 1999, MOL CELL BIOL, V19, P1210; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3	50	428	439	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 20	1999	399	6733					221	229		10.1038/20367	http://dx.doi.org/10.1038/20367			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198MF	10353244				2022-12-01	WOS:000080427400046
J	Cody, SH; Abbott, SL; Marfin, AA; Schulz, B; Wagner, P; Robbins, K; Mohle-Boetani, JC; Vugia, DJ				Cody, SH; Abbott, SL; Marfin, AA; Schulz, B; Wagner, P; Robbins, K; Mohle-Boetani, JC; Vugia, DJ			Two outbreaks of multidrug-resistant Salmonella serotype Typhimurium DT104 infections linked to raw-milk cheese in northern California	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CALIFORNIA	Infect Dis Soc Amer			UNITED-STATES	Context Salmonella serotype Typhimurium definitive type 104 (DT104), with resistance to 5 drugs (ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline), has emerged as the most common multidrug-resistant Salmonella strain in the United States, However, illnesses resulting from this strain have not been associated definitively with a source in this country. Objective To determine the source of 2 outbreaks of Salmonella Typhimurium DT104. Design Matched case-control study conducted between March 24 and April 5, 1997 (outbreak 1), enhanced surveillance for new cases dating from February 1, 1997 (outbreak 2), and environmental and laboratory investigations. Setting and Participants The case-control study included residents of 2 adjacent counties in northern California infected with the outbreak strain of Salmonella Typhimurium var Copenhagen and age-matched controls. For enhanced surveillance, a case was defined as Salmonella Typhimurium infection in a person exposed to fresh Mexican-style cheese. Main Outcome Measures Risk factors for infection and source of implicated food. Results Outbreak 1 peaked in February 1997; 31 patients were confirmed by culture as' having Salmonella Typhimurium var Copenhagen infection, isolates of which showed indistinguishable pulsed-field gel electrophoresis (PFGE) patterns. The outbreak strain was phage type DT104 with the 5-drug resistance pattern. Sixteen cases and 25 controls were enrolled in the case-control study; 15 of 16 Salmonella Typhimurium var Copenhagen cases compared with 14 of 24 matched controls reported eating unpasteurized Mexican-style cheese, (matched odds ratio, 7.9; 95% confidence interval, 1.1-354.9). Enhanced surveillance uncovered outbreak 2, which peaked in April 1997 and was caused by a non-Copenhagen variant of Salmonella Typhimurium. During outbreak 2, Salmonella Typhimurium was isolated from 79 persons who ate fresh Mexican-style cheese from street vendors and from cheese samples and raw milk. The PFGE pattern of the milk isolate matched 1 of the 3 patterns recovered from patients; all strains were phage type DT104b with the 5-drug resistance pattern. Conclusion Raw-milk products pose a risk for multidrug-resistant Salmonella Typhimurium DT104 infections.	Calif Dept Hlth Serv, Div Communicable Dis Control, Berkeley, CA 94704 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Atlanta, GA USA; Santa Clara Valley Hlth & Hosp Syst, Dept Publ Hlth, San Jose, CA USA; San Mateo Cty Dept Hlth, San Mateo, CA USA; Calif Dept Food & Agr, Milk & Dairy Branch, Sacramento, CA 95814 USA	California Department of Health Care Services; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; California Department of Food & Agriculture	Cody, SH (corresponding author), Santa Clara Cty Dept Publ Hlth, 2220 Moorpark Ave 115, San Jose, CA 95128 USA.		Mohle-Boetani, Janet/AAH-4221-2019					ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; *CDCP, 1995, SALM SURV ANN TAB SU; Cooke, 1996, COMMUN DIS REP CDR R, V6, P159; Dean A.G., 1994, EPI INFO VERSION 6 W; Fone D. L., 1994, COMMUNICAB DIS REP, V4, P136; FRIEDMAN CR, 1998, INT C EM INF DIS MAR; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; Headrick ML, 1998, AM J PUBLIC HEALTH, V88, P1219, DOI 10.2105/AJPH.88.8.1219; Headrick ML, 1997, PUBLIC HEALTH REP, V112, P418; HELMICK CG, 1994, NIH PUBLICATION, P85; HICKMANBRENNER FW, 1991, J CLIN MICROBIOL, V29, P2817, DOI 10.1128/JCM.29.12.2817-2823.1991; Keene WE, 1997, J INFECT DIS, V176, P815, DOI 10.1086/517310; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; Murthy G.K., 1992, STANDARD METHODS EXA, P413; POTTER ME, 1984, JAMA-J AM MED ASSOC, V252, P2048, DOI 10.1001/jama.252.15.2048; Threlfall EJ, 1996, LANCET, V347, P1053, DOI 10.1016/S0140-6736(96)90199-3; Villar RG, 1999, JAMA-J AM MED ASSOC, V281, P1811, DOI 10.1001/jama.281.19.1811; Wall P G, 1994, Commun Dis Rep CDR Rev, V4, pR130; WOOD RC, 1992, JAMA-J AM MED ASSOC, V268, P3228, DOI 10.1001/jama.268.22.3228	19	126	128	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1805	1810		10.1001/jama.281.19.1805	http://dx.doi.org/10.1001/jama.281.19.1805			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340367	Bronze			2022-12-01	WOS:000080288800033
J	Des Jarlais, DC; Paone, D; Milliken, J; Turner, CF; Miller, H; Gribble, J; Shi, QH; Hagan, H; Friedman, SR				Des Jarlais, DC; Paone, D; Milliken, J; Turner, CF; Miller, H; Gribble, J; Shi, QH; Hagan, H; Friedman, SR			Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial	LANCET			English	Article								Background We aimed to assess audio-computer-assisted self-interviewing (audio-CASI) as a method of reducing underreporting of HIV risk behaviour among injecting drug users. Methods Injecting drug users were interviewed at syringe exchange programmes in four US cities. Potential respondents were randomly selected from participants in the syringe exchanges, with weekly alternate assignment to either traditional face-to-face interviews or audio-CASI. The questionnaire included items on sociodemographic characteristics, drug use, and HIV risk behaviours for 30 days preceding the interview. We calculated odds ratios for the difference in reporting of HIV risk behaviours between interview methods. Findings 757 respondents were interviewed face-to-face, and 724 were interviewed by audio-CASI. More respondents reported HIV risk behaviours and other sensitive behaviours in audio-CASI than in face-to-face interviews (odds ratios for reporting of rented or bought used injection equipment in audio-CASI vs face-to-face interview 2.1 [95% CI 1.4-3.3] p=0.001; for injection with borrowed used injection equipment 1.5 [1.1-2.2] p=0.02; for renting or selling used equipment 2.3 [1.3-4.0] p=0.003). Interpretation Although validation of these self-reported behaviours was not possible, we propose that audio-CASI enables substantially more complete reporting of HIV risk behaviour. More complete reporting might increase understanding of the dynamics of HIV transmission and make the assessment of HIV-prevention efforts easier.	Beth Israel Deaconess Med Ctr, Inst Chem Dependency, New York, NY 10003 USA; Res Triangle Inst, Washington, DC USA; Seattle King Cty Dept Publ Hlth, Seattle, WA USA; Natl Dev & Res Inst Inc, New York, NY USA	Harvard University; Beth Israel Deaconess Medical Center; Research Triangle Institute; National Development & Research Institutes, Inc	Des Jarlais, DC (corresponding author), Beth Israel Deaconess Med Ctr, Inst Chem Dependency, 1st Ave & 16th St, New York, NY 10003 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009536] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA 09536] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; COYLE SL, 1991, EVALUATING AIDS PREV; CROFTS N, 1996, HCV INJECTIONG DRUG; DESJARIAIS DC, 1996, P 21 INT C AIDS VANC, P244; DesJarlais DC, 1996, AM J PUBLIC HEALTH, V86, P1780, DOI 10.2105/AJPH.86.12.1780; DESJARLAIS DC, 1994, AM J PUBLIC HEALTH, V84, P452, DOI 10.2105/AJPH.84.3.452; FRIEDMAN SR, 1998, AIDS SOC, V11, P12; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; HAGAN H, 1992, P 8 INT C AIDS AMST, pC292; HAGAN H, 1996, P 10 INT C AIDS VANC, P232; Jarlais DCD, 1996, LANCET, V348, P987, DOI 10.1016/S0140-6736(96)02536-6; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; Kretzschmar M, 1998, AIDS, V12, P801, DOI 10.1097/00002030-199807000-00017; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MILLER HG, 1990, 2 DECADE; MILLER HG, 1998, SCI SELF REPORT; NORMAND J, 1995, PREVENTING HIV TRANS; PETERSON D, 1990, J ACQ IMMUN DEF SYND, V3, P1086; Turner C. F., 1992, SURVEY MEASUREMENT D; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; TURNER CF, 1989, AIDS SEXUAL BEHAV IN; TURNER CF, 1998, COMPUTER ASSISTED SU	22	338	341	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1657	1661						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198DT	10335785				2022-12-01	WOS:000080408000010
J	Portenoy, RK; Lesage, P				Portenoy, RK; Lesage, P			Management of cancer pain	LANCET			English	Article							QUALITY-OF-LIFE; THERAPY; MORPHINE	Patients with cancer have diverse symptoms, impairments In physical and psychological functioning, and other difficulties that can undermine their quality of life. If inadequately controlled, pain can have a profoundly adverse impact on the patient and his or her family. The critical importance of pain management as part of routine cancer care has been forcefully advanced by WHO, international and national professional organisations, and governmental agencies. The prevalence of chronic pain is about 30-50% among patients with cancer who are undergoing active treatment for a solid tumour and 70-90% among those with advanced disease. Prospective surveys indicate that as many as 90% of patients could attain adequate relief with simple drug therapies, but this success rate is not achieved in routine practice. Inadequate management of pain is the result of various issues that include: undertreatment by clinicians with insufficient knowledge of pain assessment and therapy; inappropriate concerns about opioid side-effects and addiction; a tendency to give lower priority to symptom control than to disease management; patients under-reporting of pain and non-compliance with therapy; and impediments to optimum analgesic therapy in the healthcare system. To improve the management of cancer pain, every practitioner involved in the care of these patients must ensure that his or her medical information is current and that patients receive appropriate education.	Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA	Harvard University; Beth Israel Deaconess Medical Center	Portenoy, RK (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA.	Rportenoy@bethisraelny.org						Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; *AM PAIN SOC, 1992, PRINC AN US TREATM A; Bloomfield DJ, 1998, J CLIN ONCOL, V16, P1218, DOI 10.1200/JCO.1998.16.3.1218; BRUERA E, 1990, ADV PAIN RES THER, V16, P203; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CELLA DF, 1994, J PAIN SYMPTOM MANAG, V9, P186, DOI 10.1016/0885-3924(94)90129-5; Cherny N I, 1994, J Palliat Care, V10, P57; CHERNY NI, IN PRESS TXB PAIN; Curtis E B, 1991, J Palliat Care, V7, P25; Derby S, 1998, CNS DRUGS, V9, P99, DOI 10.2165/00023210-199809020-00003; DERBY S, 1997, T PALLIAT CARE, V1, P95; DOYLE E, 1998, OXFORD TXB PALLIATIV; Ingham JM, 1993, CURR OPIN ANAESTH, V6, P838; Jacox A., 1994, AHCPR PUBLICATION; Portenoy R. K., 1994, Annals Academy of Medicine Singapore, V23, P160; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; PORTENOY RK, 1992, LANCET, V339, P1026, DOI 10.1016/0140-6736(92)90545-E; PORTENOY RK, 1998, CONT DIAGNOSIS MANAG, P40; PORTENOY RK, 1998, OXFORD TXB PALLIATIV, P361; RIPAMONTI C, 1994, J PAIN SYMPTOM MANAG, V9, P193, DOI 10.1016/0885-3924(94)90130-9; Saunders C, 1984, MANAGEMENT TERMINAL, P232; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; VENTAFRIDDA V, 1990, ANN ONCOL, V1, P415, DOI 10.1093/oxfordjournals.annonc.a057794; Waldman Steven D., 1993, P285; World Health Organization, 1996, CANC PAIN REL PALL C	29	452	478	3	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1695	1700		10.1016/S0140-6736(99)01310-0	http://dx.doi.org/10.1016/S0140-6736(99)01310-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335806				2022-12-01	WOS:000080408000047
J	Horwitz, GD; Newsome, WT				Horwitz, GD; Newsome, WT			Separate signals for target selection and movement specification in the superior colliculus	SCIENCE			English	Article							NEURONAL-ACTIVITY; EYE-MOVEMENTS; MONKEY; DISSOCIATION; RESPONSES; MACAQUES; MOTION; MEMORY; CELLS	At any given instant, multiple potential targets for saccades are present in the: visual world, implying that a "selection process" within the brain determines: the target of the next eye movement, Some superior colliculus (SC) neurons: begin discharging seconds before saccade initiation, suggesting involvement in target selection or, alternatively, in postselectional saccade preparation. SC neurons were recorded in monkeys who selected saccade targets on the basis of motion direction in a visual display. Some neurons carried a direction- selective visual signal, consistent with a role in target selection in this task, whereas other SC neurons appeared to be more involved in postselection specification of saccade parameters.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Newsome, WT (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.	bill@monkeybiz.stanford.edu	Newsome, William T./W-7171-2019	Horwitz, Gregory/0000-0001-5130-5259	NIH HHS [5T32NH17047-17] Funding Source: Medline	NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Basso MA, 1998, J NEUROSCI, V18, P7519; Bichot NP, 1996, NATURE, V381, P697, DOI 10.1038/381697a0; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; GNADT JW, 1988, EXP BRAIN RES, V70, P216; Green DG., 1966, SIGNAL DETECTION THE, DOI 10.1901/jeab.1969.12-475; Kim JN, 1999, NAT NEUROSCI, V2, P176, DOI 10.1038/5739; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; Mazzoni P, 1996, J NEUROPHYSIOL, V76, P1439, DOI 10.1152/jn.1996.76.3.1439; MUNOZ DP, 1995, J NEUROPHYSIOL, V73, P2313, DOI 10.1152/jn.1995.73.6.2313; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; Roitman J. D., 1998, Society for Neuroscience Abstracts, V24, P262; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; SCHILLER PH, 1971, J NEUROPHYSIOL, V34, P920, DOI 10.1152/jn.1971.34.5.920; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; SPARKS DL, 1978, BRAIN RES, V156, P1, DOI 10.1016/0006-8993(78)90075-6; WURTZ RH, 1971, SCIENCE, V171, P82, DOI 10.1126/science.171.3966.82; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	18	243	244	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1999	284	5417					1158	1161		10.1126/science.284.5417.1158	http://dx.doi.org/10.1126/science.284.5417.1158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325224				2022-12-01	WOS:000080359100034
J	Perry, ACF; Wakayama, T; Kishikawa, H; Kasai, T; Okabe, M; Toyoda, Y; Yanagimachi, R				Perry, ACF; Wakayama, T; Kishikawa, H; Kasai, T; Okabe, M; Toyoda, Y; Yanagimachi, R			Mammalian transgenesis by intracytoplasmic sperm injection	SCIENCE			English	Article							GREEN FLUORESCENT PROTEIN; MEDIATED GENE-TRANSFER; GERM-LINE; MOUSE EMBRYOS; EXOGENOUS DNA; FOREIGN DNA; MICE; SPERMATOZOA; OOCYTES; CELLS	Coinjection of-unfertilized mouse oocytes with sperm heads and exogenous DNA encoding either a green fluorescent protein (GFP) or beta-galactosidase reporter produced 64 to 94 percent transgene-expressing embryos, reflecting DNA-sperm head association before coinjection. Nonselective transfer to surrogate mothers of embryos in the GFP series generated about 20 percent offspring expressing the integrated transgene. These data indicate that exogenous DNA can reproducibly be delivered into an oocyte by microinjected spermatozoa and suggest an adaptable method of transgenesis.	Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA; Osaka Univ, Genome Informat Res Ctr, Osaka 5650871, Japan; Obihiro Univ Agr & Vet Med, Res Ctr Protozoan Mol Immunol, Obihiro, Hokkaido 080, Japan	University of Hawaii System; Osaka University; Obihiro University of Agriculture & Veterinary Medicine	Perry, ACF (corresponding author), Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA.	perry@hawaii.edu	; Okabe, Masaru/B-6917-2015	Perry, Tony/0000-0003-3136-5355; Okabe, Masaru/0000-0002-0803-9044	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034362] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-34362] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BosMikich A, 1997, DEV BIOL, V182, P172, DOI 10.1006/dbio.1996.8468; BRINSTER RL, 1989, CELL, V59, P239, DOI 10.1016/0092-8674(89)90282-1; Chan AWS, 1998, P NATL ACAD SCI USA, V95, P14028, DOI 10.1073/pnas.95.24.14028; CHATOT CL, 1990, BIOL REPROD, V42, P432, DOI 10.1095/biolreprod42.3.432; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GORDON JW, 1989, INT REV CYTOL, V115, P171; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; GOTO K, 1990, VET REC, V127, P517; Huguet E, 1998, MOL REPROD DEV, V51, P42, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;42::AID-MRD5&gt;3.0.CO;2-W; JAHNER D, 1985, P NATL ACAD SCI USA, V82, P6927, DOI 10.1073/pnas.82.20.6927; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kim NH, 1998, MOL REPROD DEV, V51, P436, DOI 10.1002/(SICI)1098-2795(199812)51:4&lt;436::AID-MRD11&gt;3.0.CO;2-Q; KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/biolreprod52.4.709; Kimura Y, 1998, BIOL REPROD, V58, P1407, DOI 10.1095/biolreprod58.6.1407; Kroll KL, 1996, DEVELOPMENT, V122, P3173; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; Kuretake S, 1996, BIOL REPROD, V55, P789, DOI 10.1095/biolreprod55.4.789; Ladha S, 1997, J CELL SCI, V110, P1041; LAVITRANO M, 1989, CELL, V57, P717, DOI 10.1016/0092-8674(89)90787-3; LAVITRANO M, 1992, MOL REPROD DEV, V31, P161, DOI 10.1002/mrd.1080310302; LONGO FJ, 1987, J CELL BIOL, V105, P1105, DOI 10.1083/jcb.105.3.1105; Maione B, 1997, DNA CELL BIOL, V16, P1087, DOI 10.1089/dna.1997.16.1087; Maione B, 1998, MOL REPROD DEV, V50, P406, DOI 10.1002/(SICI)1098-2795(199808)50:4&lt;406::AID-MRD4&gt;3.0.CO;2-M; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKABE M, UNPUB; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; Toyoda Y., UNPUB; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tsukui T, 1996, NAT BIOTECHNOL, V14, P982, DOI 10.1038/nbt0896-982; Wakayama T, 1998, J REPROD FERTIL, V112, P11, DOI 10.1530/jrf.0.1120011; Wakayama T, 1998, NAT BIOTECHNOL, V16, P639, DOI 10.1038/nbt0798-639; WAKAYAMA T, UNPUB; Yanagimachi R., 1994, P189; Zhang GH, 1996, BIOCHEM BIOPH RES CO, V227, P707, DOI 10.1006/bbrc.1996.1573	36	340	391	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1999	284	5417					1180	1183		10.1126/science.284.5417.1180	http://dx.doi.org/10.1126/science.284.5417.1180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325231				2022-12-01	WOS:000080359100041
J	Engert, F; Bonhoeffer, T				Engert, F; Bonhoeffer, T			Dendritic spine changes associated with hippocampal long-term synaptic plasticity	NATURE			English	Article							POTENTIATION; SYNAPSES; DENSITY; LTP; SPECIFICITY; INDUCTION; CULTURES; NEURONS; SLICE; CA1	Long-term enhancement of synaptic efficacy in the hippocampus is an important model for studying the cellular mechanisms of neuronal plasticity, circuit reorganization, and even learning and memory(1). Although these long-lasting functional changes are easy to induce, it has been very difficult to demonstrate that they are accompanied or even caused by morphological changes on the subcellular level Here we combined a local superfusion technique(2,3) with two-photon imaging(4), which allowed us to scrutinize specific regions of the postsynaptic dendrite where we knew that the synaptic changes had to occur. We show that after induction of long-lasting (but not short-lasting) functional enhancement of synapses in area CAI, new spines appear on the postsynaptic dendrite, whereas in control regions on the same dendrite or in slices where long-term potentiation was blocked, no significant spine growth occurred.	Max Planck Inst Neurobiol, D-82152 Munich, Germany	Max Planck Society	Bonhoeffer, T (corresponding author), Max Planck Inst Neurobiol, Klopferspitz 18A, D-82152 Munich, Germany.		Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bolshakov VY, 1997, NEURON, V19, P635, DOI 10.1016/S0896-6273(00)80377-3; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; Collin C, 1997, J NEUROPHYSIOL, V77, P1614, DOI 10.1152/jn.1997.77.3.1614; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DESMOND NL, 1990, SYNAPSE, V5, P139, DOI 10.1002/syn.890050208; DUNAEVSKY A, 1998, SOC NEUR ABSTR, V24; Engert F, 1997, NATURE, V388, P279, DOI 10.1038/40870; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GRAY EG, 1959, NATURE, V183, P1592, DOI 10.1038/1831592a0; HOSOKAWA T, 1995, J NEUROSCI, V15, P5560; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; MILLER KD, 1994, NEURAL COMPUT, V6, P100, DOI 10.1162/neco.1994.6.1.100; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; Sorra KE, 1998, J NEUROSCI, V18, P658; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Veselovsky NS, 1996, PFLUG ARCH EUR J PHY, V432, P351, DOI 10.1007/s004240050143; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035, DOI 10.1523/JNEUROSCI.10-12-04035.1990	23	1283	1305	2	125	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					66	70		10.1038/19978	http://dx.doi.org/10.1038/19978			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331391				2022-12-01	WOS:000080172100056
J	Lerman, C; Hughes, C; Trock, BJ; Myers, RE; Main, D; Bonney, A; Abbaszadegan, MR; Harty, AE; Franklin, BA; Lynch, JF; Lynch, HT				Lerman, C; Hughes, C; Trock, BJ; Myers, RE; Main, D; Bonney, A; Abbaszadegan, MR; Harty, AE; Franklin, BA; Lynch, JF; Lynch, HT			Genetic testing in families with hereditary nonpolyposis colon cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CANCER; BREAST-CANCER; PSYCHOLOGICAL DISTRESS; SEX-DIFFERENCES; RISK; SUSCEPTIBILITY; PARTICIPATION; ADHERENCE; OUTCOMES; LINKAGE	Context Genetic testing for hereditary nonpolyposis colon cancer (HNPCC) is available, but the rates of acceptance of testing or barriers to participation are not known. Objective To investigate rates and predictors of utilization of genetic testing for HNPCC. Design Cohort study conducted between July 1996 and July 1998, Setting Hereditary nonpolyposis colon cancer family registry, Participants Adult male and female members (n = 208) of 4 extended HNPCC families contacted for a baseline telephone interview. Interventions Family education and individual genetic counseling. Main Outcome Measure Participant acceptance of HNPCC test results. Results Of the 208 family members, 90 (43%) received test results and 118 (57%) declined. Of 139 subjects (67%) who completed a baseline telephone interview, 84 (60%) received test results and 55 (40%) declined. Of the 84 subjects who received test results, 35 (42%) received information indicating that they had HNPCC-associated mutations and 49 (58%) that they did not. Test acceptors had higher education levels (odds ratio [OR], 3.74; 95% confidence interval [CI], 2.49-5.61) and were more likely to have participated in a previous genetic linkage study (OR, 4.30; 95% CI, 1.84-10.10). The presence of depression symptoms significantly reduced rates of HNPCC test use (OR, 0.34; 95% CI, 0.17-0.66). Although rates of test use were identical among men and women, the presence of depression symptoms resulted in a 4-fold decrease in test use among women (OR, 0.25; 95% CI, 0.08-0.80) and a smaller, nonsignificant reduction among men (OR, 0.49; 95% CI, 0.19-1.27). Conclusions Despite having significantly elevated risks of developing colon cancer, a relatively small proportion of HNPCC family members are likely to use genetic testing. Barriers to test acceptance may include less formal education and the presence of depression symptoms, especially among women. Additional research is needed to generalize these findings to different clinical settings and racially diverse populations.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA; Creighton Univ, Hereditary Canc Inst, Omaha, NE 68178 USA	Georgetown University; Jefferson University; Creighton University	Lerman, C (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 2233 Wisconsin Ave NW,Suite 317, Washington, DC 20007 USA.		Lerman, Caryn/AHC-5180-2022	Myers, Ronald E./0000-0002-8059-7390	NATIONAL CANCER INSTITUTE [R01CA074684] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA74684] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; ANDERSON LM, 1995, AM J PUBLIC HEALTH, V85, P840, DOI 10.2105/AJPH.85.6.840; Belle D., 1990, HDB STRESS; BLALOCK SJ, 1987, PREV MED, V16, P9, DOI 10.1016/0091-7435(87)90002-8; BROWN ML, 1990, PREV MED, V19, P562, DOI 10.1016/0091-7435(90)90054-N; *CDCP, 1996, JAMA-J AM MED ASSOC, V275, P830; CROYLE RT, 1993, PREV MED, V22, P284, DOI 10.1006/pmed.1993.1023; Ginsberg, 1975, LIFE SPAN DEV PSYCH, P191; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; KESSLER RC, 1984, AM SOCIOL REV, V49, P620, DOI 10.2307/2095420; Kunkel EJS, 1997, PSYCHO-ONCOL, V6, P139, DOI 10.1002/(SICI)1099-1611(199706)6:2<139::AID-PON256>3.0.CO;2-O; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Lerman C, 1997, J CONSULT CLIN PSYCH, V65, P414, DOI 10.1037/0022-006X.65.3.414; LERMAN C, 1995, J NATL CANCER I, V87, P286, DOI 10.1093/jnci/87.4.286; Lerman C, 1996, INT J CANCER, V69, P58, DOI 10.1002/(SICI)1097-0215(19960220)69:1<58::AID-IJC15>3.0.CO;2-G; LERMAN C, 1993, J NATL CANCER I, V85, P1074, DOI 10.1093/jnci/85.13.1074; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Lynch Henry T., 1998, Current Opinion in Oncology, V10, P349, DOI 10.1097/00001622-199807000-00012; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Lynch HT, 1997, CANCER GENET CYTOGEN, V93, P84, DOI 10.1016/S0165-4608(96)00290-7; MYERS RE, 1994, PREV MED, V23, P142, DOI 10.1006/pmed.1994.1020; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; Pearlin L.I., 1979, RES COMMUNITY MENTAL, VVol. 1, P217; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RADLOFF L, 1975, SEX ROLES, V1, P249; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Vasen HFA, 1998, CANCER, V82, P1632, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1632::AID-CNCR6>3.0.CO;2-C; Vernon SW, 1997, HEALTH PSYCHOL, V16, P73, DOI 10.1037/0278-6133.16.1.73; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Watson M, 1996, PSYCHO-ONCOL, V5, P233; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	34	193	193	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1618	1622		10.1001/jama.281.17.1618	http://dx.doi.org/10.1001/jama.281.17.1618			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	191MJ	10235155	Bronze			2022-12-01	WOS:000080025900026
J	Ellis, H; Moran, BJ; Thompson, JN; Parker, MC; Wilson, MS; Menzies, D; McGuire, A; Lower, AM; Hawthorn, RJS; O'Brien, F; Buchan, S; Crowe, AM				Ellis, H; Moran, BJ; Thompson, JN; Parker, MC; Wilson, MS; Menzies, D; McGuire, A; Lower, AM; Hawthorn, RJS; O'Brien, F; Buchan, S; Crowe, AM			Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study	LANCET			English	Article							INTESTINAL-OBSTRUCTION	Background Adhesions after abdominal and pelvic surgery are important complications, although their basic epidemiology is unclear. We investigated the frequency of such complications in the general population to provide a basis for the targeting and assessment of new adhesion-prevention measures. Methods We used validated data from the Scottish National Health Service medical record linkage database to identify patients undergoing open abdominal or pelvic surgery in 1986, who had no record of such surgery in the preceding 5 years; Patients were followed up for 10 years and subsequent readmissions were:reviewed and outcomes classified by the degree of adhesion. We also assessed the rate of adhesion-related admissions in 1994 for the population of 5 million people. Findings 1209 (5.7%) of all readmissions (21 347) were classified as being directly related to adhesions, with 1169 (3.8%) managed operatively. Overall, 34.6% of the 29 790 patients who underwent open abdominal or pelvic surgery in 1986 were readmitted a mean of 2.1 times over 10 years for a disorder directly or possibly related to adhesions, or for abdominal or pelvic surgery that could be potentially complicated by adhesions. 22.1% of all outcome readmissions occurred in the first year after initial:surgery, but readmissions continued steadily throughout the 10-year period. In 1994, 4199 admissions were directly related to adhesions. Interpretation Postoperative adhesions have important consequences to patients, surgeons, and the health system. Surgical procedures with a high risk of adhesion-related complications need to be identified and adhesion prevention carefully assessed.	Guys Kings Coll & St Thomass, Sch Biomed Sci, Div Anat Cell & Human Biol, London SE1 9RT, England; N Hampshire Hosp, Dept Surg, Basingstoke, Hants, England; Chelsea & Westminster Hosp, Dept Surg, London, England; Joyce Green Hosp, Dept Surg, Dartford, England; Macclesfield Hosp, Dept Surg, Macclesfield, Cheshire, England; Stepping Hill Hosp, Stockport, England; Colchester Dist Gen Hosp, Dept Surg, Colchester, Essex, England; City Univ London, Sch Social Sci, London EC1V 0HB, England; Univ Oxford, Inst Hlth Sci, Oxford Hlth Econ Grp, Oxford, England; St Bartholomews Hosp, Fertil Ctr, London, England; So Gen Hosp NHS Trust, Dept Gynecol, Glasgow, Lanark, Scotland; Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh, Midlothian, Scotland; Strategan Dis & Therapy Management, Basingstoke, Hants, England	University of London; King's College London; Imperial College London; City University London; University of Greenwich; University of Oxford; University of London; Queen Mary University London; NHS National Services Scotland	Ellis, H (corresponding author), Guys Kings Coll & St Thomass, Sch Biomed Sci, Div Anat Cell & Human Biol, Guys Campus, London SE1 9RT, England.							*CENTR STAT OFF, 1995, SOC TRENDS, V25; Ellis H, 1997, EUR J SURG, V163, P5; Ellis H, 1998, ANN CHIR GYNAECOL FE, V87, P9; FAZIO VW, 1995, ANN SURG, V222, P120, DOI 10.1097/00000658-199508000-00003; Harley K, 1996, Health Bull (Edinb), V54, P410; HERSHLAG A, 1991, CLIN OBSTET GYNECOL, V34, P395, DOI 10.1097/00003081-199106000-00023; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; KROOK S, 1947, ACTA CHIR SCAND    S, V95, P1; MENZIES D, 1993, ANN ROY COLL SURG, V75, P147; MENZIES D, 1990, ANN ROY COLL SURG, V72, P60; *NAT HLTH SERV SCO, 1996, SCOTT HLTH STAT 1996, V38, P50; Ray NF, 1998, J AM COLL SURGEONS, V186, P1, DOI 10.1016/S1072-7515(97)00127-0	12	659	689	4	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1476	1480		10.1016/S0140-6736(98)09337-4	http://dx.doi.org/10.1016/S0140-6736(98)09337-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232313				2022-12-01	WOS:000080278200010
J	Hu, FB; Stampfer, MJ; Rimm, EB; Manson, JE; Ascherio, A; Colditz, GA; Rosner, BA; Spiegelman, D; Speizer, FE; Sacks, FR; Hennekens, CH; Willett, WC				Hu, FB; Stampfer, MJ; Rimm, EB; Manson, JE; Ascherio, A; Colditz, GA; Rosner, BA; Spiegelman, D; Speizer, FE; Sacks, FR; Hennekens, CH; Willett, WC			A prospective study of egg consumption and risk of cardiovascular disease in men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; DIETARY-CHOLESTEROL; SERUM-CHOLESTEROL; HEALTH-PROFESSIONALS; HORMONAL RESPONSES; FATTY-ACIDS; LIPOPROTEIN; PLASMA; METAANALYSIS	Context Reduction in egg consumption has been widely recommended to lower blood cholesterol levels and prevent coronary heart disease (CHD), Epidemiologic studies on egg consumption and risk of CHD are sparse. Objective To examine the association between egg consumption and risk of CHD and stroke in men and women. Design and Setting Two prospective cohort studies, the Health Professionals Follow-up Study (1986-1994) and the Nurses' Health Study (1980-1994), Participants A total of 37 851 men aged 40 to 75 years at study outset and 80 082 women aged 34 to 59 years at study outset, free of cardiovascular disease, diabetes, hypercholesterolemia, or cancer. Main Outcome Measures Incident nonfatal myocardial infarction, fatal CHD, and stroke corresponding to daily egg consumption as determined by a food-frequency questionnaire. Results We documented 866 incident cases of CHD and 258 incident cases of stroke in men during 8 years of follow-up and 939 incident cases of CHD and 563 incident cases of stroke in women during 14 years of follow-up. After adjustment for age, smoking, and other potential CHD risk factors, we found no evidence of an overall significant association between egg consumption and risk of CHD or stroke in either men or women. The relative risks (RRs) of CHD across categories of intake were less than 1 per week (1.0), 1 per week (1.06), 2 to 4 per week (1.12), 5 to 6 per week (0.90), and greater than or equal to 1 per day (1.08) (P for trend = .75) for men; and less than 1 per week (1.0), 1 per week (0.82), 2 to 4 per week (0.99), 5 to 6 per week (0.95), and greater than or equal to 1 per day (0.82) (P for trend = .95) for women. In subgroup analyses, higher egg consumption appeared to be associated with increased risk of CHD only among diabetic subjects (RR of CHD comparing more than 1 egg per day with less than 1 egg per week among diabetic men, 2.02 [95% confidence interval, 1.05-3.87; P for trend = .04], and among diabetic women, 1.49 [0.88-2.52; P for trend = .008]). Conclusions These findings suggest that consumption of up to 1 egg per day is unlikely to have substantial overall impact on the risk of CHD or stroke among healthy men and women. The apparent increased risk of CHD associated with higher egg consumption among diabetic participants warrants further research.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA USA; Brigham & Womens Hosp, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Hu, FB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	Frank.hu@channing.harvard.edu	Colditz, Graham/A-3963-2009; Hu, Frank/C-1919-2013	Colditz, Graham/0000-0002-7307-0291; 	NHLBI NIH HHS [HL24074, HL34594, HL35464] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464, R01HL034594] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, ARCH INTERN MED, V151, P1071, DOI 10.1001/archinte.151.6.1071; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAWBER TR, 1982, AM J CLIN NUTR, V36, P617, DOI 10.1093/ajcn/36.4.617; Esrey KL, 1996, J CLIN EPIDEMIOL, V49, P211, DOI 10.1016/0895-4356(95)00066-6; *FED AM SOC EXP BI, 1995, 3 FED AM SOC EXP BIO, V1; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FIELDING CJ, 1986, J LIPID RES, V27, P1052; FRASER GE, 1994, AM J CLIN NUTR, V59, p1117S, DOI 10.1093/ajcn/59.5.1117S; Gillman MW, 1997, JAMA-J AM MED ASSOC, V278, P2145, DOI 10.1001/jama.278.24.2145; GINSBERG HN, 1994, ARTERIOSCLER THROMB, V14, P576, DOI 10.1161/01.ATV.14.4.576; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; GRANFELDT Y, 1991, EUR J CLIN NUTR, V45, P489; HEGSTED DM, 1986, AM J CLIN NUTR, V44, P299, DOI 10.1093/ajcn/44.2.299; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; Holt SHA, 1997, AM J CLIN NUTR, V66, P1264, DOI 10.1093/ajcn/66.5.1264; HOPKINS PN, 1992, AM J CLIN NUTR, V55, P1060, DOI 10.1093/ajcn/55.6.1060; Howell WH, 1997, AM J CLIN NUTR, V65, P1747, DOI 10.1093/ajcn/65.6.1747; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; KEYS A, 1966, AM J CLIN NUTR, V19, P175; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KROMHOUT D, 1984, AM J EPIDEMIOL, V119, P733, DOI 10.1093/oxfordjournals.aje.a113794; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; MCGEE DL, 1984, AM J EPIDEMIOL, V119, P667, DOI 10.1093/oxfordjournals.aje.a113788; MCGILL HC, 1979, AM J CLIN NUTR, V32, P2664, DOI 10.1093/ajcn/32.12.2664; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; PACKARD CJ, 1983, J CLIN INVEST, V72, P45, DOI 10.1172/JCI110983; Pedersen TR, 1998, AM J CARDIOL, V81, P333, DOI 10.1016/S0002-9149(97)00904-1; Pelletier X, 1996, ANN NUTR METAB, V40, P109, DOI 10.1159/000177903; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; ROBERTS SL, 1981, AM J CLIN NUTR, V34, P2092, DOI 10.1093/ajcn/34.10.2092; Rose GA., 1982, WHO MONOGRAPH SERIES, V58; SACKS FM, 1984, LANCET, V1, P647; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SCHNOHR P, 1994, J INTERN MED, V235, P249, DOI 10.1111/j.1365-2796.1994.tb01068.x; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; SHEKELLE RB, 1981, NEW ENGL J MED, V304, P65, DOI 10.1056/NEJM198101083040201; STAMLER J, 1988, ARCH PATHOL LAB MED, V112, P1032; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; *USDA, 1989, AGR HDB USDA, V8; VENKATESAN S, 1995, BIOCHEM SOC T, V23, pS278, DOI 10.1042/bst023278s; VILLAUME C, 1986, DIABETES CARE, V9, P46, DOI 10.2337/diacare.9.1.46; VORSTER HH, 1992, AM J CLIN NUTR, V55, P400; Walker AE, 1981, STROKE S1, V12, pI13; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	54	331	348	1	55	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1999	281	15					1387	1394		10.1001/jama.281.15.1387	http://dx.doi.org/10.1001/jama.281.15.1387			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185ZF	10217054	Bronze			2022-12-01	WOS:000079701000028
J	Merfeld, DM; Zupan, L; Peterka, RJ				Merfeld, DM; Zupan, L; Peterka, RJ			Humans use internal models to estimate gravity and linear acceleration	NATURE			English	Article							SQUIRREL-MONKEY; VESTIBULOOCULAR REFLEX; SEMICIRCULAR CANALS; ECCENTRIC ROTATION; OCULAR RESPONSES; VIEWING DISTANCE; ROLL TILT; MOTION; ORIENTATION; INTEGRATION	Because sensory systems often provide ambiguous information, neural processes must exist to resolve these ambiguities. It is likely that similar neural processes are used by different sensory systems. For example, many tasks require neural processing to distinguish linear acceleration from gravity(1), but Einstein's equivalence principle states that all linear accelerometers must measure both linear acceleration and gravity. Here we investigate whether the brain uses internal models, defined as neural systems that mimic physical principles, to help estimate linear acceleration and gravity(2-4). Internal models may be used in motor control(5-7), sensorimotor integration(8-10) and sensory processing(11-14), but direct experimental evidence for such models is limited. To determine how humans process ambiguous gravity and linear acceleration cues, subjects were tilted after being rotated at a constant velocity about an Earth-vertical axis. We show that the eye movements evoked by this post-rotational tilt include a response component that compensates for the estimated Linear acceleration even when no actual linear acceleration occurs. These measured responses are consistent with our internal model predictions that the nervous system can develop a non-zero estimate of linear acceleration even when no true linear acceleration is present.	Oregon Hlth & Sci Univ, Inst Neurol Sci, Portland, OR 97209 USA	Oregon Health & Science University	Merfeld, DM (corresponding author), Massachusetts Eye & Ear Infirm, Vestibular Physiol Lab, 243 Charles St, Boston, MA 02114 USA.	dan_merfeld@meei.harvard.edu						Angelaki DE, 1999, J NEUROSCI, V19, P316, DOI 10.1523/JNEUROSCI.19-01-00316.1999; Bell C, 1997, BRAIN BEHAV EVOLUT, V50, P17, DOI 10.1159/000113352; Benson A.J., 1974, VESTIBULAR SYSTEM 2, P281, DOI [10.1007/978-3-642-65920-1_6, DOI 10.1007/978-3-642-65920-1_6]; BENSON AJ, 1966, AEROSPACE MED, V37, P889; Darlot C, 1996, BIOL CYBERN, V75, P173, DOI 10.1007/s004220050285; DICHGANS J, 1972, SCIENCE, V178, P1217, DOI 10.1126/science.178.4066.1217; Droulez J, 1989, ATTENTION PERFORM, VXIII, P495; FETTER M, 1992, EXP BRAIN RES, V91, P121; GLASAUER S, 1992, ANN NY ACAD SCI, V656, P847, DOI 10.1111/j.1749-6632.1992.tb25272.x; GOLDBERG JM, 1971, J NEUROPHYSIOL, V34, P635, DOI 10.1152/jn.1971.34.4.635; GUEDRY E, 1974, HDB SENSORY PHYSL, P1; KUO AD, 1995, IEEE T BIO-MED ENG, V42, P87, DOI 10.1109/10.362914; Lewald J, 1998, EXP BRAIN RES, V121, P230, DOI 10.1007/s002210050456; Merfeld D M, 1993, J Vestib Res, V3, P141; MERFELD DM, 1995, EXP BRAIN RES, V106, P111; MERFELD DM, 1995, EXP BRAIN RES, V106, P123; MERFELD DM, 1995, ACTA OTO-LARYNGOL, P354; ORMSBY CC, 1977, MATH BIOSCI, V34, P1, DOI 10.1016/0025-5564(77)90032-3; PAIGE GD, 1991, J NEUROPHYSIOL, V65, P1170, DOI 10.1152/jn.1991.65.5.1170; PAULIN MG, 1993, BRAIN BEHAV EVOLUT, V41, P39, DOI 10.1159/000113822; Rao RPN, 1997, NEURAL COMPUT, V9, P721, DOI 10.1162/neco.1997.9.4.721; SCHWARZ U, 1989, SCIENCE, V245, P1394, DOI 10.1126/science.2506641; SCHWARZ U, 1991, J NEUROPHYSIOL, V66, P851, DOI 10.1152/jn.1991.66.3.851; STOCKWELL CW, 1970, ACTA OTO-LARYNGOL, V70, P170, DOI 10.3109/00016487009181874; Wilson V. J., 1979, MAMMALIAN VESTIBULAR; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931; YASUI S, 1975, SCIENCE, V190, P906, DOI 10.1126/science.1188373; Young L, 1984, HDB PHYSL NERVOUS SY, P1023	28	346	353	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 15	1999	398	6728					615	618		10.1038/19303	http://dx.doi.org/10.1038/19303			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217143				2022-12-01	WOS:000079754700056
J	Sainsbury, R; Johnston, C; Haward, B				Sainsbury, R; Johnston, C; Haward, B			Effect on survival of delays in referral of patients with breast-cancer symptoms: a retrospective analysis	LANCET			English	Article								Background From April 1, 1999, family physicians are required to refer all patients who have suspected breast cancer in the UK urgently to hospital, to be seen within 14 days of referral. We investigated whether delays by providers in routine practice for diagnosis influence survival. Methods We did a retrospective analysis of 36 222 patients with breast cancer listed in the Yorkshire Cancer Registry. Data on delay after family-physician referral. hospital visit, and start of treatment were available, as weil as on tumour grade and stage of presentation. Results There was no evidence that provider delays of longer than 90 days adversely influenced survival. The time from family-physician referral to first hospital visit changed little (median 10 vs 13 days) from 1976 to 1995, whereas time from first visit to first treatment doubted (7 vs 13 days). More than 8% of patients younger than 50 years delayed longer than 90 days, compared with 3% of patients older than 50 years (p<0.001). 48% of younger patients had their first treatment within 30 days compared with 64% of those older than 50 (p<0.001). The survival for 5708 patients diagnosed in 1986-90 selected for survival analysis was 63% at 5 years, and 51% at 8 years. Patients who presented early and were treated in less than 30 days had significantly worse outcomes (p<0.001). Interpretation Delays by providers in months or more do not seem to be associated with decreased survival in patients presenting with breast cancer. The drive for all women with possible breast cancer to be seen within 14 days will divert resources from other services and is not supported by this study.	Huddersfield Royal Infirm, Dept Surg, Huddersfield HD3 3EA, W Yorkshire, England; NYCRIS, Leeds, W Yorkshire, England		Sainsbury, R (corresponding author), Huddersfield Royal Infirm, Dept Surg, Huddersfield HD3 3EA, W Yorkshire, England.							*BRIT ASS SURG ONC, 1995, EUR J SURG ONCOL SA, V21, P1; *BRIT BREAST GROUP, 1994, PROV BREAST SERV UK; *CLIN OUTC GROUP C, 1996, IMPR OUTC BREAST CAN; Physician Insurers Association of America, 1995, BREAST CANC STUD; Richards MA, 1999, LANCET, V353, P1119, DOI 10.1016/S0140-6736(99)02143-1; SAINSBURY JRC, 1995, BRIT J CANCER, V71, P1275; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S	8	150	152	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 3	1999	353	9159					1132	1135						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PZ	10209976				2022-12-01	WOS:000079858400010
J	Moss, ME; Lanphear, BP; Auinger, P				Moss, ME; Lanphear, BP; Auinger, P			Association of dental caries and blood lead levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; NATIONAL-HEALTH; NHANES-III; CHILDREN; POPULATION; DENTITION	Context Experiments show that dental caries rates are higher among lead-exposed animals, but this association has not been established in humans. Objective To examine the relationship between blood lead levels and dental caries. Design Cross-sectional survey conducted from 1988 to 1994 that included a dental examination and venipuncture blood lead assay. Setting and Participants A total of 24 901 persons aged 2 years and older who participated in the Third National Health and Nutrition Examination Survey, which assessed the health and nutritional status of children and adults in the United States. Main Outcome Measures For children aged 2 to 11 years, the sum of decayed and filled deciduous or primary surfaces; for persons aged 6 years and older, the sum of decayed and filled permanent surfaces; for those 12 years and older, the sum of decayed, missing, and filled surfaces. Results The log of blood lead level was significantly associated with the number of affected surfaces for both deciduous and permanent teeth in all age groups, even after adjusting for sociodemographic characteristics, diet, and dental care. Among children aged 5 to 17 years, a 0.24-mu mol/L (5-mu g/dL) change in blood lead level was associated with an elevated risk of dental caries (odds ratio, 1.8; 95% confidence interval, 1.3-2.5). Differences in blood lead level explained some of the differences in caries prevalence in different income levels and regions of the United States. We estimated the population attributable risk of lead exposure to be 13.5% and 9.6% of dental caries occurring in 5- to 17-year-olds exposed to the high and moderate levels, respectively. Conclusions Environmental lead exposure is associated with an increased prevalence of dental caries in the US population, Findings may help explain the distribution of caries by income and region of the United States.	Univ Rochester, Sch Med & Dent, Eastman Dept Dent, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Childrens Hosp, Med Ctr, Dept Pediat, Rochester, NY USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA	University of Rochester; University of Rochester; University System of Ohio; University of Cincinnati	Moss, ME (corresponding author), Univ Rochester, Med Ctr, Dept Community & Prevent Med, Box 644,601 Elmwood Ave, Rochester, NY 14642 USA.	moss@prevmed.rochester.edu	Moss, Mark E/Q-3014-2019; Moss, Mark E/AAF-1697-2020	Moss, Mark E/0000-0003-0105-0416	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [D15PE010027] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES-08338] Funding Source: Medline; BHP HRSA HHS [1T-32 PE-10027] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); BHP HRSA HHS		BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; BRUDEVOLD F, 1977, J DENT RES, V56, P1165, DOI 10.1177/00220345770560100701; Brunelle J A, 1990, J Dent Res, V69 Spec No, P723; BRUNELLE JA, 1982, J DENT RES, V61, P1346; *CDC, 1992, MMWR-MORBID MORTAL W, V41, P381; *CDC, 1992, MMWR-MORBID MORTAL W, V41, P372; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P141; Curzon M.E.J., 1983, TRACE ELEMENTS DENT; DAVIES BE, 1987, EXPERIENTIA, V43, P87, DOI 10.1007/BF01940359; Drury TF, 1996, J DENT RES, V75, P620, DOI 10.1177/002203459607502S02; EDELSTEIN BL, 1995, PUBLIC HEALTH REP, V110, P522; Gil F, 1996, SCI TOTAL ENVIRON, V192, P183, DOI 10.1016/S0048-9697(96)05313-2; GIL F, 1994, SCI TOTAL ENVIRON, V156, P145, DOI 10.1016/0048-9697(94)90351-4; HAYES EB, 1994, PEDIATRICS, V93, P195; Kaste LM, 1996, J DENT RES, V75, P631, DOI 10.1177/002203459607502S03; McClure Frank J., 1970, WATER FLUORIDATION S; RAO GS, 1984, ANNU REV NUTR, V4, P115, DOI 10.1146/annurev.nu.04.070184.000555; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V104, P587, DOI 10.1093/oxfordjournals.aje.a112335; Stack MV, 1983, TRACE ELEMENTS DENTA, P357; Stamm J. W., 1991, RISK MARKERS ORAL DI, V1, P132; Vargas CM, 1998, J AM DENT ASSOC, V129, P1229, DOI 10.14219/jada.archive.1998.0420; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; Watson GE, 1997, NAT MED, V3, P1024, DOI 10.1038/nm0997-1024; Winn DM, 1996, J DENT RES, V75, P642, DOI 10.1177/002203459607502S04; [No title captured]	26	81	85	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2294	2298		10.1001/jama.281.24.2294	http://dx.doi.org/10.1001/jama.281.24.2294			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386553				2022-12-01	WOS:000080925600028
J	Bacon, BR; Olynyk, JK; Brunt, EM; Britton, RS; Wolff, RK				Bacon, BR; Olynyk, JK; Brunt, EM; Britton, RS; Wolff, RK			HFE genotype in patients with hemochromatosis and other liver diseases	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM SURVIVAL; HEPATIC IRON INDEX; HEREDITARY HEMOCHROMATOSIS; NONALCOHOLIC STEATOHEPATITIS; GENETIC HEMOCHROMATOSIS; MUTATION ANALYSIS; HLA-H; FIBROSIS; HETEROZYGOTES; OVERLOAD	Background: Hereditary hemochromatosis is a common inherited disorder of iron metabolism. The gene HFE, which contains two missense mutations (C282Y and H63D), was recently identified. Objective: To determine how HFE genotyping for the C282Y and H63D mutations contributes to the diagnosis of hemochromatosis and to determine the prevalence of HFE mutations in a group of patients with liver disease. Design: Cross-sectional study. Setting: Academic medical center. Patients: 66 patients with hereditary hemochromatosis and 132 referred patients with other liver diseases. Measurements: At initial diagnosis, fasting transferrin saturation, ferritin level, routine chemistry panel, and complete blood count were determined. Percutaneous liver biopsy was done on all patients for histologic analysis and measurement of hepatic iron concentration and hepatic iron index. HFE genotyping for the C282Y and H63D mutations was done on all patients by using genomic DNA samples. Results: Of the 66 patients with hemochromatosis diagnosed on the basis of serum iron studies and liver biopsy findings, 60 (91%) were C282Y homozygotes, 2 (3%) were compound heterozygotes, 1 (1.5%)was a C282Y heterozygote, 2 (3%) were H63D heterozygotes, and 1 (1.5%) was negative for both mutations, Of the 132 patients with liver disease, 6 (5%) were C282Y homozygotes, 8 (6%) were compound heterozygotes, 6 (5%) were C282Y heterozygotes, 5 (4%) were H63D homozygotes, 20 (15%) were H63D heterozygotes, and 87 (66%) were negative for both mutations, All 66 C282Y homozygotes had an elevated hepatic iron concentration, and 65 of the 66 patients (98%) had a transferrin saturation of at least 45%, Ten of the 66 patients (15% [95% Cl, 7.5% to 26%]) had a hepatic iron index less than 1.9 mmol/kg per year; hemochromatosis was not suspected in 6 of the 10 patients before genotyping. Cirrhosis or substantial hepatic fibrosis was not seen in any (0% [Cl, 0% to 18%]) of the 19 patients younger than 40 years of age who were homozygous for the C282Y mutation. Conclusions: All 66 patients homozygous for the C282Y mutation of HFE had an elevated hepatic iron concentration, but approximately 15% of these patients did not meet a previous diagnostic criterion for hemochromatosis (hepatic iron index > 1.9 mmol/kg per year). Determination of HFE genotype is clinically useful in patients with liver disease and suspected iron overload and may lead to identification of otherwise unsuspected C282Y homozygotes.	Univ Dept Med, Dept Gastroenterol, Fremantle Hosp, Fremantle 6160, Australia; St Louis Univ, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Sch Med,Dept Pathol, St Louis, MO 63110 USA; Progenitor Inc, Menlo Pk, CA 94025 USA	University of Western Australia; Saint Louis University	Bacon, BR (corresponding author), St Louis Univ, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Sch Med,Dept Pathol, 3635 Vista Ave, St Louis, MO 63110 USA.	baconbr@slu.edu		Olynyk, John/0000-0003-0417-3411	NIDDK NIH HHS [DK-41816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; Bacon BR, 1997, AM J GASTROENTEROL, V92, P784; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BONKOVSKY HL, 1990, GASTROENTEROLOGY, V99, P1079, DOI 10.1016/0016-5085(90)90629-F; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Carella M, 1997, AM J HUM GENET, V60, P828; CHAPMAN RW, 1982, DIGEST DIS SCI, V27, P909, DOI 10.1007/BF01316575; DEUGNIER YM, 1993, HEPATOLOGY, V17, P30, DOI 10.1016/0270-9139(93)90187-R; DIBISCEGLIE AM, 1992, GASTROENTEROLOGY, V102, P2108, DOI 10.1016/0016-5085(92)90339-Z; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; FARGION S, 1994, HEPATOLOGY, V20, P1426, DOI 10.1002/hep.1840200608; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2; Grove J, 1998, GUT, V43, P262, DOI 10.1136/gut.43.2.262; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; Jawaid O, 1998, GASTROENTEROLOGY, V114, pA1264; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kazemi-Shirazi L, 1999, GASTROENTEROLOGY, V116, P127, DOI 10.1016/S0016-5085(99)70236-2; Kowdley KV, 1997, GASTROENTEROLOGY, V113, P1270, DOI 10.1053/gast.1997.v113.pm9322522; Ludwig J, 1997, GASTROENTEROLOGY, V112, P882, DOI 10.1053/gast.1997.v112.pm9041250; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OLYNYK J, 1990, HEPATOLOGY, V12, P26, DOI 10.1002/hep.1840120106; Piperno A, 1998, HEPATOLOGY, V28, P1105, DOI 10.1002/hep.510280427; SEARLE JW, 1994, PATHOLOGY LIVER, P223; Smith BC, 1998, HEPATOLOGY, V27, P1695, DOI 10.1002/hep.510270631; Torrance JD., 1980, METHODS HEMATOL, V1, P90	32	153	158	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					953	962		10.7326/0003-4819-130-12-199906150-00002	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383365				2022-12-01	WOS:000080894700001
J	Adams, JFA; Scholvinck, EH; Gie, RP; Potter, PC; Beyers, N; Beyers, AD				Adams, JFA; Scholvinck, EH; Gie, RP; Potter, PC; Beyers, N; Beyers, AD			Decline in total serum IgE after treatment for tuberculosis	LANCET			English	Article							CELLULAR IMMUNE-RESPONSES; T-CELL; RECEPTOR DEFICIENCY; SKIN-TEST; INFECTION; MYCOBACTERIAL; HELMINTH; MICE; MODULATION	Background. Infection with Mycobacterium tuberculosis induces a type-1 immune response, whereas intestinal parasites elicit a type-2 response. Given that type-1 and type-2 responses inhibit each other, we investigated. if M tuberculosis downregulates serum IgE, a marker of a type-2 response. Methods. A prospective study was done in the Western Cape Province of South Africa, where tuberculosis and intestinal-parasite infection are common. Total serum IgE was determined for 37 controls and for 33 adolescent patients at presentation with tuberculosis and after successful completion of treatment. IgE specific for ascaris and allergens were measured in a subset of these individuals. Mantoux skin tests were done on 35 controls and on 31 patients at diagnosis. Findings. Total IgE concentrations were high in controls (mean 313 kU/L) and in patients before treatment (mean 457 kU/L, p = 0.085) and declined in all patients following successful treatment (mean 175 kU/L, p < 0.0001). Posttreatment IgE concentrations did not differ from concentrations in controls. Ascaris-specific IgE was lower in controls (mean 1.73 kU/L) than in patients before treatment (4.62 kU/L, p = 0.023) and was 2.39 kU/L in patients after treatment (p = 0.0625). Tuberculin induration correlated inversely with IgE in patients but not in controls. Interpretation. Infection with M tuberculosis as such is not incompatible with a prominent IgE response. IgE concentrations decreased after successful treatment of tuberculosis, showing that IgE concentrations in human beings can be downregulated under these circumstances, presumably due to enhancement of a type-1 response.	Univ Stellenbosch, Sch Med, Ctr Cellular & Mol Biol, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Sch Med, Dept Biochem Med, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Sch Med, Dept Paediat & Child Hlth, ZA-7505 Tygerberg, South Africa; Univ Cape Town, Sch Med, Dept Immunol, ZA-7700 Rondebosch, South Africa	Stellenbosch University; Stellenbosch University; Stellenbosch University; University of Cape Town	Beyers, AD (corresponding author), Univ Stellenbosch, Sch Med, Ctr Cellular & Mol Biol, POB 19063, ZA-7505 Tygerberg, South Africa.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Arnadottir T, 1996, TUBERCLE LUNG DIS, V77, P1, DOI 10.1016/S0962-8479(96)90127-6; BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; Beyers N, 1996, S AFR MED J, V86, P40; BUNDY DAP, 1991, PARASITE IMMUNOL, V13, P629, DOI 10.1111/j.1365-3024.1991.tb00558.x; Calleja C, 1998, NAT MED, V4, P92, DOI 10.1038/nm0198-092; CHAN MS, 1994, PARASITOLOGY, V109, P373, DOI 10.1017/S0031182000078410; de Jong R, 1998, SCIENCE, V280, P1435; *DEP HLTH, 1996, EPIDEMIOLOGICAL COMM, V23, P22; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; FERREIRA AP, 1995, CELL IMMUNOL, V162, P202, DOI 10.1006/cimm.1995.1070; GREENE BM, 1985, REV INFECT DIS, V7, P789; Gunders AE, 1993, S AFR J EPIDEMIOL IN, V8, P48; Israel HL., 1941, JAMA-J AM MED ASSOC, V117, P461; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; KAHN EA, 1995, EMERG INFECT DIS, V1, P115; MAHER J, 1992, RESP MED, V86, P481, DOI 10.1016/S0954-6111(96)80006-0; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; NEEDHAM CS, 1992, PARASITOLOGY, V105, P273, DOI 10.1017/S0031182000074205; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PEARLMAN E, 1993, J IMMUNOL, V151, P4857; Ramirez F, 1996, J IMMUNOL, V156, P2406; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; SARTONO E, 1995, J INFECT DIS, V171, P1683, DOI 10.1093/infdis/171.6.1683; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SNIDER DE, 1982, AM REV RESPIR DIS, V125, P108; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; Wang CC, 1998, IMMUNOLOGY, V93, P307; Wilkinson RJ, 1998, J INFECT DIS, V178, P760, DOI 10.1086/515336; YONG AJ, 1989, TUBERCLE, V70, P273, DOI 10.1016/0041-3879(89)90021-4	35	52	56	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2030	2033		10.1016/S0140-6736(98)08510-9	http://dx.doi.org/10.1016/S0140-6736(98)08510-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376618				2022-12-01	WOS:000080812200013
J	Bermingham, NA; Hassan, BA; Price, SD; Vollrath, MA; Ben-Arie, N; Eatock, RA; Bellen, HJ; Lysakowski, A; Zoghbi, HY				Bermingham, NA; Hassan, BA; Price, SD; Vollrath, MA; Ben-Arie, N; Eatock, RA; Bellen, HJ; Lysakowski, A; Zoghbi, HY			Math1: An essential gene for the generation of inner ear hair cells	SCIENCE			English	Article							TECTORIAL MEMBRANE; PRONEURAL GENE; NERVOUS-SYSTEM; MICE; CALRETININ; DEFECTS	The mammalian inner ear contains the cochlea and vestibular organs, which are responsible for hearing and balance, respectively. The epithelia of these sensory organs contain hair cells that function as mechanoreceptors to transduce sound and head motion. The molecular mechanisms underlying hair cell development and differentiation are poorly understood. Math1, a mouse homolog of the Drosophila proneural gene atonal, is expressed in inner ear sensory epithelia. Embryonic Math1-null mice failed to generate cochlear and vestibular hair cells. This gene is thus required for the genesis of hair cells.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dev Biol Program, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Bobby R Alford Dept Otorhinolaryngol & Commun Sci, Houston, TX 77030 USA; Univ Illinois, Dept Anat & Cell Biol, Chicago, IL 60612 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Zoghbi, HY (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.		Hassan, Bassem A/D-5221-2012; Ben-Arie, Nissim/K-4997-2012; Lysakowski, Anna/F-9534-2010; Eatock, Ruth A/F-6404-2013	Hassan, Bassem A/0000-0001-9533-4908; Lysakowski, Anna/0000-0001-6259-0294; Bellen, Hugo/0000-0001-5992-5989; Eatock, Ruth Anne/0000-0001-7547-2051; Zoghbi, Huda/0000-0002-0700-3349	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002290] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC002290] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adam J, 1998, DEVELOPMENT, V125, P4645; AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; BenArie N, 1997, NATURE, V390, P169, DOI 10.1038/36579; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; BENARIE N, UNPUB; BERMINGHAM NA, UNPUB; COHEN GM, 1985, HEARING RES, V18, P29, DOI 10.1016/0378-5955(85)90108-X; DECHESNE CJ, 1994, J COMP NEUROL, V346, P517, DOI 10.1002/cne.903460405; EBERL D, COMMUNICATION; Fekete DM, 1998, J NEUROSCI, V18, P7811; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Haddon C, 1998, DEVELOPMENT, V125, P4637; HASSAN B, UNPUB; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; Kim P, 1997, DEV BIOL, V187, P1, DOI 10.1006/dbio.1997.8572; Lanford PJ, 1999, NAT GENET, V21, P289, DOI 10.1038/6804; LO JC, 1991, GENE DEV, V5, P1524; Lysakowski A, 1997, J COMP NEUROL, V389, P419, DOI 10.1002/(SICI)1096-9861(19971222)389:3<419::AID-CNE5>3.0.CO;2-3; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; Rusch A, 1998, J NEUROSCI, V18, P7487; SHIEL MJ, 1990, HEARING RES, V47, P147, DOI 10.1016/0378-5955(90)90172-L; Torres MA, 1996, DEVELOPMENT, V122, P3381; Wang WD, 1998, DEVELOPMENT, V125, P621; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; Xiang MQ, 1998, DEVELOPMENT, V125, P3935; Zheng JL, 1997, J NEUROSCI, V17, P8270	29	814	876	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1837	1841		10.1126/science.284.5421.1837	http://dx.doi.org/10.1126/science.284.5421.1837			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10364557				2022-12-01	WOS:000080809000051
J	Jacob, J; Baltimore, D				Jacob, J; Baltimore, D			Modelling T-cell memory by genetic marking of memory T cells in vivo	NATURE			English	Article							LYMPHOCYTES-T; IMMUNOLOGICAL MEMORY; GERMINAL-CENTERS; VIRUS-INFECTION; ANTIGEN; PERSISTENCE; EXPRESSION; REGION; CD2	Immunological memory is the ability of the immune system to respond with enhanced vigour to pathogens that have been encountered in the past. Following infection or immunization, most effector T cells undergo apoptotic cell death, but a small fraction of these cells, proportional to the early antigen load and initial clonal burst size(1), persist in the host as a stable pool of memory T cells(2-7). The existence of immunological memory has been recognized for over 2,000 years, but our understanding of this phenomenon is limited, primarily because memory lymphocytes cannot be unequivocally identified as they lack specific, permanent markers. Here we have developed a transgenic mouse model system whereby memory T cells and their precursors can be irreversibly marked with a reporter gene and thus can be unambiguously identified. Adoptive transfer of marked CD8(+) T cells specific for lymphocytic choriomeningitis virus protected naive recipients following viral challenge, demonstrating that we have marked memory T cells. We also show that cytotoxic effector lymphocytes that develop into memory T cells can be identified in the primary response.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Baltimore, D (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; AHMED R, 1984, J VIROL, V51, P34, DOI 10.1128/JVI.51.1.34-41.1984; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Castan J, 1997, IMMUNOLOGY, V90, P265, DOI 10.1046/j.1365-2567.1997.00162.x; CEPKO C, 1995, METHOD ENZYMOL, V254, P387; Doherty PC, 1996, IMMUNOL REV, V150, P23, DOI 10.1111/j.1600-065X.1996.tb00694.x; FULLER KA, 1993, J IMMUNOL, V151, P4505; GulbransonJudge A, 1996, EUR J IMMUNOL, V26, P1830, DOI 10.1002/eji.1830260825; HANSON RD, 1991, J BIOL CHEM, V266, P24433; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; JAMIESON BD, 1989, J EXP MED, V169, P1993, DOI 10.1084/jem.169.6.1993; Kundig TM, 1996, IMMUNOL REV, V150, P63, DOI 10.1111/j.1600-065X.1996.tb00696.x; LASKO M, 1992, P NATL ACAD SCI USA, V89, P6232; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; Mullbacher A, 1996, IMMUNOL REV, V150, P113, DOI 10.1111/j.1600-065X.1996.tb00698.x; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nagy A, 1998, CURR BIOL, V8, P661, DOI 10.1016/S0960-9822(98)70254-4; NAHILL SR, 1993, J EXP MED, V177, P317, DOI 10.1084/jem.177.2.317; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; TOUGH DF, 1995, IMMUNOL RES, V14, P1, DOI 10.1007/BF02918494; Welsh RM, 1997, IMMUNOL REV, V159, P79, DOI 10.1111/j.1600-065X.1997.tb01008.x; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WOTTON D, 1989, P NATL ACAD SCI USA, V86, P4195, DOI 10.1073/pnas.86.11.4195; YANG HY, 1989, J IMMUNOL, V142, P1710; Zheng B, 1996, NATURE, V384, P263, DOI 10.1038/384263a0; ZHUMABEKOV T, 1991, J BIOL CHEM, V266, P24433; Zimmermann C, 1996, J EXP MED, V183, P1367, DOI 10.1084/jem.183.4.1367; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	30	235	239	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					593	597		10.1038/21208	http://dx.doi.org/10.1038/21208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376601				2022-12-01	WOS:000080778400058
J	Banerjee, AK				Banerjee, AK			Sexual dysfunction after surgery for rectal cancer	LANCET			English	Editorial Material							PRESERVATION; OPERATION; CARCINOMA; EXCISION		Royal Halifax Infirm, Dept Surg, Halifax HX1 2YP, England		Banerjee, AK (corresponding author), Royal Halifax Infirm, Dept Surg, Halifax HX1 2YP, England.							BALSLEV I, 1983, DIS COLON RECTUM, V26, P785, DOI 10.1007/BF02554748; Dahlberg M, 1998, DIS COLON RECTUM, V41, P543, DOI 10.1007/BF02235256; DANZI M, 1983, DIS COLON RECTUM, V26, P665, DOI 10.1007/BF02553339; HEALD RJ, 1986, LANCET, V1, P1479; HOJO K, 1991, DIS COLON RECTUM, V34, P532, DOI 10.1007/BF02049890; LAMONICA G, 1985, DIS COLON RECTUM, V28, P937; LEVECKIS J, 1995, BRIT J UROL, V76, P752, DOI 10.1111/j.1464-410X.1995.tb00768.x; Maas CP, 1998, BRIT J SURG, V85, P92; Masui H, 1996, DIS COLON RECTUM, V39, P1140, DOI 10.1007/BF02081416; Ooi BS, 1999, DIS COLON RECTUM, V42, P403, DOI 10.1007/BF02236362; Sugihara K, 1996, CANCER-AM CANCER SOC, V78, P1871, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1871::AID-CNCR5>3.0.CO;2-I; WALSH PC, 1988, ANN SURG, V208, P391, DOI 10.1097/00000658-198810000-00001; WILLIAMS NS, 1983, BRIT J SURG, V70, P460, DOI 10.1002/bjs.1800700805	13	46	47	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 5	1999	353	9168					1900	1902		10.1016/S0140-6736(99)00127-0	http://dx.doi.org/10.1016/S0140-6736(99)00127-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TP	10371565				2022-12-01	WOS:000080668500006
J	Harris, SF; Botchan, MR				Harris, SF; Botchan, MR			Crystal structure of the human papillomavirus type 18 E2 activation domain	SCIENCE			English	Article							DNA-BINDING DOMAIN; BOVINE PAPILLOMAVIRUS; TRANSACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; FUNCTIONAL INTERACTION; GENETIC-ANALYSIS; IN-VITRO; REPLICATION; PROTEIN; E1	The papillomavirus E2 protein regulates viral transcription and DNA replication through interactions with cellular and viral proteins. The amino-terminal activation domain, which represents a protein class whose structural themes are poorly understood, contains key residues that mediate these functional contacts, The crystal structure of a protease-resistant core of the human papillomavirus type 18 E2 activation domain reveals a novel fold creating a cashew-shaped form with a glutamine-rich alpha helix packed against a beta-sheet framework. The protein surface shows extensive overlap of determinants for replication and transcription. The structure broadens the concept of activators to include proteins with potentially malleable, but certainly ordered, structures.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Botchan, MR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NATIONAL CANCER INSTITUTE [R37CA030490, R01CA030490, R01CA042414] Funding Source: NIH RePORTER; NCI NIH HHS [CA42414, CA30490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABROI A, 1992, P NATL ACAD SCI USA, V70, P6169; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Benson JD, 1997, J VIROL, V71, P8041, DOI 10.1128/JVI.71.10.8041-8047.1997; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Breiding DE, 1997, MOL CELL BIOL, V17, P7208, DOI 10.1128/MCB.17.12.7208; Breiding DE, 1996, VIROLOGY, V221, P34, DOI 10.1006/viro.1996.0350; Brokaw JL, 1996, J VIROL, V70, P23, DOI 10.1128/JVI.70.1.23-29.1996; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; Cho HS, 1996, PROTEIN SCI, V5, P262; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DELAFORTELLE E, CRYSTALLOGRAPHIC COM, V7; FERGUSON MAJ, UNPUB; Ferguson MK, 1996, J VIROL, V70, P4193, DOI 10.1128/JVI.70.7.4193-4199.1996; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRATTINI MG, 1994, VIROLOGY, V204, P799, DOI 10.1006/viro.1994.1596; Harris S. E., UNPUB; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kasukawa H, 1998, J VIROL, V72, P8166, DOI 10.1128/JVI.72.10.8166-8173.1998; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lehman CW, 1998, P NATL ACAD SCI USA, V95, P4338, DOI 10.1073/pnas.95.8.4338; Leslie AGW, 1990, CRYSTALLOGRAPHIC COM; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; LUSKY M, 1991, P NATL ACAD SCI USA, V88, P6363, DOI 10.1073/pnas.88.14.6363; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOHR IJ, 1990, SCIENCE, V250, P1694, DOI 10.1126/science.2176744; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RANK NM, 1995, J VIROL, V69, P6323, DOI 10.1128/JVI.69.10.6323-6334.1995; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Sedman T, 1997, J VIROL, V71, P2887, DOI 10.1128/JVI.71.4.2887-2896.1997; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; Skiadopoulos MH, 1998, J VIROL, V72, P2079, DOI 10.1128/JVI.72.3.2079-2088.1998; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; Stubenrauch F, 1998, J VIROL, V72, P8115, DOI 10.1128/JVI.72.10.8115-8123.1998; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WANG BC, 1985, METHOD ENZYMOL, V115, P90; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; Yao JM, 1998, J VIROL, V72, P1013, DOI 10.1128/JVI.72.2.1013-1019.1998; Zou NX, 1998, J VIROL, V72, P3436, DOI 10.1128/JVI.72.4.3436-3441.1998	52	57	61	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1673	1677		10.1126/science.284.5420.1673	http://dx.doi.org/10.1126/science.284.5420.1673			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356398				2022-12-01	WOS:000080668300046
J	West, GB; Brown, JH; Enquist, BJ				West, GB; Brown, JH; Enquist, BJ			The fourth dimension of life: Fractal geometry and allometric scaling of organisms	SCIENCE			English	Article							BIOLOGY	Fractal-like networks effectively endow Life with an additional fourth spatial dimension. This is the origin of quarter-power scaling that is so pervasive in biology, Organisms have evolved hierarchical branching networks that terminate in size-invariant units, such as capillaries, Leaves, mitochondria, and oxidase molecules. Natural selection has tended to maximize both metabolic capacity, by maximizing the scaling of exchange surface areas, and internal efficiency, by minimizing the scaling of transport distances and times. These design principles are independent of detailed dynamics and explicit models and should apply to virtually all organisms.	Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; The Santa Fe Institute; University of New Mexico	West, GB (corresponding author), Los Alamos Natl Lab, Div Theoret, MS B285, Los Alamos, NM 87545 USA.	gbw@lanl.gov	Enquist, Brian J/B-6436-2008	Enquist, Brian J/0000-0002-6124-7096				BLUM JJ, 1977, J THEOR BIOL, V64, P599, DOI 10.1016/0022-5193(77)90292-2; BROWN JH, IN PRESS SCALING BIO; Calder W. A, 1984, SIZE FUNCTION LIFE H; HAINSWORTH FR, ANIMAL PHYSL ADAPTAT, P170; MANDELBROT BB, 1977, FRACTAL GEOEMTRY NAT; Niklas K.J., 1994, PLANT ALLOMETRY SCAL; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; Rubner M., 1883, Z BIOL, V19, P535; TAKAYASU H, 1992, FRACTALS PHYSICAL SC; Turcotte DL, 1998, J THEOR BIOL, V193, P577, DOI 10.1006/jtbi.1998.0723; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; WEST GB, SCALING BIOL	12	1144	1204	12	318	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 4	1999	284	5420					1677	1679		10.1126/science.284.5420.1677	http://dx.doi.org/10.1126/science.284.5420.1677			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10356399				2022-12-01	WOS:000080668300047
J	Cohn, MJ; Tickle, C				Cohn, MJ; Tickle, C			Developmental basis of limblessness and axial patterning in snakes	NATURE			English	Article							CHICK LIMB BUD; APICAL ECTODERMAL RIDGE; SONIC-HEDGEHOG; VERTEBRATE LIMB; HOMEOBOX GENE; FEEDBACK LOOP; MOUSE EMBRYOS; EXPRESSION; GROWTH; EVOLUTION	The evolution of snakes involved major changes in vertebrate body plan organization, but the developmental basis of those changes is unknown. The python axial skeleton consists of hundreds of similar vertebrae, forelimbs are absent and hindlimbs are severely reduced, Combined limb loss and trunk elongation is found in many vertebrate taxa(1), suggesting that these changes may be linked by a common developmental mechanism. Here we show that Hox gene expression domains are expanded along the body axis in python embryos, and that this can account for both the absence of forelimbs and the expansion of thoracic identity in the axial skeleton, Hindlimb buds are initiated, but apical-ridge and polarizing-region signalling pathways that are normally required for limb development: are not activated, Leg bud outgrowth and signalling by Sonic hedgehog in pythons can be rescued by application of fibroblast growth factor or by recombination with chick apical ridge. The failure to activate these signalling pathways during normal python development may also stem from changes in Hox gene expression that occurred early in snake evolution.	Univ Reading, Sch Anim & Microbial Sci, Div Zool, Reading RG6 6AJ, Berks, England; Univ Dundee, Dept Anat & Physiol, Dundee DD1 5EH, Scotland; UCL, Dept Anat & Dev Biol, London WC1E 6BT, England	University of Reading; University of Dundee; University of London; University College London	Cohn, MJ (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Div Zool, Reading RG6 6AJ, Berks, England.	M.J.Cohn@reading.ac.uk						Altabef M, 1997, DEVELOPMENT, V124, P4547; BURKE AC, 1995, DEVELOPMENT, V121, P333; Carroll RL., 1988, VERTEBRATE PALEONTOL; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; DAVIDSON DR, 1991, NATURE, V352, P429, DOI 10.1038/352429a0; DAVIS CA, 1991, DEVELOPMENT, V111, P287; Fang H, 1996, DEV BIOL, V179, P160, DOI 10.1006/dbio.1996.0248; FERRARI D, 1995, MECH DEVELOP, V52, P257, DOI 10.1016/0925-4773(95)98113-O; Gasc JP, 1966, B MUS NATION HISTOIR, V38, P99; GAUNT SJ, 1994, INT J DEV BIOL, V38, P549; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lee MSY, 1998, PHILOS T ROY SOC B, V353, P1521, DOI 10.1098/rstb.1998.0308; Marigo V, 1996, DEVELOPMENT, V122, P1225; MARTI E, 1995, DEVELOPMENT, V121, P2537; Nelson CE, 1996, DEVELOPMENT, V122, P1449; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; PANGANIBAN G, 1995, SCIENCE, V270, P1363, DOI 10.1126/science.270.5240.1363; RANCOURT DE, 1995, GENE DEV, V9, P108, DOI 10.1101/gad.9.1.108; RAYNAUD A, 1995, CR ACAD SCI III-VIE, V318, P573; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; Shashikant CS, 1995, DEVELOPMENT, V121, P4339; WALL NA, 1992, MECH DEVELOP, V37, P111, DOI 10.1016/0925-4773(92)90073-S; Wilson V, 1997, DEV BIOL, V192, P45, DOI 10.1006/dbio.1997.8701; Yang Y, 1997, DEVELOPMENT, V124, P4393; Zeller R, 1997, BIOESSAYS, V19, P541, DOI 10.1002/bies.950190703; 1995, EYEWITNESS ENCY NATU	33	337	343	7	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					474	479		10.1038/20944	http://dx.doi.org/10.1038/20944			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365960				2022-12-01	WOS:000080667900050
J	Cooke, RWI				Cooke, RWI			New approach to prevention of kernicterus	LANCET			English	Editorial Material							BILIRUBIN PRODUCTION; TERM NEWBORNS; TIN-MESOPORPHYRIN; INHIBITOR; HYPERBILIRUBINEMIA; PROTOPORPHYRIN; PHOTOTHERAPY		Univ Liverpool, Dept Child Hlth, Liverpool Womens Hosp, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Cooke, RWI (corresponding author), Univ Liverpool, Dept Child Hlth, Liverpool Womens Hosp, Liverpool L8 7SS, Merseyside, England.							GALBRAITH RA, 1992, PEDIATRICS, V89, P175; KAPPAS A, 1995, PEDIATRICS, V95, P468; KAPPAS A, 1988, PEDIATRICS, V81, P485; MAISELS MJ, 1995, PEDIATRICS, V96, P730; Martinez JC, 1999, PEDIATRICS, V103, P1, DOI 10.1542/peds.103.1.1; Rodgers PA, 1996, PEDIATR RES, V39, P1041, DOI 10.1203/00006450-199606000-00018; TURKEL SB, 1980, PEDIATRICS, V66, P502; VALAES T, 1994, PEDIATRICS, V93, P1; WATCHKO JF, 1994, PEDIATRICS, V93, P996	9	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 29	1999	353	9167					1814	1815		10.1016/S0140-6736(99)90077-6	http://dx.doi.org/10.1016/S0140-6736(99)90077-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TG	10359401				2022-12-01	WOS:000080667800004
J	Howitt, A; Armstrong, D				Howitt, A; Armstrong, D			Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY	Objective To determine the extent to which implementation of an evidence based treatment, antithrombotic treatment in atrial fibrillation, is possible in general practice. Design Audit and qualitative study of patients with atrial fibrillation and an educational intervention for patients judged eligible for antithrombotic treatment Setting South east England. Subjects 56 patients with a history of atrial fibrillation. Interventions Assessment and interview to ascertain patients' views on antithrombotic treatment Main outcome measures Number of patients receiving antithrombotic treatment Results Out of 13 239 patients, 132 had a history of atrial fibrillation of which 100 were at risk of thromboembolism. After the study, 52 patients were taking warfarin. Of the remaining 48 patients (of whom 41 were taking aspirin), eight were too ill to participate, 16 were unable to consent, four refused the interview and 20 declined warfarin. Patients declining warfarin were inclined to seek a higher level of benefit than those taking it, as measured by the minimal clinically important difference. Qualitative data obtained during the interviews suggested that patients' health beliefs were important factors in determining their choice of treatment Conclusion Patients' unwillingness to take warfarin seemed to be a major factor in limiting the number who would eventually take it.	Warders Med Ctr, Tonbridge TN9 1LA, Kent, England; Guys Kings & St Thomas Sch Med, Dept Gen Practice, London SE11 6SP, England	University of London; King's College London	Howitt, A (corresponding author), Warders Med Ctr, Tonbridge TN9 1LA, Kent, England.	ajhowitt@warders.co.uk	Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lip GYH, 1997, BRIT J GEN PRACT, V47, P285; Lip GYH, 1996, BRIT MED J, V312, P45, DOI 10.1136/bmj.312.7022.45; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; OConnell JE, 1996, AGE AGEING, V25, P307, DOI 10.1093/ageing/25.4.307; Roderick E, 1997, BRIT J GEN PRACT, V47, P660; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; TAYLOR F, 1993, BRIT MED J, V307, P1493, DOI 10.1136/bmj.307.6917.1493; Thomson R, 1998, BRIT MED J, V316, P509, DOI 10.1136/bmj.316.7130.509; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50	11	128	133	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	1999	318	7194					1324	1327		10.1136/bmj.318.7194.1324	http://dx.doi.org/10.1136/bmj.318.7194.1324			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323820	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000080418400028
J	Nam, HJ; Poy, F; Krueger, NX; Saito, H; Frederick, CA				Nam, HJ; Poy, F; Krueger, NX; Saito, H; Frederick, CA			Crystal structure of the tandem phosphatase domains of RPTP LAR	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LEUKOCYTE COMMON ANTIGEN; CATALYTIC DOMAINS; MOLECULAR REPLACEMENT; ALPHA; EXPRESSION; MUTANTS; COMPLEX; ROLES; LCA	Most receptor-like protein tyrosine phosphatases (RPTPs) contain two conserved phosphatase domains (D1 and D2) in their intracellular region. The carboxyterminal D2 domain has little or no catalytic activity. The crystal structure of the tandem D1 and D2 domains of the human RPTP LAR revealed that the tertiary structures of the LAR D1 and D2 domains are very similar to each other, with the exception of conformational differences at two amino acid positions in the D2 domain. Site-directed mutational changes at these positions (Leu-1644-to-Tyr and Glu-1779-to-Asp) conferred a robust PTPase activity to the D2 domain. The catalytic sites of both domains are accessible, in contrast to the dimeric blocked orientation model previously suggested. The relative orientation of the LAR D1 and D2 domains, constrained by a short linker, is stabilized by extensive interdomain interactions, suggesting that this orientation might be favored in solution.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Frederick, CA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	caf@red.dfci.harvard.edu	Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689	NIGMS NIH HHS [GM 53415] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; EVANS R, 1990, VIA, V11, P134; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; ITOH M, 1992, J BIOL CHEM, V267, P12356; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LESLIE AG, 1988, DARESBURY LAB INFORM, P33; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Saito H, 1993, Semin Cell Biol, V4, P379, DOI 10.1006/scel.1993.1045; SEIMIYA H, 1995, ONCOGENE, V10, P1731; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	33	146	151	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					449	457		10.1016/S0092-8674(00)80755-2	http://dx.doi.org/10.1016/S0092-8674(00)80755-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338209	Bronze			2022-12-01	WOS:000080299100006
J	Smith, JK; Dykes, R; Douglas, JE; Krishnaswamy, G; Berk, S				Smith, JK; Dykes, R; Douglas, JE; Krishnaswamy, G; Berk, S			Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; ENDOTHELIAL-CELLS; CORONARY-ARTERIES; INTERFERON-GAMMA; HEALTHY-MEN; ATHEROSCLEROSIS; IL-10; EXPRESSION	Context Increasing evidence demonstrates that atherosclerosis is an immunologically mediated disease in which the secretion of atherogenic and atheroprotective cytokines, by infiltrating blood mononuclear cells, plays an important role. It is not known whether long-term exercise alters this atherogenic and atheroprotedive activity directly. Objective To determine the effect of long-term exercise on the atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. Design Before-after trial using a 6-month individualized, supervised exercise program, with an enrollment period from December 1996 to October 1997. Setting Hospital-based community wellness center. Participants Of 110 persons who responded to a public request for volunteers, 52 met the inclusion criteria (risk ratio for myocardial infarction greater than or equal to 1.7 based on serum complement and/or C-reactive protein levels, and normal exercise treadmill test results). Forty-three of the 52 enrollees (25 women [mean age, 49.7 years] and 18 men [mean age, 48.1 years]) completed the study; 9 withdrew for personal reasons. Additional risk factors for ischemic heart disease included hypercholesterolemia (65.1%), a family history of coronary heart disease (62.8%), inactivity (60.5%), hypertension (32.6%), obesity (25.6%), smoking (11.6%), and diabetes mellitus (4.7%). Main Outcome Measures Blood levels were compared at baseline and after the exercise program had been completed for the following: spontaneous and phytohemagglutinin-induced production of interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma (atherogenic cytokines), and interleukin 4, interleukin 10, and transforming growth factor beta 1 (atheroprotective cytokines) by blood mononuclear cells; lymphocyte phenotypes and mitogenic responses to phytohemagglutinin; and serum C-reactive protein levels. Results Subjects exercised for a mean of 2.5 (range, 0.3-7.4) hours per week. Mononuclear cell production of atherogenic cytokines fell by 58.3% (P < .001) following the exercise program, whereas the production of atheroprotective cytokines rose by 35.9% (P < .001). Changes in transforming growth factor beta 1 and in phytohemagglutinin-induced atherogenic cytokine production after the exercise program were proportionate to the time subjects spent performing repetitive lower-body motion exercises (P < .02), indicating a dose-response relationship. After the exercise program, changes in cellular function were reflected systemically by a 35% decrease in serum levels of C-reactive protein (P = .12). Conclusions Our data suggest that long-term exercise decreases the atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. This may be a mechanism whereby physical activity protects against ischemic heart disease.	E Tennessee State Univ, James H Quillen Coll Med, Dept Internal Med, Div Immunol, Johnson City, TN 37614 USA; E Tennessee State Univ, James H Quillen Coll Med, Dept Internal Med, Div Cardiol, Johnson City, TN 37614 USA	East Tennessee State University; East Tennessee State University	Smith, JK (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Internal Med, Div Immunol, Johnson City, TN 37614 USA.	smithj@access.etsu.edu	Krishnaswamy, Guha/R-9076-2019; KRISHNASWAMY, GUHA/AAR-8844-2021	KRISHNASWAMY, GUHA/0000-0002-9848-6197				ADAM E, 1987, LANCET, V2, P291; AnglesCano E, 1997, BRAZ J MED BIOL RES, V30, P1271, DOI 10.1590/S0100-879X1997001100002; [Anonymous], 1996, JAMA, V276, P241; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; Campbell JH, 1997, AUST NZ J MED, V27, P497, DOI 10.1111/j.1445-5994.1997.tb02225.x; Centre for Disease Control Prevention, 1997, MMWR-MORBID MORTAL W, V46, P941; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; Di Febbo C, 1998, ATHEROSCLEROSIS, V136, P377, DOI 10.1016/S0021-9150(97)00240-2; ELLIOTT MJ, 1991, BLOOD, V77, P2739; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FENTON MJ, 1992, J IMMUNOL, V149, P1283; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Grainger DJ, 1997, J LIPID RES, V38, P2344; GRAZINELLI TT, 1992, J IMMUNOL, V148, P1792; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; HOLLOSZY JO, 1993, MED SCI SPORT EXER, V25, P1; KRAKAUER T, 1995, IMMUNOL LETT, V45, P61, DOI 10.1016/0165-2478(94)00226-H; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; Kushi LH, 1997, JAMA-J AM MED ASSOC, V277, P1287, DOI 10.1001/jama.277.16.1287; Labarrere CA, 1997, JAMA-J AM MED ASSOC, V278, P1169, DOI 10.1001/jama.278.14.1169; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LIBBY P, 1991, LAB INVEST, V64, P5; Maluish A, 1986, MANUAL CLIN LAB IMMU, P274; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; MUNRO JM, 1988, LAB INVEST, V58, P249; MUSCARI A, 1995, AM J MED, V98, P357, DOI 10.1016/S0002-9343(99)80314-3; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Reckless J, 1997, CIRCULATION, V95, P1542; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Selwyn AP, 1997, AM J CARDIOL, V80, pH3, DOI 10.1016/S0002-9149(97)00813-8; Stefanovic-Racic M., 1994, P417; Takami S, 1998, CIRCULATION, V97, P721, DOI 10.1161/01.CIR.97.8.721; Tashiro H, 1997, CORONARY ARTERY DIS, V8, P143, DOI 10.1097/00019501-199703000-00004; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; Vadas MA, 1997, CLIN EXP PHARMACOL P, V24, pA33, DOI 10.1111/j.1440-1681.1997.tb03052.x; VANDERWAL AC, 1989, LAB INVEST, V61, P166; Vasse M, 1996, BRIT J HAEMATOL, V93, P955, DOI 10.1046/j.1365-2141.1996.d01-1731.x; Velde AA, 1990, BLOOD, V76, P1392; Watanabe T, 1996, INT J CARDIOL, V54, pS51, DOI 10.1016/S0167-5273(96)88773-0; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0; Wick G, 1997, FASEB J, V11, P1199, DOI 10.1096/fasebj.11.13.9367355; Witztum JL, 1997, ATHEROSCLEROSIS, V131, pS9, DOI 10.1016/S0021-9150(97)06116-9; YAMASHIROYA HM, 1988, AM J PATHOL, V130, P71; Yokota T, 1995, J INTERN MED, V238, P479, DOI 10.1111/j.1365-2796.1995.tb01229.x	53	305	319	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1722	1727		10.1001/jama.281.18.1722	http://dx.doi.org/10.1001/jama.281.18.1722			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328073	Bronze			2022-12-01	WOS:000080161200030
J	Marubio, LM; Arroyo-Jimenez, MD; Cordero-Erausquin, M; Lena, C; Le Novere, N; d'Exaerde, AD; Huchet, M; Damaj, MI; Changeux, JP				Marubio, LM; Arroyo-Jimenez, MD; Cordero-Erausquin, M; Lena, C; Le Novere, N; d'Exaerde, AD; Huchet, M; Damaj, MI; Changeux, JP			Reduced antinociception in mice lacking neuronal nicotinic receptor subunits	NATURE			English	Article							NUCLEUS RAPHE MAGNUS; CENTRAL NERVOUS-SYSTEM; ACETYLCHOLINE-RECEPTORS; ANALGESIC ACTIVITY; RAT-BRAIN; MODULATION; THALAMUS; GENE; PAIN	Nicotine exerts antinociceptive effects by interacting with one or more of the subtypes of nicotinic acetylcholine receptors (nAChRs) that are present throughout the neuronal pathways that respond to pain(1-5). To identify the particular subunits involved in this process, we generated mice lacking the alpha 4 subunit of the neuronal nAChR by homologous recombination techniques and studied these together with previously generated mutant mice lacking the beta 2 nAChR subunit(6). Here we show that the homozygous alpha 4(-/-) mice no longer express high-affinity [H-3]nicotine and [H-3]epibatidine binding sites throughout the brain. In addition, both types of mutant mice display a reduced antinociceptive effect of nicotine on the hot-plate test and diminished sensitivity to nicotine in the tail-flick test. Patch-clamp recordings further reveal that raphe magnus and thalamic neurons no longer respond to nicotine. The alpha 4 nAChR subunit, possibly associated with the beta 2 nAChR subunit, is therefore crucial for nicotine-elicited antinociception.	Inst Pasteur, CNRS, UA D1284, F-75724 Paris 15, France; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Virginia Commonwealth University	Changeux, JP (corresponding author), Inst Pasteur, CNRS, UA D1284, 28 Rue Dr Roux, F-75724 Paris 15, France.		Léna, Clément/P-6929-2019; de Kerchove d'Exaerde, Alban/R-6984-2019; Le Novère, Nicolas/F-9973-2010; Beldar, Sagar V/C-8542-2011; Léna, Clément/ABE-4862-2021; Léna, Clément/T-8458-2018; , clement/ADN-8076-2022; Arroyo-Jimenez, Maria del Mar/R-6124-2017	Léna, Clément/0000-0002-1431-7717; Le Novère, Nicolas/0000-0002-6309-7327; Léna, Clément/0000-0002-1431-7717; Léna, Clément/0000-0002-1431-7717; Arroyo-Jimenez, Maria del Mar/0000-0002-8390-5352; de Kerchove d'Exaerde, Alban/0000-0002-0682-5877				ASGHAR K, 1971, BIOCHEM PHARMACOL, V20, P2787, DOI 10.1016/0006-2952(71)90189-4; Bannon AW, 1998, SCIENCE, V279, P77, DOI 10.1126/science.279.5347.77; Bitner RS, 1998, J NEUROSCI, V18, P5426, DOI 10.1523/JNEUROSCI.18-14-05426.1998; CAGGIULA AR, 1995, PSYCHOPHARMACOLOGY, V122, P301, DOI 10.1007/BF02246552; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; Damaj MI, 1997, J PHARMACOL EXP THER, V282, P410; Flores CM, 1996, J NEUROSCI, V16, P7892; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA; IWAMOTO ET, 1991, J PHARMACOL EXP THER, V257, P120; JURNA I, 1993, CLIN INVESTIGATOR, V72, P65; Lena C, 1997, J NEUROSCI, V17, P576; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; PAN ZZ, 1993, NEUROSCIENCE, V54, P421, DOI 10.1016/0306-4522(93)90263-F; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; Rao TS, 1996, NEUROPHARMACOLOGY, V35, P393, DOI 10.1016/0028-3908(96)00013-5; SAHLEY TL, 1979, PSYCHOPHARMACOLOGY, V65, P279, DOI 10.1007/BF00492216; SPANDE TF, 1992, J AM CHEM SOC, V114, P3475, DOI 10.1021/ja00035a048; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; TRIPATHI HL, 1982, J PHARMACOL EXP THER, V221, P91; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zoli M, 1998, J NEUROSCI, V18, P4461	27	473	492	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 29	1999	398	6730					805	810		10.1038/19756	http://dx.doi.org/10.1038/19756			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235262				2022-12-01	WOS:000080058100058
J	Tremblay, L; Schultz, W				Tremblay, L; Schultz, W			Relative reward preference in primate orbitofrontal cortex	NATURE			English	Article							PREFRONTAL CORTEX; NEURONAL-ACTIVITY; WORKING-MEMORY; RHESUS-MONKEY; DISSOCIATION; EXPECTATION; CONNECTIONS; RESPONSES; STRIATUM; MACAQUE	The orbital part of prefrontal cortex appears to be crucially involved in the motivational control of goal-directed behaviour(1,2). Patients with lesions of orbitofrontal cortex show impairments in making decisions about the expected outcome of actions(3). Monkeys with orbitofrontal lesions respond abnormally to changes in reward expectations(4,5) and show altered reward preferences(6). As rewards constitute basic goals of behaviour(7) we investigated here how neurons in the orbitofrontal cortex of monkeys process information about liquid and food rewards in a typical frontal task, spatial delayed responding(8). The activity of orbitofrontal neurons increases in response to reward-predicting signals, during: the expectation of rewards, and after the receipt of rewards. Neurons discriminate between different rewards, mainly irrespective of the spatial and visual features of reward-predicting stimuli and behavioural reactions. Most reward discriminations reflect the animals' relative preference among the available rewards, as expressed by their choice behaviour, rather than physical reward properties. Thus, neurons in the orbitofrontal cortex appear to process the motivational value of rewarding outcomes of voluntary action.	Univ Fribourg, Inst Physiol, CH-1700 Fribourg, Switzerland; Univ Fribourg, Program Neurosci, CH-1700 Fribourg, Switzerland; Univ Freiburg, Inst Physiol, CH-1700 Fribourg, Switzerland; Hop La Pitie Salpetriere, F-75651 Paris, France	University of Fribourg; University of Fribourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Schultz, W (corresponding author), Hop La Pitie Salpetriere, INSERM, Unit 289, 47 Blvd Hop, F-75651 Paris, France.		Tremblay, Leon/H-1559-2017	Tremblay, Leon/0000-0001-8370-6903				BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; BAYLIS LL, 1991, EXP BRAIN RES, V86, P617; Bechara A, 1998, J NEUROSCI, V18, P428; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Critchley HD, 1996, J NEUROPHYSIOL, V75, P1659, DOI 10.1152/jn.1996.75.4.1659; Critchley HD, 1996, J NEUROPHYSIOL, V75, P1673, DOI 10.1152/jn.1996.75.4.1673; DAMASIO AR, 1994, DESCARTES ERROR; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; DICKINSON A, 1994, ANIM LEARN BEHAV, V22, P1, DOI 10.3758/BF03199951; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P814, DOI 10.1152/jn.1989.61.4.814; Hollerman JR, 1998, J NEUROPHYSIOL, V80, P947, DOI 10.1152/jn.1998.80.2.947; IVERSEN SD, 1970, EXP BRAIN RES, V11, P376; Jacobsen CF, 1937, J COMP PSYCHOL, V23, P101, DOI 10.1037/h0056632; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; Miller EK, 1996, J NEUROSCI, V16, P5154; Pandya DN, 1996, PHILOS T ROY SOC B, V351, P1423, DOI 10.1098/rstb.1996.0127; PETRIDES M, 1988, J COMP NEUROL, V273, P52, DOI 10.1002/cne.902730106; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; Rolls ET, 1996, PHILOS T ROY SOC B, V351, P1433, DOI 10.1098/rstb.1996.0128; Rolls ET, 1996, J NEUROPHYSIOL, V75, P1970, DOI 10.1152/jn.1996.75.5.1970; ROSENKILDE CE, 1981, BRAIN RES, V209, P375, DOI 10.1016/0006-8993(81)90160-8; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P733, DOI 10.1152/jn.1995.74.2.733; Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407; SCHULTZ W, 1992, J NEUROSCI, V12, P4595, DOI 10.1523/jneurosci.12-12-04595.1992; THORPE SJ, 1983, EXP BRAIN RES, V49, P93; Tinklepaugh OL, 1928, J COMP PSYCHOL, V8, P197, DOI 10.1037/h0075798; Watanabe M, 1996, NATURE, V382, P629, DOI 10.1038/382629a0; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	30	935	947	2	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					704	708		10.1038/19525	http://dx.doi.org/10.1038/19525			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227292				2022-12-01	WOS:000079920100050
J	Adams, JS; Song, CF; Kantorovich, V				Adams, JS; Song, CF; Kantorovich, V			Rapid recovery of bone mass in hypercalciuric, osteoporotic men treated with hydrochlorothiazide	ANNALS OF INTERNAL MEDICINE			English	Article							IDIOPATHIC HYPERCALCIURIA; MINERAL DENSITY; THIAZIDE; FRACTURES; HYPERPARATHYROIDISM; ETIOLOGY; THERAPY	Background: Chronic hypercalciuria can contribute to osteoporosis, particularly in men. Objective: To ascertain the effects of resolution of hypercalciuria on bone mineral density. Design: Case series. Setting: Referral service for metabolic bone disease in a tertiary-care teaching hospital. Patients: Five male patients (42 to 66 years of age) with hypercalciuria and osteoporosis. Intervention: Hydrochlorothiazide, 25 mg twice daily, for a mean (+/- SD) of 7.8 +/- 3.6 months. Measurements: Fasting urinary calcium:creatinine ratio, serum calciotropic hormone levels, and bone mineral density before and after hydrochlorothiazide administration. Results: Hydrochlorothiazide resolved hypercalciuria and increased bone mineral density at a rate of 8% and 3% per year at the spine and hip, respectively. Conclusions: Hydrochlorothiazide treatment in hypercalciuric and osteoporotic men was associated with a rapid rebound increase in bone mineral density.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Los Angeles, CA 90048 USA; Burns & Allen Res Inst, Los Angeles, CA USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Adams, JS (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	adamsj@cshs.org	Adams, John S/I-3365-2013	Adams, John S/0000-0001-9607-5020	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00425] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams JS, 1997, ANN INTERN MED, V127, P203, DOI 10.7326/0003-4819-127-3-199708010-00004; Anderson FH, 1998, INT J CLIN PRACT, V52, P176; BURCKHARDT P, 1981, J CLIN ENDOCR METAB, V53, P550, DOI 10.1210/jcem-53-3-550; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; CUMMINGS SR, 1995, AM J MED, V98, pS24, DOI 10.1016/S0002-9343(05)80041-5; Feskanich D, 1997, OSTEOPOROSIS INT, V7, P79, DOI 10.1007/BF01623465; Ghazali A, 1997, J CLIN ENDOCR METAB, V82, P32, DOI 10.1210/jc.82.1.32; Jodar E, 1997, CLIN ENDOCRINOL, V47, P279, DOI 10.1046/j.1365-2265.1997.2261041.x; JONES G, 1995, J BONE MINER RES, V10, P106; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; Pacifici R, 1997, J CLIN ENDOCR METAB, V82, P29, DOI 10.1210/jc.82.1.29; PACIFICI R, 1990, J CLIN ENDOCR METAB, V71, P138, DOI 10.1210/jcem-71-1-138; PERIS P, 1995, BRIT J RHEUMATOL, V34, P936; PERRY HM, 1982, ARCH INTERN MED, V142, P1295, DOI 10.1001/archinte.142.7.1295; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P729, DOI 10.1210/jc.80.3.729; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605	19	69	72	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 20	1999	130	8					658	660		10.7326/0003-4819-130-8-199904200-00012	http://dx.doi.org/10.7326/0003-4819-130-8-199904200-00012			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187KW	10215562				2022-12-01	WOS:000079786600005
J	Heaney, LG; McAllister, D; MacMahon, J				Heaney, LG; McAllister, D; MacMahon, J			Cost minimisation analysis of provision of oxygen at home: Are the Drug Tariff guidelines cost effective?	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine the level of oxygen cylinder use at which it becomes more cost effective to provide oxygen by concentrator at home in Northern Ireland, and to examine potential cost savings if cylinder use above this level had been replaced by concentrator in 1996. Design Cost minimisation analysis. Setting Area health boards in Northern Ireland. Main outcome measures Cost effective cut off point for switch to provision of oxygen from cylinder to concentrator. Potential maximum and minimum savings in Northern Ireland (sensitivity analysis) owing to switch to more cost effective strategy on the basis of provision of cylinders in 1996. Results In Northern Ireland it is currently cost effective to provide oxygen by concentrator when the patient is using three or more cylinders per month independent of the duration of the prescription. More widespread use of concentrators at this level of provision is likely to lead to a cost saving. Conclusions The Drug Tariff prescribing guidelines, advocating that provision of oxygen by concentrator becomes cheaper when 21 cylinders are being used per month-are currently inaccurate in Northern Ireland, Regional health authorities should review their current arrangements for provision of oxygen at home and perform a cost analysis to determine at what level it becomes more cost effective to provide oxygen by concentrator.	Belfast City Hosp, Dept Resp Med, Belfast BT9 7AB, Antrim, North Ireland; Univ Ulster, Sch Publ Policy & Law, Jordanstown, North Ireland	Belfast City Hospital; Ulster University	Heaney, LG (corresponding author), Belfast City Hosp, Dept Resp Med, Belfast BT9 7AB, Antrim, North Ireland.	LiamHeaney@ukgateway.net						[Anonymous], 1980, ANN INTERN MED, V93, P391; *DEP HLTH, 1996, DRUG TAR 10; Drummond MF., 2015, METHODS EC EVALUATIO; FLENLEY DC, 1981, LANCET, V1, P681; Rees P. J., 1998, BMJ, V317, P935	5	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					19	23		10.1136/bmj.319.7201.19	http://dx.doi.org/10.1136/bmj.319.7201.19			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390453	Bronze, Green Published			2022-12-01	WOS:000081326500024
J	Cacciola, I; Pollicino, T; Squadrito, G; Cerenzia, G; Orlando, ME; Raimondo, G				Cacciola, I; Pollicino, T; Squadrito, G; Cerenzia, G; Orlando, ME; Raimondo, G			Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; POSITIVE PATIENTS; CHRONIC CARRIERS; DNA; REACTIVATION; REPLICATION; HBSAG; GENE; TRANSPLANTATION	Background Hepatitis B virus (HBV) infections in patients who lack detectable hepatitis B surface antigen (HBsAg) are called occult infections. Although such infections have been identified in patients with chronic hepatitis C liver disease, their prevalence and clinical significance are not known. Methods With the polymerase chain reaction, we searched for HBV DNA in liver and serum samples from 200 HBsAg-negative patients with hepatitis C virus (HCV)-related liver disease (147 with chronic hepatitis, 48 with cirrhosis, and 5 with minimal histologic changes). One hundred of the patients had detectable antibodies to the HBV core antigen (anti-HBc); 100 were negative for all HBV markers. Eighty-three were treated with interferon alfa. We also studied 50 patients with liver disease who were negative both for HBsAg and for HCV markers. In six patients found to have occult HBV infection, we evaluated possible genomic rearrangements through cloning or direct sequencing procedures. Results Sixty-six of the 200 patients with chronic hepatitis C liver disease (33 percent) had HBV sequences, as did 7 of the 50 patients with liver disease unrelated to hepatitis C (14 percent, P = 0.01). Among the 66 patients, 46 were anti-HBc-positive and 20 were negative for all HBV markers (P<0.001). Twenty-two of these 66 patients (33 percent) had cirrhosis, as compared with 26 of the 134 patients with hepatitis C infection but no HBV sequences (19 percent, P = 0.04). HBV sequences were detected in 26 of the 55 patients in whom interferon therapy was ineffective and 7 of the 28 patients in whom interferon therapy was effective (P = 0.06). None of the sequenced HBV genomes had changes known to interfere with viral activity and gene expression. Conclusions Occult hepatitis B infection occurs frequently in patients with chronic hepatitis C liver disease and may have clinical significance. (N Engl J Med 1999;341:22-6.) (C)1999, Massachusetts Medical Society.	Univ Messina, Policlin Univ, Dipartimento Med Interna, I-98100 Messina, Italy	AOU Policlinico Gaetano Martino; University of Messina	Raimondo, G (corresponding author), Univ Messina, Policlin Univ, Dipartimento Med Interna, I-98100 Messina, Italy.		Pollicino, Teresa/K-5790-2016; Cacciola, Irene/K-1174-2019; Pollicino, Teresa/HDN-3708-2022	Pollicino, Teresa/0000-0001-6602-3035; Cacciola, Irene/0000-0001-7721-6799; 				ALBERTI A, 1995, J HEPATOL, V22, P38; Armitage P, 1994, STAT METHODS MED RES; BLUM HE, 1991, J VIROL, V65, P1836, DOI 10.1128/JVI.65.4.1836-1842.1991; BRECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P3906, DOI 10.1073/pnas.78.6.3906; Brunetto MR, 1998, LANCET, V351, P1535; Carman WF, 1997, HEPATOLOGY, V26, P1658, DOI 10.1002/hep.510260640; CHAZOUILLERES O, 1994, LANCET, V343, P142, DOI 10.1016/S0140-6736(94)90934-2; CRESPO J, 1994, AM J GASTROENTEROL, V89, P1147; FATTOVICH G, 1991, J INFECT DIS, V163, P400, DOI 10.1093/infdis/163.2.400; FERAY C, 1992, J CLIN INVEST, V89, P1361, DOI 10.1172/JCI115723; GROTZINGER T, 1992, VIROLOGY, V187, P383, DOI 10.1016/0042-6822(92)90332-J; GRUMAYER ER, 1989, J HEPATOL, V8, P232, DOI 10.1016/0168-8278(89)90012-3; HOOFNAGLE JH, 1982, ANN INTERN MED, V96, P447, DOI 10.7326/0003-4819-96-4-447; Huo TI, 1998, HEPATOLOGY, V28, P231, DOI 10.1002/hep.510280130; Koike K, 1998, J MED VIROL, V54, P249, DOI 10.1002/(SICI)1096-9071(199804)54:4&lt;249::AID-JMV3&gt;3.0.CO;2-4; KORBA BE, 1989, HEPATOLOGY, V9, P461, DOI 10.1002/hep.1840090321; LIANG TJ, 1991, HEPATOLOGY, V13, P1044, DOI 10.1002/hep.1840130607; LIANG TJ, 1990, HEPATOLOGY, V12, P204, DOI 10.1002/hep.1840120205; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; MARCELLIN P, 1991, GASTROENTEROLOGY, V100, P1432; MARION PL, 1991, MOL BIOL HEPATITIS B, P39; MICHALAK TI, 1994, J CLIN INVEST, V93, P230, DOI 10.1172/JCI116950; MICHALAK TI, 1994, J CLIN INVEST, V94, pA905; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; PATERLINI P, 1990, NEW ENGL J MED, V323, P80, DOI 10.1056/NEJM199007123230202; Penna A, 1996, J CLIN INVEST, V98, P1185, DOI 10.1172/JCI118902; Pollicino T, 1997, HEPATOLOGY, V26, P495, DOI 10.1002/hep.510260235; Pollicino T, 1996, J GEN VIROL, V77, P1833, DOI 10.1099/0022-1317-77-8-1833; POLLICINO T, 1995, VIROLOGY, V208, P672, DOI 10.1006/viro.1995.1198; SATO S, 1994, J HEPATOL, V21, P159, DOI 10.1016/S0168-8278(05)80389-7; Schepis F, 1997, J HEPATOL, V26, P765, DOI 10.1016/S0168-8278(97)80240-1; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; SHEEN IS, 1992, J INFECT DIS, V165, P831, DOI 10.1093/infdis/165.5.831; SHEU JC, 1992, GASTROENTEROLOGY, V103, P1322, DOI 10.1016/0016-5085(92)91523-7; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Siegel S., 1998, NONPARAMETRIC STAT B; THIERS V, 1988, LANCET, V2, P1273; VILLA E, 1993, LANCET, V341, P1413, DOI 10.1016/0140-6736(93)90980-U; VILLARI D, 1989, J CLIN PATHOL, V42, P689, DOI 10.1136/jcp.42.7.689; WAITE J, 1988, AIDS, V2, P443, DOI 10.1097/00002030-198812000-00006; YAMAMOTO K, 1994, J VIROL, V68, P2671, DOI 10.1128/JVI.68.4.2671-2676.1994; Yotsuyanagi H, 1998, HEPATOLOGY, V27, P1377, DOI 10.1002/hep.510270526; Zarski JP, 1998, J HEPATOL, V28, P27, DOI 10.1016/S0168-8278(98)80198-0; ZHANG YY, 1993, HEPATOLOGY, V17, P538, DOI 10.1002/hep.1840170403; Zignego AL, 1997, J MED VIROL, V51, P313, DOI 10.1002/(SICI)1096-9071(199704)51:4&lt;313::AID-JMV9&gt;3.0.CO;2-8	46	517	544	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					22	26		10.1056/NEJM199907013410104	http://dx.doi.org/10.1056/NEJM199907013410104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387938				2022-12-01	WOS:000081195600004
J	Gilon, D; Buonanno, FS; Joffe, MM; Leavitt, M; Marshall, JE; Kistler, JP; Levine, RA				Gilon, D; Buonanno, FS; Joffe, MM; Leavitt, M; Marshall, JE; Kistler, JP; Levine, RA			Lack of evidence of an association between mitral-valve prolapse and stroke in young patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL ISCHEMIC EVENTS; LEAFLET PROLAPSE; EMBOLIC STROKE; RISK-FACTORS; PREVALENCE; DIAGNOSIS; CLASSIFICATION; REGURGITATION; POPULATION	Background Previous studies have reported a high prevalence of mitral-valve prolapse among patients with embolic stroke (28 to 40 percent), especially among young patients (those less than or equal to 45 years old); this finding has practical implications for prophylaxis. However, diagnostic criteria for prolapse have changed and are now based on three-dimensional analysis of the shape of the valve; use of the current criteria reduces markedly the frequency of such a diagnosis and increases its specificity. Previously described complications must therefore be reconsidered. Methods In a case-control study, we reviewed data on 213 consecutive patients 45 years of age or younger with documented ischemic stroke or transient ischemic attack between 1985 and 1995; they underwent complete neurologic and echocardiographic evaluations. The prevalence of prolapse in these patients was compared with that in 263 control subjects without known heart disease, who were referred to our institution for assessment of ventricular function before receiving chemotherapy. Results Mitral-valve prolapse was present in 4 of the 213 young patients with stroke (1.9 percent), as compared with 7 of the 263 controls (2.7 percent); prolapse was present in 2 of 71 patients (2.8 percent) with otherwise unexplained stroke. The crude odds ratio for mitral-valve prolapse among the patients who had strokes, as compared with those who did not have strokes, was 0.70 (95 percent confidence interval, 0.15 to 2.80; P = 0.80); after adjustment for age and sex, the odds ratio was 0.59 (95 percent confidence interval, 0.12 to 2.50; P = 0.62). Conclusions Mitral-valve prolapse is considerably less common than previously reported among young patients with stroke or transient ischemic attack, including unexplained stroke, and no more common than among controls. Using more specific and currently accepted echocardiographic criteria, therefore, we could not demonstrate an association between the presence of mitral-valve prolapse and acute ischemic neurologic events in young people. (N Engl J Med 1999;341:8-13.) (C)1999, Massachusetts Medical Society.	Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Stroke Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Levine, RA (corresponding author), Massachusetts Gen Hosp, Cardiac Ultrasound Lab, VBK-508,32 Fruit St, Boston, MA 02114 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038176, R01HL053702, R29HL038176] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38176, HL53702] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARLETTA G A, 1984, Journal of Cardiovascular Ultrasonography, V3, P147; BARNETT HJM, 1980, NEW ENGL J MED, V302, P139, DOI 10.1056/NEJM198001173020303; BOUGHNER DR, 1985, STROKE, V16, P175, DOI 10.1161/01.STR.16.2.175; BRAUNWALD E, 1992, HEART DIS TXB CARDIO, V2, P1029; BUSCH EH, 1986, CHEST, V90, P454, DOI 10.1378/chest.90.3.454; DEBONO DP, 1981, LANCET, V1, P343; DEVEREUX RB, 1987, AM HEART J, V113, P1265, DOI 10.1016/0002-8703(87)90955-0; EGEBLAD H, 1984, ACTA MED SCAND, V216, P385; EGEBLAD H, 1987, AM HEART J, V114, P648, DOI 10.1016/0002-8703(87)90765-4; Freed LA, 1999, NEW ENGL J MED, V341, P1, DOI 10.1056/NEJM199907013410101; Gross C M, 1989, J Am Soc Echocardiogr, V2, P94; HECK AF, 1989, ANGIOLOGY, V40, P743, DOI 10.1177/000331978904000810; JONES HR, 1982, STROKE, V13, P451, DOI 10.1161/01.STR.13.4.451; KELLEY RE, 1988, STROKE, V19, P443, DOI 10.1161/01.STR.19.4.443; KISTLER JP, 1994, NEW ENGL J MED, V331, P1517, DOI 10.1056/NEJM199412013312211; KISTLER JP, 1994, HARRISONS PRINCIPLES, P2233; KOUVARAS G, 1985, Q J MED, V56, P387; KRIWISKY M, 1987, AM J CARDIOL, V59, P1149, DOI 10.1016/0002-9149(87)90864-2; LEVINE RA, 1989, CIRCULATION, V80, P589, DOI 10.1161/01.CIR.80.3.589; LEVINE RA, 1988, J AM COLL CARDIOL, V11, P1010, DOI 10.1016/S0735-1097(98)90059-6; LEVY D, 1987, AM HEART J, V113, P1281, DOI 10.1016/0002-8703(87)90956-2; MARKIEWICZ W, 1978, AM HEART J, V96, P555, DOI 10.1016/0002-8703(78)90172-2; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; NIDORF SM, 1993, J AM SOC ECHOCARDIOG, V6, pS8; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P1305, DOI 10.1056/NEJM198511213132101; PERLOFF JK, 1982, NEW ENGL J MED, V307, P369, DOI 10.1056/NEJM198208053070609; PERLOFF JK, 1989, CIRCULATION, V80, P710, DOI 10.1161/01.CIR.80.3.710; PETTY GW, 1994, MAYO CLIN PROC, V69, P632, DOI 10.1016/S0025-6196(12)61338-X; RANGANATHAN N, 1973, CIRCULATION, V48, P514, DOI 10.1161/01.CIR.48.3.514; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; ROTHROCK J, 1993, NEUROLOGY, V43, P2473, DOI 10.1212/WNL.43.12.2473; SAHN DJ, 1977, AM J CARDIOL, V39, P422, DOI 10.1016/S0002-9149(77)80100-8; SANDOK BA, 1982, STROKE, V13, P448, DOI 10.1161/01.STR.13.4.448; SCHARF RE, 1982, STROKE, V13, P454, DOI 10.1161/01.STR.13.4.454; THARAKAN J, 1982, ACTA NEUROL SCAND, V66, P295; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WARTH DC, 1985, J AM COLL CARDIOL, V5, P1173, DOI 10.1016/S0735-1097(85)80021-8; WILSON LA, 1977, BRIT MED J, V2, P86, DOI 10.1136/bmj.2.6079.86; WOLF PA, 1983, STROKE, V14, P1010, DOI 10.1161/01.STR.14.6.1010; WOOLEY CF, 1988, MITRAL VALVE PROLAPS, P149	40	96	99	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					8	13		10.1056/NEJM199907013410102	http://dx.doi.org/10.1056/NEJM199907013410102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387936				2022-12-01	WOS:000081195600002
J	Thompson, JN				Thompson, JN			The evolution of species interactions	SCIENCE			English	Editorial Material							COEVOLUTION; HOSTS; MODEL	Interactions between species are as evolutionarily malleable as the species themselves and have played a central role in the diversification and organization of life. This malleability creates complex geographic mosaics in interspecific interactions that can evolve rapidly over decades, blurring the distinction between evolutionary time and ecological time and making the study of coevolution crucial for human health and welfare.	Washington State Univ, Dept Bot, Pullman, WA 99164 USA; Washington State Univ, Dept Zool, Pullman, WA 99164 USA	Washington State University; Washington State University	Thompson, JN (corresponding author), Washington State Univ, Dept Bot, Pullman, WA 99164 USA.		Thompson, Jessica/GXW-0323-2022					BENKMAN CW, IN PRESS AM NAT; Berenbaum MR, 1998, P NATL ACAD SCI USA, V95, P13743, DOI 10.1073/pnas.95.23.13743; Brown JM, 1997, MOL ECOL, V6, P215, DOI 10.1046/j.1365-294X.1997.t01-1-00171.x; BURDON JJ, IN PRESS AM NAT; DAVIES NB, 1989, J ANIM ECOL, V58, P225, DOI 10.2307/4996; DWYER G, 1990, ECOL MONOGR, V60, P423, DOI 10.2307/1943014; Gandon S, 1996, P ROY SOC B-BIOL SCI, V263, P1003, DOI 10.1098/rspb.1996.0148; Hochberg ME, 1998, AM NAT, V152, P620, DOI 10.1086/286194; JANZEN DH, 1984, CRAWFORD LECT R SWED, V3, P1; Kearns CA, 1998, ANNU REV ECOL SYST, V29, P83, DOI 10.1146/annurev.ecolsys.29.1.83; LIVELY CM, IN PRESS AM NAT; Margulis L, 1991, SYMBIOSIS SOURCE EVO; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; Maynard Smith J., 1995, MAJOR TRANSITIONS EV; Nuismer SL, 1999, P ROY SOC B-BIOL SCI, V266, P605, DOI 10.1098/rspb.1999.0679; PARKER MA, IN PRESS AM NAT; Pellmyr O, 1996, AM NAT, V148, P827, DOI 10.1086/285958; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; SOLTIS DE, 1992, SYST BOT, V17, P607, DOI 10.2307/2419730; Thompson J.N., 1994, COEVOLUTIONARY PROCE; Thompson J. O. F., UNPUB; Thompson JN, 1998, TRENDS ECOL EVOL, V13, P329, DOI 10.1016/S0169-5347(98)01378-0	22	271	286	3	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2116	2118		10.1126/science.284.5423.2116	http://dx.doi.org/10.1126/science.284.5423.2116			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381869				2022-12-01	WOS:000081099300038
J	Goodwin, AW				Goodwin, AW			Sensorimotor coordination in cerebral palsy	LANCET			English	Editorial Material							CHILDREN		Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3054, Australia	University of Melbourne	Goodwin, AW (corresponding author), Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3054, Australia.							ELIASSON AC, 1991, DEV MED CHILD NEUROL, V33, P661; Gordon A.M., 1997, NEUROPHYSIOLOGY NEUR, P214; Gordon AM, 1999, DEV MED CHILD NEUROL, V41, P176, DOI 10.1017/S0012162299000365; Gordon AM, 1999, DEV MED CHILD NEUROL, V41, P166, DOI 10.1017/S0012162299000353; Johansson RS, 1996, NATO ADV SCI I D-BEH, V85, P205; NEILSON PD, 1990, DEV MED CHILD NEUROL, V32, P778; WESTLING G, 1984, EXP BRAIN RES, V53, P277; YEKUTIEL M, 1994, DEV MED CHILD NEUROL, V36, P619	8	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2090	2091		10.1016/S0140-6736(99)00136-1	http://dx.doi.org/10.1016/S0140-6736(99)00136-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382689				2022-12-01	WOS:000080969300005
J	Dhalluin, C; Carlson, JE; Zeng, L; He, C; Aggarwal, AK; Zhou, MM				Dhalluin, C; Carlson, JE; Zeng, L; He, C; Aggarwal, AK; Zhou, MM			Structure and ligand of a histone acetyltransferase bromodomain	NATURE			English	Article							PROTEINS; NMR; COACTIVATOR; ACETYLATION; ACTIVATION; ASSIGNMENT; C-13; CBP	Histone acetylation is important in chromatin remodelling and gene activation(1-4). Nearly all known histone-acetyltransferase (HAT)-associated transcriptional co-activators contain bromodomains, which are similar to 110-amino-acid modules found in many chromatin-associated proteins(5-9). Despite the wide occurrence of these bromodomains, their three-dimensional structure and binding partners remain unknown. Here we report the solution structure of the bromodomain of the HAT co-activator P/CAF (p300/CBP-associated factor)(10,11). The structure reveals an unusual left-handed up-and-down four-helix bundle. In addition, we show by a combination of structural and site-directed mutagenesis studies that bromodomains can interact specifically with acetylated lysine, making them the first known protein modules to do so, The nature of the recognition of acetyl-lysine by the P/CAF bromodomain is similar to that of acetyl-CoA by histone acetyltransferase. Thus, the bromodomain is functionally linked to the HAT activity of co-activators in the regulation of gene transcription.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Zhou, MM (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, Box 1218, New York, NY 10029 USA.							Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Brunger AT, 1993, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CLORE GM, 1994, METHOD ENZYMOL, V239, P249; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; GEOGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kuo CH, 1996, IEEE SIGNAL PROC LET, V3, P269, DOI 10.1109/97.536598; KUROKAWA R, 1998, NATURE, V279, P700; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; PURI PL, 1997, CELL, V1, P35; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; [No title captured]	29	1229	1271	6	130	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					491	496		10.1038/20974	http://dx.doi.org/10.1038/20974			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365964				2022-12-01	WOS:000080667900054
J	Romo, R; Brody, CD; Hernandez, A; Lemus, L				Romo, R; Brody, CD; Hernandez, A; Lemus, L			Neuronal correlates of parametric working memory in the prefrontal cortex	NATURE			English	Article							PSYCHOPHYSICAL MEASUREMENTS; FRONTAL-CORTEX; MONKEYS; DISCRIMINATION; FLUTTER; FIELDS; SENSE; TASK	Humans and monkeys have similar abilities to discriminate the difference in frequency between two mechanical vibrations applied sequentially to the fingertips(1-3). A key component of this sensory task is that the second stimulus is compared with the trace left by the first (base) stimulus, which must involve working memory,Where and how is this trace held in the brain? This question was investigated by recording from single neurons in the prefrontal cortex of monkeys while they performed the somatosensory discrimination task, Here we describe neurons in the inferior convexity of the prefrontal cortex whose discharge rates varied, during the delay period between the two stimuli, as a monotonic function of the base stimulus frequency. We describe this as 'monotonic stimulus encoding: and we suggest that the result may generalize: monotonic stimulus encoding may be the basic representation of one-dimensional sensory stimulus quantities in working memory. Thus we predict that other behavioural tasks that require ordinal comparisons between scalar analogue stimuli would give rise to monotonic responses similar to those reported here.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Romo, R (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Mexico City 04510, DF, Mexico.		Lemus, Luis/E-6760-2019	Lemus, Luis/0000-0002-6608-3684; romo, ranulfo/0000-0003-3529-3635				Asaad WF, 1998, NEURON, V21, P1399, DOI 10.1016/S0896-6273(00)80658-3; Bodner M, 1996, NEUROREPORT, V7, P1905, DOI 10.1097/00001756-199608120-00006; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; FUNAHASHI S, 1990, J NEUROPHYSIOL, V63, P814, DOI 10.1152/jn.1990.63.4.814; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster J, 1989, PREFRONTAL CORTEX; Hernandez A, 1997, J NEUROSCI, V17, P6391; Hoshi E, 1998, J NEUROPHYSIOL, V80, P3392, DOI 10.1152/jn.1998.80.6.3392; KOJIMA S, 1982, BRAIN RES, V248, P43, DOI 10.1016/0006-8993(82)91145-3; Miller EK, 1996, J NEUROSCI, V16, P5154; MOUNTCASTLE VB, 1990, J NEUROSCI, V10, P3032; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; Pandya DN., 1987, FRONTAL LOBES REVISI, P41; Press W., 1992, NUMERICAL RECIPES, V2nd; PREUSS TM, 1989, J COMP NEUROL, V282, P293, DOI 10.1002/cne.902820210; QUINTANA J, 1992, NEUROREPORT, V3, P721, DOI 10.1097/00001756-199208000-00018; Rainer G, 1998, P NATL ACAD SCI USA, V95, P15008, DOI 10.1073/pnas.95.25.15008; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; Romo R, 1998, NATURE, V392, P387, DOI 10.1038/32891; Ross S.M, 1987, INTRO PROBABILITY SC; Salinas E., 1998, Society for Neuroscience Abstracts, V24, P1126; SCHULTZ W, 1992, EXP BRAIN RES, V91, P363; Seung HS, 1996, P NATL ACAD SCI USA, V93, P13339, DOI 10.1073/pnas.93.23.13339; TALBOT WH, 1968, J NEUROPHYSIOL, V31, P301, DOI 10.1152/jn.1968.31.2.301; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P10533, DOI 10.1073/pnas.93.19.10533	27	571	578	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 3	1999	399	6735					470	473		10.1038/20939	http://dx.doi.org/10.1038/20939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TH	10365959				2022-12-01	WOS:000080667900049
J	Mills, KD; Sinclair, DA; Guarente, L				Mills, KD; Sinclair, DA; Guarente, L			MEC1-dependent redistribution of the Sir3 silencing protein from telomeres to DNA double-strand breaks	CELL			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ATAXIA-TELANGIECTASIA GENE; END-JOINING REPAIR; CELL-CYCLE; II TRANSCRIPTION; CHECKPOINT GENES; BUDDING YEAST; LIGASE-IV; KU; DAMAGE	The yeast Sir2/3/4p complex is found in abundance at telomeres, where it participates in the formation of silent heterochromatin and telomere maintenance. Here, we show that Sir3p is released from telomeres in response to DNA double-strand breaks (DSBs), binds to DSBs, and mediates their repair, independent of cell mating type. Sir3p relocalization is S phase specific and, importantly, requires the DNA damage checkpoint genes MEC1 and RADS. MEC1 is a homolog of ATM, mutations in which cause ataxia telangiectasia (A-T), a disease characterized by various neurologic and immunologic abnormalities, a predisposition for cancer, and a cellular defect in repair of DSBs. This novel mode by which preformed DNA repair machinery is mobilized by DNA damage sensors may have implications for human diseases resulting from defective DSB repair.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [AG11119] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011119, R01AG011119] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahne F, 1997, NUCLEIC ACIDS RES, V25, P743, DOI 10.1093/nar/25.4.743; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Astrom SU, 1999, NATURE, V397, P310, DOI 10.1038/16833; BARNES G, 1985, P NATL ACAD SCI USA, V82, P1354, DOI 10.1073/pnas.82.5.1354; Barnes G, 1997, P NATL ACAD SCI USA, V94, P867, DOI 10.1073/pnas.94.3.867; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BLOCHER D, 1991, INT J RADIAT BIOL, V60, P791, DOI 10.1080/09553009114552601; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Fan HY, 1996, GENETICS, V142, P749; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HECHT SM, 1986, FASEB J, V45, P2784; HEUDE M, 1993, GENETICS, V133, P489; HITTELMAN WN, 1988, CANCER RES, V48, P276; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Jin YJ, 1997, J BIOL CHEM, V272, P7352, DOI 10.1074/jbc.272.11.7352; Kanaar Roland, 1997, Genes and Function, V1, P165; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lewis LK, 1998, MOL CELL BIOL, V18, P1891, DOI 10.1128/MCB.18.4.1891; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; MARSHALL M, 1987, MOL CELL BIOL, V7, P4441, DOI 10.1128/MCB.7.12.4441; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Milne GT, 1996, MOL CELL BIOL, V16, P4189; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MITCHEL REJ, 1987, MUTAT RES, V183, P149, DOI 10.1016/0167-8817(87)90057-5; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHWARTZ JL, 1989, MUTAT RES, V216, P111, DOI 10.1016/0165-1161(89)90011-3; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; Siede W, 1996, GENETICS, V142, P91; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 1998, GENETICS, V149, P1205; Stone EM, 1998, BIOESSAYS, V20, P30; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SULLIVAN N, 1990, MUTAT RES, V245, P171, DOI 10.1016/0165-7992(90)90046-M; Takiguchi Y, 1996, GENOMICS, V35, P129, DOI 10.1006/geno.1996.0331; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TAYLOR AMR, 1994, INT J RADIAT BIOL, V65, P65, DOI 10.1080/09553009414550091; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Vamvakas S, 1997, CRIT REV TOXICOL, V27, P155, DOI 10.3109/10408449709021617; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; WEI YF, 1995, MOL CELL BIOL, V15, P3206; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhou PK, 1998, RADIOTHER ONCOL, V47, P271, DOI 10.1016/S0167-8140(97)00200-4	65	279	289	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 28	1999	97	5					609	620		10.1016/S0092-8674(00)80772-2	http://dx.doi.org/10.1016/S0092-8674(00)80772-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	202VD	10367890	Bronze			2022-12-01	WOS:000080672100010
J	Guyatt, GH; Sinclair, J; Cook, DJ; Glasziou, P				Guyatt, GH; Sinclair, J; Cook, DJ; Glasziou, P		Evidence-Based Med Working Grp; Cochrane Applicability Methods Working Grp	Users' guides to the medical literature - XVI. How to use a treatment recommendation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-TRACT INFECTIONS; CLINICAL-PRACTICE GUIDELINES; ATRIAL-FIBRILLATION; DIGESTIVE-TRACT; SELECTIVE DECONTAMINATION; MYOCARDIAL-INFARCTION; DECISION-ANALYSIS; HELP ME; WILL; PREFERENCES	Clinicians can often find treatment recommendations in traditional narrative reviews and the discussion sections of original articles and meta-analyses. Making a treatment recommendation involves framing a question, identifying management options and outcomes, collecting and summarizing evidence, and applying value judgments or preferences to arrive at an optimal course of action, Each step in this process can be conducted systematically (thus protecting against bias) or unsystematically (leaving the process open to bias). Clinicians faced with a plethora of recommendations may wish to attend to those that are less likely to be biased. Therefore, we propose a hierarchy of rigor of recommendations to guide clinicians when judging the usefulness of particular recommendations. Recommendations with the highest rigor consider all relevant options and outcomes, include a comprehensive collection of the methodologically highest quality data with an explicit strategy for summarizing the data (that is, a systematic review), and make an explicit statement of the values or preferences involved in moving from evidence to action, High rigor recommendations come from systematically developed, evidence-based practice guidelines or rigorously conducted decision analyses. Systematic reviews, which typically do not consider all relevant options and outcomes or make the preferences underlying recommendations explicit, offer intermediate rigor recommendations. Traditional approaches in which the collection and assessment of evidence remains unsystematic, all relevant options and outcomes may not be considered, and values remain implicit, provide recommendations of weak rigor. In an era in which clinicians are barraged by recommendations as to how to manage their patients, this hierarchy provides a potentially useful set of guides.	McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; Univ Queensland, Sch Med, Dept Social & Prevent Med, Herston, Qld, Australia	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University; University of Queensland	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X				AERDTS SJA, 1993, BRIT MED J, V307, P525; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; CARO JJ, 1993, LANCET, V341, P1381, DOI 10.1016/0140-6736(93)90950-L; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GLASZIOU PP, 1994, MED J AUSTRALIA, V161, P532, DOI 10.5694/j.1326-5377.1994.tb127596.x; GROOTENDOORST P, IN PRESS MED CARE; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; MCBRIDE R, 1994, LANCET, V343, P687; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; Robbins JM, 1998, ARCH PEDIAT ADOL MED, V152, P358; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630	29	118	124	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1836	1843		10.1001/jama.281.19.1836	http://dx.doi.org/10.1001/jama.281.19.1836			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340372				2022-12-01	WOS:000080288800038
J	Hines, SC; Glover, JJ; Holley, JL; Babrow, AS; Badzek, LA; Moss, AH				Hines, SC; Glover, JJ; Holley, JL; Babrow, AS; Badzek, LA; Moss, AH			Dialysis patients' preferences for family-based advance care planning	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED TRIAL; HEALTH-CARE; DIRECTIVES	Background: Most patients do not participate in advance care planning with physicians. Objective: To examine patients' preferences for involving their physicians and families in advance care planning. Design: Pace-to-face interviews with randomly selected patients. Setting: Community-based dialysis units in one rural and one urban region. Participants: 400 hemodialysis patients. Measurements: Questions about whom patients involve in advance care planning, whom patients would like to include in this planning, and patients' reactions to state legislation on surrogate decision makers in End-of-life care. Results: Patients more frequently discussed preferences for end-of-life care with family members than with physicians (50% compared with 6%; P < 0.001). More patients wanted to include family members in future discussions of advance care planning than wanted to include physicians (91% compared with 36%; P < 0.001). Patients were most comfortable with legislation that granted their family end-of-life decision-making authority in the event of their own incapacity (P < 0.001). Conclusion: Most patients want to include their families more than their physicians in advance care planning.	W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Ctr Hlth Eth & Law, Morgantown, WV 26506 USA; Univ Rochester, Sch Med, Rochester, NY 14642 USA; Purdue Univ, W Lafayette, IN 47907 USA	West Virginia University; University of Rochester; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Moss, AH (corresponding author), W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Ctr Hlth Eth & Law, Box 9022, Morgantown, WV 26506 USA.	amoss@wvu.edu						*AM HLTH DEC, 1997, QUEST DIE DIGN AN AM, P5; *CHOIC DYING INC, 1997, STAT STAT GOV SURR D; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; HARE J, 1991, J GEN INTERN MED, V6, P41, DOI 10.1007/BF02599390; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; JOHNSTON SC, 1995, ARCH INTERN MED, V155, P1025, DOI 10.1001/archinte.155.10.1025; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; Martin DK, 1999, ARCH INTERN MED, V159, P86, DOI 10.1001/archinte.159.1.86; MENIKOFF JA, 1992, NEW ENGL J MED, V327, P1165, DOI 10.1056/NEJM199210153271612; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; Moss AH, 1996, CHEST, V110, P249, DOI 10.1378/chest.110.1.249; *NIH NAT I DIAB DI, 1997, US REN DAT SYST 1997; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; Sehgal AR, 1996, JAMA-J AM MED ASSOC, V276, P1652, DOI 10.1001/jama.276.20.1652; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Sulmasy DP, 1998, ANN INTERN MED, V128, P621, DOI 10.7326/0003-4819-128-8-199804150-00002; *VERM ETH NETW, 1997, VERM VOIC CAR DYING	20	77	77	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 18	1999	130	10					825	828		10.7326/0003-4819-130-10-199905180-00016	http://dx.doi.org/10.7326/0003-4819-130-10-199905180-00016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196JJ	10366372				2022-12-01	WOS:000080305000005
J	James, O; Day, C				James, O; Day, C			Non-alcoholic steatohepatitis: another disease of affluence	LANCET			English	Editorial Material							NONALCOHOLIC STEATOHEPATITIS; FATTY LIVER; OBESITY		Newcastle Univ, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	James, O (corresponding author), Newcastle Univ, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Day, Christopher/Z-3305-2019					Arner P, 1998, LANCET, V351, P1301, DOI 10.1016/S0140-6736(05)79052-8; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Bass NM, 1999, HEPATOLOGY, V29, P606, DOI 10.1002/hep.510290247; Byron D, 1996, HEPATOLOGY, V24, P813; Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347; Day CP, 1998, HEPATOLOGY, V27, P1463, DOI 10.1002/hep.510270601; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; James OFW, 1998, J HEPATOL, V29, P495, DOI 10.1016/S0168-8278(98)80073-1; Kim WR, 1996, TRANSPLANTATION, V62, P1802, DOI 10.1097/00007890-199612270-00021; LUDWIG J, 1980, MAYO CLIN PROC, V55, P434; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1016/0270-9139(95)90196-5; WANLESS IR, 1990, HEPATOLOGY, V12, P1106, DOI 10.1002/hep.1840120505; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Younossi ZM, 1998, HEPATOLOGY, V28, p303A	15	238	251	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1634	1636		10.1016/S0140-6736(99)00163-4	http://dx.doi.org/10.1016/S0140-6736(99)00163-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335777				2022-12-01	WOS:000080408000002
J	Dessen, A; Tang, J; Schmidt, H; Stahl, M; Clark, JD; Seehra, J; Somers, WS				Dessen, A; Tang, J; Schmidt, H; Stahl, M; Clark, JD; Seehra, J; Somers, WS			Crystal structure of human cytosolic phospholipase A(2) reveals a novel topology and catalytic mechanism	CELL			English	Article							LIPID-BINDING DOMAIN; ARACHIDONIC-ACID; MACROMOLECULAR STRUCTURES; INTERFACIAL CATALYSIS; NUCLEAR-ENVELOPE; C2 DOMAIN; CALCIUM; PHOSPHORYLATION; IDENTIFICATION; TRANSLOCATION	Cytosolic phospholipase A, initiates the biosynthesis of prostaglandins, leukotrienes, and platelet-activating factor (PAF), mediators of the pathophysiology of asthma and arthritis. Here, we report the X-ray crystal structure of human cPLA(2) at 2.5 Angstrom. cPLA(2) consists of an N-terminal calcium-dependent lipid-binding/C2 domain and a catalytic unit whose topology is distinct from that of other lipases. An unusual Ser-Asp dyad located in a deep cleft at the center of a predominantly hydrophobic funnel selectively cleaves arachidonyl phospholipids. The structure reveals a flexible lid that must move to allow substrate access to the active site, thus explaining the interfacial activation of this important lipase.	Wyeth Ayerst Res, Biochem, Cambridge, MA 02140 USA	Pfizer	Dessen, A (corresponding author), Wyeth Ayerst Res, Biochem, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.	adessen@genetics.com; wsomers@genetics.com		Clark, James D./0000-0002-4801-0123; Dessen, Andrea/0000-0001-6487-4020				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BRICOGNE G, 1993, ACTA CRYSTALLOGR D, V49, P37, DOI 10.1107/S0907444992010400; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Cygler M, 1997, METHOD ENZYMOL, V284, P3; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nicholls A., 1992, GRASP GRAPHICAL REPR; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Schrag JD, 1997, METHOD ENZYMOL, V284, P85; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VENABLE ME, 1993, J BIOL CHEM, V268, P7965; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	58	293	305	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					349	360		10.1016/S0092-8674(00)80744-8	http://dx.doi.org/10.1016/S0092-8674(00)80744-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319815	Bronze			2022-12-01	WOS:000080100500008
J	Gervais, FG; Xu, DG; Robertson, GS; Vaillancourt, JP; Zhu, YX; Huang, JQ; LeBlanc, A; Smith, D; Rigby, M; Shearman, MS; Clarke, FE; Zheng, H; Van Der Ploeg, LHT; Ruffolo, SC; Thornberry, NA; Xanthoudakis, S; Zamboni, RJ; Roy, S; Nicholson, DW				Gervais, FG; Xu, DG; Robertson, GS; Vaillancourt, JP; Zhu, YX; Huang, JQ; LeBlanc, A; Smith, D; Rigby, M; Shearman, MS; Clarke, FE; Zheng, H; Van Der Ploeg, LHT; Ruffolo, SC; Thornberry, NA; Xanthoudakis, S; Zamboni, RJ; Roy, S; Nicholson, DW			Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation	CELL			English	Article							APOPTOTIC CELL-DEATH; COMBINATORIAL APPROACH; ICE/CED-3 PROTEASE; TRANSGENIC MICE; DISEASE; DAMAGE; BRAIN; MODEL; RAT; SPECIFICITIES	The amyloid-beta precursor protein (APP) is directly and efficiently cleaved by caspases during apoptosis, resulting in elevated amyloid-beta (A beta) peptide formation. The predominant site of caspase-mediated proteolysis is within the cytoplasmic tail of APP, and cleavage at this site occurs in hippocampal neurons in vivo following acute excitotoxic or ischemic brain injury. Caspase-3 is the predominant caspase involved in APP cleavage, consistent with its marked elevation in dying neurons of Alzheimer's disease brains and colocalization of its APP cleavage product with A beta in senile plaques. Caspases thus appear to play a dual role in proteolytic processing of APP and the resulting propensity for A beta peptide formation, as well as in the ultimate apoptotic death of neurons in Alzheimer's disease.	Merck Res Labs, Merck Frosst Ctr Therapeut Res, Dept Pharmacol Biochem & Mol Biol, Kirkland, PQ H9H 3L1, Canada; Merck Res Labs, Merck Frosst Ctr Therapeut Res, Dept Med Chem, Kirkland, PQ H9H 3L1, Canada; Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Pharmacol Biochem & Mol Biol, Harlow CM20 2QR, Essex, England; Merck Res Labs, Dept Enzymol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; McGill University; Lady Davis Institute; McGill University	Nicholson, DW (corresponding author), Merck Res Labs, Merck Frosst Ctr Therapeut Res, Dept Pharmacol Biochem & Mol Biol, Kirkland, PQ H9H 3L1, Canada.			Robertson, George/0000-0001-8411-7721				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Barnes NY, 1998, J NEUROSCI, V18, P5869; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cotman CW, 1996, BRAIN PATHOL, V6, P493, DOI 10.1111/j.1750-3639.1996.tb00878.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Forloni G, 1996, MOL CHEM NEUROPATHOL, V28, P163, DOI 10.1007/BF02815218; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; Li WP, 1997, J MOL NEUROSCI, V8, P75, DOI 10.1007/BF02736774; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Su JH, 1997, J NEUROPATH EXP NEUR, V56, P86, DOI 10.1097/00005072-199701000-00009; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhang L, 1997, BIOCHEM BIOPH RES CO, V235, P845, DOI 10.1006/bbrc.1997.6698	41	672	718	1	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					395	406		10.1016/S0092-8674(00)80748-5	http://dx.doi.org/10.1016/S0092-8674(00)80748-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319819	Bronze			2022-12-01	WOS:000080100500012
J	Yarnell, WS; Roberts, JW				Yarnell, WS; Roberts, JW			Mechanism of intrinsic transcription termination and antitermination	SCIENCE			English	Article							ESCHERICHIA-COLI RNA; PHAGE-LAMBDA; NASCENT RNA; ELONGATION COMPLEX; CHAIN ELONGATION; POLYMERASE ALTER; BETA-SUBUNIT; DNA HYBRID; SEQUENCES; PROMOTER	Gene expression is modulated by regulatory elements that influence transcription elongation by RNA polymerase: terminators that disrupt the elongation complex and release RNA, and regulators that overcome termination signals. RNA release from Escherichia coli RNA polymerase can be induced by a complementary oligonucleotide that replaces the upstream half of the RNA hairpin stem of intrinsic terminator transcripts, implying that RNA hairpins act by extracting RNA from the transcription complex. A transcription antiterminator inhibits this activity of oligonucleotides and therefore protects the elongation complex from destabilizing attacks on the emerging transcript. These effects illuminate the structure of the complex and the mechanism of transcription termination.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	Cornell University	Roberts, JW (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, Biotechnol Bldg, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM 21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021941, R01GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Artsimovitch I, 1998, GENE DEV, V12, P3110, DOI 10.1101/gad.12.19.3110; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; DAS A, 1992, J BACTERIOL, V174, P6711, DOI 10.1128/JB.174.21.6711-6716.1992; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; FISHER RF, 1983, J BIOL CHEM, V258, P8146; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; Reeder RH, 1997, TRENDS BIOCHEM SCI, V22, P473, DOI 10.1016/S0968-0004(97)01133-X; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; Rees WA, 1997, J MOL BIOL, V273, P797, DOI 10.1006/jmbi.1997.1327; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; Roberts Jeffrey W., 1996, P27; RYDER A, UNPUB; Shaaban SA, 1996, MOL CELL BIOL, V16, P6468; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; WILSON KS, 1994, J MOL BIOL, V244, P36, DOI 10.1006/jmbi.1994.1702; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YARNELL W, UNPUB; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T	43	257	269	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					611	615		10.1126/science.284.5414.611	http://dx.doi.org/10.1126/science.284.5414.611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10213678				2022-12-01	WOS:000079951100036
J	Kops, GJPL; de Ruiter, ND; De Vries-Smits, AMM; Powell, DR; Bos, JL; Burgering, BMT				Kops, GJPL; de Ruiter, ND; De Vries-Smits, AMM; Powell, DR; Bos, JL; Burgering, BMT			Direct control of the Forkhead transcription factor AFX by protein kinase B	NATURE			English	Article							INSULIN-RESPONSE SEQUENCE; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; FAMILY MEMBER; S6 KINASE; ACTIVATION; RAS; STIMULATION; LONGEVITY	The phosphatidylinositol-3-OH-kinase (PI(3)K) effector protein kinase B (refs 1, 2) regulates certain insulin-responsive genes(3,4) but the transcription factors regulated by protein kinase B have yet to be identified. Genetic analysis in Caenorhabditis elegans has shown that the Forkhead transcription factor daf-16 is regulated by a pathway consisting of insulin-receptor-like daf-2 and PI(3)K-like age-1 (refs 5-8). Here we show that protein kinase B phosphorylates AFX, a human orthologue of daf-16 (refs 5, 6, 9), both in vitro and in vivo. Inhibition of endogenous PI(3)K and protein kinase B activity prevents protein kinase B-dependent phosphorylation of AFX and reveals residual protein kinase B-independent phosphorylation that requires Ras signalling towards the Ra1 GTPase. In addition, phosphorylation of AFX by protein kinase B inhibits its transcriptional activity. Together, these results delineate a pathway for PT(3)K-dependent signalling to the nucleus.	Univ Utrecht, Physiol Chem Lab, NL-3584 CG Utrecht, Netherlands; Univ Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Utrecht University; Utrecht University; Baylor College of Medicine	Burgering, BMT (corresponding author), Univ Utrecht, Physiol Chem Lab, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.	b.m.t.burgering@med.uu.nl		Kops, Geert/0000-0003-3555-5295				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Duyndam MCA, 1996, J VIROL, V70, P5852, DOI 10.1128/JVI.70.9.5852-5859.1996; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Peters U, 1997, HUM GENET, V100, P569, DOI 10.1007/s004390050553; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; UNTERMAN TG, 1994, BIOCHEM BIOPH RES CO, V203, P1835, DOI 10.1006/bbrc.1994.2401; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353	30	933	963	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 15	1999	398	6728					630	634		10.1038/19328	http://dx.doi.org/10.1038/19328			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	186WX	10217147				2022-12-01	WOS:000079754700060
J	Reagan, P				Reagan, P			Helen	LANCET			English	Article											Reagan, P (corresponding author), 2406 NE 19th Ave, Portland, OR 97212 USA.								0	16	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 10	1999	353	9160					1265	1267		10.1016/S0140-6736(98)12219-5	http://dx.doi.org/10.1016/S0140-6736(98)12219-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	186TB	10217100				2022-12-01	WOS:000079744100042
J	Nightingale, SL				Nightingale, SL			Electronic "Orange book"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1580	1580		10.1001/jama.281.17.1580	http://dx.doi.org/10.1001/jama.281.17.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235141				2022-12-01	WOS:000080025900008
J	Nightingale, SL				Nightingale, SL			Dietary supplement labeling more informative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1580	1580		10.1001/jama.281.17.1580	http://dx.doi.org/10.1001/jama.281.17.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235141				2022-12-01	WOS:000080025900009
